



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 162646

**TO: Terra Gibbs
Location: 2d10 / 2c18
Art Unit: 1635
Thursday, August 18, 2005**

Case Serial Number: 10/667022

**From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556**

Noble.jarrell@uspto.gov

Search Notes

THIS PAGE BLANK (USPTO)

Schreiber, David

162645

From: Gibbs, Terra
Sent: Thursday, August 04, 2005 10:37 AM
To: Schreiber, David
Subject: Sequence search request...

Hi David,

I have another request for a score over length search:

I need a length limited nucleotide sequence search of SEQ ID NO:4 in USSN 10/667022, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 80 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched.

David, is it possible to only return patent hits from ISIS?????

*Terra Cotta Gibbs, Ph.D.
Art Unit 1635
Remsen Building 2D10
Mailbox 2C18
571-272-0758*

THIS PAGE BLANK (USPTO)

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: _____ Examiner #: _____ Date: _____
Art Unit: _____ Phone Number: 2- _____ Serial Number: _____
Location (Bldg/Room#): _____ (Mailbox #): _____ Results Format Preferred (circle): PAPER . DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

STAFF USE ONLYSearcher: not

Type of Search

15 NA Sequence (#)

Vendors and cost where applicable

_____ STN _____ Dialog

Searcher Phone #: _____

_____ AA Sequence (#)

_____ Questel/Orbit _____ Lexis/Nexis

Searcher Location: _____

_____ Structure (#)

_____ Westlaw _____ WWW/Internet

Date Searcher Picked Up: _____

_____ Bibliographic

☒ In-house sequence systemsDate Completed: 8/18/05

_____ Litigation

☒ Commercial _____ Oligomer _____ Score/Length☒ Interference _____ SPDI _____ Encode/TranslSearcher Prep & Review Time: 10

_____ Fulltext

_____ Other (specify)

Online Time: 40

_____ Other

THIS PAGE BLANK (USPTO)

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 75.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 09:13:44 ; Search time 5 seconds
(without alignments)
3.936 Million cell updates/sec

Title: US-10-667-022-4
Perfect score: 5085
Sequence: 1 ggaatccccgggtgcagga.....tcgagggggggcccggtacc 5085

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 58 seqs, 1935 residues

Total number of hits satisfying chosen parameters: 116

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 58 summaries

Database : fetch4rst.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	44.4	0.9	56	1	CV058129
C 2	42	0.8	53	1	CV05817
C 3	41.4	0.8	45	1	CV06098
C 4	41.4	0.8	46	1	CV059173
C 5	41.4	0.8	48	1	CV064988
C 6	41	0.8	54	1	CV057724
C 7	41	0.8	54	1	CV307126
C 8	40.4	0.8	46	1	CV081744
C 9	39.8	0.8	46	1	CV063340
C 10	39.6	0.8	51	1	CV059332
C 11	39.4	0.8	43	1	CV062138
C 12	38.4	0.8	42	1	CV062024
C 13	36.6	0.7	47	1	CV060361
C 14	36.6	0.7	47	1	CV080559
C 15	35.6	0.7	44	1	CV060847
C 16	35.6	0.7	47	1	CV058836
C 17	35.6	0.7	47	1	CV061673
C 18	34.8	0.7	43	1	CV066153
C 19	34.4	0.7	38	1	CV064759
C 20	34.4	0.7	40	1	CV062707
C 21	33.6	0.7	42	1	CV059301
C 22	33.4	0.7	40	1	CV064457
C 23	32.8	0.6	41	1	CV054826
C 24	32.4	0.6	36	1	CV066718
C 25	31.4	0.6	35	1	CV066327
C 26	30.4	0.6	36	1	CV091545
C 27	30.4	0.6	37	1	CV055204
C 28	30	0.6	30	1	CV020481
C 29	29.8	0.6	35	1	CV064432
C 30	29.4	0.6	31	1	CV057897
C 31	27	0.5	28	1	CF305592
C 32	25	0.5	33	1	R38731
C 33	24.8	0.5	31	1	CV066570

34	24.6	0.5	31	1	AI153615	ACCESSION:AI153615
C 35	24.4	0.5	31	1	BM588370	ACCESSION:BM588370
C 36	22.8	0.4	26	1	CW020478	ACCESSION:CW020478
C 37	22.8	0.4	28	1	CV091538	ACCESSION:CV091538
C 38	21.4	0.4	28	1	CV065010	ACCESSION:CV065010
C 39	20	0.4	20	1	CF305590	ACCESSION:CF305590
C 40	19.4	0.4	23	1	CV064628	ACCESSION:CV064628
C 41	19.4	0.4	23	1	CV066488	ACCESSION:CV066488
C 42	19.2	0.4	24	1	AZ308225	ACCESSION:AZ308225
C 43	19.2	0.4	24	1	AZ814559	ACCESSION:AZ814559
C 44	19.2	0.4	24	1	TA250E05P	ACCESSION:AL483684
C 45	18.8	0.4	24	1	AZ827015	ACCESSION:AZ827015
C 46	18	0.4	19	1	CF306449	ACCESSION:CF306449
C 47	17.8	0.4	21	1	AZ597932	ACCESSION:AZ597932
C 48	17	0.3	19	1	CF303019	ACCESSION:CF303019
C 49	17	0.3	19	1	CO578459	ACCESSION:CO578459
C 50	16.4	0.3	18	1	AJ725584	ACCESSION:AJ725584
C 51	16.4	0.3	18	1	CR786637	ACCESSION:CR786637
C 52	16	0.3	16	1	AJ679356	ACCESSION:AJ679356
C 53	16	0.3	16	1	CR786853	ACCESSION:CR786853
C 54	16	0.3	17	1	BM398023	ACCESSION:BM398023
C 55	16	0.3	17	1	BM398024	ACCESSION:BM398024
C 56	16	0.3	17	1	BM399768	ACCESSION:BM399768
C 57	16	0.3	20	1	CF307519	ACCESSION:CF307519
C 58	16	0.3	20	1	CF326591	ACCESSION:CF326591

ALIGNMENTS

RESULT 1
CV058129/c
LOCUS
DEFINITION

CV058129 56 bp mRNA linear EST 24-AUG-2004
BNEL34f4 Barley EST endosperm library Hordeum vulgare subsp.
vulgare cDNA clone BNEL34f4 5' similar to Unknown Function, mRNA
sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE

CV058129
CV058129.1 GI:51521268
EST.

ORGANISM

Hordeum vulgare subsp. vulgare
Hordeum vulgare subsp. vulgare

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Poideae; Triticeae; Hordeum.

REFERENCE

1 (bases 1 to 56)
Ali S. Holloway, B. and Taylor, W.C.

AUTHORS

Ali S. Holloway, B. and Taylor, W.C.

TITLE

Normalisation of cereal endosperm EST libraries for structural and
functional genomic analysis

JOURNAL

Plant Mol. Biol. Rep. 18, 123-132 (2000)

COMMENT

Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry.

CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000

FEATURES

Seq primer: M13 reverse primer
High quality sequence stop: 56.

Location/Qualifiers

source

1..56
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL34f4"
/issue_type="endosperm"
/dev_stage="developing endosperm tissue 10, 12, 15 dpa
(days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endosperm library"
/note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA
was prepared from endosperm tissues of the barley cultivar

gibbs-10-667-022-4.rst

RESULT 3	
CV066098	
LOCUS	
DEFINITION	
ACCESSION	

KEYWORDS
SOURCE
ORGANIS

**JOURNAL
COMMENT**

FEATURES

Query Name
Best Location
Matched
Qy
Db
RESULT 4
CV059173
LOCUS
DEFINITION

VERSION
KEYWORDS
SOURCE
ORGANI

RESULT 3	REFERENCE
CV066098	AUTHORS
LOCUS	TITLE
DEFINITION	JOURNAL
ACCESSION	COMMENT
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	

FEATURES

Query N
Best Lc
Matches

RESULT 4
CV059173
LOCUS
DEFINITION

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANI

REFERENCE
AUTHOR

TITLE Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry,
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au

Seq primer: M13 reverse primer
High quality sequence stop: 46.
FEATURES
source Location/Qualifiers
1. .46
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL45B8"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 10, 12, 15 dpa
(days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endosperm library"
/notes="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 41.4; DB 1; Length 46;
Best Local Similarity 97.7%; Pred. No. 4.1;
Matches 42; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTC 5067
|||||
DB 2 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 44
RESULT 5
CV064988 48 bp mRNA linear EST 24-AUG-2004
LOCUS WNEL17h3 Wheat EST endosperm library, Triticum aestivum cDNA clone
DEFINITION WNEL17h3 5' similar to Unknown Function, mRNA sequence.
ACCESSION CV064988.1 GI:51528165
VERSION EST.
KEYWORDS Triticum aestivum (bread wheat)
SOURCE Triticum aestivum
ORGANISM Triticum aestivum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae; Triticeae; Triticum.
REFERENCE 1 (bases 1 to 48)
AUTHORS Ali, S., Holloway, B. and Taylor, W.C.
TITLE Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry,
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 48.
FEATURES
source Location/Qualifiers
1. .48
/organism="Triticum aestivum"

/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/clone="WNEL17h3"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endosperm library"
/notes="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 41.4; DB 1; Length 48;
Best Local Similarity 97.7%; Pred. No. 4.2;
Matches 42; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTC 5067
DB 4 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 46
RESULT 6
CV057724 54 bp mRNA linear EST 24-AUG-2004
LOCUS BNEL30a8 Barley EST endosperm library, Hordeum vulgare subsp.
DEFINITION BNEL30a8 5' similar to Unknown Function, mRNA sequence.
ACCESSION CV057724.1 GI:51520863
VERSION EST.
KEYWORDS Hordeum vulgare subsp. vulgare
SOURCE Hordeum vulgare subsp. vulgare
ORGANISM Hordeum vulgare subsp. vulgare
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae; Triticeae; Hordeum.
REFERENCE 1 (bases 1 to 54)
AUTHORS Ali, S., Holloway, B. and Taylor, W.C.
TITLE Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry,
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 54.
FEATURES
source Location/Qualifiers
1. .54
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL30a8"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 10, 12, 15 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endosperm library"
/notes="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I

site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 41; DB 1; Length 54;
Best Local Similarity 89.8%; Pred. No. 4.7; Indels 0; Gaps 0;
Matches 44; Conservative 0; Mismatches 5;

QY 5018 AACTGTAAAAA.....AAAAAAAAAAAAAAAAAAAAAAAAAAAACT 5066

Db 1 AAT 49

RESULT 7
CV307126 54 bp mRNA linear EST 23-SEP-2004
LOCUS tJ41a2.b7 Mouse 5' RACE clones Mus musculus cDNA 5', mRNA

DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

1. .54
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone_lib="Mouse 5' RACE clones"
/note="Vector: PCR-TOPO2.1; Cloned 5' RACE fragments amplified from 5' RACE cDNA generated from 15 pooled mouse tissues and stages: 7, 11, 15, & 17-day total embryo, whole brain, eye, kidney, liver, lung, prostate, and submaxillary gland, smooth muscle, spleen, testes and uterus."

Query Match 0.8%; Score 41; DB 1; Length 54;
Best Local Similarity 100.0%; Pred. No. 4.7; Indels 0; Gaps 0;
Matches 41; Conservative 0; Mismatches 0;

QY 5025 AAAC 5065

Db 4 AAAC 44

RESULT 8
CV061744 46 bp mRNA linear EST 24-AUG-2004
LOCUS BNEL71d8 Barley EST endospERM library Hordeum vulgare subsp.
DEFINITION vulgare cDNA clone BNEL71d8 5' similar to Unknown Function, mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

1. .54
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone_lib="Mouse 5' RACE clones"
/note="Vector: PCR-TOPO2.1; Cloned 5' RACE fragments amplified from 15 pooled mouse tissues and stages: 7, 11, 15, & 17-day total embryo, whole brain, eye, kidney, liver, lung, prostate, and submaxillary gland, smooth muscle, spleen, testes and uterus."

Query Match 0.8%; Score 41; DB 1; Length 54;
Best Local Similarity 100.0%; Pred. No. 4.7; Indels 0; Gaps 0;
Matches 41; Conservative 0; Mismatches 0;

QY 5025 AAAC 5065

Db 4 AAAC 44

RESULT 8
CV061744 46 bp mRNA linear EST 24-AUG-2004
LOCUS BNEL71d8 Barley EST endospERM library Hordeum vulgare subsp.
DEFINITION vulgare cDNA clone BNEL71d8 5' similar to Unknown Function, mRNA sequence.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

1. .46
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL71d8"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endospERM library"
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 40.4; DB 1; Length 46;
Best Local Similarity 97.6%; Pred. No. 4.7; Indels 0; Gaps 0;
Matches 41; Conservative 0; Mismatches 1;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACT 5066

Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATT 42

RESULT 9
CV063340 46 bp mRNA linear EST 24-AUG-2004
LOCUS BNEL89c2 Barley EST endospERM library Hordeum vulgare subsp.
DEFINITION vulgare cDNA clone BNEL89c2 5' similar to Unknown Function, mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

1. .46
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL71d8"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endospERM library"
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 40.4; DB 1; Length 46;
Best Local Similarity 97.6%; Pred. No. 4.7; Indels 0; Gaps 0;
Matches 41; Conservative 0; Mismatches 1;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACT 5066

Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATT 42

RESULT 9
CV063340 46 bp mRNA linear EST 24-AUG-2004
LOCUS BNEL89c2 Barley EST endospERM library Hordeum vulgare subsp.
DEFINITION vulgare cDNA clone BNEL89c2 5' similar to Unknown Function, mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

1. .46
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL71d8"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endospERM library"
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 40.4; DB 1; Length 46;
Best Local Similarity 97.6%; Pred. No. 4.7; Indels 0; Gaps 0;
Matches 41; Conservative 0; Mismatches 1;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACT 5066

1 (bases 1 to 46)
Ali, S. Holloway, B. and Taylor, W.C.
Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis
Plant Mol. Biol. Rep. 18, 123-132 (2000)
Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 46.

Location/Qualifiers
1. 46
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL71d8"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endospERM library"
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 40.4; DB 1; Length 46;
Best Local Similarity 97.6%; Pred. No. 4.7; Indels 0; Gaps 0;
Matches 41; Conservative 0; Mismatches 1;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACT 5066

Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATT 42

RESULT 9
CV063340 46 bp mRNA linear EST 24-AUG-2004
LOCUS BNEL89c2 Barley EST endospERM library Hordeum vulgare subsp.
DEFINITION vulgare cDNA clone BNEL89c2 5' similar to Unknown Function, mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

1. .46
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL71d8"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endospERM library"
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 40.4; DB 1; Length 46;
Best Local Similarity 97.6%; Pred. No. 4.7; Indels 0; Gaps 0;
Matches 41; Conservative 0; Mismatches 1;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACT 5066

Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATT 42

RESULT 9
CV063340 46 bp mRNA linear EST 24-AUG-2004
LOCUS BNEL89c2 Barley EST endospERM library Hordeum vulgare subsp.
DEFINITION vulgare cDNA clone BNEL89c2 5' similar to Unknown Function, mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

1. .46
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL71d8"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endospERM library"
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 40.4; DB 1; Length 46;
Best Local Similarity 97.6%; Pred. No. 4.7; Indels 0; Gaps 0;
Matches 41; Conservative 0; Mismatches 1;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACT 5066

FEATURES source Location/Qualifiers

1. 46 /organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL76g12"
/issue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa
(days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endospERM library"
/notes="vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.8%; Score 39.8; DB 1; Length 46;
Best Local Similarity 95.3%; Pred. No. 5.1;
Matches 41; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5025 AAACTC 5067
|||||
DB 2 AAAAAAAAAAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 44

RESULT 10
CW509332/c

LOCUS BGA334 BayGenomics Gene Trap Library pGTILxf Mus musculus cDNA,
DEFINITION mRNA sequence.

ACCESSION CW509332

VERSION CW509332.1 GI:53838837

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

AUTHORS 1 (bases 1 to 51)

TITLE BayGenomics.

JOURNAL http://baygenomics.ucsf.edu/
Unpublished (2001)

COMMENT Contact: BayGenomics
Bay Area Functional Genomics Consortium (BayGenomics)

Email: info@baygenomics.ucsf.edu

Sequence tag generated by 5' RACE of total RNA from gene trap ES

cell line. ES cell lines harboring insertion mutation of target

gene are available upon request from BayGenomics. Annotation

information available from

http://baygenomics.ucsf.edu/cgi-bin/BaySearch.py?OPTION=EXACT&TYPE=

CELL_LINEKEY=BGA334

Class: Gene Trap.

FEATURES Location/Qualifiers

1. 51 /organism="Mus musculus"

/mol_type="mRNA"

/strain="129 ola"

/db_xref="taxon:10090"

/sex="Male"

/cell_type="Embryonic stem cell"

/clone_lib="BayGenomics Gene Trap Library pGTILxf"

/notes="Vector: pGTILxf"

Query Match 0.8%; Score 39.6; DB 1; Length 51;

Best Local Similarity 91.3%; Pred. No. 5.5;

Matches 42; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 5031 AAACTCGAGGGGGG 5076

Db 46 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACCCCGGGGGGG 1

RESULT 11
CV062138

LOCUS BNEL76g12

DEFINITION Barley EST endospERM library Hordeum vulgare subsp.

sequence. cDNA clone BNEL76g12 5' similar to Unknown Function, mRNA

ACCESSION CV062138

VERSION CV062138.1 GI:51525277

KEYWORDS EST.

SOURCE Hordeum vulgare subsp. vulgare

ORGANISM Hordeum vulgare subsp. vulgare

REFERENCE Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

Poideae; Triticeae; Hordeum.

1 (bases 1 to 43)

AUTHORS Ali, S., Holloway, B. and Taylor, W.C.

TITLE Normalisation of cereal endospERM EST libraries for structural and

JOURNAL functional genomic analysis

COMMENT Contact: Bill Taylor

Commonwealth Scientific and Industrial Research Organisation

Division of Plant Industry.

CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia

Tel: 61 2 6246 5223

Fax: 61 2 6246 5000

Email: Bill.Taylor@csiro.au

Seq primer: M13 reverse primer

High quality sequence stop: 43.

FEATURES Location/Qualifiers

1. 43

/organism="Hordeum vulgare subsp. vulgare"

/mol_type="mRNA"

/cultivar="Himalaya"

/sub_species="vulgare"

/db_xref="taxon:112509"

/clone="BNEL76g12"

/issue_type="endospERM"

/dev_stage="developing endospERM tissue 10, 12, 15 dpa

(days post anthesis)"

/lab_host="DH10B (Life Technology)"

/clone_lib="Barley EST endospERM library"

/notes="vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA

was prepared from endospERM tissues of the barley cultivar

Himalaya. cDNA was synthesised from pooled 10, 12, and 15

dpa endospERM using Not I-oligo(dT)18 primer/adaptor

(Pharmacia Biotech), and then ligated to the Sal I-Not I

site of Ziplox vector (Life Technology) after adding a

Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan

Ali and Bill Taylor."

Query Match 0.8%; Score 39.4; DB 1; Length 43;

Best Local Similarity 97.6%; Pred. No. 5.1;

Matches 40; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5027 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTC 5067

DB 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 41

RESULT 12

CV062024

LOCUS BNEL75e2

DEFINITION Barley EST endospERM library Hordeum vulgare subsp.

vulgare cDNA clone BNEL75e2 5' similar to Unknown Function, mRNA

sequence.

ACCESSION CV062024

VERSION CV062024.1 GI:51525163

KEYWORDS EST.

SOURCE Hordeum vulgare subsp. vulgare

ORGANISM Hordeum vulgare subsp. vulgare
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Poideae; Triticeae; Hordeum.

REFERENCE 1 (bases 1 to 42)
AUTHORS Ali,S, Holloway,B. and Taylor,W.C.
TITLE Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)

COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry.
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223

Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 42.

FEATURES
source Location/Qualifiers

1..42
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL75e2"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa
(days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endospERM library"
/note="Vector: _Ziplox; Site 1: Sal I; Site 2: Not I; mRNA
was prepared from endospERM tissues of the Barley cultivar
Himalaya. cDNA was synthesised from pooled 10, 12, and 15
dpa endospERM using Not I-oligo(dT)18 primer/adaptor
(Pharmacia Biotech), and then ligated to the Sal I-Not I
site of Ziplox vector (Life Technology) after adding a
Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan
Ali and Bill Taylor."

Query Match 0.8%; Score 38.4; DB 1; Length 42;
Best Local Similarity 97.5%; Pred. No. 5.8;
Matches 39; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5028 AAACTC 5067
|||||
Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 40

RESULT 13
CV060361/c
LOCUS
DEFINITION CV060361 47 bp mRNA linear EST 24-AUG-2004
vulgare cDNA clone BNEL57c6 5' similar to Unknown Function, mRNA
sequence.

ACCESSION CV060361 GI:51523500
VERSION
KEYWORDS
SOURCE
ORGANISM Hordeum vulgare subsp. vulgare
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Poideae; Triticeae; Hordeum.

REFERENCE 1 (bases 1 to 47)
AUTHORS Ali,S, Holloway,B. and Taylor,W.C.
TITLE Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)

COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry.
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223

FEATURES
source Location/Qualifiers

1..47
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL57c6"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa
(days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endospERM library"
/note="Vector: _Ziplox; Site 1: Sal I; Site 2: Not I; mRNA
was prepared from endospERM tissues of the Barley cultivar
Himalaya. cDNA was synthesised from pooled 10, 12, and 15
dpa endospERM using Not I-oligo(dT)18 primer/adaptor
(Pharmacia Biotech), and then ligated to the Sal I-Not I
site of Ziplox vector (Life Technology) after adding a
Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan
Ali and Bill Taylor."

Query Match 0.7%; Score 36.6; DB 1; Length 47;
Best Local Similarity 90.7%; Pred. No. 7.8;
Matches 39; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 5031 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTCGAGGG 5073
|||||
Db 46 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTCCTCGCG 4

RESULT 14
CV060559/c
LOCUS
DEFINITION CV060559 47 bp mRNA linear EST 24-AUG-2004
vulgare cDNA clone BNEL59e10 5' similar to Unknown Function, mRNA
sequence.

ACCESSION CV060559 GI:51523698
VERSION
KEYWORDS
SOURCE
ORGANISM Hordeum vulgare subsp. vulgare
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Poideae; Triticeae; Hordeum.

REFERENCE 1 (bases 1 to 47)
AUTHORS Ali,S, Holloway,B. and Taylor,W.C.
TITLE Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)

COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry.
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 47.

FEATURES
source Location/Qualifiers

1..47
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="BNEL59e10"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 10, 12, 15 dpa

```

Matches 38; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
Qy 5026 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTC 5067
      |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 1 AAAAAAAAAATTTTAAAAAAAAAAAAAAAAAAAAAAAAAATTC 42

RESULT 16
CV055836/c
LOCUS CV055836 47 bp mRNA linear EST 24-AUG-2004
DEFINITION RNE112412 Barley EST endosome library Hordeum vulgare subsp.

```

vulgate cDNA clone BNE0124a12 3' terminal to unknown function, mRNA sequence.

ACCESSION	CV055836
VERSION	CV055836.1
KEYWORDS	GI:51518975
SOURCE	EST.
ORGANISM	Hordeum vulgare subsp. vulgare
	Hordeum vulgare subsp. vulgare
	Eukaryota: Viridiplantae: Streptophyta: Embryophyta: Tracheophyta:

REFERENCE	Footaceae; Iridaceae; nordeum.
AUTHORS	1 (bases 1 to 47) Ali, S., Holloway, B. and Taylor, W. C.
TITLE	Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis
JOURNAL	Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT	Contact: Bill Taylor

Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M3 reverse primer
Bill.Taylor@csiro.au

```

FEATURES
source
high quality sequence map: 47.
Location/Qualifiers
1. .47
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="ENEL124a12"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 10, 12, 15 dpa
(days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endosperm library"
/note="Vector: ZiploX; Site 1: Sal I; Site 2: Not I; mRNA

```

was prepared from endosperm tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endosperm using Not I-oligo(dT)₁₈ primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.7%; Score 35.6; DB 1; Length 47;
Best Local Similarity 90.5%; Pred. No. 8.9;
Matches 38; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 5031 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATCGAGGG 5072
|||||
DB 46 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTCCTGCG 5

RESULT 17
CV061673/c
LOCUS
DEFINITION BNEI70f11 Barley EST endosperm library Hordeum vulgare subsp.

ACCESSION CV061673

Thu Aug 18 09:13:58 2005

```

VERSION      CV061673.1  GI:51524812
KEYWORDS     EST.
SOURCE       Hordeum vulgare subsp. vulgare
ORGANISM     Hordeum vulgare subsp. vulgare
             Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
             Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
             Poideae; Triticeae; Hordeum.
REFERENCE    1 (bases 1 to 47)
AUTHORS      Ali,S, Holloway,B. and Taylor,W.C.
TITLE        Normalisation of cereal endosperm EST libraries for structural and
             functional genomic analysis
JOURNAL      Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT      Contact: Bill Taylor
             Commonwealth Scientific and Industrial Research Organisation
             Division of Plant Industry.
             CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
             Tel: 61 2 6246 5223
             Fax: 61 2 6246 5000
             Email: Bill.Taylor@csiro.au
             Seq primer: M13 reverse primer
             High quality sequence stop: 47.
FEATURES     Location/Qualifiers
             source
               1..47
               /organism="Hordeum vulgare subsp. vulgare"
               /mol_type="mRNA"
               /cultivar="Himalaya"
               /sub_species="vulgare"
               /db_xref="taxon:112509"
               /clone="BNEL70f11"
               /tissue_type="endosperm"
               /dev_stage="developing endosperm tissue 10, 12, 15 dpa
               (days post anthesis)"
               /lab_host="DH10B (Life Technology)"
               /clone_lib="Barley EST endosperm library"
               /note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA
               was prepared from endosperm tissues of the barley cultivar
               Himalaya. cDNA was synthesised from pooled 10, 12, and 15
               dpa endosperm using Not I-oligo(dT)18 primer/adaptor
               (Pharmacia Biotech), and then ligated to the Sal I-Not I
               site of Ziplox vector (Life Technology) after adding a
               Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan
               Ali and Bill Taylor."
             Query Match          0.7%; Score 35.6; DB 1; Length 47;
             Best Local Similarity 88.4%; Pred. No. 8.9;
             Matches 38; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY  5031 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTCGAGGG 5073
     |||||
Db   46 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTCCTGCGG 4

             Query Match          0.7%; Score 35.6; DB 1; Length 47;
             Best Local Similarity 88.4%; Pred. No. 8.9;
             Matches 38; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

RESULT 18
CV066153
LOCUS      WNEL30e11 Wheat EST endosperm library Triticum aestivum cDNA clone
DEFINITION WNEL30e11 5' similar to Unknown Function, mRNA sequence.
ACCESSION  CV066153
VERSION     CV066153.1  GI:51529330
KEYWORDS    EST.
SOURCE      Triticum aestivum (bread wheat)
ORGANISM    Triticum aestivum
             Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
             Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
             Poideae; Triticeae; Triticum.
REFERENCE    1 (bases 1 to 43)
AUTHORS      Ali,S, Holloway,B. and Taylor,W.C.
TITLE        Normalisation of cereal endosperm EST libraries for structural and
             functional genomic analysis
JOURNAL      Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT      Contact: Bill Taylor
             Commonwealth Scientific and Industrial Research Organisation
             Division of Plant Industry.
             CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
             Tel: 61 2 6246 5223
             Fax: 61 2 6246 5000
             Email: Bill.Taylor@csiro.au
             Seq primer: M13 reverse primer
             High quality sequence stop: 38.
FEATURES     Location/Qualifiers
             source
               1..38
               /organism="Triticum aestivum"
               /mol_type="mRNA"
               /cultivar="Hartog"
               /db_xref="taxon:4565"
               /clone="WNEL1498"
               /tissue_type="endosperm"
               /dev_stage="developing endosperm tissue 6, 8, 10 dpa (days
               post anthesis)"
               /lab_host="DH10B (Life Technology)"
               /clone_lib="Wheat EST endosperm library"
               /note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA
               was prepared from endosperm tissues of the wheat cultivar
               Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa
               endosperm using Not I-oligo(dT)18 primer/adaptor
               (Pharmacia Biotech), and then ligated to the Sal I-Not I
               site of Ziplox vector (Life Technology) after adding a
               Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan
               Ali and Bill Taylor."
             Query Match          0.7%; Score 34.8; DB 1; Length 43;
             Best Local Similarity 94.7%; Pred. No. 9.4;
             Matches 36; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  5023 GTAAAAA
     |||||
Db   1  GTAAATTA

```

```

CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 43.
FEATURES     Location/Qualifiers
             source
               1..43
               /organism="Triticum aestivum"
               /mol_type="mRNA"
               /cultivar="Hartog"
               /db_xref="taxon:4565"
               /clone="WNEL30e11"
               /tissue_type="endosperm"
               /dev_stage="developing endosperm tissue 6, 8, 10 dpa (days
               post anthesis)"
               /lab_host="DH10B (Life Technology)"
               /clone_lib="Wheat EST endosperm library"
               /note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA
               was prepared from endosperm tissues of the wheat cultivar
               Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa
               endosperm using Not I-oligo(dT)18 primer/adaptor
               (Pharmacia Biotech), and then ligated to the Sal I-Not I
               site of Ziplox vector (Life Technology) after adding a
               Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan
               Ali and Bill Taylor."
             Query Match          0.7%; Score 34.8; DB 1; Length 43;
             Best Local Similarity 94.7%; Pred. No. 9.4;
             Matches 36; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  5023 GTAAAAA
     |||||
Db   1  GTAAATTA

```

```

RESULT 19
CV064759
LOCUS      WNEL1498 Wheat EST endosperm library Triticum aestivum cDNA clone
DEFINITION WNEL1498 5' similar to Unknown Function, mRNA sequence.
ACCESSION  CV064759
VERSION     CV064759.1  GI:51527936
KEYWORDS    EST.
SOURCE      Triticum aestivum (bread wheat)
ORGANISM    Triticum aestivum
             Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
             Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
             Poideae; Triticeae; Triticum.
REFERENCE    1 (bases 1 to 38)
AUTHORS      Ali,S, Holloway,B. and Taylor,W.C.
TITLE        Normalisation of cereal endosperm EST libraries for structural and
             functional genomic analysis
JOURNAL      Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT      Contact: Bill Taylor
             Commonwealth Scientific and Industrial Research Organisation
             Division of Plant Industry.
             CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
             Tel: 61 2 6246 5223
             Fax: 61 2 6246 5000
             Email: Bill.Taylor@csiro.au
             Seq primer: M13 reverse primer
             High quality sequence stop: 38.
FEATURES     Location/Qualifiers
             source
               1..38
               /organism="Triticum aestivum"
               /mol_type="mRNA"
               /cultivar="Hartog"
               /db_xref="taxon:4565"
               /clone="WNEL1498"
               /tissue_type="endosperm"
               /dev_stage="developing endosperm tissue 6, 8, 10 dpa (days
               post anthesis)"

```

/lab_host="DH10B (Life Technology)"
 /clone_lib="Wheat EST endospERM library"
 /note="vector: ZipLox; Site_1: Sal I; Site_2: Not I; mRNA
 was prepared from endospERM tissues of the wheat cultivar
 Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa
 endospERM using Not I-oligo(dT)18 primer/adaptor
 (Pharmacia Biotech), and then ligated to the Sal I-Not I
 site of _zipLox vector (Life Technology) after adding a
 Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan
 Ali and Bill Taylor."

Query Match 0.7%; Score 34.4; DB 1; Length 38;
 Best Local Similarity 97.2%; Pred. No. 9.2; Indels 0; Gaps 0;
 Matches 35; Conservative 0; Mismatches 1;

QY 5032 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATC 5067
 |||||||
 Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATC 36

RESULT 20
 CR762707 40 bp mRNA linear EST 23-SEP-2004
 LOCUS DKFZp469F0617 r1 469 (synonym: pkid1) Pongo pygmaeus cDNA clone
 DEFINITION DKFZp469F0617_5', mRNA sequence.

ACCESSION CR762707.1 GI:52600068
 VERSION CR762707
 KEYWORDS EST.

SOURCE Pongo pygmaeus (orangutan)

ORGANISM

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.

AUTHORS

Ansoerge, W., Krieger, S., Regiert, T., Rittmueller, C., Schwager, B.,
 Mewes, H. W., Well, B., Amid, C., Oeanger, A., Fobo, G., Han, M. and
 Wiemann, S.

Pongo pygmaeus mRNA (Ansoerge, W., Krieger, S., Regiert, T., et al.)
 Unpublished (2004)
 Contact: MIPS

TITLE

JOURNAL This is the 5' sequence of the clone insert. Clone from S. Wiemann,
 COMMENT Molecular Genome Analysis, German Cancer Research Center (DKFZ);
 Email s.wiemann@dkfz-heidelberg.de; rlin, Germany. Please contact
 RZPD for ordering:
 http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp469F0617
 Further information about the clone and the sequencing project is
 available at http://mips.gsf.de/projects/cdna/.

FEATURES Location/Qualifiers

source

1. .40

/organism="Pongo pygmaeus"
 /mol_type="mRNA"
 /db_xref="taxon:9600"
 /clone="DKFZp469F0617"
 /dev_stage="adult"
 /tissue_type="kidney"
 /lab_host="DH10B"
 /clone_lib="469 (synonym: pkid1)"
 /note="vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match 0.7%; Score 34.4; DB 1; Length 40;
 Best Local Similarity 97.2%; Pred. No. 9.5;
 Matches 35; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5060
 |||||||
 Db 5 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 40

RESULT 21

CW509301/c

LOCUS

DEFINITION BGA402 BayGenomics Gene Trap Library pGTL1xf Mus musculus cDNA,
 42 bp mRNA linear GSS 06-OCT-2004

ACCESSION CW509301.1 GI:53838806
 VERSION GSS.
 KEYWORDS Mus musculus (house mouse)
 SOURCE Mus musculus

ORGANISM

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 BayGenomics.
 1 (bases 1 to 42)

AUTHORS

TITLE http://baygenomics.ucsf.edu/

JOURNAL Unpublished (2001)

COMMENT Contact: BayGenomics

Bay Area Functional Genomics Consortium (BayGenomics)

Email: info@baygenomics.ucsf.edu

Sequence tag generated by 5' RACE of total RNA from gene trap ES
 cell line. ES cell lines harboring insertion mutation of target
 gene are available upon request from BayGenomics. Annotation
 information available from

http://baygenomics.ucsf.edu/cgi-bin/BaySearch.py?OPTION=EXACT&TYPE=CELL_LINE&KEY=BGA402
 Class: Gene Trap.

FEATURES Location/Qualifiers

source

1. .42

/organism="Mus musculus"
 /mol_type="mRNA"
 /strain="129 ola"
 /db_xref="taxon:10090"
 /sex="Male"
 /cell_type="Embryonic stem cell"
 /clone_lib="BayGenomics Gene Trap Library pGTL1xf"
 /note="Vector: pGTL1xf"

Query Match 0.7%; Score 33.6; DB 1; Length 42;

Best Local Similarity 90.0%; Pred. No. 11;

Matches 36; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 5028 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATC 5067
 |||||||
 Db 42 AAAAAAAAAAGNAAAAACAAATAAAAAAAAAAAAAACCC 3

RESULT 22

CV064457

LOCUS

DEFINITION CV064457 Wheat EST endospERM library Triticum aestivum cDNA clone
 WNEL11b6 5' similar to Unknown Function, mRNA sequence.

ACCESSION CV064457.1 GI:51527634

VERSION CV064457

KEYWORDS EST.

SOURCE Triticum aestivum (bread wheat)

ORGANISM Triticum aestivum

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Poideae; Triticeae; Triticum.

REFERENCE 1 (bases 1 to 40)

AUTHORS Ali, S. Holloway, B. and Taylor, W. C.

TITLE Normalisation of cereal endospERM EST libraries for structural and
 functional genomic analysis

JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)

COMMENT Contact: Bill Taylor

Commonwealth Scientific and Industrial Research Organisation
 Division of Plant Industry.

CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
 Tel: 61 2 6246 5223

Fax: 61 2 6246 5000

Email: Bill.Taylor@csiro.au

Seq primer: M13 reverse primer

High quality sequence stop: 40.

FEATURES Location/Qualifiers

source

1. .40

/organism="Triticum aestivum"
 /mol_type="mRNA"

	/cultivar="Hartog"	
	/db_xref=taxon:4565"	
	/clones="WNE11b6"	
	/tissue_type="endospERM"	
	/dev_stage="developing endospERM tissue 6, 8, 10 dpa (days post anthesis)"	
	/lab_host="DH10B (Life Technology)"	
	/clone_lib="Wheat EST endospERM library"	
	/note=Vector; _zipLocx; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."	
Query Match	0.7%; Score 33.4; DB 1; Length 40;	
Best Local Similarity	97.1%; Pred. NO. 11;	
Matches 34; Conservative	0; Mismatches 1; Indels 0; Gaps 0;	
QY	5022 TGTATATAAAAAAAAAAAAAAAAAAAAAA 5056	
DB	1 TGTAGAAAAAAAAAAAAAAAAAAAAA 35	
RESULT 23		
CV054826		
LOCUS		
DEFINITION	CV054826 41 bp mRNA linear EST 24-AUG-2004 BNEL113g2 Barley EST endospERM library Hordeum vulgare subsp. vulgare cDNA clone BNEL113g2 5' similar to Unknown Function, mRNA sequence.	
ACCESSION	CV054826	
VERSION	GI:51517847	
KEYWORDS	EST.	
SOURCE	Hordeum vulgare subsp. vulgare	
ORGANISM	Hordeum vulgare subsp. vulgare Eukaryota; Viridiplantae; Streptophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Pooidae; Triticeae; Hordeum. 1 (bases 1 to 41)	
REFERENCE	Ali, S., Holloway, B. and Taylor, W.C. Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis Plant Mol. Biol. Rep. 18, 123-132 (2000)	
JOURNAL	Contact: Bill Taylor	
COMMENT	Commonwealth Scientific and Industrial Research Organisation Division of Plant Industry, CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia Tel: 61 2 6246 5223 Fax: 61 2 6246 5000 Email: Bill.Taylor@csiro.au Seq primer: M13 reverse primer High quality sequence stop: 41. Location/Qualifiers 1. .41 /organism="Hordeum vulgare subsp. vulgare" /mol_type="mRNA" /cultivar="Himalaya" /sub_species="vulgare" /db_xref="taxon:112509" /clones="BNEL113g2" /tissue_type="endospERM" /dev_stage="developing endospERM tissue 10, 12, 15 dpa (days post anthesis)" /lab_host="DH10B (Life Technology)" /clone_lib="Barley EST endospERM library" /note=Vector; _zipLocx; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a	
FEATURES		
source		

WNEJ322 5' similar to Unknown Function, mRNA sequence.
CV066327
VERSION CV066327.1 GI:51529504
KEYWORDS EST.
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae; Triticeae; Triticum.
1 (bases 1 to 35)
Ali, S., Holloway, B. and Taylor, W.C.
Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis.
Plant Mol. Biol. Rep. 18, 123-132 (2000)
Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry.
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 35.
Location/Qualifiers
1. .35
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/clone="WNEJ322"
/tissue_type="endospERM"
/dev_stages="developing endospERM tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endospERM library"
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.6%; Score 31.4; DB 1; Length 35;
Best Local Similarity 97.0%; Pred. No. 13;
Matches 32; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5035 AAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 5067
|||||
1 AAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 33

DB

RESULT 26
CV091545/c
LOCUS
DEFINITION NA112.R cDNA non acclimated Bluecrop library Vaccinium corymbosum cDNA 37, mRNA sequence.
ACCESSION CV091545
VERSION CV091545.1 GI:51570884
KEYWORDS EST.
SOURCE Vaccinium corymbosum
ORGANISM Vaccinium corymbosum

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids; Ericales; Ericaceae; Vaccinioideae; Vacciniaceae; Vaccinium.
1 (bases 1 to 36)
Dhanaraj, A.L., Alkharouf, N.W., Beard, H.S., Chouikha, I.B., Matthews, B.F. and Rowland, L.J.
Monitoring gene expression changes during cold acclimation of blueberry (Vaccinium corymbosum L.) using a cDNA microarray Unpublished (2004)

REFERENCE
AUTHORS
TITLE
JOURNAL

CV066327
VERSION CV066327.1 GI:51529504
KEYWORDS EST.
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae; Triticeae; Triticum.
1 (bases 1 to 35)
Ali, S., Holloway, B. and Taylor, W.C.
Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis.
Plant Mol. Biol. Rep. 18, 123-132 (2000)
Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry.
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 35.
Location/Qualifiers
1. .35
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/clone="WNEJ322"
/tissue_type="endospERM"
/dev_stages="developing endospERM tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endospERM library"
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.6%; Score 31.4; DB 1; Length 35;
Best Local Similarity 97.0%; Pred. No. 13;
Matches 32; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5035 AAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 5067
|||||
1 AAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 33

DB

RESULT 26
CV091545/c
LOCUS
DEFINITION NA112.R cDNA non acclimated Bluecrop library Vaccinium corymbosum cDNA 37, mRNA sequence.
ACCESSION CV091545
VERSION CV091545.1 GI:51570884
KEYWORDS EST.
SOURCE Vaccinium corymbosum
ORGANISM Vaccinium corymbosum

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids; Ericales; Ericaceae; Vaccinioideae; Vacciniaceae; Vaccinium.
1 (bases 1 to 36)
Dhanaraj, A.L., Alkharouf, N.W., Beard, H.S., Chouikha, I.B., Matthews, B.F. and Rowland, L.J.
Monitoring gene expression changes during cold acclimation of blueberry (Vaccinium corymbosum L.) using a cDNA microarray Unpublished (2004)

REFERENCE
AUTHORS
TITLE
JOURNAL

was prepared from endosperm tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.6%; Score 30.4; DB 1; Length 37;
Best Local Similarity 96.9%; Pred. No. 15; Indels 0; Gaps 0;
Matches 31; Conservative 0; Mismatches 1;

QY 5036 AAAAAAAAAAAAAAAAAAAAAAAAAAAAACTC 5067
Db 6 AAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 37

RESULT 28
LOCUS CW020481/c 30 bp mRNA linear GSS 28-SEP-2004
DEFINITION GC0748 TIGEM gene trap library Mus musculus cDNA clone A015.C10, mRNA sequence.

ACCESSION CW020481 GI:52789741
VERSION CW020481
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 30)
AUTHORS Cobellis,G., Nicolaus,G., Marra,E., Barbarisi,M., Sardiello,M., Di Giorgio,F.P., Iovino,N., Zollo,M., Ballabio,A. and Cortese,R.
TITLE Tagging genes with cassette-exchange sites
JOURNAL Unpublished (2004)
COMMENT Contact: TIGEM 107

FEATURES
source
1..30
/organism="Mus musculus"
/mol_type="mRNA"
/strain="129 Ola"
/db_xref="taxon:10090"
/clone="A015.C10"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/clone_lib="TIGEM gene trap library"
/note="Vector: pFLIPI"

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 14; Indels 0; Gaps 0;
Matches 30; Conservative 0; Mismatches 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5054
Db 30 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 29
LOCUS CV064432 35 bp mRNA linear EST 24-AUG-2004
DEFINITION WNEL10h12 Wheat EST endosperm library Triticum aestivum cDNA clone WNEL10h12 5' similar to Unknown Function, mRNA sequence.

ACCESSION CV064432
VERSION CV064432
KEYWORDS EST.
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum

ACCESSION CV064432
VERSION CV064432.1 GI:51527609
KEYWORDS EST.
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum

REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae; Triticeae; Triticum. 1 (bases 1 to 35)

AUTHORS Ali,S, Holloway,B. and Taylor,W.C.
TITLE Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry,
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 35.
Location/Qualifiers
1..35
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/clone="WNEL10h12"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endosperm library"
/note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

QY 5035 AAAAAAAAAAAAAAAAAAAAAAAAAAAAACTC 5067
Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 33

RESULT 30
LOCUS CV057897
DEFINITION BNEL32a8 Barley EST endosperm library Hordeum vulgare subsp. vulgare cDNA clone BNEL32a8 5' similar to Unknown Function, mRNA sequence.

ACCESSION CV057897
VERSION CV057897.1 GI:51521036
KEYWORDS EST.
SOURCE Hordeum vulgare subsp. vulgare
ORGANISM Hordeum vulgare subsp. vulgare

REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae; Triticeae; Hordeum. 1 (bases 1 to 31)

AUTHORS Ali,S, Holloway,B. and Taylor,W.C.
TITLE Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation

Query Match 0.6%; Score 29.8; DB 1; Length 35;
Best Local Similarity 93.9%; Pred. No. 16; Indels 0; Gaps 0;
Matches 31; Conservative 0; Mismatches 2;

Division of Plant Industry,
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 31.
Location/Qualifiers

FEATURES

source

1. .31

/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clone="ENEL32a8"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 10, 12, 15 dpa
(days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endosperm library"
/notes="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA
was prepared from endosperm tissues of the barley cultivar
Himalaya. cDNA was synthesised from pooled 10, 12, and 15
dpa endosperm using Not I-oligo(dT)18 primer/adaptor
(Pharmacia Biotech), and then ligated to the Sal I-Not I
site of ZipLox vector (Life Technology) after adding a
Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan
Ali and Bill Taylor."

Query Match 0.68; Score 29.4; DB 1; Length 31;
Best Local Similarity 96.8; Pred. No. 16;
Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5037 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 5067

|||||

Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 31

RESULT 31

CF305592

LOCUS

DEFINITION

CF305592 28 bp mRNA linear EST 15-AUG-2003
HDAL-01-C11.g1 OsHDAC1-overexpressing transgenic rice lambda phage
cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL-01-C11, mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE

AUTHORS

Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

TITLE

JOURNAL

COMMENT

Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1. .28

/organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:39947"

/clone="HDAL-01-C11"

/tissue_type="callus"

/dev_stage="proliferated callus on 2N6 media for 2 weeks"

/lab_host="E.coli SOLR"

/clone_lib="OsHDAC1-overexpressing transgenic rice lambda
phage cDNA library I (HDAL)"

/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

Query Match

Best Local Similarity

Matches

27; Conservative

0; Mismatches

0; Indels

0; Gaps

0;

QY

Db

7

1

CCCCGGCTGCAGGAATTCGACGAGG 33

|||||

Db

1

CCCCGGCTGCAGGAATTCGACGAGG 27

|||||

Db

32

R38731/c

LOCUS

DEFINITION

R38731

33 bp mRNA linear

EST 04-MAY-1995

IMAGE:24658 3' similar to gb:A18658 INSULIN RECEPTOR PRECURSOR

(HUMAN); mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Homo sapiens (human)

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 33)

Hillier, L., Clark, N., Dubouque, T., Elliston, K., Hawkins, M.,

Hollman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M.,

Parsons, J., Rifkin, L., Rohlfsing, T., Soares, M., Tan, P.,

Trevaskis, E., Waterston, R., Williamson, A., Woldmann, P. and

Wilson, R.

The WashU-Merck EST Project

Unpublished (1995)

Contact: Wilson RK

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@watson.wustl.edu

Insert Size: 2331

High quality sequence starts: 1 High quality sequence stops: 1

Source: IMAGE Consortium, LNL This clone is available royalty-free

through LNL; contact the IMAGE Consortium (info@image.llnl.gov)

for further information. Trace considered overall poor quality

Insert Length: 2331 Std Error: 0.00

Seq primer: -21m13

High quality sequence stop: 1.

Location/Qualifiers

1. .33

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="GDB:397005"

/db_xref="taxon:9606"

/clone="IMAGE:24658"

/sex="female"

/dev_stage="73 days post natal"

/lab_host="DH10B (ampicillin resistant)"

/clone_lib="Soares infant brain LNUB"

/notes="Organ: whole brain; vector: Lafmid BA; Site 1: Not

I; Site 2: Hind III; 1st strand cDNA was primed with a Not

I - oligo(dT) primer [5'

AACTGGAGATTCGCGCGGAGGAATTTTTCCTTTT 3'];

double-stranded cDNA was ligated to Hind III adaptors

(Pharmacia), digested with Not I and directionally cloned

into the Not I and Hind III sites of the Lafmid BA vector.

Library went through one round of normalization. Library

constructed by Bento Soares and M.Patima Bonaudo."

Query Match 0.5%; Score 25; DB 1; Length 33;
 Best Local Similarity 84.8%; Pred. No. 28;
 Matches 28; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5057
 DB 33 AAAAAAAAAAAAAAAAAAGAAAGAAAGAAAGAAATA 1

RESULT 33
 CV066570 31 bp mRNA linear EST 24-AUG-2004
 LOCUS WNEL5f11 Wheat EST endosperm library Triticum aestivum cDNA clone
 DEFINITION WNEL5f11 5' similar to Unknown Function, mRNA sequence.

ACCESSION CV066570
 VERSION CV066570.1 GI:51529747
 SOURCE EST.
 ORGANISM Triticum aestivum (bread wheat)

REFERENCE
 AUTHORS Ali, S., Holloway, B. and Taylor, W. C.
 TITLE Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis
 JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)
 COMMENT Contact: Bill Taylor
 Commonwealth Scientific and Industrial Research Organisation
 Division of Plant Industry,
 CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
 Tel: 61 2 6246 5223
 Fax: 61 2 6246 5000
 Email: Bill.Taylor@csiro.au
 Seq primer: M13 reverse primer
 High quality sequence stop: 31.
 Location/Qualifiers
 1. .31
 /organism="Triticum aestivum"
 /mol_type="mRNA"
 /cultivar="Hartog"
 /db_xref="taxon:4565"
 /clone="WNEL5f11"
 /tissue_type="endosperm"
 /dev_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"
 /lab_host="DH10B (Life Technology)"
 /note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.5%; Score 24.8; DB 1; Length 31;
 Best Local Similarity 92.9%; Pred. No. 28;
 Matches 26; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5040 AAAAAAAAAAAAAAAAAAAAAAAAAAACTC 5067
 DB 2 AAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 29

RESULT 34
 A1153615 31 bp mRNA linear EST 30-SEP-1998
 LOCUS WZ89f11.r1 Soares thymus 2NbMT Mus musculus cDNA clone
 DEFINITION IMAGE:1344429 5' similar to TR:Q99570 Q99570 ADAPTOR PROTEIN. ; mRNA sequence.

ACCESSION A1153615
 VERSION A1153615.1 GI:3682084
 KEYWORDS Mus musculus (house mouse)
 SOURCE EST.
 ORGANISM Mus musculus

REFERENCE
 AUTHORS Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.
 TITLE The WashU-HMI Mouse EST Project
 JOURNAL Unpublished (1996)
 COMMENT Contact: Marra M/Mouse EST Project
 WashU-HMI Mouse EST Project
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: mouseest@watson.wustl.edu
 This clone is available royalty-free through LfNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
 MGI:693221

FEATURES
 source
 1. .31
 /organism="Mus musculus"
 /mol_type="mRNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="IMAGE:1344429"
 /sex="male"
 /tissue_type="Thymus"
 /dev_stage="4 weeks"
 /lab_host="DH10B"
 /note="Vector: pT7T3D-pac (Pharmacia) with a modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5' GTTACCATCTGAGTGGGAGCGCGGTTTTTTTTTTTTTTTTTTT 3']; double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT7T3 vector. RNA provided by Dr. Bertrand Jordan. Library went through two rounds of normalization, and was constructed by Bento Soares and M.Fatima Bonaldo."

Query Match 0.5%; Score 24.6; DB 1; Length 31;
 Best Local Similarity 87.1%; Pred. No. 29;
 Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 4068 TTGGGACATCAGGTTCCAGTTGCCAATTTC 4098
 DB 1 TTGGGACATCAGGTTCCAGTTGCCATCTCA 31

RESULT 35
 BW588370/c 31 bp mRNA linear EST 01-SEP-2004
 LOCUS BW588370 Yutaka Satou unpublished cDNA library (csefi) Ciona
 DEFINITION savignyi cDNA clone csef003122 5', mRNA sequence.

ACCESSION BW588370
 VERSION BW588370.1 GI:51839170
 SOURCE EST.
 KEYWORDS Ciona savignyi
 ORGANISM Ciona savignyi
 Eukaryota; Metazoa; Chordata; Urochordata; Ascidiacea; Enterogona; Phlebobranchia; Cionidae; Ciona.

```

REFERENCE
AUTHORS      Satou, Y., Shin-i, T., Kohara, Y. and Satoh, N.
TITLE        Expressed genes in Ciona savignyi (Satou, Shin-i, Kohara, Satoh)
JOURNAL      Unpublished (2004)
COMMENT      Contact: Yutaka Satou
              Department of Zoology
              Kyoto University
              Sakyo-ku, Kyoto, Kyoto 606-8502, Japan
              Tel: 81-75-753-4095
              Fax: 81-75-705-1113
              Email: yutaka@scidian.zool.kyoto-u.ac.jp.

FEATURES
source
1..31
/organism="Ciona savignyi"
/mol_type="mRNA"
/db_xref="taxon:51511"
/clone="ceef003122"
/dev_stage="egg"
/clone_lib="Yutaka Satou unpublished cDNA library (ceef1)"

Query Match      0.5%; Score 24.4; DB 1; Length 31;
Best Local Similarity 96.2%; Pred. No. 29;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5045 AAAAAAAAAAAAAAAAAAACTCGAG 5070
Db 29 AAAAAAAAAAAAAAAAAAACTCGAG 4

RESULT 36
LOCUS      CW020478/c
DEFINITION CW020478 TIGEM gene trap library Mus musculus cDNA clone A015.B4, mRNA sequence.
ACCESSION  CW020478
VERSION     CW020478.1 GI:52789738
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1 (bases 1 to 26)
AUTHORS     Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.
TITLE       Tagging genes with cassette-exchange sites
JOURNAL     Unpublished (2004)
COMMENT     Contact: TIGEM
107
TIGEM
Via P. Castellino, 111, 80131 NAPOLI, ITALY
Tel: +390816132205
Fax: +390815790919
Email: cobellis@tigem.it
Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM
Class: Gene Trap.
Location/Qualifiers
1..26
/organism="Mus musculus"
/mol_type="mRNA"
/strain="129 ola"
/db_xref="taxon:10090"
/clone="A015.B4"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/clone_lib="TIGEM gene trap library"
/note="Vector: pFLIP1"

Query Match      0.4%; Score 22.8; DB 1; Length 26;
Best Local Similarity 92.3%; Pred. No. 33;

REFERENCE
AUTHORS      Satou, Y., Shin-i, T., Kohara, Y. and Satoh, N.
TITLE        Expressed genes in Ciona savignyi (Satou, Shin-i, Kohara, Satoh)
JOURNAL      Unpublished (2004)
COMMENT      Contact: Yutaka Satou
              Department of Zoology
              Kyoto University
              Sakyo-ku, Kyoto, Kyoto 606-8502, Japan
              Tel: 81-75-753-4095
              Fax: 81-75-705-1113
              Email: yutaka@scidian.zool.kyoto-u.ac.jp.

FEATURES
source
1..31
/organism="Ciona savignyi"
/mol_type="mRNA"
/db_xref="taxon:51511"
/clone="ceef003122"
/dev_stage="egg"
/clone_lib="Yutaka Satou unpublished cDNA library (ceef1)"

Query Match      0.5%; Score 24.4; DB 1; Length 31;
Best Local Similarity 96.2%; Pred. No. 29;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5045 AAAAAAAAAAAAAAAAAAACTCGAG 5070
Db 29 AAAAAAAAAAAAAAAAAAACTCGAG 4

RESULT 36
LOCUS      CW020478/c
DEFINITION CW020478 TIGEM gene trap library Mus musculus cDNA clone A015.B4, mRNA sequence.
ACCESSION  CW020478
VERSION     CW020478.1 GI:52789738
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1 (bases 1 to 26)
AUTHORS     Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.
TITLE       Tagging genes with cassette-exchange sites
JOURNAL     Unpublished (2004)
COMMENT     Contact: TIGEM
107
TIGEM
Via P. Castellino, 111, 80131 NAPOLI, ITALY
Tel: +390816132205
Fax: +390815790919
Email: cobellis@tigem.it
Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM
Class: Gene Trap.
Location/Qualifiers
1..26
/organism="Mus musculus"
/mol_type="mRNA"
/strain="129 ola"
/db_xref="taxon:10090"
/clone="A015.B4"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/clone_lib="TIGEM gene trap library"
/note="Vector: pFLIP1"

Query Match      0.4%; Score 22.8; DB 1; Length 26;
Best Local Similarity 92.3%; Pred. No. 33;

```

```

Matches 24; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5024 TAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5049
Db 26 TAACAATAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 37
LOCUS      CV091538/c
DEFINITION CV091538 R cDNA non-acclimated Bluecrop library Vaccinium corymbosum cDNA 37, mRNA sequence.
ACCESSION  CV091538
VERSION     CV091538.1 GI:51570877
KEYWORDS    EST.
SOURCE      Vaccinium corymbosum
ORGANISM    Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids; Ericales; Ericaceae; Vaccinioideae; Vaccinieae; Vaccinium.
REFERENCE   1 (bases 1 to 28)
AUTHORS     Dhanaraj, A.L., Alkharouf, N.W., Beard, H.S., Chouikha, I.B., Matthews, B.F. and Rowland, L.J.
TITLE       Monitoring gene expression changes during cold acclimation of blueberry (Vaccinium corymbosum L.) using a cDNA microarray
JOURNAL     Unpublished (2004)
COMMENT     Contact: Rowland, L.J.
              Fruit Lab
              US Department of Agriculture (USDA), ARS, PSI
              Bldg 010A, 10300 Baltimore avenue, BARC West, Beltsville, MD
              20705-2350, USA
              Tel: 301-504-6654
              Fax: 301-504-5653
              Email: rowlandj@ba.ars.ueda.gov.

FEATURES
source
1..28
/organism="Vaccinium corymbosum"
/mol_type="mRNA"
/cultivar="Bluecrop"
/db_xref="taxon:69266"
/tissue_type="Flower buds including bud scales"
/dev_stage="Mature plants"
/clone_lib="cDNA non acclimated Bluecrop library"
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium corymbosum cv. Bluecrop. RNA for preparation of library was extracted from flower buds collected in the fall from non acclimated plants"

Query Match      0.4%; Score 22.8; DB 1; Length 28;
Best Local Similarity 85.7%; Pred. No. 34;
Matches 24; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5052
Db 28 ANAAAAAGTNAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 38
LOCUS      CV065010
DEFINITION WNE118a9 Wheat EST endosperm library Triticum aestivum cDNA clone WNE118a9 5', similar to Unknown Function, mRNA sequence.
ACCESSION  CV065010
VERSION     CV065010.1 GI:51528187
KEYWORDS    EST.
SOURCE      Triticum aestivum (bread wheat)
ORGANISM    Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae; Triticeae; Triticum.
REFERENCE   1 (bases 1 to 28)
AUTHORS     Ali, S., Holloway, B. and Taylor, W.C.

```

Thu Aug 18 09:13:58 2005

TITLE Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry,
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 28.
Location/Qualifiers
1. .28
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/clone="WNE118a9"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endosperm library"
/note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.4%; Score 21.4; DB 1; Length 28;
Best Local Similarity 95.7%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5022 TGTAAGAAAAAAGAAAAAAGAAAAA 5044
DB 1 TCTAAGAAAAAAGAAAAAAGAAAAA 23

RESULT 39
CF305590
LOCUS HDAL-01-C09.g1 OshDACL-overexpressing transgenic rice lambda phage
DEFINITION cDNA library 1 (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL-01-C09, mRNA sequence.
ACCESSION CF305590
VERSION CF305590.1 GI:33677351
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Eriophytidae; Oryzaceae; Oryza.
1 (bases 1 to 20)
Kim.J.S., Jun.K.M., Cheong,P.J., Kim.M.J., Lee.T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.
Location/Qualifiers
1. .20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"

/db_xref="taxon:39947"
/clone="HDAL-01-C09"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OshDACL-overexpressing transgenic rice lambda phage cDNA library 1 (HDAL)"
/note="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2: XhoI; Callus was treated with ABA(20um) for 1hour. cDNA was inserted into lambda Uni-ZAP XR vector at 5' end with EcoRI and 3' end with XhoI site. mRNA was derived from rice Histone Deacetylase overexpression line."
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 GGCTGCAGGAATTCGGCAGC 30
DB 1 GGCTGCAGGAATTCGGCAGC 20

RESULT 40
CV064628
LOCUS WNE113b6 Wheat EST endosperm library Triticum aestivum cDNA clone
DEFINITION WNE113b6 5' similar to Unknown Function, mRNA sequence.
ACCESSION CV064628
VERSION CV064628.1 GI:51527805
KEYWORDS EST.
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae; Triticeae; Triticum.
1 (bases 1 to 23)
Ali,S., Holloway,B. and Taylor,W.C.
Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis
Plant Mol. Biol. Rep. 18, 123-132 (2000)
Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry,
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 23.
Location/Qualifiers
1. .23
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/clone="WNE113b6"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="Wheat EST endosperm library"
/note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.4%; Score 19.4; DB 1; Length 23;
Best Local Similarity 95.2%; Pred. No. 47;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5047 AAAAAAAAAAAAAAAAAAACTC 5067
 Db 1 AAAAAAAAAAAAAAAAAAACTC 21

RESULT 41

CV066488 23 bp mRNA linear EST 24-AUG-2004
 LOCUS WNEL4e6 Wheat EST endospERM library Triticum aestivum cDNA clone
 DEFINITION WNEL4e6 5' similar to Unknown Function, mRNA sequence.
 ACCESSION CV066488
 VERSION WNEL4e6.1 GI:51529665
 KEYWORDS EST.
 SOURCE Triticum aestivum (bread wheat)
 ORGANISM Triticum aestivum

REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 AUTHORS Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 TITLE Poideae; Triticeae; Triticum.
 JOURNAL 1. (bases 1 to 23)

COMMENT Ali, S., Holloway, B. and Taylor, W.C.
 Functional genomic analysis
 Normalisation of cereal endospERM EST libraries for structural and
 Plant Mol. Biol. Rep. 18, 123-132 (2000)

CONTACT: Bill Taylor
 Commonwealth Scientific and Industrial Research Organisation
 Division of Plant Industry.
 CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
 Tel: 61 2 6246 5223
 Fax: 61 2 6246 5000
 Email: Bill.Taylor@csiro.au
 Seq primer: M13 reverse primer
 High quality sequence stop: 23.

FEATURES

source 1. .23

/organism="Triticum aestivum"
 /mol_type="mRNA"
 /cultivar="Hartog"
 /db_xref="taxon:4565"
 /clone="WNEL4e6"
 /tissue_type="endospERM"
 /dev_stage="developing endospERM tissue 6, 8, 10 dpa (days post anthesis)"
 /lab_host="DH10B (Life Technology)"
 /clone_lib="Wheat EST endospERM library"
 /notes="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 0.4%; Score 19.4; DB 1; Length 23;
 Best Local Similarity 95.2%; Pred. No. 47;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5047 AAAAAAAAAAAAAAAAAAACTC 5067
 Db 1 AAAAAAAAAAAAAAAAAAACTC 21

RESULT 42

AZ308225/c 24 bp DNA linear GSS 29-SEP-2000
 LOCUS IM0011E06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 DEFINITION clone UUGC1M0011E06 F, genomic survey sequence.
 ACCESSION AZ308225
 VERSION AZ308225.1 GI:10348004
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1. (bases 1 to 24)

AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
 Reilly, M., Rose, M., Stokes, R., Tingey, A., von
 Niederhausern, A. and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 Unpublished (2000)

COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: dunn@genetics.utah.edu

Insert length: 10000 Std Error: 0.00

Plate: 0011 row: E column: 06

Seq primer: CGTGTAAACACGACGCCAGT

Class: plasmid ends

High quality sequence stop: 24.

FEATURES

source 1. .24

/organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0011E06"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, Ti-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 49;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5043 AAAAAAAAAAAAAAAAAAACT 5066
 Db 24 AAAAAAAAAACAAACAAACAAACT 1

RESULT 43

AZ814559/c 24 bp DNA linear GSS 20-FEB-2001
 LOCUS 2M0082P18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 DEFINITION clone UUGC2M0082P18 F, genomic survey sequence.
 ACCESSION AZ814559
 VERSION AZ814559.1 GI:12984467
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE AUTHORS	1 (bases 1 to 24) Hall, N., Bowman, S., Lennard, N. J., Doggett, J., Atkin, R., Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L., Melville, S. E., Rajandream, M. A. and Barrell, B. G.
TITLE JOURNAL	Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and nh@sanger.ac.uk
COMMENT	Constructed at the Institute for Genomic Research (TIGR), Rockville, MD. Genomic DNA isolated from a cloned population of Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared to give a tight size distribution (4 kb). The v + i method used for the library construction is described in detail in Smith, H. and Venter, J. C. (Making small insert libraries for whole genome shotgun sequencing projects. In Genome Sequencing: A Practical Approach, eds. M. Vaudin and B. Barrell, Oxford University Press, 1999). Email: nelsayed@tigr.org Details of T. brucei sequencing at the Sanger Centre are available at http://www.sanger.ac.uk/Projects/T_brucei/ .
FEATURES source	1..24 Location/Qualifiers /organism="Trypanosoma brucei" /mol_type="genomic DNA" /strain="TREU927" /db_xref="taxon:5691" /clone="250e05"
Query Match	0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity	87.5%; Pred. No. 49;
Matches	21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	3462 GGAAATGCTGAATCGGAGAGTAA 3485
Db	1 GGAAATGCGAATCGAGTGTA 24
RESULT 45	
AZ827015/c	
LOCUS	2M103J11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION	clone UUGC2M0103J11 F, genomic survey sequence.
ACCESSION	AZ827015
VERSION	AZ827015.1 GI:12996923
KEYWORDS	GSS.
SOURCE	Mus musculus (house mouse)
ORGANISM	Mus musculus
REFERENCE AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 24) Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D. Weiss, R. Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts Unpublished (2000)
TITLE	Unpublished (2000)
JOURNAL	Contact: Robert B. Weiss
COMMENT	University of Utah Genome Center Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0082 row: P column: 18 Seq primer: CGTTGTAACGACGCCAGT Class: plasmid ends High quality sequence stop: 24. Location/Qualifiers 1..24 /organism="Mus musculus" /mol_type="genomic DNA" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="UUGC2M0082P18" /sex="Male" /lab_host="E. Coli strain XL10-Gold, Ti-resistant, F-" /clone_lib="Mouse 10kb plasmid UUGC1M library" /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gi 4732114 gb AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
Query Match	0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity	87.5%; Pred. No. 49;
Matches	21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db	24 AAAAAAAAAAGAAAAAGAAAAA 1
RESULT 44	
TA250E05P	
LOCUS	T. brucei sheared genomic DNA clone 250e05, forward sequence,
DEFINITION	genomic survey sequence.
ACCESSION	AL483684
VERSION	AL483684.1 GI:11849145
KEYWORDS	GSS.
SOURCE	Trypanosoma brucei
ORGANISM	Trypanosoma brucei Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.


```

/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0103J11"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match      0.4%; Score 18.8; DB 1; Length 24;
Best Local Similarity 90.9%; Pred. No. 51;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 5045 AAAAAAAAAAAAAAAAAAACT 5066
Db 24 AAAAAAAAAACAAAAAAACT 3

RESULT 46
CF306449
LOCUS
DEFINITION
HDAL--03-002.g1 OshDAC1-overexpressing transgenic rice lambda phage cDNA library 1 (HDAL) Oryza sativa (japonica cultivar-group) cDNA
CF306449
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE
1 (bases 1 to 19)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhnm@gbio.com, bnhnm@bio.myongji.ac.kr.
Location/Qualifiers
1..19
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAL--03-002"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"

```

```

/clone_lib="OshDAC1-overexpressing transgenic rice lambda phage cDNA library 1 (HDAL)"
/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2: XhoI; Callus was treated with ABA(20um) for 1hour. cDNA was inserted into lambda Uni-ZAP XR vector at 5' end with EcoRI and 3' end with XhoI site. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match      0.4%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 51;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGGCTGCAG 18
Db 2 GGATCCCCCGGGCTGCAG 19

RESULT 47
AZ597932/c
LOCUS
DEFINITION
1M0412D23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0412D23 F, genomic survey sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 21)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiser,R.
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0412 row: D column: 23
Seq primer: CGTGTAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 21.
Location/Qualifiers
1..21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0412D23"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

```

Thu Aug 18 09:13:58 2005

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 54;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5045
||||| ||||| ||||| |||||
Db 21 AAAAAAAAAAGAAAGAAAGAAA 1

RESULT 48
CF303019 19 bp mRNA linear EST 15-AUG-2003
LOCUS
DEFINITION
ABF1--01-B20. g1 ABF3-overexpressing transgenic rice lambda phage
cDNA library (ABF1) Oryza sativa (japonica cultivar-group) cDNA
clone ABF1--01-B20, mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

1 (bases 1 to 19)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1..19
Location/Qualifiers
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="ABF1--01-B20"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli SOLR"
/clone_lib="ABF3-overexpressing transgenic rice lambda
phage cDNA library (ABF1)"
/note="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Leaf was dried for 2hrs. cDNA was inserted into
lambda Uni-ZAP XR vector at 5' end with EcoRI and 3' end
with XhoI site. mRNA was prepared from ABA-responsive
element binding transcription factor 3 overexpression
line."

Query Match 0.3%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGATCCCCCGGCTGCA 17
||||| ||||| ||||| |||||
Db 3 GGATCCCCCGGCTGCA 19

RESULT 49
COS78459 19 bp mRNA linear EST 20-JUL-2004
LOCUS

DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

TVEST093E02 Tv30236_PT cDNA Library Trichomonas vaginalis cDNA 5',
mRNA sequence.
COS78459 18 bp mRNA linear EST 07-OCT-2004
COS78459.1 GI:50409027
EST.
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

Trichomonas vaginalis
Trichomonas vaginalis
Trichomonas vaginalis
Trichomonadidae; Trichomonadinae; Trichomonas.
1 (bases 1 to 19)
Zhou, Y., Shu, W.M., Huang, S.C.C., Huang, K.Y. and Tang, P.
Analysis of Gene Expression Profile in Trichomonas vaginalis by EST
Sequencing
Unpublished (2003)
Contact: Tang, P.
Molecular Regulation and Bioinformatics Laboratory, College of
Medicine
Chang Gung University
259 Wenhu 1st. Road, Kweihsan, Taoyuan 333, Taiwan
Tel: +886 3 3283016 EXT5136
Fax: +886 3 3283031
Email: petang@mail.cgu.edu.tw
PCR Primers
FORWARD: T7
BACKWARD: T3
Seq primer: T3.
Location/Qualifiers
1..19
/organism="Trichomonas vaginalis"
/mol_type="mRNA"
/db_xref="taxon:5722"
/cell_line="ATCC30236"
/dev_stage="Trophozoites at mid-log phase"
/lab_host="XL1 Blue-MRF"
/clone_lib="Tv30236_PT cDNA Library"
/note="Vector: Lambda ZAP-Express (Stratagene); Site_1:
EcoRI; Site_2: XhoI"

FEATURES
source

Query Match 0.3%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 GAATTCGGCAGCGAGGGG 35
||||| ||||| ||||| |||||
Db 2 GAATTCGGCAGCGAGGGG 18

RESULT 50
AJ725584
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

AJ725584 riken1 Gallus gallus cDNA clone 2c16r4, mRNA sequence.
AJ725584
AJ725584.1 GI:53890998
EST.
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS

Gallus gallus (chicken)
Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 18)
Caldwell, R.B., Kierzek, A.M., Arakawa, H., Bezzubov, Y., Zaim, J.,
Fiedler, P., Kutter, S., Blagodatki, A., Kostovska, D., Koter, M.,
Plachy, J., Carninci, P., Hayaishizaki, Y. and Buerstedde, J.M.
Full-length cDNAs from bursal lymphocytes to facilitate gene
function analysis
Unpublished (2004)
Contact: Caldwell RB
GSF - Forschungszentrum, Institut fuer Molekulare Strahlenbiologie
Ingolstaedter Landstr. 1, D-85764 Neuherberg, GERMANY.

TITLE
JOURNAL
COMMENT
FEATURES
source

1..18
/organism="Gallus gallus"
/mol_type="mRNA"

```

/db_xref="taxon:9031"
/clones="2c16r4"
/cell_type="bursal lymphocyte"
/dev_stage="2-3 weeks old"
/clone_lib="riken1"
/notes="CB inbred strain"

Query Match      0.3%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 60;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5024 TAAAAAAAAAAAAAAAAA 5041
Db 1 TCAAAAAAAAAAAAAAAAAA 18

RESULT 51
LOCUS CR786637 18 bp mRNA linear EST 01-OCT-2004
DEFINITION DKFZp468J2331_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
CR786637
CR786637.1 GI:53705634
EST.
Pongo pygmaeus (orangutan)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
REFERENCE 1 (bases 1 to 18)
AUTHORS Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
Fobo,G., Han,M. and Wiemann,S.
Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
Unpublished (2004)
Contact: MIPS
MIPS
Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468J2331
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.
Location/Qualifiers
1..18
/organism="Pongo pygmaeus"
/mol_type="mRNA"
/db_xref="taxon:9600"
/clone="DKFZp468J2331"
/dev_stage="heart"
/tissue_type="adult"
/lab_host="DH10B"
/clone_lib="468 (synonym: phrt1)"
/notes="Vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match      0.3%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 60;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 1 AAAAAAAAAAAAAAAAAA 18

RESULT 52
AJ679356/c
LOCUS AJ679356 16 bp mRNA linear EST 29-JUN-2004
DEFINITION AJ679356 KN224 Bos taurus cDNA clone KN227-028_N23, mRNA sequence.
ACCESSION AJ679356
VERSION AJ679356.1 GI:49411943
KEYWORDS EST.
SOURCE Bos taurus (cow)
ORGANISM Bos taurus

/db_xref="taxon:9031"
/clones="2c16r4"
/cell_type="bursal lymphocyte"
/dev_stage="2-3 weeks old"
/clone_lib="riken1"
/notes="CB inbred strain"

Query Match      0.3%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 60;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5024 TAAAAAAAAAAAAAAAAA 5041
Db 1 TCAAAAAAAAAAAAAAAAAA 18

RESULT 51
LOCUS CR786637 18 bp mRNA linear EST 01-OCT-2004
DEFINITION DKFZp468J2331_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
CR786637
CR786637.1 GI:53705634
EST.
Pongo pygmaeus (orangutan)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
REFERENCE 1 (bases 1 to 18)
AUTHORS Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
Fobo,G., Han,M. and Wiemann,S.
Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
Unpublished (2004)
Contact: MIPS
MIPS
Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468J2331
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.
Location/Qualifiers
1..18
/organism="Pongo pygmaeus"
/mol_type="mRNA"
/db_xref="taxon:9600"
/clone="DKFZp468J2331"
/dev_stage="heart"
/tissue_type="adult"
/lab_host="DH10B"
/clone_lib="468 (synonym: phrt1)"
/notes="Vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match      0.3%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 60;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 ATCCCCCGGCTGCAG 18
Db 16 ATCCCCCGGCTGCAG 1

RESULT 53
CR786853 16 bp mRNA linear EST 01-OCT-2004
LOCUS DKFZp468E2231_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
DEFINITION DKFZp468E2231_5', mRNA sequence.
CR786853
CR786853.1 GI:53705850
EST.
Pongo pygmaeus (orangutan)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
REFERENCE 1 (bases 1 to 16)
AUTHORS Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
Fobo,G., Han,M. and Wiemann,S.
Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
Unpublished (2004)
Contact: MIPS
MIPS
Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468E2231
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.
Location/Qualifiers
1..16
/organism="Pongo pygmaeus"
/mol_type="mRNA"
/db_xref="taxon:9600"
/clone="DKFZp468E2231"

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovinae; Bos.

REFERENCE 1 (bases 1 to 16)
 AUTHORS Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
 TITLE Development of cDNA and EST resources for studying reproduction and embryo development in pigs and cattle
 JOURNAL Unpublished (2004)
 COMMENT Contact: Anderson SI
 Genomics and Bioinformatics
 Roslin Institute
 Roslin, Midlothian, EH25 9PS, UNITED KINGDOM

Single pass sequencing. Bases called and trimmed with phred v0.020425.c. Vector identified by cross match with the -minscore 20 and -mismatch 12 options. Vector: pBluescriptII(SK+) R. Site 1: EcoRI R. Site 2: NotI 5' Seq primer M13p Description: Normalised library constructed from Bovine Uterus tissue. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.

FEATURES
 source
 1..16
 /organism="Bos taurus"
 /mol_type="mRNA"
 /db_xref="taxon:9913"
 /clone="KN227-028_N23"
 /tissue_type="uterus"
 /clone_lib="KN224"
 /notes="Vector: pBluescriptII(SK+); Site 1: EcoRI; Site 2: NotI; Single pass sequencing. Normalised library constructed from Bovine Uterus tissue."

Query Match 0.3%; Score 16; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 60;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 ATCCCCCGGCTGCAG 18
 Db 16 ATCCCCCGGCTGCAG 1

RESULT 53
 CR786853 16 bp mRNA linear EST 01-OCT-2004
 LOCUS DKFZp468E2231_5', mRNA sequence.
 DEFINITION DKFZp468E2231_5', mRNA sequence.

ACCESSION CR786853
 VERSION CR786853.1 GI:53705850
 KEYWORDS EST.
 SOURCE Pongo pygmaeus (orangutan)
 ORGANISM Pongo pygmaeus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
 REFERENCE 1 (bases 1 to 16)
 AUTHORS Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A., Fobo,G., Han,M. and Wiemann,S.
 TITLE Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
 JOURNAL Unpublished (2004)
 COMMENT Contact: MIPS
 MIPS
 Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
 This is the 5' sequence of the clone insert. Clone from S. Wiemann, Molecular Genome Analysis, German Cancer Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin, Germany. Please contact RZPD for ordering:
 http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468E2231
 Further information about the clone and the sequencing project is available at http://mips.gsf.de/projects/cdna/.

FEATURES
 source
 1..16
 /organism="Pongo pygmaeus"
 /mol_type="mRNA"
 /db_xref="taxon:9600"
 /clone="DKFZp468E2231"

Thu Aug 18 09:13:58 2005

```

/tissue_type="heart"
/dev_stage="adult"
/lab_host="DH108"
/clone_lib="468 (synonym: phrt1)"
/note="Vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match      0.3%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 60;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAA 5040
Db 1 AAAAAAAAAAAAAA 16

RESULT 54
BM398023      17 bp mRNA linear EST 17-JAN-2002
LOCUS      5009-0-4-E01.t.1 Chilcoat/Turkewitz cDNA (large fraction)
DEFINITION      Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION      BM398023.1 GI:18198076
VERSION
KEYWORDS
SOURCE
ORGANISM      Tetrahymena thermophila
               Tetrahymena thermophila
               Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
               Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
REFERENCE
AUTHORS      Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E.,
               Frankel,J. and Klobutcher,L.
TITLE      EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL
COMMENT      Molecular Genetics and Cell Biology
               University of Chicago
               920 E. 58th Street, Chicago, IL 60637, USA
               Tel: 773 702 4374
               Fax: 773 702 3172
               Email: apturkew@midway.uchicago.edu
               Seq primer: T3.
               Location/Qualifiers
                 1..17
                 /organism="Tetrahymena thermophila"
                 /mol_type="mRNA"
                 /strain="CU428.1"
                 /db_xref="taxon:5911"
                 /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
                 /note="Vector: Bluescript2 SK+; Details on library
                 preparation can be found in Chilcoat and Turkewitz (2001)
                 Proc. Natl. Acad. Sci USA, 98: 8709-8713."

REFERENCE
AUTHORS      Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E.,
               Frankel,J. and Klobutcher,L.
TITLE      EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL
COMMENT      Molecular Genetics and Cell Biology
               University of Chicago
               920 E. 58th Street, Chicago, IL 60637, USA
               Tel: 773 702 4374
               Fax: 773 702 3172
               Email: apturkew@midway.uchicago.edu
               Seq primer: T3.
               Location/Qualifiers
                 1..17
                 /organism="Tetrahymena thermophila"
                 /mol_type="mRNA"
                 /strain="CU428.1"
                 /db_xref="taxon:5911"
                 /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
                 /note="Vector: Bluescript2 SK+; Details on library
                 preparation can be found in Chilcoat and Turkewitz (2001)
                 Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match      0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5070 GGGGGGGCCCGGTACC 5085
Db 1 GGGGGGGCCCGGTACC 16

RESULT 55
BM398024      17 bp mRNA linear EST 17-JAN-2002
LOCUS      5009-0-4-E01.t.2 Chilcoat/Turkewitz cDNA (large fraction)
DEFINITION      Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION      BM398024.1 GI:18198077
VERSION
KEYWORDS
SOURCE
ORGANISM      Tetrahymena thermophila
               Tetrahymena thermophila
               Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
               Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
REFERENCE
AUTHORS      Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E.,
               Frankel,J. and Klobutcher,L.
TITLE      EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL
COMMENT      Molecular Genetics and Cell Biology
               University of Chicago
               920 E. 58th Street, Chicago, IL 60637, USA
               Tel: 773 702 4374
               Fax: 773 702 3172
               Email: apturkew@midway.uchicago.edu
               Seq primer: T3.
               Location/Qualifiers
                 1..17
                 /organism="Tetrahymena thermophila"
                 /mol_type="mRNA"
                 /strain="CU428.1"
                 /db_xref="taxon:5911"
                 /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
                 /note="Vector: Bluescript2 SK+; Details on library
                 preparation can be found in Chilcoat and Turkewitz (2001)
                 Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match      0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5070 GGGGGGGCCCGGTACC 5085
Db 1 GGGGGGGCCCGGTACC 16

RESULT 55
BM398024      17 bp mRNA linear EST 17-JAN-2002
LOCUS      5009-0-4-E01.t.2 Chilcoat/Turkewitz cDNA (large fraction)
DEFINITION      Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION      BM398024.1 GI:18198077
VERSION
KEYWORDS
SOURCE
ORGANISM      Tetrahymena thermophila
               Tetrahymena thermophila
               Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
               Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
REFERENCE
AUTHORS      Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E.,
               Frankel,J. and Klobutcher,L.
TITLE      EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL
COMMENT      Molecular Genetics and Cell Biology
               University of Chicago
               920 E. 58th Street, Chicago, IL 60637, USA
               Tel: 773 702 4374
               Fax: 773 702 3172
               Email: apturkew@midway.uchicago.edu
               Seq primer: T3.
               Location/Qualifiers
                 1..17
                 /organism="Tetrahymena thermophila"
                 /mol_type="mRNA"
                 /strain="CU428.1"
                 /db_xref="taxon:5911"
                 /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
                 /note="Vector: Bluescript2 SK+; Details on library
                 preparation can be found in Chilcoat and Turkewitz (2001)
                 Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match      0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5070 GGGGGGGCCCGGTACC 5085
Db 1 GGGGGGGCCCGGTACC 16
```

```

AUTHORS      Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E.,
               Frankel,J. and Klobutcher,L.
TITLE      EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL
COMMENT      Molecular Genetics and Cell Biology
               University of Chicago
               920 E. 58th Street, Chicago, IL 60637, USA
               Tel: 773 702 4374
               Fax: 773 702 3172
               Email: apturkew@midway.uchicago.edu
               Seq primer: T3.
               Location/Qualifiers
                 1..17
                 /organism="Tetrahymena thermophila"
                 /mol_type="mRNA"
                 /strain="CU428.1"
                 /db_xref="taxon:5911"
                 /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
                 /note="Vector: Bluescript2 SK+; Details on library
                 preparation can be found in Chilcoat and Turkewitz (2001)
                 Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match      0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5070 GGGGGGGCCCGGTACC 5085
Db 1 GGGGGGGCCCGGTACC 16

RESULT 56
BM399768      17 bp mRNA linear EST 17-JAN-2002
LOCUS      5009-0-61-C01.t.1 Chilcoat/Turkewitz cDNA (large fraction)
DEFINITION      Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION      BM399768
VERSION      BM399768.1 GI:18199821
KEYWORDS
SOURCE
ORGANISM      Tetrahymena thermophila
               Tetrahymena thermophila
               Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
               Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
REFERENCE
AUTHORS      Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E.,
               Frankel,J. and Klobutcher,L.
TITLE      EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL
COMMENT      Molecular Genetics and Cell Biology
               University of Chicago
               920 E. 58th Street, Chicago, IL 60637, USA
               Tel: 773 702 4374
               Fax: 773 702 3172
               Email: apturkew@midway.uchicago.edu
               Seq primer: T3.
               Location/Qualifiers
                 1..17
                 /organism="Tetrahymena thermophila"
                 /mol_type="mRNA"
                 /strain="CU428.1"
                 /db_xref="taxon:5911"
                 /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
                 /note="Vector: Bluescript2 SK+; Details on library
                 preparation can be found in Chilcoat and Turkewitz (2001)
                 Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match      0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5070 GGGGGGGCCCGGTACC 5085
Db 1 GGGGGGGCCCGGTACC 5085
```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 08:32:01 ; Search time 9 Seconds
(without alignments)
3.614 Million cell updates/sec

Title: US-10-667-022-4
Perfect score: 5085
Sequence: 1 ggatccccgggtgcagga.....tcgagggggggcccggtacc 5085

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 150 seqs, 3198 residues

Total number of hits satisfying chosen parameters: 300

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 150 summaries

Database : fetch4rge.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	ID	Description
1	60	1.2	1	C0540998
2	40.6	0.8	50	1 C0878333
3	40.6	0.8	50	1 C0878333
4	33.2	0.7	40	1 AR014711
5	33.2	0.7	40	1 I55635
6	30	0.6	30	1 AR541545
7	30	0.6	30	1 AR541546
8	27.6	0.5	35	1 A63566
9	27	0.5	35	1 A63565
10	27	0.5	35	1 A63574
11	22.6	0.4	30	1 AR559409
12	21	0.4	21	1 E13974
13	21	0.4	21	1 E14908
14	21	0.4	21	1 E64706
15	21	0.4	21	1 AR559758
16	21	0.4	24	1 A87299
17	21	0.4	24	1 BD057377
18	20	0.4	20	1 AR532682
19	20	0.4	20	1 AR559396
20	20	0.4	20	1 AR559411
21	20	0.4	20	1 AR561993
22	20	0.4	20	1 AR565165
23	20	0.4	20	1 AX085176
24	20	0.4	20	1 AX085373
25	20	0.4	21	1 AR222119
26	20	0.4	24	1 C0855140
27	19.2	0.4	24	1 AX103868
28	19.2	0.4	24	1 AX546921
29	19	0.4	19	1 C0817044
30	19	0.4	19	1 AR541350
31	19	0.4	19	1 AR541351
32	19	0.4	19	1 AR541352
33	19	0.4	19	1 AR541353

C 34	19	0.4	19	1	AR541361
C 35	19	0.4	20	1	AR562157
C 36	18.8	0.4	25	1	AR239256
C 37	18.8	0.4	25	1	AX279058
C 38	18.4	0.4	20	1	AS2122
C 39	18.4	0.4	20	1	AR068314
C 40	18.4	0.4	22	1	AX815621
C 41	18.4	0.4	22	1	AX815622
C 42	18.2	0.4	19	1	AR528447
C 43	18	0.4	20	1	SSAJ777
C 44	18	0.4	20	1	AR562156
C 45	18	0.4	20	1	AR562158
C 46	17.4	0.3	19	1	AR072061
C 47	17.4	0.3	19	1	AX130055
C 48	17.4	0.3	21	1	AX498248
C 49	17	0.3	17	1	AR067856
C 50	17	0.3	17	1	AR164207
C 51	17	0.3	17	1	AR164645
C 52	17	0.3	17	1	AR168088
C 53	17	0.3	17	1	AR232188
C 54	17	0.3	17	1	AR236040
C 55	17	0.3	17	1	AR337628
C 56	17	0.3	17	1	AR473351
C 57	17	0.3	17	1	AR492475
C 58	17	0.3	17	1	AR533532
C 59	17	0.3	20	1	AR024174
C 60	17	0.3	20	1	AR060565
C 61	17	0.3	20	1	IS4907
C 62	17	0.3	20	1	AR370189
C 63	16.8	0.3	20	1	AR136554
C 64	16.8	0.3	20	1	E60050
C 65	16.8	0.3	20	1	AR482351
C 66	16.8	0.3	21	1	C0801070
C 67	16.8	0.3	22	1	AR120179
C 68	16.8	0.3	22	1	AR126177
C 69	16.8	0.3	22	1	AR177993
C 70	16.8	0.3	22	1	AR220297
C 71	16.8	0.3	22	1	AX751620
C 72	16.8	0.3	22	1	BD063767
C 73	16.4	0.3	18	1	AX837871
C 74	16.4	0.3	19	1	AR179243
C 75	16.4	0.3	19	1	BD078905
C 76	16.4	0.3	20	1	A95627
C 77	16.4	0.3	20	1	AR215742
C 78	16.4	0.3	20	1	AR429226
C 79	16.4	0.3	20	1	BD091431
C 80	16.4	0.3	21	1	AX247921
C 81	16.4	0.3	21	1	AX675429
C 82	16.2	0.3	21	1	C0881300
C 83	16.2	0.3	21	1	AX937073
C 84	16.2	0.3	21	1	AX951931
C 85	16	0.3	16	1	AR561628
C 86	16	0.3	16	1	AR561693
C 87	16	0.3	17	1	AX215201
C 88	16	0.3	17	1	AX757347
C 89	16	0.3	17	1	AX762159
C 90	16	0.3	20	1	AR148114
C 91	16	0.3	20	1	AR173949
C 92	16	0.3	21	1	AR173955
C 93	16	0.3	21	1	BD271297
C 94	16	0.3	21	1	BD271303
C 95	16	0.3	21	1	AX154243
C 96	15.8	0.3	19	1	I95654
C 97	15.8	0.3	19	1	AR292422
C 98	15.8	0.3	20	1	AR001320
C 99	15.8	0.3	20	1	AR037500
C 100	15.8	0.3	20	1	AR062780
C 101	15.8	0.3	20	1	AR087858
C 102	15.8	0.3	20	1	AR091328
C 103	15.8	0.3	20	1	AR118034
C 104	15.8	0.3	20	1	AR127753
C 105	15.8	0.3	20	1	AR144920
C 106	15.8	0.3	20	1	AR145921

ACCESSION: AR541361
ACCESSION: AR562157
ACCESSION: AR239256
ACCESSION: AX279058
ACCESSION: AS2122
ACCESSION: AR068314
ACCESSION: AX815621
ACCESSION: AX815622
ACCESSION: AR528447
ACCESSION: AJ000777
ACCESSION: AR562156
ACCESSION: AR562158
ACCESSION: AR072061
ACCESSION: AX130055
ACCESSION: AX498248
ACCESSION: AR067856
ACCESSION: AR164207
ACCESSION: AR164645
ACCESSION: AR168088
ACCESSION: AR232188
ACCESSION: AR236040
ACCESSION: AR337628
ACCESSION: AR473351
ACCESSION: AR492475
ACCESSION: AR533532
ACCESSION: AR024174
ACCESSION: AR060565
ACCESSION: IS4907
ACCESSION: AR370189
ACCESSION: AR136554
ACCESSION: E60050
ACCESSION: AR482351
ACCESSION: C0801070
ACCESSION: AR120179
ACCESSION: AR126177
ACCESSION: AR177993
ACCESSION: AR220297
ACCESSION: AX751620
ACCESSION: BD063767
ACCESSION: AX837871
ACCESSION: AR179243
ACCESSION: BD078905
ACCESSION: A95627
ACCESSION: AR215742
ACCESSION: AR429226
ACCESSION: BD091431
ACCESSION: AX247921
ACCESSION: AX675429
ACCESSION: C0881300
ACCESSION: AX937073
ACCESSION: AX951931
ACCESSION: AR561628
ACCESSION: AR561693
ACCESSION: AX215201
ACCESSION: AX757347
ACCESSION: AX762159
ACCESSION: AR148114
ACCESSION: AR173949
ACCESSION: AR173955
ACCESSION: BD271297
ACCESSION: BD271303
ACCESSION: AX154243
ACCESSION: I95654
ACCESSION: AR292422
ACCESSION: AR001320
ACCESSION: AR037500
ACCESSION: AR062780
ACCESSION: AR087858
ACCESSION: AR091328
ACCESSION: AR118034
ACCESSION: AR127753
ACCESSION: AR144920
ACCESSION: AR145921

AR014711 LOCUS AR014711 40 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 11 from patent US 5773699.
ACCESSION AR014711
VERSION AR014711.1 GI:3972165
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 40)
AUTHORS Kerr, P.S., Pearlstein, R.W., Schweiger, B.J., Becker-Manley, M.F. and
Pierce, J.W.
TITLE Nucleotide sequences of galactinol synthase from zucchini and
soybean
JOURNAL Patent: US 5773699-A 11 30-JUN-1998;
FEATURES Location/Qualifiers
source 1..40
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 33.2; DB 1; Length 40;
Best Local Similarity 92.1%; Pred. No. 2.5;
Matches 35; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1 GGATCCCCCGGCTGCAGGAATTCGGCACGAGGGAGT 38
Db 3 GGATCCCCCGGCTGCAGGAATTCGGCACGAGTGTGT 40
RESULT 5
155635 LOCUS 155635 40 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 11 from patent US 5648210.
ACCESSION 155635
VERSION 155635.1 GI:2476429
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 40)
AUTHORS Kerr, P.S., Pearlstein, R.W., Schweiger, B.J., Becker-Manley, M.F. and
Pierce, J.W.
TITLE Nucleotide sequences of galactinol synthase from zucchini and
soybean
JOURNAL Patent: US 5648210-A 11 15-JUL-1997;
FEATURES Location/Qualifiers
source 1..40
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 33.2; DB 1; Length 40;
Best Local Similarity 92.1%; Pred. No. 2.5;
Matches 35; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1 GGATCCCCCGGCTGCAGGAATTCGGCACGAGGGAGT 38
Db 3 GGATCCCCCGGCTGCAGGAATTCGGCACGAGTGTGT 40
RESULT 6
AR541545 LOCUS AR541545 30 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 1 from patent US 6743588.
ACCESSION AR541545
VERSION AR541545.1 GI:53933523
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 30)
AUTHORS Tokunaga, T., Ishiguro, T. and Horie, R.
TITLE Fluorescent dye and method of measuring nucleic acid
JOURNAL Patent: US 6743588-A 1 01-JUN-2004;

FEATURES source Location/Qualifiers
1..30
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 4.8;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5054
Db 30 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1
RESULT 7
AR541546 LOCUS AR541546 30 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 2 from patent US 6743588.
ACCESSION AR541546
VERSION AR541546.1 GI:53933524
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 30)
AUTHORS Tokunaga, T., Ishiguro, T. and Horie, R.
TITLE Fluorescent dye and method of measuring nucleic acid
JOURNAL Patent: US 6743588-A 2 01-JUN-2004;
FEATURES Location/Qualifiers
source 1..30
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 4.8;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5054
Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 30
RESULT 8
A63566/c LOCUS A63566 35 bp DNA linear PAT 12-MAR-1998
DEFINITION Sequence 7 from Patent WO9720924.
ACCESSION A63566
VERSION A63566.1 GI:3717221
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Scagliante, B. and Quadrifoglio, F.
TITLE A CLASS OF OLIGONUCLEOTIDES, THERAPEUTICALLY USEFUL AS ANTITUMORAL
AGENTS
JOURNAL Patent: WO 9720924-A 7 12-JUN-1997;
COMMENT SAICOM S.R.L. (IT)
Other publication IT M1952539 19970604
Other publication AU 1175497 19970627.
FEATURES Location/Qualifiers
source 1..35
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.5%; Score 27.6; DB 1; Length 35;
Best Local Similarity 88.2%; Pred. No. 8.4;
Matches 30; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
Qy 5032 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5065
Db 35 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2

Thu Aug 18 08:33:57 2005

gibbs-10-667-022-4.rge

```

RESULT 9
LOCUS      A63565/c                      35 bp      DNA      linear      PAT 12-MAR-1998
DEFINITION Sequence 6 from Patent WO9720924.
ACCESSION  A63565
VERSION     A63565.1  GI:3717220
KEYWORDS   .
SOURCE     unidentified
ORGANISM   unidentified
           unclassified.
REFERENCE  1
AUTHORS    Scagliante,B. and Quadrifoglio,F.
TITLE      A CLASS OF OLIGONUCLEOTIDES, THERAPEUTICALLY USEFUL AS ANTITUMORAL
JOURNAL    AGENTS
COMMENT    Patent: WO 9720924-A 6 12-JUN-1997;
           SAICOM S R L (IT)
           Other publication IT MI952539 19970604
           Other publication AU 1175497 19970627.
FEATURES   .
           source
           1..35
           /organism="unidentified"
           /mol_type="unassigned DNA"
           /db_xref="taxon:32644"
           Query Match      0.5%; Score 27; DB 1; Length 35;
           Best Local Similarity 85.7%; Pred. No. 9.6;
           Matches 30; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy  5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5059
Db  35 AAACACAAACAAACAAACAAACAAACAAACAAACAA 1

RESULT 10
LOCUS      A63574/c                      35 bp      DNA      linear      PAT 12-MAR-1998
DEFINITION Sequence 15 from Patent WO9720924.
ACCESSION  A63574
VERSION     A63574.1  GI:3717229
KEYWORDS   .
SOURCE     unidentified
ORGANISM   unidentified
           unclassified.
REFERENCE  1
AUTHORS    Scagliante,B. and Quadrifoglio,F.
TITLE      A CLASS OF OLIGONUCLEOTIDES, THERAPEUTICALLY USEFUL AS ANTITUMORAL
JOURNAL    AGENTS
COMMENT    Patent: WO 9720924-A 15 12-JUN-1997;
           SAICOM S R L (IT)
           Other publication IT MI952539 19970604
           Other publication AU 1175497 19970627.
FEATURES   .
           source
           1..35
           /organism="unidentified"
           /mol_type="unassigned DNA"
           /db_xref="taxon:32644"
           Query Match      0.5%; Score 27; DB 1; Length 35;
           Best Local Similarity 85.7%; Pred. No. 9.6;
           Matches 30; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy  5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5059
Db  35 AAAAAAAAAACAAACAAACAAACAAACAAACAAACAA 1

RESULT 11
LOCUS      AR559409                      30 bp      DNA      linear      PAT 08-OCT-2004
DEFINITION Sequence 68 from patent US 6750016.
ACCESSION  AR559409

RESULT 12
LOCUS      E13974                       21 bp      DNA      linear      PAT 27-APR-1998
DEFINITION PCR primer for tobacco PRLa terminator.
ACCESSION  E13974
VERSION     E13974.1  GI:3252741
KEYWORDS   JP 1997252779-A/4.
SOURCE     unidentified
ORGANISM   unidentified
           unclassified.
REFERENCE  1 (bases 1 to 21)
AUTHORS    Mitsuhashi,I., Oshima,M., Matsufuru,H., Matsukawa,K., Natori,S. and
           Ohashi,Y.
TITLE      PRODUCTION OF PROTEIN IN RECOMBINANT PLANT
JOURNAL    NORIN SUISANSYO NOGYO SEIBUTSU SHIGEN KENKYUSHO
COMMENT    OS None
           OC Artificial sequences.
           PN JP 1997252779-A/4
           PD 30-SEP-1997
           PF 25-MAR-1996 JP 1996068809
           PI MITSUHASHI ICHIRO, OSHIMA MASAHIRO, MATSUFURU HIROKI, PI
           MATSUKAWA KASUMI,
           PI NATORI SHUNJI, OHASHI YUKO
           PC C12N15/09,A01H5/00,C12N5/10,C12P21/02;
           CC strandedness: Single;
           CC topology: Linear;
           FH Key
           FH Location/Qualifiers
           FT source
           FT 1..21
           /organism="Artificial sequences".
           /organism="unidentified"
           /mol_type="genomic DNA"
           /db_xref="taxon:32644"
           Query Match      0.4%; Score 21; DB 1; Length 21;
           Best Local Similarity 100.0%; Pred. No. 32;
           Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy  4 TCCCCCGGGCTGCAGGAATTC 24
Db  1 TCCCCCGGGCTGCAGGAATTC 21

RESULT 13
LOCUS      E14908                       21 bp      DNA      linear      PAT 28-JUL-1999
DEFINITION
ACCESSION  E14908
```

```

DEFINITION PCR primer for tobacco PRLa terminator.
ACCESSION E14908
VERSION E14908.1 GI:5709591
KEYWORDS JP 1998028487-A/4.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Mitsuhashi, I., Oshima, M. and Ohashi, Y.
TITLE PLANT HAVING RESISTANCE TO PATHOGENIC FUNGI AND ITS CREATION
JOURNAL Patent: JP 1998028487-A 4 03-FEB-1998;
NORIN SUIJANSYO NOGYO SEIBUTSU SHIGEN KENKYUSHO
OS None
OC Artificial sequences.
PN JP 1998028487-A/4
PD 03-FEB-1998
PF 17-JUL-1996 JP 1996187763
PI MITSUHASHI ICHIRO, OSHIMA MASAHIRO, OHASHI YUKO PC
A01H5/00, C12N5/10, C12N15/09//C12P21/02;
CC strandedness: Single;
CC topology: Linear;
FH Key Location/Qualifiers
FH source 1..21
FT /organism='Artificial sequences'.
FEATURES
source
1..21
Location/Qualifiers
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 TCCCCCGGCTGCAGGAATTC 24
| | | | | | | | | | | | | | | | | | | |
Db 1 TCCCCCGGCTGCAGGAATTC 21

RESULT 15
LOCUS AR559758
DEFINITION Sequence 4 from patent US 6750381.
ACCESSION AR559758
VERSION AR559758.1 GI:53969858
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Mitsuhashi, I., Oshima, M. and Ohashi, Y.
TITLE Pathogen-resistant plants transformed with a DNA encoding sarcotoxin 1A linked to a signal peptide and a method for production thereof
JOURNAL Patent: US 6750381-A 4 15-JUN-2004;
FEATURES
source
1..21
Location/Qualifiers
/organism='unknown'
/mol_type='genomic DNA'

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 TCCCCCGGCTGCAGGAATTC 24
| | | | | | | | | | | | | | | | | | | |
Db 1 TCCCCCGGCTGCAGGAATTC 21

RESULT 16
LOCUS AR7299
DEFINITION Sequence 24 from Patent WO9837211.
ACCESSION AR7299
VERSION AR7299.1 GI:6736064
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 24)
AUTHORS Huttner, E. and Betzner, A. S.
TITLE PROTEIN COMPLEMENTATION IN TRANSGENIC PLANTS
JOURNAL Patent: WO 9837211-A 24 27-AUG-1998;
GENE SHEARS PTY LTD (AU); HUTTNER ERIC (AU)
FEATURES
source
1..24
Location/Qualifiers
/organism='unidentified'
/mol_type='unassigned DNA'
/db_xref='taxon:32644'

Query Match 0.4%; Score 21; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGAA 21
| | | | | | | | | | | | | | | | | | | |
Db 4 GGATCCCCCGGCTGCAGGAA 24

RESULT 17
LOCUS BD057377
DEFINITION
ACCESSION BD057377
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
1..21
Location/Qualifiers
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

```

DEFINITION Protein complementation in transgenic plants.
ACCESSION BD057377 GI:22602983
VERSION BD057377.1 GI:22602983
KEYWORDS JP 2001512322-A/21.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 24)
AUTHORS Paul, W., Perez, P., Huttner, E. and Betzner, A.S.
TITLE Protein complementation in transgenic plants
JOURNAL Patent: JP 2001512322-A 21 21-AUG-2001;
GENE SHEARS PTY LTD
COMMENT PN JP 2001512322-A/21
PD 21-AUG-2001
PF 20-FEB-1998 JP 1998536400
PR 21-FEB-1997 GB 9703681.8
PI WYATT PAUL, PASCUAL PEREZ, ERIC HUTTNER, ANDREAS STEFAN BETZNER
PC A01H5/00, C12N5/10, C12N9/22, C12N15/09//C12Q1/68, C12N15/00, C12N5/ PC
00
CC Strandedness: Single;
CC Topology: Linear;
FH key Location/Qualifiers.
FEATURES
source
1..24
/mol_type="synthetic construct"
/db_xref="taxon:32630"
Query Match 0.4%; Score 21; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GGATCCCCCGGCTGCAGGAA 21
Db 4 GGATCCCCCGGCTGCAGGAA 24
RESULT 18
AR532682
LOCUS AR532682 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6730269.
ACCESSION AR532682
VERSION AR532682.1 GI:53922053
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin, C.A., Letsinger, R.L., Mucic, R.C., Storhoff, J.J., Elghanian, R. and Taton, T.A.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNAL Patent: US 6730269-A 55 04-MAY-2004;
FEATURES
source
1..20
/mol_type="genomic DNA"
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 19
AR559396
LOCUS AR559396 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6750016.
ACCESSION AR559396
VERSION AR559396.1 GI:53975645
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin, C.A., Letsinger, R.L., Mucic, R.C., Storhoff, J.J., Elghanian, R. and Taton, T.A.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNAL Patent: US 6750016-A 55 06-JUL-2004;
FEATURES
source
1..20
/mol_type="genomic DNA"

ACCESSION AR559396 GI:53968812
VERSION AR559396.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin, C.A., Letsinger, R.L. and Park, S.-J.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNAL Patent: US 6750016-A 55 15-JUN-2004;
FEATURES
source
1..20
/mol_type="genomic DNA"
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 20
AR559411
LOCUS AR559411 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 70 from patent US 6750016.
ACCESSION AR559411
VERSION AR559411.1 GI:53968827
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin, C.A., Letsinger, R.L. and Park, S.-J.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNAL Patent: US 6750016-A 70 15-JUN-2004;
FEATURES
source
1..20
/mol_type="genomic DNA"
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 21
AR561993
LOCUS AR561993 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6759199.
ACCESSION AR561993
VERSION AR561993.1 GI:53975645
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin, C.A., Letsinger, R.L., Mucic, R.C., Storhoff, J.J., Elghanian, R. and Taton, T.A.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNAL Patent: US 6759199-A 55 06-JUL-2004;
FEATURES
source
1..20
/mol_type="genomic DNA"

```

/mo1_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 22
AR565165
LOCUS AR565165 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6767702.
ACCESSION AR565165
VERSION AR565165.1 GI:53981003
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 20)
Minkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,
Elghanian,R., Taton,R.A., Garimella,V. and Li,Z.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL Patent: US 6767702-A 55 27-JUL-2004;
FEATURES Location/Qualifiers
source 1..20
/mo1_type="unknown"
/mo1_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 23
AR085176
LOCUS AR085176 20 bp DNA linear PAT 09-MAR-2001
DEFINITION Sequence 26 from Patent WO0112798.
ACCESSION AR085176
VERSION AR085176.1 GI:13275268
KEYWORDS
SOURCE Zea mays
ORGANISM Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
clade; Panicoideae; Andropogoneae; Zea.
REFERENCE
AUTHORS 1
Loerz,H., Dresselhaus,T., Schreiber,D. and Heuer,S.
TITLE Male sterile plants
JOURNAL Patent: WO 0112798-A 26 22-FEB-2001;
Suedwestdeutsche Saatzucht (DE)
FEATURES Location/Qualifiers
source 1..20
/mo1_type="Zea mays"
/mo1_type="unassigned DNA"
/db_xref="taxon:4577"

Query Match
Best Local Similarity 0.4%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 CCCCCGGGCTGCAGGAATTC 24
Db 1 CCCCCGGGCTGCAGGAATTC 20

RESULT 24
AX085373
LOCUS AX085373 20 bp DNA linear PAT 09-MAR-2001
DEFINITION Sequence 26 from Patent WO0112799.
ACCESSION AX085373
VERSION AX085373.1 GI:13275428
KEYWORDS
SOURCE Zea mays
ORGANISM Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
clade; Panicoideae; Andropogoneae; Zea.
REFERENCE
AUTHORS 1
Loerz,H., Dresselhaus,T., Schreiber,D. and Heuer,S.
TITLE Regulatory sequences for pollen specific or pollen abundant gene
expression in plants
JOURNAL Patent: WO 0112799-A 26 22-FEB-2001;
Suedwestdeutsche Saatzucht (DE)
FEATURES Location/Qualifiers
source 1..20
/mo1_type="Zea mays"
/mo1_type="unassigned DNA"
/db_xref="taxon:4577"

Query Match
Best Local Similarity 0.4%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 CCCCCGGGCTGCAGGAATTC 24
Db 1 CCCCCGGGCTGCAGGAATTC 20

RESULT 25
AR222119
LOCUS AR222119 21 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 35 from patent US 6429014.
ACCESSION AR222119
VERSION AR222119.1 GI:23329493
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 21)
Steele,C.L., Bohlmann,J. and Croteau,R.B.
TITLE Monoterpene synthases from grand fir (Abies grandis)
JOURNAL Patent: US 6429014-A 35 06-AUG-2002;
FEATURES Location/Qualifiers
source 1..21
/mo1_type="unknown"
/mo1_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 20; DB 1; Length 21;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 CTGCAGGAATTCGCACGAG 32
Db 1 CTGCAGGAATTCGCACGAG 20

RESULT 26
CO855140
LOCUS CO855140 24 bp DNA linear PAT 23-AUG-2004
DEFINITION Sequence 6 from Patent WO2004058808.
ACCESSION CO855140
VERSION CO855140.1 GI:51510569
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
Hooper,J.W., Schmaljohn,C.S. and Custer,M.

```

TITLE Dna vaccines against hantavirus infections
 JOURNAL Patent: WO 2004058808-A 6 15-JUL-2004;
 U.S. Army Medical Research Institute of Infectious Diseases
 Department of the Army (US)
 Location/Qualifiers
 FEATURES
 source 1..24
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Sequence of 24 bp extraneous sequence"
 Query Match 0.4%; Score 20; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 40;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 13 CTGAGGAATTCGGCAGAG 32
 Db 5 CTGAGGAATTCGGCAGAG 24
 RESULT 27
 AX103868/c
 LOCUS AX103868 24 bp DNA linear PAT 30-APR-2001
 DEFINITION Sequence 60 from Patent WO0122972.
 ACCESSION AX103868
 VERSION AX103868.1 GI:13920065
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.
 REFERENCE 1
 AUTHORS Krieg,A.M., Schetter,C. and Vollmer,J.C.
 TITLE Immunostimulatory nucleic acids
 JOURNAL Patent: WO 0122972-A 6 05-APR-2001;
 UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
 GmbH (DE)
 FEATURES
 source 1..24
 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 Query Match 0.4%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 47;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
 Db 24 AAAAAAAAAAAAAAAAAAAAAA 1
 RESULT 28
 AX546921/c
 LOCUS AX546921 24 bp DNA linear PAT 01-MAR-2003
 DEFINITION Sequence 60 from Patent WO2053141.
 ACCESSION AX546921
 VERSION AX546921.1 GI:25812065
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.
 REFERENCE 1
 AUTHORS Bratzler,R.L.
 TITLE Inhibition of angiogenesis by nucleic acids
 JOURNAL Patent: WO 02053141-A 6 01-JUL-2002;
 Coley Pharmaceutical Group, Inc. (US)
 FEATURES
 source 1..24
 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Synthetic Sequence"
 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 48;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5043
 Db 19 AAAAAAAAAAAAAAAAAAAAAA 1
 RESULT 31
 AR541351/c
 LOCUS AR541351 19 bp DNA linear PAT 08-OCT-2004
 DEFINITION Sequence 16 from patent US 6737520.

Query Match 0.4%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 47;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
 Db 24 AAAAAAAAAAAAAAAAAAAAAA 1
 RESULT 29
 CQ817044/c
 LOCUS CQ817044 19 bp DNA linear PAT 03-JUN-2004
 DEFINITION Sequence 6 from Patent WO2004042066.
 ACCESSION CQ817044
 VERSION CQ817044.1 GI:48145282
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.
 REFERENCE 1
 AUTHORS Touraev,A., Tashpulatov,A.S. and Heberle-Bors,E.
 TITLE NtSM GENE
 JOURNAL Patent: WO 2004042066-A 6 21-MAY-2004;
 ARC Seibersdorf research GmbH (AT)
 FEATURES
 source 1..19
 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence:primer"
 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 48;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 5065 CTCAGGGGGGGCCCGGTA 5083
 Db 19 CTCAGGGGGGGCCCGGTA 1
 RESULT 30
 AR541350/c
 LOCUS AR541350 19 bp DNA linear PAT 08-OCT-2004
 DEFINITION Sequence 15 from patent US 6737520.
 ACCESSION AR541350
 VERSION AR541350.1 GI:53932997
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Manoharan,M. and Mohan,V.
 TITLE Oligonucleotides having A-DNA form and B-DNA form conformational
 JOURNAL Geometry
 Patent: US 6737520-A 15 18-MAY-2004;
 Location/Qualifiers
 FEATURES
 source 1..19
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 48;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5043
 Db 19 AAAAAAAAAAAAAAAAAAAAAA 1
 RESULT 31
 AR541351/c
 LOCUS AR541351 19 bp DNA linear PAT 08-OCT-2004
 DEFINITION Sequence 16 from patent US 6737520.

Query Match	0.4%;	Score 19;	DB 1;	Length 19;
Best Local Similarity	100.0%;	Pred. No. 48;		
Matches	19;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	5025	AAAAAAAAAAAAAAAAAAAAA	5043	
Db	19	AAAAAAAAAAAAAAAAAAAAA	1	
RESULT 34				
AR541361/c				
LOCUS	AR541361	19 bp	DNA	linear
DEFINITION	Sequence 26 from patent US 6737520.			
ACCESSION	AR541361			
VERSION	AR541361.1	GI:53933008		
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	1 (bases 1 to 19)			
AUTHORS	Manoharan,M. and Mohan,V.			
TITLE	Oligonucleotides having A-DNA form and B-DNA form conformational geometry			
JOURNAL	Patent: US 6737520-A	26 18-MAY-2004;		
FEATURES	Location/Qualifiers			
source	1..19			
	/organism="unknown"			
	/mol_type="genomic DNA"			
Query Match	0.4%;	Score 19;	DB 1;	Length 19;
Best Local Similarity	100.0%;	Pred. No. 48;		
Matches	19;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	5025	AAAAAAAAAAAAAAAAAAAAA	5043	
Db	19	AAAAAAAAAAAAAAAAAAAAA	1	
RESULT 35				
AR562157/c				
LOCUS	AR562157	20 bp	DNA	linear
DEFINITION	Sequence 33 from patent US 6759215.			
ACCESSION	AR562157			
VERSION	AR562157.1	GI:53976020		
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	1 (bases 1 to 20)			
AUTHORS	Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.			
TITLE	Method of preparing human stem cell factor polypeptide			
JOURNAL	Patent: US 6759215-A	33 06-JUL-2004;		
FEATURES	Location/Qualifiers			
source	1..20			
	/organism="unknown"			
	/mol_type="genomic DNA"			
Query Match	0.4%;	Score 19;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 48;		
Matches	19;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	5024	TAATAAAAAAAAAAAAAAA	5042	
Db	19	TAATAAAAAAAAAAAAAAA	1	
RESULT 36				
AR239256/c				
LOCUS	AR239256	25 bp	DNA	linear
DEFINITION	Sequence 391 from patent US 6468749.			
ACCESSION	AR239256			
VERSION	AR239256.1	GI:27284331		

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 25)
AUTHORS Ulanovsky,L., Mugasimangalam,R.C., Einat,P., Zezin-Sonkin,D. and Gilad,S.
TITLE Sequence-dependent gene sorting techniques
JOURNAL Patent: US 6468749-A 391 22-OCT-2002;
FEATURES
source Location/Qualifiers
1..25
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 51;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2851 CCAGAGGATCCTGCCATAGCAC 2872
Db 25 CCAGAGGATCCTGCTGTAGCAC 4
RESULT 37
AX279058/c
LOCUS AX279058 25 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 391 from Patent WO01/75180.
ACCESSION AX279058
VERSION AX279058.1 GI:16606512
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Ulanovsky,L., Mugasimangalam,R., Einat,P., Zezin-Sonkin,D. and Shlomit,G.
TITLE Sequence-dependent gene sorting techniques
JOURNAL Patent: WO 01/75180-A 391 11-OCT-2001;
Qbi Enterprises Ltd. (US)
FEATURES
source Location/Qualifiers
1..25
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"
Query Match 0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 51;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2851 CCAGAGGATCCTGCCATAGCAC 2872
Db 25 CCAGAGGATCCTGCTGTAGCAC 4
RESULT 38
A52122
LOCUS A52122 20 bp DNA linear PAT 11-MAR-1997
DEFINITION Sequence 15 from Patent WO9619583.
ACCESSION A52122
VERSION A52122.1 GI:2304728
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Hesse,F., Ambrosius,D. and Burtscher,H.
TITLE RECOMBINANT PROTEINASE FROM CLOSTRIDIUM HYSTOLYTICUM AND THE USE THEREOF FOR ISOLATING CELLS AND CELL GROUPS
JOURNAL Patent: WO 9619583-A 15 27-JUN-1996;
BOEHRINGER MANNHEIM GMBH (DE)
COMMENT Other publication AU 4346696 960710
Other publication DE 4445891 960627.

FEATURES
source Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 54;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 817 TGCTACCTTTCCAGAAAGC 836
Db 1 TGCTACCATTCAGAAAGC 20
RESULT 39
AR068314
LOCUS AR068314 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 15 from patent US 5853976.
ACCESSION AR068314
VERSION AR068314.1 GI:6000521
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Hesse,F., Ambrosius,D. and Burtscher,H.
TITLE Recombinant proteinase from clostridium histolyticum and its use for isolating cells and groups of cells
JOURNAL Patent: US 5853976-A 15 29-DEC-1998;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 54;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 817 TGCTACCTTTCCAGAAAGC 836
Db 1 TGCTACCATTCAGAAAGC 20
RESULT 40
AX815621/c
LOCUS AX815621 22 bp DNA linear PAT 09-DEC-2003
DEFINITION Sequence 7 from Patent WO03066892.
ACCESSION AX815621
VERSION AX815621.1 GI:39646318
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Schwab,M. and Schaeffeler,E.
TITLE Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
JOURNAL Patent: WO 03066892-A 7 14-AUG-2003;
Epidaurus Biotechnologie AG (DE)
FEATURES
source Location/Qualifiers
1..22
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.4%; Score 18.4; DB 1; Length 22;
Best Local Similarity 95.0%; Pred. No. 55;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1731 CCTTAATACTGTGATTCCA 1750
|||||


```
Db      22 COTTAATAACTGTGTTCCA 3
RESULT 41
LOCUS   AX815622                22 bp      DNA      linear      PAT 09-DEC-2003
DEFINITION Sequence 8 from Patent WO03066892.
ACCESSION AX815622
VERSION   AX815622.1 GI:39646319
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
TITLE     Schwab, M. and Schaeffeler, E.
JOURNAL   Polymorphisms in the human gene for tpmt and their use in
          diagnostic and therapeutic applications
          Patent: WO 03066892-A 8 14-AUG-2003;
          Epidauros Biotechnologie AG (DE)
FEATURES
source    Location/Qualifiers
          1..22
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"
Query Match      0.4%; Score 18.4; DB 1; Length 22;
Best Local Similarity 95.0%; Pred. No. 55;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy      1731 COTTAATAACTGTGTTCCA 1750
Db      1 COTTAATAACTGTGTTCCA 20
RESULT 42
LOCUS   AR528447                19 bp      DNA      linear      PAT 08-OCT-2004
DEFINITION Sequence 85 from patent US 6723897.
ACCESSION AR528447
VERSION   AR528447.1 GI:53916512
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Brown, S.M., Elich, T.D., Heck, G.R., Kishore, G.M., Logusch, E.W.,
          Logusch, S.J., Piller, K.J., Rao, S., Ream, J.E. and Baerson, S.R.
TITLE     Methods for controlling gibberellin levels
JOURNAL   Patent: US 6723897-A 85 20-APR-2004;
FEATURES
source    Location/Qualifiers
          1..19
          /organism="unknown"
          /mol_type="genomic DNA"
Query Match      0.4%; Score 18.2; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 56;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Oy      5024 TAAAAAATAAAAAAAAAA 5042
Db      19 BAAAAAATAAAAAAAAAA 1
RESULT 43
LOCUS   SSAJ777                20 bp      mRNA      linear      MAM 29-JUL-1997
DEFINITION Sus scrofa EST GTR forward primer.
ACCESSION AJ000777
VERSION   AJ000777.1 GI:2286000
KEYWORDS PCR primer.
SOURCE   Sus scrofa (pig)
ORGANISM Sus scrofa
```

```
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
TITLE     Fridolfsson, A.K., Hori, T., Wintero, A.K., Fredholm, M., Yarle, M.,
          Robic, A., Andersson, L. and Ellegren, H.
JOURNAL   Expansion of the pig comparative map by expressed sequence tags
          (EST) mapping
          Unpublished
REFERENCE 2 (bases 1 to 20)
AUTHORS Fridolfsson, A.K.
TITLE     Direct Submission
JOURNAL
FEATURES
source    Location/Qualifiers
          1..20
          /organism="Sus scrofa"
          /mol_type="mRNA"
          /db_xref="taxon:9823"
Query Match      0.4%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 59;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy      9 CGGGCTGCAGGAATTCGG 26
Db      1 CGGGCTGCAGGAATTCGG 18
RESULT 44
LOCUS   AR562156                20 bp      DNA      linear      PAT 08-OCT-2004
DEFINITION Sequence 32 from patent US 6759215.
ACCESSION AR562156
VERSION   AR562156.1 GI:53976019
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zsebo, K.M., Bosselman, R.A., Suggs, S.V. and Martin, F.H.
TITLE     Method of preparing human stem cell factor polypeptide
JOURNAL   Patent: US 6759215-A 32 06-JUL-2004;
FEATURES
source    Location/Qualifiers
          1..20
          /organism="unknown"
          /mol_type="genomic DNA"
Query Match      0.4%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 59;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy      5025 AAAAAAATAAAAAAAAAA 5042
Db      18 AAAAAAATAAAAAAAAAA 1
RESULT 45
LOCUS   AR562158                20 bp      DNA      linear      PAT 08-OCT-2004
DEFINITION Sequence 34 from patent US 6759215.
ACCESSION AR562158
VERSION   AR562158.1 GI:53976021
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zsebo, K.M., Bosselman, R.A., Suggs, S.V. and Martin, F.H.
TITLE     Method of preparing human stem cell factor polypeptide
JOURNAL   Patent: US 6759215-A 34 06-JUL-2004;
FEATURES
source    Location/Qualifiers
```

REFERENCE
1 (bases 1 to 17)
Alnemri, E.S., Fernandes-Alnemri, T. and Litwack, G.
AUTHORS
TITLE
Apoptotic protease Mch6, nucleic acids encoding same and methods of

```
use
JOURNAL Patent: US 6271361-A 5 07-AUG-2001;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.3%; Score 17; DB 1; Length 17;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 51
AR164645 LOCUS 17 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 5 from patent US 6274318.
ACCESSION AR164645
VERSION AR164645.1 GI:16237730
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Alnemri,E.S., Fernandes-Alnemri,T. and Litwack,G.
TITLE Apoptotic protease Mch6, nucleic acids encoding same and methods of
use
JOURNAL Patent: US 6274318-A 5 14-AUG-2001;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.3%; Score 17; DB 1; Length 17;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 52
AR168088 LOCUS 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 6 from patent US 6287795.
ACCESSION AR168088
VERSION AR168088.1 GI:17903908
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
Tonaselli,K.
TITLE Mch4 and Mch5, apoptotic protease, nucleic acids encoding and
methods of use
JOURNAL Patent: US 6287795-A 6 11-SEP-2001;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.3%; Score 17; DB 1; Length 17;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 53
AR232188 LOCUS 17 bp mRNA linear PAT 20-DEC-2002
DEFINITION Sequence 5 from patent US 6455296.
ACCESSION AR232188
VERSION AR232188.1 GI:27274091
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Alnemri,E.S., Fernandes-Alnemri,T. and Litwack,G.
TITLE Apoptotic protease Mch6, nucleic acids encoding same and methods of
use
JOURNAL Patent: US 6455296-A 5 24-SEP-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="mRNA"

Query Match
Best Local Similarity 0.3%; Score 17; DB 1; Length 17;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 54
AR236040 LOCUS 17 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 6 from patent US 6462175.
ACCESSION AR236040
VERSION AR236040.1 GI:27279634
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
Tonaselli,K.
TITLE Mch3, a novel apoptotic protease, nucleic acids encoding and
methods of use
JOURNAL Patent: US 6462175-A 6 08-OCT-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.3%; Score 17; DB 1; Length 17;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 55
AR337628 LOCUS 17 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 5 from patent US 6566505.
ACCESSION AR337628
VERSION AR337628.1 GI:33724059
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Alnemri,E.S., Fernandes-Alnemri,T. and Litwack,G.
```

Thu Aug 18 08:33:57 2005

gibbs-10-667-022-4.rge

```

TITLE   Antibodies to Mch6 polypeptides
JOURNAL Patent: US 6566505-A 5 20-MAY-2003;
FEATURES Location/Qualifiers
         source
         1..17
         /organism="unknown"
         /mol_type="mRNA"

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   16 CAGGAATTCGGCAGCAG 32
      |||||||
Db   1 CAGGAATTCGGCAGCAG 17

RESULT 56
LOCUS   AR473351
DEFINITION Sequence 6 from patent US 6686459.
ACCESSION AR473351
VERSION   AR473351.1 GI:42708800
KEYWORDS .
SOURCE   Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
Tomaselli,K.
TITLE   Mch3, a novel apoptotic protease, nucleic acids encoding and
methods of use
JOURNAL Patent: US 6686459-A 6 03-FEB-2004;
FEATURES Location/Qualifiers
         source
         1..17
         /organism="unknown"
         /mol_type="genomic DNA"

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   16 CAGGAATTCGGCAGCAG 32
      |||||||
Db   1 CAGGAATTCGGCAGCAG 17

RESULT 57
LOCUS   AR492475
DEFINITION Sequence 6 from patent US 6716960.
ACCESSION AR492475
VERSION   AR492475.1 GI:47261885
KEYWORDS .
SOURCE   Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
Tomaselli,K.
TITLE   Mch3, a novel apoptotic protease, nucleic acids encoding and
methods of use
JOURNAL Patent: US 6716960-A 6 06-APR-2004;
FEATURES Location/Qualifiers
         source
         1..17
         /organism="unknown"
         /mol_type="genomic DNA"

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   16 CAGGAATTCGGCAGCAG 32
      |||||||
Db   1 CAGGAATTCGGCAGCAG 17

RESULT 58
LOCUS   AR533532
DEFINITION Sequence 6 from patent US 6730779.
ACCESSION AR533532
VERSION   AR533532.1 GI:53923390
KEYWORDS .
SOURCE   Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
Tomaselli,K.
TITLE   Antibody that specifically binds an Mch4 polypeptide
JOURNAL Patent: US 6730779-A 6 04-MAY-2004;
FEATURES Location/Qualifiers
         source
         1..17
         /organism="unknown"
         /mol_type="genomic DNA"

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   16 CAGGAATTCGGCAGCAG 32
      |||||||
Db   1 CAGGAATTCGGCAGCAG 17

RESULT 59
LOCUS   AR024174/c
DEFINITION Sequence 23 from patent US 5795862.
ACCESSION AR024174
VERSION   AR024174.1 GI:3977468
KEYWORDS .
SOURCE   Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Frank,G.R., Hunter,S.Wu. and Wallenfels,L.
TITLE   Ectoparasite saliva proteins and apparatus to collect such proteins
JOURNAL Patent: US 5795862-A 23 18-AUG-1998;
FEATURES Location/Qualifiers
         source
         1..20
         /organism="unknown"
         /mol_type="unassigned DNA"

Query Match      0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   5069 AGGGGGGGCCCGGTACC 5085
      |||||||
Db   20 AGGGGGGGCCCGGTACC 4

RESULT 60
LOCUS   AR060565/c
DEFINITION Sequence 23 from patent US 5840695.
ACCESSION AR060565
VERSION   AR060565.1 GI:5987015
KEYWORDS .
SOURCE   Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Frank,G.R., Hunter,S.Wu. and Wallenfels,L.
TITLE   Ectoparasite saliva proteins and apparatus to collect such proteins

```

JOURNAL Patent: US 5840695-A 23 24-NOV-1998;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5069 AGGGGGGGCCCGGTACC 5085
Db 20 AGGGGGGGCCCGGTACC 4

RESULT 61
LOCUS I54907 20 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 23 from patent US 5646115.
ACCESSION I54907
VERSION I54907.1 GI:2476110
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Frank,G.R., Hunter,S.Wu. and Wallenfels,L.
TITLE Ectoparasite saliva proteins and apparatus to collect such proteins
JOURNAL Patent: US 5646115-A 23 08-JUL-1997;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5069 AGGGGGGGCCCGGTACC 5085
Db 20 AGGGGGGGCCCGGTACC 4

RESULT 62
LOCUS AR370189 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 10 from patent US 6300132.
ACCESSION AR370189
VERSION AR370189.1 GI:34606695
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Cowseert,L.M.
TITLE Antisense inhibition of telomeric repeat binding factor 2
expression
JOURNAL Patent: US 6300132-A 10 09-OCT-2001;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 18 GGAATTCGGCACGAGGG 34
Db 20 GGAATTCGGCACGAGGG 4

RESULT 63

LOCUS ARI136554 20 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 44 from patent US 6136952.
ACCESSION ARI136554
VERSION ARI136554.1 GI:14477226
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Li,L. and Hood,L.
TITLE Human jagged polypeptide, encoding nucleic acids and methods of use
JOURNAL Patent: US 6136952-A 44 24-OCT-2000;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 622 TATTTTCAGATATTCATGA 641
Db 1 TATTTTTCAGATATTCATGA 20

RESULT 64
LOCUS E80050 20 bp DNA linear PAT 09-JAN-2004
DEFINITION Gene encoding 1,5-anhydroglucitol dehydrogenase, recombinant vector containing said gene, transformant containing said recombinant vector, and recombinant 1,5-anhydroglucitol dehydrogenase protein obtained from said transformant.
ACCESSION E80050
VERSION E80050.1 GI:18622791
KEYWORDS JP 2000316570-A/20.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kanetani,K., Miyoshi,M., Ebinuma,H., Mori,A. and Ushizawa,K.
TITLE Gene encoding 1,5-anhydroglucitol dehydrogenase, recombinant vector containing said gene, transformant containing said recombinant vector, and recombinant 1,5-anhydroglucitol dehydrogenase protein obtained from said transformant
JOURNAL Patent: JP 2000316570-A 20 21-NOV-2000;
COMMENT DAIICHI PURE CHEMICALS CO LTD
OS Artificial Sequence
PN JP 2000316570-A/20
PD 21-NOV-2000
PF 13-MAY-1999 JP 1999133157
PR
PI KIMI KANETANI, MAKOTO MIYOSHI, HIROYUKI EBINUMA, ATSUSO MORI, PI KOJI USHIZAWA
PC C12N9/04, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N15/09, PC C12N5/00, C12N15/00
CC
FH Key Location/Qualifiers
FT source
FT Location/Qualifiers
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.3%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 587 GCATTGCTCCCTCCAGATC 606
|||||

Db 1 GCATTGCTCCCTCAAGATC 20

RESULT 65
AR482351
LOCUS AR482351 20 bp mRNA linear PAT 14-MAY-2004
DEFINITION Sequence 44 from patent US 6703198.
ACCESSION AR482351
VERSION AR482351.1 GI:47244672
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Li,L., Hood,L., Krantz,I.D. and Spinner,N.B.
TITLE Methods of diagnosing alagille syndrome
JOURNAL Patent: US 6703198-A 44 09-MAR-2004;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="mRNA"

Query Match 0.3%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 622 TATTTTCAGATATTCATGA 641
|||||
Db 1 TATTTTATAGATATTAATGA 20

RESULT 66
CQ801070
LOCUS CQ801070 21 bp DNA linear PAT 05-MAY-2004
DEFINITION Sequence 61 from Patent WO2004033728.
ACCESSION CQ801070
VERSION CQ801070.1 GI:47057842
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS van Dongen,J.J., Langerak,A.W., Schuurink,E.M., van Miquel,J.F.,
garzia Sanz,R., Parreira,A., Smith,J.L.,Lavender,F.L.,
Morgan,G.J., Evans,P.A., Kneba,M., Hummel,M., Macintyre,E.A. and
Bastard,C.
TITLE Nucleic acid amplification primers for pcr-based clonality studies
JOURNAL Patent: WO 2004033728-A 61 22-APR-2004;
Erasmus Universiteit Rotterdam (NL); Van Dongen, Jacobus, Johannes,
Maria (NL)
FEATURES
source Location/Qualifiers
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: V beta 7 primer"

Query Match 0.3%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4032 GCTCTGCATTGTACAAGCA 4051
|||||
Db 2 GCTATGTATTGTACAAGCA 21

RESULT 67
AR120179
LOCUS AR120179 22 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 52 from patent US 6153814.
ACCESSION AR120179
VERSION AR120179.1 GI:14102878

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Baum,J.A., Gilmer,A.Jelen. and Mettus,A.-M.Light.
TITLE Lepidopteran-resistant transgenic plants
JOURNAL Patent: US 6153814-A 52 28-NOV-2000;
FEATURES
source Location/Qualifiers
1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGGCTGCAGGA 20
|||||
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 68
AR126177
LOCUS AR126177 22 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 52 from patent US 6177615.
ACCESSION AR126177
VERSION AR126177.1 GI:14112239
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Baum,J.A.
TITLE Lepidopteran-toxic polypeptide and polynucleotide compositions and
methods for making and using same
JOURNAL Patent: US 6177615-A 52 23-JAN-2001;
FEATURES
source Location/Qualifiers
1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGGCTGCAGGA 20
|||||
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 69
AR177993
LOCUS AR177993 22 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 52 from patent US 6313378.
ACCESSION AR177993
VERSION AR177993.1 GI:17920348
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Baum,J.A., Gilmer,A.Jelen. and Mettus,A.-M.Light.
TITLE Lepidopteran-resistant transgenic plants
JOURNAL Patent: US 6313378-A 52 06-NOV-2001;
FEATURES
source Location/Qualifiers
1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGGCTGCAGGA 20
|||||
Db 1 GGATCCCTCGAGCTGCAGGA 20

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Baum,J.A., Gilmer,A.Jelen. and Mettus,A.-M.Light.
TITLE Lepidopteran-resistant transgenic plants
JOURNAL Patent: US 6313378-A 52 06-NOV-2001;
FEATURES
source Location/Qualifiers
1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches	18;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	1	GGATCCCCCGGGCTGCAGGA	20						
Db	1	GGATCCCTCGAGCTGCAGGA	20						
RESULT 70									
LOCUS	AR220297			22 bp	DNA	linear		PAT 26-SEP-2002	
DEFINITION	Sequence 52 from patent US 6423828.								
ACCESSION	AR220297								
VERSION	AR220297.1	GI:23325058							
KEYWORDS									
SOURCE	Unknown.								
ORGANISM	Unknown.								
REFERENCE	Unclassified.								
AUTHORS	1 (bases 1 to 22)								
TITLE	Baum,J.A., Gilmer,A.J. and Mettuss,A.-M.L.								
	Nuclei acid and polypeptide compositions encoding								
	lepidopteran-toxic polypeptides								
JOURNAL	Patent: US 6423828-A	52 23-JUL-2002;							
FEATURES	Location/Qualifiers								
source	1..22								
	/organism="unknown"								
	/mol_type="genomic DNA"								
Query Match	0.3%;	Score 16.8;	DB 1;	Length 22;					
Best Local Similarity	90.0%;	Pred. No. 75;							
Matches	18;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	1	GGATCCCCCGGGCTGCAGGA	20						
Db	1	GGATCCCTCGAGCTGCAGGA	20						
RESULT 71									
LOCUS	AX751620			22 bp	DNA	linear		PAT 20-JUN-2003	
DEFINITION	Sequence 41 from Patent WO03034072.								
ACCESSION	AX751620								
VERSION	AX751620.1	GI:32133899							
KEYWORDS									
SOURCE	synthetic construct								
ORGANISM	synthetic construct								
REFERENCE	1								
AUTHORS	Wilson,D.I., Hearn,T. and Walker,M.								
TITLE	Diagnosis and therapy of conditions involving ALMS1								
JOURNAL	Patent: WO 03034072-A	41 24-APR-2003;							
	UNIVERSITY OF SOUTHAMPTON (GB)								
FEATURES	Location/Qualifiers								
source	1..22								
	/organism="synthetic construct"								
	/mol_type="unassigned DNA"								
	/db xref="taxon:32630"								
	/note="Primer"								
Query Match	0.3%;	Score 16.8;	DB 1;	Length 22;					
Best Local Similarity	90.0%;	Pred. No. 75;							
Matches	18;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	3911	CCACTGTGAATGGCTCTCTG	3930						
Db	2	CCCTGTGAATGGCTGTCTG	21						
RESULT 72									
LOCUS	BD063767			22 bp	DNA	linear		PAT 27-AUG-2002	
DEFINITION	DNA encoding lepidopteran-active delta-endotoxins and its use.								
ACCESSION	BD063767								
VERSION	BD063767.1	GI:22609370							

KEYWORDS					
JP 2001506490-A/19.					
SOURCE ORGANISM					
synthetic construct synthetic construct other sequences; artificial sequences. 1 (bases 1 to 22)					
REFERENCE AUTHORS					
Baum,J.A., Gilmer,A.J. and Mettuss,A.M.					
TITLE JOURNAL					
DNA encoding lepidopteran-active delta-endotoxins and its use					
Patent: JP 2001506490-A 19 22-MAY-2001;					
COMMENT					
ECOGEN INC					
PN JP 2001506490-A/19					
PD 22-MAY-2001					
PF 26-NOV-1997 JP 1998524917					
PR 27-NOV-1996 US 08/757536					
PI JAMES A BAUM,AMY JELEN GILMER,ANNE MARIE METTUS PC					
C07K34/325,C12N15/82//A01H5/00					
CC Strandedness: Single;					
CC Topology: Linear;					
FH Key Location/Qualifiers.					
FEATURES					
source					
1..22					
/organism="synthetic construct"					
/mol_type="genomic DNA"					
/db_xref="taxon:32630"					
Query Match 0.3%; Score 16.8; DB 1; Length 22;					
Best Local Similarity 90.0%; Pred.No.75;					
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
Qy					
1 GGATCCCCCGGCTGCAGGA 20					
Db					
1 GGATCCCTCGAGCTGCAGGA 20					
RESULT 73					
AX837871					
LOCUS AX837871 18 bp DNA linear PAT 15-DEC-2003					
DEFINITION Sequence 4995 from Patent EP1347046.					
ACCESSION AX837871					
VERSION AX837871.1 GI:39921563					
KEYWORDS					
unidentified					
unidentified					
unclassified.					
REFERENCE					
1					
AUTHORS					
Isogai,T., Sugiyama,T., Otsuki,T., Wakamatsu,A., Sato,H., Ishii,S., Yamanoto,J.I., Isono,Y., Hio,Y., Otsuka,K., Nagai,K., Irie,R., Tamechika,I., Seki,N., Yoshikawa,T., Otsuka,M., Nagahari,K. and Masuno,Y.					
TITLE					
Full-length cDNA sequences					
JOURNAL					
Patent: Ep 1347046-A 4995 24-SEP-2003; Research Association for Biotechnology (JP)					
FEATURES					
source					
1..18					
/organism="unidentified"					
/mol_type="unassigned DNA"					
/db_xref="taxon:32644"					
/note="Description of Artificial Sequence: an artificially synthesized primer se q"					
Query Match 0.3%; Score 16.4; DB 1; Length 18;					
Best Local Similarity 94.4%; Pred.No.81;					
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
Qy					
3813 CCATCCTCTACAAGCAG 3830					
Db					
1 CCATCCTCTACACAGCAG 18					
RESULT 74					
AR179243					
LOCUS AR179243 19 bp DNA linear PAT 20-APR-2002					
DEFINITION Sequence 31 from patent US 6326170.					
ACCESSION AR179243					

VERSION	AR179243.1	GI:20220798	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
	Unclassified.		
REFERENCE	1 (bases 1 to 19)		
AUTHORS	Russel Burnham,M.Karl., Lonetto,M.Arthur. and Warren,P.Vernon.		
TITLE	Prokaryotic polynucleotides, polypeptides and their uses		
JOURNAL	Patent: US 6326170-A 31 04-DEC-2001;		
FEATURES	Location/Qualifiers		
source	1. .19		
	/organism="unknown"		
	/mol_type="unassigned DNA"		
Query Match	0.3%;	Score 16.4;	DB 1; Length 19;
Best Local Similarity	94.4%;	Pred. No. 81;	
Matches	17; Conservative	0; Mismatches	1; Indels 0; Gaps 0;
Qy	18	GGAAATTCGGCAGCGGG	35
Db	1	GGAAATTCGGCAGCGCG	18
RESULT 75			
BD078905			
LOCUS			
DEFINITION	BD078905	19 bp DNA	linear PAT 27-AUG-2002
	Novel prokaryotic polynucleotide and polypeptide and utilization thereof.		
ACCESSION	BD078905		
VERSION	BD078905.1	GI:22624508	
KEYWORDS	JP 2001515707-A/21.		
SOURCE	unidentified		
ORGANISM	unclassified.		
REFERENCE	1 (bases 1 to 19)		
AUTHORS	Burnham,M.K.R., Lonetto,M.A. and Warren,P.V.		
TITLE	Novel prokaryotic polynucleotide and polypeptide and utilization		
JOURNAL	Patent: JP 2001515707-A 21 25-SEP-2001;		
	SMITHKLINE BEECHAM CORP		
COMMENT	OS Staphylococcus aureus		
	PN JP 2001515707-A/21		
	PD 25-SEP-2001		
	PF 14-SEP-1998	JP 2000510454	
	PR 12-SEP-1997	US 60/058710	
	PI MARTIN K R BURNHAM,MICHAEL A LONETTO,PATRICK V WARREN PC		
	C12N15/09,A61K38/00,A61K45/00,A61K48/00,A61P31/04,C07H21/02,C07H21/04,		
	PC		
	C07K14/31,C07K16/12,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12P21/PC		
	02,		
	PC C12Q1/68// (C12N15/09,C12R1:445),C12N15/00,A61K37/02,C12N5/00,		
	PC (C12N15/00,C12R1:445)		
	CC Novel prokaryotic polynucleotide and polypeptide and CC		
	utilization thereof		
	FH Key	Location/Qualifiers	
	FT source	1. .19	
	FT	/organism='Staphylococcus aureus'.	
FEATURES			
source	Location/Qualifiers		
	1. .19		
	/organism="unidentified"		
	/mol_type="genomic DNA"		
	/db_xref="taxon:32644"		
Query Match	0.3%;	Score 16.4;	DB 1; Length 19;
Best Local Similarity	94.4%;	Pred. No. 81;	
Matches	17; Conservative	0; Mismatches	1; Indels 0; Gaps 0;
Qy	18	GGAAATTCGGCAGCGGG	35
Db	1	GGAAATTCGGCAGCGCG	18
RESULT 76			

FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 81;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3412 CAGCAAAAGCGGAGCAG 3429
|||||
Db 3 CAGCAAAAGCGGAGCAG 20

RESULT 79
BD091431
LOCUS
DEFINITION Nucleic acids involved in the responder phenotype and applications thereof.
ACCESSION BD091431
VERSION BD091431.1 GI:22637042
KEYWORDS JP 2001523449-A/20.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)
AUTHORS Hartmann, B., Koschorz, B. and Kispert, A.
TITLE Nucleic acids involved in the responder phenotype and applications thereof
JOURNAL Patent: JP 2001523449-A 20 27-NOV-2001;
COMMENT MAX PLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN EV
OS Artificial Sequence
PN JP 2001523449-A/20
PD 27-NOV-2001
PF 18-NOV-1998 JP 2000521181
PR 18-NOV-1997 EP 97120190.0, 02-MAR-1998 EP 98103596.7 PI
BERNHARD HERRMANN, BIRGIT KOSCHORZ, ANDREAS KISPERT PC
C12N15/09, A01K67/027, A61K31/7088, A61K38/45, A61K39/395, A61K48/ PC
00, A61P15/16,
PC C07K16/40, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N9/12 PC
C12Q1/68/A61K35/42, A61K37/52, C12N5/00
PC C12P21/08, C12N15/00, A61K37/52, C12N5/00
CC Description of Artificial Sequence: synthetic no-natural CC
origin
FH Key Location/Qualifiers
FT source
FT 1..20
/organism="Artificial Sequence".
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 81;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3412 CAGCAAAAGCGGAGCAG 3429
|||||
Db 3 CAGCAAAAGCGGAGCAG 20

RESULT 80
AX247921/c
LOCUS
DEFINITION Sequence 22 from Patent WO0166801.
ACCESSION AX247921
VERSION AX247921.1 GI:15862544
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Engert, J., Vohl, M.C., Brewer, C., Morgan, K., Gaudet, D. and Hudson, T.J.
TITLE Very low density lipoprotein receptor polymorphisms and uses there for
JOURNAL Patent: WO 0166801-A 22 13-SEP-2001;
FEATURES Complexe Hopitalier de la Sagamie (CA); MCGILL UNIVERSITY (CA)
source Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.3%; Score 16.4; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 81;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3576 TGAACACTCAGCTTTTGTCAA 3595
|||||
Db 20 TGAACACTCAGCTTTTGTCAA 1

RESULT 81
AX675429
LOCUS
DEFINITION Sequence 153 from Patent WO0246408.
ACCESSION AX675429
VERSION AX675429.1 GI:29333495
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Li, L., Furtak, K., Perna, A., Patturajan, M., Shimkets, R.A., Guo, X., Casman, S.J., Burgess, C.E., Malyankar, U.M., Tchernev, V.T., Vermet, C.A., Spytek, K.A., Agee, M., Rastelli, L., Shenoy, S.G., Grobse, W.M., Alsobrook, J.P., Lepley, D.M., Gerlach, V., Edinger, S., Macdougall, J.R., Peyman, J.A., Gunther, E., Stone, D.J., Ellerman, K. and Gangolli, E.A.
TITLE Human proteins, polynucleotides encoding them and methods of using the same
JOURNAL Patent: WO 0246408-A 153 13-JUN-2002;
FEATURES Curagen Corporation (US)
source Location/Qualifiers
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="PCR Primer sequence"

Query Match 0.3%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 81;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1161 TCCTGAACGTTTGTGTGA 1178
|||||
Db 4 TCCTGAAGGTTTGTGTGA 21

RESULT 82
CQ881300
LOCUS
DEFINITION Sequence 16 from Patent WO2004083430.
ACCESSION CQ881300
VERSION CQ881300.1 GI:54034352
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS elm N.J., Wahlestedt, C., Liang, Z., g Rensen, A.M., Rum, H. and Koch, T.
TITLE SHORT INTERFERING RNA (siRNA) ANALOGUES

JOURNAL Patent: WO 2004083430-A 16 30-SEP-2004;
Santaris Pharma A/S (DK)
FEATURES Location/Qualifiers
source
1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="siRNA targeting SARS"

Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3855 TTGTTGTGTGATGATGATCA 3875

Db 1 TTCTGTTGAGGATAAGCATCA 21

RESULT 83
LOCUS AX937073/c 21 bp DNA linear PAT 06-JAN-2004
DEFINITION Sequence 26 from Patent EP1361268.
ACCESSION AX937073
VERSION AX937073.1 GI:40713260
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Busslinger, M., Mikkola, I. and Heavey, B.
TITLE Pax-5-deficient pro-B cells, methods of producing them and the use of such cells in human therapy
JOURNAL Patent: EP 1361268-A 26 12-NOV-2003;
Boehringer Ingelheim International GmbH (DE)
FEATURES Location/Qualifiers
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: PCR Primer"

Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2648 AACTGATGCCCTATTTGACC 2668

Db 21 AACTGATGCCCTATTTGCCC 1

RESULT 84
LOCUS AX951931/c 21 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 26 from Patent WO03095634.
ACCESSION AX951931
VERSION AX951931.1 GI:40782314
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Busslinger, M., Mikkola, I. and Heavey, B.
TITLE Pax-5-deficient pro-B-cells, methods of producing them and the use of such cells in human therapy
JOURNAL Patent: WO 03095634-A 26 20-NOV-2003;
BOEHRINGER INGELHEIM INTERNATIONAL GMBH; CD Patents (DE)
FEATURES Location/Qualifiers
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: PCR Primer"

Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2648 AACTGATGCCCTATTTGACC 2668

Db 21 AACTGATGCCCTATTTGCCC 1

RESULT 85
LOCUS AR561628 16 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 1 from patent US 6756492.
ACCESSION AR561628
VERSION AR561628.1 GI:53974736
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 16)
AUTHORS Beier, M. and Honeiseel, J.
TITLE Nucleoside derivatives with photo-unstable protective groups
JOURNAL Patent: US 6756492-A 1 29-JUN-2004;
FEATURES Location/Qualifiers
source
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.3%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAA 5040

Db 1 AAAAAAAAAAAAAA 16

RESULT 86
LOCUS AR561693/c 16 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 9 from patent US 6759039.
ACCESSION AR561693
VERSION AR561693.1 GI:53974843
KEYWORDS Unknown.
SOURCE Unknown.

REFERENCE 1 (bases 1 to 16)
AUTHORS Teang, W.-G., Zheng, T. and Huang, C.J.
TITLE Culturing pancreatic stem cells having a specified, intermediate stage of development
JOURNAL Patent: US 6759039-A 9 06-JUL-2004;
FEATURES Location/Qualifiers
source
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.3%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAA 5040

Db 16 AAAAAAAAAAAAAA 1

RESULT 87
LOCUS AX215201/c 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 643 from Patent WO0159103.
ACCESSION AX215201
VERSION AX215201.1 GI:15525244
KEYWORDS

SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE other sequences; artificial sequences.
AUTHORS 1
TITLE Blatt, L., McSwiggen, J. and Chowrira, B.M.
METHOD and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 643 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3735 TTTAGCCATAGCATCT 3750
|||||
Db 17 TTTAGCCATAGCATCT 2

RESULT 88
AX757347 17 bp DNA linear PAT 25-JUN-2003
LOCUS
DEFINITION Sequence 668 from Patent WO03040369.
ACCESSION AX757347
VERSION AX757347.1 GI:32251963
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 668 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2857 GATCCTGCATAGCAC 2872
|||||
Db 1 GATCCTGCATAGCAC 16

RESULT 89
AX762153/c 17 bp DNA linear PAT 25-JUN-2003
LOCUS
DEFINITION Sequence 5480 from Patent WO03040369.
ACCESSION AX762159
VERSION AX762159.1 GI:32256775
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,

apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 5480 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4929 TTGTATTGAAAAAGAT 4944
|||||
Db 17 TTGTATTGAAAAAGAT 2

RESULT 90
AR148114 20 bp DNA linear PAT 08-AUG-2001
LOCUS
DEFINITION Sequence 1 from patent US 6225056.
ACCESSION AR148114
VERSION AR148114.1 GI:15112204
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Abe, S. and Sato, Y.
TITLE Solid phases for target nucleic acid detection, process for
production thereof, and method of target nucleic acid detection
JOURNAL Patent: US 6225056-A 1 01-MAY-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGGCTGC 16
|||||
Db 5 GGATCCCCCGGGCTGC 20

RESULT 91
AR173949 21 bp DNA linear PAT 17-DEC-2001
LOCUS
DEFINITION Sequence 6 from patent US 6306612.
ACCESSION AR173949
VERSION AR173949.1 GI:17914269
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Schwarz, M.A., Zhang, F. and Gebb, S.A.
TITLE Methods of facilitating vascular growth
JOURNAL Patent: US 6306612-A 6 23-OCT-2001;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 16; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2988 GAGCCATCTTCATGAT 3003
|||||

Db 5 GAGCCATCTTCATGAT 20

RESULT 92
BD271297
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AR173955
Sequence 12 from patent US 6306612.
AR173955
AR173955.1 GI:17914275
Unknown.
Unknown.
Unclassified.
1 (bases 1 to 21)
Schwarz, M.A., Zhang, F. and Gebb, S.A.
Methods of facilitating vascular growth
Patent: US 6306612-A 12 23-OCT-2001;
Location/Qualifiers
1. .21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 16; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2988 GAGCCATCTTCATGAT 3003
|||||
Db 5 GAGCCATCTTCATGAT 20

RESULT 93
BD271297
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

BD271297
Methods of facilitating vascular growth.
BD271297
BD271297.1 GI:33081065
JP 2002542145-A/6.
synthetic construct
synthetic construct
other sequences; artificial sequences.
1 (bases 1 to 21)
Schwarz, M., Zhang, F. and Gebb, S.A.
Methods of facilitating vascular growth
Patent: JP 2002542145-A 6 10-DEC-2002;
CHILDREN'S HOSPITAL OF LOS ANGELES
FH Key Location/Qualifiers
FT source 1. .21
/organism="Artificial Sequence".

Query Match 0.3%; Score 16; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2988 GAGCCATCTTCATGAT 3003
|||||
Db 5 GAGCCATCTTCATGAT 20

RESULT 94
BD271303
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

BD271303
Methods of facilitating vascular growth.
BD271303
BD271303.1 GI:33081071
JP 2002542145-A/12.
synthetic construct
synthetic construct
other sequences; artificial sequences.
1 (bases 1 to 21)
Schwarz, M., Zhang, F. and Gebb, S.A.
Methods of facilitating vascular growth
Patent: JP 2002542145-A 12 10-DEC-2002;
CHILDREN'S HOSPITAL OF LOS ANGELES
OS Artificial Sequence
PN JP 2002542145-A/12
PD 10-DEC-2002
PP 12-NOV-1999 JP 2000582601
PR 13-NOV-1998 US 60/108435
PI MARGARET SCHWARZ, FANGRONG ZHANG, SARAH A GEBB
PC A61K45/00, A61K9/08, A61K39/395, A61K45/06, A61K47/02, A61P9/00, PC
A61P11/00,
PC A61P43/00, C07K2/00, C07K16/18, C12N15/09, C12Q1/02, C12Q1/68, PC
G01N33/15,
PC G01N33/50, G01N33/53, G01N33/566, C12N15/00 CC
Description of Artificial Sequence: primer
FH Key Location/Qualifiers
FT source 1. .21
/organism="Artificial Sequence".

Query Match 0.3%; Score 16; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2988 GAGCCATCTTCATGAT 3003
|||||
Db 5 GAGCCATCTTCATGAT 20

RESULT 95
AX154243
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AX154243
Sequence 341 from Patent WO0138576.
AX154243
AX154243.1 GI:14535857
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Cargill, M., Ireland, J.S. and Lander, E.S.
Human single nucleotide polymorphisms
Patent: WO 0138576-A 341 31-MAY-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
Location/Qualifiers
1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.3%; Score 16; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2988 GAGCCATCTTCATGAT 3003
|||||

```
Qy 4030 TGGCTCTGCATGTGTACA 4047
Db 1 TGGCTCTGAAATGTGTACA 18

RESULT 96
195654/c
LOCUS AR037500.1 19 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 21 from patent US 5733732.
ACCESSION I95654
VERSION I95654.1 GI:3940124
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Campbell,K.P., Roberds,S.L., Sunada,Y., Piccolo,P., Jeanpierre,M.
and Kaplan,J.-C.
TITLE Methods for detecting primary adhalinopathy
JOURNAL Patent: US 5733732-A 21 31-MAR-1998;
FEATURES
LOCATION/Qualifiers
source 1..19
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4171 GCAGCTGTTTCAGGCAACA 4189
Db 19 GCAGGTGTTTCAGGCGACGA 1

RESULT 97
AR292422/c
LOCUS AR292422 19 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 4157 from patent US 6537751.
ACCESSION AR292422
VERSION AR292422.1 GI:31679706
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
JOURNAL disequilibrium map of the human genome
FEATURES Patent: US 6537751-A 4157 25-MAR-2003;
LOCATION/Qualifiers
source 1..19
/mol_type="unknown"
/mol_type="genomic DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3884 CTGGAGCAGCTGCTGTTCT 3902
Db 19 CTGGAGCTGAGTCTGTTCT 1

RESULT 98
AR001320/c
LOCUS AR001320 20 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 8 from patent US 5739027.
ACCESSION AR001320
VERSION AR001320.1 GI:3963387
KEYWORDS
SOURCE
ORGANISM Unknown.

Qy 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCAGTTTCCAATTC 2

RESULT 99
AR037500/c
LOCUS AR037500 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 8 from patent US 5801236.
ACCESSION AR037500
VERSION AR037500.1 GI:5955356
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kamb,A.
TITLE Probes for MTS1 gene and polynucleotides encoding mutant MTS1 genes
JOURNAL Patent: US 5801236-A 8 01-SEP-1998;
FEATURES Location/Qualifiers
source 1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCAGTTTCCAATTC 2

RESULT 100
AR062780/c
LOCUS AR062780 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 8 from patent US 5843756.
ACCESSION AR062780
VERSION AR062780.1 GI:5990471
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Stone,S., Jiang,P. and Kamb,A.
TITLE Mouse MTS1 gene
JOURNAL Patent: US 5843756-A 8 01-DEC-1998;
FEATURES Location/Qualifiers
source 1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCAGTTTCCAATTC 2
```

source	1. .20	/organism="unknown"	/mol_type="unassigned DNA"
Query Match	0.3%;	Score 15.8;	DB 1; Length 20;
Best Local Similarity	89.5%;	Pred. No. 91;	
Matches	17;	Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	4079	GGTCCAGTTGCCAATTTC	4097
Db	20	GCTTCCAGTTTCCAATTTC	2
RESULT 104			
AR127753			
LOCUS	AR127753	20 bp	DNA
DEFINITION	Sequence 8 from patent US 6180776.		
ACCESSION	AR127753		
VERSION	AR127753.1	GI:14114348	
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unclassified.		
REFERENCE	1 (bases 1 to 20)		
AUTHORS	Kamb,A.		
TITLE	MTS2 gene		
JOURNAL	Patent: US 6180776-A 8 30-JAN-2001;		
FEATURES	Location/Qualifiers		
source	1. .20		
/organism="unknown"			
/mol_type="unassigned DNA"			
Query Match	0.3%;	Score 15.8;	DB 1; Length 20;
Best Local Similarity	89.5%;	Pred. No. 91;	
Matches	17;	Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	4079	GGTCCAGTTGCCAATTTC	4097
Db	20	GCTTCCAGTTTCCAATTTC	2
RESULT 105			
AR144920/c			
LOCUS	AR144920	20 bp	DNA
DEFINITION	Sequence 8 from patent US 6210949.		
ACCESSION	AR144920		
VERSION	AR144920.1	GI:15106787	
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unclassified.		
REFERENCE	1 (bases 1 to 20)		
AUTHORS	Stone,S., Jiang,P. and Kamb,A.		
TITLE	Mouse MTS2 gene		
JOURNAL	Patent: US 6210949-A 8 03-APR-2001;		
FEATURES	Location/Qualifiers		
source	1. .20		
/organism="unknown"			
/mol_type="unassigned DNA"			
Query Match	0.3%;	Score 15.8;	DB 1; Length 20;
Best Local Similarity	89.5%;	Pred. No. 91;	
Matches	17;	Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	4079	GGTCCAGTTGCCAATTTC	4097
Db	20	GCTTCCAGTTTCCAATTTC	2
RESULT 106			
AR145921/c			
LOCUS	AR145921	20 bp	DNA
DEFINITION	Sequence 8 from patent US 6218146.		
ACCESSION	AR145921		
VERSION	AR145921.1	GI:15106787	
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unclassified.		
REFERENCE	1 (bases 1 to 20)		
AUTHORS	Kamb,A.		
TITLE	Antibodies specific for MTS2 Polypeptide		
JOURNAL	Patent: US 6140473-A 8 31-OCT-2000;		
FEATURES	Location/Qualifiers		
source	1. .20		
/organism="unknown"			
/mol_type="unassigned DNA"			
Query Match	0.3%;	Score 15.8;	DB 1; Length 20;
Best Local Similarity	89.5%;	Pred. No. 91;	
Matches	17;	Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	4079	GGTCCAGTTGCCAATTTC	4097
Db	20	GCTTCCAGTTTCCAATTTC	2
RESULT 107			
AR118034/c			
LOCUS	AR118034	20 bp	DNA
DEFINITION	Sequence 8 from patent US 6140473.		
ACCESSION	AR118034		
VERSION	AR118034.1	GI:14098940	
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unclassified.		
REFERENCE	1 (bases 1 to 20)		
AUTHORS	Kamb,A.		
TITLE	Antibodies specific for MTS2 Polypeptide		
JOURNAL	Patent: US 6140473-A 8 31-OCT-2000;		
FEATURES	Location/Qualifiers		
source	1. .20		
/organism="unknown"			
/mol_type="unassigned DNA"			
Query Match	0.3%;	Score 15.8;	DB 1; Length 20;
Best Local Similarity	89.5%;	Pred. No. 91;	
Matches	17;	Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	4079	GGTCCAGTTGCCAATTTC	4097
Db	20	GCTTCCAGTTTCCAATTTC	2
RESULT 108			
AR118034/c			
LOCUS	AR118034	20 bp	DNA
DEFINITION	Sequence 8 from patent US 6140473.		
ACCESSION	AR118034		
VERSION	AR118034.		

```
ACCESSION ARI45921
VERSION ARI45921.1 GI:15109110
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kamb,A.
TITLE MTS2 gene
JOURNAL Patent: US 6218146-A 8 17-APR-2001;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTCGCAATTC 4097
| | | | | | | | | | | | | | | | | | | |
Db 20 GGTTCAGTTCGCAATTC 2

RESULT 107
BD211609
LOCUS BD211609 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Canine and feline immunoregulatory proteins, nucleic acid molecules
and method of using the same.
ACCESSION BD211609
VERSION BD211609.1 GI:33021379
KEYWORDS JP 2002516104-A/115.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sim,G., Yang,S., Dreitz,M.J. and Wonderling,R.S.
TITLE Canine and feline immunoregulatory proteins, nucleic acid molecules
and method of using the same
JOURNAL Patent: JP 2002516104-A 115 04-JUN-2002;
HESKA CORP.
COMMENT OS Artificial Sequence
PN JP 2002516104-A/115
PD 04-JUN-2002
PF 28-MAY-1999 JP 2000551002
PR 29-MAY-1998 US 60/087306
PI GEKKEE SIM,SHUMIN YANG,MATTHEW J DREITZ,RAMANI S WONDERLING PC
C12N15/09,A61K31/7088,A61K38/00,A61K38/21,A61K39/00,A61K39/395,
PC A61K39/395,
PC A61K45/00,A61K48/00,A61P37/02,A61P37/04,C07K14/475,C07K14/535,
PC C07K14/54,
PC C07K14/56,C07K14/705,C07K16/24,C07K16/28,C12N1/21,C12N5/10, PC
G01N33/15,
PC G01N33/50,C12N15/00,A61K37/02,A61K37/66,C12N5/00 CC
Description of Artificial Sequence: Synthetic Primer FH Key
Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
FT Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3920 ATGGCTCTCTGGTGGCTG 3938
| | | | | | | | | | | | | | | | | | | |
Db 1 ATGGCGCTCTGGTGACTG 19

ACCESSION ARI45921
VERSION ARI45921.1 GI:15109110
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kamb,A.
TITLE MTS2 gene
JOURNAL Patent: US 6218146-A 8 17-APR-2001;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTCGCAATTC 4097
| | | | | | | | | | | | | | | | | | | |
Db 20 GGTTCAGTTCGCAATTC 2

RESULT 107
BD211609
LOCUS BD211609 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Canine and feline immunoregulatory proteins, nucleic acid molecules
and method of using the same.
ACCESSION BD211609
VERSION BD211609.1 GI:33021379
KEYWORDS JP 2002516104-A/115.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sim,G., Yang,S., Dreitz,M.J. and Wonderling,R.S.
TITLE Canine and feline immunoregulatory proteins, nucleic acid molecules
and method of using the same
JOURNAL Patent: JP 2002516104-A 115 04-JUN-2002;
HESKA CORP.
COMMENT OS Artificial Sequence
PN JP 2002516104-A/115
PD 04-JUN-2002
PF 28-MAY-1999 JP 2000551002
PR 29-MAY-1998 US 60/087306
PI GEKKEE SIM,SHUMIN YANG,MATTHEW J DREITZ,RAMANI S WONDERLING PC
C12N15/09,A61K31/7088,A61K38/00,A61K38/21,A61K39/00,A61K39/395,
PC A61K39/395,
PC A61K45/00,A61K48/00,A61P37/02,A61P37/04,C07K14/475,C07K14/535,
PC C07K14/54,
PC C07K14/56,C07K14/705,C07K16/24,C07K16/28,C12N1/21,C12N5/10, PC
G01N33/15,
PC G01N33/50,C12N15/00,A61K37/02,A61K37/66,C12N5/00 CC
Description of Artificial Sequence: Synthetic Primer FH Key
Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
FT Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3920 ATGGCTCTCTGGTGGCTG 3938
| | | | | | | | | | | | | | | | | | | |
Db 1 ATGGCGCTCTGGTGACTG 19

RESULT 108
CQ762074/c
LOCUS CQ762074 20 bp DNA linear PAT 03-MAR-2004
DEFINITION Sequence 692 from Patent WO2004003201.
ACCESSION CQ762074
VERSION CQ762074.1 GI:44905310
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Kane,C.D.
TITLE Antisense modulation of lhr1 expression
JOURNAL Patent: WO 2004003201-A 692 08-JAN-2004;
Pharmacia Corporation (US)
FEATURES Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Human LRH1 antisense"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3303 AACTGTCCAAATAAAAAA 3321
| | | | | | | | | | | | | | | | | | | |
Db 19 AACAGTCCAAATAATAA 1

RESULT 109
CQ763022/c
LOCUS CQ763022 20 bp DNA linear PAT 03-MAR-2004
DEFINITION Sequence 1640 from Patent WO2004003201.
ACCESSION CQ763022
VERSION CQ763022.1 GI:44906258
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Kane,C.D.
TITLE Antisense modulation of lhr1 expression
JOURNAL Patent: WO 2004003201-A 1640 08-JAN-2004;
Pharmacia Corporation (US)
FEATURES Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Human LRH1 antisense"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3303 AACTGTCCAAATAAAAAA 3321
| | | | | | | | | | | | | | | | | | | |
Db 20 AACAGTCCAAATAATAA 2

RESULT 110
I41154/c
LOCUS I41154 20 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 8 from patent US 5624819.
ACCESSION I41154
VERSION I41154.1 GI:2081744
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
```

AUTHORS Skolnick,M.H., Cannon-Albright,L.A. and Kamb,A.
 TITLE Germline mutations in the MTS gene
 JOURNAL Patent: US 5624819-A 8 29-APR-1997;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 91;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTCCCAATTC 4097
 Db 20 GCTCCAGTTCCAATTC 2

RESULT 111
 AR205352/c
 LOCUS 20 bp DNA linear PAT 20-JUN-2002
 DEFINITION Sequence 36 from patent US 6368856.
 ACCESSION AR205352
 VERSION AR205352.1 GI:21502914
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Monia,B.P. and Wyatt,J.
 TITLE Antisense inhibition of Phosphorylase kinase beta expression
 JOURNAL Patent: US 6368856-A 36 09-APR-2002;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 91;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3672 TCTTACATACGCCGAATT 3690
 Db 19 TCTTGCATACGCCGAATT 1

RESULT 112
 AR215823/c
 LOCUS 20 bp DNA linear PAT 25-SEP-2002
 DEFINITION Sequence 138 from patent US 6410324.
 ACCESSION AR215823
 VERSION AR215823.1 GI:23314079
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Bennett,C.F. and Watt,A.T.
 TITLE Antisense modulation of tumor necrosis factor receptor 2 expression
 JOURNAL Patent: US 6410324-A 138 25-JUN-2002;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 91;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4489 CAGAAAGTAGGACCAAGTG 4507
 Db 20 CAGCAAGTAGGACCAAGTG 2

RESULT 113
 AR241587
 LOCUS 20 bp DNA linear PAT 20-DEC-2002
 DEFINITION Sequence 143 from patent US 6471957.
 ACCESSION AR241587
 VERSION AR241587.1 GI:27287296
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Sim,G.-K., Yang,S., Dreitz,M.J. and Wonderling,R.S.
 TITLE Canine IL-4 immunoregulatory proteins and uses thereof
 JOURNAL Patent: US 6471957-A 143 29-OCT-2002;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 91;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3920 ATGGCTCTCTGGTTGGCTG 3938
 Db 1 ATGGCGCTCTGGTTGACTG 19

RESULT 114
 AR254543
 LOCUS 20 bp DNA linear PAT 20-DEC-2002
 DEFINITION Sequence 143 from patent US 6482403.
 ACCESSION AR254543
 VERSION AR254543.1 GI:27303431
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Sim,G.-K., Yang,S., Dreitz,M.J. and Wonderling,R.S.
 TITLE Canine IL-13 immunoregulatory proteins and uses thereof
 JOURNAL Patent: US 6482403-A 143 19-NOV-2002;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 91;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3920 ATGGCTCTCTGGTTGGCTG 3938
 Db 1 ATGGCGCTCTGGTTGACTG 19

RESULT 115
 AR352007
 LOCUS 20 bp DNA linear PAT 17-AUG-2003
 DEFINITION Sequence 5 from patent US 6589726.
 ACCESSION AR352007
 VERSION AR352007.1 GI:33756966
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Butler,J.H. and Brennan,T.M.
 TITLE Method and apparatus for in situ synthesis on a solid support
 JOURNAL Patent: US 6589726-A 5 08-JUL-2003;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"


```
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.3%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4769 TGACTGACTGACTGAATCA 4787
Db 2 TGACTGACTGACTGACTGA 20

RESULT 116
AR454044/c
LOCUS AR454044 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 4 from patent US 6680209.
ACCESSION AR454044
VERSION AR454044.1 GI:42686891
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Buechler,J., Valkirs,G., Gray,J. and Lonberg,N.
TITLE Human antibodies as diagnostic reagents
JOURNAL Patent: US 6680209-A 4 20-JAN-2004;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.3%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 366 CCTCCACCAACAGCCCATC 384
Db 19 CCTCCACCAAGGCCCATC 1

RESULT 117
AR473568/c
LOCUS AR473568 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6 from patent US 6689561.
ACCESSION AR473568
VERSION AR473568.1 GI:42711893
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Carson,D.A. and Nobori,T.
TITLE Tumor suppressor gene and methods for detection of cancer,
monitoring of tumor progression and cancer treatment
JOURNAL Patent: US 6689561-A 6 10-FEB-2004;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.3%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCAGTTTCCAATTC 2

RESULT 118
AR474038/c
LOCUS AR474038 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6 from patent US 6689864.
ACCESSION AR474038
```

```
VERSION AR474038.1 GI:42712791
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Carson,D.A. and Nobori,T.
TITLE Cyclin dependent kinase 4 inhibitor
JOURNAL Patent: US 6689864-A 6 10-FEB-2004;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.3%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCAGTTTCCAATTC 2

RESULT 119
AX184029
LOCUS AX184029 20 bp DNA linear PAT 06-AUG-2001
DEFINITION Sequence 1782 from Patent WO0142511.
ACCESSION AX184029
VERSION AX184029.1 GI:15135365
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Daly,M., Hudson,T.J., Lander,E.S., Rioux,J. and Siminovitch,K.
TITLE Ibd-related polymorphisms
JOURNAL Patent: WO 0142511-A 1782 14-JUN-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Ellipsis
Biotherapeutics Corporation (CA)
FEATURES
source Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.3%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAGAAAA 20

RESULT 120
AR296992
LOCUS AR296992 21 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 8727 from patent US 6537751.
ACCESSION AR296992
VERSION AR296992.1 GI:31684276
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 8727 25-MAR-2003;
FEATURES
source Location/Qualifiers
1..21
/organism="unknown"
```

/mol_type="genomic DNA"		0.3%; Score 15.8; DB 1; Length 21;		DB 1; Length 21;	
Query Match	Best Local Similarity	89.5%; Pred. No. 91;	Matches 17; Conservative	0; Mismatches	2; Indels
0; Gaps					
QY	4736	TTTTCAAAATATGCTCC	4754		
DB	3	TTTTCAAAATGATGCCCC	21		
RESULT 121					
AX140444					
LOCUS	AX140444	21 bp	DNA	linear	PAT 31-MAY-2001
DEFINITION	Sequence 66 from Patent EP1114862.				
ACCESSION	AX140444				
VERSION	AX140444.1	GI:14280586			
KEYWORDS	synthetic construct				
SOURCE	synthetic construct				
ORGANISM	other sequences; artificial sequences.				
REFERENCE	1				
AUTHORS	Wolf, E., Werner, S., Halle, J.P., Regenbogen, J. and Goppelt, A.				
TITLE	Use of polypeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in identifying pharmacologically active substances				
JOURNAL	Patent: EP 1114862-A 66 11-JUL-2001;				
FEATURES	Switch Biotech Aktiengesellschaft (DE)				
source	Location/Qualifiers				
1..21					
/organism="synthetic construct"					
/mol_type="unassigned DNA"					
/db_xref="taxon:32630"					
/note="Universal primer"					
Query Match					
Best Local Similarity 0.3%; Score 15.8; DB 1; Length 21;					
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	3258	CATTGTGTCCTTTGTCA	3276		
DB	3	CAGTTGTGTCCTTTGTCA	21		
RESULT 122					
AX140446					
LOCUS	AX140446	21 bp	DNA	linear	PAT 31-MAY-2001
DEFINITION	Sequence 68 from Patent EP1114862.				
ACCESSION	AX140446				
VERSION	AX140446.1	GI:14280588			
KEYWORDS	Mus musculus (house mouse)				
SOURCE	Mus musculus				
ORGANISM	Mus musculus				
REFERENCE	1				
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.				
TITLE	Wolf, E., Werner, S., Halle, J.P., Regenbogen, J. and Goppelt, A.				
JOURNAL	Use of polypeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in identifying pharmacologically active substances				
FEATURES	Patent: EP 1114862-A 68 11-JUL-2001;				
source	Switch Biotech Aktiengesellschaft (DE)				
1..21					
/organism="Mus musculus"					
/mol_type="unassigned DNA"					
/db_xref="taxon:10090"					
Query Match					
Best Local Similarity 0.3%; Score 15.8; DB 1; Length 21;					
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	3258	CATTGTGTCCTTTGTCA	3276		

```

VERSION      AX642667.1  GI:28474969
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE    1
AUTHORS      Halle,J.P., Goppelt,A. and Hof,P.
TITLE        Use of alpha 1-antichymotrypsin polypeptides or nucleic acids
              encoding them, or of a cell which is expressing an act polypeptide,
              or a nucleic acid encoding it, for treatment and/or prevention of
              diabetes-associated and/or arterial poorly healing wounds and for
              identifying pharmacologically active substances
JOURNAL      Patent: WO 0208180-A 13 07-NOV-2002;
              Switch Biotech GmbH (DE)
FEATURES     source
              1..21
              /organism="Mus musculus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:10090"

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3258 CATTGTGTCCCTTTGTCA 3276
      |||||||
Db 3 CAGTTGTGTCCTTGTCA 21

RESULT 126
AX754893/c
LOCUS       AX754893                21 bp  DNA  linear  PAT 23-JUN-2003
DEFINITION Sequence 4 from Patent WO03035692.
ACCESSION  AX754893
VERSION    AX754893.1  GI:32167321
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.

REFERENCE    1
AUTHORS      Kadler,K.E. and Bulleid,N.J.
TITLE        Modified peptides and their uses
JOURNAL      Patent: WO 03035692-A 4 01-MAY-2003;
              THE VICTORIA UNIVERSITY OF MANCHESTER (GB)
FEATURES     source
              1..21
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="Primer"

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. NO. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1876 GCCTTGAGGACCTTGACCA 1894
      |||||||
Db 21 GCCTTGAGGCTCTTGACCA 3

RESULT 127
BD079122
LOCUS       BD079122                21 bp  DNA  linear  PAT 27-AUG-2002
DEFINITION Use of polypeptides for diagnosis or remedy of dermatology diseases
              or nucleic acids encoding the same, and use thereof for
              identification of pharmacologically active substances.
ACCESSION  BD079122
VERSION    BD079122.1  GI:22624725
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.

REFERENCE    1
AUTHORS      Wolf,E., Werner,S., Halle,J.P., Regenbogen,J. and Goppelt,A.
TITLE        Use of polypeptides for diagnosis or remedy of dermatology diseases
              or nucleic acids encoding the same, and use thereof for
              identification of pharmacologically active substances
JOURNAL      Patent: JP 2001292783-A 10 23-OCT-2001;
              SWITCH BIOTECH AG
COMMENT     OS Artificial Sequence
              PN JP 2001292783-A/8
              PD 23-OCT-2001
              PF 17-NOV-2000 JP 2000351811
              PR 17-NOV-1999 DE 19955349.1,17-DEC-1999 US 172511 PR
              20-JUN-2000 DE 10030149.5
              PI ECKARD WOLF,SABINE WERNER,JOERN PETER HALLE,JOHANNES PI
              REGENBOGEN,
              PI ANDREAS GOPPELT
              PC C12N15/09,A01K67/027,A61K31/713,A61K38/00,A61K39/395,A61K39/
              PC 395,A61K48/00,
              PC A61P17/02,C07K14/47,C07K16/18,C07K16/40,C12M1/00,C12N5/10, PC
              C12N9/00,
              PC C12N9/02,C12N9/16,C12N15/02,C12P21/02,C12P21/08,C12Q1/68, PC
              GOIN33/15,
              PC
              GOIN33/50,GOIN33/50,GOIN33/53,GOIN33/53,GOIN33/566,GOIN33/577// PC
              (C12N5/10,C12R1:91),C12N15/00,A61K37/02,C12N5/00,C12N15/00, PC
              (C12N5/00,C12R1:91)
              CC Description of Artificial Sequence: Universal Primer PH Key
              CC Location/Qualifiers
              FT source 1..21
              FT /organism='Artificial Sequence'.

REFERENCE    1
AUTHORS      Wolf,E., Werner,S., Halle,J.P., Regenbogen,J. and Goppelt,A.
TITLE        Use of polypeptides for diagnosis or remedy of dermatology diseases
              or nucleic acids encoding the same, and use thereof for
              identification of pharmacologically active substances
JOURNAL      Patent: JP 2001292783-A 8 23-OCT-2001;
              SWITCH BIOTECH AG
COMMENT     OS Artificial Sequence
              PN JP 2001292783-A/8
              PD 23-OCT-2001
              PF 17-NOV-2000 JP 2000351811
              PR 17-NOV-1999 DE 19955349.1,17-DEC-1999 US 172511 PR
              20-JUN-2000 DE 10030149.5
              PI ECKARD WOLF,SABINE WERNER,JOERN PETER HALLE,JOHANNES PI
              REGENBOGEN,
              PI ANDREAS GOPPELT
              PC C12N15/09,A01K67/027,A61K31/713,A61K38/00,A61K39/395,A61K39/
              PC 395,A61K48/00,
              PC A61P17/02,C07K14/47,C07K16/18,C07K16/40,C12M1/00,C12N5/10, PC
              C12N9/00,
              PC C12N9/02,C12N9/16,C12N15/02,C12P21/02,C12P21/08,C12Q1/68, PC
              GOIN33/15,
              PC
              GOIN33/50,GOIN33/50,GOIN33/53,GOIN33/53,GOIN33/566,GOIN33/577// PC
              (C12N5/10,C12R1:91),C12N15/00,A61K37/02,C12N5/00,C12N15/00, PC
              (C12N5/00,C12R1:91)
              CC Description of Artificial Sequence: Universal Primer PH Key
              CC Location/Qualifiers
              FT source 1..21
              FT /organism='Artificial Sequence'.

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3258 CATTGTGTCCCTTTGTCA 3276
      |||||||
Db 3 CAGTTGTGTCCTTGTCA 21

RESULT 128
BD079124
LOCUS       BD079124                21 bp  DNA  linear  PAT 27-AUG-2002
DEFINITION Use of polypeptides for diagnosis or remedy of dermatology diseases
              or nucleic acids encoding the same, and use thereof for
              identification of pharmacologically active substances.
ACCESSION  BD079124
VERSION    BD079124.1  GI:22624727
KEYWORDS   Mus musculus (house mouse)
SOURCE     Mus musculus
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE    1
AUTHORS      Wolf,E., Werner,S., Halle,J.P., Regenbogen,J. and Goppelt,A.
TITLE        Use of polypeptides for diagnosis or remedy of dermatology diseases
              or nucleic acids encoding the same, and use thereof for
              identification of pharmacologically active substances
JOURNAL      Patent: JP 2001292783-A 10 23-OCT-2001;
              SWITCH BIOTECH AG
COMMENT     OS Mus musculus (mouse)
              PN JP 2001292783-A/10
              PD 23-OCT-2001
              PF 17-NOV-2000 JP 2000351811
              PR 17-NOV-1999 DE 19955349.1,17-DEC-1999 US 172511 PR
              20-JUN-2000 DE 10030149.5
              PI ECKARD WOLF,SABINE WERNER,JOERN PETER HALLE,JOHANNES PI
              REGENBOGEN,

```

PI ANDREAS GOPPELT
PC C12N15/09,A01K67/027,A61K31/713,A61K38/00,A61K39/395,A61K39/
PC 395,A61K48/00
PC A61P17/02,C07K16/18,C07K16/40,C12M1/00,C12N5/10, PC
C12N9/00,
PC C12N9/02,C12N9/16,C12N15/02,C12P21/02,C12P21/08,C12Q1/68, PC
G01N33/15,
PC
G01N33/50,G01N33/53,G01N33/53,G01N33/566,G01N33/577// PC
(C12N5/10,C12R1:91),C12N15/00,A61K37/02,C12N5/00,C12N15/00, PC
(C12N5/00,C12R1:91)
CC Use of polypeptides for diagnosis or remedy of dermatology CC
diseases or
CC nucleic acids encoding the same, and use thereof for CC
identification of
CC pharmacologically active substances
FH Key Location/Qualifiers
FT source 1..21 /organism='Mus musculus (mouse)'.
FT Location/Qualifiers
FEATURES
source
1..21
/organism='Mus musculus'
/mol_type='genomic DNA'
/db_xref='taxon:10090'
Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 91;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3258 CATTGTGTCCTTTGTCA 3276
Db ||||| ||||| |||||
3 CAGTTGTGTCCTTTGTCA 21
RESULT 129
AX214621/c
LOCUS AX214621 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 63 from Patent WO0159103.
ACCESSION AX214621
VERSION AX214621.1 GI:15524664
KEYWORDS
synthetic construct
synthetic construct
other sequences; artificial sequences.
SOURCE
ORGANISM
REFERENCE
1
Blatt,L., McSwiggen,J. and Chowrira,B.M.
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
TITLE nogo gene expression
JOURNAL Patent: WO 0159103-A 63 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
MCSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism='synthetic construct'
/mol_type='unassigned RNA'
/db_xref='taxon:32630'
/note='Nucleic Acid'
Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 97;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1577 TTCTGCAGATGAGCGT 1593
Db ||||| ||||| |||||
17 TTCTGCAGAGGAGCGT 1
RESULT 130
AX215520/c
LOCUS AX215520 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 962 from Patent WO0159103.
ACCESSION AX215520
VERSION AX215520.1 GI:15525563

KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1
Blatt,L., McSwiggen,J. and Chowrira,B.M.
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
TITLE nogo gene expression
JOURNAL Patent: WO 0159103-A 962 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
MCSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism='synthetic construct'
/mol_type='unassigned RNA'
/db_xref='taxon:32630'
/note='Nucleic Acid'
Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 97;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1579 TCTGCAGATGAGCGTAT 1595
Db ||||| ||||| |||||
17 TCTGCAGAGGAGCGTAT 1
RESULT 131
AX215521/c
LOCUS AX215521 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 963 from Patent WO0159103.
ACCESSION AX215521
VERSION AX215521.1 GI:15525564
KEYWORDS
synthetic construct
synthetic construct
other sequences; artificial sequences.
SOURCE
ORGANISM
REFERENCE
1
Blatt,L., McSwiggen,J. and Chowrira,B.M.
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
TITLE nogo gene expression
JOURNAL Patent: WO 0159103-A 963 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
MCSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism='synthetic construct'
/mol_type='unassigned RNA'
/db_xref='taxon:32630'
/note='Nucleic Acid'
Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 97;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1578 TTCTGCAGATGAGCGTA 1594
Db ||||| ||||| |||||
17 TTCTGCAGAGGAGCGTA 1
RESULT 132
AX724695/c
LOCUS AX724695 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2382 from Patent WO03025176.
ACCESSION AX724695
VERSION AX724695.1 GI:30504038
KEYWORDS
Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 Telerman,A., Amson,R. and Tuijnder,M.

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025176-A 2382 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers

1. .17
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"

Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 97;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1401 AAATAAAATTCGAAGATC 1417
 Db 17 AATAGAAATTCGAAGATC 1

RESULT 133
 AX727643
 LOCUS AX727643 17 bp DNA linear PAT 08-MAY-2003

DEFINITION Sequence 5330 from Patent WO03025176.
 ACCESSION AX727643
 VERSION AX727643.1 GI:30506986
 KEYWORDS Mus musculus (house mouse)
 SOURCE Mus musculus

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1
 AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025176-A 5330 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers

1. .17
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"

Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 97;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 960 GATCCTGACAGCTGTGG 976
 Db 1 GATCCTGACAGCTGTGG 17

RESULT 134
 AX756789/c
 LOCUS AX756789 17 bp DNA linear PAT 25-JUN-2003

DEFINITION Sequence 110 from Patent WO03040369.
 ACCESSION AX756789
 VERSION AX756789.1 GI:32251343
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
 TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines

JOURNAL Patent: WO 03040369-A 110 15-MAY-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers

1. .17

/organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 97;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1332 TGTACCATTTATTTGATC 1348
 Db 17 TGTACCTTTATTTGATC 1

RESULT 135
 AX759799
 LOCUS AX759799 17 bp DNA linear PAT 25-JUN-2003

DEFINITION Sequence 3120 from Patent WO03040369.
 ACCESSION AX759799
 VERSION AX759799.1 GI:32254415
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
 TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines

JOURNAL Patent: WO 03040369-A 3120 15-MAY-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers

1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 97;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3061 GATCTTGTCTTAAACCAA 3077
 Db 1 GATCTTGTCTTAAACCAA 17

RESULT 136
 AX378533
 LOCUS AX378533 18 bp DNA linear PAT 18-MAR-2002

DEFINITION Sequence 322 from Patent WO0206525.
 ACCESSION AX378533
 VERSION AX378533.1 GI:19574386
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Cohen,D., Blumenfeld,M., Chumakov,I., Abderrahim,H. and Bihain,B.
 TITLE Obesity associated biallelic marker maps

JOURNAL Patent: WO 0206525-A 322 24-JAN-2002;
 FEATURES GENSET (FR)
 source Location/Qualifiers

1. .18
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

primer_bind 1. .18
 /note="upstream amplification primer 99-28352 for SEQ 151"

Query Match 0.3%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 98;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Query Match      0.3%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1896 AGTTCTTGCTCTCGTCA 1912
    ||||| ||||| |||||
Db 17 AGTTCTTGCTCTCGTCA 1

RESULT 139
AX765627 18 bp DNA linear PAT 25-JUN-2003
LOCUS
DEFINITION Sequence 13 from Patent WO03014154.
ACCESSION AX765627
VERSION AX765627.1 GI:32259820
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Boshoff, C.
TITLE Vaccines against kaposi's sarcoma-associated herpesvirus
JOURNAL Patent: WO 03014154-A 13 20-FEB-2003;
UNIVERSITY College London (GB)
LOCATION/Qualifiers
FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PRIMER"

Query Match      0.3%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1955 TTCTGCCAGGCATAGCC 1971
    ||||| ||||| |||||
Db 2 TTCTGCCAGGCATAGTC 18

RESULT 138
BD124158/18 bp DNA linear PAT 18-SEP-2002
LOCUS
DEFINITION Treatment of bone loss with osteoblastoma precursor cells.
ACCESSION BD124158
VERSION BD124158.1 GI:23219103
KEYWORDS JP 2002502822-A/11.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Hollinger, J.O., Win, S.R., Edmondo, F. and Wang, S.S.
TITLE Treatment of bone loss with osteoblastoma precursor cells
JOURNAL Patent: JP 2002502822-A 11 29-JAN-2002;
COMMENT OREGON HEALTH SCIENCES UNIVERSITY
OS Artificial Sequence
PN JP 2002502822-A/11
PD 29-JAN-2002
PF 10-FEB-1999 JP 2000530221
PR 10-FEB-1998 US 60/074420, 12-FEB-1998 US 60/074451, PI
JEFFREY O HOLLINGER, SHELLEY R WIN, FRANK EDMONDO, SHU SI WANG PC
A61K35/12, A61B17/56, A61F2/28, A61K9/00, A61K38/22, A61L27/00, PC
A61L29/00,
PC A61P19/00, A61P19/10, C07K14/51, C12N5/10, C12N15/09, A61K37/24, PC
C12N5/00,
PC C12N15/00
CC Description of Artificial Sequence: PCR primer FH Key
LOCATION/Qualifiers
FT source 1..18
FT Location/Qualifiers
source 1..18
/organism="Artificial Sequence".
/mol_type="synthetic construct"
/db_xref="taxon:32630"

```

LOCUS AR161668 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 6 from patent US 6258359.
ACCESSION AR161668
VERSION AR161668.1 GI:16228523
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Labigne,A., Suerbaum,S., Ferrero,R.L. and Thiberge,J.-M.
TITLE Immunogenic compositions against helicobacter infection,
polypeptides for use in the compositions, and nucleic acid
sequences encoding said polypeptides
JOURNAL Patent: US 6258359-A 6 10-JUL-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1800 TGAATCCTTTTGGATC 1816
Db 18 TGAATCCTTTTGGATC 2
||||| |||||||
RESULT 142
BD228503 20 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION IL-17 homologous polypeptide and its application to remedy.
ACCESSION BD228503
VERSION BD228503.1 GI:33038273
KEYWORDS JP 2002515246-A/98.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Chen,J., Filvaroff,E., Goddard,A., Gurney,A.L., Li,H. and Wood,W.I.
TITLE IL-17 homologous polypeptide and its application to remedy
JOURNAL Patent: JP 2002515246-A 98 28-MAY-2002;
COMMENT GENETECH INC
OS Unidentified
PN JP 2002515246-A/98
PD 28-MAY-2002
PF 14-MAY-1999 JP 2000549734
PR 15-MAY-1998 US 60/085579, 23-DEC-1998 US 60/113621 PI
JIAN CHEN, ELLEN FILVAROFF, AUDLEY GODDARD, AUSTIN L GURNEY, PI
HANZHONG LI,
PI WILLIAM I WOOD
PC C12N15/09, A61K38/21, A61K45/00, A61P19/00, C07K14/52, C07K16/24,
C07K19/00,
PC C12N1/19, C12N1/21, C12N5/10, C12P21/02, C12P21/08, C12Q1/00 PC
C12Q1/68, C12N15/00,
PC A61K37/66, C12N5/00
CC Strandedness: Single;
CC Topology: Linear;
CC IL-17 homologous polypeptide and its application to remedy FH
Key Location/Qualifiers
FT source 1..20
/organism="Unidentified".
FT Location/Qualifiers
source 1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 4586 CCACAGGGGCTTCATC 4602

LOCUS AR231312 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 49 from patent US 6451968.
ACCESSION AR231312
VERSION AR231312.1 GI:27272243
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Egholm,M., Nielsen,P., Buchardt,O., Dueholm,K.L., Christensen,L.,
Coull,J.M., Kiely,J. and Griffith,M.
TITLE Peptide nucleic acids
JOURNAL Patent: US 6451968-A 49 17-SEP-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 19 AAAAAAAAAAAGAAAAA 2
||||| |||||||
RESULT 144
AR294465/c 20 bp DNA linear PAT 12-JUN-2003
LOCUS
DEFINITION Sequence 6200 from patent US 6537751.
ACCESSION AR294465
VERSION AR294465.1 GI:31681749
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 6200 25-MAR-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 4356 GAAATAAGGTTTGGG 4372
Db 17 GAAATAAGTGTGGG 1
||||| |||||||
RESULT 145
AR308288 20 bp DNA linear PAT 12-JUN-2003
LOCUS
DEFINITION Sequence 6 from patent US 655311.
ACCESSION AR308288
VERSION AR308288.1 GI:31699681
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)

AUTHORS Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and de Man,R.A.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: US 6555311-A 6 29-APR-2003;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred.No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 525 TTATATCCTTAACCTTAC 541
Db 3 TTCTATCCTTAACCTTAC 19
RESULT 146
AR359728 AR359728 20 bp DNA linear PAT 17-AUG-2003
LOCUS Sequence 98 from patent US 6593456.
DEFINITION AR359728
ACCESSION AR359728
VERSION AR359728.1 GI:33766472
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 20)
AUTHORS Gatanaga,T. and Granger,G.A.
TITLE Tumor necrosis factor receptor releasing enzyme
JOURNAL Patent: US 6593456-A 98 15-JUL-2003;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred.No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 4586 CCACACAGGGTTCATC 4602
Db 2 CCACAGAGGGTTCATC 18
RESULT 147
AX010862
LOCUS Sequence 31 from Patent WO9958556.
DEFINITION AX010862 20 bp DNA linear PAT 06-SEP-2000
ACCESSION AX010862
VERSION AX010862.1 GI:9997573
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Ballabio,A. and Casari,G.
TITLE Protein associated to hereditary spastic paraplegia
JOURNAL Patent: WO 9958556-A 31 18-NOV-1999;
FONDAZIONE TELETHON (IT); BALLABIO ANDREA (IT); CASARI GIORGIO (IT)
FEATURES Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="oligonucleotide"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred.No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1715 CATCTGCCTACGACC 1731
|||||

Db 1 CATCTGCCTACTGACC 17
RESULT 148
AX029045
LOCUS Sequence 6 from Patent WO9821317.
DEFINITION AX029045 20 bp DNA linear PAT 16-SEP-2000
ACCESSION AX029045
VERSION AX029045.1 GI:10190033
KEYWORDS
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE
1
AUTHORS Bartholomeusz,A.I., Locarnini,S.A., Aye,T.T. and de Man,R.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: WO 9821317-A 6 22-MAY-1998;
BARTHOLOMEUSZ ANGELINE INGRID (AU); LOCARNINI STEPHEN ALISTER (AU)
; WESTERN HEALTH CARE NETWORK (AU); AYE THEIN THEIN (AU); MAN
ROBERT A DE (AU)
FEATURES Location/Qualifiers
source
1..20
/organism="Hepatitis B virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10407"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred.No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 525 TTATATCCTTAACCTTAC 541
Db 3 TTCTATCCTTAACCTTAC 19
RESULT 149
AX699215/c
LOCUS Sequence 156 from Patent WO03000727.
DEFINITION AX699215 20 bp DNA linear PAT 29-MAY-2003
ACCESSION AX699215
VERSION AX699215.1 GI:29499865
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Zhang,Y., Moffatt,M., Cookson,W. and Tinsley,J.O.
TITLE Atopy
JOURNAL Patent: WO 03000727-A 156 03-JAN-2003;
ISIS INNOVATION LIMITED (GB)
FEATURES Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred.No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2636 ATGTCTACTGTAAACG 2652
Db 17 ATGTCTACTGTAAACAG 1
RESULT 150
BD009330
LOCUS Viral variants and methods for detecting same.
DEFINITION BD009330 20 bp DNA linear PAT 31-JAN-2002
ACCESSION BD009330
VERSION BD009330.1 GI:18637703
KEYWORDS JP 2001503277-A/6.

SOURCE unidentified
ORGANISM unidentified
REFERENCE unclassified.
AUTHORS 1 (bases 1 to 20)
TITLE Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and Man,R.A.D.
JOURNAL Viral variants and methods for detecting same
PATENT: JP 2001503277-A 6 13-MAR-2001;
NORTH WESTERN HEALTH CARE NETWORK
COMMENT OS Hepatitis virus (hepatitis B virus)
PN JP 2001503277-A/6
PD 13-MAR-2001
PF 15-AUG-1997 JP 1998521944
PR 08-NOV-1996 AU PO 3519
PI STEPHEN ALISTER LOCARNINI,ANGELINE INGRID BARTHOLOMEUSZ, PI
THEIN THEIN AYE,
PI ROBERT A DE MAN
PC C12N7/01,C12N7/00,C12N15/36,C12N15/54,C07K14/02 CC
FH Key Location/Qualifiers
FT source 1..20
FT /organism='Hepatitis virus (hepatitis B FT
virus)';
FEATURES Location/Qualifiers
source 1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred.No.98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 525 TTATATCCTAACCTTAC 541
||| ||||| |||||
Db 3 TTCTATCCTAACCTTAC 19

Search completed: August 18, 2005, 08:32:12
Job time : 10 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 08:36:54 ; Search time 32 Seconds
(without alignments)
3.559 Million cell updates/sec

Title: US-10-667-022-4
Perfect score: 5085
Sequence: 1 ggaatccccgggtgcagga.....tcgagggggggcccggtacc 5085

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 536 seqs, 11197 residues

Total number of hits satisfying chosen parameters: 1072

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 542 summaries

Database : fetch4rng.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	60	1.2	60	1	Human spliced tran
2	44	0.9	54	1	Cotton androecium
3	41.2	0.8	51	1	Cotton androecium
4	41.2	0.8	51	1	Cotton androecium
5	40.6	0.8	50	1	TSO element used i
6	40.6	0.8	50	1	ASO element used i
7	37.8	0.7	50	1	Oligonucleotide oc
8	33.8	0.7	43	1	238P1B2 gene relat
9	33.2	0.7	40	1	Sequence of the 5'
10	27.6	0.5	35	1	Antitumoural phosph
11	27	0.5	35	1	Antitumoural phosph
12	27	0.5	35	1	Antitumoural phosph
13	26	0.5	26	1	Human P13K regulat
14	26	0.5	26	1	Human phosphoinosi
15	26	0.5	34	1	Tomato spotted wil
16	25.4	0.5	27	1	Duo binding moiety
17	24	0.5	24	1	Microarray synthes
18	24	0.5	24	1	Microarray synthes
19	24	0.5	30	1	Levanucrase mutan
20	23	0.5	23	1	Human P13K regulat
21	23	0.5	23	1	Human P13K regulat
22	23	0.5	23	1	Human phosphoinosi
23	23	0.5	23	1	Human phosphoinosi
24	22	0.4	25	1	Caenorhabditis ele
25	21	0.4	21	1	PCR primer BKSBE u
26	21	0.4	24	1	Inverse PCR primer
27	21	0.4	24	1	Human GM2 activati
28	21	0.4	24	1	Human molecular ch
29	21	0.4	24	1	Human zinc finger
30	21	0.4	24	1	Caenorhabditis ele
31	20.4	0.4	24	1	Human natural kill
32	20.2	0.4	22	1	Oligo dr PCR prime
33	20	0.4	20	1	pBluescript vector

34	20	0.4	20	1	AAF76469	Maize ZmMAD92 codi
35	20	0.4	20	1	ADH26676	Human P13K regulat
36	20	0.4	20	1	ADH26709	Human P13K regulat
37	20	0.4	20	1	ADH26726	Human P13K regulat
38	20	0.4	20	1	ADH26733	Human P13K regulat
39	20	0.4	20	1	ADH26739	Human P13K regulat
40	20	0.4	20	1	ADH26749	Human P13K regulat
41	20	0.4	20	1	ADH26756	Human P13K regulat
42	20	0.4	20	1	ADH26678	Human P13K regulat
43	20	0.4	20	1	ADH26681	Human P13K regulat
44	20	0.4	20	1	ADH26701	Human P13K regulat
45	20	0.4	20	1	ADH26717	Human P13K regulat
46	20	0.4	20	1	ADH26741	Human P13K regulat
47	20	0.4	20	1	ADH26748	Human P13K regulat
48	20	0.4	20	1	ADH26752	Human P13K regulat
49	20	0.4	20	1	ADH26754	Human P13K regulat
50	20	0.4	20	1	ADH26764	Human P13K regulat
51	20	0.4	20	1	ADH26775	Human P13K regulat
52	20	0.4	20	1	ADH26797	Human P13K regulat
53	20	0.4	20	1	ADH26811	Human P13K regulat
54	20	0.4	20	1	ADH26695	Human P13K regulat
55	20	0.4	20	1	ADH26735	Human P13K regulat
56	20	0.4	20	1	ADH26794	Human P13K regulat
57	20	0.4	20	1	ADH26683	Human P13K regulat
58	20	0.4	20	1	ADH26704	Human P13K regulat
59	20	0.4	20	1	ADH26743	Human P13K regulat
60	20	0.4	20	1	ADH26747	Human P13K regulat
61	20	0.4	20	1	ADH26760	Human P13K regulat
62	20	0.4	20	1	ADH26780	Human P13K regulat
63	20	0.4	20	1	ADH26790	Human P13K regulat
64	20	0.4	20	1	ADH26805	Human P13K regulat
65	20	0.4	20	1	ADH26682	Human P13K regulat
66	20	0.4	20	1	ADH26707	Human P13K regulat
67	20	0.4	20	1	ADH26723	Human P13K regulat
68	20	0.4	20	1	ADH26727	Human P13K regulat
69	20	0.4	20	1	ADH26732	Human P13K regulat
70	20	0.4	20	1	ADH26737	Human P13K regulat
71	20	0.4	20	1	ADH26744	Human P13K regulat
72	20	0.4	20	1	ADH26768	Human P13K regulat
73	20	0.4	20	1	ADH26779	Human P13K regulat
74	20	0.4	20	1	ADH26791	Human P13K regulat
75	20	0.4	20	1	ADH26793	Human P13K regulat
76	20	0.4	20	1	ADH26798	Human P13K regulat
77	20	0.4	20	1	ADH26742	Human P13K regulat
78	20	0.4	20	1	ADH26761	Human P13K regulat
79	20	0.4	20	1	ADH26692	Human P13K regulat
80	20	0.4	20	1	ADH26703	Human P13K regulat
81	20	0.4	20	1	ADH26715	Human P13K regulat
82	20	0.4	20	1	ADH26716	Human P13K regulat
83	20	0.4	20	1	ADH26771	Human P13K regulat
84	20	0.4	20	1	ADH26795	Human P13K regulat
85	20	0.4	20	1	ADH26690	Human P13K regulat
86	20	0.4	20	1	ADH26708	Human P13K regulat
87	20	0.4	20	1	ADH26710	Human P13K regulat
88	20	0.4	20	1	ADH26734	Human P13K regulat
89	20	0.4	20	1	ADH26757	Human P13K regulat
90	20	0.4	20	1	ADH26807	Human P13K regulat
91	20	0.4	20	1	ADH26729	Human P13K regulat
92	20	0.4	20	1	ADH26745	Human P13K regulat
93	20	0.4	20	1	ADH26759	Human P13K regulat
94	20	0.4	20	1	ADH26784	Human P13K regulat
95	20	0.4	20	1	ADH26784	Human P13K regulat
96	20	0.4	20	1	ADH26804	Human P13K regulat
97	20	0.4	20	1	ADH26806	Human P13K regulat
98	20	0.4	20	1	ADH26808	Human P13K regulat
99	20	0.4	20	1	ADH26684	Human P13K regulat
100	20	0.4	20	1	ADH26688	Human P13K regulat
101	20	0.4	20	1	ADH26691	Human P13K regulat
102	20	0.4	20	1	ADH26693	Human P13K regulat
103	20	0.4	20	1	ADH26713	Human P13K regulat
104	20	0.4	20	1	ADH26724	Human P13K regulat
105	20	0.4	20	1	ADH26730	Human P13K regulat
106	20	0.4	20	1	ADH26751	Human P13K regulat

107	20	0.4	20	1	ADH26758	Human PI3K regulat	180	20	0.4	20	1	ADL34659	Phosphoinositide-3
108	20	0.4	20	1	ADH26762	Human PI3K regulat	181	20	0.4	20	1	ADL34660	Phosphoinositide-3
109	20	0.4	20	1	ADH26766	Human PI3K regulat	182	20	0.4	20	1	ADL34677	Phosphoinositide-3
110	20	0.4	20	1	ADH26773	Human PI3K regulat	183	20	0.4	20	1	ADL34700	Phosphoinositide-3
111	20	0.4	20	1	ADH26781	Human PI3K regulat	C 184	20	0.4	20	1	ADL34602	ISIS antisense oli
112	20	0.4	20	1	ADH26796	Human PI3K regulat	C 185	20	0.4	20	1	ADL34605	ISIS antisense oli
113	20	0.4	20	1	ADH26800	Human PI3K regulat	186	20	0.4	20	1	ADL34651	Phosphoinositide-3
C 114	20	0.4	20	1	ADH26696	Human PI3K regulat	187	20	0.4	20	1	ADL34671	Phosphoinositide-3
C 115	20	0.4	20	1	ADH26697	Human PI3K regulat	188	20	0.4	20	1	ADL34699	Phosphoinositide-3
C 116	20	0.4	20	1	ADH26706	Human PI3K regulat	C 189	20	0.4	20	1	ADL34576	ISIS antisense oli
C 117	20	0.4	20	1	ADH26720	Human PI3K regulat	C 190	20	0.4	20	1	ADL34598	ISIS antisense oli
C 118	20	0.4	20	1	ADH26753	Human PI3K regulat	C 191	20	0.4	20	1	ADL34607	ISIS antisense oli
C 119	20	0.4	20	1	ADH26750	Human PI3K regulat	C 192	20	0.4	20	1	ADL34614	ISIS antisense oli
C 120	20	0.4	20	1	ADH26788	Human PI3K regulat	C 193	20	0.4	20	1	ADL34616	ISIS antisense oli
121	20	0.4	20	1	ADH26789	Human PI3K regulat	C 194	20	0.4	20	1	ADL34630	ISIS antisense oli
122	20	0.4	20	1	ADH26774	Human PI3K regulat	C 195	20	0.4	20	1	ADL34640	ISIS antisense oli
123	20	0.4	20	1	ADH26782	Human PI3K regulat	196	20	0.4	20	1	ADL34649	Phosphoinositide-3
C 124	20	0.4	20	1	ADH26689	Human PI3K regulat	197	20	0.4	20	1	ADL34669	Phosphoinositide-3
C 125	20	0.4	20	1	ADH26721	Human PI3K regulat	198	20	0.4	20	1	ADL34687	Phosphoinositide-3
C 126	20	0.4	20	1	ADH26736	Human PI3K regulat	C 200	20	0.4	20	1	ADL34593	ISIS antisense oli
127	20	0.4	20	1	ADH26770	Human PI3K regulat	C 201	20	0.4	20	1	ADL34597	ISIS antisense oli
128	20	0.4	20	1	ADH26774	Human PI3K regulat	C 202	20	0.4	20	1	ADL34613	ISIS antisense oli
129	20	0.4	20	1	ADH26778	Human PI3K regulat	C 203	20	0.4	20	1	ADL34621	ISIS antisense oli
130	20	0.4	20	1	ADH26782	Human PI3K regulat	204	20	0.4	20	1	ADL34652	Phosphoinositide-3
131	20	0.4	20	1	ADH26785	Human PI3K regulat	205	20	0.4	20	1	ADL34664	Phosphoinositide-3
132	20	0.4	20	1	ADH26799	Human PI3K regulat	206	20	0.4	20	1	ADL34682	Phosphoinositide-3
133	20	0.4	20	1	ADH26801	Human PI3K regulat	207	20	0.4	20	1	ADL34684	Phosphoinositide-3
134	20	0.4	20	1	ADH26803	Human PI3K regulat	C 208	20	0.4	20	1	ADL34608	ISIS antisense oli
135	20	0.4	20	1	ADH26686	Human PI3K regulat	C 209	20	0.4	20	1	ADL34618	ISIS antisense oli
C 136	20	0.4	20	1	ADH26687	Human PI3K regulat	C 210	20	0.4	20	1	ADL34618	ISIS antisense oli
C 137	20	0.4	20	1	ADH26699	Human PI3K regulat	C 211	20	0.4	20	1	ADL34633	ISIS antisense oli
C 138	20	0.4	20	1	ADH26700	Human PI3K regulat	C 212	20	0.4	20	1	ADL34647	Phosphoinositide-3
C 139	20	0.4	20	1	ADH26711	Human PI3K regulat	C 213	20	0.4	20	1	ADL34577	ISIS antisense oli
C 140	20	0.4	20	1	ADH26705	Human PI3K regulat	C 214	20	0.4	20	1	ADL34583	ISIS antisense oli
C 141	20	0.4	20	1	ADH26763	Human PI3K regulat	C 215	20	0.4	20	1	ADL34592	ISIS antisense oli
142	20	0.4	20	1	ADH26783	Human PI3K regulat	C 216	20	0.4	20	1	ADL34595	ISIS antisense oli
143	20	0.4	20	1	ADH26786	Human PI3K regulat	C 217	20	0.4	20	1	ADL34600	ISIS antisense oli
144	20	0.4	20	1	ADH26792	Human PI3K regulat	C 218	20	0.4	20	1	ADL34617	ISIS antisense oli
145	20	0.4	20	1	ADH26810	Human PI3K regulat	C 219	20	0.4	20	1	ADL34620	ISIS antisense oli
146	20	0.4	20	1	ADH26677	Human PI3K regulat	C 220	20	0.4	20	1	ADL34623	ISIS antisense oli
C 147	20	0.4	20	1	ADH26681	Human PI3K regulat	C 221	20	0.4	20	1	ADL34629	ISIS antisense oli
C 148	20	0.4	20	1	ADH26694	Human PI3K regulat	222	20	0.4	20	1	ADL34663	Phosphoinositide-3
C 149	20	0.4	20	1	ADH26712	Human PI3K regulat	223	20	0.4	20	1	ADL34666	Phosphoinositide-3
C 150	20	0.4	20	1	ADH26714	Human PI3K regulat	224	20	0.4	20	1	ADL34675	Phosphoinositide-3
C 151	20	0.4	20	1	ADH26718	Human PI3K regulat	225	20	0.4	20	1	ADL34681	Phosphoinositide-3
C 152	20	0.4	20	1	ADH26722	Human PI3K regulat	226	20	0.4	20	1	ADL34686	Phosphoinositide-3
C 153	20	0.4	20	1	ADH26767	Human PI3K regulat	227	20	0.4	20	1	ADL34694	Phosphoinositide-3
154	20	0.4	20	1	ADH26777	Human PI3K regulat	C 228	20	0.4	20	1	ADL34586	ISIS antisense oli
C 155	20	0.4	20	1	ADH26702	Human PI3K regulat	C 229	20	0.4	20	1	ADL34589	ISIS antisense oli
C 156	20	0.4	20	1	ADH26719	Human PI3K regulat	C 230	20	0.4	20	1	ADL34601	ISIS antisense oli
C 157	20	0.4	20	1	ADH26725	Human PI3K regulat	C 231	20	0.4	20	1	ADL34624	ISIS antisense oli
C 158	20	0.4	20	1	ADH26731	Human PI3K regulat	C 232	20	0.4	20	1	ADL34636	ISIS antisense oli
C 159	20	0.4	20	1	ADH26740	Human PI3K regulat	233	20	0.4	20	1	ADL34689	Phosphoinositide-3
C 160	20	0.4	20	1	ADH26746	Human PI3K regulat	234	20	0.4	20	1	ADL34693	Phosphoinositide-3
C 161	20	0.4	20	1	ADH26755	Human PI3K regulat	C 235	20	0.4	20	1	ADL34591	ISIS antisense oli
162	20	0.4	20	1	ADH26772	Human PI3K regulat	C 236	20	0.4	20	1	ADL34594	ISIS antisense oli
163	20	0.4	20	1	ADH26776	Human PI3K regulat	C 237	20	0.4	20	1	ADL34596	ISIS antisense oli
C 164	20	0.4	20	1	ADH26680	Human PI3K regulat	C 238	20	0.4	20	1	ADL34606	ISIS antisense oli
C 165	20	0.4	20	1	ADH26685	Human PI3K regulat	C 239	20	0.4	20	1	ADL34611	ISIS antisense oli
C 166	20	0.4	20	1	ADH26698	Human PI3K regulat	C 240	20	0.4	20	1	ADL34622	ISIS antisense oli
C 167	20	0.4	20	1	ADH26728	Human PI3K regulat	241	20	0.4	20	1	ADL34657	Phosphoinositide-3
C 168	20	0.4	20	1	ADH26738	Human PI3K regulat	242	20	0.4	20	1	ADL34662	Phosphoinositide-3
C 169	20	0.4	20	1	ADH26787	Human PI3K regulat	243	20	0.4	20	1	ADL34680	Phosphoinositide-3
170	20	0.4	20	1	ADH26809	Human PI3K regulat	244	20	0.4	20	1	ADL34691	ISIS antisense oli
C 171	20	0.4	20	1	ADL34585	ISIS antisense oli	C 245	20	0.4	20	1	ADL34588	ISIS antisense oli
C 172	20	0.4	20	1	ADL34599	ISIS antisense oli	C 246	20	0.4	20	1	ADL34639	Phosphoinositide-3
C 173	20	0.4	20	1	ADL34603	ISIS antisense oli	247	20	0.4	20	1	ADL34643	Phosphoinositide-3
C 174	20	0.4	20	1	ADL34610	ISIS antisense oli	248	20	0.4	20	1	ADL34646	Phosphoinositide-3
C 175	20	0.4	20	1	ADL34637	ISIS antisense oli	249	20	0.4	20	1	ADL34695	Phosphoinositide-3
C 176	20	0.4	20	1	ADL34638	Phosphoinositide-3	250	20	0.4	20	1	ADL34697	Phosphoinositide-3
C 177	20	0.4	20	1	ADL34654	Phosphoinositide-3	C 251	20	0.4	20	1	ADL34590	ISIS antisense oli
178	20	0.4	20	1	ADL34656	Phosphoinositide-3	C 252	20	0.4	20	1	ADL34627	ISIS antisense oli

C 253	20	0.4	20	1	ADL34628	ISIS antisense oli	C 326	19	0.4	19	1	ADR82257	Hepatitis C virus
C 254	20	0.4	20	1	ADL34635	ISIS antisense oli	C 327	19	0.4	19	1	ADR82261	Hepatitis C virus
C 255	20	0.4	20	1	ADL34650	Phosphoinositide-3	C 328	19	0.4	19	1	ADR82258	Hepatitis C virus
C 256	20	0.4	20	1	ADL34667	Phosphoinositide-3	C 329	19	0.4	19	1	ADR82256	Hepatitis C virus
C 257	20	0.4	20	1	ADL34573	ISIS antisense oli	C 330	19	0.4	19	1	ADR82259	Hepatitis C virus
C 258	20	0.4	20	1	ADL34581	ISIS antisense oli	C 331	18.4	0.4	20	1	AA732292	Primer for manipul
C 259	20	0.4	20	1	ADL34612	ISIS antisense oli	C 332	18.4	0.4	22	1	ACF79629	Thiopurine S-methy
C 260	20	0.4	20	1	ADL34644	Phosphoinositide-3	C 333	18.4	0.4	23	1	AAH75578	Human transcrip
C 261	20	0.4	20	1	ADL34658	Phosphoinositide-3	C 334	18.4	0.4	24	1	AAH75578	Rhodospiridium mut
C 262	20	0.4	20	1	ADL34674	Phosphoinositide-3	C 335	18.2	0.4	24	1	AAZ07017	Murine alpha-L-idu
C 263	20	0.4	20	1	ADL34568	ISIS antisense oli	C 336	18.2	0.4	24	1	ABQ78896	Human zinc finger
C 264	20	0.4	20	1	ADL34569	ISIS antisense oli	C 337	18.2	0.4	24	1	ABQ78896	Kringle protein 14
C 265	20	0.4	20	1	ADL34570	ISIS antisense oli	C 338	18.2	0.4	24	1	AA519218	Human protease reg
C 266	20	0.4	20	1	ADL34579	ISIS antisense oli	C 339	18.2	0.4	24	1	AD081152	Prion protein poly
C 267	20	0.4	20	1	ADL34582	ISIS antisense oli	C 340	18	0.4	18	1	ADR32355	Rat KDR cytosolic
C 268	20	0.4	20	1	ADL34587	ISIS antisense oli	C 341	18	0.4	18	1	ADR57967	Nucleotide #4 for
C 269	20	0.4	20	1	ADL34609	ISIS antisense oli	C 342	18	0.4	22	1	AAA63751	PCR primer used to
C 270	20	0.4	20	1	ADL34635	ISIS antisense oli	C 343	17.8	0.4	21	1	ABA10153	Tail primer #146 f
C 271	20	0.4	20	1	ADL34619	ISIS antisense oli	C 344	17.8	0.4	22	1	ADR32218	Human Pdx-1 revers
C 272	20	0.4	20	1	ADL34641	ISIS antisense oli	C 345	17.4	0.3	19	1	AAH787932	Primer for rat cer
C 273	20	0.4	20	1	ADL34648	Phosphoinositide-3	C 346	17.4	0.3	19	1	AAH83687	cdk-we-hu ribozyme
C 274	20	0.4	20	1	ADL34673	Phosphoinositide-3	C 347	17.4	0.3	19	1	AAH58849	Cdk-we-hu ribozyme
C 275	20	0.4	20	1	ADL34685	Phosphoinositide-3	C 348	17.4	0.3	20	1	AA514499	Primer #24 in inve
C 276	20	0.4	20	1	ADL34567	ISIS antisense oli	C 349	17.4	0.3	20	1	ADR18861	2'-MOE gapmer anti
C 277	20	0.4	20	1	ADL34574	ISIS antisense oli	C 350	17.4	0.3	20	1	ADR33402	Antisense 2'-MOE g
C 278	20	0.4	20	1	ADL34584	ISIS antisense oli	C 351	17.4	0.3	21	1	ABL57072	Molecular beacon t
C 279	20	0.4	20	1	ADL34632	ISIS antisense oli	C 352	17.4	0.3	22	1	ADR42646	Acetylated aminopr
C 280	20	0.4	20	1	ADL34672	Phosphoinositide-3	C 353	17.4	0.3	23	1	AAQ92371	DNA primer. Synth
C 281	20	0.4	20	1	ADL34678	Phosphoinositide-3	C 354	17.4	0.3	23	1	AAH45480	PCR primer specifi
C 282	20	0.4	20	1	ADL34688	Phosphoinositide-3	C 355	17.2	0.3	22	1	ADR70614	Human Vbeta gene r
C 283	20	0.4	20	1	ADL34696	Phosphoinositide-3	C 356	17.2	0.3	22	1	AD016062	4 synthesis-period
C 284	20	0.4	20	1	ADL34701	Phosphoinositide-3	C 357	17.2	0.3	22	1	ADR32106	Hepatitis B virus
C 285	20	0.4	20	1	ADL34572	ISIS antisense oli	C 358	17.2	0.3	22	1	ADR67796	Hepatitis B virus
C 286	20	0.4	20	1	ADL34575	ISIS antisense oli	C 359	17	0.3	17	1	AA766995	Vector-specific pr
C 287	20	0.4	20	1	ADL34604	ISIS antisense oli	C 360	17	0.3	17	1	AA790091	Primer SK-zap for
C 288	20	0.4	20	1	ADL34625	ISIS antisense oli	C 361	17	0.3	17	1	AAH77930	PCR primer used to
C 289	20	0.4	20	1	ADL34634	ISIS antisense oli	C 362	17	0.3	17	1	AA512632	T3 PCR primer for
C 290	20	0.4	20	1	ADL34653	Phosphoinositide-3	C 363	17	0.3	17	1	AAH25659	Mch6 cloning prime
C 291	20	0.4	20	1	ADL34670	Phosphoinositide-3	C 364	17	0.3	17	1	AAH25194	Primer for DNA enc
C 292	20	0.4	20	1	ADL34678	Phosphoinositide-3	C 365	17	0.3	17	1	AD52023	Mammalian ced-3 ho
C 293	20	0.4	20	1	ADL34698	Phosphoinositide-3	C 366	17	0.3	19	1	ADR81681	Hepatitis C virus
C 294	20	0.4	20	1	ADL34565	ISIS antisense oli	C 367	17	0.3	20	1	AAH18426	Primer for amplif
C 295	20	0.4	20	1	ADL34578	ISIS antisense oli	C 368	17	0.3	20	1	AAH20641	Human telomeric re
C 296	20	0.4	20	1	ADL34580	ISIS antisense oli	C 369	17	0.3	22	1	ADJ45219	p21 promoter, olig
C 297	20	0.4	20	1	ADL34642	ISIS antisense oli	C 370	16.8	0.3	20	1	ADH26737	Human p13K regulat
C 298	20	0.4	20	1	ADL34645	Phosphoinositide-3	C 371	16.8	0.3	20	1	ADL34626	ISIS antisense oli
C 299	20	0.4	20	1	ADL34668	Phosphoinositide-3	C 372	16.8	0.3	20	1	AAH06717	Human JAGGED1 gene
C 300	20	0.4	20	1	ADL34676	Phosphoinositide-3	C 373	16.8	0.3	20	1	AAH32481	1,5-anhydroglucito
C 301	20	0.4	20	1	ADL34690	Phosphoinositide-3	C 374	16.8	0.3	20	1	AAH83180	Negative control p
C 302	20	0.4	20	1	ADL34692	Phosphoinositide-3	C 375	16.8	0.3	20	1	ADJ22895	Human endothelial
C 303	20	0.4	20	1	ADL34566	ISIS antisense oli	C 376	16.8	0.3	20	1	ADH80790	Chimeric phosphoro
C 304	20	0.4	20	1	ADL34631	ISIS antisense oli	C 377	16.8	0.3	20	1	ADL59618	Human ESM-1 antise
C 305	20	0.4	20	1	ADL34655	Phosphoinositide-3	C 378	16.8	0.3	20	1	ADL59444	Human ESM-1 antise
C 306	20	0.4	20	1	ADL34661	Phosphoinositide-3	C 379	16.8	0.3	20	1	ADL59682	Human ESM-1 antise
C 307	20	0.4	20	1	ADL34665	Phosphoinositide-3	C 380	16.8	0.3	21	1	AA511777	VIDR gene, single
C 308	20	0.4	20	1	ADL34683	Phosphoinositide-3	C 381	16.8	0.3	21	1	ACC57852	Matrix metalloprot
C 309	20	0.4	20	1	ADH69805	Micro-channel mole	C 382	16.8	0.3	21	1	ADH94102	TCTB tubes A and B
C 310	20	0.4	21	1	AAH08666	Primer used for su	C 383	16.8	0.3	21	1	ADQ90421	Mouse VEGF reverse
C 311	20	0.4	21	1	AAH73394	Grand fir monoterp	C 384	16.8	0.3	22	1	AAV27859	PCR primer H used
C 312	20	0.4	24	1	ADG55560	A gossypii ribofla	C 385	16.8	0.3	22	1	AAH80013	B. thuringiensis c
C 313	20	0.4	24	1	ADK15557	Hantaan hantavir	C 386	16.8	0.3	22	1	AAH08162	B. thuringiensis c
C 314	19.6	0.4	26	1	AAQ471178	MHC DR A intron bi	C 387	16.8	0.3	22	1	ADH44228	PCR primer H used
C 315	19.4	0.4	24	1	ABA01951	Human TNF receptor	C 388	16.8	0.3	22	1	ABS70799	B. thuringiensis c
C 316	19.2	0.4	24	1	AAH98935	Immunostimulatory	C 389	16.8	0.3	22	1	AD559856	PCR primer H used
C 317	19.2	0.4	24	1	ABS77576	Angiogenesis inhib	C 390	16.8	0.3	22	1	AD64016	PCR primer H used
C 318	19.2	0.4	24	1	ACD99368	Immunostimulatory	C 391	16.8	0.3	22	1	ACF42669	Human ALMS1 PCR pr
C 319	19.2	0.4	24	1	ADG36437	Immunostimulatory	C 392	16.8	0.3	22	1	AD104018	Bovine GHR exon am
C 320	19.2	0.4	24	1	ADG76001	Non-CpG DNA oligon	C 393	16.8	0.3	22	1	ADQ16768	4 synthesis-period
C 321	19.2	0.4	24	1	ADG76035	Non-CpG DNA oligon	C 394	16.4	0.3	18	1	AAH06310	Human PCR primer S
C 322	19.2	0.4	25	1	ACI76263	Human microarray D	C 395	16.4	0.3	19	1	AAH33800	S. aureus coding a
C 323	19.2	0.4	25	1	ACI76262	Human microarray D	C 396	16.4	0.3	20	1	AAH76854	PCR primer for clo
C 324	19	0.4	19	1	ADOS7809	Tobacco plant PCR	C 397	16.4	0.3	20	1	ABQ74807	Human TNFR2 antise
C 325	19	0.4	19	1	ADR82260	Hepatitis C virus	C 398	16.4	0.3	20	1	ABZ85728	Human oligonucleot

399	16.4	0.3	20	1	ABD21958	Human stannocalci
400	16.4	0.3	20	1	ADK77211	Chimeric phosphoro
401	16.4	0.3	20	1	ADK76861	Chimeric phosphoro
402	16.4	0.3	20	1	ADK78504	Chimeric phosphoro
403	16.4	0.3	20	1	ADO71038	Human CD90 reverse
404	16.4	0.3	21	1	AAH62440	Proteasome 26S sub
405	16.4	0.3	21	1	ABT08334	Human NOV4a PCR pr
406	16.4	0.3	21	1	ADH17700	Reverse PCR primer
407	16.4	0.3	21	1	AAQ86460	IFN-alpha nt723-73
408	16.2	0.3	21	1	AAZ26585	Human polymorphic
409	16.2	0.3	21	1	AAZ26585	Primer for CTACK f
410	16.2	0.3	21	1	ABX11428	Human CTACK compet
411	16.2	0.3	21	1	ABE86772	rRST2 Primer #2
412	16.2	0.3	21	1	ADJ97635	Human Fit-1 DNA se
413	16.2	0.3	21	1	ADJ97636	Human Fit-1 DNA se
414	16	0.3	17	1	ABK00643	Human NOGO Hammer
415	16	0.3	17	1	ADB40345	Tumour suppression
416	16	0.3	17	1	ADB45157	Analytical solid p
417	16	0.3	20	1	AAV37774	5'-phosphorylated
418	16	0.3	20	1	AAH89313	Streptomyces hygro
419	16	0.3	20	1	ABK50593	Human PLA2G1B gene
420	16	0.3	20	1	ADJ35091	PCR primer 8 to ge
421	16	0.3	20	1	ADJ09992	Human matrix metal
422	16	0.3	20	1	ADP27118	Antisense oligo ta
423	16	0.3	20	1	ADP72469	Primer for amplify
424	16	0.3	21	1	AAZ98879	Human gene single
425	16	0.3	21	1	AAF95501	Adhadin gene fragm
426	15.8	0.3	19	1	AAV22621	Human biallelic ma
427	15.8	0.3	19	1	AAZ69801	HIV siNA oligonuc
428	15.8	0.3	19	1	ADG35257	HIV siNA oligonuc
429	15.8	0.3	19	1	ADG35995	Human HER2 (EGFR2)
430	15.8	0.3	19	1	ADL79331	Human HER2 (EGFR2)
431	15.8	0.3	19	1	ADL79082	Human apolipoprote
432	15.8	0.3	19	1	ADR77519	Human apolipoprote
433	15.8	0.3	19	1	ADR80463	Probe for CDK41 ge
434	15.8	0.3	20	1	AAQ91171	Human MTS1 exon2 P
435	15.8	0.3	20	1	AAQ91171	Human multiple tum
436	15.8	0.3	20	1	AAV69775	Nucleotide sequenc
437	15.8	0.3	20	1	AAV11244	Seq ID#8 from US57
438	15.8	0.3	20	1	AAV11244	PCR primer 42F use
439	15.8	0.3	20	1	AAV70589	Human MTS1 gene mu
440	15.8	0.3	20	1	AAZ95641	PCR primer for hum
441	15.8	0.3	20	1	AAZ48780	Human MTS related
442	15.8	0.3	20	1	AAZ39359	Human MTS1 gene ex
443	15.8	0.3	20	1	AAZ11171	Canine IL-13 sense
444	15.8	0.3	20	1	AAZ55597	Oligonucleotide #8
445	15.8	0.3	20	1	AAZ90517	Hco7 mice cDNA hea
446	15.8	0.3	20	1	AAH41615	Primer #7. Homo s
447	15.8	0.3	20	1	AAF58177	PCR primer #3 used
448	15.8	0.3	20	1	AAZ02570	Mice of genotype H
449	15.8	0.3	20	1	AAH29961	Human multiple tum
450	15.8	0.3	20	1	AAJ04699	Human inflammatory
451	15.8	0.3	20	1	AAH91454	Primer 42F for scr
452	15.8	0.3	20	1	AAZ83077	Crygs gene related
453	15.8	0.3	20	1	AAZ37733	Mammary gland btor
454	15.8	0.3	20	1	AAZ45671	Human phosphorilas
455	15.8	0.3	20	1	ABK68899	Mouse TNFR2 antise
456	15.8	0.3	20	1	ABQ74888	Heavy chain variab
457	15.8	0.3	20	1	ADG44459	Humanized antibody
458	15.8	0.3	20	1	ADG44508	Synthetic linker s
459	15.8	0.3	20	1	ABX13334	Mouse urokinase pl
460	15.8	0.3	20	1	ABX17785	Human MTS1 exon 2
461	15.8	0.3	20	1	ABZ25516	Vitamin D nuclear
462	15.8	0.3	20	1	ADB99900	Human CDKN2A gene-
463	15.8	0.3	20	1	ADF83451	Human oligonucleot
464	15.8	0.3	20	1	ABZ87942	Human oligonucleot
465	15.8	0.3	20	1	ABZ89500	Human oligonucleot
466	15.8	0.3	20	1	ABZ89500	Human oligonucleot
467	15.8	0.3	20	1	ABZ90375	Template (CTGA)5 f
468	15.8	0.3	20	1	ABZ94043	Human calmodulin 2
469	15.8	0.3	20	1	ABZ75637	
470	15.8	0.3	20	1	ABD24172	
471	15.8	0.3	20	1		
472	15.8	0.3	20	1	ABD30273	AA284245-derived o
473	15.8	0.3	20	1	ABD25730	AA465687-derived o
474	15.8	0.3	20	1	ABD26605	AA909635-derived o
475	15.8	0.3	20	1	ADH64788	Human glucocortico
476	15.8	0.3	20	1	ADH64940	Human glucocortico
477	15.8	0.3	20	1	ADH54718	Human VEGF-C antis
478	15.8	0.3	20	1	ADH54788	Human VEGF-C targ
479	15.8	0.3	20	1	ADJ17090	Antisense DNA olig
480	15.8	0.3	20	1	ADJ16142	Antisense DNA olig
481	15.8	0.3	20	1	ADJ23137	Human endothelial
482	15.8	0.3	20	1	ADJ22653	Human endothelial
483	15.8	0.3	20	1	ADK81523	Chimeric phosphoro
484	15.8	0.3	20	1	ADK80970	Chimeric phosphoro
485	15.8	0.3	20	1	ADL59715	Human ESM-1 antise
486	15.8	0.3	20	1	ADL59601	Human ESM-1 antise
487	15.8	0.3	20	1	ADL59376	Human ESM-1 antise
488	15.8	0.3	20	1	ADL59258	Osmolyte-stabilise
489	15.8	0.3	20	1	ADN53886	Farnesoid X recept
490	15.8	0.3	20	1	ADN53504	Farnesoid X recept
491	15.8	0.3	20	1	ADN53202	Endothelial differ
492	15.8	0.3	20	1	ADN01338	KIAA1096 forward P
493	15.8	0.3	20	1	ADQ59323	CAPN3/DYSF PCR pri
494	15.8	0.3	20	1	ADQ14094	5' PCR primer for
495	15.8	0.3	21	1	AAV37276	Banana BFE gene fr
496	15.8	0.3	21	1	AAZ7520	Human biallelic ma
497	15.8	0.3	21	1	AAZ74371	Wound healing rela
498	15.8	0.3	21	1	ABA81997	Mouse wound healin
499	15.8	0.3	21	1	AAZ99920	PCR primer #4 used
500	15.8	0.3	21	1	AAH62183	APLP2 polymorphis
501	15.8	0.3	21	1	ABK94358	Endothelin convert
502	15.8	0.3	21	1	ABK94357	Endothelin convert
503	15.8	0.3	21	1	ABK94357	Mouse alpha 1-anti
504	15.8	0.3	21	1	ABV76147	Pro-alpha (I)II ch
505	15.8	0.3	21	1	ACV58762	Template (CTGA)5-A
506	15.8	0.3	21	1	ABZ75638	Porcine PULG3 UP-
507	15.8	0.3	21	1	ABQ80726	Human NOGO Hammer
508	15.4	0.3	17	1	ABK00063	Human NOGO Inozyme
509	15.4	0.3	17	1	ABK00962	Human NOGO Inozyme
510	15.4	0.3	17	1	ABK00963	Murine oligonucleo
511	15.4	0.3	17	1	ACC68083	Murine oligonucleo
512	15.4	0.3	17	1	ACC65135	Tumour suppression
513	15.4	0.3	17	1	ADB39787	Tumour suppression
514	15.4	0.3	17	1	ADB42797	Procollagen I reve
515	15.4	0.3	17	1	ADZ05333	Silkworm juvenile
516	15.4	0.3	18	1	AAZ08552	Human obesity-asso
517	15.4	0.3	18	1	ABK41074	PCR primer used to
518	15.4	0.3	18	1	ABZ77709	Human apolipoprote
519	15.4	0.3	19	1	ADZ76576	Human apolipoprote
520	15.4	0.3	19	1	ADZ79520	Urease gene PCR pr
521	15.4	0.3	20	1	AAQ75326	Helicobacter UreB
522	15.4	0.3	20	1	AAZ45687	PI3K antisense inh
523	15.4	0.3	20	1	AAZ13146	Forward primer aa2
524	15.4	0.3	20	1	AAZ28930	Human biallelic ma
525	15.4	0.3	20	1	AAZ71844	Human biallelic ma
526	15.4	0.3	20	1	ABX03737	Human REQL5 inhib
527	15.4	0.3	20	1	ADG70287	Human exon 12 and
528	15.4	0.3	20	1	ACC82889	Human TRIP6 antise
529	15.4	0.3	20	1	ADH66356	Human glucocortico
530	15.4	0.3	20	1	ADH66905	Human glucocortico
531	15.4	0.3	20	1	ADJ23055	Human endothelial
532	15.4	0.3	20	1	ADJ22915	Human endothelial
533	15.4	0.3	20	1	ADK81043	Chimeric phosphoro
534	15.4	0.3	20	1	ADK76762	Chimeric phosphoro
535	15.4	0.3	20	1	ADN12104	Primer of the inve
536	15.4	0.3	20	1	ADQ54095	Farnesoid X recept
537	15.4	0.3	20	1	ADQ53680	Farnesoid X recept
538	15.4	0.3	20	1	ADT01052	Novel mutant prote
539	15.2	0.3	20	1	ADH26724	Human PI3K regulat
540	15.2	0.3	20	1	ADH26792	Human PI3K regulat
541	15.2	0.3	20	1	ADL34613	ISIS antisense oli
542	15.2	0.3	20	1	ADL34681	Phosphoinositide-3

ALIGNMENTS

RESULT 1
ABN37885
ID ABN37885 standard; DNA; 60 BP.
XX AC ABN37885;
XX DT 15-JUL-2002 (first entry)
XX DE Human spliced transcript detection oligonucleotide SEQ ID NO:10633.
XX KW Human; mouse; rat; splice transcript; detection; RNA transcript;
KW splice variant; transcriptome; oligonucleotide library; ss.
XX OS Homo sapiens.
XX PN W0200210449-A2.
XX PD 07-FEB-2002.
XX PF 20-JUL-2001; 2001WO-IB001903.
XX PR 28-JUL-2000; 2000US-0221607P.
XX PR 02-MAY-2001; 2001US-0287724P.
XX PA (COMP-) COMPUGEN INC.
XX PI Shoshan A, Wasserman A, Mintz E, Mintz L, Faigler S;
XX WPI; 2002-257383/30.
XX PT New oligonucleotide libraries comprising oligonucleotides which
PT selectively hybridize to mRNAs transcribed from a transcription unit of a
PT genome, useful for detecting tissue-, pathology-, and developmental-
PT specific genes.
XX PS Example 1; SEQ ID NO 10633; 47pp; English.
XX CC The present invention describes oligonucleotide libraries for detecting
CC messenger RNAs that populate a (sub-)transcriptome, where the (sub-
CC)transcriptome comprises messenger RNAs transcribed from multiple
CC transcription units that populate a genome. The library comprises several
CC oligonucleotides, each capable of hybridizing selectively to a set of
CC messenger RNAs transcribed from a given transcription unit of the genome,
CC which encodes one or more messenger RNA splice variants. The
CC oligonucleotide libraries are useful for detecting mRNAs from a
CC biological sample, in expression profiling studies, in qualitatively or
CC quantitatively characterizing the corresponding transcriptome, and in
CC detecting RNA transcripts and splice variants of human or animal
CC transcriptomes. The libraries may also be used as specialized mini
CC libraries to detect transcripts of a sub-transcriptome under a particular
CC biological or pathological state, and so allowing the detection of tissue
CC - and pathology-specific genes such as those genes only expressed in
CC specific tissue under a specific pathological condition; to detect
CC developmental specific genes; and to detect RNA transcripts and splice
CC variants of a transcriptome of a patient suffering from a particular
CC disorder. ABN27253 to ABN59589 represent oligonucleotide sequences from
CC rats, humans and mice, which are used in the exemplification of the
CC present invention. N.B. The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 60 BP; 14 A; 17 C; 12 G; 17 T; 0 U; 0 Other;
Query Match 1.2%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 0.04;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 4290 CGTCCATGGTATCTACTGTAGTCTCGAGATGGAAATCCTACTACTACAGCTGGCTC 4349
DB 1 CGTCCATGGTATCTACTGTAGTCTCGAGATGGAAATCCTACTACTACAGCTGGCTC 60

RESULT 2
ACN54858
ID ACN54858 standard; cDNA; 54 BP.
XX AC ACN54858;
XX DT 02-DEC-2004 (first entry)
XX DE Cotton androecium tissue EST Clone ID: LIB3828-025-Q6-K6-H9, SEQ:9639.
XX KW Cotton; plant; EST; expressed sequence tag; transgenic plant; androecium;
KW variety Nucton33B; library LIB3828; molecular tag; molecular marker;
KW genetic mapping; molecular mapping; seed germination; plant growth;
KW plant quality; plant yield; plant breeding; tissue printing; ss.
XX OS Gossypium hirsutum.
XX PN US2004123340-A1.
XX PD 24-JUN-2004.
XX PF 12-DEC-2001; 2001US-00021323.
XX PR 14-DEC-2000; 2000US-0255619P.
XX PA (DEIK/) DEIKMAN J.
PA (FENG/) FENG P C C.
PA (FINC/) FINCHER K L.
PA (ZIEG/) ZIEGLER T E.
XX PI Daikman J, Feng PCC, Fincher KL, Ziegler TE;
XX WPI; 2004-479808/45.
XX PT New isolated nucleic acid molecule that encodes a plant protein or its
PT fragment, useful for isolating a variety of agronomically significant
PT genes associated with plant growth, quality or yield, and as molecular
PT tags to map genes.
XX PS Claim 1; SEQ ID NO 9639; 34pp; English.
XX CC The invention relates to 17880 cotton expressed sequence tags (ESTs;
CC ACN45220-ACN63099). The ESTs were isolated from cDNA libraries generated
CC from primed or non-primed seeds from variety DP50B, mature seeds from
CC variety Coker 312 Boswell 96 Field, and androecium tissue, gynoecium
CC tissue, developing fibres, carpal walls and septa from variety
CC Nucton33B. The invention also relates to substantially purified
CC proteins or their fragments encoded by nucleic acid molecules of the
CC invention, and to transformed plants having a nucleic acid construct
CC comprising a nucleic acid of the invention. The cotton ESTs are useful as
CC molecular tags to isolate genetic regions, to isolate genes, to map
CC genes, to determine gene function and to determine whether genes are
CC members of a particular gene family. The nucleic acid molecules may be
CC used for isolating a variety of agronomically significant genes
CC associated with plant growth, quality, yield, and could also serve as
CC links in metabolic and catabolic pathways. The nucleic acid molecules are
CC also useful for identifying genes important in initiating and maintaining
CC seed germination or that may be used to mitigate stresses encountered
CC during seed germination. The ESTs additionally enable the acquisition of
CC promoters and cis-regulatory elements which will be useful to express
CC agronomically significant genes in these tissues and/or other tissues,
CC and also permits the acquisition of molecular markers useful in breeding
CC schemes, genetic and molecular mapping, and in cloning of agronomically
CC significant genes. The nucleic acid molecules are further useful for
CC detecting the expression level or pattern of a protein or mRNA and for
CC detecting the presence or quantity of a protein by tissue printing. The
CC present sequence represents a specifically claimed EST isolated from a
CC cotton variety Nucton33B androecium tissue cDNA library (LIB3828). The
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from the US
CC patent office at seqdata.uspto.gov/sequence.html?DocID=US20040123340

CC and also permits the acquisition of molecular markers useful in breeding
CC schemes, genetic and molecular mapping, and in cloning of agronomically
CC significant genes. The nucleic acid molecules are further useful for
CC detecting the expression level or pattern of a protein or mRNA and for
CC detecting the presence or quantity of a protein by tissue printing. The
CC present sequence represents a specifically claimed EST isolated from a
CC cotton variety Nucleotide33B androecium tissue cDNA library (LIB3828). The
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from the US
CC patent office at seqdata.uspto.gov/sequence.html?DocID=US20040123340
XX
SQ Sequence 51 BP; 49 A; 1 C; 0 G; 0 T; 0 U; 1 Other;

Query Match 0.8%; Score 41.2; DB 1; Length 51;
Best Local Similarity 93.5%; Pred. No. 2.2;
Matches 43; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5018 AAACCTGTAAAAA...AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5063
Db 6 AAACAAAAA...AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 51

RESULT 4
ACN51219/c
ID ACN51219 standard; cDNA; 51 BP.
XX
AC ACN51219;
XX
DT 02-DEC-2004 (first entry)
XX
DE Cotton androecium tissue EST Clone ID: LIB3828-012-Q1-N6-A4, SEQ:6000.
XX
KW Cotton; plant; EST; expressed sequence tag; transgenic plant; androecium;
KW variety Nucleotide33B; library LIB3828; molecular tag; molecular marker;
KW genetic mapping; molecular mapping; seed germination; plant growth;
KW plant quality; plant yield; plant breeding; tissue printing; ss.
XX
OS Gossypium hirsutum.
XX
OS US2004123340-A1.
XX
PN 24-JUN-2004.
XX
PF 12-DEC-2001; 2001US-00021323.
XX
PR 14-DEC-2000; 2000US-0255619P.
XX
PA (DEIK/) DEIKMAN J.
PA (FENG/) FENG P C C.
PA (FINC/) FINCHER K L.
PA (ZIEG/) ZIEGLER T E.
XX
PI Deikman J, Feng PCC, Fincher KL, Ziegler TE;
XX
DR WPI; 2004-479808/45.
XX
XX New isolated nucleic acid molecule that encodes a plant protein or its
XX fragment, useful for isolating a variety of agronomically significant
XX genes associated with plant growth, quality or yield, and as molecular
XX tags to map genes.
XX
PS Claim 1; SEQ ID NO 6904; 34pp; English.
XX
XX The invention relates to 17880 cotton expressed sequence tags (ESTs;
XX ACN45220-ACN63099). The ESTs were isolated from cDNA libraries generated
XX from primed or non-primed seeds from variety DP50B, mature seeds from
XX variety Coker 312 Boswell 96 Field, and androecium tissue, gynoecium
XX tissue, developing fibres, carpel walls and septa from variety
XX Nucleotide33B. The invention also relates to substantially purified
XX proteins or their fragments encoded by nucleic acid molecules of the
XX invention, and to transformed plants having a nucleic acid construct
XX comprising a nucleic acid of the invention. The cotton ESTs are useful as
XX genes, to determine gene function and to determine whether genes are
XX members of a particular gene family. The nucleic acid molecules may be
XX used for isolating a variety of agronomically significant genes
XX associated with plant growth, quality, yield, and could also serve as
XX links in metabolic and catabolic pathways. The nucleic acid molecules are
XX also useful for identifying genes important in initiating and maintaining
XX seed germination or that may be used to mitigate stresses encountered
XX during seed germination. The ESTs additionally enable the acquisition of
XX promoters and cis-regulatory elements which will be useful to express
XX agronomically significant genes in these tissues and/or other tissues,
XX

XX
SQ Sequence 54 BP; 46 A; 1 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 44; DB 1; Length 54;
Best Local Similarity 90.4%; Pred. No. 1.2;
Matches 47; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 5025 AAACTCAGAGGGGGG 5076
Db 3 AAGAGAGAGGAGG 54

RESULT 3
ACN52123
ID ACN52123 standard; cDNA; 51 BP.
XX
AC ACN52123;
XX
DT 02-DEC-2004 (first entry)
XX
DE Cotton androecium tissue EST Clone ID: LIB3828-012-Q1-K6-A4, SEQ:6904.
XX
KW Cotton; plant; EST; expressed sequence tag; transgenic plant; androecium;
KW variety Nucleotide33B; library LIB3828; molecular tag; molecular marker;
KW genetic mapping; molecular mapping; seed germination; plant growth;
KW plant quality; plant yield; plant breeding; tissue printing; ss.
XX
OS Gossypium hirsutum.
XX
PN US2004123340-A1.
XX
PN 24-JUN-2004.
XX
PF 12-DEC-2001; 2001US-00021323.
XX
PR 14-DEC-2000; 2000US-0255619P.
XX
PA (DEIK/) DEIKMAN J.
PA (FENG/) FENG P C C.
PA (FINC/) FINCHER K L.
PA (ZIEG/) ZIEGLER T E.
XX
PI Deikman J, Feng PCC, Fincher KL, Ziegler TE;
XX
DR WPI; 2004-479808/45.
XX
XX New isolated nucleic acid molecule that encodes a plant protein or its
XX fragment, useful for isolating a variety of agronomically significant
XX genes associated with plant growth, quality or yield, and as molecular
XX tags to map genes.
XX
PS Claim 1; SEQ ID NO 6904; 34pp; English.
XX
XX The invention relates to 17880 cotton expressed sequence tags (ESTs;
XX ACN45220-ACN63099). The ESTs were isolated from cDNA libraries generated
XX from primed or non-primed seeds from variety DP50B, mature seeds from
XX variety Coker 312 Boswell 96 Field, and androecium tissue, gynoecium
XX tissue, developing fibres, carpel walls and septa from variety
XX Nucleotide33B. The invention also relates to substantially purified
XX proteins or their fragments encoded by nucleic acid molecules of the
XX invention, and to transformed plants having a nucleic acid construct
XX comprising a nucleic acid of the invention. The cotton ESTs are useful as
XX genes, to determine gene function and to determine whether genes are
XX members of a particular gene family. The nucleic acid molecules may be
XX used for isolating a variety of agronomically significant genes
XX associated with plant growth, quality, yield, and could also serve as
XX links in metabolic and catabolic pathways. The nucleic acid molecules are
XX also useful for identifying genes important in initiating and maintaining
XX seed germination or that may be used to mitigate stresses encountered
XX during seed germination. The ESTs additionally enable the acquisition of
XX promoters and cis-regulatory elements which will be useful to express
XX agronomically significant genes in these tissues and/or other tissues,
XX

CC genes, to determine gene function and to determining whether genes are
 CC members of a particular gene family. The nucleic acid molecules may be
 CC used for isolating a variety of agronomically significant genes
 CC associated with plant growth, quality, yield, and could also serve as
 CC links in metabolic and catabolic pathways. The nucleic acid molecules are
 CC also useful for identifying genes important in initiating and maintaining
 CC seed germination or that may be used to mitigate stresses encountered
 CC during seed germination. The ESTs additionally enable the acquisition of
 CC promoters and cis-regulatory elements which will be useful to express
 CC agronomically significant genes in these tissues and/or other tissues,
 CC and also permits the acquisition of molecular markers useful in breeding
 CC schemes, genetic and molecular mapping, and in cloning of agronomically
 CC significant genes. The nucleic acid molecules are further useful for
 CC detecting the expression level or pattern of a protein or mRNA and for
 CC detecting the presence or quantity of a protein by tissue printing. The
 CC present sequence represents a specifically claimed EST isolated from a
 CC cotton variety Nucleon33B androecium tissue cDNA library (L1B3828). The
 CC sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from the US
 CC patent office at seqdata.uspto.gov/sequence.html?DocID=US20040123340
 XX
 SQ Sequence 51 BP; 0 A; 0 C; 1 G; 50 T; 0 U; 0 Other;

Query Match 0.8%; Score 41.2; DB 1; Length 51;
 Best Local Similarity 93.5%; Pred. No. 2.2; Mismatches 0; Gaps 0;
 Matches 43; Conservative 0; Indels 3; Indels 0; Gaps 0;
 QY 5018 AAACCTGTAAAAA 5063
 DB 46 AAACAAAAA 1

RESULT 5
 ADS74280/c
 ID ADS74280 standard; DNA; 50 BP.
 XX
 AC ADS74280;
 DT 16-DEC-2004 (first entry)
 XX
 DE T50 element used in RNA probe.
 XX
 KW AU-rich element; ARE; antiinflammatory; antiarthritic; antirheumatic;
 KW RNA stability; immunostimulant; ss.
 XX
 OS Synthetic.
 XX
 PN WO2004081179-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 05-MAR-2004; 2004WO-US006703.
 XX
 PR 06-MAR-2003; 2003US-0451976P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Lai WS, Blackshear PJ;
 XX
 DR WPI; 2004-668946/65.
 XX

Screening an agent for its ability to modulate RNA processing comprises
 PT contacting the agent with a sample comprising tristetraprolin (TTP), a
 PT poly(A)-preferring, 3'-5' ribo-exonuclease (PARN) polypeptide and an RNA.
 XX
 PS Example; SEQ ID NO 35; 94pp; English.

XX The present sequence is that of an T50 element found in RNA probes used
 CC in examples from the invention. The invention provides a method for
 CC screening an agent for its ability to modulate RNA processing. The method
 CC comprises: (a) contacting the agent with a sample comprising (i)
 CC tristetraprolin (TTP), TTP-related polypeptide, fragment or variant,
 CC (ii) a polyA-preferring 3'-5'-ribo-exonuclease (PARN) polypeptide or its
 CC translation of the RNA; and (b) detecting processing of the RNA, e.g. by

CC active fragment or variant (if the PARN is in a cell, the cell comprises
 CC exogenous PARN) and (iii) an RNA which comprises an ARE downstream of a
 CC reporter sequence and a 3' polyA tail, where processing of the RNA can be
 CC detected, under conditions effective for processing and, optionally,
 CC translation of the RNA; and (b) detecting processing of the RNA, e.g. by
 CC measuring the amount and/or structure of the RNA, deadenylation of the
 CC RNA, or binding of the TTP to the ARE. The method can be used to screen
 CC for an agent able to inhibit RNA processing for the treatment of a
 CC condition mediated by insufficient granulocyte-macrophage colony
 CC stimulating factor or for treating granulocytopenia. It may also be used
 CC to screen for an agent able to stimulate RNA processing for treatment of
 CC a condition mediated by excess tumour necrosis factor-alpha, an
 CC inflammatory condition, rheumatoid arthritis, Crohn's disease or
 CC arthritis (all claimed). The method can be conducted in vitro or in a
 CC cell-based format. A high-throughput screening method may be used.
 XX
 SQ Sequence 50 BP; 0 A; 0 C; 0 G; 50 T; 0 U; 0 Other;

Query Match 0.8%; Score 40.6; DB 1; Length 50;
 Best Local Similarity 91.5%; Pred. No. 2.5;
 Matches 43; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 5018 AAACCTGTAAAAA 5064
 DB 50 AAAAAA 4

RESULT 6
 ADS74279
 ID ADS74279 standard; RNA; 50 BP.
 XX
 AC ADS74279;
 DT 16-DEC-2004 (first entry)
 XX
 DE A50 element used in RNA probe.
 XX
 KW AU-rich element; ARE; antiinflammatory; antiarthritic; antirheumatic;
 KW RNA stability; immunostimulant; ss.
 XX
 OS Synthetic.
 XX
 PN WO2004081179-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 05-MAR-2004; 2004WO-US006703.
 XX
 PR 06-MAR-2003; 2003US-0451976P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Lai WS, Blackshear PJ;
 XX
 DR WPI; 2004-668946/65.
 XX

Screening an agent for its ability to modulate RNA processing comprises
 PT contacting the agent with a sample comprising tristetraprolin (TTP), a
 PT poly(A)-preferring, 3'-5' ribo-exonuclease (PARN) polypeptide and an RNA.
 XX
 PS Example; SEQ ID NO 35; 94pp; English.

XX The present sequence is that of an A50 element found in RNA probes used
 CC in examples from the invention. The invention provides a method for
 CC screening an agent for its ability to modulate RNA processing. The method
 CC comprises: (a) contacting the agent with a sample comprising (i)
 CC tristetraprolin (TTP), TTP-related polypeptide, fragment or variant,
 CC (ii) a polyA-preferring 3'-5'-ribo-exonuclease (PARN) polypeptide or its
 CC active fragment or variant (if the PARN is in a cell, the cell comprises
 CC exogenous PARN) and (iii) an RNA which comprises an ARE downstream of a
 CC reporter sequence and a 3' polyA tail, where processing of the RNA can be
 CC detected, under conditions effective for processing and, optionally,
 CC translation of the RNA; and (b) detecting processing of the RNA, e.g. by

measuring the amount and/or structure of the RNA, deadenylation of the RNA, or binding of the TTP to the ARE. The method can be used to screen for an agent able to inhibit RNA processing for the treatment of a condition mediated by insufficient granulocyte-macrophage colony stimulating factor or for treating granulocytopenia. It may also be used to screen for an agent able to stimulate RNA processing for treatment of a condition mediated by excess tumour necrosis factor-alpha, an inflammatory condition, rheumatoid arthritis, Crohn's disease or arthritis (all claimed). The method can be conducted in vitro or in a cell-based format. A high-throughput screening method may be used.

Sequence 50 BP; 50 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 40.6; DB 1; Length 50;
Best Local Similarity 91.5%; Pred. No. 2.5;
Matches 43; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 5018 AAACGTGTAAAAA 5064
1 AA 47

RESULT 7
ADRI8577/c
ID ADRI8577 standard; DNA; 50 BP.
XX
AC ADRI8577;
XX
DT 07-OCT-2004 (first entry)
XX
DE Oligonucleotide ocdl.1.3 used in construction of a cDNA library.
XX
KW ss; cardiac hypertrophy factor; CHF; cardiostrophin; cardiostrophin-1;
KW cardiac hypertrophy; heart failure; arrhythmic; inotropic disorder;
KW congestive heart failure; neurodegenerative disease;
KW peripheral neuropathy; Alzheimer's disease; stroke; Parkinson's disease.
XX
OS Synthetic.
XX
XX US2004116678-A1.
XX
XX 17-JUN-2004.
XX
XX 24-NOV-2003; 2003US-00722095.
XX
XX 25-APR-1994; 94US-00233609.
XX
XX 05-AUG-1994; 94US-00286304.
XX
XX 17-MAY-1995; 95US-00443129.
XX
XX 18-OCT-1996; 96US-00733850.
XX
XX 02-MAR-1998; 98US-00033114.
XX
XX 29-JUN-2001; 2001US-0089856.
XX
XX (GETH) GENENTECH INC.
XX
XX (REGC) UNIV CALIFORNIA.
XX
XX Baker J, Chien K, King K, Pennica D, Wood W;
XX
XX WPI; 2004-560446/54.
XX
XX New isolated cardiac hypertrophy factor (cardiostrophin), useful for
XX treating heart failure, arrhythmic disorders and neurodegenerative
XX diseases.
XX
XX Example 1; SEQ ID NO 5; 52pp; English.
XX
XX The invention relates to an isolated cardiac hypertrophy factor (CHF),
XX excluding rat CHF. The cardiac hypertrophy factor (also known as
XX cardiostrophin or cardiostrophin-1) is useful for treating cardiac
XX hypertrophy, heart failure, arrhythmic or inotropic disorder, congestive
XX heart failure and neurodegenerative diseases such as peripheral
XX neuropathies, Alzheimer's disease, stroke, or Parkinson's disease. The
XX nucleic acid and antibody are useful as diagnostic reagents. The present
XX sequence represents oligonucleotide ocdl.1.3 used in construction of a

CDNA library.

Sequence 50 BP; 3 A; 7 C; 7 G; 33 T; 0 U; 0 Other;

Query Match 0.7%; Score 37.8; DB 1; Length 50;
Best Local Similarity 85.7%; Pred. No. 4.6;
Matches 42; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 5032 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTCGAGGGGGGCGCCG 5080
1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGATTTCGAGCTCGCGCCG 2

RESULT 8
ADRI9735/c
ID ADRI9735 standard; DNA; 43 BP.
XX
AC ADRI9735;
XX
DT 04-NOV-2004 (first entry)
XX
DE 238PIB2 gene related DPNCND cDNA synthesis primer.
XX
KW 238PIB2; transgenic animal; cytotoxic; cancer; cytostatic; gene therapy;
KW vaccine; prostate cancer; humoral; cellular immune response; primer; ss.
XX
OS Unidentified.
XX
XX WO2003085081-A2.
XX
XX 16-OCT-2003.
XX
XX 01-APR-2002; 2002WO-US010132.
XX
XX 01-APR-2002; 2002WO-US010132.
XX
XX (AGEN-) AGENSYS INC.
XX
XX Raitano AB, Challita-Eid PM, Faris M, Hubert RS, Morrison RK;
XX Ge W, Jakobovits A;
XX
XX WPI; 2003-812724/76.
XX
XX A composition useful for detecting, preventing or treating cancer (e.g.
XX prostate cancer) comprises a substance that modulates the status of
XX 238PIB2, or a molecule that is modulated by 238PIB2.
XX
XX Example 1; Page 68; 315pp; English.
XX
XX The invention relates to a novel composition comprising a substance that
XX modulates the status of 238PIB2, or a molecule that is modulated by
XX 238PIB2. The invention further relates to: a non-human transgenic animal
XX that produces an antibody; a hybridoma that produces an antibody;
XX delivering a cytotoxic agent or a diagnostic agent to a cell that
XX expresses 238PIB2; a polynucleotide that encodes a peptide; a
XX pharmaceutical composition that comprises the substance comprising above, in
XX a human unit dosage form, where the substance comprises a ribozyme that
XX cleaves a polynucleotide having 238PIB2 coding sequence or a nucleic acid
XX molecule that encodes the ribozyme, and a carrier; or human T-cells that
XX specifically recognise a 238PIB2 peptide sequence in the context of a
XX particular HLA molecule; inhibiting growth of cancer cells that express
XX 238PIB2; generating a mammalian immune response directed to 238PIB2; an
XX assay for detecting the presence of a 238PIB2-related protein or
XX polynucleotide in a biological sample; and monitoring the presence of
XX cancer in an individual. The novel composition has cytostatic activity.
XX The 238PIB2 polynucleotide can be used in gene therapy to treat
XX disorders. The 238PIB2 polypeptide can be used in the creation of a
XX vaccine. The composition and methods are useful in detecting, preventing,
XX prognosing or treating cancer (e.g. prostate cancer). The genes, proteins
XX or antibodies can be used to elicit a humoral or cellular immune
XX response. The polynucleotide may be used as a probe or a primer, or in
XX chromosomal mapping. This polynucleotide represents a primer used in the
XX exemplification of the invention.

```
XX SQ Sequence 43 BP; 3 A; 2 C; 2 G; 36 T; 0 U; 0 Other;
XX Query Match 0.7%; Score 33.8; DB 1; Length 43;
XX Best Local Similarity 94.6%; Pred. No. 10;
XX Matches 35; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5033 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTCGA 5069
Db 43 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGTTGA 7

RESULT 9
AAQ36506
ID AAQ36506 standard; DNA; 40 BP.
XX AC AAQ36506;
XX
XX 25-MAR-2003 (revised)
XX 06-JUN-1993 (first entry)
XX
XX Sequence of the 5' junction between the vector and insert of p812.
XX DE
XX Galactinol synthase; enzyme; raffinose saccharide; sucrose; ss.
XX KW
XX Galactinol synthase.
XX OS
XX Synthetic.
XX PN WO9302196-A1.
XX
XX 04-FEB-1993.
XX
XX 24-JUL-1992; 92WO-US006057.
XX
XX 24-JUL-1991; 91US-00735066.
XX
XX (DUPO ) DU PONT DE NEMOURS & CO E I.
XX PA
XX Kerr PS, Pearlstein RW, Schweiger BJ, Becker-Manley MF, Pierce JW;
XX WPI; 1993-058793/07.
XX
XX Nucleotide sequence of galactinol synthase from zucchini and soybean -
XX used to produce plants having altered levels of raffinose saccharide (S)
XX and/or sucrose.
XX
XX Example; Page 66; 80pp; English.
XX
XX Sequencing p812 revealed that the cDNA insert was within the EcoRI and
XX XhoI sites of that plasmid and was directionally correct by out of frame
XX with respect to the beta-galactosidase sequences. To improve the
XX production of galactinol synthase, p821 was modified to place the
XX galactinol synthase sequences in-frame with those of beta-galactosidase.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 40 BP; 6 A; 10 C; 15 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 33.2; DB 1; Length 40;
XX Best Local Similarity 92.1%; Pred. No. 11;
XX Matches 35; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 GGATCCCCCGGTGTCAGGAATTCGGCAGGAGGAGT 38
Db 3 GGATCCCCCGGTGTCAGGAATTCGGCAGGAGTGTGT 40

RESULT 10
AAT93816/c
ID AAT93816 standard; DNA; 35 BP.
XX AC AAT93816;
XX
XX 25-MAR-2003 (revised)
XX 24-FEB-1998 (first entry)
XX
```

```
XX XX
XX Antitumoural phosphodiester oligonucleotide 6 with cytotoxic activity.
XX
XX Phosphodiester; selective binding; cell viability; growth;
XX tumoural cell line; cytotoxic activity; tumour cell; lymphoma;
XX lymphoblastic tumour; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..35
XX /*tag= a
XX /note= "phosphodiester oligonucleotide"
XX
XX WO9720924-A1.
XX
XX 12-JUN-1997.
XX
XX 04-DEC-1996; 96WO-EP005388.
XX
XX 04-DEC-1995; 95IT-MI002539.
XX (SAIC-) SAICOM SRL.
XX
XX Scaggiante B, Quadrifoglio F;
XX WPI; 1997-319771/29.
XX
XX New phosphodiesteric oligonucleotide(s) - which exert a specific and
XX selective cytotoxic effect on tumour cells, for treating both solid and
XX liquid tumours.
XX
XX Claim 10; Page 5; 38pp; English.
XX
XX Novel phosphodiesteric oligonucleotides AAT93811-27 are based on the
XX generic formula, in the 3'-5' or 5'-3' direction: (Gata')a'-(Gbrb')b'-'-
XX (Gc'c')c'-(Gd'q')d'-'-(Gere')e'-'-(Gff')f'-'-(G-g'g')g'-'-N', where: N and
XX N' = T or G, equal or different from each other; x = 0-8, equal or
XX different from each other; a, b, c, d, e, f, and g = 0-10, equal or
XX different from each other; a', b', c', d', e', f', and g' = 0-30, equal
XX or different from each other; a'', b'', c'', d'', e'', f'', and g'' = 1-
XX 16, equal or different from each other; The oligonucleotides are believed
XX to selectively bind and sequester some proteins which are essential to
XX the viability and growth of tumoural cell line. They have specific and
XX selective cytotoxic activity against tumour cells, and can be used for
XX treating tumours of the liquid type, in particular of lymphoblastic
XX origin, and of solid type, in particular lymphomas. The present
XX phosphodiester oligonucleotide, at a concentration of 15 micromolar,
XX reduced growth of CCRP-CEM tumoural cells by 83%, which is detectable 48
XX hours after administration. (Updated on 25-MAR-2003 to correct PR field.)
XX
XX SQ Sequence 35 BP; 0 A; 0 C; 5 G; 30 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 27.6; DB 1; Length 35;
XX Best Local Similarity 88.2%; Pred. No. 36;
XX Matches 30; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 5032 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAC 5065
Db 35 ACNAAAAAAAAAAAAAAAAACAAAAAAAAAAC 2

RESULT 11
AAT93815/c
ID AAT93815 standard; DNA; 35 BP.
XX AC AAT93815;
XX
XX 25-MAR-2003 (revised)
XX 24-FEB-1998 (first entry)
XX
XX Antitumoural phosphodiester oligonucleotide 5 with cytotoxic activity.
XX
```

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

Phosphodiester; selective binding; cell viability; growth; tumoural cell line; cytotoxic activity; tumour cell; lymphoma; lymphoblastic tumour; ss.

Synthetic.

Key modified_base 1..35 Location/Qualifiers

/*tag= a

/note= "phosphodiester oligonucleotide"

WO9720924-A1.

12-JUN-1997.

04-DEC-1996; 96WO-EP005388.

04-DEC-1995; 95IT-MI002539.

(SAIC-) SAICOM SRL.

Scaggiante B, Quadrifoglio F;

WPI; 1997-319771/29.

New phospho:di:esteric oligo:nucleotide(s) - which exert a specific and selective cytotoxic effect on tumour cells, for treating both solid and liquid tumours.

Claim 10; Page 5; 38pp; English.

Novel phosphodiesteric oligonucleotides AAT93811-27 are based on the generic formula, in the 3'-5' or 5'-3' direction: (Gata')a'-(Gbrb')b'-(Gctc')c'-(Gdtd')d'-(Gefe')e'-(Gftr')f'-(Ggtg')g'-N', where: N and N' = T or G, equal or different from each other; x = 0-8, equal or different from each other; a', b', c', d', e', f', and g' = 0-30, equal or different from each other; a'', b'', c'', d'', e'', f'', and g'' = 1-16, equal or different from each other; The oligonucleotides are believed to selectively bind and sequester some proteins which are essential to the viability and growth of tumoural cell line. They have specific and selective cytotoxic activity against tumour cells, and can be used for treating tumours of the liquid type, in particular of lymphoblastic origin, and of solid type, in particular lymphomas. The present phosphodiester oligonucleotide, at a concentration of 15 micromolar, reduced growth of CCRP-CEM tumoural cells by 87%, which is detectable 48 hours after administration. (Updated on 25-MAR-2003 to correct PR field.)

Sequence 35 BP; 0 A; 0 C; 5 G; 30 T; 0 U; 0 Other;

Query Match .0.5%; Score 27; DB 1; Length 35;

Best Local Similarity 85.7%; Pred. No. 41;

Matches 30; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5059

Db 35 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 12

AAT93823/c

ID AAT93823 standard; DNA; 35 BP.

XX AAT93823;

XX 25-MAR-2003 (revised)

DT 24-FEB-1998 (first entry)

XX Antitumoural phosphodiester oligonucleotide 13 with cytotoxic activity.

XX Phosphodiester; selective binding; cell viability; growth;

KW tumoural cell line; cytotoxic activity; tumour cell; lymphoma;

KW lymphoblastic tumour; ss.

Synthetic.

Key modified_base 1..35 Location/Qualifiers

/*tag= a

/note= "phosphodiester oligonucleotide"

WO9720924-A1.

12-JUN-1997.

04-DEC-1996; 96WO-EP005388.

04-DEC-1995; 95IT-MI002539.

(SAIC-) SAICOM SRL.

Scaggiante B, Quadrifoglio F;

WPI; 1997-319771/29.

New phospho:di:esteric oligo:nucleotide(s) - which exert a specific and selective cytotoxic effect on tumour cells, for treating both solid and liquid tumours.

Claim 10; Page 6; 38pp; English.

Novel phosphodiesteric oligonucleotides AAT93811-27 are based on the generic formula, in the 3'-5' or 5'-3' direction: (Gata')a'-(Gbrb')b'-(Gctc')c'-(Gdtd')d'-(Gefe')e'-(Gftr')f'-(Ggtg')g'-N', where: N and N' = T or G, equal or different from each other; x = 0-8, equal or different from each other; a', b', c', d', e', f', and g' = 0-30, equal or different from each other; a'', b'', c'', d'', e'', f'', and g'' = 1-16, equal or different from each other; The oligonucleotides are believed to selectively bind and sequester some proteins which are essential to the viability and growth of tumoural cell line. They have specific and selective cytotoxic activity against tumour cells, and can be used for treating tumours of the liquid type, in particular of lymphoblastic origin, and of solid type, in particular lymphomas. The present phosphodiester oligonucleotide, at a concentration of 15 micromolar, reduced growth of CCRP-CEM tumoural cells by 87%, which is detectable 48 hours after administration. (Updated on 25-MAR-2003 to correct PR field.)

Sequence 35 BP; 0 A; 0 C; 5 G; 30 T; 0 U; 0 Other;

Query Match .0.5%; Score 27; DB 1; Length 35;

Best Local Similarity 85.7%; Pred. No. 41;

Matches 30; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5059

Db 35 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 13

ADH26672

ID ADH26672 standard; DNA; 26 BP.

XX ADH26672;

XX 11-MAR-2004 (first entry)

DT Human PI3K regulatory subunit 4, p150 DNA probe.

DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;

KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;

KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

KW neurodegenerative disorder; metabolic disorders; inflammation;

KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;

KW antiinflammatory; probe.

```
XX OS Homo sapiens.
XX FT
XX PN US2003225013-A1.
XX FT
XX PD 04-DEC-2003.
XX FT
XX PF 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-051923/05.
XX FT
XX FT New antisense oligonucleotides inhibiting the expression of
XX FT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX FT preventing or treating diseases associated with the subunit, e.g.
XX FT hyperproliferative disorders.
XX PS Example 13; SEQ ID NO 7; 62pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX CC p150. The compound is an antisense oligonucleotide that specifically
XX CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX CC 4, p150 and inhibits expression of the polypeptide. The antisense
XX CC oligonucleotide comprises at least one modified internucleoside linkage
XX CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX CC useful for modulating the expression of PI3K regulatory subunit 4, p150
XX CC and for preventing or treating hyperproliferative disorders (i.e.
XX CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX CC metabolic disorders. These may also be used in research and diagnostics
XX CC and in preventing or delaying infection or inflammation. This sequence
XX CC represents a probe which hybridises to DNA encoding the human PI3K
XX CC regulatory subunit 4, p150 polypeptide of the invention.
XX SQ Sequence 26 BP; 7 A; 3 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2447 CTGAGGAATTGTCATTGTGAAGCT 2472
Db 1 CTGAGGAATTGTCATTGTGAAGCT 26

RESULT 14
ADL34561
XX ID ADL34561 standard; DNA; 26 BP.
XX AC ADL34561;
XX AC
XX DT 17-JUN-2004 (first entry)
XX DE Human phosphoinositide-3-kinase regulator subunit 4 p150 probe.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytostatic; gene therapy; ss; probe.
XX OS Homo sapiens.
XX FT
XX FT Key Location/Qualifiers
XX FT modified_base 1
```

```
/*tag= a
/mod_base= OTHER
/notes= "PAM labelled"
modified_base 26
/*tag= b
/mod_base= OTHER
/notes= "TAMRA labelled"

US2004063657-A1.
01-APR-2004.
18-SEP-2003; 2003US-00667022.
31-MAY-2002; 2002US-00160786.
(FREI/) FREIER S M.
(DOBIE/) DOBIE K W.
Freier SM, Dobie KW;
WPI; 2004-282523/26.

New antisense compound targeted to a nucleic acid molecule encoding
phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

Example 13; SEQ ID NO 7; 60pp; English.

This invention describes a novel antisense oligonucleotides which
specifically hybridises to and inhibits the expression of human
phosphoinositide-3-kinase, regulatory subunit 4, p150. The
oligonucleotides comprises at least one modified internucleoside linkage,
preferably a phosphorothioate linkage. It also comprises at least one
modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
antisense oligonucleotide further comprises at least one modified
nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
can be used in diagnostics and as research reagents and kits. It can also
be used prophylactically, e.g. to prevent or delay infection,
inflammation or tumour formation. It can also be used to treat a disease
or condition associated with phosphoinositide-3-kinase, regulatory
subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
Chediak-Higashi syndrome or a metabolic disorder. The products of the
invention are immunomodulators with cytostatic activity and can be used
for gene therapy.

Sequence 26 BP; 7 A; 3 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2447 CTGAGGAATTGTCATTGTGAAGCT 2472
Db 1 CTGAGGAATTGTCATTGTGAAGCT 26

RESULT 15
AAC90605/c
XX ID AAC90605 standard; RNA; 34 BP.
XX AC AAC90605;
XX AC
XX DT 20-MAR-2001 (first entry)
XX DE Tomato spotted wilt virus S RNA partial sequence #9.
XX KW Tomopovirus resistance; transgenic plant; tomato spotted wilt virus;
XX KW Impatiens necrotic spot virus; TSWV; ss.
XX KW Tomato spotted wilt virus.
XX OS
XX FT
XX FT Key Location/Qualifiers
XX FT modified_base 1
```

```
FT misc_binding 1
FT FT /tag= a
FT /bound_moiety= "binds nucleotide 32 of AAC89654"
FT PD 2..10
FT FT /tag= b
FT /bound_moiety= "binds nucleotides 30-22 of AAC89654"
FT FT 17..32
FT FT /tag= c
FT /bound_moiety= "binds nucleotides 30-5 of AAC89564"
FT FT 33..34
FT FT /tag= d
FT /bound_moiety= "binds nucleotides 1-2 of AAC89654"
FT XX
PN US6150585-A.
XX
XX 21-NOV-2000.
XX
XX 26-NOV-1996; 96US-00757011.
XX
XX 03-NOV-1989; 89US-00431259.
XX 05-DEC-1989; 89US-00446024.
XX 02-MAY-1991; 91US-00694734.
XX 14-APR-1993; 93US-00047346.
XX 26-OCT-1993; 93US-00143397.
XX 27-JUL-1994; 94US-00280903.
XX
XX (NOVS ) NOVARTIS FINANCE CORP.
XX PA
XX
XX Peters D, Gielen JUL, De Haan PT, Van Grinsven MQJM, Kool AJ;
XX Goldbach RW;
XX
XX WPI; 2001-060031/07.
XX
XX Recombinant DNA construct comprising a DNA sequence encoding an RNA
XX sequence that codes for a tospovirus protein, useful for producing plants
XX with reduced susceptibility to tospovirus infection.
XX
XX Example 9; Fig 16B; 49pp; English.
XX
XX The present invention provides DNA constructs encoding RNA sequences from
XX a tospovirus which can be used to produce transgenic plants with immunity
XX to tospoviruses. Examples of tospoviruses include the tomato spotted wilt
XX virus and the Impatiens necrotic spot virus
XX
XX Sequence 34 BP; 4 A; 0 C; 2 G; 0 T; 28 U; 0 Other;
XX
XX Query Match 0.5%; Score 26; DB 1; Length 34;
XX Best Local Similarity 85.3%; Pred. No. 50;
XX Matches 29; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
XX
XX QY 5032 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5065
XX | | | | | | | | | | | | | | | | | | | | | |
XX 34 ATAAATAATAATAATAATAATAATAATAATAATAATAA 1
XX
XX
XX RESULT 16
XX ADR51048/c
XX ID ADR51048 standard; DNA; 27 BP.
XX
XX AC ADR51048;
XX
XX 21-OCT-2004 (first entry)
XX
XX Duo binding moiety multivalent compound associated primer #1.
XX
XX ss; primer; antiarthritic; cytostatic; ophthalmological;
XX angiogenesis inhibitor; Kdr tyrosine kinase inhibitor; VEGF antagonist;
XX hepatocyte growth factor antagonist; multivalent compound;
XX binding moiety; euplastic tumour growth; angiogenesis;
XX hyperproliferation; arthritis; atherosclerotic plaque;
XX corneal graft neovascularization; ocular disease.
XX
XX Synthetic.
XX
OS
```

```
XX WO2004064595-A2.
XX
XX 05-AUG-2004.
XX
XX 11-SEP-2003; 2003WO-US028838.
XX
XX 15-JAN-2003; 2003US-0440201P.
XX 03-MAR-2003; 2003US-00379287.
XX
XX (BRAC ) BRACCO INT BV.
XX (DYAX-) DYAX CORP.
XX
XX Arbogast C, Bussat P, Dransfield DT, Fan H, Linder K;
XX Marinelli ER, Nanjappan P, Nunn A, Pillai R, Pochon S, Ramalingam K;
XX Sato A, Shrivastava A, Song B, Swenson RE, Von Wronski MA;
XX Walker SM;
XX
XX WPI; 2004-593275/57.
XX
XX Multivalent compounds with at least two binding moieties having
XX specificity for different binding sites on the same target, useful for
XX treating and diagnosing, e.g. angiogenic and hyperproliferative
XX disorders.
XX
XX Example 6; SEQ ID NO 72; 320pp; English.
XX
XX The invention relates to a multivalent compound (C) comprising at least
XX two binding moieties having specificity for different binding sites on
XX the same target. (C) is useful for treating euplastic tumour growth and
XX disease associated with angiogenesis or hyperproliferation (claimed). (C)
XX is useful for treating diseases such as arthritis, atherosclerotic
XX plaques, corneal graft neovascularization or ocular diseases. (C) is
XX small and can more easily reach a target. (C) localizes more effectively
XX to the target site than other targeting compounds due to its binding to
XX more than one site on the same target. This sequence represents a DNA
XX oligonucleotide used in the invention.
XX
XX Sequence 27 BP; 0 A; 1 C; 1 G; 25 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 25.4; DB 1; Length 27;
XX Best Local Similarity 96.3%; Pred. No. 52;
XX Matches 26; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 5023 GTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5049
XX | | | | | | | | | | | | | | | | | | | | | |
XX 27 GCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1
XX
XX
XX RESULT 17
XX ADR48246
XX ID ADR48246 standard; DNA; 24 BP.
XX
XX AC ADR48246;
XX
XX 18-NOV-2004 (first entry)
XX
XX Microarray synthesised oligonucleotide #10.
XX
XX ss; deposition unit misalignment; polymeric array synthesis;
XX pulse jet misalignment; printhead misalignment; microarray.
XX
XX Synthetic.
XX
XX US2004170984-A1.
XX
XX 02-SEP-2004.
XX
XX 25-FEB-2003; 2003US-00374307.
XX
XX 25-FEB-2003; 2003US-00374307.
XX
XX (LEPR/) LEPROUST E M.
```

```

PA (AMOR/) AMORESE D A.
PA (KRON/) KRONICK M N.
XX
XX Leproust EM, Amorese DA, Kronick MN;
XX
XX WPI; 2004-634540/61.
XX
XX Detection of deposition unit misalignment of in situ polymeric array
XX synthesis device, by contacting test probe feature with different
XX distinguishably labeled targets, and evaluating binding of labeled
XX targets to test probe feature.
XX
XX Example 2; Page 16; 36pp; English.
XX
XX The invention relates to a method of detection of deposition unit
XX misalignment of an in situ polymeric array synthesis device which
XX comprises synthesizing test probe feature(s) on substrate using in situ
XX polymeric array synthesis device, contacting test probe feature with at
XX least two different distinguishably labelled targets and evaluating
XX binding of labelled targets to test probe feature to detect any pulse jet
XX misalignment of polymeric array synthesis device. The method is useful
XX for detecting deposition unit misalignment e.g. printhead misalignment,
XX of an in situ polymeric, e.g. nucleic acid, array synthesis device. The
XX method is easy to use, cost effective, effective at detecting printhead
XX misalignments and may enable immediate detection and/or adjustments of
XX one or more printheads of an in situ nucleic acid array synthesis fluid
XX deposition device if misalignment is detected. The present sequence
XX represents an oligonucleotide synthesised on a microarray.
XX
XX Sequence 24 BP; 24 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
DB 1 AAAAAAAAAAAAAAAAAAAAAA 24
RESULT 18
ADR48249/C
ID ADR48249 standard; DNA; 24 BP.
XX
XX ADR48249;
XX
XX 18-NOV-2004 (first entry)
XX
XX Microarray synthesised oligonucleotide #13.
XX
XX ss; deposition unit misalignment; polymeric array synthesis;
XX pulse jet misalignment; printhead misalignment; microarray.
XX
XX Synthetic.
XX
XX US2004170984-A1.
XX
XX 02-SEP-2004.
XX
XX 25-FEB-2003; 2003US-00374307.
XX
XX 25-FEB-2003; 2003US-00374307.
PA (LEPR/) LEPROUST E M.
PA (AMOR/) AMORESE D A.
PA (KRON/) KRONICK M N.
XX
XX Leproust EM, Amorese DA, Kronick MN;
XX
XX WPI; 2004-634540/61.
XX
XX Detection of deposition unit misalignment of in situ polymeric array
XX synthesis device, by contacting test probe feature with different
XX distinguishably labeled targets, and evaluating binding of labeled
XX targets to test probe feature.
XX
XX Example 2; Page 16; 36pp; English.
XX
XX The invention relates to a method of detection of deposition unit
XX misalignment of an in situ polymeric array synthesis device which
XX comprises synthesizing test probe feature(s) on substrate using in situ
XX polymeric array synthesis device, contacting test probe feature with at
XX least two different distinguishably labelled targets and evaluating
XX binding of labelled targets to test probe feature to detect any pulse jet
XX misalignment of polymeric array synthesis device. The method is useful
XX for detecting deposition unit misalignment e.g. printhead misalignment,
XX of an in situ polymeric, e.g. nucleic acid, array synthesis device. The
XX method is easy to use, cost effective, effective at detecting printhead
XX misalignments and may enable immediate detection and/or adjustments of
XX one or more printheads of an in situ nucleic acid array synthesis fluid
XX deposition device if misalignment is detected. The present sequence
XX represents an oligonucleotide synthesised on a microarray.
XX
XX Sequence 24 BP; 24 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
DB 1 AAAAAAAAAAAAAAAAAAAAAA 24
RESULT 19
AAT68809
ID AAT68809 standard; DNA; 30 BP.
XX
XX AAT68809;
XX
XX 07-AUG-1997 (first entry)
XX
XX Levansucrase mutant sacB(BamP)W29 gene PCR primer MB2.
XX
XX Gram-positive bacterium; positive selection vector; levansucrase;
XX Bacillus amyloliquefaciens; signal peptide cleavage; sacB(BamP)W29;
XX primer; PCR; polymerase chain reaction; ss.
XX
XX Synthetic.
XX
XX WO9716558-A1.
XX
XX 09-MAY-1997.
XX
XX 31-OCT-1996; 96WO-US017636.
XX
XX 03-NOV-1995; 95US-0006201P.
XX
XX (DUPO ) DU PONT DE NEMOURS & CO E I.
XX
XX Bramucci MG, Nagarajan V;
XX
XX WPI; 1997-272125/24.
XX
XX Positive selection for transformed Gram positive bacteria, especially
XX Bacillus - useful for cloning heterologous genes encoding e.g. industrial
XX enzymes, immunoglobulin(s), etc.
XX
XX Example 5; Page 30; 54pp; English.
XX
XX PCR primers MB2 (AAT68809) and MB3 (AAT68810) are based on the nucleotide
XX sequences for the Bacillus amyloliquefaciens sacB gene and the polylinker
XX region of pBE504. MB3 overlaps Arg codon 331 of the sacB(BamP)W29 mutant
XX gene (see also AAT68806) and was designed to convert codon 331 into a Leu
XX codon in the amplified DNA. The primers were used to amplify a region of
XX plasmid pMGB161deicat1 that included the 473 bp between the BamHI and

```

```

PT distinguishably labeled targets, and evaluating binding of labeled
PT targets to test probe feature.
XX
XX Example 2; Page 16; 36pp; English.
XX
XX The invention relates to a method of detection of deposition unit
XX misalignment of an in situ polymeric array synthesis device which
XX comprises synthesizing test probe feature(s) on substrate using in situ
XX polymeric array synthesis device, contacting test probe feature with at
XX least two different distinguishably labelled targets and evaluating
XX binding of labelled targets to test probe feature to detect any pulse jet
XX misalignment of polymeric array synthesis device. The method is useful
XX for detecting deposition unit misalignment e.g. printhead misalignment,
XX of an in situ polymeric, e.g. nucleic acid, array synthesis device. The
XX method is easy to use, cost effective, effective at detecting printhead
XX misalignments and may enable immediate detection and/or adjustments of
XX one or more printheads of an in situ nucleic acid array synthesis fluid
XX deposition device if misalignment is detected. The present sequence
XX represents an oligonucleotide synthesised on a microarray.
XX
XX Sequence 24 BP; 0 A; 0 C; 0 G; 24 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
DB 24 AAAAAAAAAAAAAAAAAAAAAA 1
RESULT 19
AAT68809
ID AAT68809 standard; DNA; 30 BP.
XX
XX AAT68809;
XX
XX 07-AUG-1997 (first entry)
XX
XX Levansucrase mutant sacB(BamP)W29 gene PCR primer MB2.
XX
XX Gram-positive bacterium; positive selection vector; levansucrase;
XX Bacillus amyloliquefaciens; signal peptide cleavage; sacB(BamP)W29;
XX primer; PCR; polymerase chain reaction; ss.
XX
XX Synthetic.
XX
XX WO9716558-A1.
XX
XX 09-MAY-1997.
XX
XX 31-OCT-1996; 96WO-US017636.
XX
XX 03-NOV-1995; 95US-0006201P.
XX
XX (DUPO ) DU PONT DE NEMOURS & CO E I.
XX
XX Bramucci MG, Nagarajan V;
XX
XX WPI; 1997-272125/24.
XX
XX Positive selection for transformed Gram positive bacteria, especially
XX Bacillus - useful for cloning heterologous genes encoding e.g. industrial
XX enzymes, immunoglobulin(s), etc.
XX
XX Example 5; Page 30; 54pp; English.
XX
XX PCR primers MB2 (AAT68809) and MB3 (AAT68810) are based on the nucleotide
XX sequences for the Bacillus amyloliquefaciens sacB gene and the polylinker
XX region of pBE504. MB3 overlaps Arg codon 331 of the sacB(BamP)W29 mutant
XX gene (see also AAT68806) and was designed to convert codon 331 into a Leu
XX codon in the amplified DNA. The primers were used to amplify a region of
XX plasmid pMGB161deicat1 that included the 473 bp between the BamHI and

```

CC BamHI restriction sites. The mutation showed that the polymerase activity
CC of the sacB(Bamp)W29 gene product is necessary for inhibition of growth
CC on medium with sucrose by sacB(Bamp)W29. Inactivation of sacB(Bamp)W29
CC could be used to select for growth of colonies of B. subtilis with cloned
CC inserts in sacB(Bamp)W29

XX SQ Sequence 30 BP; 6 A; 10 C; 9 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 24; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGATCCCCCGGCTGCAGGAATTC 24
|||||
DB 4 GGATCCCCCGGCTGCAGGAATTC 27
|||||

RESULT 20
ADH26671/c
ID ADH26671 standard; DNA; 23 BP.
XX
XX AC ADH26671;
XX
XX DT 11-MAR-2004 (first entry)
XX
XX DE Human PI3K regulatory subunit 4, p150 DNA PCR primer #2.
XX
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; PCR; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory; primer.

XX OS Homo sapiens.
XX
XX PN US2003225013-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 31-MAY-2002; 2002US-00160786.
XX
XX PR 31-MAY-2002; 2002US-00160786.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Freier SM, Dobie KW;
XX
XX DR WPI; 2004-051923/05.
XX
XX PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

XX Example 13; SEQ ID NO 6; 62pp; English.
XX
XX CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PCR primer used to amplify DNA encoding the human PI3K

CC regulatory subunit 4, p150 polypeptide of the invention.
XX
XX SQ Sequence 23 BP; 9 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2476 TATGCCCTTACTGTATGTGCCA 2498
|||||
DB 23 TATGCCCTTACTGTATGTGCCA 1
|||||

RESULT 21
ADH26670
ID ADH26670 standard; DNA; 23 BP.
XX
XX AC ADH26670;
XX
XX DT 11-MAR-2004 (first entry)
XX
XX DE Human PI3K regulatory subunit 4, p150 DNA PCR primer #1.
XX
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; PCR; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory; primer.

XX OS Homo sapiens.
XX
XX PN US2003225013-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 31-MAY-2002; 2002US-00160786.
XX
XX PR 31-MAY-2002; 2002US-00160786.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Freier SM, Dobie KW;
XX
XX DR WPI; 2004-051923/05.
XX
XX PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

XX Example 13; SEQ ID NO 5; 62pp; English.
XX
XX CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PCR primer used to amplify DNA encoding the human PI3K

XX regulatory subunit 4, p150 polypeptide of the invention.

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2422 CTGCTGCAACAAGGCTCTTAGTGA 2444
DB 1 CTGCTGCNACAGGCTCTTAGTGA 23

RESULT 22
ADL34560/c
ID ADL34560 standard; DNA; 23 BP.
XX
AC ADL34560;
XX
DT 17-JUN-2004 (first entry)
XX
DE Human phosphoinositide-3-kinase regulator subunit 4 p150 PCR primer 2.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ss; primer; PCR.
XX
OS Homo sapiens.
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (PREI/) PREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Preier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 13; SEQ ID NO 6; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 23 BP; 9 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2476 TATGCCCTTACTTGTATGTGCCA 2498

DB 23 TATGCCCTTACTTGTATGTGCCA 1

RESULT 23
ADL34559
ID ADL34559 standard; DNA; 23 BP.
XX
AC ADL34559;
XX
DT 17-JUN-2004 (first entry)
XX
DE Human phosphoinositide-3-kinase regulator subunit 4 p150 PCR primer 1.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ss; primer; PCR.
XX
OS Homo sapiens.
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (PREI/) PREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Preier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 13; SEQ ID NO 5; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 23 BP; 6 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2422 CTGCTGCAACAAGGCTCTTAGTGA 2444
DB 1 CTGCTGCNACAGGCTCTTAGTGA 23

RESULT 24

ADR44220
ID ADR44220 standard; DNA; 25 BP.
AC ADR44220;
XX
XX
DT 04-NOV-2004 (first entry)
KW Caenorhabditis elegans heat-shock promoter DNA #1.
DE
XX
KW Nematode; gene therapy; tumour; cancer; heat-shock promoter; ss.
XX
XX
OS Caenorhabditis elegans.
XX
FH Key Location/Qualifiers
FT misc_feature 4 /*tag= a
FT /*note= "N can be repeated X times"
FT misc_feature 22 /*tag= b
FT /*note= "N can be repeated Y times"
XX
XX US2004161782-A1.
XX
XX
PD 19-AUG-2004.
XX
XX
PF 21-NOV-2003; 2003US-00719995.
XX
XX 22-MAY-2001; 2001EP-00201936.
PR 22-MAY-2002; 2002WO-NL000322.
PR 28-NOV-2002; 2002WO-WO095071.
XX
XX (TIJS/) TIJSTERMAN M.
PA (PLAS/) PLASTERK R H A.
XX
XX Tijsterman M, Plasterk RHA;
XX
XX WPI; 2004-603554/58.
DR
XX
PT Determining if a gene product/compound is involved in preventing
PT replication error in a cell, useful for treating cancer, comprises
PT determining expression level of a marker gene in a cell treated with a
PT gene product inhibitor/compound.
XX
XX
PS Disclosure; Fig 3; 25pp; English.
XX
XX The present invention relates to a method for determining if a gene
XX product or compound is involved in preventing replication error in a
XX cell. The method involves providing a cell with a specific inhibitor for
XX a gene product or with a compound and determining the expression level of
XX a marker gene in the cell, where the expression level of the marker gene
XX is dependent on the occurrence of a replication error. The invention is
XX useful in gene therapy and for treating a subject having tumours or
XX cancer. The present sequence is a Caenorhabditis elegans heat-shock
XX promoter DNA. This sequence is used to illustrate the method of
XX invention.
XX
SQ Sequence 25 BP; 21 A; 0 C; 1 G; 1 T; 0 U; 2 Other;

Query Match 0.4%; Score 22; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5022 TGTAAAAA...AAAAA 5045
Db 2 TGNAAAAA...AAAAA 25

RESULT 25
AAV03154
ID AAV03154 standard; DNA; 21 BP.
XX
AC AAV03154;
XX

DT 09-APR-1998 (first entry)
XX
XX PCR primer BKSBE used to amplify a region of the PR-1a gene.
DE
XX
KW PR-1a gene terminator; tobacco; antibacterial peptide; sarcotoxin 1a;
KW hinge region; tobacco chitinase; plant promoter; plant resistance;
KW pathogenic fungi; pathogenic bacteria; PCR primer; ss.
XX
XX Synthetic.
XX
XX EP798381-A2.
XX
XX 01-OCT-1997.
PD
XX
PF 27-FEB-1997; 97EP-00301299.
XX
XX 25-MAR-1996; 96JP-00068809.
PR 17-JUL-1996; 96JP-00187763.
XX
XX (NORQ) NAT INST AGROBIOLOGICAL RESOURCES.
XX
XX Mitsuhashi I, Ohashi Y, Ohshima M;
PI WPI; 1997-473191/44.
XX
XX
XX Plant resistant to pathogenic fungi and bacteria - especially containing
XX insect gene encoding sarcotoxin 1a.
XX
XX Example 1; Page 14; 32pp; English.
XX
XX PCR primers AAV03153-54 were used to amplify a terminator region of the
XX PR-1a gene from tobacco. This fragment was used to create a recombinant
XX gene in which a gene encoding an anti-bacterial peptide (e.g. sarcotoxin
XX 1a) is bound to a plant gene via a hinge region of tobacco chitinase, an
XX expression cassette in which the recombinant gene is bound to a plant
XX promoter, and a gene having the expression cassette and a drug resistance
XX gene linked to a plant promoter which is constitutively expressed. Plants
XX transformed with this expression vector are resistant to pathogenic fungi
XX and bacteria
XX
XX SQ Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 TCCCCCGGCTGAGGAATTC 24
Db 1 TCCCCCGGCTGAGGAATTC 21

RESULT 26
AAV60992
ID AAV60992 standard; DNA; 24 BP.
XX
XX AAV60992;
AC
XX
XX 03-DEC-1998 (first entry)
DT
XX
XX Inverse PCR primer Ubqla from WO9837211 Example 1.
DE
XX
XX Barnase; barstar; IPCR; inverse polymerase chain reaction; phenotype;
KW transgenic plant; hybrid seed; male sterile plant; active enzyme;
KW regulatory protein; embryoless seed; herbicide resistance; primer; ss.
XX
XX Synthetic.
XX
XX WO9837211-A1.
PN
XX
XX 27-AUG-1998.
PD
XX
XX 20-FEB-1998; 98WO-GB000542.
PF
XX

PI Mao Y, Xie Y;
XX WPI; 2002-217511/28.
DR New polypeptide human chaparonin CPN 60 protein 14 and polynucleotides for
XX encoding same.
PT
XX
XX Example 2; Page 17 (Disclosure); 32pp; Chinese.
PS
XX The invention relates to human molecular chaperone cpn60 protein 14,
CC polynucleotide encoding for this polypeptide and a method for producing
CC this polypeptide by using DNA recombinant techniques. The invention also
CC discloses the method for curing several diseases, such as malignant
CC tumour, haemopathy, HIV infection, immunological disease and various
CC inflammations by using the polypeptide. The invention also discloses an
CC antagonist for resisting said polypeptide and its therapeutic action and
CC the application of polynucleotide encoding this novel human molecular
CC chaperone cpn60 protein 14. The present sequence is that of a human
CC molecular chaperone cpn60 protein 14 PCR primer, useful in examples of
CC the invention
XX
XX Sequence 24 BP; 2 A; 10 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 21; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5065 CTCGAGGGGGGGCCCGGTACC 5085
DB 23 CTCGAGGGGGGGCCCGGTACC 3
RESULT 29
ABZ57354/c
ID ABZ57354 standard; DNA; 24 BP.
XX
AC ABZ57354;
XX
DT 01-APR-2003 (first entry)
XX
DE Human zinc finger protein 12.54 RT-PCR primer, SEQ ID NO:3.
XX
KW Human; zinc finger protein 12.54; recombinant production; gene therapy;
KW cancer; tumour; human immunodeficiency virus; HIV infection; cytostatic;
KW reverse transcription-PCR; RT-PCR; primer; ss.
XX
OS Homo sapiens.
XX
XX CN1363573-A.
XX
PD 14-AUG-2002.
XX
PF 05-JAN-2001; 2001CN-00105045.
XX
XX 05-JAN-2001; 2001CN-00105045.
XX
XX (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX
PI Mao Y, Xie Y;
XX
XX WPI; 2003-000314/01.
DR
XX Polypeptide-human zinc finger protein 12.54 and polynucleotide for coding
XX it.
PT
PT
XX Example 2; Page 17 (Disclosure); 32pp; Chinese.
PS
XX The invention relates to human zinc finger protein 12.54 (ABP58744) and
CC nucleic acids encoding it (ABZ57353). The protein has a molecular weight
CC of 12.54 kD. The invention also relates to a method for the recombinant
CC production of the protein, an antagonist of the protein, and the use of
CC the protein, gene and antagonist in therapeutic applications. Zinc finger
CC protein 12.54 can be used in the treatment of a variety of diseases such

CC as cancer and HIV (human immunodeficiency virus) infection. Sequences
CC ABZ57354-ABZ57355 represent reverse transcription-PCR (RT-PCR) primers
CC used in an exemplification of the invention to isolate human zinc finger
CC protein 12.54 cDNA
XX
SQ Sequence 24 BP; 2 A; 10 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 21; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5065 CTCGAGGGGGGGCCCGGTACC 5085
DB 24 CTCGAGGGGGGGCCCGGTACC 4
RESULT 30
ADR44221
ID ADR44221 standard; DNA; 24 BP.
XX
AC ADR44221;
XX
DT 04-NOV-2004 (first entry)
XX
DE Caenorhabditis elegans heat-shock promoter DNA #2.
XX
KW Nematode; gene therapy; tumour; cancer; heat-shock promoter; ss.
XX
OS Caenorhabditis elegans.
XX
FH Key Location/Qualifiers
FT misc_feature 4 /*tag= a
FT /*note= "N can be repeated X times"
FT 21
FT misc_feature 21 /*tag= b
FT /*note= "N can be repeated Y times"
XX
XX US2004161782-A1.
XX
XX 19-AUG-2004.
XX
XX 21-NOV-2003; 2003US-00719995.
XX
XX 22-MAY-2001; 2001EP-00201936.
PR 22-MAY-2002; 2002WO-NL000322.
PR 28-NOV-2002; 2002WO-WO095071.
XX
XX (TIJS/) TIJSTERMAN M.
PA (PLAS/) PLASTERK R H A.
XX
XX Tijsterman M, Plasterk RHA;
PI
XX WPI; 2004-603554/58.
XX
XX Determining if a gene product/compound is involved in preventing
XX replication error in a cell, useful for treating cancer, comprises
XX determining expression level of a marker gene in a cell treated with a
XX gene product inhibitor/compound.
XX
XX Disclosure; Fig 3; 25pp; English.
XX
XX The present invention relates to a method for determining if a gene
XX product or compound is involved in preventing replication error in a
XX cell. The method involves providing a cell with a specific inhibitor for
XX a gene product or with a compound and determining the expression level of
XX a marker gene in the cell, where the expression level of the marker gene
XX is dependent on the occurrence of a replication error. The invention is
XX useful in gene therapy and for treating a subject having tumours or
XX cancer. The present sequence is a Caenorhabditis elegans heat-shock
XX promoter DNA. This sequence is used to illustrate the method of
XX invention.

```

SQ Sequence 24 BP; 20 A; 0 C; 1 G; 1 T; 0 U; 2 Other;
Query Match      0.4%; Score 21; DB 1; Length 24;
Best Local Similarity 91.3%; Pred. NO. 1.2e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 5022 TGTAAAAA...AAAAA 5044
Db 2 TGNAAAAA...AAAAA 24

RESULT 31
ABA95469/c
ID ABA95469 standard; DNA; 24 BP.
XX
AC ABA95469;
XX
DT 04-APR-2002 (first entry)
XX
DE Human natural killer cell enhancing factor B13.64 PCR primer #1.
XX
KW Human; natural killer cell; enhancing factor; B13.64; cytostatic;
KW haemostatic; virucide; immunomodulatory; antiinflammatory; gene therapy;
KW tumour; haemopathy; HIV infection; immunological disease; inflammation;
KW PCR primer; sb.
XX
OS Homo sapiens.
XX
PN WO200190177-A1.
XX
PD 29-NOV-2001.
XX
PF 21-MAY-2001; 2001WO-CN000855.
XX
PR 24-MAY-2000; 2000CN-00115801.
XX
PA (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
XX
PI Mao Y, Xie Y;
XX
WPI; 2002-089921/12.
XX
PT Human natural killer cell enhancing factor B13.64 and encoded
PT polynucleotide, used in diagnosis and treatment of malignant tumors,
PT hemopathy, human immunodeficiency virus infection, immunological diseases
PT and inflammation.
XX
PS Example 2; Page 18; 38pp; Chinese.
XX
CC The present invention relates to human natural killer cell enhancing
CC factor B13.64 (see AAM48184). The enhancing factor and its coding
CC sequence are useful in the diagnosis and treatment of malignant tumours,
CC haemopathy, HIV infection, immunological diseases and various
CC inflammations. The present sequence is a PCR primer, which was used in an
CC example from the present invention
XX
SQ Sequence 24 BP; 2 A; 11 C; 8 G; 3 T; 0 U; 0 Other;
Query Match      0.4%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. NO. 1.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5063 AACTCGAGGGGGGCGCGGTAC 5084
Db 22 ACCTCGAGGGGGGCGCGGTAC 1

RESULT 32
ADS13095/c
ID ADS13095 standard; DNA; 22 BP.
XX
AC ADS13095;
XX

```

```

DT 02-DEC-2004 (first entry)
XX
DE, Oligo dt PCR primer used in the cloning of PON1 genes Seq 11.
XX
KW PCR; primer; ss; paraoxonase; PON1; praaxon; nerve agent; sarin; soman;
KW in vitro evolution; hyperlipidaemia; atherosclerosis;
KW neurological disease; Alzheimer's disease; neurofibromatosis;
KW Huntington's disease; depression; amyotrophic lateral sclerosis;
KW multiple sclerosis; stroke; Parkinson's disease; multi-infarct dementia;
KW cancer; organophosphate poisoning; antilipemic; antiarteriosclerotic;
KW neuroprotective; nootropic; cytostatic; anticonvulsant; antidepressant;
KW antiparkinsonian; antidote.
XX
OS Synthetic.
XX
PN WO2004078991-A2.
XX
PD 16-SEP-2004.
XX
PF 04-MAR-2004; 2004WO-IL000216.
XX
PR 04-MAR-2003; 2003US-0451267P.
PR 22-OCT-2003; 2003US-0512925P.
XX
PA (YEDA ) YEDA RES & DEV CO LTD.
XX
PI Tawfik DS, Aharoni A, Gaydukov L, Sussman JL, Silman I;
XX
WPI; 2004-668627/65.
XX
PT Novel mutant of PON enzyme exhibiting increased substrate specificity to
PT PON substrate, useful for treating or preventing PON1-related diseases
XX e.g., hyperlipidemia, atherosclerosis, neurological disease or cancer.
XX
PS Example 1; SEQ ID NO 11; 240pp; English.
XX
CC This invention relates to novel mutant serum paraoxonase (PON1) nucleic
CC acid molecules and the encoded proteins thereof. Specifically, it refers
CC to enzymes that are calcium dependent phosphotriesterases essential to
CC the detoxification process of organophosphates such as the insecticide
CC praaxon and the nerve agents sarin and soman. The present invention
CC describes a method to identify mutated PONs that exhibit substantially
CC identical (or improved) substrate specificity in comparison with the wild
CC -type PON and also those mutants that do not form aggregates when
CC expressed in bacteria. In particular, the method employed an in vitro
CC evolution process to identify proteins with desired traits such as
CC structural plasticity, catalytic activity and maintaining substrate
CC binding. These mutants have been found to be useful for treating or
CC preventing PON1-related diseases including hyperlipidaemia,
CC atherosclerosis, neurological disease (e.g. Alzheimer's disease,
CC neurofibromatosis, Huntington's disease, depression, amyotrophic lateral
CC sclerosis, multiple sclerosis, stroke, Parkinson's disease or multi-
CC infarct dementia), cancer and organophosphate poisoning. Accordingly,
CC they exhibit antilipemic, antiarteriosclerotic, neuroprotective,
CC nootropic, cytostatic, anticonvulsant, antidepressant and
CC antiparkinsonian activities, as well as being an antidote in a case of
CC poisoning. This oligonucleotide sequence is a PCR primer used for the
CC cloning and expression of a wild type PON1 gene of the invention.
XX
SQ Sequence 22 BP; 0 A; 0 C; 0 G; 20 T; 0 U; 2 Other;
Query Match      0.4%; Score 20.2; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. NO. 1.4e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5024 TAAAAA...AAAAA 5044
Db 21 BAAAAA...AAAAA 1

RESULT 33
AAF76082
ID AAF76082 standard; DNA; 20 BP.

```

XX AAF76082;
 XX 22-MAY-2001 (first entry)
 DT pBluescript vector PCR primer, SEQ ID:26, used to isolate ZmMADS2 cDNA.
 DE
 XX
 XX Maize MADS box gene; ZmMADS2; pollen-specific expression;
 XX pollen development; function; transgenic plant; male sterility;
 KW hybrid seed production; PCR primer; ss.
 KW
 XX Synthetic.
 OS
 XX WO200112799-A2.
 XX
 XX 22-FEB-2001.
 PD
 XX 16-AUG-2000; 2000WO-EP008002.
 XX
 XX 18-AUG-1999; 99EP-00116268.
 XX
 XX (SUED-) SUEDEWESTDEUTSCHE SAATZUCHT.
 PA
 XX Loerz H, Dresselhaus T, Schreiber D, Heuer S;
 PI WPI; 2001-211214/21.
 XX
 XX Novel nucleic acid molecule useful for cloning and expressing a pollen
 XX specific sequence in a plant.
 XX
 XX Example 1; Page 32; 66pp; English.
 PS
 XX The invention relates to regulatory elements (AAF76059-AAF76067) from the
 XX maize MADS box gene ZmMADS2 (AAF76068) which are capable of directing
 CC expression in a pollen-specific manner. The ZmMADS2 protein (AAF73333) is
 CC expressed particularly in mature pollen after dehiscence, indicating that
 CC it has an essential role in pollen development and function, in
 CC particular in pollen tube growth. The invention also relates to vectors
 CC and host cells comprising the ZmMADS2 regulatory or genomic sequence, and
 CC their use in the generation of transgenic plants. The ZmMADS2 regulatory
 CC sequences are useful for cloning and expressing a pollen-specific or
 CC pollen-abundant gene in a plant, and may also be used to drive the
 CC expression of a gene of interest in a pollen-specific or pollen-preferred
 CC manner. The ZmMADS2 regulatory sequences are useful for isolating related
 CC regulatory sequences of other plant species which confer pollen or group
 CC specificity to genes of interest in plant breeding, especially for the production of
 CC hybrid seed. In particular, they may be used to drive the pollen-specific
 CC expression of heterologous genes which confer nuclear or cytoplasmic male
 CC sterility in transgenic plants (e.g., cereals). Sequences AAF76081-
 CC AAF76084 represent PCR primers used in the isolation of cDNA encoding
 CC ZmMADS2 (AAF76058)
 XX
 XX Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 5 CCCCCGGGCTGCAGGAATTC 24
 Db 1 CCCCCGGGCTGCAGGAATTC 20
 RESULT 34
 AAF76469
 ID AAF76469 standard; DNA; 20 BP.
 XX
 XX AAF76469;
 AC
 XX 11-MAY-2001 (first entry)
 DT
 XX Maize ZmMADS2 coding sequence PCR primer SEQ ID NO: 26.
 DE

XX Male sterile plant; maize; hybrid breeding; pollen tube; ZmMADS2; grain;
 KW cereal; corn; PCR primer; ss.
 XX
 XX Zea mays.
 OS
 XX WO200112798-A2.
 XX
 XX 22-FEB-2001.
 PD
 XX 16-AUG-2000; 2000WO-EP008001.
 XX
 XX 18-AUG-1999; 99EP-00116267.
 XX
 XX (SUED-) SUEDEWESTDEUTSCHE SAATZUCHT.
 PA
 XX Loerz H, Dresselhaus T, Schreiber D, Heuer S;
 PI WPI; 2001-211213/21.
 XX
 XX Novel nucleic acid molecule, ZmMADS2 derived from pollen of Zea mays
 XX useful for cloning and expressing a pollen specific sequence in a plant
 XX and for producing male sterile plants.
 XX
 XX Example 1; Page 74; 76pp; English.
 PS
 XX The present invention provides the protein and coding sequences of the
 XX Zea mays ZmMADS2 protein, which is specifically expressed in pollen. The
 CC sequences can be used to produce male sterile plants, as ZmMADS2 is
 CC essential for pollen tube growth. These are useful in hybrid breeding,
 CC particularly of corn, cereal and grain. The present sequence is a PCR
 CC primer for the ZmMADS2 coding sequence
 XX
 XX Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 5 CCCCCGGGCTGCAGGAATTC 24
 Db 1 CCCCCGGGCTGCAGGAATTC 20
 RESULT 35
 ADH26676/c
 ID ADH26676 standard; DNA; 20 BP.
 XX
 XX ADH26676;
 AC
 XX 11-MAR-2004 (first entry)
 DT
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #1.
 DE
 XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 XX
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA

XX PI Freier SM, Dobie KW;
 XX DR WPI; 2004-051923/05.
 XX PS New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 11; 62pp; English.
 XX CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 43 CGTTGCTGGGCTGCAGCA 62
 Db 20 CGTTGCTGGGCTGCAGCA 1
 RESULT 36
 ADH26709/c
 ID ADH26709 standard; DNA; 20 BP.
 XX AC ADH26709;
 XX DT 11-MAR-2004 (first entry)
 XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #34.
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX OS Homo sapiens.
 XX PN US2003225013-A1.
 XX PD 04-DEC-2003.
 XX PF 31-MAY-2002; 2002US-00160786.
 XX PR 31-MAY-2002; 2002US-00160786.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Freier SM, Dobie KW;
 XX DR WPI; 2004-051923/05.
 XX PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 11; 62pp; English.
 XX CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 43 CGTTGCTGGGCTGCAGCA 62
 Db 20 CGTTGCTGGGCTGCAGCA 1
 RESULT 37
 ADH26726/c
 ID ADH26726 standard; DNA; 20 BP.
 XX AC ADH26726;
 XX DT 11-MAR-2004 (first entry)
 XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #51.
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX OS Homo sapiens.
 XX PN US2003225013-A1.
 XX PD 04-DEC-2003.
 XX PF 31-MAY-2002; 2002US-00160786.
 XX PR 31-MAY-2002; 2002US-00160786.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Freier SM, Dobie KW;
 XX DR WPI; 2004-051923/05.
 XX PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 44; 62pp; English.
 XX CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2041 ACAGCTCTGAGATTCTCTGGA 2060
 Db 20 ACAGCTCTGAGATTCTCTGGA 1
 RESULT 37
 ADH26726/c
 ID ADH26726 standard; DNA; 20 BP.
 XX AC ADH26726;
 XX DT 11-MAR-2004 (first entry)
 XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #51.
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX OS Homo sapiens.
 XX PN US2003225013-A1.
 XX PD 04-DEC-2003.
 XX PF 31-MAY-2002; 2002US-00160786.
 XX PR 31-MAY-2002; 2002US-00160786.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Freier SM, Dobie KW;
 XX DR WPI; 2004-051923/05.
 XX PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

PS Example 15; SEQ ID NO 61; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,

CC p150. The compound is an antisense oligonucleotide that specifically

CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

CC 4, p150 and inhibits expression of the polypeptide. The antisense

CC oligonucleotide comprises at least one modified internucleoside linkage

CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,

CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified

CC nucleobase comprising a 5-methylcytosine. The antisense compounds are

CC useful for modulating the expression of PI3K regulatory subunit 4, p150

CC and for preventing or treating hyperproliferative disorders (i.e.

CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and

CC metabolic disorders. These may also be used in research and diagnostics

CC and in preventing or delaying infection or inflammation. This sequence

CC represents an antisense oligonucleotide of the invention.

XX

SQ Sequence 20 BP; 4 A; 2 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3388 AAACTGAATTCAGCAACT 3407

DB 20 AAACTGAATTCAGCAACT 1

RESULT 38

ADH26733/c

ID ADH26733 standard; DNA; 20 BP.

XX

AC ADH26733;

XX

DT 11-MAR-2004 (first entry)

XX

DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #58.

XX

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;

KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;

KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

KW neurodegenerative disorder; metabolic disorders; inflammation;

KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;

KW antiinflammatory.

XX

OS Homo sapiens.

XX

XX US2003225013-A1.

XX

XX 04-DEC-2003.

XX

XX 31-MAY-2002; 2002US-00160786.

XX

XX 31-MAY-2002; 2002US-00160786.

XX

XX (ISIS-) ISIS PHARM INC.

XX

XX Freier SM, Dobie KW;

XX

XX WPI; 2004-051923/05.

XX

XX New antisense oligonucleotides inhibiting the expression of

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

PT preventing or treating diseases associated with the subunit, e.g.

PT hyperproliferative disorders.

XX

XX Example 15; SEQ ID NO 68; 62pp; English.

PS

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,

CC p150. The compound is an antisense oligonucleotide that specifically

CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

CC 4, p150 and inhibits expression of the polypeptide. The antisense

CC oligonucleotide comprises at least one modified internucleoside linkage

CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,

CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified

CC nucleobase comprising a 5-methylcytosine. The antisense compounds are

CC useful for modulating the expression of PI3K regulatory subunit 4, p150

CC and for preventing or treating hyperproliferative disorders (i.e.

CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and

CC metabolic disorders. These may also be used in research and diagnostics

CC and in preventing or delaying infection or inflammation. This sequence

CC represents an antisense oligonucleotide of the invention.

XX

SQ Sequence 20 BP; 4 A; 2 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3388 AAACTGAATTCAGCAACT 3407

DB 20 AAACTGAATTCAGCAACT 1

RESULT 39

ADH26739/c

ID ADH26739 standard; DNA; 20 BP.

XX

AC ADH26739;

XX

DT 11-MAR-2004 (first entry)

XX

DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #64.

XX

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;

KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;

KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

KW neurodegenerative disorder; metabolic disorders; inflammation;

KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;

KW antiinflammatory.

XX

OS Homo sapiens.

XX

XX US2003225013-A1.

XX

XX 04-DEC-2003.

XX

XX 31-MAY-2002; 2002US-00160786.

XX

XX 31-MAY-2002; 2002US-00160786.

XX

XX (ISIS-) ISIS PHARM INC.

XX

XX Freier SM, Dobie KW;

XX

XX WPI; 2004-051923/05.

XX

XX New antisense oligonucleotides inhibiting the expression of

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

PT preventing or treating diseases associated with the subunit, e.g.

PT hyperproliferative disorders.

XX

XX Example 15; SEQ ID NO 74; 62pp; English.

PS

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,

CC p150. The compound is an antisense oligonucleotide that specifically

CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

CC 4, p150 and inhibits expression of the polypeptide. The antisense

CC oligonucleotide comprises at least one modified internucleoside linkage

CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,

CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified

CC nucleobase comprising a 5-methylcytosine. The antisense compounds are

CC useful for modulating the expression of PI3K regulatory subunit 4, p150

CC and for preventing or treating hyperproliferative disorders (i.e.

CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and

CC metabolic disorders. These may also be used in research and diagnostics

CC and in preventing or delaying infection or inflammation. This sequence

CC represents an antisense oligonucleotide of the invention.

XX

SQ Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3762 TGTCCAGCTTCTTGAATTG 3781

DB 20 TGTCCAGCTTCTTGAATTG 1

RESULT 39

ADH26739/c

ID ADH26739 standard; DNA; 20 BP.

XX

AC ADH26739;

XX

DT 11-MAR-2004 (first entry)

XX

DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #64.

XX

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;

KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;

KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

KW neurodegenerative disorder; metabolic disorders; inflammation;

KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;

KW antiinflammatory.

XX

OS Homo sapiens.

XX

XX US2003225013-A1.

XX

XX 04-DEC-2003.

XX

XX 31-MAY-2002; 2002US-00160786.

XX

XX 31-MAY-2002; 2002US-00160786.

XX

XX (ISIS-) ISIS PHARM INC.

XX

XX Freier SM, Dobie KW;

XX

XX WPI; 2004-051923/05.

XX

XX New antisense oligonucleotides inhibiting the expression of

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

PT preventing or treating diseases associated with the subunit, e.g.

PT hyperproliferative disorders.

XX

XX Example 15; SEQ ID NO 74; 62pp; English.

PS

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,

CC p150. The compound is an antisense oligonucleotide that specifically

CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

CC 4, p150 and inhibits expression of the polypeptide. The antisense

CC oligonucleotide comprises at least one modified internucleoside linkage

CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,

CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified

CC nucleobase comprising a 5-methylcytosine. The antisense compounds are

CC useful for modulating the expression of PI3K regulatory subunit 4, p150

CC and for preventing or treating hyperproliferative disorders (i.e.

CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and

CC metabolic disorders. These may also be used in research and diagnostics

CC and in preventing or delaying infection or inflammation. This sequence

CC represents an antisense oligonucleotide of the invention.

XX

SQ Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3762 TGTCCAGCTTCTTGAATTG 3781

DB 20 TGTCCAGCTTCTTGAATTG 1

CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of p13K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4050 CAGTGGTACCATGCTTGT 4069
 Db 20 CAGTGGTACCATGCTTGT 1

RESULT 40
 ADH26749/c
 ID ADH26749 standard; DNA; 20 BP.
 XX AC ADH26749;
 XX 11-MAR-2004 (first entry)
 DT Human p13K regulatory subunit 4, p150 DNA antisense oligonucleotide #74.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; p13K;
 KW p13 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

XX Homo sapiens.
 OS
 XX US2003225013-A1.
 PN 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 84; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (p13K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding p13K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of p13K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics

CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;
 SQ

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4633 GTGTGGAAATAAAACCTACT 4652
 Db 20 GTGTGGAAATAAAACCTACT 1

RESULT 41
 ADH26756
 ID ADH26756 standard; DNA; 20 BP.
 XX AC ADH26756;
 XX 11-MAR-2004 (first entry)
 DT Human p13K regulatory subunit 4, p150 DNA target region #3.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; p13K;
 KW p13 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

XX Homo sapiens.
 OS
 XX US2003225013-A1.
 PN 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 91; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (p13K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding p13K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of p13K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a p13K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.

XX Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
 SQ

QY	377	AGCCCATCTCCTGCTATGA	396		
Db	20	AGCCCATCTCCTGCTATGA	1		
Query Match 0.4%; Score 20; DB 1; Length 20;					
Best Local Similarity 100.0%; Pred. No. 1.4e+02;					
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	377	AGCCCATCTCCTGCTATGA	396		
Db	1	AGCCCATCTCCTGCTATGA	20		
RESULT 42					
ADH26678/c					
ID	ADH26678	standard; DNA; 20 BP.			
XX	AC	ADH26678;			
XX	DT	11-MAR-2004 (first entry)			
XX	DE	Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #3.			
XX	KW	Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;			
XX	KW	PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;			
XX	KW	2'-O-methoxyethyl sugar moiety; 5-methylcytosine;			
XX	KW	hyperproliferative disorder; cancer; Chediak-Higashi syndrome;			
XX	KW	neurodegenerative disorder; metabolic disorders; inflammation;			
XX	KW	cytostatic; immunomodulator; neurodegenerative; antimicrobial;			
XX	KW	antiinflammatory.			
OS	Homo sapiens.				
XX	US2003225013-A1.				
XX	04-DEC-2003.				
XX	31-MAY-2002; 2002US-00160786.				
XX	31-MAY-2002; 2002US-00160786.				
XX	(ISIS-) ISIS PHARM INC.				
XX	Freier SM, Dobie KW;				
XX	WPI; 2004-051923/05.				
XX	New antisense oligonucleotides inhibiting the expression of				
XX	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for				
XX	preventing or treating diseases associated with the subunit, e.g.				
XX	hyperproliferative disorders.				
XX	Example 15; SEQ ID NO 13; 62pp; English.				
XX	The invention relates to a compound targeted to a nucleic acid molecule				
XX	encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,				
XX	p150. The compound is an antisense oligonucleotide that specifically				
XX	hybridises with a nucleic acid molecule encoding PI3K regulatory subunit				
XX	4, p150 and inhibits expression of the polypeptide. The antisense				
XX	oligonucleotide comprises at least one modified internucleoside linkage				
XX	i.e. a phosphorothioate linkage, at least one modified sugar moiety,				
XX	preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified				
XX	nucleobase comprising a 5-methylcytosine. The antisense compounds are				
XX	useful for modulating or treating hyperproliferative disorders (i.e.				
XX	cancer), Chediak-Higashi syndrome, neurodegenerative disorders and				
XX	metabolic disorders. These may also be used in research and diagnostics				
XX	and in preventing or delaying infection or inflammation. This sequence				
XX	represents an antisense oligonucleotide of the invention.				
XX	Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;				
Query Match 0.4%; Score 20; DB 1; Length 20;					
Best Local Similarity 100.0%; Pred. No. 1.4e+02;					
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					

QY	377	AGCCCATCTCCTGCTATGA	396		
Db	20	AGCCCATCTCCTGCTATGA	1		
Query Match 0.4%; Score 20; DB 1; Length 20;					
Best Local Similarity 100.0%; Pred. No. 1.4e+02;					
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	377	AGCCCATCTCCTGCTATGA	396		
Db	20	AGCCCATCTCCTGCTATGA	1		
RESULT 43					
ADH26681/c					
ID	ADH26681	standard; DNA; 20 BP.			
XX	AC	ADH26681;			
XX	DT	11-MAR-2004 (first entry)			
XX	DE	Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #6.			
XX	KW	Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;			
XX	KW	PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;			
XX	KW	2'-O-methoxyethyl sugar moiety; 5-methylcytosine;			
XX	KW	hyperproliferative disorder; cancer; Chediak-Higashi syndrome;			
XX	KW	neurodegenerative disorder; metabolic disorders; inflammation;			
XX	KW	cytostatic; immunomodulator; neurodegenerative; antimicrobial;			
XX	KW	antiinflammatory.			
OS	Homo sapiens.				
XX	US2003225013-A1.				
XX	04-DEC-2003.				
XX	31-MAY-2002; 2002US-00160786.				
XX	31-MAY-2002; 2002US-00160786.				
XX	(ISIS-) ISIS PHARM INC.				
XX	Freier SM, Dobie KW;				
XX	WPI; 2004-051923/05.				
XX	New antisense oligonucleotides inhibiting the expression of				
XX	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for				
XX	preventing or treating diseases associated with the subunit, e.g.				
XX	hyperproliferative disorders.				
XX	Example 15; SEQ ID NO 16; 62pp; English.				
XX	The invention relates to a compound targeted to a nucleic acid molecule				
XX	encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,				
XX	p150. The compound is an antisense oligonucleotide that specifically				
XX	hybridises with a nucleic acid molecule encoding PI3K regulatory subunit				
XX	4, p150 and inhibits expression of the polypeptide. The antisense				
XX	oligonucleotide comprises at least one modified internucleoside linkage				
XX	i.e. a phosphorothioate linkage, at least one modified sugar moiety,				
XX	preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified				
XX	nucleobase comprising a 5-methylcytosine. The antisense compounds are				
XX	useful for modulating or treating hyperproliferative disorders (i.e.				
XX	cancer), Chediak-Higashi syndrome, neurodegenerative disorders and				
XX	metabolic disorders. These may also be used in research and diagnostics				
XX	and in preventing or delaying infection or inflammation. This sequence				
XX	represents an antisense oligonucleotide of the invention.				
XX	Sequence 20 BP; 3 A; 2 C; 6 G; 9 T; 0 U; 0 Other;				
Query Match 0.4%; Score 20; DB 1; Length 20;					
Best Local Similarity 100.0%; Pred. No. 1.4e+02;					
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					

```
RESULT 44
ADH26701/c
ID ADH26701 standard; DNA; 20 BP.
XX AC
XX ADH26701;
XX
XX
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #26.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytosolic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 36; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents an antisense oligonucleotide of the invention.
XX
XX Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1498 CAGCGTGGCAATGCTTTCC 1517
XX
XX 20 CAGCGTGGCAATGCTTTCC 1
XX
XX RESULT 45
ADH26717/c
ID ADH26717 standard; DNA; 20 BP.
XX AC
XX ADH26717;
XX
```

```
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #42.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytosolic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 52; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents an antisense oligonucleotide of the invention.
XX
XX Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 2731 GAACCAAGTAAAGTCTTCTAT 2750
XX
XX 20 GAACCAAGTAAAGTCTTCTAT 1
XX
XX RESULT 46
ADH26741/c
ID ADH26741 standard; DNA; 20 BP.
XX AC
XX ADH26741;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #66.
XX
```

KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 PN
 XX 04-DEC-2003.
 PD
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 PS
 XX Example 15; SEQ ID NO 76; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4212 GGAGACTGCTGACAGAGAT 4231
 DB 20 GGAGACTGCTGACAGAGAT 1
 RESULT 47
 ADH26748/c
 ID ADH26748 standard; DNA; 20 BP.
 XX
 XX AC ADH26748;
 XX
 XX 11-MAR-2004 (first entry)
 DT
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #73.
 DE
 XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 XX PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 XX Homo sapiens.
 OS

KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 PN
 XX 04-DEC-2003.
 PD
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 PS
 XX Example 15; SEQ ID NO 83; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4461 TGAAGTTGTCAGGAAATTC 4480
 DB 20 TGAAGTTGTCAGGAAATTC 1
 RESULT 48
 ADH26752/c
 ID ADH26752 standard; DNA; 20 BP.
 XX
 XX AC ADH26752;
 XX
 XX 11-MAR-2004 (first entry)
 DT
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #77.
 DE
 XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 XX PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 XX Homo sapiens.
 OS

PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 87; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 4792 CAAAATGGTTAGATGTA 4811
 DB 20 CAAAATGGTTAGATGTA 1
 RESULT 49
 ADH26754
 ID ADH26754 standard; DNA; 20 BP.
 XX
 AC ADH26754;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA target region #1.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytoskeletal; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.

XX 31-MAY-2002; 2002US-00160786.
 XX (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 89; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 43 CGTTTCTGGGCTGCAGCA 62
 DB 1 CGTTTCTGGGCTGCAGCA 20
 RESULT 50
 ADH26764
 ID ADH26764 standard; DNA; 20 BP.
 XX
 AC ADH26764;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA target region #11.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytoskeletal; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.

```

XX  Freier SM, Dobie KW;
PI  WPI; 2004-051923/05.
DR
XX
XX  New antisense oligonucleotides inhibiting the expression of
PT  phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT  preventing or treating diseases associated with the subunit, e.g.
PT  hyperproliferative disorders.
XX
XX  Example 15; SEQ ID NO 99; 62pp; English.
PS
XX  The invention relates to a compound targeted to a nucleic acid molecule
CC  encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC  p150. The compound is an antisense oligonucleotide that specifically
CC  hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC  4, p150 and inhibits expression of the polypeptide. The antisense
CC  oligonucleotide comprises at least one modified internucleoside linkage
CC  i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC  preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC  nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC  useful for modulating the expression of PI3K regulatory subunit 4, p150
CC  and for preventing or treating hyperproliferative disorders (i.e.
CC  cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC  metabolic disorders. These may also be used in research and diagnostics
CC  and in preventing or delaying infection or inflammation. This sequence
CC  represents a PI3K regulatory subunit 4, p150 DNA antisense
CC  oligonucleotide target region of the invention.
XX
SQ  Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
      Query Match      0.4%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 1.4e+02;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  914 CCGTCCATCTTGAATAAC 933
DB  1 CCGTCCATCTTGAATAAC 20
      |||||
      |||||

RESULT 51
ADH26775
ID  ADH26775 standard; DNA; 20 BP.
XX
XX  ADH26775;
AC
XX
DT  11-MAR-2004 (first entry)
XX
XX  Human PI3K regulatory subunit 4, p150 DNA target region #22.
DE
XX  Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW  PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW  2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW  hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW  neurodegenerative disorder; metabolic disorders; inflammation;
KW  cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW  antiinflammatory.
XX
OS  Homo sapiens.
XX
XX  US2003225013-A1.
XX
XX  04-DEC-2003.
XX
XX  31-MAY-2002; 2002US-00160786.
XX
XX  31-MAY-2002; 2002US-00160786.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
XX  Freier SM, Dobie KW;
PI  WPI; 2004-051923/05.
DR

```

```

XX  New antisense oligonucleotides inhibiting the expression of
PT  phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT  preventing or treating diseases associated with the subunit, e.g.
PT  hyperproliferative disorders.
XX
XX  Example 15; SEQ ID NO 110; 62pp; English.
PS
XX  The invention relates to a compound targeted to a nucleic acid molecule
CC  encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC  p150. The compound is an antisense oligonucleotide that specifically
CC  hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC  4, p150 and inhibits expression of the polypeptide. The antisense
CC  oligonucleotide comprises at least one modified internucleoside linkage
CC  i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC  preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC  nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC  useful for modulating the expression of PI3K regulatory subunit 4, p150
CC  and for preventing or treating hyperproliferative disorders (i.e.
CC  cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC  metabolic disorders. These may also be used in research and diagnostics
CC  and in preventing or delaying infection or inflammation. This sequence
CC  represents a PI3K regulatory subunit 4, p150 DNA antisense
CC  oligonucleotide target region of the invention.
XX
SQ  Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;
      Query Match      0.4%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 1.4e+02;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1706 CTGTATACATCTGCTTA 1725
DB  1 CTGTATACATCTGCTTA 20
      |||||
      |||||

RESULT 52
ADH26797
ID  ADH26797 standard; DNA; 20 BP.
XX
XX  ADH26797;
AC
XX
DT  11-MAR-2004 (first entry)
XX
XX  Human PI3K regulatory subunit 4, p150 DNA target region #44.
DE
XX  Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW  PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW  2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW  hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW  neurodegenerative disorder; metabolic disorders; inflammation;
KW  cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW  antiinflammatory.
XX
OS  Homo sapiens.
XX
XX  US2003225013-A1.
XX
XX  04-DEC-2003.
XX
XX  31-MAY-2002; 2002US-00160786.
XX
XX  31-MAY-2002; 2002US-00160786.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
XX  Freier SM, Dobie KW;
PI  WPI; 2004-051923/05.
XX
XX  New antisense oligonucleotides inhibiting the expression of
PT  phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT  preventing or treating diseases associated with the subunit, e.g.

```

PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 132; 62pp; English.
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3504 GCGTCTTAAGGCTGTAG 3523
 DB 1 GCGTCTTAAGGCTGTAG 20
 RESULT 53
 ADH26811
 ID ADH26811 standard; DNA; 20 BP.
 XX
 AC ADH26811;
 XX
 DT 11-MAR-2004. (first entry)
 DE Human PI3K regulatory subunit 4, p150 DNA target region #58.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 146; 62pp; English.
 XX

CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX
 SQ Sequence 20 BP; 8 A; 2 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4792 CAAAATGGTTAAGATGCTACT 4811
 DB 1 CAAAATGGTTAAGATGCTACT 20
 RESULT 54
 ADH26695/C
 ID ADH26695 standard; DNA; 20 BP.
 XX
 AC ADH26695;
 XX
 DT 11-MAR-2004 (first entry)
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #20.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 30; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit

Thu Aug 18 08:38:09 2005

CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
XX
SQ Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1215 AGATCCTTCAACTCGCTTG 1234
Db 20 AGATCCTTCAACTCGCTTG 1
RESULT 55
ADH26735/c
ID ADH26735 standard; DNA; 20 BP.
XX
XX ADH26735;
XX
XX 11-MAR-2004 (first entry)
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #60.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Preier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 70; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention. This sequence

CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
XX
SQ Sequence 20 BP; 8 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3899 TTCTTGCTATGCCACTGTG 3918
Db 20 TTCTTGCTATGCCACTGTG 1
RESULT 56
ADH26794
ID ADH26794 standard; DNA; 20 BP.
XX
XX ADH26794;
XX
XX 11-MAR-2004 (first entry)
XX Human PI3K regulatory subunit 4, p150 DNA target region #41.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Preier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 129; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence

CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.

XX Sequence 20 BP; 9 A; 5 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3388 AAAACTGAACCTTCAGCAACT 3407

Db 1 AAAACTGAACCTTCAGCAACT 20

RESULT 57

ADH26683/C

ID ADH26683 standard; DNA; 20 BP.

XX

AC ADH26683;

XX

DT 11-MAR-2004 (first entry)

XX

DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #8.

XX

KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

KW neurodegenerative disorder; metabolic disorders; inflammation;

KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;

KW antiinflammatory.

XX

OS Homo sapiens.

XX

PN US2003225013-A1.

XX

PD 04-DEC-2003.

XX

PF 31-MAY-2002; 2002US-00160786.

XX

PR 31-MAY-2002; 2002US-00160786.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Freier SM, Dobie KW;

XX

WPI; 2004-051923/05.

XX

PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

PS Example 15; SEQ ID NO 18; 62pp; English.

XX

CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 8 A; 3 C; 2 G; 7 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 GATATTCATGACTTTGAATA 650

Db 20 GATATTCATGACTTTGAATA 1

RESULT 58

ADH26704/C

ID ADH26704 standard; DNA; 20 BP.

XX

AC ADH26704;

XX

DT 11-MAR-2004 (first entry)

XX

DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #29.

XX

KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

KW neurodegenerative disorder; metabolic disorders; inflammation;

KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;

KW antiinflammatory.

XX

OS Homo sapiens.

XX

PN US2003225013-A1.

XX

PD 04-DEC-2003.

XX

PF 31-MAY-2002; 2002US-00160786.

XX

PR 31-MAY-2002; 2002US-00160786.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Freier SM, Dobie KW;

XX

WPI; 2004-051923/05.

XX

PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

PS Example 15; SEQ ID NO 39; 62pp; English.

XX

CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1630 CACAATCTCTGTGGACATGA 1649

Db	20 CACATCTCTGTGGACATCA 1	
RESULT 59		
ADH26743/c		
ID	ADH26743 standard; DNA; 20 BP.	
XX		
AC	ADH26743;	
XX		
DT	11-MAR-2004 (first entry)	
XX		
DE	Human P13K regulatory subunit 4, p150 DNA antisense oligonucleotide #69.	
XX		
KW	Human: phosphoinositide-3-kinase regulatory subunit 4; p150; P13K;	
KW	P13 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;	
KW	2'-O-methoxyethyl sugar moiety; 5-methylcytosine;	
KW	hyperproliferative disorder; cancer; Chediak-Higashi syndrome;	
KW	neurodegenerative disorder; metabolic disorders; inflammation;	
KW	cytostatic; immunomodulator; neurodegenerative; antimicrobial;	
KW	antiinflammatory.	
XX		
OS	Homo sapiens.	
XX		
XX	US2003225013-A1.	
XX		
PD	04-DEC-2003.	
XX		
PF	31-MAY-2002; 2002US-00160786.	
XX		
PR	31-MAY-2002; 2002US-00160786.	
XX		
PA	(ISIS-) ISIS PHARM INC.	
XX		
PI	Freier SM, Dobie KW;	
XX		
DR	WPI; 2004-051923/05.	
XX		
PT	New antisense oligonucleotides inhibiting the expression of	
PT	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for	
PT	preventing or treating diseases associated with the subunit, e.g.	
PT	hyperproliferative disorders.	
XX		
PS	Example 15; SEQ ID NO 78; 62pp; English.	
XX		
CC	The invention relates to a compound targeted to a nucleic acid molecule	
CC	encoding human phosphoinositide-3-kinase (P13K) regulatory subunit 4,	
CC	p150. The compound is an antisense oligonucleotide that specifically	
CC	hybridises with a nucleic acid molecule encoding P13K regulatory subunit	
CC	4, p150 and inhibits expression of the polypeptide. The antisense	
CC	oligonucleotide comprises at least one modified internucleoside linkage	
CC	i.e. a phosphorothioate linkage, at least one modified sugar moiety,	
CC	preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified	
CC	nucleobase comprising a 5-methylcytosine. The antisense compounds are	
CC	useful for modulating the expression of P13K regulatory subunit 4, p150	
CC	and for preventing or treating hyperproliferative disorders (i.e.	
CC	cancer), Chediak-Higashi syndrome, neurodegenerative disorders and	
CC	metabolic disorders. These may also be used in research and diagnostics	
CC	and in preventing or delaying infection or inflammation. This sequence	
CC	represents an antisense oligonucleotide of the invention.	
XX		
SQ	Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 U; 0 Other;	
		0.4%; Score 20; DB 1; Length 20;
Query Match		
Best Local Similarity	100.0%;	Pred. No. 1.4e+02;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	4292 TCCATGGTATCTACTGTAGT 4311	
Db	20 TCCATGGTATCTACTGTAGT 1	

DT 11-MAR-2004 (first entry)
 DE Human PI3K regulatory subunit 4, p150 DNA target region #7.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 95; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX
 SQ Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 703 CGAGAGGCGCTGCTGTGT 722
 Db 1 CGAGAGGCGCTGCTGTGT 20
 RESULT 62
 ADH26780
 ID ADH26780 standard; DNA; 20 BP.
 XX
 AC ADH26780;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA target region #27.
 XX

KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 115; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2391 TGGCTGGCAAGCTCTCTCAA 2410
 Db 1 TGGCTGGCAAGCTCTCTCAA 20
 RESULT 63
 ADH26790
 ID ADH26790 standard; DNA; 20 BP.
 XX
 AC ADH26790;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA target region #37.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW

KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 125; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2',O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents a PI3K regulatory subunit 4, p150 DNA antisense
XX oligonucleotide target region of the invention.
XX
XX Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02; 0 Gaps 0
XX Matches 20; Conservative 0; Mismatches 0; Indels 0
XX
XX QY 3057 AGTTGATCTTGTTAAACCA 3076
XX Db 1 AGTTGATCTTGTTAAACCA 20
XX
XX
XX RESULT 64
XX ADH26805
XX ID: ADH26805 standard; DNA; 20 BP.
XX AC ADH26805;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA target region #52.
XX
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX

OS	Homo sapiens.
XX	
PN	US2003225013-Al.
XX	
PD	04-DEC-2003.
XX	
PF	31-MAY-2002; 2002US-00160786.
XX	
PR	31-MAY-2002; 2002US-00160786.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Freier SM, Dobie KW;
XX	
DR	WPI; 2004-051923/05.
XX	
PT	New antisense oligonucleotides inhibiting the expression of
PT	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT	preventing or treating diseases associated with the subunit, e.g.
PT	hyperproliferative disorders.
XX	
PS	Example 15; SEQ ID NO 140; 62pp; English.
XX	
CC	The invention relates to a compound targeted to a nucleic acid molecule
CC	encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC	p150. The compound is an antisense oligonucleotide that specifically
CC	hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC	4, p150 and inhibits expression of the polypeptide. The antisense
CC	oligonucleotide comprises at least one modified internucleoside linkage
CC	i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC	preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC	nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC	useful for modulating the expression of PI3K regulatory subunit 4, p150
CC	and for preventing or treating hyperproliferative disorders (i.e.
CC	cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC	metabolic disorders. These may also be used in research and diagnostics
CC	and in preventing or delaying infection or inflammation. This sequence
CC	represents a PI3K regulatory subunit 4, p150 DNA antisense
CC	oligonucleotide target region of the invention.
XX	
XX	Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
XX	
QY	Query Match 0.4%; Score 20; DB 1; Length 20;
DB	Best Local Similarity 100.0%; Pred. NO. 1.4e+02;
DB	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps
DB	
QY	4309 AGTCCTGCAGATGGAAATCC 4328
DB	
DB	1 AGTCCTGCAGATGGAAATCC 20
DB	
RESULT 65	
ADH26682/C	
ID	ADH26682 standard; DNA; 20 BP.
XX	
AC	ADH26682;
XX	
DT	11-MAR-2004 (first entry)
XX	
DE	Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #7.
XX	
KW	Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW	PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW	2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW	hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW	neurodegenerative disorder; metabolic disorders; inflammation;
KW	cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW	antiinflammatory.
XX	
OS	Homo sapiens.
XX	
PN	US2003225013-Al.
XX	

PD 04-DEC-2003.
 XX 31-MAY-2002; 2002US-00160786.
 XX 31-MAY-2002; 2002US-00160786.
 XX (ISIS-) ISIS PHARM INC.
 XX Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 17; 62pp; English.
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 559 CTTGCCATTATGGGAATCA 578
 DB 20 CTTGCCATTATGGGAATCA 1
 RESULT 66
 ADH26707/c
 ID ADH26707 standard; DNA; 20 BP.
 AC ADH26707;
 XX 11-MAR-2004 (first entry)
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #32.
 XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS US2003225013-A1.
 XX 04-DEC-2003.
 XX 31-MAY-2002; 2002US-00160786.
 XX 31-MAY-2002; 2002US-00160786.
 XX (ISIS-) ISIS PHARM INC.
 XX Freier SM, Dobie KW;
 XX 31-MAY-2002; 2002US-00160786.

XX (ISIS-) ISIS PHARM INC.
 XX Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 42; 62pp; English.
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1978 GCCCAAGATGATGCTACTAT 1997
 DB 20 GCCCAAGATGATGCTACTAT 1
 RESULT 67
 ADH26723/c
 ID ADH26723 standard; DNA; 20 BP.
 AC ADH26723;
 XX 11-MAR-2004 (first entry)
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #48.
 XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS US2003225013-A1.
 XX 04-DEC-2003.
 XX 31-MAY-2002; 2002US-00160786.
 XX 31-MAY-2002; 2002US-00160786.
 XX (ISIS-) ISIS PHARM INC.
 XX Freier SM, Dobie KW;
 XX 31-MAY-2002; 2002US-00160786.

CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

XX
 SQ Sequence 20 BP; 9 A; 2 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3583 TCACCTTTTGCACATGTTTC 3602
 DB 20 TCACCTTTTGCACATGTTTC 1
 |||||

RESULT 70
 ADH26737/c
 ID ADH26737 standard; DNA; 20 BP.
 XX
 AC ADH26737;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #62.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

OS Homo sapiens.
 XX
 XX US2003225013-A1.
 PN
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 72; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

XX
 SQ Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3967 ACITTTAAAGCATGATTAAA 3986
 DB 20 ACITTTAAAGCATGATTAAA 1
 |||||

RESULT 71
 ADH26744/c
 ID ADH26744 standard; DNA; 20 BP.
 XX
 AC ADH26744;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #69.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

OS Homo sapiens.
 XX
 XX US2003225013-A1.
 PN
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 79; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4309 AGTCTGCAGATGGAATCC 4328
 |||||
 Db 20 AGTCTGCAGATGGAATCC 1

RESULT 72
 ADH26768
 ID ADH26768 standard; DNA; 20 BP.
 XX
 AC ADH26768;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA target region #15.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 FN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 103; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.

XX
 SQ Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1083 CACTTATCTTCCAGAGACA 1102
 |||||
 Db 1 CACTTATCTTCCAGAGACA 20

RESULT 73
 ADH26779
 ID ADH26779 standard; DNA; 20 BP.
 XX
 AC ADH26779;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA target region #26.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 FN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 114; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.

SQ Sequence 20 BP; 9 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;


```
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2131 CCAATGGAATTTATGACAC 2150
DB 1 CCAATGGAATTTATGACAC 20

RESULT 74
ADH26791
ID ADH26791 standard; DNA; 20 BP.
XX
AC ADH26791;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA target region #38.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
PS Example 15; SEQ ID NO 126; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 1 A; 6 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3250 TCTGCTGGCATTTGTGTCC 3269
```

```
DB: 1 TCTGCTGGCATTTGTGTCC 20

RESULT 75
ADH26793
ID ADH26793 standard; DNA; 20 BP.
XX
AC ADH26793;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA target region #40.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
PS Example 15; SEQ ID NO 128; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 6 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3341 GTAGTACAATCTTACCATCC 3360
DB 1 GTAGTACAATCTTACCATCC 20
```

```

RESULT 76
ADH26798
ID ADH26798 standard; DNA; 20 BP.
XX
XX
AC ADH26798;
XX
XX
11-MAR-2004 (first entry)
XX
XX
Human PI3K regulatory subunit 4, p150 DNA target region #45.
DE
XX
Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX
XX
PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
XX
XX
2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX
XX
hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX
XX
neurodegenerative disorder; metabolic disorders; inflammation;
XX
XX
cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX
XX
antiinflammatory.
XX
OS Homo sapiens.
XX
XX
US2003225013-A1.
XX
XX
04-DEC-2003.
XX
XX
31-MAY-2002; 2002US-00160786.
XX
XX
31-MAY-2002; 2002US-00160786.
XX
XX
(ISIS-) ISIS PHARM INC.
XX
XX
Freier SM, Dobie KW;
XX
XX
WPI; 2004-051923/05.
XX
XX
New antisense oligonucleotides inhibiting the expression of
XX
XX
phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX
XX
preventing or treating diseases associated with the subunit, e.g.
XX
XX
hyperproliferative disorders.
XX
XX
Example 15; SEQ ID NO 133; 62pp; English.
XX
XX
The invention relates to a compound targeted to a nucleic acid molecule
XX
XX
encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX
XX
p150. The compound is an antisense oligonucleotide that specifically
XX
XX
hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX
XX
4, p150 and inhibits expression of the polypeptide. The antisense
XX
XX
oligonucleotide comprises at least one modified internucleoside linkage
XX
XX
i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX
XX
preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX
XX
nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX
XX
useful for modulating the expression of PI3K regulatory subunit 4, p150
XX
XX
and for preventing or treating hyperproliferative disorders (i.e.
XX
XX
cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX
XX
metabolic disorders. These may also be used in research and diagnostics
XX
XX
and in preventing or delaying infection or inflammation. This sequence
XX
XX
represents a PI3K regulatory subunit 4, p150 DNA antisense
XX
XX
oligonucleotide target region of the invention.
XX
XX
Sequence 20 BP; 6 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3555 GAATCGAATTAGTCTCTG 3574
|||||
Db 1 GAATCGAATTAGTCTCTG 20

RESULT 77
ADH26742/c
ID ADH26742 standard; DNA; 20 BP.
XX
XX

```

```

AC ADH26742;
XX
XX
11-MAR-2004 (first entry)
XX
XX
Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #67.
DE
XX
Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX
XX
PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX
XX
2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX
XX
hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX
XX
neurodegenerative disorder; metabolic disorders; inflammation;
XX
XX
cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX
XX
antiinflammatory.
XX
XX
Homo sapiens.
XX
XX
US2003225013-A1.
XX
XX
04-DEC-2003.
XX
XX
31-MAY-2002; 2002US-00160786.
XX
XX
31-MAY-2002; 2002US-00160786.
XX
XX
(ISIS-) ISIS PHARM INC.
XX
XX
Freier SM, Dobie KW;
XX
XX
WPI; 2004-051923/05.
XX
XX
New antisense oligonucleotides inhibiting the expression of
XX
XX
phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX
XX
preventing or treating diseases associated with the subunit, e.g.
XX
XX
hyperproliferative disorders.
XX
XX
Example 15; SEQ ID NO 77; 62pp; English.
XX
XX
The invention relates to a compound targeted to a nucleic acid molecule
XX
XX
encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX
XX
p150. The compound is an antisense oligonucleotide that specifically
XX
XX
hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX
XX
4, p150 and inhibits expression of the polypeptide. The antisense
XX
XX
oligonucleotide comprises at least one modified internucleoside linkage
XX
XX
i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX
XX
preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX
XX
nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX
XX
useful for modulating the expression of PI3K regulatory subunit 4, p150
XX
XX
and for preventing or treating hyperproliferative disorders (i.e.
XX
XX
cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX
XX
metabolic disorders. These may also be used in research and diagnostics
XX
XX
and in preventing or delaying infection or inflammation. This sequence
XX
XX
represents an antisense oligonucleotide of the invention.
XX
XX
Sequence 20 BP; 6 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4258 CCACCTTCTGAATTACGCC 4277
|||||
Db 20 CCACCTTCTGAATTACGCC 1

RESULT 78
ADH26761
ID ADH26761 standard; DNA; 20 BP.
XX
XX
ADH26761;
XX
XX
11-MAR-2004 (first entry)
XX
XX
Human PI3K regulatory subunit 4, p150 DNA target region #8.
DE

```

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 PN
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 96; 62pp; English.
 PS
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX
 SQ Sequence 20 BP; 8 A; 3 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 780 GGAGGAACTGAAATCAGGC 799
 DB 1 GGAGGAACTGAAATCAGGC 20
 RESULT 79
 ADH26692/c
 ID ADH26692 standard; DNA; 20 BP.
 XX
 AC ADH26692;
 XX
 XX 11-MAR-2004 (first entry)
 DT
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #17.
 DE
 XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 PN
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 27; 62pp; English.
 PS
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1032 GGTCACCACTTGAATTGGG 1051
 DB 20 GGTCACCACTTGAATTGGG 1
 RESULT 80
 ADH26703/c
 ID ADH26703 standard; DNA; 20 BP.
 XX
 AC ADH26703;
 XX
 XX 11-MAR-2004 (first entry)
 DT
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #28.
 DE
 XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

```
OS Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 38; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents an antisense oligonucleotide of the invention.
XX
XX Sequence 20 BP; 7 A; 1 C; 8 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1529 ACACCTTTCTTCAGCCCTAC 1548
XX
XX Db 20 ACACCTTTCTTCAGCCCTAC 1
XX
XX RESULT 81
XX ADH26715/c
XX ID ADH26715 standard; DNA; 20 BP.
XX
XX AC ADH26715;
XX
XX DT 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #40.
XX
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
```

```
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 50; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents an antisense oligonucleotide of the invention.
XX
XX Sequence 20 BP; 8 A; 2 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2555 TCCTGTGTCATCCCAATTTA 2574
XX
XX Db 20 TCCTGTGTCATCCCAATTTA 1
XX
XX RESULT 82
XX ADH26716/c
XX ID ADH26716 standard; DNA; 20 BP.
XX
XX AC ADH26716;
XX
XX DT 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #41.
XX
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
```

```

PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 51; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2587 GGTGCGGTGGATTATCAC 2606
DB 20 GGTGCGGTGGATTATCAC 1
|||||
RESULT 83
ADH26771
ID ADH26771 standard; DNA; 20 BP.
XX
XX ADH26771;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA target region #18.
XX
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX

XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 106; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 8 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1414 GATCACAGTATCAGAGAATT 1433
DB 1 GATCACAGTATCAGAGAATT 20
|||||
RESULT 84
ADH26795
ID ADH26795 standard; DNA; 20 BP.
XX
XX ADH26795;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA target region #42.
XX
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 106; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 8 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

hyperproliferative disorders.

Example 15; SEQ ID NO 130; 62pp; English.

The invention relates to a compound targeted to a nucleic acid molecule encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4, p150. The compound is an antisense oligonucleotide that specifically hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit 4, p150 and inhibits expression of the polypeptide. The antisense oligonucleotide comprises at least one modified internucleoside linkage, i.e. a phosphorothioate linkage, at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase comprising a 5-methylcytosine. The antisense compounds are useful for modulating the expression of PI3K regulatory subunit 4, p150 and for preventing or treating hyperproliferative disorders (i.e. cancer), Chediak-Higashi syndrome, neurodegenerative disorders and metabolic disorders. These may also be used in research and diagnostics and in preventing or delaying infection or inflammation. This sequence represents a PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide target region of the invention.

Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3431 GCAATGCTGAGAGATAGCT 3450
|||||
Db 1 GCAATGCTGAGAGATAGCT 20

RESULT 85
ADH26690/c
ID ADH26690 standard; DNA; 20 BP.
XX
AC ADH26690;
XX
XX 11-MAR-2004 (first entry)
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #15.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX Homo sapiens.
OS
XX US2003225013-A1.
PN
XX 04-DEC-2003.
PD
XX 31-MAY-2002; 2002US-00160786.
PF
XX 31-MAY-2002; 2002US-00160786.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Freier SM, Dobie KW;
PI
XX WPI; 2004-051923/05.
DR
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX Example 15; SEQ ID NO 25; 62pp; English.
XX

The invention relates to a compound targeted to a nucleic acid molecule encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4, p150. The compound is an antisense oligonucleotide that specifically hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit 4, p150 and inhibits expression of the polypeptide. The antisense oligonucleotide comprises at least one modified internucleoside linkage, i.e. a phosphorothioate linkage, at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase comprising a 5-methylcytosine. The antisense compounds are useful for modulating the expression of PI3K regulatory subunit 4, p150 and for preventing or treating hyperproliferative disorders (i.e. cancer), Chediak-Higashi syndrome, neurodegenerative disorders and metabolic disorders. These may also be used in research and diagnostics and in preventing or delaying infection or inflammation. This sequence represents an antisense oligonucleotide of the invention.

Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 982 GCACACAAATCTGGAGTTCTG 1001
|||||
Db 20 GCACACAAATCTGGAGTTCTG 1

RESULT 86
ADH26708/c
ID ADH26708 standard; DNA; 20 BP.
XX
AC ADH26708;
XX
XX 11-MAR-2004 (first entry)
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #33.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX Homo sapiens.
OS
XX US2003225013-A1.
PN
XX 04-DEC-2003.
PD
XX 31-MAY-2002; 2002US-00160786.
PF
XX 31-MAY-2002; 2002US-00160786.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Freier SM, Dobie KW;
PI
XX WPI; 2004-051923/05.
DR
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX Example 15; SEQ ID NO 43; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4, p150. The compound is an antisense oligonucleotide that specifically hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit 4, p150 and inhibits expression of the polypeptide. The antisense

CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 5 A; 3 C; 5 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2005 CTAGCCTATGCTGAACAACAT 2024
 Db 20 CTAGCCTATGCTGAACAACAT 1

RESULT 87
 ADH26710/c
 ID ADH26710 standard; DNA; 20 BP.
 XX AC
 XX ADH26710;
 XX 11-MAR-2004 (first entry)
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #35.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 XX 04-DEC-2003.
 XX 31-MAY-2002; 2002US-00160786.
 XX 31-MAY-2002; 2002US-00160786.
 XX (ISIS-) ISIS PHARM INC.
 XX Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 45; 62pp; English.

CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;
 SQ

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2080 CTTAATATGGAATAATGACCC 2099
 Db 20 CTTAATATGGAATAATGACCC 1

RESULT 88
 ADH26734/c
 ID ADH26734 standard; DNA; 20 BP.
 XX AC
 XX ADH26734;
 XX 11-MAR-2004 (first entry)
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #59.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 XX 04-DEC-2003.
 XX 31-MAY-2002; 2002US-00160786.
 XX 31-MAY-2002; 2002US-00160786.
 XX (ISIS-) ISIS PHARM INC.
 XX Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 69; 62pp; English.

CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3781 GAGGCTTCTAAGCTGCCCA 3800
DB 20 GAGGCTTCTAAGCTGCCCA 1
RESULT 89
ADH26757
ID ADH26757 standard; DNA; 20 BP.
XX
AC ADH26757;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA target region #4.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytoskeletal; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PS New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
Example 15; SEQ ID NO 92; 62pp; English.
XX
The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 486 CCTCTGAACGATTTTGACAC 505
DB 1 CCTCTGAACGATTTTGACAC 20
RESULT 90
ADH26807
ID ADH26807 standard; DNA; 20 BP.
XX
AC ADH26807;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA target region #54.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytoskeletal; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PS New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
Example 15; SEQ ID NO 142; 62pp; English.
XX
The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4424 CATCTGTGCTTACTACAGG 4443

Db 1 CATCTGTGCTCTACTACAGG 20
|||||

RESULT 91

ADH26729/c

ID ADH26729 standard; DNA; 20 BP.

XX AC

ADH26729;

XX DT

11-MAR-2004 (first entry)

XX DE

Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #54.

XX KW

Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;

XX KW

PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;

XX KW

2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

XX KW

hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

XX KW

neurodegenerative disorder; metabolic disorders; inflammation;

XX KW

cytostatic; immunomodulator; neurodegenerative; antimicrobial;

XX KW

antiinflammatory.

XX OS

Homo sapiens.

XX PN

US2003225013-A1.

XX PD

04-DEC-2003.

XX PF

31-MAY-2002; 2002US-00160786.

XX PR

31-MAY-2002; 2002US-00160786.

XX PA

(ISIS-) ISIS PHARM INC.

XX PI

Freier SM, Dobie KW;

XX DR

WPI; 2004-051923/05.

XX PT

New antisense oligonucleotides inhibiting the expression of

XX PT

phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

XX PT

preventing or treating diseases associated with the subunit, e.g.

XX PT

hyperproliferative disorders.

XX PS

Example 15; SEQ ID NO 64; 62pp; English.

XX CC

The invention relates to a compound targeted to a nucleic acid molecule

XX CC

encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,

XX CC

p150. The compound is an antisense oligonucleotide that specifically

XX CC

hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

XX CC

4, p150 and inhibits expression of the polypeptide. The antisense

XX CC

oligonucleotide comprises at least one modified internucleoside linkage

XX CC

i.e. a phosphorothioate linkage, at least one modified sugar moiety,

XX CC

preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified

XX CC

nucleobase comprising a 5-methylcytosine. The antisense compounds are

XX CC

useful for modulating the expression of PI3K regulatory subunit 4, p150

XX CC

and for preventing or treating hyperproliferative disorders (i.e.

XX CC

cancer), Chediak-Higashi syndrome, neurodegenerative disorders and

XX CC

metabolic disorders. These may also be used in research and diagnostics

XX CC

and in preventing or delaying infection or inflammation. This sequence

XX CC

represents an antisense oligonucleotide of the invention.

ADH26745/c

ID: ADH26745 standard; DNA; 20 BP.

XX AC

ADH26745;

XX DT

11-MAR-2004 (first entry)

XX DE

Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #70.

XX KW

Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;

XX KW

PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;

XX KW

2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

XX KW

hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

XX KW

neurodegenerative disorder; metabolic disorders; inflammation;

XX KW

cytostatic; immunomodulator; neurodegenerative; antimicrobial;

XX KW

antiinflammatory.

XX OS

Homo sapiens.

XX PN

US2003225013-A1.

XX PD

04-DEC-2003.

XX PF

31-MAY-2002; 2002US-00160786.

XX PR

31-MAY-2002; 2002US-00160786.

XX PA

(ISIS-) ISIS PHARM INC.

XX PI

Freier SM, Dobie KW;

XX DR

WPI; 2004-051923/05.

XX PT

New antisense oligonucleotides inhibiting the expression of

XX PT

phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

XX PT

preventing or treating diseases associated with the subunit, e.g.

XX PT

hyperproliferative disorders.

XX PS

Example 15; SEQ ID NO 80; 62pp; English.

XX CC

The invention relates to a compound targeted to a nucleic acid molecule

XX CC

encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,

XX CC

p150. The compound is an antisense oligonucleotide that specifically

XX CC

hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

XX CC

4, p150 and inhibits expression of the polypeptide. The antisense

XX CC

oligonucleotide comprises at least one modified internucleoside linkage

XX CC

i.e. a phosphorothioate linkage, at least one modified sugar moiety,

XX CC

preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified

XX CC

nucleobase comprising a 5-methylcytosine. The antisense compounds are

XX CC

useful for modulating the expression of PI3K regulatory subunit 4, p150

XX CC

and for preventing or treating hyperproliferative disorders (i.e.

XX CC

cancer), Chediak-Higashi syndrome, neurodegenerative disorders and

XX CC

metabolic disorders. These may also be used in research and diagnostics

XX CC

and in preventing or delaying infection or inflammation. This sequence

XX CC

represents an antisense oligonucleotide of the invention.

XX SQ

Sequence 20 BP; 6 A; 6 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4355 TGAATAAAGGTTTGGGAC 4374

DB 20 TGAATAAAGGTTTGGGAC 1

RESULT 92

ADH26759

ID ADH26759 standard; DNA; 20 BP.

XX AC

ADH26759;

XX XX

DT 11-MAR-2004 (first entry)
XX Human PI3K regulatory subunit 4, p150 DNA target region #6.
DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX Homo sapiens.
OS US2003225013-A1.
XX 04-DEC-2003.
XX 31-MAY-2002; 2002US-00160786.
XX 31-MAY-2002; 2002US-00160786.
XX (ISIS-) ISIS PHARM INC.
PA Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX Example 15; SEQ ID NO 94; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 559 CTTGCCATTATGGGAATCA 578
DB 1 CTTGCCATTATGGGAATCA 20
RESULT 94
ADH26769
ID ADH26769 standard; DNA; 20 BP.
XX AC ADH26769;
XX 11-MAR-2004 (first entry)
DT Human PI3K regulatory subunit 4, p150 DNA target region #16.
DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX Homo sapiens.
OS US2003225013-A1.
XX 04-DEC-2003.
XX 31-MAY-2002; 2002US-00160786.
XX 31-MAY-2002; 2002US-00160786.
XX (ISIS-) ISIS PHARM INC.
PA Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX Example 15; SEQ ID NO 94; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX Homo sapiens.
OS US2003225013-A1.
XX 04-DEC-2003.
XX 31-MAY-2002; 2002US-00160786.
XX 31-MAY-2002; 2002US-00160786.
XX (ISIS-) ISIS PHARM INC.
PA Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX Example 15; SEQ ID NO 104; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1268 AGTTGAAGAGAGCAATGGAC 1287
DB 1 AGTTGAAGAGAGCAATGGAC 20
RESULT 95
ADH26784
ID ADH26784 standard; DNA; 20 BP.
XX AC ADH26784;
XX 11-MAR-2004 (first entry)
DT Human PI3K regulatory subunit 4, p150 DNA target region #31.
DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX Homo sapiens.
OS US2003225013-A1.
XX 04-DEC-2003.
XX 31-MAY-2002; 2002US-00160786.
XX 31-MAY-2002; 2002US-00160786.
XX (ISIS-) ISIS PHARM INC.
PA Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX Example 15; SEQ ID NO 104; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

OS Homo sapiens.

PN US2003225013-A1.

XX 04-DEC-2003..

XX 31-MAY-2002; 2002US-00160786.

XX 31-MAY-2002; 2002US-00160786.

XX (ISIS-) ISIS PHARM INC.

XX Freier SM, Dobie KW;

XX WPI; 2004-051923/05.

XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 119; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.

XX Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2587 GGTGGCGTGGGATTATATCAC 2606

DB 1 GGTGGCGTGGGATTATATCAC 20

RESULT 96

ADH26804

ID ADH26804 standard; DNA; 20 BP.

XX ADH26804;

XX 11-MAR-2004 (first entry)

XX Human PI3K regulatory subunit 4, p150 DNA target region #51.

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

OS Homo sapiens.

PN US2003225013-A1.

XX 04-DEC-2003.

XX 31-MAY-2002; 2002US-00160786.

XX 31-MAY-2002; 2002US-00160786.

XX (ISIS-) ISIS PHARM INC.

XX Freier SM, Dobie KW;

XX WPI; 2004-051923/05.

XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 139; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.

XX Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4166 TGATTCAGCTGTTTCAGGC 4185

DB 1 TGATTCAGCTGTTTCAGGC 20

RESULT 97

ADH26806

ID ADH26806 standard; DNA; 20 BP.

XX ADH26806;

XX 11-MAR-2004 (first entry)

XX Human PI3K regulatory subunit 4, p150 DNA target region #53.

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

OS Homo sapiens.

PN US2003225013-A1.

XX

```

PD 04-DEC-2003.
XX 31-MAY-2002; 2002US-00160786.
XX (ISIS-) ISIS PHARM INC.
XX Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX Example 15; SEQ ID NO 141; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents a PI3K regulatory subunit 4, p150 DNA antisense
XX oligonucleotide target region of the invention.
XX Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 4397 ATGTTGTTGCAGGAGTACT 4416
XX Db | | | | | | | | | | | | | | | | | |
XX RESULT 98
XX ADH26808
XX ID ADH26808 standard; DNA; 20 BP.
XX AC ADH26808;
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA target region #55.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
XX KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX KW neurodegenerative disorder; metabolic disorders; inflammation;
XX KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.
XX PR (ISIS-) ISIS PHARM INC.
XX PA 31-MAY-2002; 2002US-00160786.

```

```

PR 31-MAY-2002; 2002US-00160786.
XX (ISIS-) ISIS PHARM INC.
XX Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX Example 15; SEQ ID NO 143; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents a PI3K regulatory subunit 4, p150 DNA antisense
XX oligonucleotide target region of the invention.
XX Sequence 20 BP; 8 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 4633 GTGTGGAAATAAACCTACT 4652
XX Db | | | | | | | | | | | | | | | | | |
XX RESULT 99
XX ADH26684/c
XX ID ADH26684 standard; DNA; 20 BP.
XX AC ADH26684;
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #9.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX KW neurodegenerative disorder; metabolic disorders; inflammation;
XX KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.

```

PI Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 19; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 XX Sequence 20 BP; 5 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 703 CGAGAGCGCTGTCGTTGT 722
 Db 20 CGAGAGCGCTGTCGTTGT 1
 RESULT 100
 ADH26688/c
 ID ADH26688 standard; DNA; 20 BP.
 AC ADH26688;
 XX
 XX 11-MAR-2004 (first entry)
 DT Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #13.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 PN
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 XX
 XX New antisense oligonucleotides inhibiting the expression of

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 XX hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 23; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 XX Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 875 GGCAGTATGTGCGAGACAAAT 894
 Db 20 GGCAGTATGTGCGAGACAAAT 1
 RESULT 101
 ADH26691/c
 ID ADH26691 standard; DNA; 20 BP.
 XX
 XX ADH26691;
 AC
 XX 11-MAR-2004 (first entry)
 DT Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #16.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 PN
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 XX hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 26; 62pp; English.

CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer). Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.

XX SQ Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 CACTTATCTTCCAGAGACA 1102
DB 20 CACTTATCTTCCAGAGACA 1
|||||

RESULT 103
ADH26713/C
ID ADH26713 standard; DNA; 20 BP.
XX AC ADH26713;
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #38.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX KW neurodegenerative disorder; metabolic disorders; inflammation;
XX KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
XX KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-051923/05.
XX PT New antisense oligonucleotides inhibiting the expression of
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT preventing or treating diseases associated with the subunit, e.g.
XX PT hyperproliferative disorders.
XX PS Example 15; SEQ ID NO 48; 62pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX CC p150. The compound is an antisense oligonucleotide that specifically
XX CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX CC 4, p150 and inhibits expression of the polypeptide. The antisense
XX CC oligonucleotide comprises at least one modified internucleoside linkage
XX CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX CC useful for modulating the expression of PI3K regulatory subunit 4, p150
XX CC and for preventing or treating hyperproliferative disorders (i.e.
XX CC cancer). Chediak-Higashi syndrome, neurodegenerative disorders and
XX CC metabolic disorders. These may also be used in research and diagnostics
XX CC and in preventing or delaying infection or inflammation. This sequence
XX CC represents an antisense oligonucleotide of the invention.

XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer). Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents an antisense oligonucleotide of the invention.

XX SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 998 TTCGTCATGGGACATCAAG 1017
DB 20 TTCGTCATGGGACATCAAG 1
|||||

RESULT 102
ADH26693/C
ID ADH26693 standard; DNA; 20 BP.
XX AC ADH26693;
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #18.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX KW neurodegenerative disorder; metabolic disorders; inflammation;
XX KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
XX KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-051923/05.
XX PT New antisense oligonucleotides inhibiting the expression of
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT preventing or treating diseases associated with the subunit, e.g.
XX PT hyperproliferative disorders.
XX PS Example 15; SEQ ID NO 28; 62pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX CC p150. The compound is an antisense oligonucleotide that specifically
XX CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX Sequence 20 BP; 8 A; 6 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2438 TTAGTGATGCTGAGGAATTT 2457
 ID ADH26724/c
 XX 20 TTAGTGATGCTGAGGAATTT 1

RESULT 104
 ADH26724/c
 ID ADH26724 standard; DNA; 20 BP.

XX AC ADH26724;
 XX DT 11-MAR-2004 (first entry)
 XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #49.
 XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

XX OS Homo sapiens.

XX US2003225013-A1.

XX PD 04-DEC-2003.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-051923/05.

XX PS New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 59; 62pp; English.

XX CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence

CC represents an antisense oligonucleotide of the invention.
 XX Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3318 AAAACACAGTAATACCGGTTT 3337
 ID ADH26730/c
 XX 20 AAAACACAGTAATACCGGTTT 1

RESULT 105
 ADH26730/c
 ID ADH26730 standard; DNA; 20 BP.

XX AC ADH26730;
 XX DT 11-MAR-2004 (first entry)
 XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #55.
 XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

XX OS Homo sapiens.

XX US2003225013-A1.

XX PD 04-DEC-2003.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-051923/05.

XX PS New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 65; 62pp; English.

XX CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

XX SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

Best Local Similarity 100.0%; Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3523 GTTCCCATCTTCATGAGCA 3542
|||||
Db 20 GTTCCCATCTTCATGAGCA 1
|||||

RESULT 106
ADH26751/c
ID ADH26751 standard; DNA; 20 BP.
XX
AC ADH26751;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #76.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PS New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 86; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 3 A; 2 C; 6 G; 9 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4776 CTGACTAAATGACACCCAAA 4795
|||||

Db 20 CTGACTAAATGACACCCAAA 1
|||||

RESULT 107
ADH26758
ID ADH26758 standard; DNA; 20 BP.
XX
AC ADH26758;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA target region #5.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PS New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 93; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 9 A; 6 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 534 AACCTTACTTAAGACCACAG 553
|||||

Db 1 AACCTTACTTAAGACCACAG 20
|||||

RESULT 108


```

ADH26762
XX ID ADH26762 standard; DNA; 20 BP.
XX AC
XX DT
XX DE
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA target region #9.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
XX KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX KW neurodegenerative disorder; metabolic disorders; inflammation;
XX KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX WP1; 2004-051923/05.
XX PT New antisense oligonucleotides inhibiting the expression of
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT preventing or treating diseases associated with the subunit, e.g.
XX PT hyperproliferative disorders.
XX PS Example 15; SEQ ID NO 97; 62pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX CC p150. The compound is an antisense oligonucleotide that specifically
XX CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX CC 4, p150 and inhibits expression of the polypeptide. The antisense
XX CC oligonucleotide comprises at least one modified internucleoside linkage
XX CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX CC useful for modulating the expression of PI3K regulatory subunit 4, p150
XX CC and for preventing or treating hyperproliferative disorders (i.e.
XX CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX CC metabolic disorders. These may also be used in research and diagnostics
XX CC and in preventing or delaying infection or inflammation. This sequence
XX CC represents a PI3K regulatory subunit 4, p150 DNA antisense
XX CC oligonucleotide target region of the invention.
XX SQ Sequence 20 BP; 8 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 824 CTTTCCAGAAAGCATCAGAA 843
DB 1 CTTTCCAGAAAGCATCAGAA 20

RESULT 109
ADH26766
XX ID ADH26766 standard; DNA; 20 BP.
XX AC ADH26766;
XX DT
XX DE
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA target region #13.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
XX KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX KW neurodegenerative disorder; metabolic disorders; inflammation;
XX KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX WP1; 2004-051923/05.
XX PT New antisense oligonucleotides inhibiting the expression of
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT preventing or treating diseases associated with the subunit, e.g.
XX PT hyperproliferative disorders.
XX PS Example 15; SEQ ID NO 97; 62pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX CC p150. The compound is an antisense oligonucleotide that specifically
XX CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX CC 4, p150 and inhibits expression of the polypeptide. The antisense
XX CC oligonucleotide comprises at least one modified internucleoside linkage
XX CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX CC useful for modulating the expression of PI3K regulatory subunit 4, p150
XX CC and for preventing or treating hyperproliferative disorders (i.e.
XX CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX CC metabolic disorders. These may also be used in research and diagnostics
XX CC and in preventing or delaying infection or inflammation. This sequence
XX CC represents a PI3K regulatory subunit 4, p150 DNA antisense
XX CC oligonucleotide target region of the invention.
XX SQ Sequence 20 BP; 8 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 998 TTCGTCATGGGACATCAAG 1017
DB 1 TTCGTCATGGGACATCAAG 20

RESULT 110
ADH26773
XX ID ADH26773 standard; DNA; 20 BP.
XX AC ADH26773;
XX DT
XX DE
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA target region #20.

```

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 FN
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 108; 62pp; English.
 PS
 XX The invention relates to a compound targeted to a nucleic acid molecule
 XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1630 CACAATCTCTGTGGACATGA 1649
 DB 1 CACAATCTCTGTGGACATGA 20
 RESULT 111
 ADH26781
 ID ADH26781 standard; DNA; 20 BP.
 XX
 AC ADH26781;
 XX
 XX 11-MAR-2004 (first entry)
 DT
 DE Human PI3K regulatory subunit 4, p150 DNA target region #29.
 XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 FN
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM, Dobie KW;
 PI
 XX WPI; 2004-051923/05.
 DR
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 116; 62pp; English.
 PS
 XX The invention relates to a compound targeted to a nucleic acid molecule
 XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX Sequence 20 BP; 5 A; 1 C; 6 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2438 TTAGTGATGCTGAGGAATTT 2457
 DB 1 TTAGTGATGCTGAGGAATTT 20
 RESULT 112
 ADH26796
 ID ADH26796 standard; DNA; 20 BP.
 XX
 AC ADH26796;
 XX
 XX 11-MAR-2004 (first entry)
 DT
 DE Human PI3K regulatory subunit 4, p150 DNA target region #43.
 XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

```

XX OS Homo sapiens.
XX PN US2003225013-A1.
XX XX
XX PD 04-DEC-2003.
XX PF
XX PR
XX PA 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-051923/05.
XX PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX PS Example 15; SEQ ID NO 131; 62pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX SQ Sequence 20 BP; 9 A; 1 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3455 AGATGATGGAATGCTGAA 3474
DB 1 AGATGATGGAATGCTGAA 20

RESULT 113
ADH26800
ID ADH26800 standard; DNA; 20 BP.
XX AC ADH26800;
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA target region #47.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.

```

```

XX PD 04-DEC-2003..
XX PF
XX PR 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-051923/05.
XX PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX PS Example 15; SEQ ID NO 135; 62pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX SQ Sequence 20 BP; 3 A; 4 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3762 TGTCAGCTCTTGGAAATTG 3781
DB 1 TGTCAGCTCTTGGAAATTG 20

RESULT 114
ADH26679/c
ID ADH26679 standard; DNA; 20 BP.
XX AC ADH26679;
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #4.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.

```

XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-051923/05.
XX PS Example 15; SEQ ID NO 14; 62pp; English.
XX PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
XX PT hyperproliferative disorders.
XX PS Example 15; SEQ ID NO 14; 62pp; English.
XX PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
XX PT hyperproliferative disorders.
XX PS Example 15; SEQ ID NO 14; 62pp; English.
XX PT The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX SQ Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 391 CTATGAAGAGACCCCTTCG 410
DB 20 CTATGAAGAGACCCCTTCG 1
RESULT 115
ADH26696/C
ID ADH26696 standard; DNA; 20 BP.
XX AC ADH26696;
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #21.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-051923/05.
XX PT New antisense oligonucleotides inhibiting the expression of

PI Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
XX PT hyperproliferative disorders.
XX PS Example 15; SEQ ID NO 31; 62pp; English.
XX PT The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX SQ Sequence 20 BP; 3 A; 7 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1268 AGTTGAAGAGCAATGGAC 1287
DB 20 AGTTGAAGAGCAATGGAC 1
RESULT 116
ADH26697/C
ID ADH26697 standard; DNA; 20 BP.
XX AC ADH26697;
XX DT 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #22.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-051923/05.
XX PT New antisense oligonucleotides inhibiting the expression of

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
PS Example 15; SEQ ID NO 32; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 6 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1299 AGGTTGTGTGATGCTGAGC 1318
DB 20 AGGTTGTGTGATGCTGAGC 1
RESULT 117
ADH26706/C
ID ADH26706 standard; DNA; 20 BP.
XX AC ADH26706;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #31.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
PS Example 15; SEQ ID NO 41; 62pp; English.

XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 7 A; 2 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1706 CTGTTATACATCTGCCTA 1725
DB 20 CTGTTATACATCTGCCTA 1
RESULT 118
ADH26720/C
ID ADH26720 standard; DNA; 20 BP.
XX AC ADH26720;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #45.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
PS Example 15; SEQ ID NO 55; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 7 A; 2 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1706 CTGTTATACATCTGCCTA 1725
DB 20 CTGTTATACATCTGCCTA 1

CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4761 CTGTTTCATGACTGACTGAC 4780
 DB 20 CTGTTTCATGACTGACTGAC 1
 RESULT 120
 ADH26753/C
 ID ADH26753 standard; DNA; 20 BP.
 XX
 AC ADH26753;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #78.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 FN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 88; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2913 AGAGGAAGACAACTTCTGG 2932
 DB 20 AGAGGAAGACAACTTCTGG 1
 RESULT 119
 ADH26750/C
 ID ADH26750 standard; DNA; 20 BP.
 XX
 AC ADH26750;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #75.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 FN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-051923/05.
 XX
 PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 PS Example 15; SEQ ID NO 85; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are

CC represents an antisense oligonucleotide of the invention.
XX Sequence 20 BP; 8 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
SQ

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4823 CTTATGCATCTCTTGGCAAG 4842
Db 20 CTTATGCATCTCTTGGCAAG 1

RESULT 121
ADH26788
ID ADH26788 standard; DNA; 20 BP.

XX
AC ADH26788;

XX DT 11-MAR-2004 (first entry)

DE Human PI3K regulatory subunit 4, p150 DNA target region #35.

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.

XX OS Homo sapiens.

XX PN US2003225013-A1.

XX PD 04-DEC-2003.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Freier SM, Dobie KW;

XX WPI; 2004-051923/05.

XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 123; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.

XX Sequence 20 BP; 8 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2913 AGAGGAAGACAAACTTCTGG 2932
Db 1 AGAGGAAGACAAACTTCTGG 20

RESULT 122
ADH26789
ID ADH26789 standard; DNA; 20 BP.

XX
AC ADH26789;

XX DT 11-MAR-2004 (first entry)

DE Human PI3K regulatory subunit 4, p150 DNA target region #36.

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.

XX OS Homo sapiens.

XX PN US2003225013-A1.

XX PD 04-DEC-2003.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Freier SM, Dobie KW;

XX WPI; 2004-051923/05.

XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 124; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.

XX Sequence 20 BP; 7 A; 2 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3009 TCAGAAAGGTGTAATGACT 3028
Dd |||||
1 TCAGAAAGGTGTAATGACT 20

RESULT 123

ADH26802
ID ADH26802 standard; DNA; 20 BP.

XX AC ADH26802;

XX DT 11-MAR-2004 (first entry)

XX Human PI3K regulatory subunit 4, p150 DNA target region #49.

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.

XX OS Homo sapiens.

XX PN US2003225013-A1.

XX PD 04-DEC-2003.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-051923/05.

XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 137; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.

XX Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3991 GGCCTCATCACTTCCTTGC 4010
Dd |||||
1 GGCCTCATCACTTCCTTGC 20

RESULT 124

ADH26689/c
ID ADH26689 standard; DNA; 20 BP.

XX AC ADH26689;

XX DT 11-MAR-2004 (first entry)

XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #14.

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.

XX OS Homo sapiens.

XX PN US2003225013-A1.

XX PD 04-DEC-2003.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-051923/05.

XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 24; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 6 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 914 CCGGCCATTCCTGATATAC 933
Dd |||||
20 CCGGCCATTCCTGATATAC 1

RESULT 125

ADH26721/c
ID ADH26721 standard; DNA; 20 BP.

XX

neurodegenerative disorder; metabolic disorders; inflammation; cytostatic; immunomodulator; neurodegenerative; antimicrobial; antiinflammatory.

Homo sapiens.

US2003225013-A1.

04-DEC-2003.

31-MAY-2002; 2002US-00160786.

31-MAY-2002; 2002US-00160786.

(ISIS-) ISIS PHARM INC.

Freier SM, Dobie KW;

WPI; 2004-051923/05.

New antisense oligonucleotides inhibiting the expression of phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for preventing or treating diseases associated with the subunit, e.g. hyperproliferative disorders.

Example 15; SEQ ID NO 105; 62pp; English.

The invention relates to a compound targeted to a nucleic acid molecule encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4, p150. The compound is an antisense oligonucleotide that specifically hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit 4, p150 and inhibits expression of the polypeptide. The antisense oligonucleotide comprises at least one modified internucleoside linkage, i.e. a phosphorothioate linkage, at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase comprising a 5-methylcytosine. The antisense compounds are useful for modulating the expression of PI3K regulatory disorders (i.e. cancer), Chediak-Higashi syndrome, neurodegenerative disorders and for preventing or treating hyperproliferative disorders (i.e. and in preventing or delaying infection or inflammation. This sequence represents a PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide target region of the invention.

Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1299 AGGTTGTGTGATGCTGAGC 1318
|||||
Db 1 AGGTTGTGTGATGCTGAGC 20
|||||

RESULT 129
ADH26774
ID ADH26774 standard; DNA; 20 BP.
XX
AC ADH26774;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA target region #21.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
OS Homo sapiens.
XX
PN US2003225013-A1.

neurodegenerative disorder; metabolic disorders; inflammation; cytostatic; immunomodulator; neurodegenerative; antimicrobial; antiinflammatory.

Homo sapiens.

US2003225013-A1.

04-DEC-2003.

31-MAY-2002; 2002US-00160786.

31-MAY-2002; 2002US-00160786.

(ISIS-) ISIS PHARM INC.

Freier SM, Dobie KW;

WPI; 2004-051923/05.

New antisense oligonucleotides inhibiting the expression of phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for preventing or treating diseases associated with the subunit, e.g. hyperproliferative disorders.

Example 15; SEQ ID NO 100; 62pp; English.

The invention relates to a compound targeted to a nucleic acid molecule encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4, p150. The compound is an antisense oligonucleotide that specifically hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit 4, p150 and inhibits expression of the polypeptide. The antisense oligonucleotide comprises at least one modified internucleoside linkage, i.e. a phosphorothioate linkage, at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase comprising a 5-methylcytosine. The antisense compounds are useful for modulating the expression of PI3K regulatory disorders (i.e. cancer), Chediak-Higashi syndrome, neurodegenerative disorders and for preventing or treating hyperproliferative disorders (i.e. and in preventing or delaying infection or inflammation. This sequence represents a PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide target region of the invention.

Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 982 GCACACAAATCTGGAGTTCTG 1001
|||||
Db 1 GCACACAAATCTGGAGTTCTG 20
|||||

RESULT 128
ADH26770
ID ADH26770 standard; DNA; 20 BP.
XX
AC ADH26770;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA target region #17.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.

PI Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 117; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage,
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
XX Sequence 20 BP; 5 A; 3 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2524 GTTACGAATTGCCAGTGA 2543
DB 1 GTTACGAATTGCCAGTGA 20
RESULT 132
ADH26785
ID ADH26785 standard; DNA; 20 BP.
XX
XX ADH26785;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX Human PI3K regulatory subunit 4, p150 DNA target region #32.
DE
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
XX Homo sapiens.
OS
XX US2003225013-A1.
PN
XX 04-DEC-2003.
PD
XX 31-MAY-2002; 2002US-00160786.
PF
XX 31-MAY-2002; 2002US-00160786.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Freier SM, Dobie KW;
PI
XX WPI; 2004-051923/05.
DR
XX

PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 120; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage,
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
XX Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2731 GAACCACTAAGTCGTTCTAT 2750
DB 1 GAACCACTAAGTCGTTCTAT 20
RESULT 133
ADH26799
ID ADH26799 standard; DNA; 20 BP.
XX
XX ADH26799;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX Human PI3K regulatory subunit 4, p150 DNA target region #46.
DE
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
XX Homo sapiens.
OS
XX US2003225013-A1.
PN
XX 04-DEC-2003.
PD
XX 31-MAY-2002; 2002US-00160786.
PF
XX 31-MAY-2002; 2002US-00160786.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Freier SM, Dobie KW;
PI
XX WPI; 2004-051923/05.
DR
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX

XX Example 15; SEQ ID NO 134; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,

CC p150. The compound is an antisense oligonucleotide that specifically

CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

CC 4, p150 and inhibits expression of the polypeptide. The antisense

CC oligonucleotide comprises at least one modified internucleoside linkage

CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,

CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified

CC nucleobase comprising a 5-methylcytosine. The antisense compounds are

CC useful for modulating the expression of PI3K regulatory subunit 4, p150

CC and for preventing or treating hyperproliferative disorders (i.e.

CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and

CC metabolic disorders. These may also be used in research and diagnostics

CC and in preventing or delaying infection or inflammation. This sequence

CC represents a PI3K regulatory subunit 4, p150 DNA antisense

CC oligonucleotide target region of the invention.

XX

SQ Sequence 20 BP; 4 A; 5 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3583 TCACCTTTTGCACATGTC 3602

Db 1 TCACCTTTTGCACATGTC 20

RESULT 134

ADH26801

ID ADH26801 standard; DNA; 20 BP.

XX

AC ADH26801;

XX

DT 11-MAR-2004 (first entry)

XX

DE Human PI3K regulatory subunit 4, p150 DNA target region #48.

XX

KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;

KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;

KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

KW neurodegenerative disorder; metabolic disorders; inflammation;

KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;

KW antiinflammatory.

XX

OS Homo sapiens.

XX

PN US2003225013-A1.

XX

PD 04-DEC-2003.

XX

PF 31-MAY-2002; 2002US-00160786.

XX

PR 31-MAY-2002; 2002US-00160786.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Freier SM, Dobie KW;

XX

DR WPI; 2004-051923/05.

XX

PT New antisense oligonucleotides inhibiting the expression of

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

PT preventing or treating diseases associated with the subunit, e.g.

PT hyperproliferative disorders.

XX

PS Example 15; SEQ ID NO 136; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,

CC p150. The compound is an antisense oligonucleotide that specifically

CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

CC 4, p150 and inhibits expression of the polypeptide. The antisense

CC oligonucleotide comprises at least one modified internucleoside linkage

CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,

CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified

CC nucleobase comprising a 5-methylcytosine. The antisense compounds are

CC useful for modulating the expression of PI3K regulatory subunit 4, p150

CC and for preventing or treating hyperproliferative disorders (i.e.

CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and

CC metabolic disorders. These may also be used in research and diagnostics

CC and in preventing or delaying infection or inflammation. This sequence

CC represents a PI3K regulatory subunit 4, p150 DNA antisense

CC oligonucleotide target region of the invention.

XX

SQ Sequence 20 BP; 2 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3899 TTCTTGCTATGCCTGCTG 3918

Db 1 TTCTTGCTATGCCTGCTG 20

RESULT 135

ADH26803

ID ADH26803 standard; DNA; 20 BP.

XX

AC ADH26803;

XX

DT 11-MAR-2004 (first entry)

XX

DE Human PI3K regulatory subunit 4, p150 DNA target region #50.

XX

KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;

KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;

KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;

KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;

KW neurodegenerative disorder; metabolic disorders; inflammation;

KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;

KW antiinflammatory.

XX

OS Homo sapiens.

XX

PN US2003225013-A1.

XX

PD 04-DEC-2003.

XX

PF 31-MAY-2002; 2002US-00160786.

XX

PR 31-MAY-2002; 2002US-00160786.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Freier SM, Dobie KW;

XX

DR WPI; 2004-051923/05.

XX

PT New antisense oligonucleotides inhibiting the expression of

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

PT preventing or treating diseases associated with the subunit, e.g.

PT hyperproliferative disorders.

XX

PS Example 15; SEQ ID NO 138; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,

CC p150. The compound is an antisense oligonucleotide that specifically

CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit

CC 4, p150 and inhibits expression of the polypeptide. The antisense

CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
XX
SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4050 CAGTGGTACCATGGCTTCTT 4069
Db 1 CAGTGGTACCATGGCTTCTT 20

RESULT 136
ID ADH26686 standard; DNA; 20 BP.
XX
AC ADH26686;
XX
11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #11.
XX
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 21; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence

CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
XX
SQ Sequence 20 BP; 2 A; 7 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 780 GGAGGAACCTGAAATCAGGC 799
Db 20 GGAGGAACCTGAAATCAGGC 1

RESULT 137
ID ADH26687/C
XX
XX ADH26687 standard; DNA; 20 BP.
XX
AC ADH26687;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #12.
XX
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 22; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence

CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 4 A; 3 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 824 CTTTCCAGAAAGCATCAGAA 843

DB 20 CTTTCCAGAAAGCATCAGAA 1

RESULT 138

ADH26699/c

ID ADH26699 standard; DNA; 20 BP.

XX AC ADH26699;

XX 11-MAR-2004. (first entry)

DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #24.

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

XX Homo sapiens.

XX US2003225013-A1.

XX 04-DEC-2003.

XX 31-MAY-2002; 2002US-00160786.

XX 31-MAY-2002; 2002US-00160786.

XX (ISIS-) ISIS PHARM INC.

XX Freier SM, Dobie KW;

XX WPI; 2004-051923/05.

XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 34; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1414 GATCACAGTATCAGAGAATT 1433

DB 20 GATCACAGTATCAGAGAATT 1

RESULT 139

ADH26700/c

ID ADH26700 standard; DNA; 20 BP.

XX AC ADH26700;

XX 11-MAR-2004 (first entry)

DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #25.

XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

XX Homo sapiens.

XX US2003225013-A1.

XX 04-DEC-2003.

XX 31-MAY-2002; 2002US-00160786.

XX 31-MAY-2002; 2002US-00160786.

XX (ISIS-) ISIS PHARM INC.

XX Freier SM, Dobie KW;

XX WPI; 2004-051923/05.

XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 35; 62pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified internucleoside linkage
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1441 CAGATGATTCACCGTAGCC 1460

ADH26711 standard; DNA; 20 BP.
ADH26711;
11-MAR-2004 (first entry)
Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #36.
Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
neurodegenerative disorder; metabolic disorders; inflammation;
cytostatic; immunomodulator; neurodegenerative; antimicrobial;
antiinflammatory.
Homo sapiens.
US2003225013-A1.
04-DEC-2003.
31-MAY-2002; 2002US-00160786.
31-MAY-2002; 2002US-00160786.
(ISIS-) ISIS PHARM INC.
Freier SM, Dobie KW;
WPI; 2004-051923/05.
New antisense oligonucleotides inhibiting the expression of
phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
preventing or treating diseases associated with the subunit, e.g.
hyperproliferative disorders.
Example 15; SEQ ID NO 46; 62pp; English.
The invention relates to a compound targeted to a nucleic acid molecule
encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
p150. The compound is an antisense oligonucleotide that specifically
hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
4, p150 and inhibits expression of the polypeptide. The antisense
oligonucleotide comprises at least one modified internucleoside linkage
i.e. a phosphorothioate linkage, at least one modified sugar moiety,
preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
nucleobase comprising a 5-methylcytosine. The antisense compounds are
useful for modulating the expression of PI3K regulatory subunit 4, p150
and for preventing or treating hyperproliferative disorders (i.e.
cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
metabolic disorders. These may also be used in research and diagnostics
and in preventing or delaying infection or inflammation. This sequence
represents an antisense oligonucleotide of the invention.
Sequence 20 BP; 4 A; 3 C; 4 G; 9 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2131 CCNAATGGAAATTTGACAC 2150
DB 20 CCNAATGGAAATTTGACAC 1
RESULT 142
ADH26763
ID ADH26763 standard; DNA; 20 BP.
XX
AC ADH26763;
XX
XX 11-MAR-2004 (first entry)

20 CAGATGATTACCGTGAGCC 1
RESULT 140
ADH26705/C
ID ADH26705 standard; DNA; 20 BP.
XX
AC
XX ADH26705;
XX 11-MAR-2004 (first entry)
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #30.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX Homo sapiens.
XX OS
XX US2003225013-A1.
XX 04-DEC-2003.
XX 31-MAY-2002; 2002US-00160786.
XX 31-MAY-2002; 2002US-00160786.
XX (ISIS-) ISIS PHARM INC.
XX Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX Example 15; SEQ ID NO 40; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents an antisense oligonucleotide of the invention.
XX Sequence 20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1658 AAAAAGCCGAGGAGAGCCT 1677
DB 20 AAAAAGCCGAGGAGAGCCT 1
RESULT 141
ADH26711/c

XX DE Human PI3K regulatory subunit 4, p150 DNA target region #10.
 XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX OS Homo sapiens.
 XX PN US2003225013-A1.
 XX PD 04-DEC-2003.
 XX PF 31-MAY-2002; 2002US-00160786.
 XX PR 31-MAY-2002; 2002US-00160786.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX PS Example 15; SEQ ID NO 98; 62pp; English.
 XX CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX SQ Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 875 GGCAGTATGTCGAGACAAAT 894
 DB 1 GGCAGTATGTCGAGACAAAT 20
 RESULT 143
 ADH26783
 ID ADH26783 standard; DNA; 20 BP.
 XX AC ADH26783;
 XX DT 11-MAR-2004 (first entry)
 XX DE Human PI3K regulatory subunit 4, p150 DNA target region #30.
 XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX OS Homo sapiens.
 XX PN US2003225013-A1.
 XX PD 04-DEC-2003.
 XX PF 31-MAY-2002; 2002US-00160786.
 XX PR 31-MAY-2002; 2002US-00160786.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX PS Example 15; SEQ ID NO 118; 62pp; English.
 XX CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX SQ Sequence 20 BP; 4 A; 6 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2555 TCCTGTGTCATCCCAATTTA 2574
 DB 1 TCCTGTGTCATCCCAATTTA 20
 RESULT 144
 ADH26786
 ID ADH26786 standard; DNA; 20 BP.
 XX AC ADH26786;
 XX DT 11-MAR-2004 (first entry)
 XX DE Human PI3K regulatory subunit 4, p150 DNA target region #33.
 XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.

KW	cytostatic; immunomodulator; neurodegenerative; antimicrobial; antiinflammatory.	XX	US2003225013-A1.
KW		PN	
XX		XX	04-DEC-2003.
OS	Homo sapiens.	PD	
XX		XX	31-MAY-2002; 2002US-00160786.
XX		XX	31-MAY-2002; 2002US-00160786.
XX		XX	(ISIS-) ISIS PHARM INC.
XX		XX	Freier SM, Dobie KW;
XX		XX	WPI; 2004-051923/05.
XX		XX	New antisense oligonucleotides inhibiting the expression of
XX		XX	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX		XX	preventing or treating diseases associated with the subunit, e.g.
XX		XX	hyperproliferative disorders.
XX		XX	Example 15; SEQ ID NO 121; 62pp; English.
XX		XX	The invention relates to a compound targeted to a nucleic acid molecule
XX		XX	encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX		XX	p150. The compound is an antisense oligonucleotide that specifically
XX		XX	hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX		XX	4, p150 and inhibits expression of the polypeptide. The antisense
XX		XX	oligonucleotide comprises at least one modified internucleoside linkage
XX		XX	i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX		XX	preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX		XX	nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX		XX	useful for modulating the expression of PI3K regulatory subunit 4, p150
XX		XX	and for preventing or treating hyperproliferative disorders (i.e.
XX		XX	cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX		XX	metabolic disorders. These may also be used in research and diagnostics
XX		XX	and in preventing or delaying infection or inflammation. This sequence
XX		XX	represents a PI3K regulatory subunit 4, p150 DNA antisense
XX		XX	oligonucleotide target region of the invention.
XX		XX	Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
SQ		SQ	
Query Match 0.4%; Score 20; DB 1; Length 20;			
Best Local Similarity 100.0%; Pred. No. 1.4e+02;			
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	2843 GCCCTCCGCCGAGGATCCT 2862	QY	3318 AAAACCCAGTAATACCGGTTT 3337
Db	1 GCCCTCCGCCGAGGATCCT 20	Db	1 AAAACCCAGTAATACCGGTTT 20
RESULT 145			
ADH26792		ADH26810	
ID	ADH26792 standard; DNA; 20 BP.	ID	ADH26810 standard; DNA; 20 BP.
XX		XX	
XX	ADH26792;	XX	ADH26810;
XX		XX	
XX	11-MAR-2004 (first entry)	XX	11-MAR-2004 (first entry)
XX		XX	Human PI3K regulatory subunit 4, p150 DNA target region #39.
XX		XX	Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX		XX	PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
XX		XX	2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX		XX	hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX		XX	neurodegenerative disorder; metabolic disorders; inflammation;
XX		XX	cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX		XX	antiinflammatory.
XX		XX	Homo sapiens.
XX		XX	US2003225013-A1.
XX		XX	04-DEC-2003.

```
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 145; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents a PI3K regulatory subunit 4, p150 DNA antisense
XX oligonucleotide target region of the invention.
XX
XX Sequence 20 BP; 9 A; 6 C; 2 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 4776 CTGACTAAATGACACCCAAA 4795
XX 1 CTGACTAAATGACACCCAAA 20
XX
XX RESULT 147
XX ADH26812
XX ID ADH26812 standard; DNA; 20 BP.
XX
XX AC ADH26812;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA target region #59.
XX
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX Freier SM, Dobie KW;
```

```
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX preventing or treating diseases associated with the subunit, e.g.
XX hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 147; 62pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX p150. The compound is an antisense oligonucleotide that specifically
XX hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
XX 4, p150 and inhibits expression of the polypeptide. The antisense
XX oligonucleotide comprises at least one modified internucleoside linkage
XX i.e. a phosphorothioate linkage, at least one modified sugar moiety,
XX preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
XX nucleobase comprising a 5-methylcytosine. The antisense compounds are
XX useful for modulating the expression of PI3K regulatory subunit 4, p150
XX and for preventing or treating hyperproliferative disorders (i.e.
XX cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
XX metabolic disorders. These may also be used in research and diagnostics
XX and in preventing or delaying infection or inflammation. This sequence
XX represents a PI3K regulatory subunit 4, p150 DNA antisense
XX oligonucleotide target region of the invention.
XX
XX Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 4823 CTTATGCATCTCTTTCGAAG 4842
XX 1 CTTATGCATCTCTTTCGAAG 20
XX
XX RESULT 148
XX ADH26677/C
XX ID ADH26677 standard; DNA; 20 BP.
XX
XX AC ADH26677;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #2.
XX
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
XX 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
XX hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
XX neurodegenerative disorder; metabolic disorders; inflammation;
XX cytostatic; immunomodulator; neurodegenerative; antimicrobial;
XX antiinflammatory.
XX
XX Homo sapiens.
XX
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Dobie KW;
```

XX WPI; 2004-051923/05.
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 12; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 XX Sequence 20 BP; 6 A; 4 C; 9 G; 1 T; 0 U; 0 Other;
 SQ

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 CGGTCTGCACCTCTCTCCG 111
 DB 20 CGGTCTGCACCTCTCTCCG 1

RESULT 149
 ADH26694/c
 ID ADH26694 standard; DNA; 20 BP.
 XX
 XX ADH26694;
 AC
 XX
 XX 11-MAR-2004 (first entry)
 DT
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #19.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 XX US2003225013-A1.
 PN
 XX
 PD 04-DEC-2003.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Freier SM, Dobie KW;
 PI
 XX
 XX WPI; 2004-051923/05.
 DR
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 29; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 XX Sequence 20 BP; 9 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 SQ

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 TCAATTATTTCCTTGACACA 1134
 DB 20 TCAATTATTTCCTTGACACA 1

RESULT 150
 ADH26712/c
 ID ADH26712 standard; DNA; 20 BP.
 XX
 XX ADH26712;
 AC
 XX
 XX 11-MAR-2004 (first entry)
 DT
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #37.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 XX US2003225013-A1.
 PN
 XX
 PD 04-DEC-2003.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 PF
 XX
 XX 31-MAY-2002; 2002US-00160786.
 PR
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Freier SM, Dobie KW;
 PI
 XX
 XX WPI; 2004-051923/05.
 DR
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 47; 62pp; English.
 PS
 XX

CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2391 TGGTGGCAAGCTCTCAA 2410
 DB 20 TGGTGGCAAGCTCTCAA 1

RESULT 151
 ADH26714/c
 ID ADH26714 standard; DNA; 20 BP.
 AC ADH26714;
 XX
 XX 11-MAR-2004 (first entry)
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #39.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 XX 04-DEC-2003.
 XX 31-MAY-2002; 2002US-00160786.
 XX 31-MAY-2002; 2002US-00160786.
 PR (ISIS-) ISIS PHARM INC.
 XX
 XX PA Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 49; 62bp; English.
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense

CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.

SQ Sequence 20 BP; 7 A; 5 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2524 GTTTACGAATTTGCCAGTGA 2543
 DB 20 GTTTACGAATTTGCCAGTGA 1

RESULT 152
 ADH26718/c
 ID ADH26718 standard; DNA; 20 BP.
 AC ADH26718;
 XX
 XX 11-MAR-2004 (first entry)
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #43.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS
 XX US2003225013-A1.
 XX 04-DEC-2003.
 XX 31-MAY-2002; 2002US-00160786.
 XX 31-MAY-2002; 2002US-00160786.
 PR (ISIS-) ISIS PHARM INC.
 XX
 XX PA Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 53; 62bp; English.
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150

```
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2843 GCCCTCCGCCAGAGATCCT 2862
DB 20 GCCCTCCGCCAGAGATCCT 1
RESULT 153
ADH26722/c
ID ADH26722 standard; DNA; 20 BP.
XX
AC ADH26722;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #47.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PS New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
PS Example 15; SEQ ID NO 57; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 3 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 3057 AGTTGATCTGTTAAACCA 3076
DB 20 AGTTGATCTGTTAAACCA 1
RESULT 154
ADH26767
ID ADH26767 standard; DNA; 20 BP.
XX
AC ADH26767;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA target region #14.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PS New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX
PS Example 15; SEQ ID NO 102; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
```

Best Local Similarity 100.0%; Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;

QY 1032 GGTCAACAGTTGGAAATGGG 1051
|||||
Db 1 GGTCAACAGTTGGAAATGGG 20

RESULT 155
ADH26777
ID ADH26777 standard; DNA; 20 BP.
XX
AC ADH26777;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA target region #24.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW P13 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
PS Example 15; SEQ ID NO 112; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.
SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2041 ACAGCTCTGAGATTCCTGGA 2060

Db 1 ACAGCTCTGAGATTCCTGGA 20
|||||
RESULT 156
ADH26702/C
ID ADH26702 standard; DNA; 20 BP.
XX
AC ADH26702;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #27.
XX
KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW P13 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
OS Homo sapiens.
XX
PN US2003225013-A1.
XX
PD 04-DEC-2003.
XX
PF 31-MAY-2002; 2002US-00160786.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-051923/05.
XX
PT New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
PS Example 15; SEQ ID NO 37; 62pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
SQ Sequence 20 BP; 9 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1513 TTTCCTGGAATATTTTACAC 1532
|||||
Db 20 TTTCCTGGAATATTTTACAC 1

RESULT 157

ADH26719/c
ID ADH26719 standard; DNA; 20 BP.
XX AC
XX ADH26719;
XX DT
XX 11-MAR-2004 (first entry)
XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #44.
XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.
XX OS Homo sapiens.
XX PN US2003225013-A1.
XX PD 04-DEC-2003.
XX PF 31-MAY-2002; 2002US-00160786.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX DE New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.
XX Example 15; SEQ ID NO 54; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents an antisense oligonucleotide of the invention.
XX SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2860 CCTGCCATAGCAGCACTTCT 2879
DB 20 CCTGCCATAGCAGCACTTCT 1
RESULT 158
ADH26725/c
ID ADH26725 standard; DNA; 20 BP.
XX AC
XX ADH26725;
XX XX

11-MAR-2004 (first entry)
Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #50.
Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
neurodegenerative disorder; metabolic disorders; inflammation;
cytosolic; immunomodulator; neurodegenerative; antimicrobial;
antiinflammatory.
Homo sapiens.
US2003225013-A1.
04-DEC-2003.
31-MAY-2002; 2002US-00160786.
31-MAY-2002; 2002US-00160786.
(ISIS-) ISIS PHARM INC.
Freier SM, Dobie KW;
WPI; 2004-051923/05.
New antisense oligonucleotides inhibiting the expression of
phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
preventing or treating diseases associated with the subunit, e.g.
hyperproliferative disorders.
Example 15; SEQ ID NO 60; 62pp; English.
The invention relates to a compound targeted to a nucleic acid molecule
encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
p150. The compound is an antisense oligonucleotide that specifically
hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
4, p150 and inhibits expression of the polypeptide. The antisense
oligonucleotide comprises at least one modified internucleoside linkage
i.e. a phosphorothioate linkage, at least one modified sugar moiety,
preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
nucleobase comprising a 5-methylcytosine. The antisense compounds are
useful for modulating the expression of PI3K regulatory subunit 4, p150
and for preventing or treating hyperproliferative disorders (i.e.
cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
metabolic disorders. These may also be used in research and diagnostics
and in preventing or delaying infection or inflammation. This sequence
represents an antisense oligonucleotide of the invention.
Sequence 20 BP; 6 A; 2 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3341 CTAGTACAACTCTTACCATCC 3360
DB 20 GTAGTACAACTCTTACCATCC 1
RESULT 159
ADH26731/c
ID ADH26731 standard; DNA; 20 BP.
XX AC
XX ADH26731;
XX 11-MAR-2004 (first entry)
XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #56.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
XX

KW P13 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 66; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3555 GAATCGAATTAGAGTCTCTG 3574
 DB 20 GAATCGAATTAGAGTCTCTG 1
 RESULT 160
 ADH26740/c
 ID ADH26740 standard; DNA; 20 BP.
 XX
 XX ADH26740;
 AC
 DT 11-MAR-2004 (first entry)
 XX
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #65.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;

KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 75; 62pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4166 TGATTGCAGCTGTTTCAGGGC 4185
 DB 20 TGATTGCAGCTGTTTCAGGGC 1
 RESULT 161
 ADH26746/c
 ID ADH26746 standard; DNA; 20 BP.
 XX
 XX ADH26746;
 AC
 DT 11-MAR-2004 (first entry)
 XX
 XX Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #71.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.

PR	31-MAY-2002; 2002US-00160786.
XX	(ISIS-) ISIS PHARM INC.
PA	
XX	Freier SM, Dobie KW;
PPI	WPI; 2004-051923/05.
DR	
XX	New antisense oligonucleotides inhibiting the expression of
XX	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT	preventing or treating diseases associated with the subunit, e.g.
PT	hyperproliferative disorders.
XX	
PS	Example 15; SEQ ID NO 90; 62pp; English.
XX	
CC	The invention relates to a compound targeted to a nucleic acid molecule
CC	encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC	p150. The compound is an antisense oligonucleotide that specifically
CC	hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
CC	4, p150 and inhibits expression of the polypeptide. The antisense
CC	oligonucleotide comprises at least one modified internucleoside linkage
CC	i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC	preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC	nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC	useful for modulating the expression of PI3K regulatory subunit 4, p150
CC	and for preventing or treating hyperproliferative disorders (i.e.,
CC	cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC	metabolic disorders. These may also be used in research and diagnostics
CC	and in preventing or delaying infection or inflammation. This sequence
CC	represents a PI3K regulatory subunit 4, p150 DNA antisense
CC	oligonucleotide target region of the invention.
XX	
XX	Sequence 20 BP; 1 A; 9 C; 4 G; 6 T; 0 U; 0 Other;
QQ	
	Query Match 0.4%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred.No. 1.4e+02;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	92 CGGTCTGCATTCCTCTCCCG 111
DB	1 CGGTCTGCATTCCTCTCCCG 20
RESULT 163	
ADH26772	
ID	ADH26772 standard; DNA; 20 BP.
XX	
AC	ADH26772;
XX	
DT	11-MAR-2004 (first entry)
XX	
DE	Human PI3K regulatory subunit 4, p150 DNA target region #19.
XX	
KW	Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW	PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW	2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW	hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW	neurodegenerative disorder; metabolic disorders; inflammation;
KW	cystostatic; immunomodulator; neurodegenerative; antimicrobial;
KW	antiinflammatory.
OS	Homo sapiens.
XX	
PN	US2003225013-A1.
XX	
PD	04-DEC-2003.
XX	
PF	31-MAY-2002; 2002US-00160786.
XX	
PR	31-MAY-2002; 2002US-00160786.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	

[illegible]

PI Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 107; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX
 XX Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1498 CAGCGTGGCAATGCCCTTCC 1517
 DB 1 CAGCGTGGCAATGCCCTTCC 20
 RESULT 164
 ADH26776
 ID ADH26776 standard; DNA; 20 BP.
 XX
 AC ADH26776;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA target region #23.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 XX WPI; 2004-051923/05.
 XX

PT New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 111; 62pp; English.
 XX
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents a PI3K regulatory subunit 4, p150 DNA antisense
 CC oligonucleotide target region of the invention.
 XX
 XX Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1978 GCCCAAGATGATGCTACTAT 1997
 DB 1 GCCCAAGATGATGCTACTAT 20
 RESULT 165
 ADH26680/C
 ID ADH26680 standard; DNA; 20 BP.
 XX
 AC ADH26680;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #5.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Freier SM, Dobie KW;
 XX
 XX WPI; 2004-051923/05.
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX

p150. The compound is an antisense oligonucleotide that specifically hybridises with a nucleic acid molecule encoding PI3K regulatory subunit 4, p150 and inhibits expression of the polypeptide. The antisense oligonucleotide comprises at least one modified internucleoside linkage, i.e. a phosphorothioate linkage, at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase comprising a 5-methylcytosine. The antisense compounds are useful for modulating the expression of PI3K regulatory subunit 4, p150 and for preventing or treating hyperproliferative disorders (i.e. cancer), Chediak-Higashi syndrome, neurodegenerative disorders and metabolic disorders. These may also be used in research and diagnostics and in preventing or delaying infection or inflammation. This sequence represents an antisense oligonucleotide of the invention.

XX Sequence 20 BP; 8 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

Query Match	0.4%;	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 1.4e+02;		
Matches	20;	Conservative 0;	Mismatches 0;	Indels 0;
Gaps	0;			

QY 726 GGTTTTGCAATTCAGGATC 745
 |||||
 Db 20 GGTTTTGCAATTCAGGATC 1

RESULT 167
 ADH26698/C
 ID ADH26698 standard; DNA; 20 BP.
 AC
 AC ADH26698;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #23.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K; PI3K kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosstatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 XX Homo sapiens.
 OS
 XX
 PN US2003225013-A1.
 XX
 PD 04-DEC-2003.
 XX
 PP 31-MAY-2002; 2002US-00160786.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Freier SM, Dobie KW;
 XX
 XX WPI; 2004-051923/05.
 XX
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX
 XX Example 15; SEQ ID NO 33; 62pp; English.
 PS
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX

CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase comprising a 5-methylcytosine. The antisense compounds are useful for modulating the expression of PI3K regulatory subunit 4, p150 and for preventing or treating hyperproliferative disorders (i.e. cancer), Chediak-Higashi syndrome, neurodegenerative disorders and metabolic disorders. These may also be used in research and diagnostics CC and in preventing or delaying infection or inflammation. This sequence CC represents an antisense oligonucleotide of the invention.

XX SQ Sequence 20 BP; 9 A; 1 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1337 CATTATTGATCTCTCTCAA 1356
DB 20 CATTATTGATCTCTCTCAA 1

RESULT 168
ADH26728/c

ID ADH26728 standard; DNA; 20 BP.

XX AC ADH26728;

XX DT 11-MAR-2004 (first entry)

XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #53.

XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K; PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety; 5-methylcytosine; hyperproliferative disorder; cancer; Chediak-Higashi syndrome; neurodegenerative disorder; metabolic disorders; inflammation; cytostatic; immunomodulator; neurodegenerative; antimicrobial; antiinflammatory.

XX OS Homo sapiens.

XX PN US2003225013-A1.

XX PD 04-DEC-2003.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-051923/05.

XX PS Example 15; SEQ ID NO 63; 62pp; English.

XX PT The invention relates to a compound targeted to a nucleic acid molecule encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4, p150. The compound is an antisense oligonucleotide that specifically hybridises with a nucleic acid molecule encoding PI3K regulatory subunit 4, p150 and inhibits expression of the polypeptide. The antisense oligonucleotide comprises at least one modified internucleoside linkage, i.e. a phosphorothioate linkage, at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase comprising a 5-methylcytosine. The antisense compounds are useful for modulating the expression of PI3K regulatory subunit 4, p150 and for preventing or treating hyperproliferative disorders (i.e. cancer), Chediak-Higashi syndrome, neurodegenerative disorders and

CC metabolic disorders. These may also be used in research and diagnostics CC and in preventing or delaying infection or inflammation. This sequence CC represents an antisense oligonucleotide of the invention.

XX SQ Sequence 20 BP; 4 A; 6 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3455 AGATGATGGAATAATGCTGAA 3474
DB 20 AGATGATGGAATAATGCTGAA 1

RESULT 169
ADH26738/c

ID ADH26738 standard; DNA; 20 BP.

XX AC ADH26738;

XX DT 11-MAR-2004 (first entry)

XX DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #63.

XX KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K; PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety; 5-methylcytosine; hyperproliferative disorder; cancer; Chediak-Higashi syndrome; neurodegenerative disorder; metabolic disorders; inflammation; cytostatic; immunomodulator; neurodegenerative; antimicrobial; antiinflammatory.

XX OS Homo sapiens.

XX PN US2003225013-A1.

XX PD 04-DEC-2003.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-051923/05.

XX PS Example 15; SEQ ID NO 73; 62pp; English.

XX PT The invention relates to a compound targeted to a nucleic acid molecule encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4, p150. The compound is an antisense oligonucleotide that specifically hybridises with a nucleic acid molecule encoding PI3K regulatory subunit 4, p150 and inhibits expression of the polypeptide. The antisense oligonucleotide comprises at least one modified internucleoside linkage, i.e. a phosphorothioate linkage, at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase comprising a 5-methylcytosine. The antisense compounds are useful for modulating the expression of PI3K regulatory subunit 4, p150 and for preventing or treating hyperproliferative disorders (i.e. cancer), Chediak-Higashi syndrome, neurodegenerative disorders and metabolic disorders. These may also be used in research and diagnostics CC and in preventing or delaying infection or inflammation. This sequence CC represents an antisense oligonucleotide of the invention.

XX SQ Sequence 20 BP; 7 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3991 GGCTCATCACTTCTTGC 4010
DB 20 GGCTCATCACTTCTTGC 1

RESULT 170
ADH26787
ID ADH26787 standard; DNA; 20 BP.

XX AC ADH26787;
XX
XX
XX 11-MAR-2004 (first entry)
XX Human PI3K regulatory subunit 4, p150 DNA target region #34.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.

XX Homo sapiens.
XX OS
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX (ISIS-) ISIS PHARM INC.
XX Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 122; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.

XX Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2860 CCTGCCATAGCACAGCTTCT 2879
DB 1 CCTGCCATAGCACAGCTTCT 20

RESULT 171
ADH26809
ID ADH26809 standard; DNA; 20 BP.

XX AC ADH26809;
XX
XX 11-MAR-2004 (first entry)
XX Human PI3K regulatory subunit 4, p150 DNA target region #56.
XX Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
KW PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
KW neurodegenerative disorder; metabolic disorders; inflammation;
KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
KW antiinflammatory.

XX Homo sapiens.
XX OS
XX US2003225013-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX (ISIS-) ISIS PHARM INC.

XX Freier SM, Dobie KW;
XX WPI; 2004-051923/05.
XX
XX New antisense oligonucleotides inhibiting the expression of
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT preventing or treating diseases associated with the subunit, e.g.
PT hyperproliferative disorders.

XX Example 15; SEQ ID NO 144; 62pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
CC p150. The compound is an antisense oligonucleotide that specifically
CC hybridizes with a nucleic acid molecule encoding PI3K regulatory subunit
CC 4, p150 and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of PI3K regulatory subunit 4, p150
CC and for preventing or treating hyperproliferative disorders (i.e.
CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC metabolic disorders. These may also be used in research and diagnostics
CC and in preventing or delaying infection or inflammation. This sequence
CC represents a PI3K regulatory subunit 4, p150 DNA antisense
CC oligonucleotide target region of the invention.

XX Sequence 20 BP; 4 A; 5 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4761 CTTTTCATGACTGACTGAC 4780
DB 1 CTTTTCATGACTGACTGAC 20

```
RESULT 172
ADL34585/c
ID ADL34585 standard; DNA; 20 BP.
XX AC ADL34585;
XX AC ADL34585;
XX DT 17-JUN-2004 (first entry)
XX DE ISIS antisense oligonucleotide ISIS 206977.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytosstatic; gene therapy; ss; primer.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate backbone"
XX PN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (PREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX PI WPI; 2004-282523/26.
XX DR
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS Example 15; SEQ ID NO 31; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 3 A; 7 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1268 AGTTGAAGAGAGCAATGGAC 1287
|||||

Db 20 AGTTGAAGAGAGCAATGGAC 1
RESULT 173
ADL34599/c
ID ADL34599 standard; DNA; 20 BP.
XX AC ADL34599;
XX AC ADL34599;
XX DT 17-JUN-2004 (first entry)
XX DE ISIS antisense oligonucleotide ISIS 206991.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytosstatic; gene therapy; ss; primer.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate backbone"
XX PN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (PREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX PI WPI; 2004-282523/26.
XX DR
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS Example 15; SEQ ID NO 45; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2080 CTTAATATGGAATGACCC 2099
```

2524 GTTTACGAATTTGCCAGTGA 2543
|||||
20 GTTTACGAATTTGCCAGTGA 1

RESULT 175
ADL34610/c
ID ADL34610 standard; DNA; 20 BP.
XX
AC ADL34610;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 207002.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.

Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM; Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 56; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 6 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

20 CTTAATATGGAATGACCC 1
|||||

RESULT 174
ADL34603/c
ID ADL34603 standard; DNA; 20 BP.
XX
AC ADL34603;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206995.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.

Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM; Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 49; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 7 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```

QY 3009 TCAGAAAGGTGTAATTGACT 3028
    |||||
Db 20 TCAGAAAGGTGTAATTGACT 1

RESULT 176
ADL34637/C
ID ADL34637 standard; DNA; 20 BP.
XX
AC ADL34637;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 207037.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FRIE/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 83; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4461 TGAAGTTGTCAGGAATTC 4480
    |||||
Db 20 TGAAGTTGTCAGGAATTC 1

RESULT 177
ADL34638/C
ID ADL34638 standard; DNA; 20 BP.
XX
AC ADL34638;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 207038.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FRIE/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 84; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

```

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

Best Local Similarity 100.0%; Pred. No. 1.4e+02; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4633 GTGTGGAAATTAACCTACT 4652
Dl 20 GTGTGGAAATTAACCTACT 1

RESULT 178
ADL34654
ID ADL34654 standard; DNA; 20 BP.
XX AC ADL34654;
XX DT 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124607.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytosstatic; gene therapy; ds.
XX OS Homo sapiens.
XX PN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FRIE/) FRIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX Example 15; SEQ ID NO 100; 60pp; English.

This invention describes a novel antisense oligonucleotides which specifically hybridises to and inhibits the expression of human phosphoinositide-3-kinase, regulatory subunit 4, p150. The oligonucleotides comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide can be used in diagnostics and as research reagents and kits. It can also be used prophylactically, e.g. to prevent or delay infection, inflammation or tumour formation. It can also be used to treat a disease or condition associated with phosphoinositide-3-kinase, regulatory subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, Chediak-Higashi syndrome or a metabolic disorder. The products of the invention are immunomodulators with cytostatic activity and can be used for gene therapy.

Qy 982 GCACAAATCTGGAGTTGCG 1001
Dl 20 GTGTGGAAATTAACCTACT 1

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 GCACAAATCTGGAGTTGCG 20

RESULT 179
ADL34656
ID ADL34656 standard; DNA; 20 BP.
XX AC ADL34656;
XX DT 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124509.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytosstatic; gene therapy; ds.
XX OS Homo sapiens.
XX PN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FRIE/) FRIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX Example 15; SEQ ID NO 102; 60pp; English.

This invention describes a novel antisense oligonucleotides which specifically hybridises to and inhibits the expression of human phosphoinositide-3-kinase, regulatory subunit 4, p150. The oligonucleotides comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide can be used in diagnostics and as research reagents and kits. It can also be used prophylactically, e.g. to prevent or delay infection, inflammation or tumour formation. It can also be used to treat a disease or condition associated with phosphoinositide-3-kinase, regulatory subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, Chediak-Higashi syndrome or a metabolic disorder. The products of the invention are immunomodulators with cytostatic activity and can be used for gene therapy.

Qy 1032 GGTCCACCAAGTTGGAATTGGG 1051
Dl 1 GGTCCACCAAGTTGGAATTGGG 20

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 180
ADL34659

KW	phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;	OS	Homo sapiens.
KW	infection; inflammation; tumour formation; hyperproliferative disorder;	XX	
KW	cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;	PN	US2004063657-A1.
KW	cytostatic; gene therapy; ds.	XX	
XX		PD	01-APR-2004.
OS		XX	
XX		XX	18-SEP-2003; 2003US-00667022.
XX		PF	
XX		PR	31-MAY-2002; 2002US-00160786.
XX		XX	
XX		XX	(FREI/) FREIER S M.
XX		PA	(DOBI/) DOBIE K W.
XX		XX	
XX		XX	Freier SM, Dobie KW;
XX		PI	WPI; 2004-282523/26.
XX		DR	
XX		XX	
XX		XX	New antisense compound targeted to a nucleic acid molecule encoding
XX		XX	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX		XX	treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX		XX	
XX		XX	Example 15; SEQ ID NO 123; 60pp; English.
XX		XX	
XX		XX	This invention describes a novel antisense oligonucleotides which
XX		XX	specifically hybridises to and inhibits the expression of human
XX		XX	phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX		XX	oligonucleotides comprises at least one modified internucleoside linkage,
XX		XX	preferably a phosphorothioate linkage. It also comprises at least one
XX		XX	modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX		XX	antisense oligonucleotide further comprises at least one modified
XX		XX	nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX		XX	can be used in diagnostics and as research reagents and kits. It can also
XX		XX	be used prophylactically, e.g. to prevent or delay infection,
XX		XX	inflammation or tumour formation. It can also be used to treat a disease
XX		XX	or condition associated with phosphoinositide-3-kinase, regulatory
XX		XX	subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX		XX	Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX		XX	invention are immunomodulators with cytostatic activity and can be used
XX		XX	for gene therapy.
XX		XX	
SQ	Sequence 20 BP; 8 A; 3 C; 6 G; 3 T; 0 U; 0 Other;	SQ	Sequence 20 BP; 8 A; 2 C; 4 G; 6 T; 0 U; 0 Other;
	Query Match 0.4%; Score 20; DB 1; Length 20;		Query Match 0.4%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 1.4e+02;		Best Local Similarity 100.0%; Pred. No. 1.4e+02;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	2913 AGAGGAGACAAACTTCTGG 2932	QY	4792 CAAATGCTTAAGATGTACT 4811
Db	1 AGAGGAGACAAACTTCTGG 20	Db	1 CAAATGCTTAAGATGTACT 20
RESULT 183		RESULT 184	
ADL34700		ADL34602/C	
ID	ADL34700 standard; DNA; 20 BP.	ID	ADL34602 standard; DNA; 20 BP.
XX		XX	
XX	ADL34700;	XX	ADL34602;
XX		XX	
XX	17-JUN-2004 (first entry)	XX	17-JUN-2004 (first entry)
XX		XX	
XX	Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124669.	XX	ISIS antisense oligonucleotide ISIS 206994.
XX		XX	
XX	antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;	XX	antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX	regulatory subunit 4; p150; internucleoside linkage;	XX	regulatory subunit 4; p150; internucleoside linkage;
XX	phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;	XX	phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX	infection; inflammation; tumour formation; hyperproliferative disorder;	XX	infection; inflammation; tumour formation; hyperproliferative disorder;
XX	cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;	XX	cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX	cytostatic; gene therapy; ds.	XX	cytostatic; gene therapy; ss; primer.
XX		XX	Synthetic.
XX		XX	
XX		XX	Key Location/Qualifiers
XX		XX	modified_base 1..20
XX		XX	/tag= a

```
FT      /mod_base= OTHER
FT      /note= "phosphorothioate backbone"
PN      US2004063657-A1.
XX      01-APR-2004.
XX      18-SEP-2003; 2003US-00667022.
XX      31-MAY-2002; 2002US-00160786.
XX      (PREI/) PREIER S M.
XX      (DOBI/) DOBIE K W.
XX      Freier SM, Dobie KW;
XX      WPI; 2004-282523/26.
XX      New antisense compound targeted to a nucleic acid molecule encoding
PT      phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT      treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX      Example 15; SEQ ID NO 48; 60pp; English.
XX      This invention describes a novel antisense oligonucleotides which
CC      specifically hybridises to and inhibits the expression of human
CC      phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC      oligonucleotides comprises at least one modified internucleoside linkage,
CC      preferably a phosphorothioate linkage. It also comprises at least one
CC      modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC      antisense oligonucleotide further comprises at least one modified
CC      nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC      can be used in diagnostics and as research reagents and kits. It can also
CC      be used prophylactically, e.g. to prevent or delay infection,
CC      inflammation or tumour formation. It can also be used to treat a disease
CC      or condition associated with phosphoinositide-3-kinase, regulatory
CC      subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC      Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC      invention are immunomodulators with cytostatic activity and can be used
CC      for gene therapy.
XX      Sequence 20 BP; 8 A; 6 C; 1 G; 5 T; 0 U; 0 Other;
SQ      Query Match      0.4%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 1.4e+02;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2438 TTACTGATGCTGAGGATTT 2457
      |||||
DB      20 TTACTGATGCTGAGGATTT 1
RESULT 185
ADL34605/C
ID      ADL34605 standard; DNA; 20 BP.
XX
XX      AC      ADL34605;
XX      17-JUN-2004 (first entry)
XX      ISIS antisense oligonucleotide ISIS 206997.
XX      antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX      regulatory subunit 4; p150; internucleoside linkage;
XX      phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX      infection; inflammation; tumour formation; hyperproliferative disorder;
XX      cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX      cytostatic; gene therapy; ss; primer.
XX      Synthetic.
OS
XX      Key      Location/Qualifiers
FH      modified_base 1..20
FT
```

```
FT      /*tag= a
FT      /mod_base= OTHER
FT      /note= "phosphorothioate backbone"
PN      US2004063657-A1.
XX      01-APR-2004.
XX      18-SEP-2003; 2003US-00667022.
XX      31-MAY-2002; 2002US-00160786.
XX      (PREI/) FREIER S M.
XX      (DOBI/) DOBIE K W.
XX      Freier SM, Dobie KW;
XX      WPI; 2004-282523/26.
XX      New antisense compound targeted to a nucleic acid molecule encoding
PT      phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT      treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX      Example 15; SEQ ID NO 51; 60pp; English.
XX      This invention describes a novel antisense oligonucleotides which
CC      specifically hybridises to and inhibits the expression of human
CC      phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC      oligonucleotides comprises at least one modified internucleoside linkage,
CC      preferably a phosphorothioate linkage. It also comprises at least one
CC      modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC      antisense oligonucleotide further comprises at least one modified
CC      nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC      can be used in diagnostics and as research reagents and kits. It can also
CC      be used prophylactically, e.g. to prevent or delay infection,
CC      inflammation or tumour formation. It can also be used to treat a disease
CC      or condition associated with phosphoinositide-3-kinase, regulatory
CC      subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC      Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC      invention are immunomodulators with cytostatic activity and can be used
CC      for gene therapy.
XX      Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
SQ      Query Match      0.4%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 1.4e+02;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2587 GGTGCCCGTGGGATTTATCAC 2606
      |||||
DB      20 GGTGCCCGTGGGATTTATCAC 1
RESULT 186
ADL34651
ID      ADL34651 standard; DNA; 20 BP.
XX
XX      AC      ADL34651;
XX      17-JUN-2004 (first entry)
XX      Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124604.
XX      antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX      regulatory subunit 4; p150; internucleoside linkage;
XX      phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX      infection; inflammation; tumour formation; hyperproliferative disorder;
XX      cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX      cytostatic; gene therapy; ds.
XX      Homo sapiens.
XX
XX      Key      Location/Qualifiers
FH      modified_base 1..20
FT
```

```
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FREI/) FREIER S M.
XX PI (DOBI/) DOBIE K W.
XX PL Freier SM, Dobie KW;
XX PS WPI; 2004-282523/26.
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS Example 15; SEQ ID NO 97; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 8 A; 5 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 824 CTTTCCAGAAAGCATCAGAA 843
DB 1 CTTTCCAGAAAGCATCAGAA 20
RESULT 187
ADL34671
ID ADL34671 standard; DNA; 20 BP.
XX AC ADL34671;
XX CC 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124631.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytosstatic; gene therapy; ds.
XX OS Homo sapiens.
XX PF US2004063657-A1.
XX PR 01-APR-2004.
XX PD 18-SEP-2003; 2003US-00667022.
XX PF 01-APR-2004.
XX PD 18-SEP-2003; 2003US-00667022.
```

```
PR 31-MAY-2002; 2002US-00160786.
XX (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX PS WPI; 2004-282523/26.
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS Example 15; SEQ ID NO 117; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 5 A; 3 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2524 GTTTACGAATTTGCCAGTGA 2543
DB 1 GTTTACGAATTTGCCAGTGA 20
RESULT 188
ADL34699
ID ADL34699 standard; DNA; 20 BP.
XX AC ADL34699;
XX CC 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124668.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytosstatic; gene therapy; ds.
XX OS Homo sapiens.
XX PF US2004063657-A1.
XX PR 01-APR-2004.
XX PD 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PF (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
```

```

PI Freier SM, Dobie KW;
DR WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 145; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
SQ Sequence 20 BP; 9 A; 6 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4776 CTGACTAAATGACACCCAAA 4795
DB 1 CTGACTAAATGACACCCAAA 20

RESULT 189
ADL34576/c
ID ADL34576 standard; DNA; 20 BP.
XX
XX ADL34576;
XX
XX 17-JUN-2004 (first entry)
XX
XX ISIS antisense oligonucleotide ISIS 206968.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytosstatic; gene therapy; ss; primer.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX

```

```

XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 22; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
SQ Sequence 20 BP; 4 A; 3 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 824 CTTTCCAGAAAGCATCAGAA 843
DB 20 CTTTCCAGAAAGCATCAGAA 1

RESULT 190
ADL34598/c
ID ADL34598 standard; DNA; 20 BP.
XX
XX ADL34598;
XX
XX 17-JUN-2004 (first entry)
XX
XX ISIS antisense oligonucleotide ISIS 206990.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytosstatic; gene therapy; ss; primer.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FREI/) FREIER S M.
XX

```

```
PA (DOB/) DOBIE K W.
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 44; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2041 ACAGCTCTGAGATTCTGGA 2060
Db 20 ACAGCTCTGAGATTCTGGA 1
|||||
|||||

RESULT 191
ADL34607/c
ID ADL34607 standard; DNA; 20 BP.
XX
XX AC ADL34607;
XX
XX 17-JUN-2004 (first entry)
XX
XX ISIS antisense oligonucleotide ISIS 206999.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytostatic; gene therapy; ss; primer.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
```

```
PA (FREI/) FREIER S M.
PA (DOB/) DOBIE K W.
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 53; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2843 GCCCTCCGCCAGAGGATCCT 2862
Db 20 GCCCTCCGCCAGAGGATCCT 1
|||||
|||||

RESULT 192
ADL34614/c
ID ADL34614 standard; DNA; 20 BP.
XX
XX AC ADL34614;
XX
XX 17-JUN-2004 (first entry)
XX
XX ISIS antisense oligonucleotide ISIS 207006.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytostatic; gene therapy; ss; primer.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
```



```
XX (FREI/) FREIER S M.  
PA (DOBI/) DOBIE K W.  
XX  
XX Freier SM, Dobie KW;  
XX  
XX WPI; 2004-282523/26.  
XX  
PT New antisense compound targeted to a nucleic acid molecule encoding  
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for  
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.  
XX  
XX Example 15; SEQ ID NO 60; 60pp; English.  
XX  
XX This invention describes a novel antisense oligonucleotides which  
CC specifically hybridises to and inhibits the expression of human  
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The  
CC oligonucleotides comprises at least one modified internucleoside linkage,  
CC preferably a phosphorothioate linkage. It also comprises at least one  
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The  
CC antisense oligonucleotide further comprises at least one modified  
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide  
CC can be used in diagnostics and as research reagents and kits. It can also  
CC be used prophylactically, e.g. to prevent or delay infection,  
CC inflammation or tumour formation. It can also be used to treat a disease  
CC or condition associated with phosphoinositide-3-kinase, regulatory  
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,  
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the  
CC invention are immunomodulators with cytostatic activity and can be used  
CC for gene therapy.  
XX  
SQ Sequence 20 BP; 6 A; 2 C; 6 G; 6 T; 0 U; 0 Other;  
Query Match 0.4%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 3341 GTAGTACAATCTTACCATCC 3360  
DB 20 GTAGTACAATCTTACCATCC 1  
RESULT 193  
ADL34616/c  
ID ADL34616 standard; DNA; 20 BP.  
XX  
XX AC ADL34616;  
XX  
XX 17-JUN-2004 (first entry)  
XX  
XX ISIS antisense oligonucleotide ISIS 207008.  
XX  
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;  
XX regulatory subunit 4; p150; internucleoside linkage;  
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;  
XX infection; inflammation; tumour formation; hyperproliferative disorder;  
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;  
XX cytostatic; gene therapy; ss; primer.  
XX  
XX Synthetic.  
XX  
XX Key Location/Qualifiers  
FH modified_base 1..20  
FT /*tag= a  
FT /mod_base= OTHER  
FT /note= "phosphorothioate backbone"  
XX US2004063657-A1.  
XX  
XX 01-APR-2004.  
XX  
XX 18-SEP-2003; 2003US-00667022.  
XX
```

```
PR 31-MAY-2002; 2002US-00160786.  
XX (FREI/) FREIER S M.  
PA (DOBI/) DOBIE K W.  
XX  
XX Freier SM, Dobie KW;  
XX  
XX WPI; 2004-282523/26.  
XX  
PT New antisense compound targeted to a nucleic acid molecule encoding  
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for  
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.  
XX  
XX Example 15; SEQ ID NO 62; 60pp; English.  
XX  
XX This invention describes a novel antisense oligonucleotides which  
CC specifically hybridises to and inhibits the expression of human  
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The  
CC oligonucleotides comprises at least one modified internucleoside linkage,  
CC preferably a phosphorothioate linkage. It also comprises at least one  
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The  
CC antisense oligonucleotide further comprises at least one modified  
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide  
CC can be used in diagnostics and as research reagents and kits. It can also  
CC be used prophylactically, e.g. to prevent or delay infection,  
CC inflammation or tumour formation. It can also be used to treat a disease  
CC or condition associated with phosphoinositide-3-kinase, regulatory  
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,  
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the  
CC invention are immunomodulators with cytostatic activity and can be used  
CC for gene therapy.  
XX  
SQ Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;  
Query Match 0.4%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 3431 GCAATGCTGAGAGATAGCT 3450  
DB 20 GCAATGCTGAGAGATAGCT 1  
RESULT 194  
ADL34630/c  
ID ADL34630 standard; DNA; 20 BP.  
XX  
XX AC ADL34630;  
XX  
XX 17-JUN-2004 (first entry)  
XX  
XX ISIS antisense oligonucleotide ISIS 207030.  
XX  
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;  
XX regulatory subunit 4; p150; internucleoside linkage;  
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;  
XX infection; inflammation; tumour formation; hyperproliferative disorder;  
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;  
XX cytostatic; gene therapy; ss; primer.  
XX  
XX Synthetic.  
XX  
XX Key Location/Qualifiers  
FH modified_base 1..20  
FT /*tag= a  
FT /mod_base= OTHER  
FT /note= "phosphorothioate backbone"  
XX US2004063657-A1.  
XX  
XX 01-APR-2004.  
XX  
XX 18-SEP-2003; 2003US-00667022.  
XX
```

XX	31-MAY-2002; 2002US-00160786.	PF	18-SEP-2003; 2003US-00667022.	XX
XX	(FREI/) FREIER S M.	PR	31-MAY-2002; 2002US-00160786.	XX
XX	(DOBI/) DOBIE K W.	PA	(FREI/) FREIER S M.	PA
XX	Freier SM, Dobie KW;	PI	(DOBI/) DOBIE K W.	PI
XX	WPI; 2004-282523/26.	DR	Freier SM, Dobie KW;	DR
XX	New antisense compound targeted to a nucleic acid molecule encoding	XX	WPI; 2004-282523/26.	XX
PT	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for	PT	New antisense compound targeted to a nucleic acid molecule encoding	PT
PT	treating cancer, Chediak-Higashi syndrome or a metabolic disorder.	PT	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for	PT
XX	Example 15; SEQ ID NO 76; 60pp; English.	XX	treating cancer, Chediak-Higashi syndrome or a metabolic disorder.	XX
PS		XX	Example 15; SEQ ID NO 86; 60pp; English.	PS
CC	This invention describes a novel antisense oligonucleotides which	XX	This invention describes a novel antisense oligonucleotides which	CC
CC	specifically hybridises to and inhibits the expression of human	CC	specifically hybridises to and inhibits the expression of human	CC
CC	phosphoinositide-3-kinase, regulatory subunit 4, p150. The	CC	phosphoinositide-3-kinase, regulatory subunit 4, p150. The	CC
CC	oligonucleotides comprises at least one modified internucleoside linkage,	CC	oligonucleotides comprises at least one modified internucleoside linkage,	CC
CC	preferably a phosphorothioate linkage. It also comprises at least one	CC	preferably a phosphorothioate linkage. It also comprises at least one	CC
CC	modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The	CC	preferably a phosphorothioate linkage. It also comprises at least one	CC
CC	antisense oligonucleotide further comprises at least one modified	CC	modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The	CC
CC	nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide	CC	antisense oligonucleotide further comprises at least one modified	CC
CC	can be used in diagnostics and as research reagents and kits. It can also	CC	nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide	CC
CC	be used prophylactically, e.g. to prevent or delay infection,	CC	can be used in diagnostics and as research reagents and kits. It can also	CC
CC	inflammation or tumour formation. It can also be used to treat a disease	CC	be used prophylactically, e.g. to prevent or delay infection,	CC
CC	or condition associated with phosphoinositide-3-kinase, regulatory	CC	inflammation or tumour formation. It can also be used to treat a disease	CC
CC	subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,	CC	or condition associated with phosphoinositide-3-kinase, regulatory	CC
CC	Chediak-Higashi syndrome or a metabolic disorder. The products of the	CC	subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,	CC
CC	invention are immunomodulators with cytostatic activity and can be used	CC	Chediak-Higashi syndrome or a metabolic disorder. The products of the	CC
CC	for gene therapy.	CC	invention are immunomodulators with cytostatic activity and can be used	CC
XX	Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;	XX	for gene therapy.	XX
SQ		SQ	Sequence 20 BP; 3 A; 2 C; 6 G; 9 T; 0 U; 0 Other;	SQ
	Query Match 0.4%; Score 20; DB 1; Length 20;		Query Match 0.4%; Score 20; DB 1; Length 20;	
	Best Local Similarity 100.0%; Pred. No. 1.4e+02;		Best Local Similarity 100.0%; Pred. No. 1.4e+02;	
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	4212 GGAGACTGGTGACAGAAGAT 4231	QY	4776 CTGACTAAATGACACCCAAA 4795	
Db	20 GGAGACTGGTGACAGAAGAT 1	Db	20 CTGACTAAATGACACCCAAA 1	
	RESULT 195		RESULT 196	
ID	ADL34640/c	ID	ADL34649	
XX	ADL34640 standard; DNA; 20 BP.	XX	ADL34649 standard; DNA; 20 BP.	
XX	ADL34640;	XX	ADL34649;	
XX	17-JUN-2004 (first entry)	XX	17-JUN-2004 (first entry)	
XX	ISIS antisense oligonucleotide ISIS 207040.	XX	Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124601.	
XX	antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;	XX	antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;	
KW	regulatory subunit 4; p150; internucleoside linkage;	KW	regulatory subunit 4; p150; internucleoside linkage;	
KW	phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;	KW	phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;	
KW	infection; inflammation; tumour formation; hyperproliferative disorder;	KW	infection; inflammation; tumour formation; hyperproliferative disorder;	
KW	cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;	KW	cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;	
XX	cytostatic; gene therapy; ss; primer.	KW	cytostatic; gene therapy; ds.	
OS	Synthetic.	OS	Homo sapiens.	
XX		XX		
PH	Key Location/Qualifiers	XX	US2004063657-A1.	
FT	modified_base 1..20	XX	01-APR-2004.	
FT	/+tag= a	XX	18-SEP-2003; 2003US-00667022.	
FT	/mod_base= OTHER	XX	31-MAY-2002; 2002US-00160786.	
FT	/note= "phosphorothioate backbone"	XX	(FREI/) FREIER S M.	
XX	US2004063657-A1.			
XX	01-APR-2004.			
XX				

```
PA (DOBI/) DOBIE K W.
PI Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 95; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
XX Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 703 CGAGAGCCCTGGTCGTGT 722
DB 1 CGAGAGCCCTGGTCGTGT 20
RESULT 197
ADL34669
ID ADL34669 standard; DNA; 20 BP.
XX
XX ADL34669;
XX
XX 17-JUN-2004 (first entry)
XX
XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124629.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytostatic; gene therapy; ds.
XX
XX Homo sapiens.
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2002US-00160786.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 115; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
XX Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2391 TGGCTGGCAAGCTCTCTCAA 2410
DB 1 TGGCTGGCAAGCTCTCTCAA 20
RESULT 198
ADL34687
ID ADL34687 standard; DNA; 20 BP.
XX
XX ADL34687;
XX
XX 17-JUN-2004 (first entry)
XX
XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124648.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytostatic; gene therapy; ds.
XX
XX Homo sapiens.
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
```

```
PS Example 15; SEQ ID NO 133; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 6 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3555 GAATCGAATTAGAGTCTCTG 3574
DB 1 GAATCGAATTAGAGTCTCTG 20
RESULT 199
ADL34571/C
ID ADL34571 standard; DNA; 20 BP.
XX
AC ADL34571;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206963.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PT
```

```
XX
PS Example 15; SEQ ID NO 17; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 559 CTTGCCATTATGGGAATCA 578
DB 20 CTTGCCATTATGGGAATCA 1
RESULT 200
ADL34593/C
ID ADL34593 standard; DNA; 20 BP.
XX
AC ADL34593;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206985.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PT
```

PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
PS Example 15; SEQ ID NO 39; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1630 CACAATCTCTGTGGACATGA 1649
DB 20 CACAATCTCTGTGGACATGA 1

RESULT 201
ADL34597/c
ID ADL34597 standard; DNA; 20 BP.
XX
AC ADL34597;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206989.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 43; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 5 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2005 CTAGCCTATGCTGAAAACAT 2024
DB 20 CTAGCCTATGCTGAAAACAT 1

RESULT 202
ADL34613/c
ID ADL34613 standard; DNA; 20 BP.
XX
AC ADL34613;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 207005.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT

PT New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 59; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3318 AAAACCAAGTAATACCGGTTT 3337

Db 20 AAAACCAAGTAATACCGGTTT 1

RESULT 203

ID ADL34621/C

ADL34621 standard; DNA; 20 BP.

XX ADL34621;

XX 17-JUN-2004 (first entry)

XX ISIS antisense oligonucleotide ISIS 207021.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone"

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (FREI/) FREIER S M.

XX (DOBI/) DOBIE K W.

XX Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX

PT New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 67; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX Sequence 20 BP; 9 A; 2 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3583 TCACCTTTTGCACATGTTT 3602

Db 20 TCACCTTTTGCACATGTTT 1

RESULT 204

ADL34652

ID ADL34652 standard; DNA; 20 BP.

XX ADL34652;

XX 17-JUN-2004 (first entry)

XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124605.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ds.

XX Homo sapiens.

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (FREI/) FREIER S M.

XX (DOBI/) DOBIE K W.

XX Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

PS Example 15; SEQ ID NO 98; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which

CC specifically hybridises to and inhibits the expression of human

CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The

CC oligonucleotides comprises at least one modified internucleoside linkage,

CC preferably a phosphorothioate linkage. It also comprises at least one

CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The

CC antisense oligonucleotide further comprises at least one modified

CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide

CC can be used in diagnostics and as research reagents and kits. It can also

CC be used prophylactically, e.g. to prevent or delay infection,

CC inflammation or tumour formation. It can also be used to treat a disease

CC or condition associated with phosphoinositide-3-kinase, regulatory

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,

CC Chediak-Higashi syndrome or a metabolic disorder. The products of the

CC invention are immunomodulators with cytostatic activity and can be used

CC for gene therapy.

XX SQ Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 GGCAGTATGTCGAGACAAT 894

DB 1 GGCAGTATGTCGAGACAAT 20

RESULT 205

ADL34664

ID ADL34664 standard; DNA; 20 BP.

XX AC ADL34664;

XX DT 17-JUN-2004 (first entry)

DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124623.

XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;

XX KW regulatory subunit 4; p150; internucleoside linkage;

XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;

XX KW infection; inflammation; tumour formation; hyperproliferative disorder;

XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;

XX KW cytostatic; gene therapy; ds.

XX OS Homo sapiens.

XX US2004063657-A1.

XX PD 01-APR-2004.

XX PF 18-SEP-2003; 2003US-00667022.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (FREI/) FREIER S M.

XX PA (DOBI/) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX PT New antisense compound targeted to a nucleic acid molecule encoding

XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX PS Example 15; SEQ ID NO 110; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which

CC specifically hybridises to and inhibits the expression of human

CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The

CC oligonucleotides comprises at least one modified internucleoside linkage,

CC preferably a phosphorothioate linkage. It also comprises at least one

CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The

CC antisense oligonucleotide further comprises at least one modified

CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide

CC can be used in diagnostics and as research reagents and kits. It can also

CC be used prophylactically, e.g. to prevent or delay infection,

CC inflammation or tumour formation. It can also be used to treat a disease

CC or condition associated with phosphoinositide-3-kinase, regulatory

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,

CC Chediak-Higashi syndrome or a metabolic disorder. The products of the

CC invention are immunomodulators with cytostatic activity and can be used

CC for gene therapy.

XX SQ Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1706 CTGTATACATCTCGCTA 1725

DB 1 CTGTATACATCTCGCTA 20

RESULT 206

ADL34682

ID ADL34682 standard; DNA; 20 BP.

XX AC ADL34682;

XX DT 17-JUN-2004 (first entry)

DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124642.

XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;

XX KW regulatory subunit 4; p150; internucleoside linkage;

XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;

XX KW infection; inflammation; tumour formation; hyperproliferative disorder;

XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;

XX KW cytostatic; gene therapy; ds.

XX OS Homo sapiens.

XX US2004063657-A1.

XX PD 01-APR-2004.

XX PF 18-SEP-2003; 2003US-00667022.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (FREI/) FREIER S M.

XX PA (DOBI/) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX PT New antisense compound targeted to a nucleic acid molecule encoding

XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX PS Example 15; SEQ ID NO 128; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which

CC specifically hybridises to and inhibits the expression of human

CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The

CC oligonucleotides comprises at least one modified internucleoside linkage,

CC preferably a phosphorothioate linkage. It also comprises at least one

CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The

CC antisense oligonucleotide further comprises at least one modified

CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide

CC can be used in diagnostics and as research reagents and kits. It can also

CC be used prophylactically, e.g. to prevent or delay infection,

CC inflammation or tumour formation. It can also be used to treat a disease

CC or condition associated with phosphoinositide-3-kinase, regulatory

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,

CC Chediak-Higashi syndrome or a metabolic disorder. The products of the

CC invention are immunomodulators with cytostatic activity and can be used

CC for gene therapy.

CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 6 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3341 GTAGTACAATCTTACCATCC 3360
Db 1 GTAGTACAATCTTACCATCC 20
|||||

RESULT 207
ADL34684
ID ADL34684 standard; DNA; 20 BP.
XX AC ADL34684;
XX DT 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124644.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.

XX OS Homo sapiens.
XX PN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX Example 15; SEQ ID NO 130; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,

CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3431 GCATCTCGAGAGATAGCT 3450
Db 1 GCATCTCGAGAGATAGCT 20
|||||

RESULT 208
ADL34608/C
ID ADL34608 standard; DNA; 20 BP.
XX AC ADL34608;
XX DT 17-JUN-2004 (first entry)
XX DE ISIS antisense oligonucleotide ISIS 207000.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.

XX OS Synthetic.
XX PH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"

XX PN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX Example 15; SEQ ID NO 54; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2860 CCTGCCATAGCAGAGCTTCT 2879
 Db 20 CCTGCCATAGCAGAGCTTCT 1

RESULT 209
 ADL34618/C
 ID ADL34618 standard; DNA; 20 BP.
 XX
 AC ADL34618;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE ISIS antisense oligonucleotide ISIS 207010.
 XX
 KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.
 XX
 OS Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 /*tag= a
 /mod_base= OTHER
 /note= "phosphorothioate backbone"

US2004063657-A1.
 01-APR-2004.
 18-SEP-2003; 2003US-00667022.
 31-MAY-2002; 2002US-00160786.
 (FREI/) FREIER S M.
 (DOBI/) DOBIE K W.
 Freier SM, Dobie KW;
 WPI; 2004-282523/26.

New antisense compound targeted to a nucleic acid molecule encoding
 phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

Example 15; SEQ ID NO 64; 60pp; English.

This invention describes a novel antisense oligonucleotides which
 specifically hybridises to and inhibits the expression of human
 phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 oligonucleotides comprises at least one modified internucleoside linkage,
 preferably a phosphorothioate linkage. It also comprises at least one
 modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 antisense oligonucleotide further comprises at least one modified
 nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 can be used in diagnostics and as research reagents and kits. It can also
 be used prophylactically, e.g. to prevent or delay infection,
 inflammation or tumour formation. It can also be used to treat a disease

CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3504 GCCTCTTAAGGCGCTGTAG 3523
 Db 20 GCCTCTTAAGGCGCTGTAG 1

RESULT 210
 ADL34626/C
 ID ADL34626 standard; DNA; 20 BP.
 XX
 AC ADL34626;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE ISIS antisense oligonucleotide ISIS 207026.
 XX
 KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.
 XX
 OS Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 /*tag= a
 /mod_base= OTHER
 /note= "phosphorothioate backbone"

US2004063657-A1.
 01-APR-2004.
 18-SEP-2003; 2003US-00667022.
 31-MAY-2002; 2002US-00160786.
 (FREI/) FREIER S M.
 (DOBI/) DOBIE K W.
 Freier SM, Dobie KW;
 WPI; 2004-282523/26.

New antisense compound targeted to a nucleic acid molecule encoding
 phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

Example 15; SEQ ID NO 72; 60pp; English.

This invention describes a novel antisense oligonucleotides which
 specifically hybridises to and inhibits the expression of human
 phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 oligonucleotides comprises at least one modified internucleoside linkage,
 preferably a phosphorothioate linkage. It also comprises at least one
 modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 antisense oligonucleotide further comprises at least one modified
 nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 can be used in diagnostics and as research reagents and kits. It can also
 be used prophylactically, e.g. to prevent or delay infection,
 inflammation or tumour formation. It can also be used to treat a disease

CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

SQ Sequence 20 BP; 9 A; 6 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 534 AACCTTACTAAAGACCACAG 553
|||||
Db 1 AACCTTACTAAAGACCACAG 20

RESULT 213
ADL34577/C
ID ADL34577 standard; DNA; 20 BP.
XX AC ADL34577;
XX 17-JUN-2004 (first entry)
XX ISIS antisense oligonucleotide ISIS 206969.

DE antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.

XX Synthetic.

OS
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.

XX Preier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 23; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,

CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

SQ Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 GGCAGTATGTGCGAGACAAT 894
|||||
Db 20 GGCAGTATGTGCGAGACAAT 1

RESULT 214
ADL34583/C
ID ADL34583 standard; DNA; 20 BP.
XX AC ADL34583;
XX 17-JUN-2004 (first entry)
XX ISIS antisense oligonucleotide ISIS 206975.

DE antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.

XX Synthetic.

OS
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.

XX Preier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 29; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.
 CC
 XX SQ Sequence 20 BP; 9 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1115 TCAATTATTTCTTTGACACA 1134
 |||||
 DB 20 TCAATTATTTCTTTGACACA 1
 RESULT 215
 ADL34592/c
 ID ADL34592 standard; DNA; 20 BP.
 XX AC ADL34592;
 XX DT 17-JUN-2004 (first entry)
 XX DE ISIS antisense oligonucleotide ISIS 206984.
 XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 XX US2004063657-A1.
 XX 01-APR-2004.
 XX 18-SEP-2003; 2003US-00667022.
 XX 31-MAY-2002; 2002US-00160786.
 XX (FREI/) FREIER S M.
 XX (DOBI/) DOBIE K W.
 XX Freier SM, Dobie KW;
 XX WPI; 2004-282523/26.
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX Example 15; SEQ ID NO 38; 60pp; English.
 XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection.
 CC inflammation or tumour formation. It can also be used to treat a disease

CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.
 CC
 XX SQ Sequence 20 BP; 7 A; 1 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1529 ACACATTTTCTTCAGCCCTAC 1548
 |||||
 DB 20 ACACATTTTCTTCAGCCCTAC 1
 RESULT 216
 ADL34595/c
 ID ADL34595 standard; DNA; 20 BP.
 XX AC ADL34595;
 XX DT 17-JUN-2004 (first entry)
 XX DE ISIS antisense oligonucleotide ISIS 206987.
 XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 XX US2004063657-A1.
 XX 01-APR-2004.
 XX 18-SEP-2003; 2003US-00667022.
 XX 31-MAY-2002; 2002US-00160786.
 XX (FREI/) FREIER S M.
 XX (DOBI/) DOBIE K W.
 XX Freier SM, Dobie KW;
 XX WPI; 2004-282523/26.
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX Example 15; SEQ ID NO 41; 60pp; English.
 XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,

CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX Sequence 20 BP; 7 A; 2 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1706 CTGTTATAACATCTCGCTA 1725
 |||||
 DB 20 CTGTTATAACATCTCGCTA 1

RESULT 217
 ADL34600/C
 ID ADL34600 standard; DNA; 20 BP.

XX AC ADL34600;

XX DT 17-JUN-2004 (first entry)

XX DE ISIS antisense oligonucleotide ISIS 206992.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.

XX Synthetic.

XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (FREI/) FREIER S M.

XX (DOBI/) DOBIE K W.

XX Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 46; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also

CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX Sequence 20 BP; 4 A; 3 C; 4 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2131 CCAAATGGAATATTATGACAC 2150
 |||||
 DB 20 CCAAATGGAATATTATGACAC 1

RESULT 218
 ADL34617/C

ID ADL34617 standard; DNA; 20 BP.

XX AC ADL34617;

XX DT 17-JUN-2004 (first entry)

XX DE ISIS antisense oligonucleotide ISIS 207009.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.

XX Synthetic.

XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (FREI/) FREIER S M.

XX (DOBI/) DOBIE K W.

XX Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 63; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide

CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX SQ Sequence 20 BP; 4 A; 6 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3455 AGATGATGGAAATGCTGAA 3474
 Db 20 AGATGATGGAAATGCTGAA 1

RESULT 219

ADL34620/C
 ID ADL34620 standard; DNA; 20 BP.

XX AC ADL34620;

XX DT 17-JUN-2004 (first entry)

XX DE ISIS antisense oligonucleotide ISIS 207012.

XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.

XX OS Synthetic.

XX FH Key Location/Qualifiers
 XX modified_base 1..20
 XX FT /*tag= a
 XX FT /mod_base= OTHER
 XX FT /note= "phosphorothioate backbone"

XX US2004063657-A1.

XX PD 01-APR-2004.

XX PF 18-SEP-2003; 2003US-00667022.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (FRIE) FREIER S M.
 XX PA (DOBI) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX PS Example 15; SEQ ID NO 66; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified

CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3555 GAATCGAATTAGAGTCTCTG 3574
 Db 20 GAATCGAATTAGAGTCTCTG 1

RESULT 220

ADL34623/C
 ID ADL34623 standard; DNA; 20 BP.

XX AC ADL34623;

XX DT 17-JUN-2004 (first entry)

XX DE ISIS antisense oligonucleotide ISIS 207023.

XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.

XX OS Synthetic.

XX FH Key Location/Qualifiers
 XX modified_base 1..20
 XX FT /*tag= a
 XX FT /mod_base= OTHER
 XX FT /note= "phosphorothioate backbone"

XX US2004063657-A1.

XX PD 01-APR-2004.

XX PF 18-SEP-2003; 2003US-00667022.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (FRIE) FREIER S M.
 XX PA (DOBI) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX PS Example 15; SEQ ID NO 69; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The

CC antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide CC can be used in diagnostics and as research reagents and kits. It can also CC be used prophylactically, e.g. to prevent or delay infection, CC inflammation or tumour formation. It can also be used to treat a disease CC or condition associated with phosphoinositide-3-kinase, regulatory CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, CC Chediak-Higashi syndrome or a metabolic disorder. The products of the CC invention are immunomodulators with cytostatic activity and can be used CC for gene therapy.

XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3781 GAGGCTTCTAAGCTGCCCA 3800
Db |||||
20 GAGGCTTCTAAGCTGCCCA 1

RESULT 221
ADL34629/C

XX AC ADL34629;
XX AC ADL34629;
XX 17-JUN-2004 (first entry)
XX ISIS antisense oligonucleotide ISIS 207029.

DE antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX Synthetic.

XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"

XX US2004063657-A1.
XX 01-APR-2004.
XX 18-SEP-2003; 2003US-00667022.
XX 31-MAY-2002; 2002US-00160786.
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 75; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,

CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection, CC
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4166 TGATTGCAGCTGTTTCAGGGC 4185
Db |||||
20 TGATTGCAGCTGTTTCAGGGC 1

RESULT 222
ADL34663

XX ID ADL34663 standard; DNA; 20 BP.
XX AC ADL34663;
XX 17-JUN-2004 (first entry)
XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124622.

DE antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX Homo sapiens.

XX US2004063657-A1.
XX 01-APR-2004.
XX 18-SEP-2003; 2003US-00667022.
XX 31-MAY-2002; 2002US-00160786.
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 109; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,

CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX
 SQ Sequence 20 BP; 9 A; 4 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1658 AAAAGCCGAGGAGGAGCCT 1677
 ID ADL34666 standard; DNA; 20 BP.
 AC ADL34666;
 ADL34666;
 17-JUN-2004 (first entry)
 Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124626.

XX
 DE antisenase; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytosstatic; gene therapy; ds.
 XX Homo sapiens.

OS
 XX US2004063657-A1.
 PN 01-APR-2004.
 XX 18-SEP-2003; 2003US-00667022.
 PF 31-MAY-2002; 2002US-00160786.
 PR (FREI/) FREIER S M.
 PA (DOBI/) DOBIE K W.
 XX Freier SM, Dobie KW;
 PI WPI; 2004-282523/26.
 DR
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 112; 60pp; English.
 CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used

CC for gene therapy.
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2041 ACAGCTCTGAGATTCTCTGGA 2060
 ID ADL34675 standard; DNA; 20 BP.
 AC ADL34675;
 ADL34675;
 17-JUN-2004 (first entry)
 Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124635.

XX
 DE antisenase; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytosstatic; gene therapy; ds.
 XX Homo sapiens.

OS
 XX US2004063657-A1.
 PN 01-APR-2004.
 XX 18-SEP-2003; 2003US-00667022.
 PF 31-MAY-2002; 2002US-00160786.
 PR (FREI/) FREIER S M.
 PA (DOBI/) DOBIE K W.
 XX Freier SM, Dobie KW;
 PI WPI; 2004-282523/26.
 DR
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 121; 60pp; English.
 CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used

XX
 SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2843 GCCCTCGCCAGAGATCCT 2862
|||||
DB 1 GCCCTCGCCAGAGATCCT 20

RESULT 225
ADL34681
ID ADL34681 standard; DNA; 20 BP.
XX
AC ADL34681;
XX
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124641.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PP 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (PREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Preier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 127; 60pp; English.
XX

This invention describes a novel antisense oligonucleotides which specifically hybridises to and inhibits the expression of human phosphoinositide-3-kinase, regulatory subunit 4, p150. The oligonucleotides comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide can be used in diagnostics and as research reagents and kits. It can also be used prophylactically, e.g. to prevent or delay infection, inflammation or tumour formation. It can also be used to treat a disease or condition associated with phosphoinositide-3-kinase, regulatory subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, Chediak-Higashi syndrome or a metabolic disorder. The products of the invention are immunomodulators with cytostatic activity and can be used for gene therapy.

SQ Sequence 20 BP; 8 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3318 AAAACCAAGTAATACCGTTT 3337
|||||

```

ID ADL34694 standard; DNA; 20 BP.
XX
AC ADL34694;
XX
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124661.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
FN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 140; 60pp; English.
XX
This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;
QY 4309 AGTCCTGCAGATGGAAATCC 4328
Db 1 AGTCCTGCAGATGGAAATCC 20
RESULT 228
ADL34586/C
ID ADL34586 standard; DNA; 20 BP.
XX
AC ADL34586;
XX
DT 17-JUN-2004 (first entry)
XX

```

```

XX DE ISIS antisense oligonucleotide ISIS 206978.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FN Key Location/Qualifiers
modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 32; 60pp; English.
XX
This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 6 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;
QY 1299 AGGTTGTGTGATGCTGAGC 1318
Db 20 AGGTTGTGTGATGCTGAGC 1
RESULT 229
ADL34589/C
ID ADL34589 standard; DNA; 20 BP.
XX
AC ADL34589;
XX
DT 17-JUN-2004 (first entry)
XX

```

```
DT 17-JUN-2004 (first entry)
DE ISIS antisense oligonucleotide ISIS 206981.
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytosstatic; gene therapy; ss; primer.
XX Synthetic.
XX OS
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 35; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1441 CAGATGATTACCGTGAGCC 1460
XX |||||
XX 20 CAGATGATTACCGTGAGCC 1
XX
XX RESULT 230
XX ADL34601/c
XX ID ADL34601 standard; DNA; 20 BP.
XX
XX AC ADL34601;
```

```
XX 17-JUN-2004 (first entry)
XX ISIS antisense oligonucleotide ISIS 206993.
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytosstatic; gene therapy; ss; primer.
XX Synthetic.
XX OS
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 47; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 2391 TGGCTGGCAAGCTCTCAA 2410
XX |||||
XX 20 TGGCTGGCAAGCTCTCAA 1
XX
XX RESULT 231
XX ADL34624/c
XX ID ADL34624 standard; DNA; 20 BP.
XX
XX XD ADL34624;
```

AC ADL34624;
XX 17-JUN-2004 (first entry)
XX ISIS antisense oligonucleotide ISIS 207024.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 70; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
XX Sequence 20 BP; 8 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3899 TTCTTGCCTATGCCACTGTG 3918
Db 20 TTCTTGCCTATGCCACTGTG 1
RESULT 232
ADL34636/C
ID ADL34636 standard; DNA; 20 BP.

XX ADL34636;
XX 17-JUN-2004 (first entry)
XX ISIS antisense oligonucleotide ISIS 207036.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 82; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4424 CATCTGTGTCTCTACTACAGG 4443
Db 20 CATCTGTGTCTCTACTACAGG 1
RESULT 233
ADL34689

ADL34689 standard; DNA; 20 BP.
 AC ADL34689;
 XX 17-JUN-2004 (first entry)
 DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124650.
 XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 DE infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytosolic; gene therapy; ds.
 XX Homo sapiens.
 OS
 XX US2004063657-A1.
 PN 01-APR-2004.
 XX 18-SEP-2003; 2003US-00667022.
 XX 31-MAY-2002; 2002US-00160786.
 XX (FREI/) FREIER S M.
 PA (DOBI/) DOBIE K W.
 XX Freier SM, Dobie KW;
 PI WPI; 2004-282523/26.
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX Example 15; SEQ ID NO 135; 60pp; English.
 XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.
 XX Sequence 20 BP; 3 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3762 TGTCAGCTTCTTGGAAATTG 3781
 Db 1 TGTCAGCTTCTTGGAAATTG 20
 RESULT 234
 ADL34693
 ID ADL34693 standard; DNA; 20 BP.
 XX
 AC ADL34693;
 XX 17-JUN-2004 (first entry)
 DT antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 DE infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytosolic; gene therapy; ds.
 XX Homo sapiens.
 OS
 XX US2004063657-A1.
 PN 01-APR-2004.
 XX 18-SEP-2003; 2003US-00667022.
 XX 31-MAY-2002; 2002US-00160786.
 XX (FREI/) FREIER S M.
 PA (DOBI/) DOBIE K W.
 XX Freier SM, Dobie KW;
 PI WPI; 2004-282523/26.
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX Example 15; SEQ ID NO 135; 60pp; English.
 XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.
 XX Sequence 20 BP; 3 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3762 TGTCAGCTTCTTGGAAATTG 3781
 Db 1 TGTCAGCTTCTTGGAAATTG 20
 RESULT 235
 ADL34591/c
 ID ADL34591 standard; DNA; 20 BP.
 XX
 AC ADL34591;
 XX 17-JUN-2004 (first entry)
 DT ISIS antisense oligonucleotide ISIS 206983.
 DE antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;

XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124657.
 DE antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytosolic; gene therapy; ds.
 XX Homo sapiens.
 OS
 XX US2004063657-A1.
 PN 01-APR-2004.
 XX 18-SEP-2003; 2003US-00667022.
 XX 31-MAY-2002; 2002US-00160786.
 XX (FREI/) FREIER S M.
 PA (DOBI/) DOBIE K W.
 XX Freier SM, Dobie KW;
 PI WPI; 2004-282523/26.
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX Example 15; SEQ ID NO 139; 60pp; English.
 XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.
 XX Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4166 TGATTGACGCTGTTACGGC 4185
 Db 1 TGATTGACGCTGTTACGGC 20
 RESULT 235
 ADL34591/c
 ID ADL34591 standard; DNA; 20 BP.
 XX
 AC ADL34591;
 XX 17-JUN-2004 (first entry)
 DT ISIS antisense oligonucleotide ISIS 206983.
 DE antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;

phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine; infection; inflammation; tumour formation; hyperproliferative disorder; cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator; cytostatic; gene therapy; ss; primer.

Synthetic.

Key Location/Qualifiers
modified_base 1..20
/tag= a
/mod_base= OTHER
/note= "phosphorothioate backbone"

US2004063657-A1.

01-APR-2004.

18-SEP-2003; 2003US-00667022.

31-MAY-2002; 2002US-00160786.

(FREI/) FREIER S M.
(DOBI/) DOBIE K W.

Freier SM, Dobie KW;
WPI; 2004-282523/26.

New antisense compound targeted to a nucleic acid molecule encoding phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

Example 15; SEQ ID NO 37; 60pp; English.

This invention describes a novel antisense oligonucleotides which specifically hybridises to and inhibits the expression of human phosphoinositide-3-kinase, regulatory subunit 4, p150. The oligonucleotides comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide can be used in diagnostics and as research reagents and kits. It can also be used prophylactically, e.g. to prevent or delay infection, inflammation or tumour formation. It can also be used to treat a disease or condition associated with phosphoinositide-3-kinase, regulatory subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, Chediak-Higashi syndrome or a metabolic disorder. The products of the invention are immunomodulators with cytostatic activity and can be used for gene therapy.

Sequence 20 BP; 9 A; 1 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1513 TTTCTCTGAATATTTTACAC 1532
|||||
Db 20 TTTCTCTGAATATTTTACAC 1

RESULT 236
ADL34594/c
ID ADL34594 standard; DNA; 20 BP.
XX
AC ADL34594;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206986.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;

regulatory subunit 4; p150; internucleoside linkage; phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine; infection; inflammation; tumour formation; hyperproliferative disorder; cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator; cytostatic; gene therapy; ss; primer.

Synthetic.

Key Location/Qualifiers
modified_base 1..20
/tag= a
/mod_base= OTHER
/note= "phosphorothioate backbone"

US2004063657-A1.

01-APR-2004.

18-SEP-2003; 2003US-00667022.

31-MAY-2002; 2002US-00160786.

(FREI/) FREIER S M.
(DOBI/) DOBIE K W.

Freier SM, Dobie KW;
WPI; 2004-282523/26.

New antisense compound targeted to a nucleic acid molecule encoding phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

Example 15; SEQ ID NO 40; 60pp; English.

This invention describes a novel antisense oligonucleotides which specifically hybridises to and inhibits the expression of human phosphoinositide-3-kinase, regulatory subunit 4, p150. The oligonucleotides comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide can be used in diagnostics and as research reagents and kits. It can also be used prophylactically, e.g. to prevent or delay infection, inflammation or tumour formation. It can also be used to treat a disease or condition associated with phosphoinositide-3-kinase, regulatory subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, Chediak-Higashi syndrome or a metabolic disorder. The products of the invention are immunomodulators with cytostatic activity and can be used for gene therapy.

Sequence 20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1658 AAAAAGCCGAGAGAGCCT 1677
|||||
Db 20 AAAAAGCCGAGAGAGCCT 1

RESULT 237
ADL34596/c
ID ADL34596 standard; DNA; 20 BP.
XX
AC ADL34596;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206988.
XX

antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase; regulatory subunit 4; p150; internucleoside linkage; phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine; infection; inflammation; tumour formation; hyperproliferative disorder; cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator; cytosstatic; gene therapy; ss; primer.

Synthetic.

Key Location/Qualifiers
modified_base 1..20
/*tag= a
/mod_base= OTHER
/note= "phosphorothioate backbone"

US2004063657-A1.

01-APR-2004.

18-SEP-2003; 2003US-00667022.

31-MAY-2002; 2002US-00160786.

(PREI/) FREIER S M.
(DOBI/) DOBIE K W.

Freier SM, Dobie KW;
WPI; 2004-282523/26.

New antisense compound targeted to a nucleic acid molecule encoding phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

Example 15; SEQ ID NO 42; 60pp; English.

This invention describes a novel antisense oligonucleotides which specifically hybridises to and inhibits the expression of human phosphoinositide-3-kinase, regulatory subunit 4, p150. The oligonucleotides comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide can be used in diagnostics and as research reagents and kits. It can also be used prophylactically, e.g. to prevent or delay infection, inflammation or tumour formation. It can also be used to treat a disease or condition associated with phosphoinositide-3-kinase, regulatory subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, Chediak-Higashi syndrome or a metabolic disorder. The products of the invention are immunomodulators with cytostatic activity and can be used for gene therapy.

Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1978 GCCCAGATGATGCTACTAT 1997
|||||
Db 20 GCCCAGATGATGCTACTAT 1

RESULT 238
ADL34606/C
ID ADL34606 standard; DNA; 20 BP.
XX
AC ADL34606;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206998.

antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase; regulatory subunit 4; p150; internucleoside linkage; phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine; infection; inflammation; tumour formation; hyperproliferative disorder; cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator; cytosstatic; gene therapy; ss; primer.

Synthetic.

Key Location/Qualifiers
modified_base 1..20
/*tag= a
/mod_base= OTHER
/note= "phosphorothioate backbone"

US2004063657-A1.

01-APR-2004.

18-SEP-2003; 2003US-00667022.

31-MAY-2002; 2002US-00160786.

(PREI/) FREIER S M.
(DOBI/) DOBIE K W.

Freier SM, Dobie KW;
WPI; 2004-282523/26.

New antisense compound targeted to a nucleic acid molecule encoding phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

Example 15; SEQ ID NO 52; 60pp; English.

This invention describes a novel antisense oligonucleotides which specifically hybridises to and inhibits the expression of human phosphoinositide-3-kinase, regulatory subunit 4, p150. The oligonucleotides comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide can be used in diagnostics and as research reagents and kits. It can also be used prophylactically, e.g. to prevent or delay infection, inflammation or tumour formation. It can also be used to treat a disease or condition associated with phosphoinositide-3-kinase, regulatory subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, Chediak-Higashi syndrome or a metabolic disorder. The products of the invention are immunomodulators with cytostatic activity and can be used for gene therapy.

Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2731 GAACCAAGTAAAGTCGTTCTAT 2750
|||||
Db 20 GAACCAAGTAAAGTCGTTCTAT 1

RESULT 239
ADL34611/C
ID ADL34611 standard; DNA; 20 BP.
XX
AC ADL34611;
XX
DT 17-JUN-2004 (first entry)
XX

DE XX ISIS antisense oligonucleotide ISIS 207003.

KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase; regulatory subunit 4; p150; internucleoside linkage;

KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine; infection; inflammation; tumour formation; hyperproliferative disorder;

KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator; cytostatic; gene therapy; ss; primer.

XX Synthetic.

OS

XX Key Location/Qualifiers

FH modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone"

XX

US2004063657-A1.

XX

01-APR-2004.

XX

18-SEP-2003; 2003US-00667022.

XX

31-MAY-2002; 2002US-00160786.

XX

(FREI/) FREIER S M.

PA (DOBI/) DOBIE K W.

XX

Freier SM, Dobie KW;

PI

XX WPI; 2004-282523/26.

DR

XX New antisense compound targeted to a nucleic acid molecule encoding phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

PT

XX Example 15; SEQ ID NO 57; 60pp; English.

PS

XX This invention describes a novel antisense oligonucleotides which specifically hybridises to and inhibits the expression of human phosphoinositide-3-kinase, regulatory subunit 4, p150. The oligonucleotides comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide can be used in diagnostics and as research reagents and kits. It can also be used prophylactically, e.g. to prevent or delay infection, inflammation or tumour formation. It can also be used to treat a disease or condition associated with phosphoinositide-3-kinase, regulatory subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, Chediak-Higashi syndrome or a metabolic disorder. The products of the invention are immunomodulators with cytostatic activity and can be used for gene therapy.

XX

SQ Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3057 AGTTGATCTTGTATAAACCA 3076

DB 20 AGTTGATCTTGTATAAACCA 1

RESULT 240

ADL34622/C

ID ADL34622 standard; DNA; 20 BP.

XX

AC ADL34622;

XX

DT 17-JUN-2004 (first entry)

XX DE ISIS antisense oligonucleotide ISIS 207022.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase; regulatory subunit 4; p150; internucleoside linkage;

KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine; infection; inflammation; tumour formation; hyperproliferative disorder;

KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator; cytostatic; gene therapy; ss; primer.

XX Synthetic.

OS

XX Key Location/Qualifiers

FH modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone"

XX

US2004063657-A1.

XX

01-APR-2004.

XX

18-SEP-2003; 2003US-00667022.

XX

31-MAY-2002; 2002US-00160786.

XX

(FREI/) FREIER S M.

PA (DOBI/) DOBIE K W.

XX

Freier SM, Dobie KW;

PI

XX WPI; 2004-282523/26.

DR

XX New antisense compound targeted to a nucleic acid molecule encoding phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

PT

XX Example 15; SEQ ID NO 68; 60pp; English.

PS

XX This invention describes a novel antisense oligonucleotides which specifically hybridises to and inhibits the expression of human phosphoinositide-3-kinase, regulatory subunit 4, p150. The oligonucleotides comprises at least one modified internucleoside linkage, preferably a phosphorothioate linkage. It also comprises at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The antisense oligonucleotide further comprises at least one modified nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide can be used in diagnostics and as research reagents and kits. It can also be used prophylactically, e.g. to prevent or delay infection, inflammation or tumour formation. It can also be used to treat a disease or condition associated with phosphoinositide-3-kinase, regulatory subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer, Chediak-Higashi syndrome or a metabolic disorder. The products of the invention are immunomodulators with cytostatic activity and can be used for gene therapy.

XX

SQ Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3762 TGTCAGCTTCTTGAATTG 3781

DB 20 TGTCAGCTTCTTGAATTG 1

RESULT 241

ADL34657

ID ADL34657 standard; DNA; 20 BP.

XX

AC ADL34657;

XX

DT 17-JUN-2004 (first entry)
XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124610.
DE
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ds.
XX
XX Homo sapiens.
OS
XX US2004063657-A1.
XX
XX 01-APR-2004.
PD
XX 18-SEP-2003; 2003US-00667022.
PF
XX 31-MAY-2002; 2002US-00160786.
XX
XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
PA
XX Freier SM, Dobie KW;
PI WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 103; 60pp; English.
PS
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1083 CACTTATCTTCCAGAGACA 1102
DB 1 CACTTATCTTCCAGAGACA 20
RESULT 242
ADL34662
ID ADL34662 standard; DNA; 20 BP.
XX
XX AC ADL34662;
AC
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124621.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;

KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ds.
XX
XX Homo sapiens.
OS
XX US2004063657-A1.
XX
XX 01-APR-2004.
PD
XX 18-SEP-2003; 2003US-00667022.
PF
XX 31-MAY-2002; 2002US-00160786.
XX
XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
PA
XX Freier SM, Dobie KW;
PI WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 108; 60pp; English.
PS
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1630 CACAATCTCTGTGGACATGA 1649
DB 1 CACAATCTCTGTGGACATGA 20
RESULT 243
ADL34680
ID ADL34680 standard; DNA; 20 BP.
XX
XX AC ADL34680;
AC
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124640.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ds.

```
XX OS Homo sapiens.
XX FN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-282523/26.
XX OS New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS Example 15; SEQ ID NO 126; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 1 A; 6 C; 5 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 3250 TCTGCTGGCATTGTGTCCC 3269
XX Db 1 TCTGCTGGCATTGTGTCCC 20
XX
XX RESULT 244
XX ADL34691
XX ID ADL34691 standard; DNA; 20 BP.
XX XX
XX AC ADL34691;
XX DT 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124655.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytostatic; gene therapy; ds.
XX OS Homo sapiens.
XX XX US2004063657-A1.
XX PN
```

```
PD 01-APR-2004.
XX 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-282523/26.
XX OS New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS Example 15; SEQ ID NO 137; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 3991 GGCCTCATCATCTTCCTTGC 4010
XX Db 1 GGCCTCATCATCTTCCTTGC 20
XX
XX RESULT 245
XX ADL34588/c
XX ID ADL34588 standard; DNA; 20 BP.
XX XX
XX AC ADL34588;
XX DT 17-JUN-2004 (first entry)
XX DE ISIS antisense oligonucleotide ISIS 206980.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytostatic; gene therapy; ss; primer.
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate backbone"
XX XX US2004063657-A1.
XX PN
```

```

XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX PI WPI; 2004-282523/26.
XX DR
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS Example 15; SEQ ID NO 34; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1414 GATCACAGTATCAGAGAATT 1433
Db 20 GATCACAGTATCAGAGAATT 1
RESULT 246
ADL34639/C
ID ADL34639 standard; DNA; 20 BP.
XX AC ADL34639;
XX DT 17-JUN-2004 (first entry)
XX DE ISIS antisense oligonucleotide ISIS 207039.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytostatic; gene therapy; ss; primer.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate backbone"
XX

```

```

PN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX PI WPI; 2004-282523/26.
XX DR
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS Example 15; SEQ ID NO 85; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4761 CTGTTTCATGACTGACTGAC 4780
Db 20 CTGTTTCATGACTGACTGAC 1
RESULT 247
ADL34643
ID ADL34643 standard; DNA; 20 BP.
XX AC ADL34643;
XX DT 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124593.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytostatic; gene therapy; ds.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate backbone"
XX

```

```

XX PR 31-MAY-2002; 2003US-00160786.
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX FI Freier SM, Dobie KW;
XX DR WPI; 2004-282523/26.
XX PS
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS
XX PS Example 15; SEQ ID NO 89; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CGTTTCTGGGGCTGCAGCA 62
DB 1 CGTTTCTGGGGCTGCAGCA 20

RESULT 248
ADL34646
ID ADL34646 standard; DNA; 20 BP.
XX AC ADL34646;
XX DT 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124597.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytostatic; gene therapy; ds.
XX OS Homo sapiens.
XX PN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.

```

```

XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-282523/26.
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX PS
XX PS Example 15; SEQ ID NO 92; 60pp; English.
XX CC This invention describes a novel antisense oligonucleotides which
XX CC specifically hybridises to and inhibits the expression of human
XX CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX CC oligonucleotides comprises at least one modified internucleoside linkage,
XX CC preferably a phosphorothioate linkage. It also comprises at least one
XX CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX CC antisense oligonucleotide further comprises at least one modified
XX CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX CC can be used in diagnostics and as research reagents and kits. It can also
XX CC be used prophylactically, e.g. to prevent or delay infection,
XX CC inflammation or tumour formation. It can also be used to treat a disease
XX CC or condition associated with phosphoinositide-3-kinase, regulatory
XX CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX CC invention are immunomodulators with cytostatic activity and can be used
XX CC for gene therapy.
XX SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CCTCTGAACGATTTGACAC 505
DB 1 CCTCTGAACGATTTGACAC 20

RESULT 249
ADL34695
ID ADL34695 standard; DNA; 20 BP.
XX AC ADL34695;
XX DT 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124663.
XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX KW regulatory subunit 4; p150; internucleoside linkage;
XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX KW cytostatic; gene therapy; ds.
XX OS Homo sapiens.
XX PN US2004063657-A1.
XX PD 01-APR-2004.
XX PF 18-SEP-2003; 2003US-00667022.
XX PR 31-MAY-2002; 2002US-00160786.
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX PI Freier SM, Dobie KW;
XX DR WPI; 2004-282523/26.

```

PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX
XX Example 15; SEQ ID NO 141; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4397 ATGTTGTTGCAGGAGTACT 4416
DB 1 ATGTTGTTGCAGGAGTACT 20
RESULT 250
ADL34697
ID ADL34697 standard; DNA; 20 BP.
XX
AC ADL34697;
XX
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124666.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 143; 60pp; English.

XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 8 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4633 GTGTGGAATAAAACCTACT 4652
DB 1 GTGTGGAATAAAACCTACT 20
RESULT 251
ADL34590/c
ID ADL34590 standard; DNA; 20 BP.
XX
AC ADL34590;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206982.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20 /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX

XX Example 15; SEQ ID NO 73; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which

CC specifically hybridises to and inhibits the expression of human

CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The

CC oligonucleotides comprises at least one modified internucleoside linkage,

CC preferably a phosphorothioate linkage. It also comprises at least one

CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The

CC antisense oligonucleotide further comprises at least one modified

CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide

CC can be used in diagnostics and as research reagents and kits. It can also

CC be used prophylactically, e.g. to prevent or delay infection,

CC inflammation or tumour formation. It can also be used to treat a disease

CC or condition associated with phosphoinositide-3-kinase, regulatory

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,

CC Chediak-Higashi syndrome or a metabolic disorder. The products of the

CC invention are immunomodulators with cytostatic activity and can be used

CC for gene therapy.

XX Sequence 20 BP; 7 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

SQ

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3991 GGCCTCATCTTCCTTC 4010

Db 20 GGCCTCATCTTCCTTC 1

RESULT 253

ADL34628/c

ID ADL34628 standard; DNA; 20 BP.

XX

AC ADL34628;

XX

DT 17-JUN-2004 (first entry)

XX

DE ISIS antisense oligonucleotide ISIS 207028.

XX

KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;

KW regulatory subunit 4; p150; internucleoside linkage;

KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;

KW infection; inflammation; tumour formation; hyperproliferative disorder;

KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;

KW cytostatic; gene therapy; ss; primer.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone"

XX

PN US2004063657-A1.

XX

PD 01-APR-2004.

XX

PF 18-SEP-2003; 2003US-00667022.

XX

PR 31-MAY-2002; 2002US-00160786.

XX

PA (FREI/) FREIER S M.

PA (DOBI/) DOBIE K W.

XX

PI Freier SM, Dobie KW;

XX

DR WPI; 2004-282523/26.

XX

PT New antisense compound targeted to a nucleic acid molecule encoding

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

PS Example 15; SEQ ID NO 36; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which

CC specifically hybridises to and inhibits the expression of human

CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The

CC oligonucleotides comprises at least one modified internucleoside linkage,

CC preferably a phosphorothioate linkage. It also comprises at least one

CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The

CC antisense oligonucleotide further comprises at least one modified

CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide

CC can be used in diagnostics and as research reagents and kits. It can also

CC be used prophylactically, e.g. to prevent or delay infection,

CC inflammation or tumour formation. It can also be used to treat a disease

CC or condition associated with phosphoinositide-3-kinase, regulatory

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,

CC Chediak-Higashi syndrome or a metabolic disorder. The products of the

CC invention are immunomodulators with cytostatic activity and can be used

CC for gene therapy.

XX Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

SQ

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1498 CAGCGTGGCAATGCTTCC 1517

Db 20 CAGCGTGGCAATGCTTCC 1

RESULT 252

ADL34627/c

ID ADL34627 standard; DNA; 20 BP.

XX

AC ADL34627;

XX

DT 17-JUN-2004 (first entry)

XX

DE ISIS antisense oligonucleotide ISIS 207027.

XX

KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;

KW regulatory subunit 4; p150; internucleoside linkage;

KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;

KW infection; inflammation; tumour formation; hyperproliferative disorder;

KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;

KW cytostatic; gene therapy; ss; primer.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone"

XX

PN US2004063657-A1.

XX

PD 01-APR-2004.

XX

PF 18-SEP-2003; 2003US-00667022.

XX

PR 31-MAY-2002; 2002US-00160786.

XX

PA (FREI/) FREIER S M.

PA (DOBI/) DOBIE K W.

XX

PI Freier SM, Dobie KW;

XX

DR WPI; 2004-282523/26.

XX

PT New antisense compound targeted to a nucleic acid molecule encoding

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
PS Example 15; SEQ ID NO 74; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4050 CAGTGGTACCACGCTTGTT 4069
|||||
DB 20 CAGTGGTACCACGCTTGTT 1
RESULT 254
ADL34635/c
ID ADL34635 standard; DNA; 20 BP.
XX
AC ADL34635;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 207035.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX PD 01-APR-2004.
XX
XX PF 18-SEP-2003; 2003US-00667022.
XX
XX PR 31-MAY-2002; 2002US-00160786.
XX
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX
XX PI Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding

PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
PS Example 15; SEQ ID NO 81; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4397 ATGTTGTTGCAGGAAGTACT 4416
|||||
DB 20 ATGTTGTTGCAGGAAGTACT 1
RESULT 255
ADL34650
ID ADL34650 standard; DNA; 20 BP.
XX
AC ADL34650;
XX
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124603.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
XX US2004063657-A1.
XX
XX PD 01-APR-2004.
XX
XX PF 18-SEP-2003; 2003US-00667022.
XX
XX PR 31-MAY-2002; 2002US-00160786.
XX
XX PA (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX
XX PI Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 96; 60pp; English.

CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 8 A; 3 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 780 GGAGGAAGTGAATCAGGC 799
DB 1 GGAGGAAGTGAATCAGGC 20
|||||

RESULT 256
ADL34667
ID ADL34667 standard; DNA; 20 BP.
XX AC ADL34667;
XX 17-JUN-2004 (first entry)
DT Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124627.
DE
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX Homo sapiens.
OS
XX US2004063657-A1.
PN
XX 01-APR-2004.
PD
XX 18-SEP-2003; 2003US-00667022.
PF
XX 31-MAY-2002; 2002US-00160786.
PR
XX (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX Freier SM, Dobie KW;
PI
XX WPI; 2004-282523/26.
DR
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 113; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 8 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2080 CTTAATATGGAATGACCC 2099
DB 1 CTTAATATGGAATGACCC 20
|||||

RESULT 257
ADL34573/C
ID ADL34573 standard; DNA; 20 BP.
XX AC ADL34573;
XX 17-JUN-2004 (first entry)
DT
XX ISIS antisense oligonucleotide ISIS 206965.
DE
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX Synthetic.
OS
XX Key Location/Qualifiers
FT modified_base 1..20 /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
PN
XX 01-APR-2004.
PD
XX 18-SEP-2003; 2003US-00667022.
PF
XX 31-MAY-2002; 2002US-00160786.
PR
XX (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX Freier SM, Dobie KW;
PI
XX WPI; 2004-282523/26.
DR
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 19; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX Sequence 20 BP; 5 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 703 CGAGAAGCCCTGGTCGTTGT 722
 |||||
 Db 20 CGAGAAGCCCTGGTCGTTGT 1

RESULT 258

ADL34581/C
 ID ADL34581 standard; DNA; 20 BP.

XX AC ADL34581;

XX DT 17-JUN-2004 (first entry)

XX DE ISIS antisense oligonucleotide ISIS 206973.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.

XX OS Synthetic.

Key	Location/Qualifiers
modified_base	1..20
/*tag=	a
/mod_base=	OTHER
/note=	"phosphorothioate backbone"

XX US2004063657-A1.

XX PN 01-APR-2004.

XX PD 18-SEP-2003; 2003US-00667022.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR (FREI/) FREIER S M.

XX PA (DOBI/) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 27; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The

CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX SQ Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1032 GGTCAACAGTTGGAATTGG 1051
 |||||
 Db 20 GGTCAACAGTTGGAATTGG 1

RESULT 259

ADL34612/C
 ID ADL34612 standard; DNA; 20 BP.

XX AC ADL34612;

XX DT 17-JUN-2004 (first entry)

XX DE ISIS antisense oligonucleotide ISIS 207004.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.

XX OS Synthetic.

Key	Location/Qualifiers
modified_base	1..20
/*tag=	a
/mod_base=	OTHER
/note=	"phosphorothioate backbone"

XX US2004063657-A1.

XX PN 01-APR-2004.

XX PD 18-SEP-2003; 2003US-00667022.

XX PF 31-MAY-2002; 2002US-00160786.

XX PR (FREI/) FREIER S M.

XX PA (DOBI/) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 58; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human

CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 8 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3250 TCTGCTGGCATTGTGTCCC 3269
DB 20 TCTGCTGGCATTGTGTCCC 1
|||||

RESULT 260
ADL34644
ID ADL34644 standard; DNA; 20 BP.
AC ADL34644;
XX
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124594.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX US2004063657-A1.
XX 01-APR-2004.
XX 18-SEP-2003; 2003US-00667022.
XX 31-MAY-2002; 2002US-00160786.
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 90; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.

CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 1 A; 9 C; 4 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 CGGCTGCACTTCTCTCCCG 111
DB 1 CGGCTGCACTTCTCTCCCG 20
|||||

RESULT 261
ADL34658
ID ADL34658 standard; DNA; 20 BP.
AC ADL34658;
XX
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124613.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX US2004063657-A1.
XX 01-APR-2004.
XX 18-SEP-2003; 2003US-00667022.
XX 31-MAY-2002; 2002US-00160786.
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 104; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

SQ Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1268 AGTTGAAGAGCAATGGAC 1287
 |||||
 Db 1 AGTTGAAGAGCAATGGAC 20

RESULT 262
 ADL34674
 ID ADL34674 standard; DNA; 20 BP.
 XX AC ADL34674;
 XX DT 17-JUN-2004 (first entry)
 XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124634.
 XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 XX KW regulatory subunit 4; p150; internucleoside linkage;
 XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
 XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 XX KW cytosstatic; gene therapy; ds.
 XX OS Homo sapiens.
 XX US2004063657-A1.
 XX 01-APR-2004.
 XX 18-SEP-2003; 2003US-00667022.
 XX 31-MAY-2002; 2002US-00160786.
 XX (FREI/) FREIER S M.
 XX (DOBI/) DOBIE K W.
 XX Freier SM, Dobie KW;
 XX WPI; 2004-282523/26.
 XX New antisense compound targeted to a nucleic acid molecule encoding
 XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX Example 15; SEQ ID NO 120; 60pp; English.

CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2731 GAACCACTAGCTCTTCTAT 2750
 |||||
 Db 1 GAACCACTAGCTCTTCTAT 20

RESULT 263
 ADL34568/C
 ID ADL34568 standard; DNA; 20 BP.
 XX AC ADL34568;
 XX DT 17-JUN-2004 (first entry)
 XX DE ISIS antisense oligonucleotide ISIS 206960.
 XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 XX KW regulatory subunit 4; p150; internucleoside linkage;
 XX KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 XX KW infection; inflammation; tumour formation; hyperproliferative disorder;
 XX KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 XX KW cytosstatic; gene therapy; ss; primer.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 XX FT modified_base 1..20
 XX FT /*tag= a
 XX FT /mod_base= OTHER
 XX FT /note= "phosphorothioate backbone"
 XX US2004063657-A1.
 XX 01-APR-2004.
 XX 18-SEP-2003; 2003US-00667022.
 XX 31-MAY-2002; 2002US-00160786.
 XX (FREI/) FREIER S M.
 XX (DOBI/) DOBIE K W.
 XX Freier SM, Dobie KW;
 XX WPI; 2004-282523/26.
 XX New antisense compound targeted to a nucleic acid molecule encoding
 XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX Example 15; SEQ ID NO 14; 60pp; English.

CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

```
XX
SQ Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 CTATGAGAGAGACCCCTTCG 410
Db 20 CTATGAGAGAGACCCCTTCG 1

RESULT 264
ADL34569/c
ID ADL34569 standard; DNA; 20 BP.
XX
AC ADL34569;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206961.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
WP1; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 15; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
```

```
CC for gene therapy.
XX
SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CCTCTGACGAGTTTGACAC 505
Db 20 CCTCTGACGAGTTTGACAC 1

RESULT 265
ADL34570/c
ID ADL34570 standard; DNA; 20 BP.
XX
AC ADL34570;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206962.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
WP1; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 16; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
```

CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 3 A; 2 C; 6 G; 9 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 534 AACCTTACTAAGACCACAG 553
|||||
Db 20 AACCTTACTAAGACCACAG 1
RESULT 266
ADL34579/c
ID ADL34579 standard; DNA; 20 BP.
XX
AC ADL34579;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206971.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 25; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,

CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 982 GCACAAATCTGGAGTTTCG 1001
|||||
Db 20 GCACAAATCTGGAGTTTCG 1
RESULT 267
ADL34582/c
ID ADL34582 standard; DNA; 20 BP.
XX
AC ADL34582;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206974.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 28; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,

CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX
SQ Sequence 20 BP; 9 A; 1 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1337 CATTATTGATCTCTCTCAA 1356
| | | | | | | | | | | | | | | | | |
DB 20 CATTATTGATCTCTCTCAA 1

RESULT 269
ADL34609/c
ID ADL34609 standard; DNA; 20 BP.
XX
AC ADL34609;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 207001.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 55; 60pp; English.

XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX
SQ Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 CACTTATCTTCAGAGACA 1102
| | | | | | | | | | | | | | | | | |
DB 20 CACTTATCTTCAGAGACA 1

RESULT 268
ADL34587/c
ID ADL34587 standard; DNA; 20 BP.
XX
AC ADL34587;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206979.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 33; 60pp; English.

XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease

CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX
 SQ Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2913 AGAGGAAGACAAACTTCTGG 2932
 |||||
 DB 20 AGAGGAAGACAAACTTCTGG 1

RESULT 270
 ADL34615/C
 ID ADL34615 standard; DNA; 20 BP.
 XX
 AC ADL34615;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE ISIS antisense oligonucleotide ISIS 207007.
 XX
 KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.
 XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 XX
 PN US2004063657-A1.
 XX
 PD 01-APR-2004.
 XX
 PF 18-SEP-2003; 2003US-00667022.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (FREI/) FREIER S M.
 PA (DOBI/) DOBIE K W.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-282523/26.
 XX
 PT New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX
 PS Example 15; SEQ ID NO 61; 60pp; English.

XX
 CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also

CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX
 SQ Sequence 20 BP; 4 A; 2 C; 5 G; 9 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3388 AAAAAGTGAACCTTCAGCAACT 3407
 |||||
 DB 20 AAAAAGTGAACCTTCAGCAACT 1

RESULT 271
 ADL34619/C
 ID ADL34619 standard; DNA; 20 BP.
 XX
 AC ADL34619;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE ISIS antisense oligonucleotide ISIS 207011.
 XX
 KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.
 XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 XX
 PN US2004063657-A1.
 XX
 PD 01-APR-2004.
 XX
 PF 18-SEP-2003; 2003US-00667022.
 XX
 PR 31-MAY-2002; 2002US-00160786.
 XX
 PA (FREI/) FREIER S M.
 PA (DOBI/) DOBIE K W.
 XX
 PI Freier SM, Dobie KW;
 XX
 DR WPI; 2004-282523/26.
 XX
 PT New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX
 PS Example 15; SEQ ID NO 65; 60pp; English.

XX
 CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide

CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX Sequence 20 BP; 6 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3523 GTTGCCCATCTTCATGAGCA 3542

Db 20 GTTGCCCATCTTCATGAGCA 1

RESULT 272

ADL34641/C

ID ADL34641 standard; DNA; 20 BP.

AC ADL34641;

XX 17-JUN-2004 (first entry)

XX ISIS antisense oligonucleotide ISIS 207041.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone"

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (FREI/) FREIER S M.

XX (DOBI/) DOBIE K W.

XX Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 87; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified

CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX Sequence 20 BP; 6 A; 4 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. NO. 1.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4792 CAAAATGGTTAAGATGTACT 4811

Db 20 CAAAATGGTTAAGATGTACT 1

RESULT 273

ADL34648

ID ADL34648 standard; DNA; 20 BP.

XX AC ADL34648;

XX 17-JUN-2004 (first entry)

XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124599.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.

XX Homo sapiens.

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (FREI/) FREIER S M.

XX (DOBI/) DOBIE K W.

XX Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 94; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory

CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 559 CTTGCCATTATGGGAATCA 578
Db 1 CTTGCCATTATGGGAATCA 20
|||||

RESULT 274
ADL34673
ID ADL34673 standard; DNA; 20 BP.
XX
AC ADL34673;
DT 17-JUN-2004 (first entry)
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124633.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
PI Freier SM, Dobie KW;
XX
XX WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 119; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

SQ Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2587 GGTGCCGTGGGATTATCAC 2606
Db 1 GGTGCCGTGGGATTATCAC 20
|||||

RESULT 275
ADL34685
ID ADL34685 standard; DNA; 20 BP.
XX
AC ADL34685;
DT 17-JUN-2004 (first entry)
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124645.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
PI Freier SM, Dobie KW;
XX
XX WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 131; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 9 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3455 AGATGATGGAATAATGCTGAA 3474
|||||
Db 1 AGATGATGGAATAATGCTGAA 20

RESULT 276
ADL34567/C
ID ADL34567 standard; DNA; 20 BP.

XX AC ADL34567;

XX DT 17-JUN-2004 (first entry)

XX DE ISIS antisense oligonucleotide ISIS 206959.

XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"

XX PN US2004063657-A1.

XX PD 01-APR-2004.

XX PF 18-SEP-2003; 2003US-00667022.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (FREI/) FREIER S M.

XX PA (DOBI/) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-282523/26.

XX PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX PS Example 15; SEQ ID NO 13; 60pp; English.

XX CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;

QY 377 AGCCCATCTCCTGCTATGA 396
|||||
Db 20 AGCCCATCTCCTGCTATGA 1

ADL34574/C
ID ADL34574 standard; DNA; 20 BP.

XX AC ADL34574;

XX DT 17-JUN-2004 (first entry)

XX DE ISIS antisense oligonucleotide ISIS 206966.

XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"

XX PN US2004063657-A1.

XX PD 01-APR-2004.

XX PF 18-SEP-2003; 2003US-00667022.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (FREI/) FREIER S M.

XX PA (DOBI/) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-282523/26.

XX PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX PS Example 15; SEQ ID NO 20; 60pp; English.

XX CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX SQ Sequence 20 BP; 8 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;

```
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 726 GGTTTTCGCAATTCAGGATC 745
    |||||
Db 20 GGTTTTCGCAATTCAGGATC 1

RESULT 278
ADL34584/C
ID ADL34584 standard; DNA; 20 BP.
AC ADL34584;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206976.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 30; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1215 AGATCCTTCAACTCCGCTTG 1234
    |||||
Db 20 AGATCCTTCAACTCCGCTTG 1

RESULT 279
ADL34632/C
ID ADL34632 standard; DNA; 20 BP.
XX
AC ADL34632;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 207032.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 78; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 U; 0 Other;
```

Query Match		0.4%;	Score 20;	DB 1;	Length 20;
Best Local Similarity		100.0%;	Pred. No. 1.4e+02;		
Matches		20;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
QY	4292	TCCATGGTATCTACTGTAGT	4311		
DB	20	TCCATGGTATCTACTGTAGT	1		
RESULT 280					
ID	ADL34672				
XX	ADL34672 standard; DNA; 20 BP.				
AC	ADL34672;				
XX	17-JUN-2004 (first entry)				
DT	Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124632.				
DE	antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;				
KW	regulatory subunit 4; p150; internucleoside linkage;				
KW	phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;				
KW	infection; inflammation; tumour formation; hyperproliferative disorder;				
KW	cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;				
KW	cytostatic; gene therapy; ds.				
XX	Homo sapiens.				
OS	US2004063657-A1.				
XX	01-APR-2004.				
PN	18-SEP-2003; 2003US-00667022.				
XX	01-APR-2004.				
PD	31-MAY-2002; 2002US-00160786.				
XX	(FREI/) FREIER S M.				
PA	(DOBI/) DOBIE K W.				
XX	Freier SM, Dobie KW;				
PI	WPI; 2004-282523/26.				
XX	New antisense compound targeted to a nucleic acid molecule encoding				
XX	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for				
PT	treating cancer, Chediak-Higashi syndrome or a metabolic disorder.				
XX	Example 15; SEQ ID NO 118; 60pp; English.				
PS	This invention describes a novel antisense oligonucleotides which				
XX	specifically hybridises to and inhibits the expression of human				
CC	phosphoinositide-3-kinase, regulatory subunit 4, p150. The				
CC	oligonucleotides comprises at least one modified internucleoside linkage,				
CC	preferably a phosphorothioate linkage. It also comprises at least one				
CC	modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The				
CC	antisense oligonucleotide further comprises at least one modified				
CC	nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide				
CC	can be used in diagnostics and as research reagents and kits. It can also				
CC	be used prophylactically, e.g. to prevent or delay infection,				
CC	inflammation or tumour formation. It can also be used to treat a disease				
CC	or condition associated with phosphoinositide-3-kinase, regulatory				
CC	subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,				
CC	Chediak-Higashi syndrome or a metabolic disorder. The products of the				
CC	invention are immunomodulators with cytostatic activity and can be used				
CC	for gene therapy.				
XX	Sequence 20 BP; 4 A; 6 C; 2 G; 8 T; 0 U; 0 Other;				
SQ	Query Match	0.4%;	Score 20;	DB 1;	Length 20;
Best Local Similarity		100.0%;	Pred. No. 1.4e+02;		
Matches		20;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Query Match					
Best Local Similarity		100.0%;	Pred. No. 1.4e+02;		
Matches		20;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
QY	2555	TCCTGTGTCATCCCAATTTA	2574		
DB	1	TCCTGTGTCATCCCAATTTA	20		
RESULT 281					
ID	ADL34679				
XX	ADL34679 standard; DNA; 20 BP.				
AC	ADL34679;				
XX	17-JUN-2004 (first entry)				
DT	Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124639.				
DE	antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;				
KW	regulatory subunit 4; p150; internucleoside linkage;				
KW	phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;				
KW	infection; inflammation; tumour formation; hyperproliferative disorder;				
KW	cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;				
KW	cytostatic; gene therapy; ds.				
XX	Homo sapiens.				
OS	US2004063657-A1.				
XX	01-APR-2004.				
PN	18-SEP-2003; 2003US-00667022.				
XX	31-MAY-2002; 2002US-00160786.				
XX	(FREI/) FREIER S M.				
PA	(DOBI/) DOBIE K W.				
XX	Freier SM, Dobie KW;				
PI	WPI; 2004-282523/26.				
XX	New antisense compound targeted to a nucleic acid molecule encoding				
XX	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for				
PT	treating cancer, Chediak-Higashi syndrome or a metabolic disorder.				
XX	Example 15; SEQ ID NO 125; 60pp; English.				
PS	This invention describes a novel antisense oligonucleotides which				
XX	specifically hybridises to and inhibits the expression of human				
CC	phosphoinositide-3-kinase, regulatory subunit 4, p150. The				
CC	oligonucleotides comprises at least one modified internucleoside linkage,				
CC	preferably a phosphorothioate linkage. It also comprises at least one				
CC	modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The				
CC	antisense oligonucleotide further comprises at least one modified				
CC	nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide				
CC	can be used in diagnostics and as research reagents and kits. It can also				
CC	be used prophylactically, e.g. to prevent or delay infection,				
CC	inflammation or tumour formation. It can also be used to treat a disease				
CC	or condition associated with phosphoinositide-3-kinase, regulatory				
CC	subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,				
CC	Chediak-Higashi syndrome or a metabolic disorder. The products of the				
CC	invention are immunomodulators with cytostatic activity and can be used				
CC	for gene therapy.				
XX	Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;				
SQ	Query Match	0.4%;	Score 20;	DB 1;	Length 20;
Best Local Similarity		100.0%;	Pred. No. 1.4e+02;		
Matches		20;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;

```
RESULT 282
ADL34688
ID ADL34688 standard; DNA; 20 BP.
XX AC ADL34688;
XX
XX
XX 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124649.
XX
XX antisenase; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytosstatic; gene therapy; ds.
XX
XX Homo sapiens.
XX OS
XX US2004063657-A1.
XX PN
XX 01-APR-2004.
XX PD
XX 18-SEP-2003; 2003US-00667022.
XX PF
XX 31-MAY-2002; 2002US-00160786.
XX PR
XX (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX PI WPI; 2004-282523/26.
XX DR
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 134; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 4 A; 5 C; 2 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 3583 TCACCTTTTTCACATGTTTC 3602
XX 1 TCACCTTTTTCACATGTTTC 20
XX
XX RESULT 283
ADL34696
ID ADL34696 standard; DNA; 20 BP.
XX AC ADL34696;
XX
XX 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124670.
XX
XX antisenase; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytosstatic; gene therapy; ds.
XX
XX Homo sapiens.
XX OS
XX US2004063657-A1.
XX PN
XX 01-APR-2004.
XX PD
XX 18-SEP-2003; 2003US-00667022.
XX PF
XX 31-MAY-2002; 2002US-00160786.
XX PR
XX (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX PI WPI; 2004-282523/26.
XX DR
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 142; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 4424 CATCTGTGTCCTACTACAGG 4443
XX 1 CATCTGTGTCCTACTACAGG 20
XX
XX RESULT 284
ADL34701
ID ADL34701 standard; DNA; 20 BP.
XX AC ADL34701;
XX
XX 17-JUN-2004 (first entry)
XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124670.
XX AC ADL34696;
```

antisenase; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 regulatory subunit 4; p150; internucleoside linkage;
 phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 infection; inflammation; tumour formation; hyperproliferative disorder;
 cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 cystostatic; gene therapy; ds.
 Homo sapiens.
 US2004063657-A1.
 01-APR-2004.
 18-SEP-2003; 2003US-00667022.
 31-MAY-2002; 2002US-00160786.
 (FREI/) FREIER S M.
 (DOBI/) DOBIE K W.
 Freier SM, Dobie KW;
 WPI; 2004-282523/26.
 New antisenase compound targeted to a nucleic acid molecule encoding
 phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 Example 15; SEQ ID NO 147; 60pp; English.
 This invention describes a novel antisenase oligonucleotides which
 specifically hybridises to and inhibits the expression of human
 phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 oligonucleotides comprises at least one modified internucleoside linkage,
 preferably a phosphorothioate linkage. It also comprises at least one
 modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 antisenase oligonucleotide further comprises at least one modified
 nucleobase, preferably a 5-methylcytosine. The antisenase oligonucleotide
 can be used in diagnostics and as research reagents and kits. It can also
 be used prophylactically, e.g. to prevent or delay infection,
 inflammation or tumour formation. It can also be used to treat a disease
 or condition associated with phosphoinositide-3-kinase, regulatory
 subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 Chediak-Higashi syndrome or a metabolic disorder. The products of the
 invention are immunomodulators with cytostatic activity and can be used
 for gene therapy.

Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4823 CTTATGCATCTCTTTGCAAG 4842
 |||||
 Db 1 CTTATGCATCTCTTTGCAAG 20

RESULT 285
 ADL34572/c
 ID ADL34572 standard; DNA; 20 BP.
 AC ADL34572;
 XX
 XX 17-JUN-2004 (first entry)
 DT
 DE ISIS antisenase oligonucleotide ISIS 206964.
 XX
 XX antisenase; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 regulatory subunit 4; p150; internucleoside linkage;
 phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 infection; inflammation; tumour formation; hyperproliferative disorder;
 cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;

cystostatic; gene therapy; ss; primer.
 Synthetic.
 Key Location/Qualifiers
 modified_base 1..20
 /*tag= a
 /mod_base= OTHER
 /note= "phosphorothioate backbone"
 US2004063657-A1.
 01-APR-2004.
 18-SEP-2003; 2003US-00667022.
 31-MAY-2002; 2002US-00160786.
 (FREI/) FREIER S M.
 (DOBI/) DOBIE K W.
 Freier SM, Dobie KW;
 WPI; 2004-282523/26.
 New antisenase compound targeted to a nucleic acid molecule encoding
 phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 Example 15; SEQ ID NO 18; 60pp; English.
 This invention describes a novel antisenase oligonucleotides which
 specifically hybridises to and inhibits the expression of human
 phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 oligonucleotides comprises at least one modified internucleoside linkage,
 preferably a phosphorothioate linkage. It also comprises at least one
 modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 antisenase oligonucleotide further comprises at least one modified
 nucleobase, preferably a 5-methylcytosine. The antisenase oligonucleotide
 can be used in diagnostics and as research reagents and kits. It can also
 be used prophylactically, e.g. to prevent or delay infection,
 inflammation or tumour formation. It can also be used to treat a disease
 or condition associated with phosphoinositide-3-kinase, regulatory
 subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 Chediak-Higashi syndrome or a metabolic disorder. The products of the
 invention are immunomodulators with cytostatic activity and can be used
 for gene therapy.

Sequence 20 BP; 8 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 GATATTTCATGACTTTGTAATA 650
 |||||
 Db 20 GATATTTCATGACTTTGTAATA 1

RESULT 286
 ADL34575/c
 ID ADL34575 standard; DNA; 20 BP.
 XX
 AC ADL34575;
 XX
 XX 17-JUN-2004 (first entry)
 DT
 DE ISIS antisenase oligonucleotide ISIS 206967.
 XX
 XX antisenase; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 regulatory subunit 4; p150; internucleoside linkage;
 phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 infection; inflammation; tumour formation; hyperproliferative disorder;

KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytosatic; gene therapy; ss; primer.
 XX
 XX Synthetic.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 XX
 XX US2004063657-A1.
 XX
 XX 01-APR-2004.
 XX
 XX 18-SEP-2003; 2003US-00667022.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX (FREI/) FREIER S M.
 XX (DOBI/) DOBIE K W.
 XX
 XX Freier SM, Dobie KW;
 XX WPI; 2004-282523/26.
 XX
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX
 XX Example 15; SEQ ID NO 21; 60pp; English.
 XX
 CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 780 GGAGGAACCTGAAATCAGGC 799
 Db 20 GGAGGAACCTGAAATCAGGC 1
 RESULT 287
 ID ADL34604/c
 XX ADL34604 standard; DNA; 20 BP.
 XX
 XX ADL34604;
 XX
 XX 17-JUN-2004 (first entry)
 DT
 XX
 DE ISIS antisense oligonucleotide ISIS 206996.
 XX
 KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;

KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytosatic; gene therapy; ss; primer.
 XX
 XX Synthetic.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 XX
 XX US2004063657-A1.
 XX
 XX 01-APR-2004.
 XX
 XX 18-SEP-2003; 2003US-00667022.
 XX
 XX 31-MAY-2002; 2002US-00160786.
 XX
 XX (FREI/) FREIER S M.
 XX (DOBI/) DOBIE K W.
 XX
 XX Freier SM, Dobie KW;
 XX WPI; 2004-282523/26.
 XX
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
 XX
 XX Example 15; SEQ ID NO 50; 60pp; English.
 XX
 CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.
 XX
 SQ Sequence 20 BP; 8 A; 2 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2555 TCCTGTGTCTATCCCAATTTA 2574
 Db 20 TCCTGTGTCTATCCCAATTTA 1
 RESULT 288
 ID ADL34625/c
 XX ADL34625 standard; DNA; 20 BP.
 XX
 XX ADL34625;
 XX
 XX 17-JUN-2004 (first entry)
 DT
 XX
 DE ISIS antisense oligonucleotide ISIS 207025.
 XX
 KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;

KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosolic; gene therapy; ss; primer.
XX Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
XX
PN US2004063657-A1.
XX
XX
PD 01-APR-2004.
XX
XX
PF 18-SEP-2003; 2003US-00667022.
XX
XX
PR 31-MAY-2002; 2002US-00160786.
XX
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
XX
PI Freier SM, Dobie KW;
XX
XX
DR WPI; 2004-282523/26.
XX
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX
PS Example 15; SEQ ID NO 71; 60pp; English.
XX
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3927 TCTGGTTGGCTGGACCTTA 3946
DB 20 TCTGGTTGGCTGGACCTTA 1

RESULT 289
ADL34634/C
ID ADL34634 standard; DNA; 20 BP.
XX
XX
AC ADL34634;
XX
XX
DT 17-JUN-2004 (first entry)
XX
XX
DE ISIS antisense oligonucleotide ISIS 207034.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;

KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosolic; gene therapy; ss; primer.
XX Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
XX
PN US2004063657-A1.
XX
XX
PD 01-APR-2004.
XX
XX
PF 18-SEP-2003; 2003US-00667022.
XX
XX
PR 31-MAY-2002; 2002US-00160786.
XX
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
XX
PI Freier SM, Dobie KW;
XX
XX
DR WPI; 2004-282523/26.
XX
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX
PS Example 15; SEQ ID NO 80; 60pp; English.
XX
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 6 A; 6 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4355 TGAAATAAGGTTTGGGAC 4374
DB 20 TGAAATAAGGTTTGGGAC 1

RESULT 290
ADL34653
ID ADL34653 standard; DNA; 20 BP.
XX
XX
AC ADL34653;
XX
XX
DT 17-JUN-2004 (first entry)
XX
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124606.
XX

KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ds.
XX
OS Homo sapiens.
FN US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 99; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 914 CCCGTCATTCTTGAATAAC 933
Db 1 CCCGTCATTCTTGAATAAC 20
RESULT 291
ADL34670
ID ADL34670 standard; DNA; 20 BP.
XX
XX ADL34670;
XX
XX 17-JUN-2004 (first entry)
XX
XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124630.
DE
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW

KW cytosstatic; gene therapy; ds.
XX
XX Homo sapiens.
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (PREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 116; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 5 A; 1 C; 6 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2438 TTAGTGATGCTGAGGAATTT 2457
Db 1 TTAGTGATGCTGAGGAATTT 20
RESULT 292
ADL34678
ID ADL34678 standard; DNA; 20 BP.
XX
XX ADL34678;
XX
XX 17-JUN-2004 (first entry)
XX
XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124638.
DE
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytosstatic; gene therapy; ds.
XX
XX Homo sapiens.
XX
XX US2004063657-A1.

31-MAY-2002; 2002US-00160786.
(PREI/) FREIER S M.
(DOBI/) DOBIE K W.
Freier SM, Dobie KW;
WPI; 2004-282523/26.
New antisense compound targeted to a nucleic acid molecule encoding
phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
Example 15; SEQ ID NO 144; 60pp; English.
This invention describes a novel antisense oligonucleotides which
specifically hybridises to and inhibits the expression of human
phosphoinositide-3-kinase, regulatory subunit 4, p150. The
oligonucleotides comprises at least one modified internucleoside linkage,
preferably a phosphorothioate linkage. It also comprises at least one
modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
antisense oligonucleotide further comprises at least one modified
nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
can be used in diagnostics and as research reagents and kits. It can also
be used prophylactically, e.g. to prevent or delay infection,
inflammation or tumour formation. It can also be used to treat a disease
or condition associated with phosphoinositide-3-kinase, regulatory
subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
Chediak-Higashi syndrome or a metabolic disorder. The products of the
invention are immunomodulators with cytostatic activity and can be used
for gene therapy.
Sequence 20 BP; 4 A; 5 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4761 CTGTTTCATGACTGACTGAC 4780
Db 1 CTGTTTCATGACTGACTGAC 20
RESULT 294
ADL34565/c
ID ADL34565 standard; DNA; 20 BP.
XX
XX ADL34565;
XX
DT 17-JUN-2004 (first entry)
XX
DE ISIS antisense oligonucleotide ISIS 206957.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ss; primer.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20 a
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
PN
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.

01-APR-2004.
18-SEP-2003; 2003US-00667022.
31-MAY-2002; 2002US-00160786.
(PREI/) FREIER S M.
(DOBI/) DOBIE K W.
Freier SM, Dobie KW;
WPI; 2004-282523/26.
New antisense compound targeted to a nucleic acid molecule encoding
phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
Example 15; SEQ ID NO 124; 60pp; English.
This invention describes a novel antisense oligonucleotides which
specifically hybridises to and inhibits the expression of human
phosphoinositide-3-kinase, regulatory subunit 4, p150. The
oligonucleotides comprises at least one modified internucleoside linkage,
preferably a phosphorothioate linkage. It also comprises at least one
modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
antisense oligonucleotide further comprises at least one modified
nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
can be used in diagnostics and as research reagents and kits. It can also
be used prophylactically, e.g. to prevent or delay infection,
inflammation or tumour formation. It can also be used to treat a disease
or condition associated with phosphoinositide-3-kinase, regulatory
subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
Chediak-Higashi syndrome or a metabolic disorder. The products of the
invention are immunomodulators with cytostatic activity and can be used
for gene therapy.
Sequence 20 BP; 7 A; 2 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3009 TCAGAAAGGTGTAATTGACT 3028
Db 1 TCAGAAAGGTGTAATTGACT 20
RESULT 293
ADL34698
ID ADL34698 standard; DNA; 20 BP.
XX
XX ADL34698;
XX
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124667.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
XX US2004063657-A1.
PN
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.

```

XX 31-MAY-2002; 2002US-00160786.
PR (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 11; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 43 CGTTTGCTGGGGCTGCAGCA 62
DB 20 CGTTTGCTGGGGCTGCAGCA 1
RESULT 295
ADL34578/c
ID ADL34578 standard; DNA; 20 BP.
XX
XX ADL34578;
XX
XX 17-JUN-2004 (first entry)
XX
XX ISIS antisense oligonucleotide ISIS 206970.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytostatic; gene therapy; ss; primer.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 24; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
XX specifically hybridises to and inhibits the expression of human
XX phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX oligonucleotides comprises at least one modified internucleoside linkage,
XX preferably a phosphorothioate linkage. It also comprises at least one
XX modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX antisense oligonucleotide further comprises at least one modified
XX nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX can be used in diagnostics and as research reagents and kits. It can also
XX be used prophylactically, e.g. to prevent or delay infection,
XX inflammation or tumour formation. It can also be used to treat a disease
XX or condition associated with phosphoinositide-3-kinase, regulatory
XX subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX invention are immunomodulators with cytostatic activity and can be used
XX for gene therapy.
XX
XX Sequence 20 BP; 6 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 914 CCGTCCCATCTCTGATAAC 933
DB 20 CCGTCCCATCTCTGATAAC 1
RESULT 296
ADL34580/c
ID ADL34580 standard; DNA; 20 BP.
XX
XX ADL34580;
XX
XX 17-JUN-2004 (first entry)
XX
XX ISIS antisense oligonucleotide ISIS 206972.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytostatic; gene therapy; ss; primer.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX

```



```

XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-282523/26.
XX
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 91; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
XX Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 377 AGCCCATCTCTCTGTCCTATGA 396
XX |||||
XX 1 AGCCCATCTCTCTGTCCTATGA 20
XX
XX
XX RESULT 299
XX ADL34668
XX ID ID ADL34668 standard; DNA; 20 BP.
XX AC ADL34668;
XX
XX XX 17-JUN-2004 (first entry)
XX
XX Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124628.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytostatic; gene therapy; ds.
XX
XX Homo sapiens.
XX OS
XX US2004063657-A1.
XX PN
XX 01-APR-2004.
XX PD
XX 18-SEP-2003; 2003US-00667022.
XX PF
XX 31-MAY-2002; 2002US-00160786.
XX PR
XX (FREI/) FREIER S M.
XX PA (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX
XX

```

```
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 122; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2860 CTTGCCATAGCAGCTTCT 2879
DB 1 CTTGCCATAGCAGCTTCT 20
RESULT 301
ADL34690
ID ADL34690 standard; DNA; 20 BP.
AC ADL34690;
XX
XX 17-JUN-2004 (first entry)
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124652.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytostatic; gene therapy; ds.
XX
XX Homo sapiens.
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 136; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
SQ Sequence 20 BP; 2 A; 6 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3899 TTCTTGCTATGCCACTGTG 3918
DB 1 TTCTTGCTATGCCACTGTG 20
RESULT 302
ADL34692
ID ADL34692 standard; DNA; 20 BP.
AC ADL34692;
XX
XX 17-JUN-2004 (first entry)
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124656.
XX
XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX regulatory subunit 4; p150; internucleoside linkage;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
XX infection; inflammation; tumour formation; hyperproliferative disorder;
XX cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
XX cytostatic; gene therapy; ds.
XX
XX Homo sapiens.
XX
XX US2004063657-A1.
XX
XX 01-APR-2004.
XX
XX 18-SEP-2003; 2003US-00667022.
XX
XX 31-MAY-2002; 2002US-00160786.
XX
XX (FREI/) FREIER S M.
XX (DOBI/) DOBIE K W.
XX
XX Freier SM, Dobie KW;
XX
XX WPI; 2004-282523/26.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
XX Example 15; SEQ ID NO 138; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.
XX
```

CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4050 CAGTGGTACCATGCGCTTGT 4059
 Db 1 CAGTGGTACCATGCGCTTGT 20

RESULT 303

ADL34566/c
 ID ADL34566 standard; DNA; 20 BP.

XX AC ADL34566;

DT 17-JUN-2004 (first entry)

XX ISIS antisense oligonucleotide ISIS 206958.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.

XX Synthetic.

XX Key Location/Qualifiers
 FH modified_base 1. .20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /not= "phosphorothioate backbone"

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (FREI/) FREIER S M.

XX (DOBI/) DOBIE K W.

XX Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 12; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one

CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX Sequence 20 BP; 6 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 92 CGGTCTGCACCTTCTCTCCCG 111
 Db 20 CGGTCTGCACCTTCTCTCCCG 1

RESULT 304

ADL34631/c
 ID ADL34631 standard; DNA; 20 BP.

XX AC ADL34631;

DT 17-JUN-2004 (first entry)

XX ISIS antisense oligonucleotide ISIS 207031.

XX antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytostatic; gene therapy; ss; primer.

XX Synthetic.

XX Key Location/Qualifiers
 FH modified_base 1. .20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /not= "phosphorothioate backbone"

XX US2004063657-A1.

XX 01-APR-2004.

XX 18-SEP-2003; 2003US-00667022.

XX 31-MAY-2002; 2002US-00160786.

XX (FREI/) FREIER S M.

XX (DOBI/) DOBIE K W.

XX Freier SM, Dobie KW;

XX WPI; 2004-282523/26.

XX New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX Example 15; SEQ ID NO 77; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,

CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX Sequence 20 BP; 6 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4258 CCACCTTCTGAATTACGCC 4277
Db 20 CCACCTTCTGAATTACGCC 1
|||||

RESULT 305
ADL34655
ID ADL34655 standard; DNA; 20 BP.
XX
AC ADL34655;
XX
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124608.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 101; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 998 TTCGTCATGGGACATCAAG 1017
Db 1 TTCGTCATGGGACATCAAG 20
|||||

RESULT 306
ADL34661
ID ADL34661 standard; DNA; 20 BP.
XX
AC ADL34661;
XX
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124618.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 107; 60pp; English.
XX
CC This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1498 CAGCGTGGCAATGCCTTCC 1517

Db 1 CAGCGTGGCAATGCCTTCC 20

RESULT 307

ADL34665

ID ADL34665 standard; DNA; 20 BP.

XX AC ADL34665;

XX DT 17-JUN-2004 (first entry)

XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124624.

XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytosstatic; gene therapy; ds.

XX OS Homo sapiens.

XX PN US2004063657-A1.

XX PD 01-APR-2004.

XX PF 18-SEP-2003; 2003US-00667022.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (FREI/) FREIER S M.

XX PA (DOBI/) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-282523/26.

XX PT New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX PS Example 15; SEQ ID NO 111; 60pp; English.

XX CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX SQ Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1978 GCCCAAGATGATGCTACTAT 1997

Db 1 GCCCAAGATGATGCTACTAT 20

RESULT 308

ADL34683

ID ADL34683 standard; DNA; 20 BP.

XX AC ADL34683;

XX DT 17-JUN-2004 (first entry)

XX DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124643.

XX KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
 KW regulatory subunit 4; p150; internucleoside linkage;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW infection; inflammation; tumour formation; hyperproliferative disorder;
 KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
 KW cytosstatic; gene therapy; ds.

XX OS Homo sapiens.

XX PN US2004063657-A1.

XX PD 01-APR-2004.

XX PF 18-SEP-2003; 2003US-00667022.

XX PR 31-MAY-2002; 2002US-00160786.

XX PA (FREI/) FREIER S M.

XX PA (DOBI/) DOBIE K W.

XX PI Freier SM, Dobie KW;

XX DR WPI; 2004-282523/26.

XX PT New antisense compound targeted to a nucleic acid molecule encoding
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.

XX PS Example 15; SEQ ID NO 129; 60pp; English.

XX CC This invention describes a novel antisense oligonucleotides which
 CC specifically hybridises to and inhibits the expression of human
 CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
 CC oligonucleotides comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
 CC antisense oligonucleotide further comprises at least one modified
 CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
 CC can be used in diagnostics and as research reagents and kits. It can also
 CC be used prophylactically, e.g. to prevent or delay infection,
 CC inflammation or tumour formation. It can also be used to treat a disease
 CC or condition associated with phosphoinositide-3-kinase, regulatory
 CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
 CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
 CC invention are immunomodulators with cytostatic activity and can be used
 CC for gene therapy.

XX SQ Sequence 20 BP; 9 A; 5 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3388 AAAACTGAACCTTCAGCAACT 3407


```

Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 CTGCAGGAATTCGGCAGCAG 32
DB 1 CTGCAGGAATTCGGCAGCAG 20

RESULT 311
AAF73394
ID AAF73394 standard; DNA; 21 BP.
XX AC AAF73394;
XX DT 30-APR-2001 (first entry)
XX DE Grand fir monoterpene synthase PCR primer 3-18-EcoRI SEQ ID NO: 35.
XX KW Monoterpene synthase; grand fir; cancer; (-)-camphene synthase;
XX KW myrcene synthase; (-)-limonene synthase; (-)-pinene synthase; probe;
XX KW terpinolene synthase; insect resistance; nutrition; PCR primer; ss.
XX OS Abies grandis.
XX PN WO200107565-A2.
XX PD 01-FEB-2001.
XX PF 24-JUL-2000; 2000WO-US020264.
XX PR 26-JUL-1999; 99US-00360545.
XX PA (UNIW ) UNIV WASHINGTON STATE RES FOUND.
XX PI Steele CL, Bohlmann J, Croteau RB, Phillips MA;
XX DR WPI; 2001-182782/18.
XX PT New nucleic acid encoding monoterpene synthases, for increasing terpene
XX PT synthesis in plants, e.g. for increasing resistance to pests or for
XX PT treatment of cancer.
XX PS Example 3; Page 140; 175pp; English.
XX SS

The present invention provides the protein and coding sequences of
monoterpene synthases from the grand fir. These include (-)-camphene
synthase, (-)-beta-phellandrene synthase, terpinolene synthase, (-)-
limonene/(-)-alpha-pinene synthase, limonene synthase, myrcene synthase
and pinene synthase. The sequences can be used to produce transgenic
plants expressing high levels of the enzymes, resulting in levels which
are useful in protecting against and treating cancers, and to confer
insect resistance on plants

Sequence 21 BP; 5 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 CTGCAGGAATTCGGCAGCAG 32
DB 1 CTGCAGGAATTCGGCAGCAG 20

RESULT 312
ADK65560/c
ID ADK65560 standard; DNA; 24 BP.
XX AC ADK65560;
XX DT 06-MAY-2004 (first entry)
XX DE A gossypii riboflavin synthesis gene rib7 PCR primer #1.

Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 CTGCAGGAATTCGGCAGCAG 32
DB 1 CTGCAGGAATTCGGCAGCAG 20

RESULT 313
ADK15557
ID ADK15557 standard; DNA; 24 BP.
XX AC ADK15557;
XX DT 03-JUN-2004 (first entry)
XX DE Hantaan hantavirus M segment derived DNA vaccine related DNA.
XX KW virucide; gene therapy; hantavirus; M segment; L segment; S segment;
XX KW hantavirus infection; immune response; vaccine; hantavirus;
XX KW hantaan virus; HNTV; DNA vaccine; HNTV M genomic segment; pWRG/HTN-M9 (x);
XX KW ds.
XX OS Unidentified.
XX PN US2004053216-A1.
XX PD 18-MAR-2004.
XX PF 21-MAR-2003; 2003US-00394388.
XX PR 29-AUG-2001; 2001US-00941974.
XX PR 22-MAR-2002; 2002US-0367128P.
XX PR 26-JUL-2002; 2002US-0398985P.
XX PA (HOOP/) HOOPER J W.
XX PA (SCHM/) SCHMALJOHN C S.

rib1; rib2; rib4; rib7; riboflavin; food; animal feed; ss; primer; PCR.
Eremothecium gossypii.
DE10159396-A1.
12-JUN-2003.
04-DEC-2001; 2001DE-01059396.
04-DEC-2001; 2001DE-01059396.
(BADI ) BASF AG.
Althoefer H, Revuelta DJL;
WPI; 2003-524771/50.
Microbial production of riboflavin (vitamin B2), useful as additive for
human food or animal fodder, comprises growth of microbes in which
activity of rib gene products is increased.
Example 1; Page 7; 22pp; German.
The present invention relates to a method of microbial production of
riboflavin using a riboflavin-producing microorganism of the genus Ashbya
in which at least two of the products of the genes rib1, rib2, rib4 and
rib7 have greater activity than in the wild type organism ATCC 10895.
Riboflavin (vitamin B2) is an additive for human foods and animal fodder.
The present sequence is a PCR primer used to isolate the Ashbya gossypii
rib7 gene which was used in the method of the invention.
Sequence 24 BP; 3 A; 11 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5066 TCGAGGGGGGGCCCGGTACC 5085
DB 24 TCGAGGGGGGGCCCGGTACC 5

RESULT 313
ADK15557
ID ADK15557 standard; DNA; 24 BP.
XX AC ADK15557;
XX DT 03-JUN-2004 (first entry)
XX DE Hantaan hantavirus M segment derived DNA vaccine related DNA.
XX KW virucide; gene therapy; hantavirus; M segment; L segment; S segment;
XX KW hantavirus infection; immune response; vaccine; hantavirus;
XX KW hantaan virus; HNTV; DNA vaccine; HNTV M genomic segment; pWRG/HTN-M9 (x);
XX KW ds.
XX OS Unidentified.
XX PN US2004053216-A1.
XX PD 18-MAR-2004.
XX PF 21-MAR-2003; 2003US-00394388.
XX PR 29-AUG-2001; 2001US-00941974.
XX PR 22-MAR-2002; 2002US-0367128P.
XX PR 26-JUL-2002; 2002US-0398985P.
XX PA (HOOP/) HOOPER J W.
XX PA (SCHM/) SCHMALJOHN C S.

```

PA (CUST/) CUSTER M.
 XX Hooper JW, Schmaljohn CS, Custer M;
 XX WPI; 2004-247721/23.
 XX
 XX New nucleic acid molecules and polypeptides useful for diagnosing,
 PT preventing and treating hantavirus (e.g. hemorrhagic fever with renal
 PT syndrome and/or hantavirus pulmonary syndrome hantavirus) infection.
 XX
 XX Claim 13; SEQ ID NO 6; 96pp; English.
 XX
 XX The invention describes a nucleic acid (I), or its fragment, comprising a
 CC fully defined sequence of 24 base pairs, as given in the specification.
 CC Also described are: a recombinant DNA construct comprising a vector, at
 CC least one hantavirus M gene nucleic acid fragment and the nucleic acid
 CC fragment (I); a composition (II) comprising inert particles and a nucleic
 CC acid coated onto the inert particles producing nucleic acid coated
 CC particles, the nucleic acid comprising a promoter operative in the cells
 CC of a mammal and a hantavirus polynucleotide M segment encoding G1 and G2
 CC symptoms of hantavirus infection, comprising the composition (II) and a
 CC pharmaceutical excipient; inducing a protective immune response against
 CC hantavirus infection in a mammal; a vaccine against infection with the
 CC hantavirus, the vaccine comprising the composition (II); treating or
 CC detecting hantavirus infection; and a hantavirus infection diagnostic kit
 CC comprising the composition (II) and ancillary reagents for detecting the
 CC presence or absence of hantavirus antigens in a sample. The composition
 CC and methods are useful for diagnosing, preventing and treating hantavirus
 CC infection. This sequence represents an exogenous DNA associated with the
 CC Hantaan hantavirus DNA vaccine comprising the HNTV M (medium) genomic
 CC segment.
 XX
 XX Sequence 24 BP; 6 A; 5 C; 9 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 20; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 13 CTGCAGGAATTCGGCAGCG 32
 DB 5 CTGCAGGAATTCGGCAGCG 24
 |||||
 RESULT 314
 AAQ47178/c
 ID AAQ47178 standard; DNA; 26 BP.
 XX
 XX AAQ47178;
 XX
 XX 25-MAR-2003 (revised)
 DT 25-JAN-1994 (first entry)
 XX
 XX MHC DR A intron binding oligomer Tcon.
 XX
 XX MHC; major histocompatibility complex; class II; control oligomers; DR A;
 KW transplantation; antigen; autoimmune disease; ss.
 KW
 XX Synthetic.
 OS
 XX WO9314769-A1.
 PN
 XX
 XX 05-AUG-1993.
 PD
 XX 29-JAN-1993; 93WO-US0000797.
 PF
 XX 31-JAN-1992; 92US-00830427.
 PR 14-SEP-1992; 92US-00944868.
 XX
 XX (REGC) UNIV CALIFORNIA.
 PA
 XX Weiss TL, Garovoy MR, Hunt A, Huey B, Tam S;
 PI
 XX

DR WPI; 1993-258367/32.
 XX
 XX Depletion of transplantation antigens in donor cells - using anti-sense
 PT or triplex-forming oligonucleotide(s), used for treating auto-immune
 PT disease and in transplants.
 XX
 XX Example; Page 22; 71pp; English.
 XX
 XX The sequences given in AAQ47176-77 represent triplex forming oligo-
 CC nucleotides which bind to the mRNA sequence of the MHC class II locus DR
 CC A structural gene at positions 851-876. The sequences given in AAQ47178-
 CC 80 represent control oligomers which contain base compositions similar to
 CC that around this DR A region but not containing the correct sequences. DR
 CC A is a transplantation antigen. Binding of this sequence to the DR A gene
 CC inhibits antigen production. This method may be used for treating
 CC individuals with autoimmune disease, characterised by dysfunctional
 CC expression of a transplantation antigen. It may also be used to produce
 CC cells which are more easily transplanted into a recipient. (Updated on 25
 CC -MAR-2003 to correct PN field.)
 XX
 XX Sequence 26 BP; 0 A; 0 C; 4 G; 22 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 19.6; DB 1; Length 26;
 Best Local Similarity 84.6%; Pred. No. 1.7e+02;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 OY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5050
 DB 26 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1
 |||||
 RESULT 315
 ABA01951/c
 ID ABA01951 standard; DNA; 24 BP.
 XX
 XX ABA01951;
 AC
 XX 06-FEB-2002 (first entry)
 DT
 XX Human TNF receptor-associated factor 16 cDNA PCR primer #1.
 DE
 XX Human; TNF receptor-associated factor 16; lymphadenoma; cancer;
 KW dysgenopathy; phlogosis; immune disease; haemopathy; HIV infection;
 KW tumour necrosis factor; cytostatic; virucide; immunomodulator;
 KW antiinflammatory; haemostatic; gene therapy; PCR primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200179279-A1.
 PN
 XX 25-OCT-2001.
 PD
 XX 26-MAR-2001; 2001WO-CN000432.
 PF
 XX 27-MAR-2000; 2000CN-00115167.
 PR
 XX (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
 PA
 XX Mao Y, Xie Y;
 PI
 XX WPI; 2002-034341/04.
 XX
 XX Human tumor necrosis factor receptor-associated factor 16 and encoded
 PT polynucleotide, applicable in diagnosis and treatment of e.g. cancer,
 PT hemopathy, HIV infection, immunological diseases and various
 PT inflammations.
 XX
 XX Example 3; Page 17; 37pp; Chinese.
 PS
 XX The present invention provides the protein and coding sequences of human
 CC tumour necrosis factor (TNF) receptor-associated factor 16. The sequences
 CC can be used in the treatment of lymphadenoma, cancer, dysgenopathy,
 CC phlogosis, immune diseases, haemopathy and HIV infection. The present

CC sequence is a PCR primer for the coding sequence of the invention
XX
SQ Sequence 24 BP; 3 A; 11 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.4%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5063 AACTCGAGGGGGCCCGGTA 5083
Db 21 ACCTCGAGGGGGCCCGGTA 1

RESULT 316
AAF98935/c
ID AAF98935 standard; DNA; 24 BP.
XX
AC AAF98935;
XX
DT 12-JUN-2001 (first entry)
XX
DE Immunostimulatory nucleic acid #51.
XX
XX Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW immunostimulatory; tumour; viral infection; bacterial infection;
KW fungal infection; parasitic infection; cancer; asthma;
KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS Synthetic.
XX
PN WO200122972-A2.
XX
PD 05-APR-2001.
XX
XX 25-SEP-2000; 2000WO-US026383.
XX
PR 25-SEP-1999; 99US-0156113P.
PR 27-SEP-1999; 99US-0156135P.
PR 23-AUG-2000; 2000US-0227436P.
XX
XX (IOWA) UNIV IOWA RES FOUND.
PA (COLE-) COLEY PHARM GMBH.
XX
XX Krieg AM, Schetter C, Vollmer J;
XX
XX WPI; 2001-273485/28.
XX
XX Vaccinating against tumors, infectious diseases, allergies and asthma
PT using immunostimulatory Py-rich and TG nucleic acids.
XX
XX Disclosure; Page 39; 338pp; English.

CC The present invention relates to a method for stimulating an immune
CC response. The method comprises administering an immunostimulatory nucleic
CC acid to a non-rodent subject in sufficient quantity to stimulate an
CC immune response. The present sequence is one such immunostimulatory
CC nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC also useful for preventing cancer, asthma, infectious disease, allergy or
CC immune deficiency. The present sequence can also be used to redirect a
CC Th2 to a Th1 immune response and to activate immune cells. Note: the
CC present sequence may have a phosphorothioate backbone

XX
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
Query Match 0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 317
ABS77576/c
ID ABS77576 standard; DNA; 24 BP.
XX
AC ABS77576;
XX
DT 13-DEC-2002 (first entry)
XX
XX Angiogenesis inhibitory oligonucleotide #60.
XX
XX Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW plaque neovascularisation; telangiectasia; haemophilic joint;
KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW scleroderma; hypertrophic scar.
XX
OS Synthetic.
XX
PN WO200253141-A2.
XX
PD 11-JUL-2002.
XX
XX 14-DEC-2001; 2001WO-US048458.
XX
PR 14-DEC-2000; 2000US-0255534P.
XX
XX (COLE-) COLEY PHARM GROUP INC.
XX
XX Bratzler RL;
XX
XX WPI; 2002-566690/60.
XX
XX Inhibiting angiogenesis in a subject, involves administering at least one
PT antiangiogenic nucleic acid molecule to the subject.
XX
XX Claim 2; Page 20; 276pp; English.

CC The invention relates to inhibiting angiogenesis in a subject, comprising
CC administering at least one antiangiogenic nucleic acid molecule. Also
CC included is a kit comprising a first container housing the antiangiogenic
CC nucleic acids, and instructions for administering them to a subject
CC having a condition characterised by unwanted angiogenesis. The method is
CC useful for inhibiting angiogenesis associated with solid tumour growth,
CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma,
CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC acid of the invention

XX
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
Query Match 0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 318
ACD99368/c

```
ID ACD99368 standard; DNA; 24 BP.
XX
AC ACD99368;
XX
AC ACD99368;
XX
DT 25-SEP-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #54.
XX
KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS Synthetic.
XX
PN US2003050268-A1.
XX
PD 13-MAR-2003.
XX
XX 29-MAR-2002; 2002US-00112653.
XX
XX 29-MAR-2001; 2001US-0279642P.
XX
PA (KRIE/) KRIEG A M.
PA (BERG/) BERG D J.
XX
PI Krieg AM, Berg DJ;
XX
XX WPI; 2003-521815/49.
XX
PT Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT disease by administering an immunostimulatory nucleic acid.
XX
XX Disclosure; Page 10; 229pp; English.
XX
XX The invention describes a method of treating non-allergic inflammatory
XX disease comprising administering to a subject having or at risk of
XX developing a non-allergic inflammatory disease an immunostimulatory
XX nucleic acid for prevention or treatment of the disease. The method is
XX useful for treating non-allergic inflammatory diseases, such as
XX psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
XX inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
XX This sequence represents an immunostimulatory nucleic acid
XX
XX Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
DB 24 AAAAAACAAAAAACAAAAAACAA 1
RESULT 319
ADB36437/C
ID ADB36437 standard; DNA; 24 BP.
XX
AC ADB36437;
XX
XX 04-DEC-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #51.
XX
XX ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW hypo-responsive subject; immunostimulatory.
XX
OS Synthetic.
XX
PN US2003087848-A1.
XX
ID ACD99368 standard; DNA; 24 BP.
XX
AC ACD99368;
XX
DT 25-SEP-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #54.
XX
KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS Synthetic.
XX
PN US2003050268-A1.
XX
PD 13-MAR-2003.
XX
XX 29-MAR-2002; 2002US-00112653.
XX
XX 29-MAR-2001; 2001US-0279642P.
XX
PA (KRIE/) KRIEG A M.
PA (BERG/) BERG D J.
XX
PI Krieg AM, Berg DJ;
XX
XX WPI; 2003-521815/49.
XX
PT Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT disease by administering an immunostimulatory nucleic acid.
XX
XX Disclosure; Page 10; 229pp; English.
XX
XX The invention describes a method of treating non-allergic inflammatory
XX disease comprising administering to a subject having or at risk of
XX developing a non-allergic inflammatory disease an immunostimulatory
XX nucleic acid for prevention or treatment of the disease. The method is
XX useful for treating non-allergic inflammatory diseases, such as
XX psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
XX inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
XX This sequence represents an immunostimulatory nucleic acid
XX
XX Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
DB 24 AAAAAACAAAAAACAAAAAACAA 1
RESULT 320
ADG76001/C
ID ADG76001 standard; DNA; 24 BP.
XX
AC ADG76001;
XX
DT 11-MAR-2004 (first entry)
XX
DE Non-CpG DNA oligonucleotide 2.
XX
XX ss; non-CpG; immunostimulatory; non-palindromic; immune response;
KW proliferation; differentiation; cytokine; antibody production; B-cell;
KW plasmacytoid dendritic cell; immunomodulator; gene therapy;
KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
KW renal cell carcinoma.
XX
OS Synthetic.
XX
PN WO2003101375-A2.
XX
PD 11-DEC-2003.
XX
XX 30-MAY-2003; 2003WO-EP005691.
XX
XX 30-MAY-2002; 2002CA-02388049.
XX
XX (IMMU-) IMMUNOTECH SA.
XX
PI Lopez RA;
XX
XX WPI; 2004-053333/05.
XX
PT New immunostimulatory oligonucleotide comprising non-palindromic nucleic
PT acid sequence motif, useful for inducing B-cell activation, treating,
PT preventing or ameliorating immune system disorder or tumoral disease e.g.
PT melanoma.
```

XX Example 17; Page 80; 139pp; English.

XX This invention relates to novel immunostimulatory oligonucleotides that

CC contain a non-palindromic sequence motif. Specifically, it refers to DNA

CC oligonucleotides (without a CpG motif), which can stimulate an immune

CC response in animals of the order of primate, including humans. The immune

CC response is characterised by the proliferation, differentiation, cytokine

CC and antibody production in B-cells, as well as cell differentiation and

CC cytokine production in plasmacytoid dendritic cells. The present

CC invention describes immunomodulator compositions that also comprise an

CC antigen selected from, for example, viruses, bacteria, parasites, tumour

CC cells and glycolipids. As such, these DNA oligos can be used in gene

CC therapy for inducing B-cell activation, treating, preventing or

CC ameliorating an immune system disorder or a tumoural disease including

CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell

CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the

CC invention.

XX SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;

Query Match 0.4%; Score 19.2; DB 1; Length 24;

Best Local Similarity 87.5%; Pred. No. 1.8e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048

Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 321

ADG76035/c

ID ADG76035 standard; DNA; 24 BP.

AC ADG76035;

XX 11-MAR-2004 (first entry)

XX Non-CpG DNA oligonucleotide 36.

DE ss; non-CpG; immunostimulatory; non-palindromic; immune response;

KW proliferation; differentiation; cytokine; antibody production; B-cell;

KW plasmacytoid dendritic cell; immunomodulator; gene therapy;

KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;

KW renal cell carcinoma.

OS Synthetic.

XX WO2003101375-A2.

XX 11-DEC-2003.

XX 30-MAY-2003; 2003WO-EP005691.

XX 30-MAY-2002; 2002CA-02388049.

XX (IMMU-) IMMUNOTECH SA.

XX Lopez RA;

XX WPI; 2004-053333/05.

XX New immunostimulatory oligonucleotide comprising non-palindromic nucleic

XX acid sequence motif, useful for inducing B-cell activation, treating,

XX preventing or ameliorating immune system disorder or tumoral disease e.g.

XX melanoma.

XX Example 17; Page 81; 139pp; English.

XX This invention relates to novel immunostimulatory oligonucleotides that

CC contain a non-palindromic sequence motif. Specifically, it refers to DNA

CC oligonucleotides (without a CpG motif), which can stimulate an immune

CC response in animals of the order of primate, including humans. The immune

CC response is characterised by the proliferation, differentiation, cytokine

CC and antibody production in B-cells, as well as cell differentiation and

CC cytokine production in plasmacytoid dendritic cells. The present

CC invention describes immunomodulator compositions that also comprise an

CC antigen selected from, for example, viruses, bacteria, parasites, tumour

CC cells and glycolipids. As such, these DNA oligos can be used in gene

CC therapy for inducing B-cell activation, treating, preventing or

CC ameliorating an immune system disorder or a tumoural disease including

CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell

CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the

CC invention.

XX SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;

Query Match 0.4%; Score 19.2; DB 1; Length 24;

Best Local Similarity 87.5%; Pred. No. 1.8e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048

Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 322

ACI76263/c

ID ACI76263 standard; DNA; 25 BP.

XX ACI76263;

XX 14-OCT-2003 (first entry)

XX Human microarray DNA oligonucleotide SEQ ID NO 76254.

DE EST; ss; probe; expressed sequence tag; microarray; gene expression;

KW genetic variation; biallelic marker; polymorphism; human;

KW cross-species comparison.

XX Homo sapiens.

XX US2003104410-A1.

XX 05-JUN-2003.

XX 15-MAR-2002; 2002US-00098263.

XX 16-MAR-2001; 2001US-0276759P.

XX (APFY-) AFFYMETRIX INC.

XX Mittmann MP;

XX WPI; 2003-567953/53.

XX New array of nucleic acid probes, useful for in situ hybridization, in

XX Southern, Northern or dot-blot hybridization to identify or detect the

XX sequence or specific mutations of any gene.

XX Claim 1; SEQ ID NO 76254; 9pp; English.

XX The invention discloses a microarray comprising a plurality of nucleic

XX acid probes including one of 2,018,500 fully defined sequences, or its

XX perfect match, perfect mismatch, antisense match or antisense mismatch.

XX Also disclosed is a method of gene expression analysis. The array is used

XX in monitoring gene expression levels by hybridisation to a DNA library,

XX in analysis of genetic variation or in hybridisation of tag-labelled

XX compounds. The nucleic acid probes are specifically designed for analysis

XX of at least one target sequence. The method of analysis comprises

XX hybridising at least one or more nucleic acids to at least two or more

XX nucleic acid probes and detecting the hybridisation. The nucleic acid

XX probes are attached to a solid support. The analysis comprises monitoring

XX gene expression levels, identifying biallelic markers or polymorphisms,

XX or family members of a gene and a cross-species comparison. Each of the

XX nucleic acids further comprises a tag sequence. The array of nucleic acid

The invention discloses a microarray comprising a plurality of nucleic acid probes including one of 2,018,500 fully defined sequences, or its perfect match, perfect mismatch, antisense match or antisense mismatch. Also disclosed is a method of gene expression analysis. The array is used in monitoring gene expression levels by hybridisation to a DNA library, in analysis of genetic variation or in hybridisation of tag-labelled compounds. The nucleic acid probes are specifically designed for analysis of at least one target sequence. The method of analysis comprises hybridising at least one or more nucleic acids to at least two or more nucleic acid probes and detecting the hybridisation. The nucleic acid probes are attached to a solid support. The analysis comprises monitoring gene expression levels, identifying allelic markers or polymorphisms, or family members of a gene and a cross-species comparison. Each of the nucleic acids further comprises a tag sequence. The array of nucleic acid probes is useful in situ hybridisation, in Southern, Northern or dot-blot hybridisation to identify or detect the sequence or specific

RESULT 325
ADR82260/c
ID ADR82260 standard; DNA; 19 BP.
XX
AC ADR82260;
XX
DT 16-DEC-2004 (first entry)
XX
DE Hepatitis C virus (HCV) oligonucleotide seqid 6759.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cyostatic; anticonvulsant; nootropic; muscular; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
OS Hepatitis C virus.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
XX
PR 12-MAR-2003; 2003US-0454265P.
XX
PR 13-MAR-2003; 2003US-0454962P.
XX
PR 14-APR-2003; 2003US-0462894P.
XX
PR 17-APR-2003; 2003US-0463772P.
XX
PR 25-APR-2003; 2003US-0465665P.
XX
PR 25-APR-2003; 2003US-0465802P.
XX
PR 09-MAY-2003; 2003US-0469612P.
XX
PR 08-AUG-2003; 2003US-0493986P.
XX
PR 11-AUG-2003; 2003US-0494597P.
XX
PR 26-SEP-2003; 2003US-0506341P.
XX
PR 09-OCT-2003; 2003US-0510246P.
XX
PR 10-OCT-2003; 2003US-0510318P.
XX
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
XX WPI; 2004-677362/66.
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
FS Example 5; SEQ ID NO 6759; 378pp; English.
XX
CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instructions for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The

CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.
XX
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5043
DB 19 AAAAAAAAAAAAAAAAAAAAAA 1
RESULT 326
ADR82257/c
ID ADR82257 standard; DNA; 19 BP.
XX
AC ADR82257;
XX
DT 16-DEC-2004 (first entry)
XX
DE Hepatitis C virus (HCV) oligonucleotide seqid 6756.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cyostatic; anticonvulsant; nootropic; muscular; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
OS Hepatitis C virus.
XX
PN WO2004080406-A2.
XX
XX 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
XX
PR 12-MAR-2003; 2003US-0454265P.
XX
PR 13-MAR-2003; 2003US-0454962P.
XX
PR 14-APR-2003; 2003US-0462894P.
XX
PR 17-APR-2003; 2003US-0463772P.
XX
PR 25-APR-2003; 2003US-0465665P.
XX
PR 25-APR-2003; 2003US-0465802P.
XX
PR 09-MAY-2003; 2003US-0469612P.
XX
PR 08-AUG-2003; 2003US-0493986P.
XX
PR 11-AUG-2003; 2003US-0494597P.
XX
PR 26-SEP-2003; 2003US-0506341P.
XX
PR 09-OCT-2003; 2003US-0510246P.
XX
PR 10-OCT-2003; 2003US-0510318P.
XX
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
XX WPI; 2004-677362/66.
XX

PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
XX
PS Example 5; SEQ ID NO 6756; 378pp; English.

XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.

XX Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5043
DB 19 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 327

ADR82261/C

ID ADR82261 standard; DNA; 19 BP.

XX ADR82261;

XX 16-DEC-2004 (first entry)

XX Hepatitis C virus (HCV) oligonucleotide seqid 6760.

XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytosstatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.

OS Hepatitis C virus.

XX WO2004080406-A2.

XX 23-SEP-2004.

XX 08-MAR-2004; 2004WO-US007070.

XX 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 09-MAY-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX (ALNY-) ALNYLAM PHARM.

Manoharan M, Bumcrot D;

WPI; 2004-677362/66.

PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.

Example 5; SEQ ID NO 6760; 378pp; English.

XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.

XX Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5043
DB 19 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 328

ADR82258/C

ID ADR82258 standard; DNA; 19 BP.

XX

AC ADR82258;
 XX 16-DEC-2004 (first entry)
 XX Hepatitis C virus (HCV) oligonucleotide seqid 6757.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cystostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
 XX
 OS Hepatitis C virus.
 XX
 XX WO2004080406-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 08-MAR-2004; 2004WO-US007070.
 XX
 XX 07-MAR-2003; 2003US-0452682P.
 XX 12-MAR-2003; 2003US-0454265P.
 XX 13-MAR-2003; 2003US-0454962P.
 XX 13-MAR-2003; 2003US-0455050P.
 XX 14-APR-2003; 2003US-0462894P.
 XX 17-APR-2003; 2003US-0463772P.
 XX 25-APR-2003; 2003US-0465665P.
 XX 25-APR-2003; 2003US-0465802P.
 XX 09-MAY-2003; 2003US-0469612P.
 XX 08-AUG-2003; 2003US-0493986P.
 XX 11-AUG-2003; 2003US-0494597P.
 XX 26-SEP-2003; 2003US-0506341P.
 XX 09-OCT-2003; 2003US-0510246P.
 XX 10-OCT-2003; 2003US-0510318P.
 XX 07-NOV-2003; 2003US-0518453P.
 XX
 XX (ALNY-) ALNYLAM PHARM.
 XX
 XX Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 XX
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 XX disease, diabetes, cancer or neurological disease, comprises sense
 XX sequence and antisense sequence which has specific modifications.
 XX
 XX Example 5; SEQ ID NO 6757; 378pp; English.
 XX
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 XX sense sequence and an antisense sequence, where the sense sequences have
 XX one or more asymmetrical 2'-O alkyl modifications, the antisense
 XX sequences have one or more asymmetrical phosphorothioate modifications
 XX and the antisense sequence targets a human gene sequence. Also described
 XX are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 XX levels or glucose-6-phosphatase levels in a subject; producing (I);
 XX stabilising (I), involves selecting a sequence with activity and
 XX introducing one or more asymmetrical modification in the sequence, where
 XX the modification decreases nuclease sensitivity while not decreasing its
 XX activity; a kit comprising (I) and instruction for its use; and a device
 XX that can be dispense or administer a composition comprising (I). (I) is
 XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 XX The subject is suffering from a disorder characterised by elevated or
 XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
 XX disorder is chosen from the HDL/LDL cholesterol imbalance,
 XX dyslipidaemias, hypercholesterolaemia, statin-resistant
 XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 XX disease (CHD) and atherosclerosis. (I) is administered to a subject to

CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
 CC be used to control HCV gene expression.
 XX
 SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 5025 AAAAAAAAAAAAAAAAAA 5043
 |||||
 Db 19 AAAAAAAAAAAAAAAAAA 1
 |||||
 RESULT 329
 ADR82256/c
 ID ADR82256 standard; DNA; 19 BP.
 XX
 XX ADR82256;
 XX
 XX 16-DEC-2004 (first entry)
 XX
 XX Hepatitis C virus (HCV) oligonucleotide seqid 6755.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cystostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
 XX
 OS Hepatitis C virus.
 XX
 XX WO2004080406-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 08-MAR-2004; 2004WO-US007070.
 XX
 XX 07-MAR-2003; 2003US-0452682P.
 XX 12-MAR-2003; 2003US-0454265P.
 XX 13-MAR-2003; 2003US-0454962P.
 XX 13-MAR-2003; 2003US-0455050P.
 XX 14-APR-2003; 2003US-0462894P.
 XX 17-APR-2003; 2003US-0463772P.
 XX 25-APR-2003; 2003US-0465665P.
 XX 25-APR-2003; 2003US-0465802P.
 XX 09-MAY-2003; 2003US-0469612P.
 XX 08-AUG-2003; 2003US-0493986P.
 XX 11-AUG-2003; 2003US-0494597P.
 XX 26-SEP-2003; 2003US-0506341P.
 XX 09-OCT-2003; 2003US-0510246P.
 XX 10-OCT-2003; 2003US-0510318P.
 XX 07-NOV-2003; 2003US-0518453P.
 XX
 XX (ALNY-) ALNYLAM PHARM.
 XX
 XX Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 XX
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 XX disease, diabetes, cancer or neurological disease, comprises sense
 XX sequence and antisense sequence which has specific modifications.
 XX
 XX Example 5; SEQ ID NO 6757; 378pp; English.
 XX
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 XX sense sequence and an antisense sequence, where the sense sequences have
 XX one or more asymmetrical 2'-O alkyl modifications, the antisense
 XX sequences have one or more asymmetrical phosphorothioate modifications
 XX and the antisense sequence targets a human gene sequence. Also described
 XX are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 XX levels or glucose-6-phosphatase levels in a subject; producing (I);
 XX stabilising (I), involves selecting a sequence with activity and
 XX introducing one or more asymmetrical modification in the sequence, where
 XX the modification decreases nuclease sensitivity while not decreasing its
 XX activity; a kit comprising (I) and instruction for its use; and a device
 XX that can be dispense or administer a composition comprising (I). (I) is
 XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 XX The subject is suffering from a disorder characterised by elevated or
 XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
 XX disorder is chosen from the HDL/LDL cholesterol imbalance,
 XX dyslipidaemias, hypercholesterolaemia, statin-resistant
 XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 XX disease (CHD) and atherosclerosis. (I) is administered to a subject to

```

PS XX Example 5; SEQ ID NO 6755; 378pp; English.
CC
CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.
XX
XX Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 5025 AAAAAAAAAAAAAAAAAA 5043
XX DB 19 AAAAAAAAAAAAAAAAAA 1
XX
XX RESULT 330
XX ID ADR82259/c
XX ID ADR82259 standard; DNA; 19 BP.
XX AC ADR82259;
XX
XX 16-DEC-2004 (first entry)
XX DE Hepatitis C virus (HCV) oligonucleotide seqid 6758.
XX
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
XX RNA interference; iRNA; antisense technology; lipid metabolism;
XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX coronary artery disease; CAD; coronary heart disease; CHD;
XX atherosclerosis; hepatic glucose production;
XX glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX colon cancer; lung cancer; neurological disease; Huntington disease;
XX spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
XX OS Hepatitis C virus.
XX
XX PN WO2004080406-A2.
XX
XX PD 23-SEP-2004.
XX
XX PF 08-MAR-2004; 2004WO-US0007070.
XX
XX PR 07-MAR-2003; 2003US-0452682P.
XX PR 12-MAR-2003; 2003US-0454265P.
XX PR 13-MAR-2003; 2003US-0454962P.
XX

```

```

PR 13-MAR-2003; 2003US-0455050P.
PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 6758; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a hepatitis C virus (HCV) antisense oligonucleotide that can
XX be used to control HCV gene expression.
XX
XX Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 5025 AAAAAAAAAAAAAAAAAA 5043
XX DB 19 AAAAAAAAAAAAAAAAAA 1
XX
XX RESULT 331
XX ID AAT32292
XX ID AAT32292 standard; DNA; 20 BP.
XX AC AAT32292;
XX
XX 16-FEB-1997 (first entry)
XX

```

DE Primer for manipulation of Clostridium protease.
XX
KW Clostridium histolyticum; neutral protease; digestion; tissue;
KW degradation; pancreatic islets; tumour; adoptive immunotherapy; cell.
XX
OS Synthetic.
XX
PN WO9619583-A1.
XX
XX
XX 27-JUN-1996.
XX
XX 20-DEC-1995; 95WO-EP005054.
XX
XX 22-DEC-1994; 94DE-04445891.
XX
XX (BOFF) BOEHRINGER MANNHEIM GMBH.
XX
XX Hesse F, Ambrosius D, Bartscher H;
XX WPI; 1996-309597/31.
XX
XX Nucleic acid encoding neutral protease of Clostridium histolyticum -
XX useful for tissue digestion and release of constituent cells or cell
XX groups.
XX
XX Example 2; Page 24; 35pp; German.
XX
XX The neutral protease of Clostridium histolyticum is used to digest tissue
XX for recovery of cells or clumps of cells, especially pancreatic islets or
XX tumour cells. The tumour cells can be modified ex vivo and then returned
XX to the patient (adoptive immunotherapy). After tissue degradation, the
XX cells or clumps of cells are separated by centrifugation and on density
XX gradients. The protease is produced by recombinant techniques. Primers
XX used for manipulation of the protease coding sequence were synthesised
XX based on peptide fragments of the protease. The primers are described in
XX AA32287-96. This primer was used to amplify a 320 base pair partial
XX sequence of the protease coding sequence which was then used for sequence
XX information
XX
SQ Sequence 20 BP; 6 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 817 TGTCTACTTCCAGAAAGC 836
DB 1 TGTCTACCATTCAGAAAGC 20

RESULT 332
ACF79629/c
ID ACF79629 standard; DNA; 22 BP.
XX
XX ACF79629;
XX
XX 18-DEC-2003 (first entry)
XX
XX Thiopurine S-methyltransferase exon 5 SNP region.
XX
XX Thiopurine S-methyltransferase; TPMT; enzyme; SNP;
XX single nucleotide polymorphism; immunostimulant; haemostatic;
XX antianemic; gastrointestinal; ds.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX variation replace(11,A)
XX /*tag= a
XX /standard_name= "Single nucleotide polymorphism"
XX
XX WO2003066892-A1.
XX

PD 14-AUG-2003.
XX
XX 04-FEB-2003; 2003WO-EP001090.
XX
XX 04-FEB-2002; 2002EP-00001978.
XX
XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
XX Schwab M, Schaeffeler E;
XX WPI; 2003-627758/59.
XX
XX New thiopurine S-methyltransferase (TPMT) polynucleotide, useful for
XX preparing diagnostic and pharmaceutical compositions for diagnosing and
XX treating a TPMT-associated disease, e.g. leukopenia, thrombocytopenia or
XX anaemia.
XX
XX Claim 1; Page 34; 63pp; English.
XX
XX The present sequence is that of a polymorphic site identified in exon 5
XX of the human thiopurine S-methyltransferase (TPMT) gene. This single
XX nucleotide polymorphism (SNP) is a C at position 463 of the TPMT gene,
XX and results in a K119T amino acid substitution (see ABR63163) in the TPMT
XX protein. It is one of six newly identified SNPs in the TPMT gene that
XX lead to low TPMT activity. A polynucleotide comprising the present
XX sequence (sense or complementary strand) is claimed. Polymorphic TPMT
XX polynucleotides, TPMT polypeptides, antibody and modulator compounds can
XX be used to prepare pharmaceutical compositions for diagnosing or treating
XX a TPMT-associated disease, or a susceptibility to such a disease, e.g.
XX thiopurine-induced toxicity, myelosuppression (pancytopenia) and
XX gastrointestinal disturbances, leukopenia, thrombocytopenia, or anaemia
XX (all claimed)
XX
SQ Sequence 22 BP; 7 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.4; DB 1; Length 22;
Best Local Similarity 95.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1731 CCTTAATACTGTGATTCCA 1750
DB 22 CCTTAATACTGTGATTCCA 3

RESULT 333
AAH75578
ID AAH75578 standard; DNA; 23 BP.
XX
XX AAH75578;
XX
XX 26-OCT-2001 (first entry)
XX
XX Human transcription termination factor binding protein 54 PCR primer 2.
XX
XX Human; transcription termination factor binding protein 54; disease;
XX malignant tumour; nosohaemia; HIV; human immunodeficiency virus;
XX infection; immunological disease; inflammation; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX CN1297918-A.
XX
XX 06-JUN-2001.
XX
XX 26-NOV-1999; 99CN-00124126.
XX
XX 26-NOV-1999; 99CN-00124126.
XX
XX (SHAN-) SHANGHAI BORONG GENE DEV CO LTD.
XX
XX Mao Y, Xie Y, Gin Y;
XX WPI; 2001-489657/54.
XX
XX

XX Human transcription termination factor binding protein 54 as one new kind
PT of polypeptide and polynucleotides encoding this polypeptide.
XX
XX Example 3; Page 17 Disclosure; 28pp; Chinese.
XX
XX The invention relates to human transcription termination factor binding
CC protein 54 useful in treating various diseases, such as malignant tumour,
CC noschaemia, HIV infection, immunological diseases and inflammations. The
CC present sequence is that of a human transcription termination factor
CC binding protein 54 PCR primer of the invention
XX
XX Sequence 23 BP; 9 A; 0 C; 4 G; 10 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 18.4; DB 1; Length 23;
Best Local Similarity 95.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 4910 GAAATGATATGTTTATTT 4929
DB 2 GTAAATGATATGTTTATTT 21
RESULT 334
ADE36253
ID ADE36253 standard; DNA; 24 BP.
AC
AC ADE36253;
XX
XX 29-JAN-2004 (first entry)
XX
XX Rhodospiridium mutant TAL enzyme 3' region oligonucleotide SEQ ID NO:201.
DE
XX recombination; nucleic acid template; recombined polypeptide;
XX altered property; combined gene; ss.
KW
KW Synthetic.
XX
XX Rhodospiridium.
OS
XX WO2003072743-A2.
XX
XX 04-SEP-2003.
XX
XX 26-FEB-2003; 2003WO-US005708.
XX
XX 26-FEB-2002; 2002US-0360279P.
XX
XX (DUPO) DU FONT DE NEMOURS & CO E I.
XX
XX Milano J, Tang X;
XX
XX WPI; 2003-721766/68.
XX
XX Recombination of nucleic acid templates, useful e.g. for producing
PT enzymes with altered properties, is based on cyclic extension of unpaired
PT primers.
XX
XX Disclosure; SEQ ID NO 201; 481pp; English.
XX
XX The present invention describes a method for the recombination of nucleic
CC acid (NA) templates. The method comprises: (a) providing at least two
CC double-stranded templates (T1, T2) having different 5' and 3' regions in
CC their sense strands; (b) contacting the templates with at least one each
CC of forward and reverse primers that anneal, respectively, only to the 3'-
CC region of the antisense strand of T1 and to the 3'-region of the sense
CC strand of T2; (c) extending the primers by no more than 1000 nucleotides
CC (nt); (d) separating extended primers from their templates; (e)
CC reannealing the extended primers, to either template; and (f) repeating
CC cycles of steps (b)-(e) until at least one full-length extension product,
CC i.e. a recombination of T1 and T2, is obtained. Also described: (1) a
CC method starting from at least one each of antisense and sense single-
CC stranded templates; (2) generating a recombined polypeptide (1) with
CC altered properties by expressing recombination products of the new

CC processes and screening the polypeptides formed for properties different
CC from those of polypeptides from either of the templates; and (3) (1)
CC produced by method (2). The methods are useful for the recombination of
CC nucleic acid templates of interest, and generation of a recombined
CC polypeptide having altered properties. The method can be used to make
CC combined genes that express proteins e.g. enzymes, cytokines, growth
CC factors, viral proteins or microbial antigens with altered properties, in
CC e.g. stability, activity or specificity. The present sequence is used in
CC the exemplification of the present invention.
XX
XX Sequence 24 BP; 2 A; 7 C; 12 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 18.4; DB 1; Length 24;
Best Local Similarity 95.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5063 AACTCGAGGGGGGCCCGGT 5082
DB 5 AGCTCGAGGGGGGCCCGGT 24
RESULT 335
AAZ07017
ID AAZ07017 standard; DNA; 24 BP.
XX
XX AAZ07017;
AC
XX
XX 09-NOV-1999 (first entry)
XX
XX Murine alpha-L-iduronidase genomic DNA oligonucleotide #3.
DE
XX
XX Murine; mouse; alpha-L-iduronidase; IDUA; hepatic sulphate transporter;
KW SAT-1; mucopolysaccharidosis type I; MPS I; transgenic mouse;
KW cell-specific targeting system; tissue-specific targeting system;
KW lysosomal disorder; ss.
XX
XX Mus sp.
OS
XX CA2205710-A.
XX
XX 20-NOV-1997.
XX
XX 20-MAY-1997; 97CA-02205710.
XX
XX 20-MAY-1996; 96US-0017156P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jirik F, Clarke LA;
XX
XX WPI; 1999-494691/42.
XX
XX New transgenic mouse, useful for modeling lysosomal disorders and testing
PT cell- or tissue-specific targeting systems.
XX
XX Example 3; Page 12; 20pp; English.
XX
XX The present invention describes a mouse (I), homozygous for a disruption
CC in the alpha-L-iduronidase (IDUA) gene but with normal expression of the
CC hepatic sulphate transporter SAT-1 gene. (I) is used to evaluate
CC therapeutic agents for use in treating mucopolysaccharidosis Type I (MPS
CC I) by administering the agent to (I) and evaluating the mouse for
CC pathology associated with iduronidase deficiency. (I) may also be used to
CC evaluate the ability of a targeting system to deliver a therapeutic agent
CC to a specific tissue or organ in the mouse using the same techniques.
CC Targeting systems which may be tested using this regime include a target-
CC specific label, a viral expression vector or a liposome coupled to
CC iduronidase. (I) may also be used as a general model for studying the
CC pathology of MPS I. The SAT-1 gene overlaps with the IDUA gene but in (I)
CC the expression of the SAT-1 gene is unaffected. Therefore any
CC pathological effects observed in (I) are due solely to the disruption of
CC the IDUA gene. The present sequence represents a IDUA genomic DNA

```
CC oligonucleotide used in the exemplification of the present invention
XX Sequence 24 BP; 20 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5043 AAAAAAAAAAAAAAAAAAAAAAC 5065
Db 1 AAACAAAAACAAAAACAAAAAC 23

RESULT 336
ABQ78896/c
ID ABQ78896 standard; DNA; 24 BP.
XX AC ABQ78896;
XX DT 17-OCT-2002 (first entry)
XX DE Human zinc finger protein 27.50 PCR primer 2.
XX KW Human; zinc finger protein 27.50; PCR; primer; ss.
XX OS Homo sapiens.
XX PN CN1341649-A.
XX PD 27-MAR-2002.
XX PF 07-SEP-2000; 2000CN-00125059.
XX PR 07-SEP-2000; 2000CN-00125059.
XX PA (SHAN-) SHANGHAI BIODOOR GENE DEV CO LTD.
XX PI Mao Y, Xie Y;
XX DR WPI; 2002-520724/56.
XX PT Novel human zinc finger protein 27.50.
XX PS Example 3; Page 17 (Disclosure); 31pp; Chinese.
XX CC The invention relates to a novel human zinc finger protein 27.50, and the
CC polynucleotide encoding it. The polypeptide is useful for treating
CC several diseases, such as solid tumour, nervous system disease, malignant
CC disease of blood, development disturbance and HIV infection. The sequence
CC represents a PCR primer used in example 3 of the invention
XX Sequence 24 BP; 5 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
SQ Query Match 0.4%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5024 TAAAAAAAAAAAAAAAAAAAAA 5046
Db 24 TAAAAAATAAATAAATAAATAA 2

RESULT 337
AAS19218
ID AAS19218 standard; DNA; 24 BP.
XX AC AAS19218;
XX DT 09-APR-2002 (first entry)
XX DE Kringle protein 14, RT-PCR primer #2.
XX KW Kringle protein 14; cytostatic; haemostatic; virucide; immunomodulatory;
```

```
KW antiinflammatory; malignant tumour; haemopathy; inflammation; primer;
KW human immunodeficiency virus; HIV; immunological disease; RT-PCR; ss;
XX reverse transcriptase PCR.
XX OS Unidentified.
XX PN WO200192318-A1.
XX PD 06-DEC-2001.
XX PF 21-MAY-2001; 2001WO-CN000845.
XX PR 24-MAY-2000; 2000CN-00115849.
XX PA (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
XX PI Mao Y, Xie Y;
XX DR WPI; 2002-090030/12.
XX PT Kringle protein 14 and encoding polynucleotide, used in diagnosis and
XX treatment of malignant tumors, hemopathy, human immunodeficiency virus
XX infection, immunological diseases and inflammation.
XX PS Example 2; Page 17; 37pp; Chinese.
XX CC The invention relates to an isolated polypeptide (I) of Kringle protein
XX 14 and the polynucleotide (II) encoding (I). (I) and (II) are used in
XX diagnosis and treatment of malignant tumour, haemopathy, human
XX immunodeficiency virus (HIV) infection, immunological diseases and
XX various inflammations. The present sequence represents a reverse
XX transcriptase (RT)-PCR primer used to isolate the coding sequence of
XX kringle protein 14 as described in the invention
SQ Sequence 24 BP; 20 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 0.4%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5047
Db 2 AAAAAACAAAAAATAAATAA 24

RESULT 338
ABZ59876/c
ID ABZ59876 standard; DNA; 24 BP.
XX AC ABZ59876;
XX DT 10-MAY-2003 (first entry)
XX DE Human protease regulatory protein 28.27 PCR primer SEQ ID NO 3.
XX KW Human; protease regulatory protein 28.27; cancer; cytostatic; HIV;
XX infection; PCR; primer; ss.
XX OS Homo sapiens.
XX PN CN1363562-A.
XX PD 14-AUG-2002.
XX PF 05-JAN-2001; 2001CN-00105028.
XX PR 05-JAN-2001; 2001CN-00105028.
XX PA (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX PI Mao Y, Xie Y;
XX DR WPI; 2003-000303/01.
```

CC diseases and for prediagnosis of such diseases, especially prion diseases
CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC metabolic diseases; also to type genes that encode milk proteins,
CC hormones or transcription factors. The method is simpler, quicker and
CC particularly less expensive than known methods based on sequencing. This
CC sequence represents a prion protein polymorphic microsatellite marker
CC consensus sequence.
XX SQ Sequence 24 BP; 20 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 5043 AAAAAAAAAAAAAAAAAAAAAAC 5065
DB 1 AAAAAAAAAAAAAAAAAAAAAAC 23
RESULT 340
ADR32355/c
ID ADR32355 standard; DNA; 18 BP.
XX AC ADR32355;
XX DT 04-NOV-2004 (first entry)
XX DE Rat KDR cytosolic domain cloning RT-PCR primer.
XX KW Rat; receptor tyrosine kinase; KDR; therapy; cancer;
XX KW ischaemic ocular disease; proliferative retinopathy; inflammation;
XX KW reverse transcription; RT; PCR; primer; ss.
XX OS Rattus norvegicus.
XX PN WO2004070004-A2.
XX PD 19-AUG-2004.
XX PF 23-JAN-2004; 2004WO-US001928.
XX PR 29-JAN-2003; 2003US-0443335P.
XX PA (MERI) MERCK & CO INC.
XX PI Thomas RA, Pan B, Mcgaughey GB;
XX DR WPI; 2004-604429/58.
XX PT New nucleic acid molecules encoding rat KDR protein, useful for
XX PT identifying inhibitors of KDR activity for treating cancer, ischemic
XX PT ocular diseases, and inflammation.
XX PS Example 2; Page 30; 77pp; English.
XX CC The invention relates to rat receptor tyrosine kinase (KDR) and its
XX CC corresponding nucleic acid sequence. The nucleic acid molecules of the
XX CC invention are useful for identifying compounds that modulate wild-type
XX CC rat KDR activity to evaluate the safety and efficacy of specific
XX CC inhibitors of KDR in rats. KDR inhibitors are useful for treating cancer,
XX CC ischaemic ocular diseases such as proliferative retinopathy and
XX CC inflammation. The present sequence is a reverse transcription (RT) PCR
XX CC primer used for cloning rat KDR cytosolic domain. This sequence is used
XX CC in the exemplification of the invention.
XX SQ Sequence 18 BP; 0 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||

CC Polypeptide-human proteinase regulatory protein 28.27 and polynucleotide
CC for coding it.
XX Example 2; Page 17 (Disclosure); 33pp; Chinese.
XX CC The invention relates to human protease regulatory protein 28.27, the
XX CC polynucleotide encoding it, the process for preparing the polypeptide by
XX CC DNA recombinant technology, the application of the polypeptide in
XX CC treating diseases (e.g. cancer, HIV infection), an antagonist of the
XX CC polypeptide and its medical function and the application of the
XX CC polynucleotide. The present sequence is that of a human protease
XX CC regulatory protein 28.27 PCR primer useful in examples of the invention
XX SQ Sequence 24 BP; 2 A; 7 C; 11 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 192 AGCGCCGGGAACGCTATGTCCTCC 214
DB 23 AGCGCCGGGAACGCTATGTCCTCC 1
RESULT 339
AD081152
ID AD081152 standard; DNA; 24 BP.
XX AC AD081152;
XX DT 29-JUL-2004 (first entry)
XX DE Prion protein polymorphic microsatellite marker consensus sequence #30.
XX KW gene typing; polymorphic microsatellite loci; PML;
XX KW disease predisposition; microsatellite marker; prion disease;
XX KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
XX KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
XX KW microsatellite; ds.
XX OS Synthetic.
XX PN DE10236711-A1.
XX PD 26-FEB-2004.
XX PF 09-AUG-2002; 2002DE-01036711.
XX PR 09-AUG-2002; 2002DE-01036711.
XX PA (UYHO-) UNIV HOHENHEIM.
XX PI Geldermann H, Preuss S, Han Y;
XX DR WPI; 2004-215730/21.
XX PT Typing genes that contain polymorphic microsatellite loci, useful for
XX PT identifying predisposition to disease, by amplification and determining
XX PT length of amplicons.
XX PS Claim 9; Page 50; 64pp; German.
XX CC The invention describes a method of typing (M1) a gene (I) that has one
XX CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
XX CC amplification of at least one DNA region of (I) that includes PML, using
XX CC as template a DNA sample containing at least one segment of (I); and
XX CC determining the length of the resulting amplicon(s). Also described are:
XX CC a method of determining (M2) microsatellite markers (MM) for
XX CC predisposition to a disease, associated with a gene that includes one or
XX CC more PML; and prediagnosis (M3) of diseases associated with gene that
XX CC include PML. The method is used to identify microsatellite markers, in a
XX CC disease-related gene, that are associated with a predisposition to


```

Db      18 AAAAAAAAAAAAAAAAAA 1
RESULT 341
ADRS7967/c
ID      ADRS7967 standard; DNA; 18 BP.
XX
XX
AC      ADRS7967;
XX
XX      18-NOV-2004 (first entry)
XX
XX      Nucleotide #4 for signal amplification method.
XX
XX      ss: signal amplification method; gene expression; reverse transcription;
KW      self-assembly reaction; DNA chip.
XX
XX      Unidentified.
XX
XX      WO2004072302-A1.
XX
XX      26-AUG-2004.
XX
XX      13-FEB-2004; 2004WO-JP001588.
XX
XX      14-FEB-2003; 2003JP-00037212.
XX
XX      (PALM-) PALMA BEEZ RES INST CO LTD.
XX
XX      Usui M, Fujikawa T;
XX
XX      WPI; 2004-642306/62.
XX
XX      Signal amplification method for detecting expressed gene, by using
PT      reverse transcription reaction and self-assembly reaction of
PT      oligonucleotide probes.
XX
XX      Disclosure; SEQ ID NO 4; 27pp; Japanese.
XX
XX      The invention relates to a signal amplification method (M1) for detecting
CC      expressed gene using reverse transcription reaction and a self-assembly
CC      reaction of forming a self assembly of oligonucleotide probes, thus
CC      improving detection sensitivity of the expressed gene in a DNA chip. (M1)
CC      is useful for signal amplification method (M1) for detecting expressed
CC      gene (claimed). (M1) improves detection sensitivity of the expressed gene
CC      in a DNA chip (claimed). (M1) does not require use of expensive enzymes
CC      and enables detection corresponding to the original RNA length or
CC      expression amount because of using neither linear amplification nor PCR.
CC      This sequence corresponds to a nucleotide used in the method of the
CC      invention.
XX
XX      Sequence 18 BP; 0 A; 0 C; 0 G; 18 T; 0 U; 0 Other;
      Query Match      0.4%; Score 18; DB 1; Length 18;
      Best Local Similarity 100.0%; Pred. No. 2.1e+02;
      Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      5025 AAAAAAAAAAAAAAAAAA 5042
      |||||
Db      18 AAAAAAAAAAAAAAAAAA 1

RESULT 342
AAA63751
ID      AAA63751 standard; DNA; 22 BP.
XX
XX      AAA63751;
AC
XX      04-DEC-2000 (first entry)
XX
XX      PCR primer used to amplify cDNA encoding murine NL-1.
XX
XX      Neprilysin; neutral endopeptidase metalloproteinase-like enzyme;
KW      NEP-like enzyme; protein production; protein secretion;

```

```

KW      neurological disease; Alzheimer's disease; pain; psychiatric disorder;
XX      fertility; bone disease; abnormal phosphate metabolism; PCR primer; ss.
XX      Mus sp.
XX      WO2000047750-A2.
XX      17-AUG-2000.
XX      11-FEB-2000; 2000WO-CA000147.
XX      11-FEB-1999; 99CA-02260376.
XX      (UYMO-) UNIV MONTREAL.
XX      Desgroseillers L, Boileau G;
XX      WPI; 2000-549148/50.
XX      Novel neutral endopeptidase-like metalloproteinase polypeptides and
PT      polynucleotides, used to screen for related sequences and enzyme
PT      inhibitors, used for the treatment of NL-3 related bone disorders.
XX
XX      Disclosure; Page 12; 59pp; English.
XX
XX      PCR primers AAA63751-52 were used to amplify a murine cDNA sequence
CC      encoding a neutral endopeptidase metalloproteinase (NEP)-like polypeptide,
CC      designated NL-1. The specification also describes NL-2 and NL-3. The NL
CC      enzymes are used to test for specific inhibitors. The N-terminal region
CC      of the enzymes can be used to promote production and secretion of foreign
CC      proteins and active bioproteins, using chimeric constructs containing the
CC      foreign protein downstream from and in phase with the N-terminal region.
CC      The NL enzymes have been localised to the brain, and may be useful in
CC      the treatment of neurological diseases such as Alzheimer's disease, pain,
CC      and psychiatric disorders. NL enzymes have also been localised to the
CC      testis and ovaries, and may be used to control fertility. They have also
CC      been localised to bones, and may be used to treat bone diseases, and
CC      abnormal phosphate metabolisms related to improper peptide processing by
CC      the NL-3 enzyme
XX
XX      Sequence 22 BP; 3 A; 7 C; 8 G; 4 T; 0 U; 0 Other;
      Query Match      0.4%; Score 18; DB 1; Length 22;
      Best Local Similarity 100.0%; Pred. No. 2.2e+02;
      Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 GGATCCCCCGGCTGCAG 18
      |||||
Db      5 GGATCCCCCGGCTGCAG 22

RESULT 343
ABA10153/c
ID      ABA10153 standard; DNA; 21 BP.
XX
XX      ABA10153;
AC
XX      26-FEB-2002 (first entry)
XX
XX      Tail primer #146 from primer set 256 used in gene sorting method.
XX
XX      Gene sorting; PCR primer; disease diagnosis; disease analysis;
KW      cell differentiation; gene therapy; ss.
XX
XX      Synthetic.
XX      WO200175180-A2.
XX      11-OCT-2001.
XX      23-MAR-2001; 2001WO-US009392.
XX      30-MAR-2000; 2000US-00538709.
PR

```

XX PA (OBIO-) QBI ENTERPRISES LTD.

XX PI Ulanovsky L, Mugasimangalam R, Einat P, Zezin-Sonkin D, Shlomit G;

XX PT WPI; 2001-626451/72.

XX DR Sorting genes into non-redundant groups, useful e.g. for gene isolation,

XX PT diagnosis and in gene therapy, by amplifying cDNA fragments attached to

XX PT selective adaptors.

XX PS Example 2; Fig 13; 67pp; English.

XX CC The present invention relates to a method for sorting genes. The method

XX CC comprises producing first double stranded (ds) cDNA from mRNA by reverse

XX CC transcription using a poly-T primer. The ds cDNA is then digested with a

XX CC restriction enzyme that generates cohesive ends with overhanging single

XX CC stranded sequence containing a constant number of nucleotides, and the

XX CC digestion products are ligated to a set of ds DNA oligonucleotide

XX CC adaptors. Each adaptor has at one end, a sequence complementary to a

XX CC possible overhang and the other end a primer-template sequence specific

XX CC for the adaptor complementary sequence, and between these two ends the

XX CC same sequence is present for all adaptors. The ligated cDNA molecules are

XX CC amplified in separate PCR assays, using for each a primer that anneals to

XX CC polyT and a second primer, from a set that anneals to the cDNA specific

XX CC primer-template sequences. Amplicons are finally sorted into non-

XX CC redundant groups defined by the specific primer that annealed to the

XX CC primer-template sequence and thus primed PCR. The method is useful for

XX CC producing a collection of non-redundant cDNA groups, especially where

XX CC every expressed-gene transcript in the original sample is represented by

XX CC its own subgroup. The method is also useful for isolation, identification

XX CC or analysis of genes, analysis and diagnosis of diseases, for studying

XX CC cell differentiation and in gene therapy. The present sequence was used

XX CC to illustrate the method of the present invention

XX SQ Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.8; DB 1; Length 21;

Best Local Similarity 90.5%; Pred. No. 2.3e+02;

Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2851 CCAGAGGATCTGCGCATAGCA 2871

DB 21 CCAGAGGATCTGCTGTAGCA 1

RESULT 344

ADR32218

ID ADR32218 standard; DNA; 22 BP.

XX AC ADR32218;

XX DT 18-NOV-2004 (first entry)

XX DE Human Pdx-1 reverse RT-PCR primer, SEQ ID NO:10.

XX KW Human; salivary gland; stem cell; hSGSC; CD49f-positive; differentiation;

XX KW liver; pancreas; nestin-positive cell; albumin-positive cell;

XX KW insulin-positive cell; glucagon-positive cell; organ regeneration;

XX KW organ transplant; hepatotropic; Pdx-1; reverse transcription-PCR;

XX KW expression analysis; RT-PCR; primer; ss.

XX OS Homo sapiens.

XX XX WO2004074465-A1.

XX PN 02-SEP-2004.

XX PD 20-FEB-2004; 2004WO-JP002002.

XX PF 20-FEB-2003; 2003JP-00043339.

XX PR (BIOS-) BIOS RES INST INC.

XX PA

(ENDO/) ENDO F.

XX PI Endo F, Okumura K, Nakamura K;

XX PT WPI; 2004-642513/62.

XX DR New isolated human stem cell from a salivary gland, capable of

XX PT differentiating into a nestin-positive and albumin-positive cell, insulin

XX PT positive and glucagon-positive cell, for use in the regeneration of

XX PT liver.

XX PS Example 3; SEQ ID NO 10; 28pp; Japanese.

XX CC The invention relates to an isolated CD49f-positive adult human salivary

XX CC gland stem cell (hSGSC) which is capable of differentiating into cells

XX CC characteristic of various organs such as the liver or pancreas when

XX CC cultured in vitro. Specifically, the hSGSCs are capable of

XX CC differentiating into nestin-positive and albumin-positive cells, insulin-

XX CC positive cells or glucagon-positive cells. The invention also relates to

XX CC the differentiated cells produced from hSGSCs; methods of inducing

XX CC differentiation of hSGSCs into nestin-positive/albumin positive, insulin-

XX CC positive or glucagon-positive cells by in vitro culture in the presence

XX CC of a fibroblast growth factor, epithelial cell growth factor and

XX CC leukaemia inhibitory factor; and a method of isolating hSGSCs from human

XX CC salivary gland and culturing them in the presence of epithelial cell

XX CC growth factor. The hSGSCs can be used to regenerate human liver and

XX CC pancreas. The regenerated organs eliminate transplant rejection, as the

XX CC stem cells used to produce the organs are taken from the patient.

XX CC Sequences ADR32209-ADR32230 represent reverse transcription-PCR (RT-PCR)

XX CC primers used to analyse gene expression in hSGSCs in an example of the

XX CC invention.

XX SQ Sequence 22 BP; 8 A; 3 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.8; DB 1; Length 22;

Best Local Similarity 90.5%; Pred. No. 2.3e+02;

Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2902 ATGACAGAGGAGGAGGAGGAC 2922

DB 1 ATGCCAGAGGAGGAGGAGGAC 21

RESULT 345

AAT87932

ID AAT87932 standard; cDNA; 19 BP.

XX AC AAT87932;

XX DT 18-DEC-1997 (first entry)

XX DE Primer for rat cerebellum derived growth factor 1 cDNA.

XX KW Rat; cerebellum derived growth factor; CDGF1; screening; binding;

XX KW modulation; erbB type receptor; identification; induction; risk;

XX KW proliferation; differentiation; induction; neuron; hyperplasia;

XX KW stem cell culture; intracerebral graft; alleviation; repair;

XX KW behavioural defect; nervous system; central; peripheral; nerve;

XX KW prothesis; damage; entubulation; cell survival; treatment; injury;

XX KW trauma; ischaemia; ischemia; stroke; infection; disorder; inflammation;

XX KW neurodegeneration; disease; Parkinson's; Huntington's;

XX KW amyotrophic lateral sclerosis; sensory; retina;

XX KW spinocerebellar degeneration; multiple sclerosis; neoplasia;

XX KW amalignant glioma; medulloblastoma; neuroectodermal tumour; primer;

XX KW polymerase chain reaction; PCR; amplification; ss.

XX OS Synthetic.

XX XX WO9709425-A1.

XX PN 13-MAR-1997.

XX PD 09-SEP-1996; 96WO-US014484.

XX PF

```

XX PR 08-SEP-1995; 95US-00525864.
XX PA (HARD ) HARVARD COLLEGE.
XX PA (STRD ) UNIV LELAND S STANFORD.
XX XX Chang H;
XX PI WPI; 1997-192900/17.
XX DR Rat and human cerebellum-derived growth factors - used in the treatment
XX PT of neuronal injury and proliferative disorders.
XX PS Example; Page 57; 94pp; English.
XX CC The present sequence is a primer for the PCR amplification of rat
XX CC cerebellum derived growth factor 1 (CDGFI) cDNA. CDGF can be used to
XX CC screen for modulators of CDGF binding to erbB type receptors.
XX CC Identification of a modification or mutation in a CDGF gene, or aberrant
XX CC expression of a CDGF gene or levels of soluble CDGF may be used to
XX CC indicate the risk of unwanted cell proliferation or differentiation. CDGF
XX CC may be used to induce neuronal differentiation in stem cell culture, and
XX CC maintain the integrity of a terminally differentiated neuronal cell
XX CC culture, e.g. useful for intracerebral grafting to alleviate behavioural
XX CC defects. CDGF may also be used in nerve protheses to repair central and
XX CC peripheral nerve damage, especially where a crushed or severed axon is
XX CC entubulated by a prosthetic. CDGF may also be used to enhance neuronal
XX CC cell survival in the central or peripheral nervous system, to treat
XX CC neurological conditions associated with nervous system injury, e.g.
XX CC traumatic, chemical or vascular injury and deficits such as ischaemia
XX CC resulting from stroke, infectious/inflammatory and tumour induced injury,
XX CC chronic neurodegenerative disease including Parkinson's and Huntington's,
XX CC amyotrophic lateral sclerosis, spinocerebellar degeneration, chronic
XX CC immunological disease of the nervous system including multiple sclerosis,
XX CC disorders of the sensory neurons and degenerative diseases of the retina.
XX CC CDGF may also be used to treat neoplastic or hyperplastic
XX CC transformations, particularly of the central nervous system, e.g.
XX CC amalignant gliomas, medulloblastomas and neuroectodermal tumours
XX SQ Sequence 19 BP; 5 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 19 GAATTCGGCAGGGGAG 37
Db 1 GAATTCGGCAGGGGAG 19

RESULT 346
AAA83687/c
ID AAA83687 standard; DNA; 19 BP.
XX AC AAA83687;
XX DT 04-DEC-2000 (first entry)
XX DE cdk-we-hu ribozyme binding site #162.
XX KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX OS Mammalia.
XX PN WO200032765-A2.
XX PD 08-JUN-2000.
XX PF 06-DEC-1999; 99WO-US028772.
XX XX 04-DEC-1998; 98US-0110954P.
XX PA (IMMU-) IMMUSOL INC.

Query Match 0.3%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1215 AGATCCTTCAACTCGCTT 1233
Db 19 AGATCCTTCAACTCGCTT 1

RESULT 347
AAH58849/c
ID AAH58849 standard; DNA; 19 BP.
XX AC AAH58849;
XX DT 10-SEP-2001 (first entry)
XX DE Cdk-we-hu ribozyme binding site SEQ ID NO:1273.
XX KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX KW recognition site; target; ribozyme binding site; eye disease; vulnary;
XX KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
XX KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
XX KW atopic dermatitis; actinic keratosis; keratolytic; gene therapy; viral wart;
XX KW basal cell carcinoma; seborrhic wart; vitreoretinopathy; scar;
XX KW sickle cell retinopathy; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200130362-A2.
XX PD 03-MAY-2001.
XX PF 26-OCT-2000; 2000WO-US029500.
XX XX 26-OCT-1999; 99US-0161532P.
XX PA (IMMU-) IMMUSOL INC.
XX PI Robbins JM, Tritz R;
XX XX WPI; 2001-300427/31.
XX DR Treating proliferative skin or eye diseases and scarring, using ribozymes
XX PT that cleave RNA encoding cytokines involved in inflammation, matrix
XX PT metalloproteinases, growth factors and cell-cycle dependent kinases.

```

```

XX PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX DR WPI; 2000-412314/35.
XX XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PT PCNA and Cyclin B1.
XX PS Disclosure; Page 65; 109pp; English.
XX CC The present invention relates to a hairpin or hammerhead ribozyme,
XX CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX CC Representative examples of ribozyme recognition sites are given in
XX CC AA82415 to AA86787. The ribozyme of the invention is useful for
XX CC inhibiting restenosis by introduction of the ribozyme into cells. The
XX CC ribozyme is resistant to endonuclease activity and hence is efficient in
XX CC restenosis treatment
XX SQ Sequence 19 BP; 7 A; 2 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1215 AGATCCTTCAACTCGCTT 1233
Db 19 AGATCCTTCAACTCGCTT 1

RESULT 347
AAH58849/c
ID AAH58849 standard; DNA; 19 BP.
XX AC AAH58849;
XX DT 10-SEP-2001 (first entry)
XX DE Cdk-we-hu ribozyme binding site SEQ ID NO:1273.
XX KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX KW recognition site; target; ribozyme binding site; eye disease; vulnary;
XX KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
XX KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
XX KW atopic dermatitis; actinic keratosis; keratolytic; gene therapy; viral wart;
XX KW basal cell carcinoma; seborrhic wart; vitreoretinopathy; scar;
XX KW sickle cell retinopathy; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200130362-A2.
XX PD 03-MAY-2001.
XX PF 26-OCT-2000; 2000WO-US029500.
XX XX 26-OCT-1999; 99US-0161532P.
XX PA (IMMU-) IMMUSOL INC.
XX PI Robbins JM, Tritz R;
XX XX WPI; 2001-300427/31.
XX DR Treating proliferative skin or eye diseases and scarring, using ribozymes
XX PT that cleave RNA encoding cytokines involved in inflammation, matrix
XX PT metalloproteinases, growth factors and cell-cycle dependent kinases.

```

PS Example 1; Page 164; 408pp; English.

CC The present invention describes a method for treating a proliferative

CC skin or eye disease and scarring. The method involves administering a

CC ribozyme (I) which cleaves RNA encoding a cytokine involved in

CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle

CC dependent kinase, growth factor or a reductase, or administering a

CC nucleic acid molecule (II) comprising a promoter operably linked to a

CC nucleic acid segment encoding (I). (I) can have antiproliferative,

CC dermatological, cytostatic, antiseborrheic, antidiabetic, antiscaling,

CC ophthalmological, vulnerary, keratolytic and virucide activities, and

CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used

CC in gene therapy. (I) and (II) are useful for treating proliferative skin

CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,

CC squamous or basal cell carcinoma and viral or seborrheic wart. They can

CC also be used for treating proliferative eye diseases such as diabetic

CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of

CC prematurity and retinal detachment, and for treating and preventing

CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn

CC scar. AAH57577 to AAH62099 represent sequences used in the

CC exemplification of the present invention

XX

SQ Sequence 19 BP; 7 A; 2 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 17.4; DB 1; Length 19;

Best Local Similarity 94.7%; Pred. No. 2.4e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1215 AGATCCTTCAACTCCGCTT 1233

DB 19 AGATCCTTCAACTCTGCTT 1

RESULT 348

AAAS1499/c

ID AAS1499 standard; DNA; 20 BP.

AC AAS14499;

XX

XX 06-JUN-2002 (first entry)

XX

XX Primer #24 in invention relating to von Willebrand factor.

DE

DE Von Willebrand factor; primer; ss.

KW

XX Unidentified.

OS

XX KR99066382-A.

PN

XX 16-AUG-1999.

PD

XX 24-JAN-1998; 98XR-00002265.

PF

XX 24-JAN-1998; 98XR-00002265.

PR

XX (GREC) KOREA GREEN CROSS CORP.

PA

XX Kim HC, Kim JS, Byun TH, Lee JS, Oh HG, Lee JM, Kim BJ;

PI

XX WPI; 2000-547436/50.

DR

XX

XX Method for purifying factor VIII using chimera antibody to von Willebrand

PT

PT factor.

PS

PS Disclosure; Page 4; 12pp; Korean.

XX

XX The present invention relates to von Willebrand factor. The present

CC

CC sequence represents a primer used in the methods of the present invention

XX

SQ Sequence 20 BP; 1 A; 10 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 17.4; DB 1; Length 20;

Best Local Similarity 94.7%; Pred. No. 2.4e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2503 TGACAGGAGGAGGAGAGA 2921

DB 1 TGACAGATGAAGAGAGA 19

RESULT 350

ADO33402

ID ADO33402 standard; DNA; 20 BP.

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5063 AACTCGAGGGGGGGCCCG 5081

DB 20 ACCTCGAGGGGGGGCCCG 2

RESULT 349

ADH18861

ID ADH18861 standard; DNA; 20 BP.

XX

XX ADH18861;

XX

XX 11-MAR-2004 (first entry)

DT

DE 2'-MOE gapmer antisense oligo targeted to rabbit ApoB DNA - SEQ ID 850.

XX

XX apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;

KW

KW anorectic; lipid; cholesterol metabolism; atherosclerosis;

KW

KW diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;

KW

KW antisense; 2'-O-methoxyethyl gapmer; phosphorothioate backbone; 2'-MOE;

XX

XX human; ss.

OS

XX Oryctolagus cuniculus.

XX

XX WO2003097662-A1.

PN

XX

XX 27-NOV-2003.

PD

XX

XX 15-MAY-2003; 2003WO-US015493.

PF

XX

XX 15-MAY-2002; 2002US-00147196.

PR

XX

XX 13-NOV-2002; 2002US-0426324P.

PR

XX

XX (ISIS-) ISIS PHARM INC.

PA

XX

XX Crooke RM, Graham MJ;

PI

XX

XX WPI; 2004-022840/02.

DR

XX

XX New antisense compound, useful for preparing a composition for treating

PT

PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type

PT

PT 2, obesity, hyperlipidemia or cardiovascular disease.

XX

PS Claim 1; SEQ ID NO 850; 405pp; English.

XX

XX The invention relates to a novel antisense compound targeted to a nucleic

CC

CC acid molecule encoding human apolipoprotein B (ApoB) which specifically

CC

CC hybridises with and inhibits the expression of human apolipoprotein B.

CC

CC The compound of the invention demonstrates antiarteriosclerotic,

CC

CC cardiant, antidiabetic and anorectic activities and may be useful for

CC

CC preparing a composition for treating abnormal lipid or cholesterol

CC

CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or

CC

CC cardiovascular disease. Furthermore, the compound has gene therapy

CC

CC applications. The current sequence is that of the 2'-O-methoxyethyl (2'-

CC

CC MOE) gapmer antisense oligo of the invention which has 2'-MOE 'wings', a

CC

CC phosphorothioate backbone throughout and in which all cytidine residues

CC

CC are 5-methylcytidines.

XX

SQ Sequence 20 BP; 10 A; 1 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 17.4; DB 1; Length 20;

Best Local Similarity 94.7%; Pred. No. 2.4e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX AC ADO33402;
 XX DT 12-AUG-2004 (first entry)
 XX DE Antisense 2'-MOE gapmer oligo targeted to rabbit Apob - SEQ 850.
 XX KW apolipoprotein B; Apob; cardiovascular; antiarteriosclerotic;
 KW KW antilipemic; antidiabetic; anorectic; cardiac; vasotropic; hypotensive;
 KW KW anabolic; eating disorder; cytostatic; endocrine; vasotropic;
 KW KW neuroprotective; nootropic; lipid; cholesterol metabolism;
 KW KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
 KW KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;
 KW KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
 KW KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
 KW KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
 KW KW obesity; atherosclerosis; antisense; 2'-MOE gapmer; 2'-methoxyethyl wing;
 KW KW phosphorothioate backbone; rabbit; ss.
 XX OS Oryctolagus cuniculus.
 XX FH Key Location/Qualifiers
 XX FT modified_base 1..20
 XX FT /*tag= a
 XX FT /mod_base= OTHER
 XX FT /note= "OTHER = Phosphorothioate backbone, bases 1-5 and
 XX FT 16-20 2'-MOE wing bases, all cytidine residues are 5-
 XX FT methylcytidines"
 XX PN WO200404181-A2.
 XX PD 27-MAY-2004.
 XX PF 13-NOV-2003; 2003WO-US036411.
 XX PR 13-NOV-2002; 2002US-0426234P.
 XX PR 15-MAY-2003; 2003WO-US015493.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;
 XX WPI; 2004-420321/39.
 XX DT Antisense oligonucleotide compound that inhibits expression of mRNA
 XX FT encoding human apolipoprotein B, useful for treating hyperlipidemia,
 XX FT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
 XX FT syndrome.
 XX PS Example 42; SEQ ID NO 850; 483pp; English.
 XX CC The invention relates to a novel antisense compound where the compound
 CC hybridises to and inhibits expression of mRNA encoding human
 CC apolipoprotein B (Apob) after 16-24 hours by at least 30% in 80%
 CC confluent HepG2 cells in culture at a concentration of 150 nM. The
 CC compound of the invention demonstrates cardiovascular,
 CC antiarteriosclerotic, antilipemic, antidiabetic, anorectic, cardiac,
 CC vasotropic, hypotensive, anabolic, eating disorder-related, cytostatic,
 CC endocrine, neuroprotective, neuroprotective and nootropic activities and may
 CC be useful for inhibiting the expression of apolipoprotein B in cells or
 CC tissues in vivo in order to address a condition associated with abnormal
 CC lipid or cholesterol metabolism. The compound may be useful for
 CC decreasing circulating lipoprotein levels, triglyceride levels,
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase
 CC reactants and chylomicrons and thus may be utilised during treatment of
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
 CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
 CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
 CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
 CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
 CC diabetes, obesity and atherosclerosis. The current sequence is that of an
 CC antisense 2'-MOE (2'-methoxyethyl) gapmer oligo of the invention which is
 CC targeted to rabbit Apob.

XX SQ Sequence 20 BP; 10 A; 1 C; 7 G; 2 T; 0 U; 0 Other;
 XX Query Match 0.3%; Score 17.4; DB 1; Length 20;
 XX Best Local Similarity 94.7%; Pred. No. 2.4e+02;
 XX Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2903 TGACAGAGGAGGAGGAAGA 2921
 DB 1 TGACAGATGAAGAGGAAGA 19
 RESULT 351
 ID ABL57072 standard; DNA; 21 BP.
 XX AC ABL57072;
 XX DT 22-JUL-2002 (first entry)
 XX DE Molecular beacon target sequence (single mismatch).
 XX DE Molecular beacon; fluorophore; nanoparticle; nucleic acid detection; ss.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 XX FT misc_feature 9
 XX FT /*tag= a
 XX FT /note= "mismatch site"
 XX PN WO200218951-A2.
 XX PD 07-MAR-2002.
 XX PF 29-AUG-2001; 2001WO-US041941.
 XX PR 29-AUG-2000; 2000US-0228728P.
 XX PR 30-MAR-2001; 2001US-0280350P.
 XX PA (UVRQ) UNIV ROCKEFELLER.
 XX PI Dubertret B, Calame M, Libchaber A;
 XX WPI; 2002-404569/43.
 XX DT Sensitive detecting proximity changes in a system that utilizes an
 XX FT interacting fluorophore and quencher, for high sensitivity applications,
 XX FT involves utilizing a metal surface as quencher.
 XX PS Example 3; Page 62; 62pp; English.
 XX CC The present sequence is that of a single mismatch target sequence for a
 CC molecular beacon comprising an oligonucleotide probe (see ABL57069)
 CC covalently attached at the 3' end to fluorescent dye and at the 5' end to
 CC a nanoparticle. In the native state, the probe forms a hairpin
 CC conformation with hybridised termini. The proximity of the fluorophore
 CC and quencher (gold nanoparticle) in the molecular beacon results in
 CC little or no detectable fluorescence. Upon hybridisation of the central
 CC complementary stretch of the probe to a target sequence, such as the
 CC present sequence, the hairpin undergoes a conformational change resulting
 CC in an increase in fluorescence, the extent of which is proportional to
 CC the amount of target sequence present. Experiments with the present
 CC sequence and a perfectly-matched target (see ABL57071) showed that
 CC hybridisation was very specific to the matched target. The invention
 CC relates generally to the use of metal surface quenchers such as particles
 CC or films for high sensitivity applications in, for example, detection and
 CC diagnostic systems
 XX SQ Sequence 21 BP; 14 A; 4 C; 2 G; 1 T; 0 U; 0 Other;
 XX Query Match 0.3%; Score 17.4; DB 1; Length 21;
 XX Best Local Similarity 94.7%; Pred. No. 2.4e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	5050 AAAAAAAAAAAAACTCG 5068
Db	
2 AAAAAAAAAAAAACTCG 20	
RESULT 352	
ADR42646/c	
ID	ADR42646 standard; DNA; 22 BP.
XX	
AC	ADR42646;
XX	
DT	04-NOV-2004 (first entry)
XX	
DE	Acetylated aminopropane diol activated PPAR gene analysis PCR primer #1.
XX	
KW	ss; primer; analgesic; antiangular; antidiabetic; antiarteriosclerotic;
KW	anorectic; antiallergic; antiasthmatic; dermatological; antipsoriatic;
KW	cytostatic; peroxisome proliferator-activated receptor activator;
KW	acylated aminopropane diol; lipid metabolism disorder;
KW	carbohydrate metabolism disturbance; inflammation; cell differentiation;
KW	proliferation; syndrome X; diabetes; atherosclerosis; obesity;
KW	atherosclerosis; allergy; asthma; eczema; psoriasis; itching;
KW	carcinogenesis; PPAR; gene analysis; PCR primer.
XX	
OS	Homo sapiens.
XX	
PN	FR2850869-A1.
XX	
PD	13-AUG-2004.
XX	
PF	12-FEB-2003; 2003FR-00001689.
XX	
PR	12-FEB-2003; 2003FR-00001689.
XX	
PA	(GENF-) GENFIT SA.
XX	
PI	Najib J;
XX	
DR	WPI; 2004-593504/57.
XX	
PT	Use of acylated aminopropane diols and their analogs, for the treatment
PT	of lipid and carbohydrate metabolism disorders, inflammatory disorders
PT	and cell proliferation and differentiation disorders.
XX	
PS	Example 18; Page 70; 113pp; French.
XX	
CC	The invention relates to the use of acylated aminopropane diols and their
CC	analogues (I), their optical and geometric isomers, racemates, salts, and
CC	mixtures in pharmaceutical compositions for the treatment of pathological
CC	states in which there is lipid or carbohydrate metabolism disturbance,
CC	inflammation, and/or cell differentiation or proliferation disturbance.
CC	The compounds are useful for the treatment of lipid and carbohydrate
CC	metabolism disorders such as syndrome X, diabetes, atherosclerosis and
CC	obesity, inflammatory disorders such as atherosclerosis, allergies,
CC	asthma, eczema, psoriasis, and itching, and cell proliferation and
CC	differentiation disorders such as carcinogenesis. In an example of the
CC	invention, the effectiveness of the compounds to activate peroxisome
CC	proliferator-activated receptor (PPAR) genes was tested by gene analysis
CC	using PCR. This sequence represents a primer used in the PCR analysis.
XX	
SQ	Sequence 22 BP; 5 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.3%; Score 17.4; DB 1; Length 22;	
Best Local Similarity 94.7%; Pred. No. 2.5e+02;	
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	4464 AGTTGTCAGGAATTCAG 4482
Db	
21 AGTTGTCAGGAGATTCAG 3	

RESULT 353	
AAQ92371/c	
ID	AAQ92371 standard; DNA; 23 BP.
XX	
AC	AAQ92371;
XX	
DT	25-MAR-2003 (revised)
DT	28-OCT-1995 (first entry)
XX	
DE	DNA primer.
XX	
KW	DNA primer; DNA-polymerase; Tfil; thermostable enzyme; ss.
XX	
OS	Synthetic.
XX	
PN	WO9514770-A1.
XX	
PD	01-JUN-1995.
XX	
PF	23-NOV-1994; 94WO-NZ000135.
XX	
PR	25-NOV-1993; 93NZ-00250288.
XX	
PA	(PACI-) PACIFIC ENZYMES 1993 LTD.
XX	
PI	Bergquist PL, Day DJ, Gibbs MD, Reeves RA, Saul DJ;
XX	
DR	WPI; 1995-206929/27.
XX	
PT	New heat-stable DNA polymerase from Thermus filiformis - has reverse
PT	transcriptase activity in the presence of magnesium ions.
XX	
PS	Disclosure; Page 11; 40pp; English.
XX	
CC	The DNA primer is used with primers AAQ92370-77 in the reverse
CC	transcription-polymerase chain amplification of alpha- lactalbumin from
CC	MA104 cells and topoisomerase-IIa from Jurkat cells. Amplification is
CC	carried out using DNA-polymerase Tfil from Thermus filiformis (AAR76060).
CC	(Updated on 25-MAR-2003 to correct PN field.)
XX	
SQ	Sequence 23 BP; 5 A; 4 C; 4 G; 10 T; 0 U; 0 Other;
Query Match 0.3%; Score 17.4; DB 1; Length 23;	
Best Local Similarity 94.7%; Pred. No. 2.5e+02;	
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	3450 TAAGCAGATGATGGAAT 3468
Db	
19 TAAGCAGATCGGAAT 1	
RESULT 354	
AAH45480/c	
ID	AAH45480 standard; DNA; 23 BP.
XX	
AC	AAH45480;
XX	
DT	07-SEP-2001 (first entry)
XX	
DE	PCR primer specific for cDNA encoding human FD23.
XX	
KW	Human; FD23; cytostatic; haemostatic; virucide; immunomodulatory;
KW	antlinflammatory; malignant tumour; haemopathy; HIV infection;
KW	immunological disease; inflammatory condition; PCR primer; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200138525-A1.
XX	
PD	31-MAY-2001.
XX	
PF	20-NOV-2000; 2000WO-CN000468.
XX	

PR 22-NOV-1999; 99CN-00124048.
 PA (BIORAD) BIORAD GENE DEV LTD SHANGHAI.
 PI Mao Y, Xie Y;
 XX WPI; 2001-355933/37.
 XX Human PD 23 and encoded polynucleotide, used in diagnosis and treatment
 PT of malignant tumors, hemopathy, human immunodeficiency virus infection,
 PT immunological diseases and inflammation.
 XX Example 2; Page 12; 31pp; Chinese.
 PS
 CC This invention relates to the human PD23 protein and the cDNA sequence
 CC encoding it. Included in the invention is a vector containing a PD23
 CC encoding polynucleotide, a host cell containing the vector, and an
 CC antibody directed against PD23. Both the PD23 protein, and cDNA encoding
 CC it can cause cytostatic, haemostatic, virucide, immunomodulatory or
 CC antiinflammatory activity, when used in the diagnosis and treatment of
 CC malignant tumors, haemopathy, HIV infection, immunological disease and
 CC various inflammatory conditions. The present sequence represents a PCR
 CC primer specific for cDNA encoding human PD23
 XX
 SQ Sequence 23 BP; 2 A; 12 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.3%; Score 17.4; DB 1; Length 23;
 Best Local Similarity 94.7%; Pred. No. 2.5e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 5063 AACTCGAGGGGGGGCCCGG 5081
 Db 20 ACCTCGAGGGGGGGCCCGG 2
 RESULT 355
 ADH70614
 ID ADH70614 standard; DNA; 22 BP.
 XX
 XX ADH70614;
 AC
 DT 25-MAR-2004 (first entry)
 XX
 DE Human Vbeta gene repeat sequence #404.
 XX
 KW human; T-cell associated disease; Vbeta; autoimmune disease;
 KW degenerative nervous system disease; graft versus host disease;
 KW hypersensitivity disease; infectious disease; neoplastic disease;
 KW Addison's disease; atrophic gastritis;
 KW degenerative nervous system disease; multiple sclerosis;
 KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
 KW allergy; type II hypersensitivity; Goodpasture's syndrome;
 KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
 KW HIV; fungal infection; Candida; parasitic infection; schistosoma;
 KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
 KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
 KW breast cancer; ds.
 XX
 OS Homo sapiens.
 XX
 XX US2002150891-A1.
 FN
 XX 17-OCT-2002.
 PD
 XX 05-MAR-1999; 99US-00263959.
 PF
 XX 19-SEP-1994; 94US-00309335.
 PR
 XX 19-SEP-1995; 95US-00531241.
 XX
 XX (HOOD/) HOOD L E.
 PA (ROWE/) ROWEN L.
 XX
 XX Hood LE, Rowen L;
 PI

XX WPI; 2004-059052/06.
 XX Kit for diagnosing and treating T-cell associated diseases e.g.
 PT autoimmune, degenerative nervous system and infectious disease, comprises
 PT nucleic acid primers specifically priming and allowing amplification of a
 PT Vbeta gene.
 XX
 XX Disclosure; SEQ ID NO 808; 164pp; English.
 PS
 CC The invention relates to a kit for diagnosing and treating T-cell
 CC associated diseases which comprises a panel of nucleic acid primers
 CC specifically priming and allowing amplification of each Vbeta gene,
 CC VbetarNA or cDNA. The kit is useful for diagnosing organ transplant
 CC rejection and diagnosing and treating T-cell associated diseases
 CC including autoimmune diseases, degenerative nervous system diseases,
 CC graft versus host disease, hypersensitivity diseases, infectious diseases,
 CC and neoplastic diseases. Autoimmune diseases include Addison's disease,
 CC atrophic gastritis, degenerative nervous system diseases include multiple
 CC sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
 CC I hypersensitivities such as contact with allergens that lead to
 CC allergies, Type II hypersensitivities such as those present in
 CC Goodpasture's syndrome and Type IV hypersensitivities such as those
 CC manifested in leprosy. Infectious diseases include viral infections
 CC caused by viruses such as HIV, fungal infections such as those caused by
 CC the yeast genus Candida, parasitic infections such as those caused by
 CC schistosomes, filaria and bacterial infections such as those caused by
 CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
 CC such as Leukaemias, lymphomas and cancers such as cancer of the brain,
 CC breast. The present sequence represents a Vbeta gene repeat sequence.
 XX
 SQ Sequence 22 BP; 18 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.3%; Score 17.2; DB 1; Length 22;
 Best Local Similarity 86.4%; Pred. No. 2.6e+02;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 5044 AAAAAAAAAAAAAAAAAAAAAAC 5065
 Db 1 AAAAAAAAAACAAAAACAAAAAC 22
 RESULT 356
 AD016062
 ID AD016062 standard; DNA; 22 BP.
 XX
 XX AD016062;
 AC
 XX 29-JUL-2004 (first entry)
 DT
 XX 4 synthesis-period of neuroblastoma related primer, SEQ ID 324.
 DE Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
 KW
 KW Synthetic.
 XX
 OS WO2004039975-A1.
 XX
 XX 13-MAY-2004.
 PD
 XX 30-OCT-2003; 2003WO-JP013932.
 PF
 XX 30-OCT-2002; 2002JP-00316586.
 PR
 XX (HISM) HISAMITSU PHARM CO LTD.
 PA (CHIB-) CHIBA PREFECTURE.
 XX
 XX Nakagawara A, Ohira M;
 PI
 XX WPI; 2004-390323/36.
 DR
 XX Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
 PT cells useful for prognosing and determining progress stage of

PT neuroblastomas.
XX Claim 8; SEQ ID NO 324; 455pp; Japanese.
PS
CC The present invention relates to human nucleic acid sequences (I;
CC ADO15739-ADO15912) obtained from 4 synthesis-period (stage 4S) of
CC neuroblastoma cell. (I) is useful for prognosing and determining the
CC progress stage of 4 synthesis-period of neuroblastoma. The present
CC sequence is a primer, used to illustrate the invention.
XX
XX Sequence 22 BP; 3 A; 6 C; 4 G; 9 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. NO. 2.6e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3990 GGGCTCATCAGTTCCTTGGT 4011
DB 1 GGTCAATCATCAGTTCCTTGGT 22
RESULT 357
ADR32106/c
ID ADR32106 standard; DNA; 22 BP.
XX
AC ADR32106;
XX
XX 18-NOV-2004 (first entry)
XX
XX Hepatitis B virus real time PCR primer, SEQ ID 33.
XX analysis; target; real time PCR; primer; ss.
XX
XX Hepatitis B virus.
OS
PN WO2004072230-A2.
XX
PD 26-AUG-2004.
XX
PF 10-FEB-2004; 2004WO-US002012.
XX
PR 10-FEB-2003; 2003US-00361004.
XX
XX (CLEA-) CLEARANT INC.
XX
XX Mckenney K, Gillmeister L, Marlowe K, Armistead D;
XX WPI; 2004-625843/60.
XX
XX Analyzing a target nucleic acid sequence in a biological material by real
PT time PCR using nucleic acid primers that are separated by at least 750
PT nucleic acid residues in the target sequence.
XX
XX Disclosure; SEQ ID NO 33; 96pp; English.
XX
XX The invention relates to a novel method for analysing a target nucleic
CC acid sequence in a biological material. The method comprises adding at
CC least two nucleic acid primers that hybridise under stringent conditions
CC to predetermined nucleic acid sequences of the target nucleic acid
CC sequence that are separated by at least 750 nucleic acid residues,
CC amplifying the target nucleic acid sequence by PCR, and detecting and
CC quantifying the target nucleic acid sequence. The methods and
CC compositions of the present invention are useful for analysing a target
CC nucleic acid sequence in a biological material by real time PCR using
CC nucleic acid primers that are separated by at least 750 nucleic acid
CC residues in the target sequence. This polynucleotide sequence represents
CC a primer used in the exemplification of the invention.
XX
SQ Sequence 22 BP; 6 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.3%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. NO. 2.6e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 723 GAAGGTTTTTTCATTCAGGAT 744
DB 22 GAAGGAGTTTGCATTCAGGAT 1
RESULT 358
ADR67796/c
ID ADR67796 standard; DNA; 22 BP.
XX
AC ADR67796;
XX
XX 18-NOV-2004 (first entry)
XX
XX Hepatitis B virus DNA detection primer #12.
XX ss; detection; pathogen; primer.
XX
XX Hepatitis B virus.
OS
XX WO2004072231-A2.
XX
XX 26-AUG-2004.
XX
XX 10-FEB-2004; 2004WO-US002013.
XX
XX 10-FEB-2003; 2003US-00361002.
XX
XX (CLEA-) CLEARANT INC.
XX
XX Mckenney K, Gillmeister L, Marlowe K, Armistead D;
XX WPI; 2004-625844/60.
XX
XX Determining level of potentially active biological pathogens in
PT biological material, by adding nucleic acid primer pairs to biological
PT material, amplifying target nucleic acid by PCR, detecting and
PT quantifying target nucleic acid.
XX
XX Disclosure; SEQ ID NO 33; 111pp; English.
XX
XX The invention relates to a method of determining (M1) level of
CC potentially active biological pathogens in biological material, involves
CC adding at least two nucleic acid primer pairs to biological material,
CC amplifying target nucleic acid sequences by PCR, and detecting and
CC quantifying target nucleic acid sequences, where quantity of the nucleic
CC acid sequences is proportional to number of biological pathogens in
CC biological material. (M1) is useful for determining level of potentially
CC active biological pathogens in a biological material such as cells,
CC tissues, blood or blood components, proteins, enzymes, immunoglobulins,
CC botanicals, food, ligaments, tendons, nerves, bone, teeth, skin grafts,
CC bone marrow, heart valves, cartilage, corneas, arteries, veins, organs,
CC lipids, carbohydrates, collagen, chitin and its derivatives, forensic
CC samples, mummified material, human or animal remains, stem cells, islet
CC of Langerhans cells, cells for transplantation, red blood cells, white
CC blood cells or platelets. The biological pathogen is chosen from
CC bacteria, viruses, fungi and single cell parasites. The biological
CC pathogen is chosen from Aspergillus, Candida, Histoplasma,
CC Saccharomyces, Coccidioides, Cryptococcus, Escherichia, Bacillus,
CC Campylobacter, Helicobacter, Listeria, Clostridium, Streptococcus,
CC Enterococcus, Staphylococcus, Brucella, Haemophilus, Salmonella,
CC Yersinia, Pseudomonas, Serratia, Enterobacter, Klebsiella, Proteus,
CC Citrobacter, Corynebacterium, Propionibacterium and Coxiella. The
CC biological pathogen is chosen from Adeno-associated virus (AAV),
CC Coxsackievirus-B, Eastern equine encephalitis virus (EEEV), Echovirus,
CC Hantavirus, Hepatitis A virus (HAV), Hepatitis C virus (HCV), HIV,
CC Human T-lymphotropic virus (HTLV), Influenza virus (Flu virus), Measles
CC virus (Rubeola), Mumps virus, Norwalk virus, Parainfluenza virus, Polio
CC virus, Saint Louis encephalitis virus, Western equine encephalitis virus
CC (WEEV), Yellow fever virus, Adenovirus, Cytomegalovirus (CMV), Epstein-


```

SQ      Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match          0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      16 CAGGAATTCGGCAGGAG 32
DB      1 CAGGAATTCGGCAGGAG 17
        |||||
RESULT 360
AAT90091
ID      AAT90091 standard; DNA; 17 BP.
XX
AC      AAT90091;
XX
DT      25-MAR-2003 (revised)
DT      09-APR-1998 (first entry)
XX
Primer SK-Zap for Mch4 and Mch5 coding sequences.

Mch4; Mch5; aspartic acid specific Cys protease; cell apoptosis; stroke;
increased cell survival; hormone dependent tumour; autoimmune disease;
immunoglobulin mediated glomerulonephritis; degenerative disease;
therapy; PCR primer; amplify; ss.

OS      Synthetic.
OS      Homo sapiens.
XX
PN      WO9735020-A1.
XX
PD      25-SEP-1997.
XX
PF      19-MAR-1997; 97WO-US004330.
XX
PR      19-MAR-1996; 96US-00618408.
PR      14-JUN-1996; 96US-00665220.
XX
PA      (IDJN-) IDJN PHARM INC.
PA      (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI      Alnemri ES, Fernandesalnemri T, Litwack G, Armstrong R;
PI      Tomaselli K;
XX
WPI     1997-480225/44.
XX
Aspartic acid specific cysteine protease(s) Mch4 and Mch5 - which are
involved in cell apoptosis, useful to diagnose and treat, e.g. cancer,
autoimmune, Alzheimer's or Parkinson's disease.

Example 1; Page 30; 76pp; English.

XX
CC      This sequence represents a primer for the Mch4 and Mch5 genes of the
CC      invention. Mch4 (see AAM23790) and Mch5 (see AAM27391) are members of the
CC      Aspartic acid specific Cys protease family involved in cell apoptosis.
CC      The genes and proteins can be to diagnose, treat or reduce the severity
CC      of diseases resulting from increased cell survival, e.g. hormone
CC      dependent tumours such as breast, prostate or ovarian cancers, or
CC      autoimmune diseases, such as systemic lupus erythematosus or
CC      immunoglobulin mediated glomerulonephritis, diseases resulting from
CC      decreased cell survival, e.g. degenerative diseases such as Alzheimer's
CC      or Parkinson's disease, or amyotrophic lateral sclerosis or other
CC      diseases associated with increased apoptosis such as aplastic anaemia,
CC      stroke, ischaemic injury following myocardial infarction or reperfusion
CC      injury. (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ      Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match          0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 16 CAGGAATTCGGCAGCAG 32
 ID AAS12632 standard; DNA; 17 BP.
 XX
 AC AAS12632;
 XX
 DT 13-NOV-2001 (first entry)
 DE
 DE PCR primer used to amplify cDNA encoding human Mch6 polypeptide.

RESULT 361
 AAH77930
 ID AAH77930 standard; DNA; 17 BP.
 XX
 AC AAH77930;
 XX
 DT 13-NOV-2001 (first entry)
 DE
 DE PCR primer used to amplify cDNA encoding human Mch6 polypeptide.

Mch6; ced-3 homologue; ICE; interleukin-1-beta converting enzyme;
 KW aspartate-specific cysteine protease; ASCP; apoptotic cell death;
 KW Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis;
 KW retinitis pigmentosa; cerebellar degeneration; myelodysplastic syndrome;
 KW aplastic anemia; ischemic injury; myocardial infarction; stroke; cancer;
 KW reperfusion injury; autoimmune disease; systemic lupus erythematosus;
 KW immune-mediated glomerulonephritis; viral infection; cell death;
 KW PCR primer; ss.

OS Homo sapiens.
 XX
 XX US6274318-B1.
 XX
 XX 14-AUG-2001.
 XX
 XX 13-MAY-1999; 99US-00311760.
 XX
 XX 29-MAY-1997; 97US-00865579.
 XX
 XX (UYJE-) UNIV JEFFERSON THOMAS.

PA Alnemri ES, Fernandes-Alnemri T, Litwack G;
 PI WPI; 2001-540372/60.
 XX
 XX Identifying mammalian homolog ced-3 homologue (Mch6) activity modulators,
 PT useful for treating lymphomas, carcinomas and hormone dependent tumors,
 PT Alzheimer's disease, Parkinson's disease, comprises using Mch6
 PT polypeptide.

XX Example 1; Col 12; 36pp; English.
 XX
 CC The present PCR primer was used to amplify Mch6 cDNA. Mch6 is a ced-3
 CC homologue, and is a member of the ICE (interleukin-1-beta converting
 CC enzyme) family of aspartate-specific cysteine proteases (ASCPs). The
 CC specification describes a method for identifying mammalian Mch6 activity
 CC modulators (inhibitors or enhancers). The compounds identified by the
 CC method are useful as pharmaceuticals for treating or preventing diseases
 CC characterized by increased apoptotic cell death such as Alzheimer's
 CC disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis
 CC pigmentosa, or cerebellar degeneration, myelodysplastic syndromes such as
 CC aplastic anemia, ischemic injury including myocardial infarction, stroke
 CC and reperfusion injury. The compounds are also useful for treating
 CC diseases characterized by loss of apoptotic cell death such as cancers,
 CC e.g. lymphomas, carcinomas and hormone dependent tumours such as breast,
 CC prostate and ovarian cancer. Increased cell survival or apoptosis
 CC inhibition also results in autoimmune diseases such as systemic lupus
 CC erythematosus and immune-mediated glomerulonephritis as well as viral
 CC infections such as herpes virus, pox virus and adenovirus and the novel
 CC identified compounds are useful for treating these conditions. The Mch6
 CC inhibitors are used to treat or to reduce severity of diseases
 CC characterized by increased programmed cell death

XX Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
 XX Query Match 0.3%; Score 17; DB 1; Length 17;
 XX Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
 ID AAS12632 standard; DNA; 17 BP.
 XX
 AC AAS12632;
 XX
 DT 04-DEC-2001 (first entry)
 DE
 DE T3 PCR primer for MCH6 cDNA isolation.

RESULT 362
 AAS12632
 ID AAS12632 standard; DNA; 17 BP.
 XX
 AC AAS12632;
 XX
 DT 04-DEC-2001 (first entry)
 DE
 DE T3 PCR primer for MCH6 cDNA isolation.

XX Aspartate-specific cysteine protease; MCH6; ss; nootropic;
 KW neuroprotective; anti-Parkinsonian; antianaemic; vasotropic; cardiant;
 KW cerebrotective; mammalian ced-3 homologue 6; gene therapy; apoptosis;
 KW Alzheimer's disease; Parkinson's disease; retinitis pigmentosa;
 KW cerebellar degeneration; myelodysplastic syndrome; aplastic anaemia;
 KW ischaemic injury; myocardial infarction; stroke; reperfusion injury;
 KW amyotrophic lateral sclerosis; PCR primer; T3.

XX Synthetic.

OS US2001016345-A1.

XX 23-AUG-2001.

XX 22-DEC-2000; 2000US-00746731.

XX 29-MAY-1997; 97US-00865579.

XX 25-FEB-1999; 99US-00257218.

XX (ALNE/) ALNEMRI B S.

XX (FERN/) FERNANDES-ALNEMRI T.

XX (LITW/) LITWACK G.

XX Alnemri ES, Fernandes-Alnemri T, Litwack G;

XX WPI; 2001-535542/59.

XX New Mch6 polypeptides and genes encoding the polypeptides useful for
 PT diagnosing, treating or reducing the severity of cell death-mediated
 PT diseases such as neurodegenerative diseases e.g. Alzheimer's disease,
 PT Parkinson's disease.

XX Example 1; Page 7; 15pp; English.

XX The invention relates to an isolated gene encoding MCH6 (mammalian ced-3
 CC homologue 6) an aspartate-specific cysteine protease and the MCH6
 CC polypeptide. The MCH6-encoding nucleic acids and polypeptides can be used
 CC to diagnose, treat (e.g. by gene therapy) or reduce the severity of cell
 CC death-mediated diseases (i.e. apoptotic) such as neurodegenerative
 CC diseases e.g. Alzheimer's disease, Parkinson's disease, amyotrophic
 CC lateral sclerosis, retinitis pigmentosa and cerebellar degeneration, and
 CC myelodysplastic syndromes, e.g. aplastic anaemia, ischaemic injury,
 CC myocardial infarction, stroke and reperfusion injury. The MCH6-encoding
 CC nucleic acids and polypeptides can also be used to diagnose or generate
 CC reagents to diagnose diseases mediated or characterised by programmed
 CC cell death. A purified recombinant MCH6 protein can be used to measure
 CC hydrolysis rates for various substrates such as DEVD-AMC and YVAD-AMC in
 CC a continuous fluorometric assay. The present sequence is a PCR primer
 CC used to isolate the cDNA encoding human MCH6

XX Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

XX Query Match 0.3%; Score 17; DB 1; Length 17;
 XX Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32

```

Db      1 CAGGAATTCGGCAGCAG 17
|||||
RESULT 363
AAH15659
ID AAD15659 standard; DNA; 17 BP.
AC AAD15659;
XX
DT 15-NOV-2001 (first entry)
XX
DE Mch6 cloning primer, T3.
XX
KW Apoptotic protease; mammalian ced-3 homologue 6; Mch6; cancer;
KW aspartate-specific cysteine protease; ASCP; apoptosis; therapy;
KW autoimmune disease; cerebellar degeneration; Alzheimer's disease;
KW cytostatic; Parkinson's disease; immunomodulator; antimicrobial;
KW viral infection; cell death-mediated disease; neuroprotective; primer;
KW ss.
XX
OS Unidentified.
XX
PN US6271361-B1.
XX
PD 07-AUG-2001.
XX
PF 25-FEB-1999; 99US-00257218.
XX
PR 29-MAY-1997; 97US-00865579.
XX
PA (UWJE-) UNIV JEFFERSON THOMAS.
XX
PI Alnemri ES, Fernandes-Alnemri T, Litwack G;
XX
DR WPI; 2001-528686/58.
XX
XX New apoptotic genes and their apoptotic protease products, useful for
XX modulating apoptosis for the therapeutic treatment of human diseases,
XX e.g. cancers, autoimmune disease, Alzheimer's disease or Parkinson's
XX disease.
XX
XX Example 1; Col 12; 36pp; English.
XX
XX The invention relates to an isolated gene encoding apoptotic protease,
XX mammalian ced-3 homologue 6 (Mch6). Mch6 is a member of the aspartate-
XX specific cysteine protease (ASCP) family, Mch6 DNA and protein sequences
XX are useful for modulating apoptosis for the therapeutic treatment of
XX human diseases. Mch6 sequences are useful for upregulating apoptosis
XX (e.g. for treating cancers, autoimmune disease or viral infections) or
XX downregulating apoptosis (e.g. for treating Alzheimer's disease,
XX Parkinson's disease or cerebellar degeneration). The Mch6 sequence is
XX useful for diagnosing, treating or reducing the severity of cell death-
XX mediated diseases, as well as other diseases mediated by either increased
XX or decreased programmed cell death. The present sequence is a primer,
XX used for cloning and characterization of Mch6
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 16 CAGGAATTCGGCAGCAG 32
DB 1 CAGGAATTCGGCAGCAG 17
|||||

RESULT 364
AAH25194
ID AAH25194 standard; DNA; 17 BP.
XX
AC AAH25194;
XX
XX Mammalian ced-3 homologue 6 related primer seq id 5.
XX
KW cytostatic; virucide; nootropic; neuroprotective; antiparkinsonian;
KW cardiant; apoptosis modulator; aspartate-specific cysteine protease;
KW gene therapy; aspartate-specific cysteine protease agonist;
KW aspartate-specific cysteine protease antagonist; Mch6;
KW mammalian ced-3 homologue 6; apoptosis; cancer; viral infection;
KW degenerative disorder; Alzheimers disease; Parkinsons disease;
KW myocardial infarction; human; mammalian ced-3 homologue 6; Mch6; PCR;

```

KW	primer; ss.	PN	WO2004080406-A2.
XX		XX	
OS	Synthetic.	PD	23-SEP-2004.
OS	Homo sapiens.	XX	
XX		XX	08-MAR-2004; 2004WO-US007070.
PN	US2002183504-A1.	XX	
XX		XX	07-MAR-2003; 2003US-0452682P.
XX		PR	12-MAR-2003; 2003US-0454265P.
PD	05-DEC-2002.	PR	13-MAR-2003; 2003US-0454962P.
XX		PR	13-MAR-2003; 2003US-0455050P.
XX		PR	14-APR-2003; 2003US-0462894P.
PF	29-JAN-2002; 2002US-00059749.	PR	17-APR-2003; 2003US-0463772P.
XX		PR	25-APR-2003; 2003US-0465665P.
PR	29-MAY-1997; 97US-00865579.	PR	09-MAY-2003; 2003US-0469612P.
PR	25-FEB-1999; 99US-00257218.	PR	08-AUG-2003; 2003US-0493986P.
PR	22-DEC-2000; 2000US-00746731.	PR	11-AUG-2003; 2003US-0494597P.
XX		PR	26-SEP-2003; 2003US-0506341P.
XX	(UYJE-) UNIV JEFFERSON THOMAS.	PR	09-OCT-2003; 2003US-0510246P.
XX		PR	10-OCT-2003; 2003US-0510318P.
PI	Alnemri ES, Fernandes-Alnemri T, Litwack G;	PR	07-NOV-2003; 2003US-0518453P.
XX		XX	(ALNY-) ALNYLAM PHARM.
XX		XX	Manoharan M, Bumcrot D;
XX		XX	WPI; 2004-677362/66.
XX		DR	
XX		XX	Interference RNA agent useful for treating dyslipidemias, coronary artery
CC		PT	disease, diabetes, cancer or neurological disease, comprises sense
CC		PT	sequence and antisense sequence which has specific modifications.
CC		XX	
CC		XX	Example 5; SEQ ID NO 6180; 378pp; English.
CC		XX	The invention describes a RNA interference (iRNA) agent (I) comprising a
CC		CC	sense sequence and an antisense sequence, where the sense sequences have
CC		CC	one or more asymmetrical 2'-O alkyl modifications, the antisense
CC		CC	sequences have one or more asymmetrical phosphorothioate modifications
CC		CC	and the antisense sequence targets a human gene sequence. Also described
CC		CC	are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
CC		CC	levels or glucose-6-phosphatase levels in a subject; producing (I);
CC		CC	stabilising (I), involves selecting a sequence with activity and
CC		CC	introducing one or more asymmetrical modification in the sequence, where
CC		CC	the modification decreases nuclease sensitivity while not decreasing its
CC		CC	activity; a kit comprising (I) and instruction for its use; and a device
CC		CC	that can be dispense or administer a composition comprising (I). (I) is
CC		CC	useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
CC		CC	is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
CC		CC	The subject is suffering from a disorder characterised by elevated or
CC		CC	otherwise unwanted expression of apob-100, elevated or otherwise unwanted
CC		CC	levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC		CC	disorder is chosen from the HDL/LDL cholesterol imbalance,
CC		CC	dyslipidaemias, hypercholesterolaemia, statin-resistant
CC		CC	hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC		CC	disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC		CC	inhibit hepatic glucose production or for treating glucose-metabolism-
CC		CC	related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC		CC	treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC		CC	lung cancer), neurological disease (e.g., Huntington disease or
CC		CC	spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC		CC	represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC		CC	be used to control HCV gene expression.
XX		XX	
SQ	Sequence 19 BP; 0 A; 0 C; 2 G; 17 T; 0 U; 0 Other;		
	Query Match 0.3%; Score 17; DB 1; Length 19;		
	Best Local Similarity 100.0%; Pred. No. 2.6e+02;		
	Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	16 CAGGAATTCGGCAGCAG 32	QY	5049 AAAAAAAAAAAAAAAC 5065
Db	1 CAGGAATTCGGCAGCAG 17	Db	19 AAAAAAAAAAAAAAAC 3
RESULT 366			
ADR81681/c			
ID	ADR81681 standard; DNA; 19 BP.		
AC			
AC	ADR81681;		
XX			
DT	16-DEC-2004 (first entry)		
XX			
DE	Hepatitis C virus (HCV) oligonucleotide seqid 6180.		
XX			
KW	antileptic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;		
KW	cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;		
KW	RNA interference; iRNA; antisense technology; lipid metabolism;		
KW	cholesterol imbalance; dyslipidaemia hypercholesterolaemia;		
KW	coronary artery disease; CAD; coronary heart disease; CHD;		
KW	atherosclerosis; hepatic glucose production;		
KW	glucose-metabolism-related disorder; diabetes; cancer; breast cancer;		
KW	colon cancer; lung cancer; neurological disease; Huntington disease;		
KW	spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.		
OS	Hepatitis C virus.		
XX			

```

RESULT 367
AAT18426/c
ID AAT18426 standard; DNA; 20 BP.
XX
XX
AC AAT18426;
XX
XX 16-OCT-1996 (first entry)
XX
XX Primer for amplifying flea saliva protein (fspl).
XX
XX Flea saliva protein; allergic dermatitis; treatment; desensitise; assay;
KW detection; diagnosis; mosquito; tick; mite; louse; ant; fly; true bug;
KW spider; ss.
XX
XX Synthetic.
XX
XX WO9611271-A1.
XX
XX 18-APR-1996.
XX
XX 06-OCT-1995; 95WO-US013200.
XX
XX 07-OCT-1994; 94US-00319590.
XX
XX 07-JUN-1995; 95US-00487001.
XX
XX 07-JUN-1995; 95US-00487608.
XX
XX (HESK-) HESKA CORP.
XX
XX Frank GR, Hunter SW, Wallenfels L;
XX
XX WPI; 1996-209852/21.
XX
XX Ectoparasite saliva protein - used in treatment of, to desensitise host
XX animal to, and in assay to determine if animal is susceptible to or has
XX allergic dermatitis.
XX
XX Example 6C; Page 134; 255pp; English.
XX
XX Flea saliva proteins or their fragments may be used in formulations to
XX treat or desensitise a host animal suffering from allergic dermatitis,
XX they may also be used in an assay to determine if an animal is
XX susceptible to allergic dermatitis. Saliva proteins taken from the
XX mosquito, tick, mite, louse, ant, fly, true bug or spider may also be
XX used in similar formulations. See AAR94659-R94685. Four primers (AAT18423
XX -26) were used in PCR amplification reactions to generate PCR
XX amplification products of the flea saliva protein fspl
XX
XX Sequence 20 BP; 1 A; 9 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 17; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 2.6e+02;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 5069 AGGGGGGGCCCGGTACC 5085
Db 20 AGGGGGGGCCCGGTACC 4
XX
XX
RESULT 368
AAH20641/c
ID AAH20641 standard; DNA; 20 BP.
XX
XX AAH20641;
XX
XX 13-AUG-2001 (first entry)
XX
XX Human telomeric repeat binding factor 2 oligonucleotide 111369.
XX
XX Antisense; phosphorothioate; human; telomeric repeat binding factor 2;
KW inhibitor; premature aging; hyperproliferative disorder; cancer;
KW cytostatic; ss.
XX
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX
XX modified_base 1..3
XX /*tag= a
XX /mod_base= OTHER
XX /note= "2-O-methoxyethyl"
XX
XX modified_base 13..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2-O-methoxyethyl"
XX
XX WO200143752-A1.
XX
XX 21-JUN-2001.
XX
XX 14-DEC-2000; 2000WO-US033954.
XX
XX 17-DEC-1999; 99US-00467642.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowseart LM;
XX
XX WPI; 2001-398071/42.
XX
XX Antisense compounds targeted to nucleic acid encoding telomeric repeat
XX binding factor 2 useful for treating conditions such as premature aging
XX and diseases such as cancer.
XX
XX Example 15; Page 79; 108pp; English.
XX
XX This invention describes a novel antisense compound (I) 8-30 nucleobases
XX in length targeted to a polynucleotide encoding human telomeric repeat
XX binding factor 2 (II) which specifically hybridizes with, and inhibits
XX the expression of (II). (I) is useful for treating a human having a
XX disease or condition associated with (II) such as premature aging or a
XX hyperproliferative disorder especially cancer, by inhibiting the
XX expression of (II) in human cells or tissues. (I) is useful for
XX diagnostics, therapeutics, prophylaxis and as research reagents and kits.
XX The products of the invention have cytostatic activity. This sequence
XX represents an antisense oligonucleotide used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 17; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 2.6e+02;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 18 GGAATTCGGCAGGAGG 34
Db 20 GGAATTCGGCAGGAGG 4
XX
XX
RESULT 369
ADJ45219
ID ADJ45219 standard; DNA; 22 BP.
XX
XX ADJ45219;
XX
XX 06-MAY-2004 (first entry)
XX
XX p21 promoter, oligonucleotide #3.
XX
XX p53 protein; cell cycle control; apoptosis; oesophageal tumour;
KW pancreatic tumour; colorectal tumour; renal cell carcinoma;
KW cervical carcinoma; cancer; p21 promoter; ss.
XX
XX

```

OS Homo sapiens.
 XX US2003228627-A1.
 XX 11-DEC-2003.
 XX 24-MAR-2003; 2003US-00397131.
 XX 22-MAR-2002; 2002US-0366897P.
 XX (EMER/) EMERSON B M.
 XX (ESPI/) ESPINOSA J.
 XX Emerson BM, Espinosa J;
 XX WPI; 2004-167208/16.
 XX Identifying compounds that modulate binding of p53 protein to gene, by
 PT providing gene as chromatin-assembled DNA and contacting with protein and
 PT test compound, and determining whether compound modulates binding of p53.
 XX Example 1; SEQ ID NO 7; 20pp; English.
 XX The invention relates to a method (M1) of identifying compounds that
 CC modulate the binding of p53 protein to a gene of interest, involving
 CC providing the gene of interest as chromatin-assembled DNA, contacting the
 CC gene of interest with the p53 protein and a test compound, and
 CC determining whether the presence of the test compound modulates the
 CC binding of the p53 to the gene of interest. Also described are the
 CC following: (1) Identifying a modulator that inhibits growth of cancer
 CC cells, which involves providing a gene construct comprising a chromatin
 CC assembled p21 promoter linked to a reporter gene, where the promoter
 CC binds p53 protein, incubating the gene construct in the presence of p53
 CC protein and a test compound, and determining whether the test compound
 CC increases binding of the p53 protein to the gene construct by measuring
 CC the amount of reporter gene activity in the presence and absence of the
 CC test compound; (2) Identifying a test compound that modulates the
 CC interaction of p53 protein with a transcription cofactor that associates
 CC with p53 protein when p53 protein is bound to a gene of interest, which
 CC involves providing the gene of interest as chromatin-assembled DNA,
 CC contacting the gene of interest with the p53 protein, the transcription
 CC cofactor, and the test compound, and determining whether the presence of
 CC the test compound modulates the association of the cofactor with the p53
 CC protein bound to the gene. In (M1), the p53 protein comprises a human p53
 CC protein, recombinant p53 protein or p53 protein that is purified from
 CC tissues. The step of contacting the gene of interest further comprises
 CC contacting the gene of interest with a cell nuclear extract. The gene of
 CC interest is a cell cycle control gene or an apoptotic gene. The p53
 CC protein is a full-length p53 protein. (M1) further involves determining
 CC whether the presence of the test compound modulates the p53 controlled
 CC transcription of the gene of interest. (M1) involves determining whether
 CC the presence of the test compound modulates the binding of p53 comprises
 CC a footprinting assay, an electrophoretic mobility shift assay or an
 CC chromatinimmunoprecipitation assay. The p53 modulator is useful for treating
 CC oesophageal, pancreatic, colorectal tumours, carcinoma such as renal cell
 CC carcinoma, and cervical carcinoma. The present sequence represents an
 CC oligonucleotide used in electrophoretic mobility shift assay (EMSA) of
 CC p53 and the p21 promoter.
 XX Sequence 22 BP; 5 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 XX Query Match 0.3%; Score 17; DB 1; Length 22;
 XX Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 9 CGGGCTGCAGGAATTCG 25
 Db 1 CGGGCTGCAGGAATTCG 17
 RESULT 370
 ADH26737
 ID ADH26737 standard; DNA; 20 BP.

XX ADH26737;
 AC 11-MAR-2004 (first entry)
 DT Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #62.
 DE Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 XX PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytostatic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX Homo sapiens.
 OS US2003225013-A1.
 XX 04-DEC-2003.
 XX 31-MAY-2002; 2002US-00160786.
 XX 31-MAY-2002; 2002US-00160786.
 XX (ISIS-) ISIS PHARM INC.
 XX Freier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
 PT preventing or treating diseases associated with the subunit, e.g.
 PT hyperproliferative disorders.
 XX Example 15; SEQ ID NO 72; 62pp; English.
 XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
 CC p150. The compound is an antisense oligonucleotide that specifically
 CC hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
 CC 4, p150 and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of PI3K regulatory subunit 4, p150
 CC and for preventing or treating hyperproliferative disorders (i.e.
 CC cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
 CC metabolic disorders. These may also be used in research and diagnostics
 CC and in preventing or delaying infection or inflammation. This sequence
 CC represents an antisense oligonucleotide of the invention.
 XX Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;
 XX Query Match 0.3%; Score 16.8; DB 1; Length 20;
 XX Best Local Similarity 90.0%; Pred. No. 2.7e+02;
 XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 3969 TTTAAAGCATGATTTAAAGT 3988
 Db 1 TTTAAATCATGCTTTAAAGT 20
 RESULT 371
 ADL34626
 ID ADL34626 standard; DNA; 20 BP.
 XX ADL34626;
 XX 17-JUN-2004 (first entry)
 XX

```

DE  ISIS antisense oligonucleotide ISIS 207026.
XX  antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX  regulatory subunit 4; p150; internucleoside linkage;
KW  phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW  infection; inflammation; tumour formation; hyperproliferative disorder;
KW  cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW  cytostatic; gene therapy; ss; primer.
XX  Synthetic.
XX  OS
XX  FH  Key          Location/Qualifiers
XX  FT  modified_base 1..20
XX  FT  /*tag= a
XX  FT  /mod base= OTHER
XX  FT  /note= "phosphorothioate backbone"
XX  US2004063657-A1.
XX  01-APR-2004.
XX  18-SEP-2003; 2003US-00667022.
XX  31-MAY-2002; 2002US-00160786.
XX  (FRIE) FREIER S M.
XX  (DOBI) DOBIE K W.
XX  Freier SM, Dobie KW;
XX  WPI; 2004-282523/26.
XX  New antisense compound targeted to a nucleic acid molecule encoding
XX  phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX  treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX  Example 15; SEQ ID NO 72; 60pp; English.
XX  This invention describes a novel antisense oligonucleotides which
XX  specifically hybridises to and inhibits the expression of human
XX  phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX  oligonucleotides comprises at least one modified internucleoside linkage,
XX  preferably a phosphorothioate linkage. It also comprises at least one
XX  modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX  antisense oligonucleotide further comprises at least one modified
XX  nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX  can be used in diagnostics and as research reagents and kits. It can also
XX  be used prophylactically, e.g. to prevent or delay infection,
XX  inflammation or tumour formation. It can also be used to treat a disease
XX  or condition associated with phosphoinositide-3-kinase, regulatory
XX  subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX  Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX  invention are immunomodulators with cytostatic activity and can be used
XX  for gene therapy.
XX  SQ  Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;
      Query Match          0.3%; Score 16.8; DB 1; Length 20;
      Best Local Similarity 90.0%; Pred. No. 2.7e+02;
      Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy  3969 TTTAAAGCATGATTAAAGT 3988
Db      ||||| ||||| ||||| |||||
      1 TTTAAATCATGCTTTAAAGT 20

RESULT 372
AAAX06717
ID  AAAX06717 standard; DNA; 20 BP.
XX
XX  AC  AAAX06717;
XX  DT  26-APR-1999 (first entry)

ISIS antisense oligonucleotide ISIS 207026.
XX  antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
XX  regulatory subunit 4; p150; internucleoside linkage;
KW  phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW  infection; inflammation; tumour formation; hyperproliferative disorder;
KW  cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW  cytostatic; gene therapy; ss; primer.
XX  Synthetic.
XX  OS
XX  FH  Key          Location/Qualifiers
XX  FT  modified_base 1..20
XX  FT  /*tag= a
XX  FT  /mod base= OTHER
XX  FT  /note= "phosphorothioate backbone"
XX  US2004063657-A1.
XX  01-APR-2004.
XX  18-SEP-2003; 2003US-00667022.
XX  31-MAY-2002; 2002US-00160786.
XX  (FRIE) FREIER S M.
XX  (DOBI) DOBIE K W.
XX  Freier SM, Dobie KW;
XX  WPI; 2004-282523/26.
XX  New antisense compound targeted to a nucleic acid molecule encoding
XX  phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
XX  treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX  Example 15; SEQ ID NO 72; 60pp; English.
XX  This invention describes a novel antisense oligonucleotides which
XX  specifically hybridises to and inhibits the expression of human
XX  phosphoinositide-3-kinase, regulatory subunit 4, p150. The
XX  oligonucleotides comprises at least one modified internucleoside linkage,
XX  preferably a phosphorothioate linkage. It also comprises at least one
XX  modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
XX  antisense oligonucleotide further comprises at least one modified
XX  nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
XX  can be used in diagnostics and as research reagents and kits. It can also
XX  be used prophylactically, e.g. to prevent or delay infection,
XX  inflammation or tumour formation. It can also be used to treat a disease
XX  or condition associated with phosphoinositide-3-kinase, regulatory
XX  subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
XX  Chediak-Higashi syndrome or a metabolic disorder. The products of the
XX  invention are immunomodulators with cytostatic activity and can be used
XX  for gene therapy.
XX  SQ  Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;
      Query Match          0.3%; Score 16.8; DB 1; Length 20;
      Best Local Similarity 90.0%; Pred. No. 2.7e+02;
      Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy  3969 TTTAAAGCATGATTAAAGT 3988
Db      ||||| ||||| ||||| |||||
      1 TTTAAATCATGCTTTAAAGT 20

RESULT 372
AAAX06717
ID  AAAX06717 standard; DNA; 20 BP.
XX
XX  AC  AAAX06717;
XX  DT  26-APR-1999 (first entry)

Human JAGGED1 gene intron 10-exon 11 boundary.
XX  JAGGED; JAGGED1; hJAGGED1; human; notch ligand; stem cell;
XX  progenitor cell; haematopoiesis; cell differentiation; Alagille syndrome;
XX  leukaemia; lymphoma; diagnosis; therapy; ss.
XX  OS
XX  FH  Key          Location/Qualifiers
XX  FT  intron       1..10
XX  FT  /*tag= a
XX  FT  /note= "3' end of intron 10"
XX  FT  exon         11..20
XX  FT  /*tag= b
XX  FT  /note= "5' end of exon 11 (exon length is 47 bp)"
XX  WO9858958-A2.
XX  30-DEC-1998.
XX  25-JUN-1998; 98WO-US013207.
XX  25-JUN-1997; 97US-00882046.
XX  (UNIW) UNIV WASHINGTON.
XX  (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX  Li L, Hood L, Krantz ID, Spinner NB;
XX  WPI; 1999-081220/07.
XX  New Jagged peptides for inhibiting differentiation of progenitor cells -
XX  also used for maintaining these cells in undifferentiated state, e.g. for
XX  haematopoietic reconstitution.
XX  Example 4; Fig 6B; 101pp; English.
XX  This nucleotide sequence comprises the intron 10-exon 11 boundary of the
XX  human JAGGED1 gene. 47 Intron/exon boundaries have been defined (see
XX  AAX06701-47) by comparison of genomic sequences from bacterial artificial
XX  chromosome 49D9 and an isolated cDNA clone (see AAX63753). Exon 11
XX  corresponds to nucleotides 1762-1808 of the hJAGGED1 cDNA. hJAGGED1 (see
XX  also AAX87894) is a Notch ligand capable of inhibiting the
XX  differentiation of haematopoietic progenitor cells. Mutation of the
XX  hJAGGED1 gene is associated with Alagille syndrome. The Jagged1 gene has
XX  been mapped to human chromosome 20p12
XX  SQ  Sequence 20 BP; 7 A; 0 C; 2 G; 11 T; 0 U; 0 Other;
      Query Match          0.3%; Score 16.8; DB 1; Length 20;
      Best Local Similarity 90.0%; Pred. No. 2.7e+02;
      Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy  622 TATTTTTCAGATATTCATGA 641
Db      ||||| ||||| ||||| |||||
      1 TATTTTTCAGATATTCATGA 20

RESULT 373
AAAF32481
ID  AAF32481 standard; DNA; 20 BP.
XX
XX  AC  AAF32481;
XX  DT  19-APR-2001 (first entry)
XX  DE  1,5-anhydroglucitol dehydrogenase PCR primer SEQ ID NO:25.
XX  KW  Agrobacterium tumefaciens NT1130; 1,5-anhydroglucitol dehydrogenase;
XX  1,5-AGDH; detection; diabetes; PCR primer; ss.
XX  OS  Agrobacterium tumefaciens.

```


XX The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX

SQ Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.3%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. NO. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 CACACAAATCTGGAGTTCGT 1002
DB 1 CACACAAATCTGGAGTTCGT 20

RESULT 376
ADK80790
ID ADK80790 standard; DNA; 20 BP.
AC ADK80790;
XX
XX 20-MAY-2004 (first entry)
XX
XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8124.
XX
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
XX Synthetic.
OS
XX
XX WO2004016754-A2.
XX
XX 26-FEB-2004.
XX
XX 14-AUG-2003; 2003WO-US025465.
PF
XX 14-AUG-2002; 2002US-0403416P.
PR
XX (PHAA) PHARMACIA CORP.
XX
XX Roberds SL;
XX
XX WPI; 2004-203785/19.
DR
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
XX Claim 4; SEQ ID NO 8124; 417pp; English.
PS
XX
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 17 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 0.3%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. NO. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5046 AAAAAAACAACCAAAAAAC 5065
DB 1 AAAAAAACAACCAAAAAAC 20

RESULT 377
ADL59618/C
ID ADL59618 standard; DNA; 20 BP.
XX
XX ADL59618;
XX
XX 03-JUN-2004 (first entry)
XX
XX Human ESM-1 antisense oligonucleotide seqid 1867.
XX
XX cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW gene therapy; endothelial specific molecule-1; ESM-1;
KW ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW angiogenic disorder; immunological disorder; cardiovascular disorder;
KW neurological disorder; antisense technology; ss.
XX
XX Homo sapiens.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone. All cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2004021978-A2.
XX
XX 18-MAR-2004.
XX
XX 19-AUG-2003; 2003WO-US025833.
XX
XX 19-AUG-2002; 2002US-0404495P.
PR
XX (PHAA) PHARMACIA CORP.
XX
XX Weinstein EJ, Griggs DW;
XX
XX WPI; 2004-248358/23.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT composition for treating e.g., diabetes, cancer or cardiovascular
PT disorder.
XX
XX Claim 3; SEQ ID NO 1867; 555pp; English.
PS
XX The invention describes a new antisense compound, having a sequence
CC comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC specific molecule-1 (ESM-1), that specifically hybridises with the
CC nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC nucleic acid ESM-1 inhibiting the expression of ESM-1 in cells or tissues; and
CC composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC treating an animal having a disease or condition associated with ESM-1.
CC The compound is useful for preparing a composition for treating diabetes,

Thu Aug 18 08:38:09 2005

```
CC cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC cardiovascular or neurological disorder. This sequence represents an
CC antisense oligonucleotide that can be used to modulate expression of
CC endothelial specific molecule-1 (ESM-1).
XX
SQ Sequence 20 BP; 7 A; 4 C; 0 G; 9 T; 0 U; 0 Other;
  Query Match      0.3%; Score 16.8; DB 1; Length 20;
  Best Local Similarity 90.0%; Pred. No. 2.7e+02;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4354 ATGAAAATAAGTTTGGGA 4373
Db 20 ATGAAAATAAGTTTGGGA 1

RESULT 378
ADL59444/C
ID ADL59444 standard; DNA; 20 BP.
XX
AC ADL59444;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human ESM-1 antisense oligonucleotide seqid 1693.
XX
KW cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW gene therapy; endothelial specific molecule-1; ESM-1;
KW ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW angiogenic disorder; immunological disorder; cardiovascular disorder;
KW neurological disorder; antisense technology; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone. All cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
PN WO2004021978-A2.
FD 18-MAR-2004.
XX
XX 19-AUG-2003; 2003WO-US025833.
XX
XX 19-AUG-2002; 2002US-040495P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Weinstein EJ, Griggs DW;
XX
XX WPI; 2004-248358/23.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
XX composition for treating e.g., diabetes, cancer or cardiovascular
XX disorder.
XX
XX Claim 3; SEQ ID NO 1693; 555pp; English.
XX
XX The invention describes a new antisense compound, having a sequence
XX comprising 8-30 bp targeted to a nucleic acid encoding endothelial
XX specific molecule-1 (ESM-1), that specifically hybridises with the
```

```
CC nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC treating an animal having a disease or condition associated with ESM-1.
CC The compound is useful for preparing a composition for treating diabetes,
CC cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC cardiovascular or neurological disorder. This sequence represents an
CC antisense oligonucleotide that can be used to modulate expression of
CC endothelial specific molecule-1 (ESM-1).
XX
SQ Sequence 20 BP; 8 A; 4 C; 0 G; 8 T; 0 U; 0 Other;
  Query Match      0.3%; Score 16.8; DB 1; Length 20;
  Best Local Similarity 90.0%; Pred. No. 2.7e+02;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4350 AGATATGAAAATAAGGTTTT 4369
Db 20 AGGTATGAAAATAAGTTTTT 1

RESULT 379
ADL59682/C
ID ADL59682 standard; DNA; 20 BP.
XX
AC ADL59682;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human ESM-1 antisense oligonucleotide seqid 1931.
XX
KW cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW gene therapy; endothelial specific molecule-1; ESM-1;
KW ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW angiogenic disorder; immunological disorder; cardiovascular disorder;
KW neurological disorder; antisense technology; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone. All cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
PN WO2004021978-A2.
FD 18-MAR-2004.
XX
XX 19-AUG-2003; 2003WO-US025833.
XX
XX 19-AUG-2002; 2002US-040495P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Weinstein EJ, Griggs DW;
XX
XX WPI; 2004-248358/23.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
XX composition for treating e.g., diabetes, cancer or cardiovascular
XX disorder.
XX
XX Claim 3; SEQ ID NO 1931; 555pp; English.
XX
XX PS
```

XX The invention describes a new antisense compound, having a sequence
 CC comprising 8-30 bp targeted to a nucleic acid encoding endothelial
 CC specific molecule-1 (ESM-1), that specifically hybridises with the
 CC nucleic acid ESM-1 and inhibits its expression. Also described are: a
 CC composition; inhibiting the expression of ESM-1 in cells or tissues; and
 CC treating an animal having a disease or condition associated with ESM-1.
 CC The compound is useful for preparing a composition for treating diabetes,
 CC cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
 CC cardiovascular or neurological disorder. This sequence represents an
 CC antisense oligonucleotide that can be used to modulate expression of
 CC endothelial specific molecule-1 (ESM-1).

XX SQ Sequence 20 BP; 8 A; 4 C; 0 G; 8 T; 0 U; 0 Other;
 Query Match 0.3%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 2.7e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4353 TATGAAATAAGGTTTGGG 4372
 |||||
 Db 20 TATGAAATAAGTTTAGG 1

RESULT 390
 AAS11777/c
 ID AAS11777 standard; DNA; 21 BP.
 AC AAS11777;
 XX 07-NOV-2001 (first entry)
 DT VLDLr gene, single nucleotide polymorphism #22.
 DE Very Low Density Lipoprotein Receptor; VLDLr; cardiovascular disease;
 KW single nucleotide polymorphism; SNP; coronary heart disease; forensic;
 KW paternity testing; ss.
 XX Homo sapiens.
 OS
 FH Key Location/Qualifiers
 FT variation replace(11, C)
 FT /*tag= a
 FT /*standard_name= "single nucleotide polymorphism"
 XX WO200166801-A2.
 XX 13-SEP-2001.
 XX 08-MAR-2001; 2001WO-US007444.
 XX 08-MAR-2000; 2000US-0187787P.
 XX (COMP-) COMPLEXE HOSPITALIER SAGAMIE.
 XX (UTWC-) UNIV MCGILL.
 XX Engert J, Vohl M, Brewer C, Morgan K, Gaudet D, Hudson TJ;
 XX WPI; 2001-522953/57.
 XX Polymorphic nucleic acid sequences encoding the very low density
 FT lipoprotein receptor, useful for predicting the presence, absence or
 FT severity of a particular phenotype or disorder, e.g. cardiovascular
 FT disease such as coronary heart disease.
 XX Claim 1; Page 34; 44pp; English.

XX The invention relates to polymorphic nucleic acid sequences encoding the
 CC very low density lipoprotein receptor (VLDLr) and methods of analysing a
 CC nucleic acid sample for polymorphisms. This method comprises obtaining a
 CC nucleic acid sample from one or more individuals, and determining the
 CC nucleotide occupying one or more of the polymorphic sites of one or more
 CC nucleic acid molecules. The method is useful for predicting the presence,

CC absence or severity of a particular phenotype or disorder (e.g.
 CC cardiovascular disease such as coronary heart disease associated with a
 CC particular genotype. The nucleic acids containing the polymorphic sites
 CC may also be useful in forensics and paternity testing. Wild-type or
 CC variant nucleic acid molecules encoding VLDLr or wild-type or variant
 CC VLDLr gene products can be used in the diagnosis and treatment of
 CC cardiovascular diseases and other diseases associated with VLDLr. The
 CC present sequence represents the coding sequence of VLDLr single
 CC nucleotide polymorphism #22

XX SQ Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.3%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 2.7e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3576 TGAACACTCAGTCTTTGCAA 3595
 |||||
 Db 20 TGAACACTCAGTCTTTGCAA 1

RESULT 381
 ACC57852
 ID ACC57852 standard; DNA; 21 BP.
 XX ACC57852;
 AC 11-AUG-2003 (first entry)
 DT Matrix metalloproteinase 2 sense PCR primer.
 DE Matrix metalloproteinase 2; MMP-2; human; transcription;
 KW cis-acting element; transcription factor; PCR; primer; ss.
 XX Homo sapiens.
 OS
 XX WO2003033679-A2.
 XX 24-APR-2003.
 XX 17-OCT-2002; 2002WO-US033579.
 XX 17-OCT-2001; 2001US-0329961P.
 XX (ADRE-) ADVANCED RES & TECHNOLOGY INST.
 XX Yokota H, Sun HB;
 XX WPI; 2003-393526/37.
 XX Predicting an expression level of a target gene or gene family comprises
 XX experimentally determining the number and type of cis-acting elements
 XX provided in 5' untranslated regulatory regions of the target gene.
 XX Example 4; Page 36; 78pp; English.

XX The present sequence is a sense primer for the PCR amplification of human
 CC matrix metalloproteinase 2 (MMP-2) cDNA. A 181 bp product is obtained
 CC using this sense primer with the antisense primer given in ACC57853. RT-
 CC PCR was performed in an example from the invention to determine
 CC expression profiles of MMP genes in human synovial cells in response to
 CC mechanical shear. A model-based analysis was used to identify the role of
 CC transcription factor binding motifs in gene regulation. The results
 CC provide an example of the method of the invention for determining
 CC expression levels of target genes based on sequence elements present in
 CC untranslated regulatory regions

XX SQ Sequence 21 BP; 10 A; 6 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match 0.3%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 2.7e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

4032 GCTCTGCATTGGTACAAGCA 4051

```

Best Local Similarity 90.0%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4591 CAGGCTTCATCGTAACATGC 4610
Db 1 CAGGCTTCATCGTTACAGC 20

RESULT 384
AAV27859
ID AAV27859 standard; DNA; 22 BP.
XX
AC AAV27859;
XX
DT 30-SEP-1998 (first entry)
XX
DE PCR primer H used to create the Cry1C mutants of the invention.
XX
KW Mutant; Cry1C delta-endotoxin; Cry1C.579; insecticidal activity; control;
KW insect; Lepidoptera; Spodoptera exigua; Plutella xylostella;
KW Trichoplusia ni; Spodoptera frugiperda; PCR primer; ss.
XX
OS Synthetic.
OS Bacillus thuringiensis.
XX
FN WO9823641-A1.
XX
PD 04-JUN-1998.
XX
PF 26-NOV-1997; 9TWO-US022181.
XX
PR 27-NOV-1996; 96US-00757536.
XX
PA (ECOG-) ECOGEN INC.
XX
PI Baum JA, Gilmer AJ, Mettuss A;
XX
DR WPI; 1998-322660/28.
XX
New Bacillus thuringiensis nucleic acid segments - comprising delta-
PT endotoxin gene fragments, used for the control of insects, particularly
PT Lepidopteran pests.
XX
PS Example 3; Page 98; 270pp; English.
XX
CC PCR primers AAV27859-60 were used in the course of the invention to
CC create mutants of the Cry1C delta-endotoxin of Bacillus thuringiensis.
CC The mutant proteins show insecticidal activity, and can be sprayed onto
CC plants or expressed in transgenic plants for the control of insects,
CC particularly Lepidopteran pests such as Spodoptera exigua, Plutella
CC xylostella, Trichoplusia ni and Spodoptera frugiperda
XX
SQ Sequence 22 BP; 4 A; 7 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
Db 1 GGATCCCCCGAGCTGCAGGA 20

RESULT 385
AAX80013
ID AAX80013 standard; DNA; 22 BP.
XX
AC AAX80013;
XX
DT 12-AUG-1999 (first entry)
XX
DE B. thuringiensis crystal protein Cry1C PCR mutagenesis primer H.
XX

```

```

KW Bacillus thuringiensis; delta-endotoxin; insecticide; crystal protein;
KW lepidopteran insect; Cry1C; genetic engineering; mutagenesis; mutant;
KW caterpillar; beetle; mosquito; toxic; modification; PCR primer; ss.
XX
OS Synthetic.
OS Bacillus thuringiensis.
XX
FN US5914318-A.
XX
PD 22-JUN-1999.
XX
PF 26-NOV-1997; 97US-00980071.
XX
PR 27-NOV-1996; 96US-00757536.
XX
PA (ECOG-) ECOGEN INC.
XX
PI Mettuss AL, Baum JA, Gilmer AJ;
XX
DR WPI; 1999-370510/31.
XX
New modified delta-endotoxin crystal proteins from Bacillus thuringiensis
PT are useful in insecticidal compositions.
XX
PS Example 3; Col 71; 144pp; English.
XX
CC The present invention describes a new composition comprising an isolated
CC polypeptide for modified Bacillus thuringiensis crystal proteins (Cry1C).
CC The polypeptide of the composition is insecticidally-active against
CC Lepidoptera. The composition is toxic to an insect cell and comprised
CC within an insecticidal formulation can be used as a plant protective
CC spray which is toxic to caterpillars, beetles and mosquitoes. The
CC polypeptide of the composition may be used to kill an insect through
CC ingestion of the composition directly or by ingestion of a plant coated
CC with the composition or a transgenic plant that expresses the polypeptide
CC composition. The insecticidal proteins produced by B. thuringiensis are
CC harmless to plants and other non-targeted organisms but toxic to their
CC specific target insect. The polypeptides have improved toxicity so a
CC reduced amount of bioinsecticide per unit area of treated crop can be
CC used allowing economic and efficient utilization in the field. The
CC present sequence represents a PCR mutagenesis primer for the B.
CC thuringiensis Cry1C crystal protein
XX
SQ Sequence 22 BP; 4 A; 7 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
Db 1 GGATCCCCCGAGCTGCAGGA 20

RESULT 386
AAA08162
ID AAA08162 standard; DNA; 22 BP.
XX
AC AAA08162;
XX
DT 27-JUN-2000 (first entry)
XX
DE B. thuringiensis crystal gene PCR mutagenesis primer SEQ ID NO:52.
XX
KW Bacillus thuringiensis; Cry1C; crystal protein; insecticide; insect;
KW delta-endotoxin; lepidopteran; modification; genetic engineering;
KW resistance; mutant; mutagenesis; PCR primer; ss.
XX
OS Bacillus thuringiensis.
OS Synthetic.
XX
FN US6033874-A.
XX

```

PT Transgenic plants, comprises nucleic acid encoding CryIC delta-endotoxin
PT polypeptide, has improved resistance to Lepidopteran insects.
XX
XX Example 3; Col 235; 151pp; English.
XX
XX The present invention relates to novel transgenic plants comprising CryI
CC delta-endotoxin genes, in particular cryIC genes that encode modified
CC crystal proteins having improved resistance to lepidopteran insects. The
CC plants that express the mutated CryIC delta-endotoxin crystal proteins
CC are monocotyledonous (corn, wheat, oat, rice, barley, turf grass, pasture
CC grass) or dicotyledonous (legume, soybean, cotton, fruit, berry, tree).
CC The present sequence is a PCR primer which is used for mutagenesis of
CC Bacillus thuringiensis CryIC DNA. This sequence is used in the
CC exemplification of the invention
XX
XX Sequence 22 BP; 4 A; 7 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 GGATCCCCCGGCTGCAGGA 20
Db 1 GGATCCCTCGAGCTGCAGGA 20
RESULT 388
ABS70799
ID ABS70799 standard; DNA; 22 BP.
XX
XX ABS70799;
AC
XX
XX 26-NOV-2002 (first entry)
DT
XX
XX B. thuringiensis crystal protein CryIC PCR primer H.
DE
XX Crystal protein; CryIC; ss; delta-endotoxin; insecticide; PCR; primer;
KW lepidopteran insect; mutagenic primer.
XX
XX Bacillus thuringiensis.
XX
XX US6423828-B1.
PN
XX
XX 23-JUL-2002.
PD
XX
XX 22-JUN-1999; 99US-00337280.
PF
XX
XX 27-NOV-1996; 96US-00757536.
PR
XX
XX 26-NOV-1997; 97US-00980071.
PR
XX
XX (MONS) MONSANTO TECHNOLOGY LLC.
PA
XX
XX Baum JA, Gilmer AJ, Mettuss AL;
PI
XX
XX WPI; 2002-705183/76.
PD
XX
XX New delta endotoxin polypeptides, which are Lepidopteran-toxic
PT polypeptides, useful as an insecticide, particularly for killing
PT Lepidopteran insects or insect cells.
XX
XX
XX Example 3; Col 70; 149pp; English.
XX
XX The invention relates to an isolated CryICa* delta-endotoxin polypeptide
CC useful as an insecticide. Cry is a crystal protein from B. thuringiensis.
CC The isolated CryICa* delta-endotoxin polypeptide comprises: (a) one or
CC more amino acid mutations in the loop regions between alpha helices 4 and
CC 5 of domain 1; (b) one or more amino acid mutations in the loop region
CC between alpha helices 6 and 7 of domain 1; or (c) has improved activity
CC against Lepidopteran insects relative to a native CryIC delta-endotoxin
CC polypeptide. The CryICa* delta-endotoxin polypeptide is useful as an
CC insecticide, particularly for killing Lepidopteran insects or insect
CC cells. The present sequence is a mutagenic PCR primer used to produce a
CC mutant CryIC protein of the invention

PD 07-MAR-2000.
XX
XX 18-MAY-1999; 99US-00314093.
XX
XX 27-NOV-1996; 96US-00757536.
XX
XX 26-NOV-1997; 97US-00980071.
XX
XX (ECOG-) ECOGEN INC.
PA
XX
XX Mettuss AL, Baum JA, Gilmer AJ;
PI
XX
XX WPI; 2000-255697/22.
PD
XX
XX New mutant Bacillus thuringiensis endotoxin, used for controlling
PT lepidopteran pests, has mutated loop region to impart higher insecticidal
PT activity.
XX
XX Example 3; Col 71; 153pp; English.
XX
XX The present invention describes isolated Bacillus thuringiensis CryIC
CC delta-endotoxin polypeptides having: (i) at least one amino acid (aa)
CC mutation in the loop region between alpha-helices 6 and 7 of domain 1;
CC and (ii) better activity against Lepidoptera than the native CryIC. The
CC polypeptides, possibly after activation in the digestive tract of
CC insects, kills insect cells by formation of pores and disturbing cellular
CC homeostasis. The polypeptides are used to control lepidopteran pests on
CC plants, either: (i) applied as a composition; or (ii) expressed in plants
CC from heterologous nucleic acid (generating insect-resistant plants). They
CC are more active against Lepidoptera than native CryIC. AAA08144 to
CC AAA08182, and AAY82396 to AAY82432, represent sequences used in the
CC exemplification of the present invention
XX
XX Sequence 22 BP; 4 A; 7 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 GGATCCCCCGGCTGCAGGA 20
Db 1 GGATCCCTCGAGCTGCAGGA 20
RESULT 387
AAD44228
ID AAD44228 standard; DNA; 22 BP.
XX
XX
XX AAD44228;
AC
XX
XX 13-DEC-2002 (first entry)
DT
XX
XX PCR primer H used for mutagenesis of CryIC DNA.
DE
XX
XX CryI protein; delta-endotoxin; insect resistance; lepidopteran insect;
KW transgenic plant; transgenic; PCR; primer; ss.
XX
XX Unidentified.
OS
XX
XX US6313378-B1.
PN
XX
XX 06-NOV-2001.
PD
XX
XX 21-JUN-1999; 99US-00337635.
PF
XX
XX 27-NOV-1996; 96US-00757536.
PR
XX
XX 26-NOV-1997; 97US-00980071.
PR
XX
XX (MONS) MONSANTO TECHNOLOGY LLC.
PA
XX
XX Baum JA, Gilmer AJ, Mettuss AL;
PI
XX
XX WPI; 2002-033341/04.
PD
XX
XX

```

XX SQ Sequence 22 BP; 4 A; 7 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCGGGCTGCAGGA 20
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 389
AAD59856
ID AAD59856 standard; DNA; 22 BP.
XX AC AAD59856;
XX DT 18-DEC-2003 (first entry)
XX DE PCR primer H used to amplify Cry1C DNA.
XX KW Delta-endotoxin gene; Cry1 crystal protein; bioinsecticide; transgenic;
XX KW PCR; primer; ss.
XX OS Unidentified.
XX FN US2003101482-A1.
XX PD 29-MAY-2003.
XX PF 05-OCT-2001; 2001US-00972175.
XX PR 27-NOV-1996; 96US-00757536.
XX PR 26-NOV-1997; 97US-00980071.
XX PR 21-JUN-1999; 99US-00337635.
XX PA (MONS ) MONSANTO TECHNOLOGY LLC.
XX PI Baum JA, Gilmer AJ, Mettuss AL;
XX WPI; 2003-616557/58.
XX DR New nucleic acid segment comprising a delta-endotoxin gene encoding a
PT Cry1 crystal protein, useful for a recombinant expression method to
PT prepare a recombinant polypeptide useful as bioinsecticide.
XX Example 3; Page 39; 151pp; English.
XX CC The invention relates to a nucleic acid segment comprising a delta-
CC endotoxin gene encoding a Cry1 crystal protein. The nucleic acid segment
CC is useful for a recombinant expression method to prepare a recombinant
CC polypeptide useful as bioinsecticides. The present sequence is a PCR
CC primer used to amplify Cry1C DNA
XX SQ Sequence 22 BP; 4 A; 7 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCGGGCTGCAGGA 20
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 390
AAD64016
ID AAD64016 standard; DNA; 22 BP.
XX AC AAD64016;
XX DT 12-FEB-2004 (first entry)

```

```

XX DE PCR primer H used to generate Bacillus thuringiensis Cry1C mutant gene.
XX KW Delta-endotoxin; crystal protein; Cry1C; insecticide; lepidopteran; PCR;
XX KW primer; ss.
XX OS Bacillus thuringiensis.
XX OS Synthetic.
XX FN US2003195336-A1.
XX PD 16-OCT-2003.
XX PF 22-JUL-2002; 2002US-00200522.
XX PR 27-NOV-1996; 96US-00757536.
XX PR 26-NOV-1997; 97US-00980071.
XX PR 22-JUN-1999; 99US-00337280.
XX PA (MONS ) MONSANTO TECHNOLOGY LLC.
XX PI Baum JA, Gilmer AJ, Mettuss AL;
XX WPI; 2003-844482/78.
XX DR New nucleic acid comprising delta-endotoxin gene encoding lepidopteran-
XX toxic polypeptides, useful in preparing recombinant polypeptides and as
XX probes for nucleic acid hybridization or as insecticides e.g. filed crops
XX or fruits.
XX Example 3; Page 39; Opp; English.
XX CC The invention relates to synthetically modified Bacillus thuringiensis
XX Cry1 delta-endotoxin genes in particular cry1C genes encoding modified
XX crystal proteins having improved insecticidal activity against
XX lepidopterans. The invention is useful as insecticides for topical and
XX /or systemic application to field crops, grasses, fruits or vegetables
XX and ornamental plants. The present sequence is a PCR primer used to
XX generate Bacillus thuringiensis Cry1C mutant crystal protein gene
XX SQ Sequence 22 BP; 4 A; 7 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCGGGCTGCAGGA 20
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 391
ACF42669
ID ACF42669 standard; DNA; 22 BP.
XX AC ACF42669;
XX DT 29-SEP-2003 (first entry)
XX DE Human ALMS1 PCR primer Ex7mR.
XX KW Human; ALMS1; chromosome 2; 2p13; Alstrom disease; retinal dystrophy;
XX KW cardiomyopathy; endocrinopathy; diabetes; Alstrom syndrome; cardiac;
XX KW ophthalmological; antidiabetic; hepatotropic; nephrotropic; gene therapy;
XX KW PCR primer; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FN WO2003034072-A2.
XX PD 24-APR-2003.
XX

```

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

PF 15-OCT-2002; 2002WO-GB004658.
XX
PR 15-OCT-2001; 2001GB-00024621.
PR 22-OCT-2001; 2001GB-00025318.
PR 07-JAN-2002; 2002GB-00000248.
PR 08-FEB-2002; 2002GB-00003039.
PR 08-FEB-2002; 2002GB-00003040.
XX (UYSO-) UNIV SOUTHAMPTON.
XX
XX Wilson DI, Hearn T, Walker M;
PI WPI; 2003-393556/37.
XX
XX Diagnosing the presence of, or susceptibility to, retinal dystrophy,
PT cardiomyopathy, endocrinopathy, diabetes, or Alstrom syndrome in an
PT individual, comprises detection or modulation of the ALMS1 protein or
PT gene region.
XX
XX Disclosure; Page 39; 121pp; English.
XX
XX The present invention describes a method of diagnosing the presence of,
CC or susceptibility to, retinal dystrophy, cardiomyopathy, endocrinopathy,
CC diabetes, or Alstrom syndrome in an individual. The method comprises
CC typing in a sample from the individual the ALMS1 protein or ALMS1 gene
CC region of the individual, or detecting aberrant ALMS1 activity. Human
CC ALMS1 is located to chromosome 2, more specifically to 2p13. ALMS1 has
CC ophthalmological, cardiac, antidiabetic, hepatotropic and nephrotropic
CC activities, and can be used in gene therapy. The method is useful for
CC diagnosing the presence of, or susceptibility to, retinal dystrophy,
CC cardiomyopathy, endocrinopathy (e.g. liver disease or renal impairment),
CC diabetes, or Alstrom syndrome in an individual. ALMS1 sequences can be
CC used in an agent that prevents or treats retinal dystrophy,
CC cardiomyopathy, endocrinopathy or diabetes is useful in manufacturing a
CC medicament for treating a patient who has been diagnosed as having or
CC being susceptible to retinal dystrophy, cardiomyopathy, endocrinopathy or
CC diabetes. ACP42632 to ACP42747 and ABR82113 to ABR82118 represent
CC sequences used in the exemplification of the present invention
XX
XX Sequence 22 BP; 2 A; 5 C; 6 G; 9 T; 0 U; 0 Other;
PS
Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3911 CCACTGTGAATGCTCTCTG 3930
DB 2 CCTCTGTGAATGCTCTCTG 21
RESULT 392
AD104018/c
ID AD104018 standard; DNA; 22 BP.
XX
XX AD104018;
XX
XX 15-APR-2004 (first entry)
XX
XX Bovine GHR exon amplifying primer GHRex3_R.
XX
XX GHR; growth hormone receptor; genotypic; bovine; polymorphism;
XX milk production; milk protein; milk fat; PCR; primer; ss.
XX
XX Bos taurus.
XX Synthetic.
XX
XX WO2003104492-A1.
XX
XX 18-DEC-2003.
PD
XX 16-AUG-2002; 2002WO-NZ000157.
PF
XX 05-JUN-2002; 2002NZ-00519372.
PR

PR 15-AUG-2002; 2002NZ-00520797.
XX
XX (BL0T/) BLOTT S.
PA (KIMJ/) KIM J.
PA (SCHM/) SCHMIDT-KUNTZEL A.
PA (CORN/) CORNET A.
PA (BERZ/) BERZI P.
PA (CAME/) CAMBISANO N.
PA (GRIS/) GRISART B.
PA (KARI/) KARIM L.
PA (SIMO/) SIMON P.
PA (GEOR/) GEORGES M.
PA (FARN/) FARNIR F.
PA (COPP/) COPPIETERS W.
PA (MOIS/) MOISIO S.
PA (VILK/) VILKKI J.
PA (JOHN/) JOHNSON D.
PA (SPEL/) SPELMAN R.
PA (FORD/) FORD C.
PA (SNEL/) SNELL R.
XX
XX Blott S, Kim J, Schmidt-Kuntzel A, Cornet A, Berzi P;
PI Cambisano N, Grisart B, Karim L, Simon P, Georges M, Farnir F;
PI Coppieters W, Moisis S, Vilkki J, Johnson D, Spelman R, Ford C;
PI Snell R;
XX
XX WPI; 2004-062378/06.
XX
XX Determining genetic merit of a bovine with respect to milk composition
PT and volume comprises determining the GHR genotypic state of the bovine.
PT
XX Example; SEQ ID NO 41; 74pp; English.
XX
XX The invention relates to determining genetic merit of a bovine with
CC respect to milk composition and volume and involves determining the GHR
CC (growth hormone receptor) genotypic state of the bovine. The genotypic
CC state is determined by the presence of at least one nucleotide difference
CC from the nucleotide sequence, genomic and cDNA encompassing the bovine
CC GHR gene selected from AD103978-AD103981, or by the presence of one or
CC more polymorphisms comprising Nt 7185 (del 1), Nt 1095 (C-T), Nt 1635 (C-T), Nt
CC (T-G), Nt 933+21 (A-G), Nt1922 (C-T), Nt 1583 (N528T), or by detecting the
CC 1809 (C-T), Nt 836 (T-A(F279Y)) or Nt 1583 (N528T), or by detecting the
CC presence of the F279Y polymorphism either by direct or indirect methods.
CC The presence of the polymorphism is associated with altered milk
CC production traits. The altered milk production traits comprise an altered
CC milk volume, milk protein content and milk fat content of the milk
CC composition. The method is useful for determining genetic merit of a
CC bovine with respect to milk composition and volume. Sequences AD104017-
CC AD104036 represent PCR primers for amplification and sequencing of the
CC GHR exons from bovine genomic DNA.
XX
XX Sequence 22 BP; 7 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3270 TTTGTCAACTTCTTCACAGG 3289
DB 22 TTTGTCAACTTCTTCACAGG 3
RESULT 393
AD016768/c
ID AD016768 standard; DNA; 22 BP.
XX
XX AD016768;
XX
XX 29-JUL-2004 (first entry)
XX
XX 4 synthesis-period of neuroblastoma related primer, SEQ ID 1030.
XX Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
KW

XX OS Synthetic.
 XX FN WO2004039975-A1.
 XX PD 13-MAY-2004.
 XX PP 30-OCT-2003; 2003WO-JP013932.
 XX PR 30-OCT-2002; 2002JP-00316586.
 XX PA (HISM) HISAMITSU PHARM CO LTD.
 XX PA (CHIB-) CHIBA PREFECTURE.
 XX FI Nakagawara A, Ohira M;
 XX DR WPI; 2004-390323/36.
 XX PT Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
 PT cells useful for prognosing and determining progress stage of
 PT neuroblastomas.
 XX PS Claim 8; SEQ ID NO 1030; 455pp; Japanese.
 XX CC The present invention relates to human nucleic acid sequences (I;
 CC AD015739-AD015912) obtained from 4 synthesis-period (stage 4S) of
 CC neuroblastoma cell. (I) is useful for prognosing and determining the
 CC progress stage of 4 synthesis-period of neuroblastoma. The present
 CC sequence is a primer, used to illustrate the invention.
 XX SQ Sequence 22 BP; 8 A; 9 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 0.3%; Score 16.8; DB 1; Length 22;
 Best Local Similarity 90.0%; Pred. No. 2.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 4620 TGGGATTGTGAAGTGTGGA 4639
 Db 20 TGGGATTATGAAGTGTGGA 1
 RESULT 394
 ADM06310
 ID ADM06310 standard; DNA; 18 BP.
 AC
 AD06310;
 XX 20-MAY-2004 (first entry)
 DT Human PCR primer SEQ ID NO:4995.
 XX human; gene therapy; diagnostic marker; pharmaceutical; ss; PCR; primer.
 XX Homo sapiens.
 XX EP1347046-A1.
 XX 24-SEP-2003.
 XX 12-APR-2002; 2002EP-00008400.
 XX 22-MAR-2002; 2002JP-00137785.
 XX (REAS-) RES ASSOC BIOTECHNOLOGY.
 XX Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
 FI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
 FI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;
 XX WPI; 2003-723558/69.
 XX New polynucleotides and polypeptides are useful in gene therapy, for
 PT developing a diagnostic marker or medicines for regulating their

PT expression and activity, or as a target of gene therapy.
 XX Example 8; SEQ ID NO 4995; 305pp; English.
 XX The invention relates to a novel human polynucleotide and the encoded
 CC polypeptide. A polynucleotide of the invention may have a use in gene
 CC therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful
 CC as a primer for synthesizing the polynucleotide or as a probe for
 CC detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are
 CC useful in gene therapy, for developing a diagnostic marker or medicines
 CC for regulating their expression and activity, or as a target of gene
 CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides
 CC are useful as pharmaceutical agents. The present sequence represents an
 CC oligonucleotide used in the invention.
 XX SQ Sequence 18 BP; 5 A; 8 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 2.9e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 3813 CCATCCTCTACAAAGCAG 3830
 Db 1 CCATCCTCTACACAGCAG 18
 RESULT 395
 AAX33800
 ID AAX33800 standard; DNA; 19 BP.
 XX
 AC AAX33800;
 XX 25-JUN-1999 (first entry)
 DT S. aureus coding sequence PCR primer SEQ ID NO. 31.
 XX S. aureus infection; diagnosis; therapy; central nervous system disorder;
 KW upper respiratory tract infection; otitis media; bacterial tracheitis;
 KW acute epiglottitis; thyroiditis; empyema; lung abscess; splenic abscess;
 KW cardiac infection; infective endocarditis; secretory diarrhoea; ulcer;
 KW retroperitoneal abscess; cerebral abscess; blepharitis; conjunctivitis;
 KW keratitis; endophthalmitis; preseptal cellulitis; orbital cellulitis;
 KW dacryocystitis; epidiidymitis; intrarenal abscess; perinephric abscess;
 KW toxic shock syndrome; impetigo; folliculitis; cutaneous abscess;
 KW cellulitis; wound infection; bacterial myositis; septic arthritis;
 KW osteomyelitis; Helicobacter pylori infection; stomach cancer; gastritis;
 KW PCR primer; ss.
 XX Synthetic.
 OS Staphylococcus aureus.
 XX WO9912557-A1.
 XX 18-MAR-1999.
 XX 14-SEP-1998; 98WO-US018987.
 XX 12-SEP-1997; 97US-0058710P.
 XX (SMIK) SMITHKLINE BEECHAM CORP.
 XX Burnham MKR, Lonetto MA, Warren PV;
 XX WPI; 1999-229138/19.
 XX New isolated Staphylococcus aureus polynucleotides.
 XX Disclosure; Page 83; 102pp; English.
 XX This sequence represents a PCR primer for a S. aureus polynucleotide of
 CC the invention. The invention also relates to the polypeptides encoded by
 CC the S. aureus polynucleotides. The polypeptides can be used for the
 CC treatment or prevention of disease. The polypeptide or polynucleotide can

CC also be used to diagnose diseases related to their expression. The
CC polypeptides and vectors containing them can also be used in immunisation
CC methods. The products can be used for treating infection, e.g. infections
CC of the upper respiratory tract, (e.g. otitis media, bacterial tracheitis,
CC acute epiglottitis, thyroiditis), respiratory (e.g. empyema, lung
CC abscess), cardiac (e.g. infective endocarditis), gastrointestinal (e.g.
CC secretory diarrhoea, splenic abscess, retroperitoneal abscess), central
CC nervous system (CNS) (e.g. cerebral abscess), eye (e.g. blepharitis,
CC conjunctivitis, keratitis, endophthalmitis, preseptal and orbital
CC cellulitis, dacryocystitis), kidney and urinary tract (e.g.
CC epididymitis, intrarenal and perinephric abscess, toxic shock syndrome),
CC skin (e.g. impetigo, folliculitis, cutaneous abscesses, cellulitis, wound
CC infection, bacterial myositis), bone and joint (e.g. septic arthritis,
CC osteomyelitis), or Helicobacter pylori infections, (e.g. causing stomach
CC cancer, ulcers and gastritis). The products can also be used for treating
CC in-dwelling devices and wounds
XX
SQ Sequence 19 BP; 4 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.3%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 18 GGAATTTCGACGAGCGG 35
Db 1 GGAATTTCGACGAGCGG 18
RESULT 396
AAX76854
ID AAX76854 standard; DNA; 20 BP.
XX
AC AAX76854;
XX
XX 05-AUG-1999 (first entry)
DE PCR primer for cloning of T66Bk gene.
XX
XX Transcription unit; MARK2 kinase; rsk3 kinase; regulatory region; T66Bk;
KW contraceptive; Responder/Distorter signalling cascade; t-Responder;
KW PCR primer; ss.
XX
OS Synthetic.
OS Mus sp.
XX
PN W09925815-A2.
XX
XX 27-MAY-1999.
XX
PF 18-NOV-1998; 98WO-EP007395.
XX
XX 18-NOV-1997; 97EP-00120190.
PR
PR 02-MAR-1998; 98EP-00103596.
XX
XX (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.
XX
XX Herrmann B, Koschorz B, Kispert A;
PI
XX WPI; 1999-347466/29.
XX
XX Nucleic acids involved in the Responder phenotype in mice.
XX
XX Example 7; Page 59; 117pp; English.
XX
XX This sequence is a PCR primer used in the cloning of the T66Bk gene. The
CC invention related to a nucleic acid molecule (I) comprising a
CC transcription unit encoding in its 5' portion a kinase having a homology
CC to MARK2 kinase and the 3' portion of the nucleotide sequence has a high
CC homology to rsk3 kinase. Sperm produced by transgenic creatures
CC containing (I) are useful for production of offspring. T66Bk, its
CC regulatory region, recombinant DNA, vectors, host cells, antibodies,
CC etc., are useful for the isolation of receptors on the surface of sperm
CC recognising attractants of the egg cell for the development and/or

CC production of contraceptives. They can also be used to identify chemicals
CC or biological compounds able to trigger the (premature) activation or
CC inhibition of the Responder/Distorter signalling cascade, or to identify
CC and isolate receptors and other members of the cascade that bind the
CC expression products. The methods for detecting the sperm of the
CC transgenic animal, and selecting against (i) also provide a means for
CC the Responder/Distorter signal cascade other than the t-Responder. They
CC also allow distortion, to a non-Mendelian ratio, of the transmission of a
CC genetic trait, i.e. determination of sex, from male mammals to their
CC offspring by expressing during spermatogenesis/spermiogenesis a gene
CC involved in sperm motility and/or fertilisation. The genes and proteins
CC involved in the responder phenotype and Responder/Distorter signalling
CC cascade, as well as the inventive methods are advantageous in breeding
CC strategies by allowing for specific selection of genetic traits and in
CC particular, of sex
XX
SQ Sequence 20 BP; 8 A; 5 C; 7 G; 0 T; 0 U; 0 Other;
Query Match 0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3412 CAGCAAAAGCGGAGCAG 3429
Db 3 CAGCAAAAGCGGAGCAG 20
RESULT 397
ABQ74807
ID ABQ74807 standard; DNA; 20 BP.
XX
AC ABQ74807;
XX
XX 24-OCT-2002 (first entry)
DE Human TNFR2 antisense oligonucleotide SEQ ID NO:57.
XX
XX Tumour necrosis factor receptor 2; TNFR2; antisense oligonucleotide;
KW phosphorothioate; 2'-O-methoxyethyl; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyl nucleotides"
XX
XX US6410324-B1.
PN
XX 25-JUN-2002.
PD
XX 27-APR-2001; 2001US-00844634.
PF
XX 27-APR-2001; 2001US-00844634.
PR
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Watt AT;
PI
XX WPI; 2002-606814/65.
DR
XX New compounds antisense to nucleic acid encoding human or mouse tumor
PT necrosis factor receptor 2 are useful to treat disease associated with

PT mouse tumor necrosis factor receptor 2 expression.

PS Claim 3; Col 47; 69pp; English.

XX The present invention describes compounds of 8-30 nucleobases antisense to a nucleic acid encoding human or mouse tumour necrosis factor receptor 2 (TNFR2). Also described is a method for inhibiting expression of human or mouse TNFR2 comprising contacting cells or tissues in vitro with one of the claimed compounds. The antisense compounds are used to treat a disease or condition associated with expression of TNFR2. The present sequence represents a human TNFR2 antisense chimeric phosphorothioate oligonucleotide, which is given in the present invention

XX Sequence 20 BP; 3 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 2.9e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 4106 GTCATCCTCCAGGCTC 4123
 ||||| |||||
 Db 1 GTCATCCTCCAGGCTC 18

RESULT 398
 ABD21958/c
 ID ABD21958 standard; DNA; 20 BP.

XX AC AB285728;

XX DT 17-OCT-2003 (first entry)

XX DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
 antiinflammatory steroid; ubiqunone; antiinflammatory; anti-allergic;
 antiasthmatic; hypotensive; immunosuppressive; cycostatic; gene therapy;
 antisense gene therapy; respiratory; lung; adenosine sensitivity;
 adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX OS WO200285308-A2.

XX FN 31-OCT-2002.

XX PD 23-APR-2002; 2002WO-US013135.

XX PF 24-APR-2001; 2001US-0286137P.

XX PR (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX DR WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiqunone.

XX PS Claim 15; SEQ ID NO 970; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiqunone. A composition of the invention
 CC has antiinflammatory, anti-allergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of ubiqunone or
 CC receptor, producing bronchodilation, increasing levels of ubiqunone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 4 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 2.9e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2126 CACATCCAAATGGAAATT 2143
 ||||| |||||
 Db 20 CACATCCAACTGGAAATT 3

RESULT 399
 ABD21958/c
 ID ABD21958 standard; DNA; 20 BP.

XX AC ABD21958;

XX DT 29-JUL-2004 (first entry)

XX DE Human stannocalcin-derived oligo SEQ ID 970.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cycostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX OS WO200285309-A2.

XX FN 31-OCT-2002.

XX PD 23-APR-2002; 2002WO-US013143.

XX PF 24-APR-2001; 2001US-0286036P.

XX PR (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX DR WPI; 2003-093058/08.

XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX PS Claim 15; SEQ ID NO 970; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating

expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP; 4 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2126 CACATCCAAATGGAATT 2143
|||||||
DB 20 CACATCCAACTGGAATT 3

RESULT 400
ADK77211
ID ADK77211 standard; DNA; 20 BP.
XX
AC ADK77211;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4545.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
PN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding Nav1.3, useful for treating a disease or condition associated with Nav1.3, e.g. pain, seizure disorder such as childhood seizure disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 4545; 417pp; English.

CC The present invention relates to an antisense compound targeted to a nucleic acid molecule encoding Nav1.3, where the antisense compound specifically hybridizes with and inhibits the expression of Nav1.3. The compound and composition are useful for treating a disease or condition associated with Nav1.3, e.g. pain including but not limited to neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain, diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain, pain from burns, migraine headache, cluster headache, mild-to-moderate headache; seizure disorder such as childhood seizure disorder, including but not limited to neonatal or infantile epilepsy; or ataxia. The present sequence represents a chimeric phosphorothioate oligonucleotide with 2'WOE wings and a deoxy gap. Used during the antisense inhibition of human Nav1.3 expression, the oligonucleotides are designed to target CC different regions of the human Nav1.3 RNA.

Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4458 CACTGAAGTTCTCCAGGA 4475
|||||||
DB 3 CACTGAAGTTCTCCAGGA 20

RESULT 401
ADK76861
ID ADK76861 standard; DNA; 20 BP.
XX
AC ADK76861;

DT 20-MAY-2004 (first entry)

DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4195.

KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.

OS Synthetic.

PN WO2004016754-A2.

PD 26-FEB-2004.

PF 14-AUG-2003; 2003WO-US025465.

PR 14-AUG-2002; 2002US-0403416P.

PA (PHAA) PHARMACIA CORP.

PI Roberds SL;

DR WPI; 2004-203785/19.

PT New antisense compound targeted to a nucleic acid molecule encoding Nav1.3, useful for treating a disease or condition associated with Nav1.3, e.g. pain, seizure disorder such as childhood seizure disorder, or ataxia.

Claim 4; SEQ ID NO 4195; 417pp; English.

CC The present invention relates to an antisense compound targeted to a nucleic acid molecule encoding Nav1.3, where the antisense compound specifically hybridizes with and inhibits the expression of Nav1.3. The compound and composition are useful for treating a disease or condition associated with Nav1.3, e.g. pain including but not limited to neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain, diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain, pain from burns, migraine headache, cluster headache, mild-to-moderate headache; seizure disorder such as childhood seizure disorder, including but not limited to neonatal or infantile epilepsy; or ataxia. The present

CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 4458 CACTGAAGTTCTCCAGGA 4475
Db 2 CACTGAAGTTCTCCAGGA 19
|||||

RESULT 402

ADK78504

ID ADK78504 standard; DNA; 20 BP.

XX AC ADK78504;

XX DT 20-MAY-2004 (first entry)

XX DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5838.

XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
XX diabetic neuropathy; arthritic pain; migraine headache;
XX infantile epilepsy; ataxia; ss.

XX OS Synthetic.

XX PN WO2004016754-A2.

XX PD 26-FEB-2004.

XX PF 14-AUG-2003; 2003WO-US025465.

XX PR 14-AUG-2002; 2002US-0403416P.

XX PA (PHAA) PHARMACIA CORP.

XX PI Roberds SL;

XX DR WPI; 2004-203785/19.

XX New antisense compound targeted to a nucleic acid molecule encoding
XX Nav1.3, useful for treating a disease or condition associated
XX with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
XX disorder, or ataxia.

XX PS Claim 4; SEQ ID NO 5838; 417pp; English.

XX The present invention relates to an antisense compound targeted to a
XX nucleic acid molecule encoding Nav1.3, where the antisense compound
XX specifically hybridizes with and inhibits the expression of Nav1.3. The
XX compound and composition are useful for treating a disease or condition
XX associated with Nav1.3, e.g. pain including but not limited to
XX neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
XX pain from burns, migraine headache, cluster headache, mild-to-moderate
XX headache; seizure disorder such as childhood seizure disorder, including
XX but not limited to neonatal or infantile epilepsy; or ataxia. The present
XX sequence represents a chimeric phosphorothioate oligonucleotide with
XX 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
XX human Nav1.3 expression, the oligonucleotides are designed to target
XX different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 4458 CACTGAAGTTCTCCAGGA 4475
Db 1 CACTGAAGTTCTCCAGGA 18
|||||

RESULT 403

ADO71038

ID ADO71038 standard; DNA; 20 BP.

XX AC ADO71038;

XX DT 26-AUG-2004 (first entry)

XX DE Human CD90 reverse transcription (RT)-PCR primer #1.

XX CD90; neurodegenerative disorder;
XX exogenously regulatable neurotransmitter synthesis; multiple sclerosis;
XX amyotrophic lateral sclerosis; autoimmune encephalomyelitis;
XX Alzheimer's disease; Huntington's disease; Parkinson's disease; human;
XX reverse transcription; RT-PCR; primer; ss.

XX OS Homo sapiens.

XX PN WO2004046348-A1.

XX PD 03-JUN-2004.

XX PF 17-NOV-2003; 2003WO-IL000972.

XX PR 17-NOV-2002; 2002IL-00152905.

XX PA (UYRA-) UNIV RAMOT AT TEL AVIV LTD.

XX PI Offen D, Melamed E, Levy Y;

XX DR WPI; 2004-420630/39.

XX Treating a neurodegenerative disorder, e.g. multiple sclerosis, or
XX Alzheimer's, Huntington's or Parkinson's diseases, comprises
XX administering cells capable of exogenously regulatable neurotransmitter
XX synthesis.

XX PS Example 3; SEQ ID NO 1; 110pp; English.

XX The invention relates to a method of treating a neurodegenerative
XX disorder comprising administering to an individual cells capable of
XX exogenously regulatable neurotransmitter synthesis. Treating a
XX neurodegenerative disorder comprises administering to an individual cells
XX capable of exogenously regulatable neurotransmitter synthesis and
XX periodically exposing the individual to an agent or condition capable of
XX regulating the synthesis of the neurotransmitter in the cells. The method
XX and cells are useful in treating a neurodegenerative disorder e.g.
XX multiple sclerosis, amyotrophic lateral sclerosis, autoimmune
XX encephalomyelitis, Alzheimer's disease, or Huntington's disease,
XX preferably Parkinson's disease. The present sequence represents a human
XX CD90 reverse transcription (RT)-PCR primer.

XX SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2978 TACTGGACCAAGCCATC 2995
Db 2 TAGTGGACCAAGCCATC 19
|||||

RESULT 404

AAH62440

ID AAH62440 standard; DNA; 21 BP.

XX

RESULT 406
 ADH17700
 ID ADH17700 standard; DNA; 21 BP.
 XX
 AC ADH17700;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Reverse PCR primer Ag2764 used to analyse human NOV expression.
 XX
 KW NOVX; antidiabetic; anorectic; cardiant; hypotensive;
 KW antiarteriosclerotic; anorectic; virucide; antibacterial; fungicide;
 KW protozoacide; neurotropic; neuroprotective; antiparkinsonian;
 KW dermatologic; osteopathic; antiarthritic; antiinflammatory;
 KW obesity; infection; anorexia; cancer; cardiovascular; hypertension;
 KW atherosclerosis; neurodegenerative; Alzheimer's disease; Parkinson's;
 KW epilepsy; immune; osteoarthritis; haemopoietic;
 KW inflammatory skin disorder; asthma; dyslipidaemia; neurogenesis;
 KW cell differentiation; proliferation; haemopoiesis; wound healing;
 KW angiogenesis; gene therapy; chromosome mapping; tissue typing;
 KW pharmacogenomic; human; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003093432-A2.
 XX
 PD 13-NOV-2003.
 XX
 PF 02-MAY-2003; 2003WO-US013690.
 XX
 PR 02-MAY-2002; 2002US-0377321P.
 PR 08-MAY-2002; 2002US-0378730P.
 PR 24-MAY-2002; 2002US-0383075P.
 PR 29-MAY-2002; 2002US-0384044P.
 PR 30-MAY-2002; 2002US-0384215P.
 PR 30-MAY-2002; 2002US-0384296P.
 PR 30-MAY-2002; 2002US-0384297P.
 PR 30-MAY-2002; 2002US-0384327P.
 PR 30-MAY-2002; 2002US-0384352P.
 PR 31-MAY-2002; 2002US-0385211P.
 PR 02-JUL-2002; 2002US-0393333P.
 PR 09-AUG-2002; 2002US-0402154P.
 PR 09-AUG-2002; 2002US-0402171P.
 PR 09-AUG-2002; 2002US-0402204P.
 PR 09-AUG-2002; 2002US-0402205P.
 PR 22-AUG-2002; 2002US-0405173P.
 PR 27-AUG-2002; 2002US-0406129P.
 PR 23-SEP-2002; 2002US-0412954P.
 PR 30-SEP-2002; 2002US-0414975P.
 PR 07-OCT-2002; 2002US-0416661P.
 PR 24-OCT-2002; 2002US-0420851P.
 PR 31-OCT-2002; 2002US-0422547P.
 PR 01-MAY-2003; 2003US-00428275.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Alvarez E, Anderson DW, Boldog FL, Catterton E, Edinger SR;
 PI Fernandes ER, Gerlach VL, Gorman L, Grosse WM, Guo X, Ji W;
 PI Kekuda R, Li L, Macdougall JR, Padigaru M, Patturajan M;
 PI Peterson JD, Raetelli L, Shinkets RA, Spytek KA, Stone DJ;
 PI Vernet CAM, Voss EZ, Zhong M;
 XX
 DR WPI; 2004-053040/05.
 XX
 XX New isolated NOVX polypeptide, useful for preventing, diagnosing or
 PT treating NOVX-associated disorders, e.g. osteoarthritis, obesity,
 PT atherosclerosis, cancer, Parkinson's disease, asthma, or infections.
 XX
 PS Example C; SEQ ID NO 390; 478pp; English.
 XX
 CC The invention relates to a novel isolated NOVX polypeptide. The

polypeptide of the invention demonstrates antidiabetic, anorectic,
 cardiant, hypotensive, antiarteriosclerotic, anorectic, virucide,
 antibacterial, fungicide, protozoacide, neurotropic, neuroprotective,
 antiparkinsonian, anticonvulsant, osteopathic, antiarthritic,
 antiinflammatory, dermatological, antiasthmatic and antilipemic
 activities. The polypeptides, nucleic acid molecules and antibodies may
 be useful in the manufacture of a medicament for treating metabolic
 disorders, diabetes, obesity, infectious diseases (viral, bacterial,
 fungal, helminthic, and protozoal), anorexia, cancer, cardiovascular
 diseases including hypertension and atherosclerosis, neurodegenerative
 disorders, Alzheimer's disease, Parkinson's disease, epilepsy, immune
 disorders such as osteoarthritis, haemopoietic disorders, inflammatory
 skin disorders, asthma and various types of dyslipidaemia. The nucleic
 acids and polypeptides may also be used as targets for the identification
 of small molecules that modulate or inhibit neurogenesis, cell
 differentiation, cell proliferation, haemopoiesis, wound healing and
 angiogenesis, in gene therapy and the in generation of antibodies that
 bind immunospecifically to NOVX substances for use in therapeutic or
 diagnostic methods. The nucleic acids may be further used as
 hybridisation probes, in chromosome mapping, tissue typing, preventive
 medicine and pharmacogenomics. The current sequence is that of the human
 NOVX-related PCR primer which was used in the exemplification of the
 invention.
 CC
 XX Sequence 21 BP; 3 A; 3 C; 6 G; 9 T; 0 U; 0 Other;
 SQ

Query Match 0.3%; Score 16.4; DB 1; Length 21;
 Best Local Similarity 94.4%; Pred. No. 2.9e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1161 TCCTGAGGTTTGTGTA 1178
 Db 4 TCCTGAGGTTTGTGTA 21
 RESULT 407
 AAQ86460
 ID AAQ86460 standard; DNA; 21 BP.
 XX
 AC AAQ86460;
 XX
 DT 25-MAR-2003 (revised)
 DT 16-OCT-1995 (first entry)
 XX
 DE IFN-alpha nt723-732 primer.
 KW Interferon receptor; IFN; interferon-alpha; monoclonal antibody;
 KW immunomodulator; AIDS; HIV; human immunodeficiency virus; primer; PCR;
 KW polymerase chain reaction; ss.
 XX
 OS Synthetic.
 XX
 PN WO9507716-A1.
 XX
 PD 23-MAR-1995.
 XX
 PF 16-SEP-1994; 94WO-EP003114.
 XX
 PR 17-SEP-1993; 93EP-00402279.
 XX
 PA (EUBI-) LAB EURO BIOTECHNOLOGIE SA.
 PI Tovey MG, Benizri EJ;
 XX
 DR WPI; 1995-131187/17.
 XX
 XX Compsn. of monoclonal antibodies against interferon receptor - useful as
 PT immuno-modulator, eg. for treating AIDS.
 XX
 PS Example 5; Page 49; 105pp; English.
 XX
 CC The primers and probes given in AAQ86459-75 were used to amplify and
 CC detect IFN-alpha, IFN-beta, IFN-gamma, IFN-omega and aldolase A species

XX AC ABX11428;
XX DT 20-MAY-2003 (first entry)
XX DE Human CTACK competitive RT-PCR antisense primer.
XX RT-PCR; primer; human; chemokine; skin disorder; psoriasis; skin cancer;
KW GPR2 expressing cell modulation; carcinoma; inflammation; wound healing;
KW allergy; contact dermatitis; allergic dermatitis; microbial infection;
KW cell movement to skin; cell movement within skin; parasitic infection;
KW cutaneous-T-cell-attracting chemokine; viral infection; CTACK; ss;
KW reverse transcription; cutaneous-T-cell-attracting chemokine.
XX OS Homo sapiens.
XX PN US2002160024-A1.
XX PD 31-OCT-2002.
XX PF 02-JUL-2001; 2001US-00898751.
XX PR 24-DEC-1998; 98US-0113858P.
XX PR 27-MAY-1999; 99US-0136570P.
XX PR 23-DEC-1999; 99US-00471549.
XX PA (SCHE) SCHERING CORP.
XX PI Wang W, Oldham ER, Soto H, Liu Y, Hudak SA, Homey B, Morales JM;
PI Kellermann S, McEvoy LM, Bowman EP, Zlotnik A;
XX WPI; 2003-255187/25.
XX PT Modulating movement of cell within or to the skin of mammal useful for
PT treating a skin disorder comprises administering an antagonist/agonist of
PT chemokines CTACK and Vic.
XX PS Example 5; Page 21; 39pp; English.
XX The invention relates to the movement of a cell within or to the skin of
CC a mammal that is modulated by administering to a mammal an antagonist of
CC CTACK, an agonist of CTACK, an antagonist of Vic, or an agonist of Vic.
CC The methods are useful for modulating movement of a cell within or to the
CC skin of a mammal, purifying a population of cells, producing a ligand;
CC receptor complex, modulating physiology or development of a GPR2
CC expressing cell, testing a compound for ability to affect GPR2 receptor-
CC ligand interaction, and for treating a patient suffering from a skin
CC disorder such as psoriasis, skin cancer, carcinoma, inflammation,
CC allergies, contact dermatitis, allergic dermatitis, wound healing and
CC infections (including microbial, viral and parasitic) comprising
CC administering an antagonist against GPR2, Vic or CTACK. The invention
CC regulates the development or physiology of relevant cells. The present
CC sequence represents the human cutaneous-T-cell-attracting chemokine CTACK
CC competitive reverse transcription (RT)-PCR antisense primer
XX SQ Sequence 21 BP; 3 A; 9 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1670 CAGAGCCCTAAGGAAATGGGC 1690
Db 21 GGGATGCTAAGGAAATGGGC 1
RESULT 411
ADE86772/c
ID ADE86772 standard; DNA; 21 BP.
XX AC ADE86772;
XX DT 29-JAN-2004 (first entry)

XX rEST2 primer #2.
XX DE ss; primer; pro-B cell; human; Pax5; HLA-matched donor; lymphoid system;
KW immunodeficiency; AIDS; non-myceloablative tumour therapy; antisense RNA;
KW small interfering RNA; ribozyme; lentiviral vector.
XX OS Homo sapiens.
XX PN EP1361268-A1.
XX PD 12-NOV-2003.
XX PF 08-MAY-2002; 2002EP-00010439.
XX PR 08-MAY-2002; 2002EP-00010439.
XX PA (BOEH) BOEHRINGER INGELHEIM INT GMBH.
XX PI Busslinger M, Mikkola I, Heavey B;
XX WPI; 2003-879906/82.
XX DR New Pax5-deficient pro-B cells of human origin, useful for treating
XX tumors or disorders associated with a depletion of the lymphoid system,
XX e.g. AIDS.
XX PS Disclosure; Page 18 ; 28pp; English.
XX This sequence represents a primer which was used in quantitative analysis
CC of protein expression in pro-B cells of human origin that are deficient
CC in functional Pax5 expression. The autologous human Pax5-deficient pro-B
CC cells or pax5-deficient pro-B cells derived from a HLA-matched donor are
CC useful in treating disorders associated with a depletion of the lymphoid
CC system, including immunodeficiencies or AIDS. Pax5-deficient pro-B cells
CC derived from an HLA-matched donor are also useful in treating tumours.
CC Alternatively, the pro-B cells derived from an HLA-matched donor are
CC useful in non-myceloablative tumour therapy. The expression of the Pax5
CC gene is inactivated by means of antisense RNA, small interfering RNA or a
CC ribozyme. In inactivating the expression of the Pax5 gene, an expression
CC cassette encoding one or more pax5-inhibiting oligonucleotide molecules
CC is inserted into lentiviral vector. The lentiviral vector is transfected
CC into specialized packaging cells to generate pseudotyped lentiviruses.
CC The pro-B cells obtained are infected with the pseudotyped lentiviruses and
CC cultured. Other functions of the Pax5-deficient pro-B cells are either
CC partially suppressed or completely inactivated.
XX SQ Sequence 21 BP; 7 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2648 AACTGATGCCCTTATCTTGACC 2668
Db 21 AACTGATGCCCTTATTTGCC 1
RESULT 412
ADJ97635
ID ADJ97635 standard; DNA; 21 BP.
XX AC ADJ97635;
XX DT 06-MAY-2004 (first entry)
XX DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 408.
XX human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilms' tumour;

Thu Aug 18 08:38:09 2005

XX lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX Homo sapiens.
XX WO2004009769-A2.
XX 29-JAN-2004.
XX 18-JUL-2003; 2003WO-US022444.
XX 24-JUL-2002; 2002US-0398417P.
XX 14-NOV-2002; 2002US-00294228.
XX (UYPE-) UNIV PENNSYLVANIA.
XX Tolentino MJ, Reich SJ;
XX WPI; 2004-203472/19.
XX Novel short interfering RNA (siRNA) comprises sense and antisense RNA
XX strands, useful for inhibiting expression of human vascular endothelial
XX growth factor mRNA, for treating angiogenic disease, e.g. diabetic
XX retinopathy and cancer.
XX Disclosure; SEQ ID NO 408; 218pp; English.
XX This invention relates to novel compositions that comprise short
XX interfering RNA (siRNA) molecules, which can be used to inhibit
XX angiogenesis. Specifically, it refers to siRNAs that target and cause
XX RNAi-induced degradation of mRNA from human vascular endothelial growth
XX factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
XX region) genes, as well as mutants derived thereof. The present invention
XX describes sense and antisense RNA strands that form an RNA duplex and
XX bind to the target mRNA, such that expression is inhibited and the target
XX degraded. As such, siRNA administered in combination with a therapeutic
XX agent is useful for treating diseases associated with angiogenesis and
XX the overexpression of VEGF, which include diabetic retinopathy, age-
XX related macular degeneration, inflammatory disease, psoriasis and
XX rheumatoid arthritis. Furthermore, it can be used to treat various
XX cancers including breast, retinoblastoma, Wilms' tumour and lymphoma.
XX Accordingly, these compositions exhibit cytostatic, antidiabetic,
XX ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
XX antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
XX oligo, a target for siRNA inhibition of the invention.
XX
XX Sequence 21 BP; 6 A; 1 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 2432 AAGGCTTAGTGATGCTGAGG 2452
Db 1 AAGGCTTAGTGATGCTGAGG 21
RESULT 413
ADJ97636
ID ADJ97636 standard; DNA; 21 BP.
XX
XX ADJ97636;
XX
XX 06-MAY-2004 (first entry)
XX Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 409.
XX human; ss; short interfering RNA; siRNA; angiogenesis;
XX vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
XX Flk-1/KDR; kinase domain region; diabetic retinopathy;
XX age-related macular degeneration; inflammatory disease; psoriasis;
XX rheumatoid arthritis; cancer; breast; retinoblastoma; Wilms' tumour;
XX lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;

XX antipsoriatic; antirheumatic; antiarthritic.
XX Homo sapiens.
XX WO2004009769-A2.
XX 29-JAN-2004.
XX 18-JUL-2003; 2003WO-US022444.
XX 24-JUL-2002; 2002US-0398417P.
XX 14-NOV-2002; 2002US-00294228.
XX (UYPE-) UNIV PENNSYLVANIA.
XX Tolentino MJ, Reich SJ;
XX WPI; 2004-203472/19.
XX Novel short interfering RNA (siRNA) comprises sense and antisense RNA
XX strands, useful for inhibiting expression of human vascular endothelial
XX growth factor mRNA, for treating angiogenic disease, e.g. diabetic
XX retinopathy and cancer.
XX Disclosure; SEQ ID NO 409; 218pp; English.
XX This invention relates to novel compositions that comprise short
XX interfering RNA (siRNA) molecules, which can be used to inhibit
XX angiogenesis. Specifically, it refers to siRNAs that target and cause
XX RNAi-induced degradation of mRNA from human vascular endothelial growth
XX factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
XX region) genes, as well as mutants derived thereof. The present invention
XX describes sense and antisense RNA strands that form an RNA duplex and
XX bind to the target mRNA, such that expression is inhibited and the target
XX degraded. As such, siRNA administered in combination with a therapeutic
XX agent is useful for treating diseases associated with angiogenesis and
XX the overexpression of VEGF, which include diabetic retinopathy, age-
XX related macular degeneration, inflammatory disease, psoriasis and
XX rheumatoid arthritis. Furthermore, it can be used to treat various
XX cancers including breast, retinoblastoma, Wilms' tumour and lymphoma.
XX Accordingly, these compositions exhibit cytostatic, antidiabetic,
XX ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
XX antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
XX oligo, a target for siRNA inhibition of the invention.
XX
XX Sequence 21 BP; 6 A; 1 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 2433 AGGCTTAGTGATGCTGAGGA 2453
Db 1 AAGGCTTAGTGATGCTGAGGA 21
RESULT 414
ABK00643/C
ID ABK00643 standard; RNA; 17 BP.
XX
XX ABK00643;
XX
XX 12-MAR-2002 (first entry)
XX Human NOGO Hammerhead Ribozyme #643.
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
XX muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX DNazyme; inozyme; G-cleaver; ambersyme; zynzyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;

KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.
OS Synthetic.

XX WO200159103-A2.

XX 16-AUG-2001.

XX 09-FEB-2001; 2001WO-US004273.

XX 11-FEB-2000; 2000US-0181797P.

PR 28-FEB-2000; 2000US-0185516P.

PR 06-MAR-2000; 2000US-0187128P.

XX (RISO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.

PA (CHOW/) CHOWRIRA B M.

XX Blatt L, Mcswiggen J, Chowrira BM;

XX WPI; 2001-607195/69.

DR Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense

XX constructs, which down regulate expression of a CD20 gene or neurite

PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and

PT central nervous system injury.

XX Claim 88; Page 76; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates

CC expression of a CD20 gene and a nucleic acid molecule which down

CC regulates expression of a neurite growth inhibitor gene (NOGO). The

CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a

CC DNzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule

CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or

CC an amberyze (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA

CC with a IGY motif). The CD20-targeting nucleic acid is used to cleave RNA

CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.

CC Furthermore, it may be contacted with a cell to reduce CD20 activity of

CC the cell and treat a patient having a condition associated with the level

CC of CD20. The treatment may further comprise the use of one or more

CC therapies. In particular, the CD20 targeting nucleic acid may be used to

CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-

CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic

CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell

CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,

CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-

CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the

CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the

CC nucleic acid may be contacted with a cell to reduce NOGO activity of the

CC cell and treat a patient having a condition associated with the level of

CC NOGO. The treatment may further comprise the use of one or more

CC therapies. In particular, the NOGO-targeting nucleic acid may be used to

CC treat central nervous system (CNS) injury and cerebrovascular accident

CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),

CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),

CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob

CC disease, muscular dystrophy, and/or other neurodegenerative disease

CC states which respond to the modulation of NOGO expression. The present

XX sequence is a hammerhead ribozyme of the invention

XX Sequence 17 BP; 7 A; 2 C; 4 G; 0 T; 4 U; 0 Other;

XX Query Match 0.3%; Score 16; DB 1; Length 17;

XX Best Local Similarity 100.0%; Pred. No. 3e+02;

XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3735 TTTAGCCATAGCATCT 3750
DB 17 TTTAGCCATAGCATCT 2
|||||

RESULT 415

ADB40345

ID ADB40345 standard; DNA; 17 BP.

XX AC ADB40345;

XX DT 18-DEC-2003 (revised)

DT 04-DEC-2003 (first entry)

XX Tumour suppression/reversion associated nucleotide #668.

XX cytostatic; antiviral; neuroprotective; neuroleptic; ss;

KW primer; probe; tumour suppression; tumour reversion; apoptosis;

KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;

KW diagnosis.

XX Homo sapiens.

XX WO2003040369-A2.

XX 15-MAY-2003.

XX 17-SEP-2002; 2002WO-IB004219.

XX 17-SEP-2001; 2001FR-00011981.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-441574/41.

XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.

XX Disclosure; Page 110; 771pp; French.

XX The invention relates to the isolation of 6327 nucleotide sequences,

CC fragments of at least 15 consecutive nucleotides of these nucleotides, a

CC sequence having at least 80% identity, after optimal alignment, with the

CC nucleotides, a sequence that hybridizes under stringent conditions with

CC the nucleotides, or the complement, or corresponding RNA, of the

CC nucleotides. The nucleotides are used as probes or primers for detecting,

CC identifying, quantifying and/or amplifying nucleic acids, as in vitro

CC sense and antisense sequences, of nucleotides involved in tumour

CC suppression or reversion, apoptosis and or viral resistance, to produce

CC recombinant polypeptides, and to prepare transgenic animals, as

CC experimental models. The nucleotides (also vectors containing them and

CC cells containing the vectors), the encoded polypeptides and antibodies

CC (Ab) against the polypeptide are useful for prevention and/or treatment

CC of viral infections or diseases characterized by development of tumours

CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).

CC Analysis of the expression of the nucleotides can be used for diagnosis

CC also/or prognosis of these diseases. The nucleotides and polypeptides can

CC also be used to screen for their specific interactive molecules,

CC potentially useful for treating diseases associated with abnormal

XX expression of the nucleotides.

SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

XX Query Match 0.3%; Score 16; DB 1; Length 17;

XX Best Local Similarity 100.0%; Pred. No. 3e+02;

XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2857 GATCTGCCATAGCAC 2872

DB 1 GATCTGCCATAGCAC 16

|||||

Thu Aug 18 08:38:09 2005

gibbs-10-667-022-4.rng

```

ID  AAV37774 standard; DNA; 20 BP.
XX
AC  AAV37774;
XX
DT  09-SEP-1998 (first entry)
XX
DE  Analytical solid phase nucleic acid detection hybridisation probe A.
XX
XX  Analytical solid phase; detection; hybridisation; probe; target;
XX  diagnosis; screening; disease; drug sensitivity; transplantation organ;
XX  food industry; food poisoning; ss.
XX
OS  Synthetic.
XX
PN  WO9811210-A1.
XX
PD  19-MAR-1998.
XX
PF  12-SEP-1997; 97WO-JF003232.
XX
PR  13-SEP-1996; 96JP-00243720.
XX
XX  (MOLE-) LAB MOLECULAR BIOPHOTONICS.
XX
PI  Abe S, Sato Y;
XX
XX  WPI; 1998-271664/24.
XX
XX  Analytical solid phase for detecting nucleic acids - contains a base
XX  sequence which hybridises with polynucleotide sequence of the target, and
XX  a set of probes immobilised on the solid phase via a linker.
XX
XX  Example 1; Page 13; 37pp; Japanese.
XX
XX  The present sequence represents a probe used in an example from the
XX  present invention. The present invention describes an analytical solid
XX  phase method for detecting nucleic acids. The method comprises obtaining
XX  a base sequence which hybridises with the polynucleotide sequence of the
XX  target, and a set of probes immobilised on the solid phase via a linker
XX  which is enzymatically ligated during hybridisation. The product is used
XX  for the detection of specific nucleic acids. Possible fields of
XX  application include diagnosis of disease, detection of drug sensitivity,
XX  screening for appropriate transplantation organs, testing in the food
XX  industry to prevent food poisoning. A simple, quick method for
XX  selectively detecting target in a mixed sample is obtained
XX
SQ  Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
    Query Match 0.3%; Score 16; DB 1; Length 20;
    Best Local Similarity 100.0%; Pred. No. 3.1e+02;
    Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1 GGATCCCGCGGCTGC 16
    |||||
Db   5 GGATCCCGCGGCTGC 20

RESULT 418
AA89313
ID  AAX89313 standard; DNA; 20 BP.
XX
XX  AAX89313;
XX
XX  21-SEP-1999 (first entry)
XX
XX  5'-phosphorylated and 3'-biotinylated probe (seq ID No: 5 of WO9935287) .
XX
XX  Two-probe system; nucleic acid detection; hybridisation; immobilisation;
XX  phosphorylation; diagnosis; infectious disease; drug receptor; toxin;
XX  organ transplant; probe; ss.
XX
OS  Synthetic.
XX

```

```
PN WO9935287-A1.
XX
PD 15-JUL-1999.
XX
PF 08-JAN-1999; 99WO-JP000041.
XX
PR 08-JAN-1998; 98JP-00002482.
XX
PA (MOLE-) LAB MOLECULAR BIOPHOTONICS.
XX
PI Abe S, Kodama H;
XX
DR WPI; 1999-430406/36.
XX
PT Two-probe system for specific detection of target polynucleotide
PT sequence.
XX
PS Example; Page 70; 75pp; Japanese.
XX
CC The invention describes a two-probe system for specific detection of a
CC target polynucleotide sequence. The system consists of two probes are
CC which hybridise to adjacent sections of the target polynucleotide. These
CC are immobilised by their 5' and 3' ends respectively to a solid phase and
CC the free end of one is phosphorylated. One probe is labeled and is
CC connected to the solid phase via a breakable section. The test sample is
CC introduced and after hybridisation to the target polynucleotide sequence
CC (if present) a ligase is added to join the non-immobilised ends of the
CC probes. The target polynucleotide chain is removed, and the breakable
CC section split. If the target sequence was present, the labeled probe
CC remains immobilised to the solid phase because of ligation to the other
CC probe, but if the target sequence was not present it is released.
CC Detection of the label on the solid phase shows that the target sequence
CC was present in the test sample. The method is used for the detection of
CC specific nucleotide sequences in applications such as the diagnosis of
CC infectious and other diseases, the detection of drug receptors,
CC establishing compatibility for organ transplants, and detection of toxins
CC in foodstuffs. The method is of high sensitivity and high specificity,
CC and is able to discriminate the target sequence from sequences containing
CC a single base mismatch. Sequences AAX89309-327 represent probes and
CC target sequences used in the method of the invention
XX
SQ Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GGATCCCCCGGGCTGC 16
DB 5 GGATCCCCCGGGCTGC 20
RESULT 419
ABK50593
ID ABK50593 standard; DNA; 20 BP.
XX
AC ABK50593;
XX
DT 30-JUL-2002 (first entry)
XX
DE Streptomyces hygroscopicus hygromycin probe.
XX
KW Method for screening genomic DNA; target sequence; transgenic screening;
KW organism identification; targeted mutagenesis screening method;
KW hygromycin; probe; ss.
XX
OS Streptomyces hygroscopicus.
XX
PN WO200220842-A1.
XX
PD 14-MAR-2002.
XX
PF 04-SEP-2001; 2001WO-US027404.
```

```
XX
PR 06-SEP-2000; 2000US-0230371P.
XX
PA (HODG/) HODGE T A.
XX
PI Hodge TA;
XX
DR WPI; 2002-371884/40.
XX
PT Detecting designated genetic sequence in genomic DNA sample, comprises
PT depositing genomic DNA on substrate, adding labeled probe specific for
PT portion of DNA and detecting signal from labeled probe.
XX
PS Example 2; Page 54; 126pp; English.
XX
CC The present invention relates to a method and apparatus for transgenic
CC and targeted mutagenesis screening of genomic DNA. The method comprises
CC depositing genomic DNA on a substrate, adding at least one labeled probe
CC specific for a portion of the genomic DNA, and detecting the signal from
CC the probe. The invention also provides a system for screening DNA for a
CC designated genetic sequence. The system includes a computer having a
CC processor, memory, web browser and an automatic screening device that
CC analyses samples of genomic DNA for the designated sequence. The method
CC is useful for detecting a designated genetic sequence in a sample of
CC genomic DNA. The method is useful for rapid identification of an
CC organism, whose genome possesses specific genetic sequences that exist
CC endogenously or has been modified, mutated or genetically engineered. The
CC method is more accurate, faster and is a high volume transgenic and
CC targeted mutagenesis screening method. The screening results are provided
CC to a researcher more quickly than by the prior art methods. The present
CC methods of the present invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1610 AGGATTTGGGCAACAT 1625
DB 2 AGGATTTGGGCAACAT 17
RESULT 420
ADI35091/c
ID ADI35091 standard; DNA; 20 BP.
XX
AC ADI35091;
XX
DT 22-APR-2004 (first entry)
XX
DE Human PLA2G1B gene fragment amplifying first PCR primer.
XX
KW PLA2G1B; fat deposition; leanness; single nucleotide polymorphism;
KW non-insulin dependent diabetes mellitus; NIDDM; hyperinsulinemia;
KW hypertension; glucose intolerance; dyslipidemia; hypercoagulability;
KW microalbuminuria; human; PCR; primer; ss; SNP.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004002295-A2.
XX
PD 08-JAN-2004.
XX
PF 27-JUN-2003; 2003WO-US020830.
XX
PR 27-JUN-2002; 2002US-0392361P.
XX
PA (SEQU-) SEQUENOM INC.
XX
```

```

PI Adam GIR, Langdown ML;
XX WPI; 2004-082843/08.
XX
XX Diagnosing a predisposition to fat deposition or leanness, useful for
XX diagnosing a predisposition to e.g. diabetes or hypertension, comprises
XX detecting the presence of a polymorphism in the PLA2G1B nucleic acid from
XX the subject.
XX
XX Example 2; Page 45; 91pp; English.
XX
XX The invention relates to diagnosing a predisposition to fat deposition or
XX leanness in a subject comprising detecting the presence or absence of a
XX polymorphic variation associated with fat deposition at a polymorphic
XX site in a PLA2G1B nucleotide sequence in a nucleic acid sample from a
XX subject, where the presence of the polymorphic variation indicates a
XX predisposition to fat deposition in the subject. The polymorphic
XX variation is a guanine at position 7328 or thymine at position 9182 of
XX the present sequence. The method is useful for diagnosing a
XX predisposition to fat deposition or leanness in a subject, and
XX consequently for diagnosing a predisposition to non-insulin dependent
XX diabetes mellitus (NIDDM) in a subject and conditions such as
XX hyperinsulinemia, hypertension, glucose intolerance, dyslipidemia,
XX hypercoagulability, or microalbuminuria, which can lead to early
XX prescription of preventive measures. Sequences ADI35084-ADI35103
XX represent PCR primers used in assays for verifying and genotyping single
XX nucleotide polymorphism (SNPs) in a human PLA2G1B nucleotide sequence.
XX
XX Sequence 20 BP; 7 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 16; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 3.1e+02;
XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 3760 GCTGTCCAGCTTCTTG 3775
DB 16 GCTGTCCAGCTTCTTG 1
XX
XX RESULT 421
XX ADJ09992/C
XX ID ADJ09992 standard; DNA; 20 BP.
XX AC ADJ09992;
XX XX
XX 17-JUN-2004 (first entry)
XX
XX PCR primer 8 to genotype SNPs of human phospholipase A2 (PLA2G1B) DNA.
XX
XX human; PCR; ss; fat reduction; fat deposition; phospholipase A2; PLA2G1B;
XX appetite suppressant; lipase inhibitor; exercise regimen; obesity;
XX non-insulin dependent diabetes mellitus; NIDDM; cardiovascular disorder;
XX hypertension; antidiabetic; primer.
XX
XX Homo sapiens.
XX
XX WO2004002296-A2.
XX
XX 08-JAN-2004.
XX
XX 27-JUN-2003; 2003WO-US020831.
XX
XX 27-JUN-2002; 2002US-0392362P.
XX
XX (SEQU-) SEQUENOM INC.
XX
XX Adam GIR, Langdown ML, Denissenko MF, Dennis E, Cantor C;
XX Rubin B;
XX
XX WPI; 2004-071944/07.
XX
XX Identifying a candidate therapeutic for fat reduction, useful for
XX treating diabetes, by introducing a test molecule to a system comprising
XX
PT PLA2G1B protein or nucleic acid, and determining the presence of
XX interaction between the compounds.
XX
XX Example 2; Page 70; 116pp; English.
XX
XX This invention relates to a novel candidate therapeutic agent useful for
XX fat reduction and disorders related to fat depositions. Specifically, it
XX refers to polymorphic variations in the phospholipase A2 (PLA2G1B) DNA,
XX which is located on chromosome 12q24 and has been associated with central
XX fat deposition. The present invention describes methods to detect the
XX presence or absence of these single nucleotide polymorphisms of PLA2G1B,
XX in particular G7328A and T9182G, and subsequently provide treatment that
XX reduces fat deposition. This treatment may consist of an appetite
XX suppressant, a lipase inhibitor, a phospholipase inhibitor, an exercise
XX regimen, a dietary regimen, psychological counselling, psychotherapy or a
XX psychotherapeutic. Accordingly, PLA2G1B is a target for reducing fat
XX deposition and it can be used to treat both obesity and non-insulin
XX dependent diabetes mellitus (NIDDM), as well as cardiovascular disorders
XX such as hypertension. As such, it exhibits antidiabetic activity. This
XX oligonucleotide sequence is a PCR primer used to amplify a region of
XX interest (i.e. genotype SNPs) in human PLA2G1B DNA of the invention.
XX
XX Sequence 20 BP; 7 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 16; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 3.1e+02;
XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 3760 GCTGTCCAGCTTCTTG 3775
DB 16 GCTGTCCAGCTTCTTG 1
XX
XX RESULT 422
XX ADP27118/C
XX ID ADP27118 standard; DNA; 20 BP.
XX AC ADP27118;
XX XX
XX 26-AUG-2004 (first entry)
XX
XX Human matrix metalloproteinase 11 DNA antisense oligonucleotide #27.
XX
XX Human; matrix metalloproteinase 11; MMP11; ss; antisense oligonucleotide;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
XX 5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.
XX
XX Homo sapiens.
XX
XX US2004110152-A1.
XX
XX 10-JUN-2004.
XX
XX 10-DEC-2002; 2002US-00316755.
XX
XX 10-DEC-2002; 2002US-00316755.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Baker BF, Cowseert LM;
XX
XX WPI; 2004-440341/41.
XX
XX New oligonucleotide compound that inhibits expression of matrix
XX metalloproteinase 11, useful for preparing a composition for treating
XX hyperproliferative disorder, e.g., cancer.
XX
XX Example 15; SEQ ID NO 44; 76pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding a matrix metalloproteinase 11 (MMP11) polypeptide. The compound
XX is an antisense oligonucleotide that specifically hybridises with the
XX nucleic acid and inhibits expression of the polypeptide. The antisense
XX

```

CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of the MMP11 polypeptide and in
 CC preparation of a composition for treating hyperproliferative disorders,
 CC e.g. cancer. This sequence represents an antisense oligonucleotide
 CC targeted to DNA encoding the human MMP11 polypeptide of the invention.
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 47 TGCTGGGGCTGCAGCA 62
 Db 16 TGCTGGGGCTGCAGCA 1
 RESULT 423
 AD72469
 ID AD72469 standard; DNA; 20 BP.
 XX
 AC AD72469;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Antisense oligo targeted to mouse kinesin-like 1, ISIS 285762.
 XX
 KW Antisense; kinesin-like 1; N2 kinesin; bimC kinesin;
 KW cellular proliferation; cancer; B-cell leukaemia; autoimmune disease;
 KW carpal tunnel syndrome; Raynaud's phenomenon; systemic sclerosis;
 KW Sjogren's syndrome; rheumatoid arthritis; polymyositis; polyarteritis;
 KW systemic lupus erythematosus; mouse; ss; human.
 XX
 OS Mus musculus.
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate nucleotide. All cytosines
 FT are 5-methylcytidines. Residues 1 to 5 and 15 to 20 are
 FT 2'-methoxyethyl nucleotides."
 XX
 PN US2004180847-A1.
 XX
 XX 16-SEP-2004.
 XX
 XX 17-NOV-2003; 2003US-00714796.
 XX
 XX 23-MAY-2002; 2002US-00156603.
 XX
 PA (DOBI/) DOBIE K W.
 PA (KOLL/) KOLLER E.
 XX
 PI Dobie KW, Koller E;
 XX
 DR WPI; 2004-652550/63.
 XX
 XX New antisense compound 8 to 80 nucleobases in length targeted to a
 PT nucleic acid molecule encoding kinesin-like 1, useful for treating an
 PT animal having a disease or condition such as cancer, tumor, autoimmune
 PT disease.
 XX
 PS Claim 36; SEQ ID NO 233; 110pp; English.
 XX
 XX The present invention relates to antisense compounds, compositions and
 CC methods for modulating the expression of kinesin-like 1. The superfamily
 CC of kinesins function as molecular engines to bind and transport vesicles

CC and organelles along microtubules using energy supplied by ATP. Kinesin-
 CC like 1, a member of the N2 (also called bimC) family of kinesins, is
 CC involved in separating the chromosomes by directing their movement along
 CC microtubules in the bipolar spindle. Kinesin-like 1 is also known as
 CC KNSL1, Eg5, HsEg5, HKSP, KIF11, thytoid interacting protein 5 and TRIP5.
 CC Inhibition of kinesin-like 1 may be a target for arresting cellular
 CC proliferation in cancer, due to its central role in mitosis. Expression
 CC of kinesin-like 1 expression may contribute to other disease states such
 CC as B-cell leukaemia, autoimmune diseases such as carpal tunnel syndrome,
 CC Raynaud's phenomenon, systemic sclerosis, Sjogren's syndrome, rheumatoid
 CC arthritis, polymyositis and polyarteritis. Kinesin-like 1 is an
 CC autoantigen identified in systemic lupus erythematosus. The invention
 CC relates to antisense nucleic acid oligomers, targeted to the gene
 CC encoding kinesin-like 1. Also provided are methods of screening for
 CC modulators of kinesin-like 1 and to methods of modulating the expression
 CC of kinesin-like 1. At least a portion of the compound hybridises with RNA
 CC to form an oligonucleotide-RNA duplex. It has at least one modified
 CC internucleoside linkage, sugar moiety, or nucleobase. It has at least one
 CC 2'-O-methoxyethyl sugar moiety, phosphorothioate internucleoside linkage,
 CC or one cytosine which is a 5-methylcytosine. The antisense compound may
 CC comprise an antisense nucleic acid molecule that is specifically
 CC hybridisable with a 5'-untranslated region (UTR), with a start region,
 CC with a coding region, with a 3'-UTR, with an intron, or with an intron-
 CC exon junction of a nucleic acid molecule encoding kinesin-like 1.
 CC Oligonucleotides were synthesised via solid phase P(III) phosphoramidite
 CC chemistry. The present sequence is an antisense oligo targeted to mouse
 CC kinesin-like 1.
 XX
 SQ Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.3%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 3488 CACCACCACCTGGATG 3503
 Db 5 CACCACCACCTGGATG 20
 RESULT 424
 AA293879
 ID AA293879 standard; DNA; 21 BP.
 XX
 AC AA293879;
 XX
 DT 29-AUG-2000 (first entry)
 XX
 DE Primer for amplifying murine SP-C.
 XX
 KW Endothelial monocyte activating peptide; EMAP-II; antagonist; antibody;
 KW treatment; therapy; ischaemic reperfusion injury;
 KW bronchopulmonary dysplasia; ss.
 XX
 OS Synthetic.
 XX
 XX WO200029620-A1.
 XX
 XX 25-MAY-2000.
 XX
 XX 12-NOV-1999; 99WO-US026743.
 XX
 XX 13-NOV-1998; 98US-0108435P.
 XX
 XX (CHIL-) CHILDRENS HOSPITAL LOS ANGELES.
 XX
 XX Schwarz M, Zhang P, Gebb SA;
 XX
 XX WPI; 2000-399730/34.
 XX
 XX Facilitating vascular growth for treating ischemic reperfusion injury in
 PT lungs and bronchopulmonary dysplasia of new born babies comprises
 PT inhibiting endothelial monocyte activating polypeptide.
 XX

PS Example 1; p15; 41pp; English.

CC A new method for facilitating vascular growth is described which

CC comprises inhibiting endothelial monocyte activating polypeptide (EMAP)

CC II by down-regulating EMAP II expression, or by using EMAP II receptor

CC antagonists or compounds that specifically bind to EMAP II e.g.

CC antibodies. The method is useful treating patients at risk for ischaemic

CC reperfusion injury to the lungs and newborn babies affected with

CC bronchopulmonary dysplasia (claimed)

XX Sequence 21 BP; 4 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

SQ

Query Match 0.3%; Score 16; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 3.2e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2988 GAGCCATCTTCATGAT 3003

Db |||||||||||||||

5 GAGCCATCTTCATGAT 20

RESULT 425

AAF95501/c

ID AAF95501 standard; DNA; 21 BP.

XX AAF95501;

AC

DT 18-NOV-2004 (revised)

DT 06-JUN-2001 (first entry)

XX

XX Human gene single nucleotide polymorphism #262.

DE

XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;

KW polymorphism; vascular disease; coronary artery disease; forensics;

KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;

KW pulmonary embolism; paternity test; ds.

XX

OS Homo sapiens.

OS Unidentified.

XX

XX

PH Key Location/Qualifiers

FT variation II

FT /*tag= a

FT /standard_name= "Single nucleotide polymorphism"

XX

PN WC000118250-A2.

XX

PD 15-MAR-2001.

XX

PF 07-SEP-2000; 2000WO-US024503.

XX

PR 10-SEP-1999; 99US-0153357P.

PR 26-JUL-2000; 2000US-0220947P.

PR 16-AUG-2000; 2000US-0225724P.

XX

XX (WHED) WHITEHEAD INST BIOMEDICAL RES.

PA (MILL-) MILLENNIUM PHARM INC.

XX

XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;

PI WPI; 2001-226749/23.

XX

XX Nucleic acids comprising single nucleotide polymorphisms, useful in

PT applications such as forensics, paternity testing, medicine, genetic

PT analysis and phenotype correlations to diseases such as diabetes and

PT atherosclerosis.

XX

XX Example; Page 67; 242pp; English.

XX

XX The present invention provides a method of diagnosing a vascular disease

CC in an individual, involving determining the sequence at various

CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4

CC genes. The sequences at a number of polymorphic sites are also provided

CC

CC in the specification. In particular, the method can be used in the

CC diagnosis of atherosclerosis, myocardial infarction, coronary heart

CC disease, stroke, peripheral vascular diseases, venous thromboembolism and

CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also

CC useful in forensics, paternity testing, genetic analysis and phenotype

CC correlations to diseases. The present sequence is an example of one of

CC the human gene SNPs shown in the specification

CC

CC Revised record issued on 18-NOV-2004 : The variation feature was

CC incorrectly given a capital V

XX

SQ Sequence 21 BP; 0 A; 8 C; 4 G; 9 T; 0 U; 0 Other;

Query Match 0.3%; Score 16; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 3.2e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 AGAGGAAGACGAGGCC 196

Db |||||||||||||||

20 AGAGGAAGACGAGGCC 5

RESULT 426

AAV22621/c

ID AAV22621 standard; DNA; 19 BP.

XX AAV22621;

AC

XX 08-JUL-1998 (first entry)

DT

XX Adhalin gene fragment showing a muscular dystrophy causing mutation.

DE

XX Human; adhalin gene; dystrophin-associated protein; muscular dystrophy;

KW detection; mutation; primary adhalinopathy;

KW Duchenne-like autosomal recessive muscular dystrophy; probe; ds.

XX

XX Homo sapiens.

XX

XX Key Location/Qualifiers

FT mutation 10

FT /*tag= a

FT /note= "wild type C changed to G"

XX

PN US5733732-A.

XX

PD 31-MAR-1998.

XX

PF 03-JAN-1996; 96US-00582539.

XX

PR 03-JAN-1996; 96US-00582539.

XX

XX (IOWA) UNIV IOWA RES FOUND.

PA

XX Piccolo F, Kaplan J, Jeanpierre M, Roberds SL, Campbell KP;

PI Sunada Y;

XX

XX WPI; 1998-229819/20.

XX

XX Genetic detection of primary adhalinopathies - using nucleic acid probes

PT which bind to mutant adhalin genes but not the wild type gene.

XX

XX Claim 1; Col 17; 14pp; English.

XX

XX The present sequence represents a fragment of the human adhalin gene. It

CC is from exon 5 and contains a mutation which causes a nonsense codon at

CC position 151 (AAV22622 is the normal wild type sequence). Adhalin belongs

CC to the sarcolemmal complex of dystrophin-associated proteins. Mutations

CC in the adhalin protein are one of the causes of muscular dystrophy. A new

CC method for the detection of a mutation in the human adhalin gene,

CC comprises incubating a sample with a nucleic acid probe (e.g. present

CC sequence). The probe specifically hybridises to the mutant form of the

CC gene but not the wild type. Any specific hybridisation is then detected.

CC

CC The method is useful for detecting mutations in the human adhalin gene


```
CC which lead to primary adhalinopathy, a Duchenne-like autosomal recessive
XX muscular dystrophy
SQ Sequence 19 BP; 3 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
    Query Match      0.3%; Score 15.8; DB 1; Length 19;
    Best Local Similarity 89.5%; Pred. No. 3.2e+02;
    Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4171 GCAGCTGTTTCAGGGCAACA 4189
Db 19 GCAGGTGTTTCAGGGCAGCA 1

RESULT 427
ID AA269801 standard; DNA; 19 BP.
AC AA269801;
XX
XX
DT 10-SEP-2001 (first entry)
DE Human biallelic marker upstream amplification primer SEQ ID NO:4157.
XX Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX Homo sapiens.
XX
XX WO9954500-A2.
XX
XX 28-OCT-1999.
XX
XX 21-APR-1999; 99WO-IB000822.
XX
XX 21-APR-1998; 98US-0082614P.
XX 23-NOV-1998; 98US-0109732P.
XX
XX (GBST ) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
XX WPI; 2000-013267/01.
XX
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX Claim 8; Page 1117; 2745pp; English.
XX
XX AA265654 to AA269578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AA269579 to AA277440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses: they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX Compositions and methods of the invention can also be useful for the
XX identification of the targets for the development of pharmaceutical
XX agents and diagnostic methods, as well as the characterisation of the
XX differential efficacious responses to and side effects from
XX pharmaceutical agents acting on a disease as well as other treatment.
XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
XX 3387, are not actually given a sequence in the Sequence Listing from the
XX present invention
XX
XX Sequence 19 BP; 7 A; 6 C; 4 G; 2 T; 0 U; 0 Other;
    Query Match      0.3%; Score 15.8; DB 1; Length 19;
    Best Local Similarity 89.5%; Pred. No. 3.2e+02;
    Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 3884 CTGGAGCACACTCTGTCTTCT 3902
Db 19 CTGGAGCTGAGTCTGTCTTCT 1

RESULT 428
ADG35257
ID ADG35257 standard; RNA; 19 BP.
XX
XX AC ADG35257;
XX
XX DT 26-FEB-2004 (first entry)
XX
XX DE HIV siNA oligonucleotide SEQ ID NO:100.
XX
XX RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW HIV replication inhibition; HIV infection; ss; target sequence.
XX
XX Synthetic.
XX Human immunodeficiency virus 1.
XX
XX WO2003070193-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005190.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 22-APR-2002; 2002US-0374722P.
XX 29-MAY-2002; 2002US-00157580.
XX 06-JUN-2002; 2002US-0386782P.
XX 23-JUL-2002; 2002US-0398036P.
XX 21-AUG-2002; 2002US-00225023.
XX 09-SEP-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX (MCSW/) MCSWIGGEN J.
XX
XX Mcswiggen J, Beigelman L, Macejak D;
XX
XX WPI; 2003-679850/64.
XX
XX New double-stranded short interfering nucleic acid, useful for treating
XX infection with human immune deficiency virus, comprises sugar-modified
XX pyrimidine bases.
XX
XX Example 3; SEQ ID NO 100; 170pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
XX downregulate expression of HIV gene by RNA interference. The siNAs may or
XX may not comprise ribonucleotides and may be double or single stranded.
XX They further comprise sense and antisense regions, or alternatively are
XX assembled from a sense oligonucleotide and an antisense oligonucleotide.
XX Specifically, the siNAs include short interfering RNA (siRNA), double-
XX stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
XX can be unmodified or chemically modified, can contain
XX deoxyribonucleotides, and can be chemically synthesised, expressed from a
XX vector or enzymatically synthesised. The invention also relates to kits
XX for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
XX of siNA; and vectors that express siNA. The siNAs are used to modulate
XX expression of the HIV gene in cells, tissue explants or organisms (e.g.,
XX by ex vivo gene therapy), or in grafts and transplants for the treatment
XX of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
XX used for inhibiting replication of HIV and may be used to treat HIV
```

CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siRNAs include short interfering RNA (siRNA), double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siRNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siRNA; conjugates and/or complexes
CC of siRNA; and vectors that express siRNA. The siRNAs are used to modulate
CC expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC by ex vivo gene therapy), or in grafts and transplants for the treatment
CC of a variety of conditions. HIV siRNAs have anti-HIV activity. They may be
CC used for inhibiting replication of HIV and may be used to treat HIV
CC infection. The siRNAs are also useful for drug screening, diagnosis,
CC therapeutic target identification and validation, genetic engineering,
CC pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC single nucleotide polymorphisms). The present sequence represents the
CC lower strand of an HIV-targeted double-stranded siRNA.
XX
SQ Sequence 19 BP; 3 A; 4 C; 6 G; 0 T; 6 U; 0 Other;
Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 4405 GCAGGAAGTACTAGTTCCTCC 4423
DB 19 GCAGGAAGTACTAGTTCCTCC 1
RESULT 430
ADL79331
ID ADL79331 standard; RNA; 19 BP.
XX
AC ADL79331;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human HER2 (EGFR2) siNA lower strand, SEQ ID NO:496.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW HER2; EGFR2; neu; erbB2; c-erbB-2; ss.
XX
OS Homo sapiens.
XX
PN WO2003070912-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005045.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.
PR 23-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
XX WPI; 2003-697612/66.

CC infection. The siRNAs are also useful for drug screening, diagnosis,
CC therapeutic target identification and validation, genetic engineering,
CC pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC single nucleotide polymorphisms). The present sequence represents the
CC upper strand of HIV-targeted double-stranded siRNA, which is identical to
CC the HIV transcript target sequence.
XX
SQ Sequence 19 BP; 6 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 3.2e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 4405 GCAGGAAGTACTAGTTCCTCC 4423
DB 1 GCAGGAAGTACTAGTTCCTCC 19
RESULT 429
ADG35995/C
ID ADG35995 standard; RNA; 19 BP.
XX
AC ADG35995;
XX
DT 26-FEB-2004 (first entry)
XX
DE HIV siNA oligonucleotide SEQ ID NO:838.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW HIV replication inhibition; HIV infection; ss.
XX
OS Synthetic.
OS Human immunodeficiency virus 1.
XX
PN WO2003070193-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005190.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 22-APR-2002; 2002US-0374722P.
PR 29-MAY-2002; 2002US-00157580.
PR 06-JUN-2002; 2002US-0386782P.
PR 23-JUL-2002; 2002US-0398036P.
PR 21-AUG-2002; 2002US-00225023.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (STRN-) STRNA THERAPEUTICS INC.
PA (MCSW/) MCSWIGGEN J.
XX
XX Mcswiggen J, Beigelman L, Macejak D;
PI
XX WPI; 2003-679850/64.
DR
XX New double-stranded short interfering nucleic acid, useful for treating
PT infection with human immune deficiency virus, comprises sugar-modified
PT pyrimidine bases.
XX
XX Example 3; SEQ ID NO 838; 170pp; English.
PS
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of HIV gene by RNA interference. The siRNAs may or
CC may not comprise ribonucleotides and may be double or single stranded.
CC They further comprise sense and antisense regions, or alternatively are

XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 496; 171pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNA may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNA include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNA can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNA are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNA are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the lower strand of a
CC HER2 (EGFR2)-targeted double-stranded siNA.
XX
XX Sequence 19 BP; 16 A; 2 C; 0 G; 0 T; 1 U; 0 Other;
SQ
Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 3.2e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
OY 5024 TAAAAAATAAAAAAAAAA 5042
DB 1 UAAAAAAAAACAAACAAAAA 19
RESULT 431
ADL79082/C
ID ADL79082 standard; RNA; 19 BP.
XX
XX ADL79082;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human HER2 (EGFR2) transcript target sequence/siNA upper strand, SEQ:247.
XX
XX RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW HER2; EGFR2; neu; erbB2; c-erbB-2; target sequence; ss.
XX
XX Homo sapiens.
OS
XX
XX WO2003070912-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005045.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.

PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
XX
XX WPI; 2003-697612/66.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 247; 171pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNA may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNA include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNA can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNA are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNA are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the upper strand of a
CC human HER2 (EGFR2)-targeted double-stranded siNA, which is identical to
CC the HER2 transcript target sequence.
XX
XX Sequence 19 BP; 1 A; 0 C; 2 G; 0 T; 16 U; 0 Other;
SQ
Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 5024 TAAAAAATAAAAAAAAAA 5042
DB 19 TAAAAAATAACAAACAAAAA 1
RESULT 432
ADL77519/C
ID ADL77519 standard; DNA; 19 BP.
XX
XX ADL77519;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human apolipoprotein B (ApoB) oligonucleotide seqid 2004.
XX
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; siRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.

XX	OS	Homo sapiens.	Db				
XX	PN	WO2004080406-A2.	19	TCACAGATGAAGATGAAGA	1		
XX	PD	23-SEP-2004.	RESULT 433				
XX	PF		ADR80463/C				
XX	XX		ADR80463 standard; DNA; 19 BP.				
XX	XX		ADR80463;				
XX	XX		16-DEC-2004 (first entry)				
XX	XX		Human apolipoprotein B (ApoB) oligonucleotide seqid 4960.				
PR	PR	07-MAR-2003; 2003US-0452682P.	antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;				
PR	PR	12-MAR-2003; 2003US-0454265P.	cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;				
PR	PR	13-MAR-2003; 2003US-0454962P.	RNA interference; RNA; antisense technology; lipid metabolism;				
PR	PR	13-MAR-2003; 2003US-0455050P.	cholesterol imbalance; dyslipidaemia hypercholesterolaemia;				
PR	PR	14-APR-2003; 2003US-0462894P.	coronary artery disease; CAD; coronary heart disease; CHD;				
PR	PR	17-APR-2003; 2003US-0463772P.	atherosclerosis; hepatic glucose production;				
PR	PR	25-APR-2003; 2003US-0465665P.	glucose-metabolism-related disorder; diabetes; cancer; breast cancer;				
PR	PR	25-APR-2003; 2003US-046912P.	coronary artery disease; CAD; coronary heart disease; CHD;				
PR	PR	09-AUG-2003; 2003US-0493986P.	atherosclerosis; hepatic glucose production;				
PR	PR	11-AUG-2003; 2003US-0494597P.	glucose-metabolism-related disorder; diabetes; cancer; breast cancer;				
PR	PR	26-SEP-2003; 2003US-0506341P.	colon cancer; lung cancer; neurological disease; Huntington disease;				
PR	PR	09-OCT-2003; 2003US-0510246P.	spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.				
PR	PR	10-OCT-2003; 2003US-0510318P.	spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.				
PR	PR	07-NOV-2003; 2003US-0518453P.	spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.				
XX	XX		Homo sapiens.				
XX	XX		OS				
XX	XX		WO2004080406-A2.				
XX	XX		23-SEP-2004.				
XX	XX		08-MAR-2004; 2004WO-US007070.				
XX	XX		07-MAR-2003; 2003US-0452682P.				
XX	XX		12-MAR-2003; 2003US-0454265P.				
XX	XX		13-MAR-2003; 2003US-0454962P.				
XX	XX		13-MAR-2003; 2003US-0455050P.				
XX	XX		14-APR-2003; 2003US-0462894P.				
XX	XX		17-APR-2003; 2003US-0463772P.				
XX	XX		25-APR-2003; 2003US-0465665P.				
XX	XX		25-APR-2003; 2003US-046912P.				
XX	XX		09-AUG-2003; 2003US-0493986P.				
XX	XX		11-AUG-2003; 2003US-0494597P.				
XX	XX		26-SEP-2003; 2003US-0506341P.				
XX	XX		09-OCT-2003; 2003US-0510246P.				
XX	XX		10-OCT-2003; 2003US-0510318P.				
XX	XX		07-NOV-2003; 2003US-0518453P.				
XX	XX		(ALNY-) ALNYLAM PHARM.				
XX	XX		Manoharan M, Bumcrot D;				
XX	XX		WPI; 2004-677362/66.				
XX	XX		Interference RNA agent useful for treating dyslipidemias, coronary artery				
XX	XX		disease, diabetes, cancer or neurological disease, comprises sense				
XX	XX		sequence and antisense sequence which has specific modifications.				
XX	XX		Example 5; SEQ ID NO 2004; 378pp; English.				
XX	XX		The invention describes a RNA interference (iRNA) agent (I) comprising a				
XX	XX		sense sequence and an antisense sequence, where the sense sequences have				
XX	XX		one or more asymmetrical 2'-O alkyl modifications, the antisense				
XX	XX		sequences have one or more asymmetrical phosphorothioate modifications				
XX	XX		and the antisense sequence targets a human gene sequence. Also described				
XX	XX		are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100				
XX	XX		levels or glucose-6-phosphatase levels in a subject; producing (I);				
XX	XX		stabilising (I), involves selecting a sequence with activity and				
XX	XX		introducing one or more asymmetrical modification in the sequence, where				
XX	XX		the modification decreases nuclease sensitivity while not decreasing its				
XX	XX		activity; a kit comprising (I) and instruction for its use; and a device				
XX	XX		that can be dispense or administer a composition comprising (I). (I) is				
XX	XX		useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)				
XX	XX		is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.				
XX	XX		The subject is suffering from a disorder characterised by elevated or				
XX	XX		otherwise unwanted expression of apoB-100, elevated or otherwise unwanted				
XX	XX		levels of cholesterol, and/or dysregulation of lipid metabolism. The				
XX	XX		disorder is chosen from the HDL/LDL cholesterol imbalance,				
XX	XX		dyslipidemias, hypercholesterolaemia, statin-resistant				
XX	XX		hypercholesterolaemia, coronary artery disease (CAD), coronary heart				
XX	XX		disease (CHD) and atherosclerosis. (I) is administered to a subject to				
XX	XX		inhibit hepatic glucose production or for treating glucose-metabolism-				
XX	XX		related disorder e.g. diabetes or type-2 diabetes. (I) is useful for				
XX	XX		treating the diseases as mentioned above, cancer (e.g. breast, colon or				
XX	XX		lung cancer), neurological disease (e.g., Huntington disease or				
XX	XX		spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence				
XX	XX		represents a human apolipoprotein B (ApoB) antisense oligonucleotide that				
XX	XX		can be used to control ApoB gene expression.				
XX	XX		Sequence 19 BP; 3 A; 6 C; 1 G; 9 T; 0 U; 0 Other;				
XX	XX		Query Match 0.3%; Score 15.8; DB 1; Length 19;				
XX	XX		Best Local Similarity 89.5%; Pred. No. 3.2e+02;				
XX	XX		Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
XX	XX		2903 TGACAGAGGAGGAGGA 2921				

CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.

SQ Sequence 19 BP; 3 A; 6 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 3.2e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2903 TGACAGAGGAGGAGGAAGA 2921

DB 19 TGACAGATGAGATGAAGA 1

RESULT 434

AAT15159/c

ID AAT15159 standard; DNA; 20 BP.

XX AC AAT15159;

XX 29-JUN-1996 (first entry)

DE Probe for CDK4I gene between sequence-tagged sites 54F and 5BS.

XX Probe; human; CDK4I; cyclin-dependent kinase-4-inhibitor;
 KW tumour suppressor; chromosome-9p21; sequence-tagged site; mutation;
 KW methylthioadenosine-phosphorylase; interferon-alpha; 54F; 5BS; deletion;
 KW leukaemia; melanoma; diagnostic; dysplastic nevus syndrome; glioma;
 KW non-small cell lung carcinoma; cancer; gene therapy; antisense; ribozyme;
 KW antibody; imaging; ss.

XX Synthetic.

XX W09528169-A1.

XX 26-OCT-1995.

XX 12-APR-1995; 95WO-US004655.

XX 14-APR-1994; 94US-00227800.

XX (REGC) UNIV CALIFORNIA.

XX Carson DA, Nobori T;

XX WPI; 1995-373630/48.

XX Cyclin dependent kinase inhibitor gene, related vectors and antibodies -
 PT useful for diagnosis, assessing predisposition and treatment of cancers.

PS Example 1; Page 89; 129pp; English.

XX This probe, along with AAT15160, binds to part of a 50-kb region between
 CC sequence-tagged sites 54F and 5BS on chromosome-9p21, between a
 CC methylthioadenosine-phosphorylase gene (AAT15167) and an interferon-alpha
 CC gene cluster, and may be used to isolate a cyclin-dependent protein-
 CC kinase-4-inhibitor (CDK4I) tumour suppressor gene. The CDK4I gene has
 CC been isolated as phase lambda clones 10B1-10 (AAT15158) and 10A1
 CC (AAT15157) in Escherichia coli. The gene and its product may be used in
 CC diagnosis of cancer, particularly melanoma (especially dysplastic nevus

CC syndrome), glioma, non-small cell lung carcinoma or leukaemia. The gene
 CC may also be used in cancer gene therapy, or in antitumour antisense
 CC oligonucleotide or ribozyme construction. Antibodies against CDK4I may be
 CC used in diagnosis or in vivo imaging

SQ Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.3e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCGAGTTCGCAATTTC 4097

DB 20 GCTTCCAGTTTCCAATTTC 2

RESULT 435

AAQ99171/c

ID AAQ99171 standard; DNA; 20 BP.

XX AC AAQ99171;

XX 07-MAY-1996 (first entry)

DE Human MTS1 exon2 PCR amplification/sequencing primer, 42F.

XX Multiple tumour suppressor; El-alpha; diagnosis; cancer; leukaemia;
 KW astrocytoma; glioblastoma; Hodgkin's lymphoma; melanoma; glioma;
 KW gene therapy; chronic; ss.

XX Homo sapiens.

XX W09525429-A1.

XX 28-SEP-1995.

XX 17-MAR-1995; 95WO-US003316.

XX 18-MAR-1994; 94US-00214581.

XX 18-MAR-1994; 94US-00214582.

XX 14-APR-1994; 94US-00227369.

XX 01-JUN-1994; 94US-00251938.

XX (MYRI-) MYRIAD GENETICS INC.

XX Kamb A;

XX WPI; 1995-344401/44.

XX Wild-type multiple tumour suppressor (MTS) gene and mutant sequences -
 PT useful in diagnosis, prognosis and therapy of human cancer, e.g. melanoma
 PT or leukaemia.

XX Example 8; Page 98; 156pp; English.

XX The cDNA sequences encoding several multiple tumour suppressor (MTS)
 CC polypeptides have been isolated and sequenced, using various sequencing
 CC and amplification primers such as the primer represented in this
 CC sequence. MTS polypeptide-encoding cDNAs and mutants of these are useful
 CC for the diagnosis or prognosis of human cancer. Germ-line mutations of
 CC MTS cDNAs can be used for diagnosing predisposition to melanoma,
 CC leukaemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's
 CC lymphoma, CLL and cancers of the pancreas, thyroid, ovary, uterus,
 CC testis, kidney, stomach and rectum. The wild-type gene is useful for gene
 CC therapy and MTS polypeptides may also be used for protein replacement
 CC therapy. Also the polypeptides or cells contg. an altered MTS gene are
 CC useful for screening for potential cancer therapeutics

SQ Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.3e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCAGTTCCCAATTC 2

RESULT 436
AAAT69775/c
ID AAT69775 standard; DNA; 20 BP.
XX
AC AAT69775;
XX
XX 25-MAR-2003 (revised)
DT 10-SEP-1997 (first entry)
XX
XX Human multiple tumour suppressor gene 1 exon 2 primer 42F.
DE
XX Primer; polymerase chain reaction; PCR; amplification; exon 2; human;
KW multiple; tumour; suppressor; MTS1; cancer; diagnosis; ss.
KW
XX Synthetic.
OS
XX US5624819-A.
PN
XX 29-APR-1997.
PD
XX
XX 07-JUN-1995; 95US-00474177.
PF
XX 18-MAR-1994; 94US-00214582.
PR 18-MAR-1994; 94US-00215086.
PR 18-MAR-1994; 94US-00215087.
PR 14-APR-1994; 94US-00227369.
PR 01-JUN-1994; 94US-00251938.
PR 17-MAR-1995; 95WO-US003537.
XX
XX (MYRI-) MYRIAD GENETICS INC.
PA (UTAH) UNIV UTAH RES FOUND.
XX
XX Cannon-Albright LA, Kamb A, Skolnick MH;
PI
XX WPI; 1997-258217/23.
XX
XX Human mutant multiple tumour suppressor gene sequences - for production
PT of recombinant mutant polypeptide(s).
PT
XX Example 8; Col 69-70; 72pp; English.
PS
XX The present sequence is primer for the PCR amplification of exon 2 of the
CC human multiple tumour suppressor gene 1 (MTS1), useful in cancer
CC diagnosis. (Updated on 25-MAR-2003 to correct PF field.)
CC
XX Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
SQ

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCAGTTCCCAATTC 2

RESULT 437
AAV53825/c
ID AAV53825 standard; DNA; 20 BP.
XX
AC AAV53825;
XX
XX 04-DEC-1998 (first entry)
DT
XX Nucleotide sequence 3.
DE
XX

Multiples tumour suppressor; MTS; human; cancer; hybridisation;
somatic mutation; gene therapy; ss.
Synthetic.
US5801236-A.
01-SEP-1998.
07-JUN-1995; 95US-00480810.
18-MAR-1994; 94US-00214582.
18-MAR-1994; 94US-00215086.
18-MAR-1994; 94US-00215087.
14-APR-1994; 94US-00227369.
01-JUN-1994; 94US-00251938.
17-MAR-1995; 95WO-US003316.
(MYRI-) MYRIAD GENETICS INC.
Kamb A;
WPI; 1998-494842/42.
Nucleic acids based on multiple tumour suppressor, MTS, sequences -
useful as hybridisation probes, primers and recombinant production of MTS
in the diagnosis and treatment of cancers related to MTS mutation(s).
Disclosure; Col 69-70; 73pp; English.
This is the nucleotide sequence of a nucleic acid used in the method of
the invention involving the use of the multiple tumour suppressor (MTS)
gene, to diagnose and treat cancer. The MTS gene is useful in the
diagnosis and prognosis of human cancer, e.g. by standard nucleic
acid hybridisation techniques, of patient samples. The mutated sequences are
those that are present in somatic mutations of the gene in cancers. The
vectors can be used for gene therapy strategies to replace function of
mutated protein in patients. These can also be used to construct protein
mimetics, also for therapeutic strategies. In addition the expression
constructs can also be used for recombinant production of MTS.
Recombinant MTS can be used to screen for drugs to be used for cancer
therapy, and the protein itself may also be used to restore MTS function
in a cell
Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCAGTTCCCAATTC 2

RESULT 438
AAV11244/c
ID AAV11244 standard; DNA; 20 BP.
XX
AC AAV11244;
XX
XX 17-OCT-2003 (revised)
DT 15-JUL-1998 (first entry)
XX
XX Seq ID#8 from US5739027.
DE
XX MTS1; multiple tumour suppressor; diagnosis; cancer; germ-line mutation;
KW familial melanoma locus; MLM; predisposition; ss.
KW
XX unidentified.
OS
XX US5739027-A.
PN
XX

```

PD 14-APR-1998.
XX
PF 07-JUN-1995; 95US-00487033.
XX
XX 18-MAR-1994; 94US-00214582.
XX 18-MAR-1994; 94US-00215086.
XX 18-MAR-1994; 94US-00215087.
XX 14-APR-1994; 94US-00227369.
XX 01-JUN-1994; 94US-00251938.
XX 17-MAR-1995; 95WO-US003316.
XX (MYRI-) MYRIAD GENETICS INC.
XX Kamb A;
XX
XX WPI; 1998-250421/22.
XX
XX DNA specific for Multiple Tumour Suppressor 1E1-beta gene - are useful
XX for the diagnosis of cancers related to MTS1E1-beta mutation(s) and their
XX treatment.
XX
XX Disclosure; Col 69-70; 72pp; English.
XX
XX This invention describes three human multiple tumour suppression
XX proteins. The MTS gene locus is also referred to as the familial melanoma
XX (FMM) gene locus, located on human chromosome 9p21. Germ line mutations
XX in MTS genes can be used in the diagnosis of predisposition to cancers,
XX e.g. melanoma, leukaemia, astrocytoma, glioblastoma, lymphoma, glioma,
XX Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid,
XX ovary, uterus, testis, kidney, stomach and rectum. NOTE: This sequence is
XX not mentioned in the specification but is given in the sequence ID
XX listing. (Updated on 17-OCT-2003 to standardise OS field)
XX
XX Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 4079 GGTTCAGTTGCCAATTTC 4097
XX | | | | | | | | | | | | | | | | | | | |
XX Db 20 GCTTCAGTTCCCAATTTC 2
XX
XX RESULT 440
XX AAA95641/c
XX ID AAA95641 standard; DNA; 20 BP.
XX AC AAA95641;
XX XX
XX DT 14-FEB-2001 (first entry)
XX XX
XX DE Human MTS1 gene mutant detection primer 42P.
XX
XX KW Cytostatic; human; multiple tumour suppressor 1; MTS1; diagnostic;
XX cancer; gene therapy; protein replacement therapy; PCR primer; ss.
XX
XX OS Homo sapiens.
XX
XX XX USG090578-A.
XX
XX PD 18-JUL-2000.
XX
XX PF 08-DEC-1997; 97US-00986515.
XX
XX PR 18-MAR-1994; 94US-00214582.
XX 18-MAR-1994; 94US-00215086.
XX 18-MAR-1994; 94US-00215087.
XX 14-APR-1994; 94US-00227369.
XX 01-JUN-1994; 94US-00251938.
XX 17-MAR-1995; 95WO-US003316.
XX 07-JUN-1995; 95US-00480810.
XX
XX (MYRI-) MYRIAD GENETICS INC.
XX
XX Kamb A;
XX
XX WPI; 2000-514036/46.
XX
XX Novel protein composition useful in protein replacement therapy for
XX diagnosing and treating cancer comprises a specific weight percent of
XX human multiple tumor suppressor 1 polypeptide.
XX
XX Example 8; Col 71; 72pp; English.
XX
XX The invention relates to the isolation of the gene encoding the human
XX multiple tumour suppressor 1 (MTS1) (AAA95633). The MTS1 protein has a
XX cytotatic activity and is used in protein replacement therapy. This
XX sequence is a PCR primer used in the amplification and detection of
XX mutations in the MTS1 gene. MTS1 is useful in diagnosing human cancers
XX such as (ocular) melanoma, leukemia, astrocytoma, glioblastoma, lymphoma,

```



```
RESULT 443
AAA39359/C
ID AAA39359 standard; DNA; 20 BP.
XX AC AAA39359;
XX DT 12-SEP-2000 (first entry)
XX DE Human MTS related oligonucleotide SEQ ID NO:8.
XX KW Human; multiple tumour suppressor; MTS; somatic mutation; cancer;
XX KW diagnosis; germ line mutation; gene therapy; cytostatic; melanoma;
XX KW leukaemia; astrocytoma; glioblastoma; lymphoma; glioma;
XX KW Hodgkin's lymphoma; ss.
XX OS Homo sapiens.
XX PN US6060301-A.
XX PD 09-MAY-2000.
XX PF 14-JUL-1998; 98US-00115252.
XX PR 18-MAR-1994; 94US-00214582.
XX PR 18-MAR-1994; 94US-00215086.
XX PR 18-MAR-1994; 94US-00215087.
XX PR 14-APR-1994; 94US-00227369.
XX PR 01-JUN-1994; 94US-00251938.
XX PR 17-MAR-1995; 95WO-US003316.
XX PR 07-JUN-1995; 95US-00480810.
XX PR 08-DEC-1997; 97US-00986147.
XX PA (MYRI-) MYRIAD GENETICS INC.
XX PI Kamb A;
XX WPI; 2000-349676/30.
XX DR New vector useful for gene therapy of cancer associated with mutation in
XX PT tumor suppressor gene, comprises DNA sequence of multiple tumor
XX PT suppressor gene.
XX PS Disclosure; Col 71; 71pp; English.
XX CC The present invention describes a vector (I) comprising an isolated DNA
XX CC sequence of a multiple tumour suppressor (MTS) gene having a
XX CC polynucleotide sequence of the human MTS1E1-beta. (I) is useful for
XX CC introducing wild-type MTS function to a cancerous or pre-cancerous cell
XX CC which carries diminished or mutant MTS alleles for suppressing neoplastic
XX CC growth of the recipient cells. (I) is also useful for increasing the
XX CC level of expression of MTS gene even in tumour cells in which the mutant
XX CC gene is expressed at a normal level but the gene product is not fully
XX CC functional. A host cell transformed with (I) is useful as a model system
XX CC to study cancer remission and drug treatment which promotes such
XX CC remission. The present invention relates to somatic mutations and germ
XX CC line mutations in the MTS gene and their use in the diagnosis and
XX CC prognosis of human cancer e.g. melanoma, leukaemia, astrocytoma,
XX CC glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, and cancers of the
XX CC pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and
XX CC rectum. The present sequence represents an oligonucleotide given in the
XX CC sequence listing from the present invention, but which does not appear to
XX CC be mentioned further within the specification
XX SQ Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 4079 GGTTCACAGTTGCCAATTTC 4097
Db 20 GCTTCCAGTTTCCAATTTC 2
RESULT 445
AAZ55597
ID AAZ55597 standard; DNA; 20 BP.
XX AC AAZ55597;
XX DT 14-MAR-2000 (first entry)
```

```
RESULT 444
AAA11171/C
ID AAA11171 standard; DNA; 20 BP.
XX AC AAA11171;
XX DT 11-OCT-2000 (first entry)
XX DE Human MTS1 gene exon screening primer 42P.
XX KW Variant; human; multiple tumour suppressor; MTS; mutation; melanoma;
XX KW cancer; diagnosis; PCR primer; ss.
XX OS Homo sapiens.
XX PN US6037462-A.
XX PD 14-MAR-2000.
XX PF 22-JUL-1998; 98US-00120130.
XX PR 18-MAR-1994; 94US-00214582.
XX PR 18-MAR-1994; 94US-00215086.
XX PR 18-MAR-1994; 94US-00215087.
XX PR 14-APR-1994; 94US-00227369.
XX PR 01-JUN-1994; 94US-00251938.
XX PR 17-MAR-1995; 95WO-US003316.
XX PR 07-JUN-1995; 95US-00480810.
XX PA (MYRI-) MYRIAD GENETICS INC.
XX PI Kamb A;
XX WPI; 2000-269915/23.
XX DR New mutants of the human multiple tumor suppressor gene, useful as
XX PT diagnostic markers of cancer, contain specific base alterations or
XX PT deletions.
XX PS Example 8; Col 69; 72pp; English.
XX CC The invention relates to variants (AAA11196-A11206) of the human multiple
XX CC tumour suppressor 1 (MTS1) gene (AAA11165). The variants have the
XX CC following changes relative to the wild type coding sequence: A at any of
XX CC positions 265, 442, 330 and 329; T at any of positions 172, 238, 341 and
XX CC 148 and deletions of nucleotides 290-294, 172-179 or 128-129. The
XX CC variants are somatic mutations of MTS1, indicative of predisposition to
XX CC melanoma and many other cancers, so detecting them is useful for
XX CC diagnosis, prognosis and monitoring of cancer (including prenatal
XX CC analysis). Cells and animals that express the variants are useful as
XX CC model systems for identifying potential anticancer agents. This sequence
XX CC represents a primer used to screen for mutations in exon 2 of the MTS 1
XX CC gene
XX SQ Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 4079 GGTTCACAGTTGCCAATTTC 4097
Db 20 GCTTCCAGTTTCCAATTTC 2
RESULT 445
AAZ55597
ID AAZ55597 standard; DNA; 20 BP.
XX AC AAZ55597;
XX DT 14-MAR-2000 (first entry)
```

XX DE Canine IL-13 sense PCR primer, SEQ ID NO:143.

XX KW Interleukin; IL-4; IL-5; IL-13; Flt-3 ligand; CD40; CD40 ligand; CD154;

XX KW interferon-alpha; IFN-alpha; GM-CSF; antibody; canine; feline;

XX KW granulocyte macrophage colony-stimulating factor; inhibitor;

XX KW immune response; immunoregulation; tumour; cancer; autoimmune disease;

XX KW vaccine; PCR; primer; ss.

OS Synthetic.

OS Canis familiaris.

XX PN WO9961618-A2.

XX PD 02-DEC-1999.

XX XX 28-MAY-1999; 99WO-US011942.

XX PR 29-MAY-1998; 98US-0087306P.

XX PA (HESK-) HESKA CORP.

XX PI Sim G, Yang S, Dreitz MJ, Wonderling RS;

XX XX WPI; 2000-072623/06.

XX XX Nucleic acids encoding immunoregulatory proteins from cats or dogs,

PT useful for treating or preventing e.g. tumors or autoimmune disease.

XX PS Example 6A; Page 108; 264pp; English.

XX CC The invention relates to canine interleukin-4 (IL-4), canine or feline

CC Flt-3 ligand, canine or feline CD40, canine or feline CD154 (CD40

CC ligand), canine IL-5, canine IL-13, feline interferon-alpha (IFN-alpha)

CC and feline granulocyte macrophage colony-stimulating factor (GM-CSF), and

CC nucleotides which encode these immunoregulatory proteins. The proteins,

CC their associated nucleic acids, specific antibodies and inhibitors may be

CC used as vaccines for therapeutic or prophylactic regulation of an immune

CC response in animals (particularly cats, dogs, horses and humans). They

CC may be used to treat autoimmune or infectious diseases including

CC allergies, tumours, inflammation and graft rejection, and to increase the

CC response from a co-administered antigen. The nucleotide sequences can

CC also be used for the recombinant production of a protein, while

CC nucleotide fragments are useful as probes, as amplification primers and

CC as sources of inhibitory therapeutics (e.g., antisense oligonucleotides).

CC The proteins may be used to raise antibodies and to screen for modulators

CC of activity, while the antibodies may be used in detection, and in drug

CC targeting. Sequences AA255491-255498, AA255513-255515 and AA255581-

CC 255608 represent PCR primers used in isolation, amplification and cloning

CC of cDNAs encoding the immunoregulatory proteins of the invention

XX SQ Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.3e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3920 ATGGCTCTCTGGTGGCTG 3938

||||| ||||||| |||||

Db 1 ATGGCGCTCTGGTGGCTG 19

RESULT 446

AAA90517/c

ID AAA90517 standard; DNA; 20 BP.

XX AC AAA90517;

XX XX 15-DEC-2000 (first entry)

DT

XX Oligonucleotide #8 produced by a novel sequencing method.

DE Nucleic acid sequencing; single-stranded nucleic acid binding protein;

XX

SSB; single nucleotide mutation; ss.

Unidentified.

WO2000493540-A1.

27-JUL-2000.

20-JAN-2000; 2000WO-GB000146.

22-JAN-1999; 99GB-00001475.

(PYRO-) PYROSEQUENCING AB.

(GARD/) GARDNER R.

Ronaghi M;

WPI; 2000-476200/41.

Identifying a target base in a nucleic acid comprising polymerase

reaction of a target sequence with a primer where a single single-

stranded nucleic acid binding protein is included in the reaction, useful

for sequencing nucleic acids.

Example 4; Fig 5; 37pp; English.

The present invention relates to a method for identifying a target base

in a nucleic acid ("template"). A primer is used in the present method,

which hybridises to the template adjacent to the target position. A

polymerase reaction is then carried out on the primer and template in the

presence of a nucleotide, which is incorporated and detected only when

the nucleotide is complementary to the base in the target position. A

single-stranded nucleic acid binding protein (SSB) is included in the

polymerase reaction step. The present sequence is an oligonucleotide

product produced by the present method. This sequence was used to

exemplify the advantages of the new method of the present invention. The

method is useful for sequencing nucleic acids such as DNA and RNA and for

identifying single nucleotide mutations which are characteristic of many

diseases e.g. cancer

Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.3e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4770 GACTGACTGACTGAATGAC 4788

||||| ||||||| |||||

Db 20 GACTGACTGACTGACTGAC 2

RESULT 447

AAH41615/c

ID AAH41615 standard; DNA; 20 BP.

XX AC AAH41615;

XX XX 28-AUG-2001 (first entry)

DT

XX Hco7 mice cDNA heavy chain PCR primer #952.

DE

XX Human antibody; detection; Fab; immunoglobulin; heterophilic antibody;

XX human anti-mouse antibody; HAMA antibody; interleukin 8; IL-8; Herpes;

XX target antigen; bacterial; fungal; viral; pathogen; human disease;

XX hepatitis A; hepatitis B; hepatitis C; influenza; Giardia; Malaria;

XX Leishmania; Staphylococcus aureus; Pseudomonas aeruginosa; diagnosis;

XX PCR primer; ss.

XX Mus sp.

OS Synthetic.

XX WO200140306-A1.

XX

```

PD 07-JUN-2001.
XX
XX 06-DEC-2000; 2000WO-US033042.
XX
XX 06-DEC-1999; 99US-00456090.
XX
XX (BIOS-) BIOSITE DIAGNOSTICS INC.
XX (GENP-) GENPHARM INT.
XX
XX Bueschler J, Valkirs G, Gray J, Lonberg N;
XX
XX WPI; 2001-374798/39.
XX
XX Detecting analyte in human sample containing human antibodies binding to
XX nonhuman-antibodies, involves contacting sample with human antibody which
XX binds to antibodies from nonhuman species and detecting binding.
XX
XX Example 3; Page 52; 135pp; English.
XX
XX The present invention describes a method for detecting an analyte in a
XX human sample containing human antibodies that specifically bind to
XX antibodies from a nonhuman species. The method involves contacting the
XX sample with a human antibody (I) which specifically binds to antibodies
XX from a nonhuman species and detecting the binding between (I) and the
XX analyte to indicate presence of the analyte. The method is used for
XX detecting an analyte in a human sample containing human anti-mouse
XX antibody (HAMA) (preferably human anti-mouse idiotype antibodies and/or
XX heterophilic antibodies). The method can also be used for detecting any
XX type of target antigen including bacterial, fungal and viral pathogens
XX that cause human diseases e.g., hepatitis (A,B and C), influenza, Herpes,
XX Giardiasis, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas
XX aeruginosa. Human antibodies can be used as detection reagents for
XX performing clinical diagnostic tests and for performing other in vitro
XX detection assays, including for research purposes. (I) can be used in
XX qualitative assays designed to indicate the presence of one or more
XX target antigens above minimally detectable amounts of antigen in the
XX sample that usually correspond to the sensitivity limitations of the
XX assays for each target antigen. Also, (I) is used to determine the amount
XX of target antigen in a sample in a semi-quantitative or relative sense.
XX Quantification of one or more target antigens in a sample can also be
XX carried out using (I). AAH41612 to AAH41686, and AAB99361 to AAB99399.
XX represent sequences used in the exemplification of the present invention
XX
XX Sequence 20 BP; 2 A; 4 C; 10 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 366 CCTCCACCAACAGGCCCATC 384
Db 19 CCTCCACCAAGGCCCATC 1
XX
RESULT 448
AAF58177/C
ID AAF58177 standard; DNA; 20 BP.
XX
XX AAF58177;
XX
XX 23-APR-2001 (first entry)
XX
XX Primer #7.
XX
XX Human; multiple tumour suppressor; MTS; cancer; gene therapy; ss.
XX
XX Homo sapiens.
XX
XX US6180776-B1.
XX
XX 30-JAN-2001.
XX
XX 22-JUL-1998; 98US-00120129.
XX
XX Query Match 0.3%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 366 CCTCCACCAACAGGCCCATC 384
Db 19 CCTCCACCAAGGCCCATC 1
XX
RESULT 448
AAF58177/C
ID AAF58177 standard; DNA; 20 BP.
XX
XX AAF58177;
XX
XX 23-APR-2001 (first entry)
XX
XX Primer #7.
XX
XX Human; multiple tumour suppressor; MTS; cancer; gene therapy; ss.
XX
XX Homo sapiens.
XX
XX US6180776-B1.
XX
XX 30-JAN-2001.
XX
XX 22-JUL-1998; 98US-00120129.
XX
XX Query Match 0.3%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 4079 GGTTCAGTTGCCAATTTC 4097
Db 20 GGTTCAGTTGCCAATTTC 2
XX
RESULT 449
AAS02570/C
ID AAS02570 standard; DNA; 20 BP.
XX
XX AAS02570;
XX
XX 29-AUG-2001 (first entry)
XX
XX PCR primer #3 used in analysis of multiple tumour suppressor MTS1/2.
XX
XX Human; multiple tumour suppressor; MTS1; MTS2; therapeutic; diagnostic;
XX cancer; gene therapy; melanoma; leukaemia; astrocytoma; glioblastoma;
XX lymphoma; glioma; Hodgkin's lymphoma; chronic lymphatic leukaemia;
XX PCR primer; ss.
XX
XX Homo sapiens.
XX
XX US6210949-B1.
XX
XX 03-APR-2001.
XX
XX 30-NOV-1998; 98US-00201139.
XX
XX 17-MAR-1995; 95WO-US003316.
XX 07-JUN-1995; 95US-00487033.
XX 28-JUL-1995; 95US-00508735.
XX
XX (MYRI-) MYRIAD GENETICS INC.
XX
XX Stone S, Jiang P, Kamb A;
XX
XX WPI; 2001-280859/29.
XX
XX New mouse multiple tumor suppressor gene, useful for diagnosing or
XX prognosing human cancer or as gene therapy for treating cancer.
XX particularly melanoma, leukemia, astrocytoma, lymphoma or cancers of the
XX pancreas or breast.

```

XX Disclosure; Col 73; 80pp; English.

XX The sequence represents PCR primer #3 used in analysis of multiple tumour

XX suppressor MTS1 and MTS2. The MTS genes, and expression products, are

XX useful for treating, diagnosing or prognosing human cancer. In

XX particular, the MTS gene is useful for diagnosing a predisposition to or

XX as a gene therapy for melanoma, leukaemia, astrocytoma, glioblastoma,

XX lymphoma, glioma, Hodgkin's lymphoma, chronic lymphatic leukaemia (CLL),

XX or cancers of the pancreas, breast, thyroid, ovary, uterus, testis,

XX kidney, stomach or rectum. The gene may be used in both cancerous and pre

XX -cancerous cells

XX Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.3e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTC 4097

Db 20 GCTTCAGTTCCATTC 2

RESULT 450

AAH29961/C

ID AAH29961 standard; DNA; 20 BP.

XX AAH29961;

XX 19-JUL-2001 (first entry)

XX Mice of genotype Hco7 heavy chain oligonucleotide PCR primer #952.

XX Human; antibody; immunoglobulin: interleukin 8; IL8; immunogen;

XX human antibody phase display library; immunisation; transgenic animal;

XX PCR primer; ss.

XX Mus sp.

XX Synthetic.

XX WO200125492-A1.

XX 12-APR-2001.

XX 02-OCT-2000; 2000WO-US027237.

XX 02-OCT-1999; 99US-0157415P.

XX 01-DEC-1999; 99US-00453234.

XX (BIOS-) BIOSITE DIAGNOSTICS INC.

XX (GENP-) GENPHARM INT SUBSIDIARY OF MEDAREX INC.

XX Buechler J, Valkirs G, Gray J, Lonberg N;

XX WPI; 2001-335567/35.

XX Producing a human antibody phase display library comprises providing a

XX transgenic animal whose genome comprises human immunoglobulin genes and

XX isolating nucleic acids encoding antibody chains from lymphatic cells.

XX Example 3; Page 56; 161pp; English.

XX The present invention describes a method (M1) for producing a human

XX antibody phase display library (I), comprising: (1) providing a nonhuman

XX transgenic animal (II) whose genome comprises human immunoglobulin genes;

XX (2) isolating nucleic acids encoding human antibody chains (III) from

XX lymphatic cells; and (3) forming a library of display packages whose

XX members comprise a nucleic acid encoding (III) which is displayed from

XX the package. The method is used for producing a human antibody display

XX library, e.g., a Fab phase display library. The display method may be

XX used to screen nucleic acids encoding antibody chains obtained from

XX immunised nonhuman transgenic animals, and from this a population of

CC antibodies may be prepared. Production of a human monoclonal antibodies

CC display library using this method means there is no need to immunise

CC humans with antigens, and the difficulties faced with immortalising B

CC cells are avoided. AAH29958 to AAH30066 and AAH74994 to AAH75056

XX represent sequences used in the exemplification of the present invention

XX Sequence 20 BP; 2 A; 4 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.3e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 366 CCTCCACCACAGCCCATC 384

Db 19 CCTCCACCAGGCGCCATC 1

RESULT 451

AAH04699/C

ID AAD04699 standard; DNA; 20 BP.

XX AAD04699;

XX 04-JUL-2001 (first entry)

XX Human multiple tumour suppressor 1 exon 2 amplifying primer, 42P.

XX Human; multiple tumour suppressor; MTS1; cytostatic; somatic mutation;

XX germ line mutation; gene therapy; melanoma; leukaemia; astrocytoma; CLL;

XX glioblastoma; lymphoma; glioma; Hodgkin's lymphoma; cancer; rectum;

XX pancreas; breast; thyroid; ovary; uterus; testis; kidney; stomach;

XX PCR primer; ss.

XX Homo sapiens.

XX US6218146-B1.

XX 17-APR-2001.

XX 22-JUL-1998; 98US-00120131.

XX 18-MAR-1994; 94US-00214582.

XX 18-MAR-1994; 94US-00215086.

XX 18-MAR-1994; 94US-00215087.

XX 14-APR-1994; 94US-00227369.

XX 01-JUN-1994; 94US-00251938.

XX 17-MAR-1995; 95WO-US003316.

XX 07-JUN-1995; 95US-00486047.

XX (MYRI-) MYRIAD GENETICS INC.

XX Kamb A;

XX WPI; 2001-289831/30.

XX Novel multiple tumor suppressor proteins useful for diagnosis and

XX prognosis of human cancer and for screening drugs for cancer treatment.

XX Example 8; Col 69-70; 71pp; English.

XX The invention relates to somatic and germ line mutations in the multiple

XX tumour suppressor (MTS) gene in human cancer. The invention also relates

XX to therapy of human cancer which have a mutation in the MTS gene,

XX including gene therapy, protein replacement therapy, and protein

XX mimetics. The MTS sequences are useful for diagnosing predisposition to

XX human cancer or for diagnosing and prognosing human cancers such as

XX melanoma, leukaemia, astrocytoma, glioblastoma, lymphoma, glioma,

XX Hodgkin's lymphoma, CLL and cancers of pancreas, breast, thyroid, ovary,

XX uterus, testis, kidney, stomach and rectum. They are also used for

XX screening drugs for cancer treatment. The present sequence is 42P primer

XX used for amplifying human MTS1 exon 2 sequence

XX Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTGCCAATTTC 4097
 Db 20 GCTTCCAGTTTCCAATTTC 2

RESULT 452
 AAH91454
 ID AAH91454 standard; DNA; 20 BP.
 XX
 AC AAH91454;
 XX
 DT 09-OCT-2001 (first entry)
 XX
 DE Human inflammatory bowel disease associated polymorphic site #529.
 XX
 KW Human; inflammatory bowel disease; Crohn's disease; ulcerative colitis;
 KW single nucleotide polymorphism; SNP; chromosome 19p13; paternity test;
 KW chromosome 5q31-33; forensic test; gene therapy; ds.
 XX
 OS Homo sapiens.
 XX
 PH Key Location/Qualifiers
 FT misc_feature 12
 FT /*tag= a
 FT /note= "SNP, optionally insertion or deletion at this
 FT position"
 XX
 PN WO200142511-A2.
 XX
 PD 14-JUN-2001.
 XX
 PF 11-DEC-2000; 2000WO-US033632.
 XX
 PR 10-DEC-1999; 99US-0170257P.
 PR 10-APR-2000; 2000US-0196046P.
 XX
 PA (WHEAT) WHITEHEAD INST BIOMEDICAL RES.
 PA (ELLI-) ELLIPSIS BIOTHERAPEUTICS CORP.
 XX
 PI Daly M, Hudson TJ, Lander ES, Rioux J, Siminovitch K;
 XX WPI; 2001-367874/38.
 XX
 DR Testing for the presence of polymorphisms associated with inflammatory
 PT bowel disease, using a hybridization assay.
 XX
 PS Claim 1; Page 61; 463pp; English.
 XX

CC The present invention describes a method for detecting the presence of
 CC polymorphisms associated with inflammatory bowel diseases such as
 CC ulcerative colitis and Crohn's disease. The methods can be used to detect
 CC the presence of genetic polymorphisms associated with inflammatory bowel
 CC disease and correlating their occurrence with disease states. They may be
 CC used in this way for phenotypic correlations, forensics, paternity
 CC testing, medicine and genetic analysis. The present sequence is a
 CC polymorphic site described in the exemplification of the invention
 XX
 SQ Sequence 20 BP; 17 A; 0 C; 2 G; 0 T; 0 U; 1 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
 Db 1 AAAAAAAAAAAAAAAAAAGAAAA 20

RESULT 453
 AAC83077/C
 ID AAC83077 standard; DNA; 20 BP.
 XX
 AC AAC83077;
 XX
 DT 23-FEB-2001 (first entry)
 XX
 DE Primer 42F for screening exon 2 in MTS1.
 XX
 KW MTS; Multiple Tumour Suppressor; cancer; antibody; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6140473-A.
 XX
 PD 31-OCT-2000.
 XX
 PF 22-JUL-1998; 98US-00120128.
 XX
 PR 18-MAR-1994; 94US-00214582.
 PR 18-MAR-1994; 94US-00215086.
 PR 18-MAR-1994; 94US-00215087.
 PR 14-APR-1994; 94US-00227369.
 PR 01-JUN-1994; 94US-00251938.
 PR 17-MAR-1995; 95WO-US003316.
 PR 07-JUN-1995; 95US-00486047.
 XX
 PA (MYRI-) MYRIAD GENETICS INC.
 XX
 PI Kamb A;
 XX
 DR WPI; 2001-014867/02.
 XX
 PT New multiple tumor suppressor 2-specific antibodies useful for detecting
 PT differences in the absence of the peptides or mutant gene products, or
 PT for screening tissues.
 XX
 PS Example 8; Col 71; 71pp; English.
 XX
 CC The present invention relates to an antibody or its fragment that
 CC specifically binds to a human multiple tumour suppressor (MTS). The
 CC invention is useful for detecting differences in the absence of MTS
 CC peptides, to screen a tissue or to detect mutant MTS gene products. The
 CC antibodies will immunoprecipitate MTS proteins from solution as well as
 CC react with MTS protein on Western or immunoblots of polyacrylamide gels
 XX
 SQ Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTGCCAATTTC 4097
 Db 20 GCTTCCAGTTTCCAATTTC 2

RESULT 454
 AAL37733/C
 ID AAL37733 standard; DNA; 20 BP.
 XX
 AC AAL37733;
 XX
 DT 19-JUL-2002 (first entry)
 XX
 DE Cryps gene related PCR primer #7.
 XX
 KW Ophthalmological; cataract; cryps gene; lesion; crystalline lens;
 KW therapy; human; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX

PN WO200240667-A1.
XX 23-MAY-2002.
XX 24-AUG-2001; 2001WO-CN001274.
XX 25-AUG-2000; 2000CN-00119756.
XX (SHAN-) SHANGHAI RES CENT BIOTECHNOLOGY.
XX Kong X, Bu L, Zhao G, Yan S, Jin M, Sulitang Y, Jin Y, Hu L;
XX WPI; 2002-427092/45.
XX Diagnosis and treatment of lesion of crystalline lens by using cryps gene
XX and its product in pharmaceutical compositions, particularly for therapy
XX of cataract.
XX
XX Example 1; Page 8; 28pp; Chinese.
XX The invention relates to a method for the diagnosis of cataract
XX susceptibility in an individual. The method comprises detecting variation
XX in the cryps gene, its transcript and/or protein of the individual by
XX comparing with the normal gene to indicate the higher possibility in
XX suffering from cataract. The cryps gene and gene-encoded protein are
XX useful in the diagnosis and in pharmaceutical compositions for the
XX treatment of a lesion of a crystalline lens, particularly for therapy of
XX cataract. This polynucleotide sequence represents an oligonucleotide
XX related to the cryps gene of the invention
XX
XX Sequence 20 BP; 5 A; 5 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 4343 CTGGCTCAGATATGAAAT 4361
DB 20 CTGGCTTAGACATGAAAT 2
XX
RESULT 455
AAL45671
ID AAL45671 standard; DNA; 20 BP.
XX AAL45671;
XX
XX 11-JUN-2002 (first entry)
XX Mammary gland bioreactor related oligonucleotide #9.
XX Mammary gland bioreactor; transgenic; goat; animal; ALA; PCR; primer; ss.
XX Unidentified.
XX CN1324952-A.
XX 05-DEC-2001.
XX 22-MAY-2000; 2000CN-00115793.
XX 22-MAY-2000; 2000CN-00115793.
XX (ZHON-) ZHONGLU BIOLOGICAL ENG CO LTD SHANGHAI.
XX Cheng G, Wang K, Chen J;
XX WPI; 2002-281676/33.
XX New method of preparing mammary gland bioreactor with macrofragment DNA
XX for implementing site-specific and fixed time expression of target genes
XX in mammary glands and producing transgenic animals.
XX
XX Example 3; Page 12(Disclosure); 20pp; Chinese.
XX The present invention relates to a method of preparing a mammary gland
XX bioreactor using a large fragment of DNA, comprising injecting the DNA
XX macrofragment into a fertilised ovum and transferring the ovum into a
XX goat, where the target gene in the macrofragment has site-specific for
XX expression in the mammary gland of the goat. The method is useful for
XX effectively implementing site-specific and fixed time expression of
XX target genes in mammary glands and producing transgenic animals e.g.
XX goats. The present sequence is an oligonucleotide described in the
XX exemplification of the invention
XX
XX Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1374 TGGACATTTTTCCTCGAA 1392
DB 1 TGGACATTATTCCAGAA 19
XX
RESULT 456
ABK68899/C
ID ABK68899 standard; DNA; 20 BP.
XX ABK68899;
XX 02-JUL-2002 (first entry)
XX Human phosphorylase kinase beta antisense oligonucleotide #12.
XX Human; phosphorylase kinase beta; metabolic disorder; diabetes;
XX infection; inflammation; tumour formation; antidiabetic;
XX antiinflammatory; cytostatic; phosphorothioate; ss.
XX Homo sapiens.
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "OTHER= Phosphorothioate internucleotide linkages,
XX optionally bases 1-5 and 16-20 are 2'-methoxyethoxy (2'-
XX MOE) bases, where the 2'-MOE cytidines are also
XX 5'-methylcytidines"
XX
XX WO200222637-A1.
XX 21-MAR-2002.
XX 12-SEP-2001; 2001WO-US028586.
XX 14-SEP-2000; 2000US-00662250.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2002-351873/38.
XX Novel antisense oligonucleotide which inhibits expression of
XX phosphorylase kinase beta, useful for treating metabolic disorder e.g.
XX diabetes, prevent or delay infection, inflammation or tumor formation.
XX
XX Claim 3; Page 83; 132pp; English.
XX The present invention relates to antisense compounds and methods for
XX modulating the expression of human phosphorylase kinase beta. The
XX antisense compounds, particularly antisense oligonucleotides, target and
XX inhibit the expression of human phosphorylase kinase beta. The antisense
XX compounds are useful for inhibiting the expression of human phosphorylase

CC kinase beta in human cells or tissues and for treating an animal,
 CC particularly a human suspected of having or being prone to a disease or
 CC condition associated with expression of phosphorolase kinase beta such as
 CC a metabolic disorder e.g. diabetes. The compounds are useful for
 CC diagnostics, therapeutics and as research reagent, e.g. prophylactically
 CC to prevent or delay infection, inflammation or tumour formation. The
 CC antisense compounds are useful in the preparation of a pharmaceutical
 CC formulation. They are highly specific, have an enhanced affinity for the
 CC nucleic acid target, and are safely and effectively administered to
 CC humans. ABK6888-ABK6895 represent human phosphorolase kinase beta
 CC antisense oligonucleotides which comprise a phosphorothioate backbone
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 3672 TCTTACATACAGCGAATT 3690
 Db 19 TCTTGCATACAGCGAATT 1

RESULT 457
 ABQ74888/c
 ID ABQ74888 standard; DNA; 20 BP.

XX AC ABQ74888;

XX DT 24-OCT-2002 (first entry)

XX DE Mouse TNFR2 antisense oligonucleotide SEQ ID NO:138.

XX KW Tumour necrosis factor receptor 2; TNFR2; antisense oligonucleotide;
 KW phosphorothioate; 2'-O-methoxyethyl; ss.

XX OS Mus musculus.

XX FH Key Location/Qualifiers

XX FT modified_base 1..20

XX FT /*tag= b

XX FT /mod_base= OTHER

XX FT /note= "phosphorothioate linkages"

XX FT modified_base 1..5

XX FT /*tag= a

XX FT /mod_base= OTHER

XX FT /note= "2'-O-methoxyethyl nucleotides"

XX FT modified_base 16..20

XX FT /*tag= c

XX FT /mod_base= OTHER

XX FT /note= "2'-O-methoxyethyl nucleotides"

XX PN US6410324-B1.

XX PD 25-JUN-2002.

XX PF 27-APR-2001; 2001US-00844634.

XX PR 27-APR-2001; 2001US-00844634.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Watt AT;

XX PI WPI; 2002-606814/65.

XX DR New compounds antisense to nucleic acid encoding human or mouse tumor

XX PT necrosis factor receptor 2 are useful to treat disease associated with

XX FT mouse tumor necrosis factor receptor 2 expression.

XX PS Claim 3; Col 50; 69pp; English.

XX CC The present invention describes compounds of 8-30 nucleobases antisense

CC to a nucleic acid encoding human or mouse tumour necrosis factor receptor
 CC 2 (TNFR2). Also described is a method for inhibiting expression of human
 CC or mouse TNFR2 comprising contacting cells or tissues in vitro with one
 CC of the claimed compounds. The antisense compounds are used to treat a
 CC disease or condition associated with expression of TNFR2. The present
 CC sequence represents a mouse TNFR2 antisense chimeric phosphorothioate
 CC oligonucleotide, which is given in the present invention
 XX
 SQ Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 4489 CAGAAAGTAGGACCAAGTG 4507
 Db 20 CAGCAAGTAGGACCAAGTG 2

RESULT 458

ADG24459/c

ID ADG24459 standard; DNA; 20 BP.

XX AC ADG24459;

XX DT 26-FEB-2004 (first entry)

XX DE Heavy chain variable mutant PCR primer, SEQ ID 6.

XX KW Virucide; hepatotropic; vaccine; gene therapy; humanized antibody;

XX KW surface antigen S; hepatitis B virus; HBV; heavy chain; light chain;

XX KW mouse; Complementarity Determining Region; CDR; HCDR1; HCDR2; HCDR3;

XX KW LCDR1; LCDR2; LCDR3; hepatitis B virus infection; PCR; primer; ss.

XX OS Synthetic.

XX PN WO200259318-A1.

XX PD 01-AUG-2002.

XX PF 04-OCT-2001; 2001WO-KR001657.

XX PR 02-OCT-2000; 2000KR-00057891.

XX PR 29-SEP-2001; 2001KR-00060966.

XX PA (KORE-) KOREA RES INST BIOSCIENCE & BIOTECHNOLOG.

XX PI Hong H, Kim K;

XX DR WPI; 2002-599792/64.

XX PT New humanized heavy or light chain antibody that specifically binds to

XX PT the surface antigen S of hepatitis B virus (HBV), useful for preventing

XX FT and/or treating HBV infection.

XX PS Example 1; SEQ ID NO 6; 97pp; English.

XX CC The present invention relates to humanized antibodies against the surface

XX CC antigen S of hepatitis B virus (HBV). The humanized antibodies comprise

XX CC heavy and light chains, which have sequences of mouse origin at the heavy

XX CC and light Complementarity Determining Regions (CDR) 1-3 (HCDR1, HCDR2,

XX CC HCDR3, LCDR1, LCDR2 and LCDR3). In addition, human anti-mouse antibody

XX CC (HAMA) response is minimized by eliminating peptide sequences from heavy

XX CC chain of the above humanized antibody which bind Major Histocompatibility

XX CC Complex (MHC) class II molecules. The antibodies are useful in preventing

XX CC and/or treating hepatitis B virus infection in humans.

XX SQ Sequence 20 BP; 2 A; 4 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
QY 366 CCTCCACCAAGGCCCATC 384
Db 19 CCTCCACCAAGGCCCATC 1

RESULT 459
ADG24508
ID ADG24508 standard; DNA; 20 BP.
XX AC
XX ADG24508;
XX DT
XX 26-FEB-2004 (first entry)
XX DE
XX Humanized antibody HZII-H67 related oligonucleotide.
XX KW
XX Virucide; hepatotropic; vaccine; gene therapy; humanized antibody;
XX surface antigen S; hepatitis B virus; HBV; heavy chain; light chain;
XX mouse; Complementarity Determining Region; CDR; HCDR1; HCDR2; HCDR3;
XX LCDR1; LCDR2; LCDR3; hepatitis B virus infection; ss.
XX OS
XX Synthetic.
XX Homo sapiens.
XX PN
XX WO200259318-A1.
XX PD
XX 01-AUG-2002.
XX PF
XX 04-OCT-2001; 2001WO-KR001657.
XX PR
XX 02-OCT-2000; 2000KR-00057891.
XX 29-SEP-2001; 2001KR-00060966.
XX PA
XX (KORE-) KOREA RES INST BIOSCIENCE & BIOTECHNOLOG.
XX Hong H, Kim K;
XX WPI; 2002-599792/64.
XX DR
XX New humanized heavy or light chain antibody that specifically binds to
XX the surface antigen S of hepatitis B virus (HBV), useful for preventing
XX and/or treating HBV infection.
XX Example 1; Fig 1; 97pp; English.
XX CC
XX The present invention relates to humanized antibodies against the surface
XX antigen S of hepatitis B virus (HBV). The humanized antibodies comprise
XX heavy and light chains, which have sequences of mouse origin at the heavy
XX and light Complementarity Determining Regions (CDR) 1-3 (HCDR1, HCDR2,
XX HCDR3, LCDR1, LCDR2 and LCDR3). In addition, human anti-mouse antibody
XX (HAMA) response is minimized by eliminating peptide sequences from heavy
XX chain of the above humanized antibody which bind Major Histocompatibility
XX Complex (MHC) class II molecules. The antibodies are useful in preventing
XX and/or treating hepatitis B virus infection in humans.
XX SQ
XX Sequence 20 BP; 4 A; 10 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 366 CCTCCACCAAGGCCCATC 384
Db 2 CCTCCACCAAGGCCCATC 20

RESULT 460
ABX13334/c
ID ABX13334 standard; DNA; 20 BP.
XX AC
XX ABX13334;
XX DT
XX 20-MAY-2003 (first entry)
XX
```

```
DE Synthetic linker sequence for heavy chain variable region PCR primer.
XX ss; PCR; primer; heavy chain variable region; insect cells; antibody;
XX Fab fragment; single chain Fv; immunoglobulin; IgG1; passive vaccine;
XX infection; negative immune reaction; serum sickness; anaphylactic shock.
XX OS
XX Synthetic.
XX PN
XX US2002197677-A1.
XX PD
XX 26-DEC-2002.
XX PF
XX 08-MAR-2002; 2002US-00094546.
XX PR
XX 08-MAR-2001; 2001US-0274164P.
XX PA
XX (GUTTI) GUTTIERI M C.
XX (SCHM/) SCHMALJOHN C S.
XX PI
XX Guttieri MC, Schmaljohn CS;
XX WPI; 2003-329047/31.
XX DR
XX Novel DNA construct for obtaining conformationally active immunoglobulin
XX G1 antibody from Fab fragment, has an antibody light or heavy chain
XX derived from Fab fragment or a light chain derived from single chain Fv.
XX Example 1; Page 12; 29pp; English.
```

The invention relates to a DNA construct for expressing in insect cells, a complete antibody light or heavy chain derived from the corresponding Fab fragment, or a complete antibody light chain derived from the corresponding single chain Fv. For a vector for expression of a light chain (including one from a single chain Fv fragment), the cassette includes a signal sequence that encodes a peptide that directs the secretion of a protein from insect cells, and a DNA sequence encoding the light chain of the desired antibody. For a vector for a expression of heavy chain, the cassette includes the same signal sequence, a DNA sequence encoding the heavy chain of the desired antibody, and the coding region for a human constant domain such as immunoglobulin (Ig) G1. The construct also contains a promoter and a transcription terminator. Also included are the transformed insect cell expressing a desired antibody, and an IgG1 antibody derived from the expression in an insect cell of the construct, a passive vaccine against an infectious agent recognised by the IgG1 antibody (comprising the IgG1 antibody). The construct is useful for obtaining a conformationally active IgG1 antibody from a corresponding Fab fragment. The method involves, for a corresponding single chain Fv fragment, producing a complete chimeric light chain gene by inserting the light chain variable region from scfv 3' to a constant domain from lambda light chain, and transforming the insect cells with the construct to isolate the IgG1 antibody. The insect cells are TN cells. The IgG1 antibody is useful for detecting an infectious agent in a biological sample. The IgG1 antibody is also useful for treating an infection caused by an agent recognised by the IgG1 antibody. The IgG1 antibody is also useful for detecting antigens specific for the passive immunisation, especially in humans, without negative immune reactions such as serum sickness or anaphylactic shock. The present sequence is a synthetic linker portion of a PCR primer preceded by part of the heavy chain variable region sequence, used in the manufacture of the construct of the invention

XX SQ Sequence 20 BP; 2 A; 4 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 366 CCTCCACCAAGGCCCATC 384
Db 19 CCTCCACCAAGGCCCATC 1


```

RESULT 461
ABX17785
ID ABX17785 standard; DNA; 20 BP.
XX
XX
AC ABX17785;
XX
XX
DT 05-FEB-2003 (first entry)
XX
XX
DE Mouse urokinase plasminogen activator antisense oligonucleotide #17.
XX
XX
KW Urokinase plasminogen activator; gene therapy; cancer;
XX hyperproliferative disorder; cancer; breast cancer; colon cancer;
XX bone cancer; brain cancer; ovary cancer; cervix cancer;
XX endometrium cancer; stomach cancer; kidney cancer; tumour metastasis;
XX antisense oligonucleotide; ss.
XX
OS Synthetic.
XX
XX
PN WO200279515-A1.
XX
XX
PD 10-OCT-2002.
XX
XX
PF 18-MAR-2002; 2002WO-US008112.
XX
XX
PR 30-MAR-2001; 2001US-00821972.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Baker BP, Freier SM, Watt AV;
XX
XX
DR WPI; 2003-058441/05.
XX
XX
PT New antisense compound, useful for preparing a composition for treating
XX hyperproliferative disorders, cancer e.g., breast, colon, bone, brain,
XX ovary, cervix, endometrium, stomach or kidney cancer, or tumor
XX metastasis.
XX
XX
Example 16; Page 93; 153pp; English.
XX
XX
SS A new compound, which is 8-50 nucleobases in length targeted to a nucleic
XX acid molecule encoding urokinase plasminogen activator, specifically
XX hybridises with and inhibits the expression of urokinase plasminogen
XX activator. The compound is useful for preparing a composition for
XX treating (e.g. by gene therapy) hyperproliferative disorder, cancer e.g.,
XX breast, colon, bone, brain, ovary, cervix, endometrium, stomach or kidney
XX cancer, or tumour metastasis. This sequence represents an antisense
XX oligonucleotide used to modulate expression of urokinase plasminogen
XX activator
XX
XX
SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 506 TTTCGCCAGGCTAGGCTA 524
Db 1 TTTCGCCAGGCTAGGCTA 19

RESULT 462
ABZ25516/c
ID ABZ25516 standard; DNA; 20 BP.
XX
XX
AC ABZ25516;
XX
XX
DT 28-MAR-2003 (first entry)
XX
XX
DE Human MTS1 exon 2 PCR primer 1.
XX
XX
KW PCR; primer; ss; neoplastic; pre-neoplastic; heterozygosity; cytostatic;
XX urothelial neoplasia; MTS1; human.
XX

OS Homo sapiens.
XX
XX
PN WO2002100246-A2.
XX
XX
PD 19-DEC-2002.
XX
XX
PF 11-JUN-2002; 2002WO-US018427.
XX
XX
PR 12-JUN-2001; 2001US-0297813P.
XX
XX
PA (TEXA ) UNIV TEXAS SYSTEM.
XX
XX
PI Czerniak B, Johnston D;
XX
XX
DR WPI; 2003-156900/15.
XX
XX
PT Detecting a cell with a neoplastic or pre-neoplastic phenotype, useful
XX for diagnosing or treating neoplasia or pre-neoplastic conditions
XX comprises testing the cell for the presence of loss of heterozygosity at
XX one or more loci.
XX
XX
PS Example 5; Page 96; 248pp; English.
XX
XX
SS The invention relates to a novel method for detecting a cell with a
XX neoplastic or pre-neoplastic phenotype, comprising testing a sample cell
XX for the presence of loss of heterozygosity at one or more loci on one or
XX more chromosomes. The chromosomes are selected from a group of chromosome
XX 1-22, where a loss of heterozygosity at one or more of the loci is
XX indicative of a neoplastic or pre-neoplastic phenotype. The method of the
XX invention has cytostatic activity. Detecting a cell with a neoplastic or
XX pre-neoplastic phenotype is useful for diagnosing, monitoring or treating
XX the progression of neoplasia or pre-neoplastic conditions, e.g.
XX urothelial neoplasia. The present sequence represents a PCR primer used
XX in the invention to amplify exon 1 of the MTS1 gene
XX
XX
SQ Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCGAGTTGCCAATTC 4097
Db 20 GCTTCGAGTTTCCCAATTC 2

RESULT 463
ADB99900/c
ID ADB99900 standard; DNA; 20 BP.
XX
XX
AC ADB99900;
XX
XX
DT 04-DEC-2003 (first entry)
XX
XX
DE Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 39.
XX
XX
KW Cytostatic; gene therapy; antisense oligonucleotide; human;
XX vitamin D nuclear receptor; cancer; developmental disorder;
XX phosphorothioate; ss.
XX
XX
OS Synthetic.
XX
XX
FH Key modified_base 1. .20
XX Location/Qualifiers
XX
XX
FT /mod_base= OTHER
XX /note= "This oligonucleotide has a phosphorothioate
XX backbone and 2'-methoxyethyl (2'-MOE) wings at the 5',
XX and 3' ends, which are 5 nucleotides in length. Also all
XX cytidine residues are 5-methylcytidines"
XX
XX
PN WO2003041657-A2.
XX
XX

```

PD 22-MAY-2003.
XX
XX
XX 13-NOV-2002; 2002WO-US036692.
XX
XX 14-NOV-2001; 2001US-00000213.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Baker BF, Dobie K, Roach MP;
XX
XX WPI; 2003-468578/44.
XX
XX New antisense oligonucleotides for modulating vitamin D nuclear receptor
PT gene expression, particularly useful for treating or preventing cancer or
PT developmental disorder, or as diagnostics or research reagents.
XX
XX Claim 3; SEQ ID NO 39; 122pp; English.
XX
XX The present invention relates to novel antisense oligonucleotides
CC (ADB99875-ADB99952) which are targeted to a human vitamin D nuclear
CC receptor coding sequence (ADB99864), and specifically hybridizes with and
CC inhibits the expression of vitamin D nuclear receptor. The antisense or
CC oligonucleotides are useful for treating an animal having a disease or
CC condition associated with vitamin D nuclear receptor, e.g. cancer or
CC developmental disorder.
XX
XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 302 AGAGCTTCCCGAGTCTCC 320
DB 20 AGAGCTGTCACGCTCTCC 2
RESULT 464
AAD64089/c
ID AAD64089 standard; DNA; 20 BP.
XX
XX AAD64089;
AC
XX
XX 12-FEB-2004 (first entry)
DT
XX
XX Human CDK4I' exon DNA specific primer #1.
DE
XX
XX Human; tumour suppressor gene; cyclin-dependent kinase 4 inhibitor;
KW CDK4I; cancer; gene therapy; primer; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003138928-A1.
PN
XX
XX 24-JUL-2003.
PD
XX
XX 18-JUL-2001; 2001US-00908671.
PF
XX
XX 26-AUG-1997; 97US-00921954.
PR
XX
XX (CARSON) CARSON D A.
PA (NOBORI) NOBORI T.
XX
XX Carson DA, Nobori T;
PI
XX
XX WPI; 2003-851737/79.
DR
XX
XX New isolated polynucleotide encoding cyclin-dependent kinase 41, useful
PT for preparing a composition for diagnosing or treating cancer.
PT
XX
XX Disclosure; SEQ ID NO 6; 46pp; English.
PS
XX
XX The present invention relates to novel tumour suppressor genes, termed as

CC cyclin-dependent kinase 4 inhibitor (CDK4I) genes and their corresponding
CC proteins. The polynucleotides are useful for preparing a composition for
CC diagnosing or treating cancer. Sequences of the invention are also useful
CC in gene therapy. The present sequence is human CDK4I' exon DNA specific
CC primer used in the invention
XX
XX Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 4079 GGTTCAGTTGCCAATTC 4097
DB 20 GCTTCCAGTTTCCAATTC 2
RESULT 465
ADF83451/c
ID ADF83451 standard; DNA; 20 BP.
XX
XX ADF83451;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human CDKN2A gene-specific primer #5.
DE
XX
XX Predisposition; melanoma; human; cyclin dependent kinase inhibitor 2A;
KW CDKN2A; mutant allele; melanocortin-1 receptor; MC1R; variant allele;
KW gene-specific; primer; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003175721-A1.
PN
XX
XX 18-SEP-2003.
PD
XX
XX 28-MAR-2002; 2002US-00108732.
PF
XX
XX 28-MAR-2001; 2001US-0279515P.
PR
XX
XX (BOXN/) BOX N F.
PA (DUFF/) DUFFY D L.
PA (HAYW/) HAYWARD N K.
PA (MART/) MARTIN N G.
PA (STUR/) STURM R A.
PA (GRUI/) GRUIS N A.
PA (VVEL/) VAN DER VELDEN P A.
PA (BERG/) BERGMAN W.
PA (FRAN/) FRANTS R R.
XX
XX Box NF, Duffy DL, Hayward NK, Martin NG, Sturm RA, Gruis NA;
PI Van Der Velden PA, Bergman W, Frants RR;
PN
XX
XX WPI; 2003-898522/82.
DR
XX
XX Identifying a predisposition to melanoma comprises determining whether an
PT individual carrying a cyclin dependent kinase inhibitor 2A (CDKN2A)
PT mutant allele also carries a melanocortin-1 receptor (MC1R) variant
PT allele.
XX
XX Claim 15; SEQ ID NO 5; 30pp; English.
PS
XX
XX The present invention relates to a method of identifying a predisposition
CC to melanoma. The method comprises determining whether a human individual
CC carrying a cyclin dependent kinase inhibitor 2A (CDKN2A) mutant allele
CC also carries a melanocortin-1 receptor (MC1R) variant allele, where the
CC presence of a MC1R variant allele indicates a predisposition of the
CC individual to melanoma greater than that expected as a consequence of the
CC CDKN2A mutant allele alone. Also disclosed is a kit for identifying a
CC predisposition to melanoma. The kit comprises MC1R gene-specific primers
CC and/or CDKN2A gene-specific primers and MC1R variant allele-specific
CC probes and/or CDKN2A mutant allele-specific probes. The kit further

CC comprises MCIR sequencing primers and/or CDKN2A sequencing primers. The
CC method is useful for identifying a predisposition to melanoma. The
CC present sequence represents a gene-specific primer that can be used in
CC the method of the present invention.

XX
SQ Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. NO. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTCCAGTTCCTCAATTTC 4097
DB 20 GCTTCAGTTTCCAATTTC 2

RESULT 466
ABZ87942
ID ABZ87942 standard; DNA; 20 BP.
XX
XX AC ABZ87942;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds..
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX
XX Disclosure; SEQ ID NO 3184; 872pp; English.

XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 20 BP; 6 A; 1 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. NO. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1261 AGAGGAGAGTTGAAGAGAG 1279
DB 2 AGGGAGAGTTGAAGAGAG 20

RESULT 467
ABZ90375
ID ABZ90375 standard; DNA; 20 BP.
XX
XX AC ABZ90375;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds..
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX
XX Disclosure; SEQ ID NO 5617; 872pp; English.

XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

The invention relates to a novel pharmaceutical composition, comprising at least one first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airflow dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiallergic, antiasthmatic, hypotensive, immunosuppressive, and cytostatic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, reducing levels of adenosine receptor, producing bronchodilation, increasing levels of ubiquinone or surfactant in a subject's tissue, or treating bronchoconstriction.

CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0

Qy 4280 CTCCTCATAGCGTCCATCG 4298
|||||
Db 1 CTCCTCATAGCGGCATTG 19
|||||

RESULT 470
ABZ75637
ID ABZ75637 standard; DNA; 20 BP.
XX
AC ABZ75637;
XX
DT 15-MAY-2003 (first entry)
XX
DE Template (CTGA)5 for second strand synthesis by HIV RT.
XX
KW DNA polymerization; drug susceptibility; HIV; reverse transcriptase; RT;
KW ds.
XX
OS Synthetic.
XX
PN WO2002103039-A1.
XX
PD 27-DEC-2002.
XX
PF 14-JUN-2002; 2002WO-SE001155.
XX
PR 14-JUN-2001; 2001US-0297773P.
XX
PA (CAVI-) CAVIDI TECH AB.
XX
PI Kaellander C, Pettersson I, Gronowitz S, Shao X;
XX
DR WPI; 2003-167535/16.
XX
PT Measuring DNA-dependent DNA polymerization in a biological sample, useful
PT for drug susceptibility testing, comprises measuring the amount of
PT incorporated modified deoxynucleoside triphosphate with the aid of a
PT labeled antibody.
XX
PS Example 1; Page 31; 36pp; English.
XX

CC The invention relates to measuring DNA-dependent DNA polymerization in a
CC biological sample and involves measuring the amount of incorporated
CC modified deoxynucleoside triphosphate with the aid of the label of a
CC bound antibody. The method is useful in measuring DNA polymerization for
CC drug susceptibility testing. Sequences ABZ75637-647 represent different
CC templates used for second strand synthesis by HIV reverse transcriptase
CC (RT)
XX
SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0

Qy 4769 TGACTGACTGACTAAATGA 4787
|||||
Db 2 TGACTGACTGACTGACTGA 20
|||||

RESULT 471
ABD24172

CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4280 CTCCTCATAGCGTCATGG 4298
Db 1 CTCCTCATAGCGCCATTG 19

RESULT 473
ABD25730
ID ABD25730 standard; DNA; 20 BP.
XX AC ABD25730;
XX DT 29-JUL-2004 (first entry)
XX DE AA465687-derived oligonucleotide SEQ ID 4742.

Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
respiratory tract inflammation; adenosine sensitivity; lung; cancer;
surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.
OS
XX WO2000285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.

Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
Miller S, Tang L, Shahabuddin S;
WPI; 2003-093058/08.
Pharmaceutical composition for treating asthma, has antisense
oligonucleotide containing less percentage of adenosine, targeted to
nucleic acids associated with lung airway or lung dysfunction, and
bronchodilating agent.
Claim 15; SEQ ID NO 4742; 763pp; English.

This invention describes a novel composition (a) a first active agent,
comprising oligonucleotides, effective for alleviating
bronchoconstriction, respiratory tract inflammation, allergies and
reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
surfactant depletion or hyposecretion, when administered to a mammal. The
oligonucleotides are derived from a gene encoding or regulating
expression of a target polypeptide associated with lung airway or lung
dysfunction or cancer and can be anti-sense to the corresponding mRNA.

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1261 AGAGGAGGTTGAAGAGAG 1279
Db 2 AGGGGAGGTGTTGAAGAGAG 20

RESULT 472
ABD30273
ID ABD30273 standard; DNA; 20 BP.
XX AC ABD30273;
XX DT 29-JUL-2004 (first entry)
XX DE AA284245-derived oligonucleotide SEQ ID 9285.

Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
respiratory tract inflammation; adenosine sensitivity; lung; cancer;
surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.
OS
XX WO2000285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.

Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
Miller S, Tang L, Shahabuddin S;
WPI; 2003-093058/08.
Pharmaceutical composition for treating asthma, has antisense
oligonucleotide containing less percentage of adenosine, targeted to
nucleic acids associated with lung airway or lung dysfunction, and
bronchodilating agent.
Claim 15; SEQ ID NO 9285; 763pp; English.

This invention describes a novel composition (a) a first active agent,
comprising oligonucleotides, effective for alleviating
bronchoconstriction, respiratory tract inflammation, allergies and
reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
surfactant depletion or hyposecretion, when administered to a mammal. The
oligonucleotides are derived from a gene encoding or regulating
expression of a target polypeptide associated with lung airway or lung
dysfunction or cancer and can be anti-sense to the corresponding mRNA.
The invention also describes a kit, that comprises: (a) a delivery
device, in separate containers, (b) the oligonucleotides, (c)
instructions for adding a carrier and for use of the kit. The composition
of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
beta-adrenergic agonist. The composition is useful for preventing or
treating a respiratory, lung or malignant disease. The administered
composition comprises oligo and is administered to reduce the production
or availability, or to increase the degradation of the target mRNA or to
reduce the amount of target polypeptide present in the lungs. The
pulmonary obstruction, and/or bronchoconstriction and/or lung
inflammation, allergies and/or surfactant hypoproduction are associated

XX inflammation, allergies and/or surfactant hypoproduction are associated

CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

CC SQ Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. NO. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 390 TCTATGAGAGACCCCTT 408
 Db 1 TTTTGAAGAAAGACCTTT 19
 |||||

RESULT 474
 ABD26605
 ID ABD26605 standard; DNA; 20 BP.
 AC ABD26605;
 DT 29-JUL-2004 (first entry)
 XX AA909635-derived oligonucleotide SEQ ID 5617.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 FT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 5617; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 16 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. NO. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 5047 AAAAAAAAAAAAAAAAAAAC 5065
 Db 1 AAAAAAAAAAAAAAAAAAAC 19
 |||||

RESULT 475
 ADH64788/c
 ID ADH64788 standard; DNA; 20 BP.
 XX AC ADH64788;
 XX DT 25-MAR-2004 (first entry)
 XX Human glucocorticoid receptor-specific antisense oligonucleotide #1622.
 XX antisense oligonucleotide; glucocorticoid receptor; infection;
 KW inflammation; tumour formation; diabetes; obesity;
 KW cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
 KW phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
 XX Homo sapiens.
 OS
 XX WO2003099215-A2.
 PN
 XX 04-DEC-2003.
 PD
 XX 20-MAY-2003; 2003WO-US016084.
 PF
 XX 20-MAY-2002; 2002US-0381857P.
 PR
 XX (PHAA) PHARMACIA CORP.
 XX

```

PI Crosby SD, Nalseth AE;
XX WPI; 2004-035034/03.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
XX cardiovascular disorder, hyperlipidaemia or Cushing's syndrome.
XX
XX Claim 4; SEQ ID NO 1622; 985pp; English.
XX
XX The invention comprises an antisense oligonucleotides that are targeted
XX to nucleic acids encoding a mammalian glucocorticoid receptor. The
XX antisense oligonucleotides of the invention are useful for preventing or
XX delaying infection, inflammation or tumour formation. The antisense
XX oligonucleotides are also useful for treating diabetes, obesity. The
XX cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
XX present DNA sequence represents an antisense oligonucleotide that targets
XX the human glucocorticoid receptor gene. NOTE: The present sequence
XX contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
XX Sequence 20 BP; 3 A; 10 C; 1 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 4203 GTGGGACATGGAGACTGGT 4221
DB 19 GAGGAGATGGAGACTGGT 1
RESULT 476
ADH64940/c
ID ADH64940 standard; DNA; 20 BP.
XX
XX AC ADH64940;
XX
XX DT 25-MAR-2004 (first entry)
XX
XX DE Human glucocorticoid receptor-specific antisense oligonucleotide #1774.
XX
XX KW antisense oligonucleotide; glucocorticoid receptor; infection;
XX inflammation; tumour formation; diabetes; obesity;
XX cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; ss;
XX phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
XX OS Homo sapiens.
XX
XX PN WO2003099215-A2.
XX
XX PD 04-DEC-2003.
XX
XX PF 20-MAY-2003; 2003WO-US016084.
XX
XX PR 20-MAY-2002; 2002US-0381857P.
XX
XX PA (PHAA ) PHARMACIA CORP.
XX
XX PI Crosby SD, Nalseth AE;
XX
XX WPI; 2004-035034/03.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
XX mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
XX cardiovascular disorder, hyperlipidaemia or Cushing's syndrome.
XX
XX Claim 4; SEQ ID NO 1774; 985pp; English.
XX
XX The invention comprises an antisense oligonucleotides that are targeted
XX to nucleic acids encoding a mammalian glucocorticoid receptor. The
XX antisense oligonucleotides of the invention are useful for preventing or
XX delaying infection, inflammation or tumour formation. The antisense
XX oligonucleotides are also useful for treating diabetes, obesity.
XX
XX Query Match 0.3%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 4203 GTGGGACATGGAGACTGGT 4221
XX DB 19 GAGGAGATGGAGACTGGT 1
XX
XX RESULT 477
XX ADH54718/c
XX ID ADH54718 standard; DNA; 20 BP.
XX
XX AC ADH54718;
XX
XX DT 25-MAR-2004 (first entry)
XX
XX DE Human VEGF-C antisense oligonucleotide ISIS 158106.
XX
XX KW human; ss; VEGF-C; cardiovascular disorder; atherosclerosis;
XX diabetic retinopathy; autoimmune disorder; inflammatory disorder;
XX vascular endothelial growth factor; antisense.
XX
XX OS Synthetic.
XX
XX OS Homo sapiens.
XX
XX PN US2003232437-A1.
XX
XX PD 18-DEC-2003.
XX
XX PF 17-JUN-2002; 2002US-00173718.
XX
XX PR 17-JUN-2002; 2002US-00173718.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Zhang H, Dobie KW;
XX
XX WPI; 2004-061284/06.
XX
XX New compounds, particularly antisense oligonucleotides targeted to a
XX nucleic acid encoding vascular endothelial growth factor-C (VEGF-C),
XX useful for treating atherosclerosis, diabetic retinopathy, or
XX inflammatory disorders.
XX
XX Example 15; SEQ ID NO 19; 83pp; English.
XX
XX The invention relates to a compound targeted to and which specifically
XX hybridises with a nucleic acid molecule encoding VEGF-C, and inhibits the
XX expression of VEGF-C. The compound, composition and methods are useful
XX for treating a disease or condition associated with VEGF-C, such as a
XX cardiovascular disorder e.g. atherosclerosis or diabetic retinopathy or
XX an autoimmune or inflammatory disorder. They are also useful in research
XX and diagnostics for modulating the expression of VEGF-C. The present
XX sequence represents a human VEGF-C antisense oligonucleotide.
XX
XX Sequence 20 BP; 3 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 966 GACAGCTGTGGACCAAGCA 984
DB 20 GACATCTGTGGACCAACA 2

```



```

RESULT 478
ADH54788
ID ADH54788 standard; DNA; 20 BP.
XX
AC ADH54788;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human VEGF-C target region ISIS 73607.
XX
KW human; ss: VEGF-C; cardiovascular disorder; atherosclerosis;
KW diabetic retinopathy; autoimmune disorder; inflammatory disorder;
KW vascular endothelial growth factor.
XX
OS Homo sapiens.
XX
PN US2003232437-A1.
XX
PD 18-DEC-2003.
XX
PF 17-JUN-2002; 2002US-00173718.
XX
PR 17-JUN-2002; 2002US-00173718.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Zhang H, Dobie KW;
XX
WPI; 2004-061284/06.
XX
New compounds, particularly antisense oligonucleotides targeted to a
PT nucleic acid encoding vascular endothelial growth factor-C (VEGF-C),
PT useful for treating atherosclerosis, diabetic retinopathy, or
PT inflammatory disorders.
XX
Example 15; SEQ ID NO 89; 83pp; English.
XX
The invention relates to a compound targeted to and which specifically
CC hybridizes with a nucleic acid molecule encoding VEGF-C, and inhibits the
CC expression of VEGF-C. The compound, composition and methods are useful
CC for treating a disease or condition associated with VEGF-C, such as a
CC cardiovascular disorder e.g. atherosclerosis or diabetic retinopathy or
CC an autoimmune or inflammatory disorder. They are also useful in research
CC and diagnostics for modulating the expression of VEGF-C. The present
CC sequence represents a human VEGF-C target region.
XX
Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 966 GACAGCTGTGGACCAAGCA 984
Db 1 GACATCTGTGGACCAACA 19
|||||
RESULT 479
ADJ17090/C
ID ADJ17090 standard; DNA; 20 BP.
XX
AC ADJ17090;
XX
DT 20-MAY-2004 (first entry)
XX
DE Antisense DNA oligo used to modulate human LRH1 expression SeqID 1640.
XX
KW human; ss: liver related homologue-1; LRH1; NR5A2; antisense;
KW phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW gall stone; triglyceridaemia; obesity; hepatitis;
KW hepatocellular carcinoma; aromatase; cytostatic; antilipaeamic;

```

```

KW antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW antinflammatory; virucidal.
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /label= OTHER= phosphorothioate backbone
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT cytidine nucleobases are 5-methylcytidine."
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT cytidine nucleobases are 5-methylcytidine."
XX
WO2004003201-A2.
XX
PD 08-JAN-2004.
XX
PF 01-JUL-2003; 2003WO-US020865.
XX
PR 01-JUL-2002; 2002US-0392813P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Kane CD;
XX
WPI; 2004-083058/08.
XX
New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT related homologue-1 (LRH1), useful for treating breast cancer,
PT dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
Example 15; SEQ ID NO 1640; 909pp; English.
XX
This invention relates to novel antisense compounds useful for modulating
CC the expression of liver related homologue-1 (LRH1) and splice variants
CC thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC length that target a portion of an active site on the nucleic acid
CC molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC nuclear receptor protein that functions as a tissue specific
CC transcription factor. The present invention describes antisense
CC oligonucleotides that comprise at least one modified internucleoside
CC linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC methylcytidine. These antisense compounds are useful for treating or
CC diagnosing a disease associated with LRH1, such as breast cancer,
CC dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC hepatitis, as well as hepatocellular carcinoma or a condition associated
CC with aromatase activity. Accordingly, these compositions exhibit
CC cytostatic, antilipaeamic, antiarteriosclerotic, anorectic, hepatotropic,
CC litholytic, antiinflammatory and virucidal activities. This
CC oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC expression of the human LRH1 protein of the invention.
XX
SQ Sequence 20 BP; 3 A; 1 C; 3 G; 13 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3303 AACTGTCGCAAAATAAATAA 3321
Db 20 AACAGTCCAAATAATAA 2
|||||

```

CC triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
 CC hepatitis, as well as hepatocellular carcinoma or a condition associated
 CC with aromatase activity. Accordingly, these compositions exhibit
 CC cytostatic, antilipaeamic, antiarteriosclerotic, anorectic, hepatotropic,
 CC litholytic, antiinflammatory and virucidal activities. This
 CC oligonucleotide sequence is an antisense DNA oligo used to modulate the
 CC expression of the human LRH1 protein of the invention.
 XX
 SQ Sequence 20 BP; 3 A; 2 C; 3 G; 12 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3303 AACTGTCACAAATAAAAAA 3321
 ||| ||||| ||||| |||||
 Db 19 AACAGTCACAAATATATAA 1

RESULT 481
 ADJ23137
 ID ADJ23137 standard; DNA; 20 BP.
 XX
 AC ADJ23137;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human endothelial lipase antisense oligonucleotide, SEQ ID 1535.
 XX
 KW Antilipaeamic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
 KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
 KW Cardiovascular disorder; metabolic syndrome X; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX

FH Key Location/Qualifiers
 modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "This oligonucleotide has a phosphorothioate
 FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
 FT and 3' ends, which are 4 nucleotides in length. Also all
 FT cytidine residues are 5-methylcytidines"
 XX
 PN WO2004009541-A2.
 XX
 PD 29-JAN-2004.
 XX
 PF 18-JUL-2003; 2003WO-US022410.
 XX
 PR 19-JUL-2002; 2002US-0397106P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Bhat BG;
 XX
 DR WPI; 2004-132912/13.
 XX
 PT New antisense oligonucleotide for modulating endothelial lipase
 PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
 PT high density lipoprotein or cardiovascular disorders.
 XX
 PS Claim 3; SEQ ID NO 1535; 1007pp; English.
 XX
 CC The present invention relates to antisense oligonucleotides (ADJ21603-
 CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
 CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
 CC with and inhibits the expression of EL. The antisense oligonucleotides
 CC are useful for modulating the expression of endothelial lipase in cells
 CC or tissues to treat diseases associated with EL expression, such as
 CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
 CC disorder or metabolic syndrome X. In addition, the oligonucleotides are

RESULT 480
 ADJ16142/C
 ID ADJ16142 standard; DNA; 20 BP.
 XX
 AC ADJ16142;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Antisense DNA oligo used to modulate human LRH1 expression SeqID 692.
 XX
 KW human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
 KW phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
 KW low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
 KW gall stone; triglyceridaemia; obesity; hepatitis;
 KW hepatocellular carcinoma; aromatase; cytostatic; antilipaeamic;
 KW antiarteriosclerotic; anorectic; hepatotropic; litholytic;
 KW antiinflammatory; virucidal.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX

FH Key Location/Qualifiers
 modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /label= OTHER= phosphorothioate backbone
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
 FT cytidine nucleobases are 5-methylcytidine."
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
 FT cytidine nucleobases are 5-methylcytidine."
 XX
 PN WO2004003201-A2.
 XX
 PD 08-JAN-2004.
 XX
 PF 01-JUL-2003; 2003WO-US020865.
 XX
 PR 01-JUL-2002; 2002US-0392813P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Kane CD;
 XX
 DR WPI; 2004-083058/08.
 XX
 PT New antisense oligonucleotides targeted to a nucleic acid encoding liver
 PT related homologue-1 (LRH1), useful for treating breast cancer,
 PT dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
 XX
 PS Example 15; SEQ ID NO 692; 909pp; English.
 XX
 CC This invention relates to novel antisense compounds useful for modulating
 CC the expression of liver related homologue-1 (LRH1) and splice variants
 CC thereof. Specifically, it refers to compositions 8-30 nucleobases in
 CC length that target a portion of an active site on the nucleic acid
 CC molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
 CC nuclear receptor protein that functions as a tissue specific
 CC transcription factor. The present invention describes antisense
 CC oligonucleotides that comprise at least one modified internucleoside
 CC linkage, a phosphorothioate linkage; at least one modified sugar moiety,
 CC a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
 CC methylcytidine. These antisense compounds are useful for treating or
 CC diagnosing a disease associated with LRH1, such as breast cancer,
 CC dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
 CC LDL (low density lipoprotein), hypercholesterolaemia, gall stones,

```
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 984 ACACAAATCTGGAGTTTCGT 1002
   |||||
Db 1 ACACAAATCTGGACTTGGT 19

RESULT 482
ADJ22653
ID ADJ22653 standard; DNA; 20 BP.
XX
AC ADJ22653;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human endothelial lipase antisense oligonucleotide, SEQ ID 1051.
XX
KW Antilipemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW Cardiovascular disorder; metabolic syndrome X; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 4 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX
PN WO2004009541-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022410.
XX
PR 19-JUL-2002; 2002US-0397106P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Bhat BG;
XX
DR WPI; 2004-132912/13.
XX
PT New antisense oligonucleotide for modulating endothelial lipase
PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT high density lipoprotein or cardiovascular disorders.
XX
PS Claim 3; SEQ ID NO 1051; 1007pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 CACACAAATCTGGAGTTTCG 1001
   |||||
Db 2 CACACAAATCTGGACTTGG 20

RESULT 483
ADK81523
ID ADK81523 standard; DNA; 20 BP.
XX
AC ADK81523;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8857.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
PN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Robert's SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 8857; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 17 A; 3 C; 0 G; 0 T; 0 U; 0 Other;

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5043
   |||||
Db 2 AAAAAAAAAAAAAAAAAA 20

RESULT 484
ADK80970
ID ADK80970 standard; DNA; 20 BP.
```

```
XX AC ADK80970;
XX XX
XX DT 20-MAY-2004 (first entry)
XX XX
XX DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8304.
XX XX
XX KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
XX KW diabetic neuropathy; arthritic pain; migraine headache;
XX KW infantile epilepsy; ataxia; ss.
XX OS Synthetic.
XX XX
XX PN WO2004016754-A2.
XX XX
XX PD 26-FEB-2004.
XX XX
XX PF 14-AUG-2003; 2003WO-US025465.
XX XX
XX PR 14-AUG-2002; 2002US-0403416P.
XX XX
XX PA (PHAA ) PHARMACIA CORP.
XX XX
XX PI Roberds SL;
XX XX
XX DR WPI; 2004-203785/19.
XX XX
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT Nav1.3, useful for treating a disease or condition associated
XX PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
XX PT disorder, or ataxia.
XX XX
XX PS Claim 4; SEQ ID NO 8304; 417pp; English.
XX XX
XX CC The present invention relates to an antisense compound targeted to a
XX CC nucleic acid molecule encoding Nav1.3, where the antisense compound
XX CC specifically hybridizes with and inhibits the expression of Nav1.3. The
XX CC compound and composition are useful for treating a disease or condition
XX CC associated with Nav1.3, e.g. pain including but not limited to
XX CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
XX CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
XX CC pain from burns, migraine headache, cluster headache, mild-to-moderate
XX CC headache; seizure disorder such as childhood seizure disorder, including
XX CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
XX CC sequence represents a chimeric phosphorothioate oligonucleotide with
XX CC 2'-MOE wings and a deoxy gap. Used during the antisense inhibition of
XX CC human Nav1.3 expression, the oligonucleotides are designed to target
XX CC different regions of the human Nav1.3 RNA.
XX XX
XX SQ Sequence 20 BP; 16 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5047 AAAAAAAAAAAAAAAAAAAC 5065
DB 1 AAAAAAAAAACAAAAAAC 19

RESULT 485
ADL59715/C
ID ADL59715 standard; DNA; 20 BP.
XX XX
XX AC ADL59715;
XX XX
XX DT 03-JUN-2004 (first entry)
XX XX
XX DE Human ESM-1 antisense oligonucleotide seqid 1964.
XX XX
XX KW cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
XX KW gene therapy; endothelial specific molecule-1; ESM-1;
XX KW ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
```

```
KW angiotenic disorder; immunological disorder; cardiovascular disorder;
KW neurological disorder; antisense technology; ss.
XX XX
XX OS Homo sapiens.
XX XX
XX FH Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "OTHER= phosphorothioate backbone. All cytidine
XX FT residues are 5-methylcytidines"
XX FT modified_base 1..5
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX FT modified_base 16..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2004021978-A2.
XX XX
XX PD 18-MAR-2004.
XX XX
XX PF 19-AUG-2003; 2003WO-US025833.
XX XX
XX PR 19-AUG-2002; 2002US-0404495P.
XX XX
XX PA (PHAA ) PHARMACIA CORP.
XX XX
XX PI Weinstein EJ, Griggs DW;
XX XX
XX DR WPI; 2004-248358/23.
XX XX
XX PT New antisense compound, having a sequence targeted to a nucleic acid
XX PT encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
XX PT composition for treating e.g., diabetes, cancer or cardiovascular
XX PT disorder.
XX XX
XX PS Claim 3; SEQ ID NO 1964; 555pp; English.
XX XX
XX CC The invention describes a new antisense compound, having a sequence
XX CC comprising 8-30 bp targeted to a nucleic acid encoding endothelial
XX CC specific molecule-1 (ESM-1), that specifically hybridises with the
XX CC nucleic acid ESM-1 and inhibits its expression. Also described are: a
XX CC composition; inhibiting the expression of ESM-1 in cells or tissues; and
XX CC treating an animal having a disease or condition associated with ESM-1.
XX CC The compound is useful for preparing a composition for treating diabetes,
XX CC cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
XX CC cardiovascular or neurological disorder. This sequence represents an
XX CC antisense oligonucleotide that can be used to modulate expression of
XX CC endothelial specific molecule-1 (ESM-1).
XX XX
XX SQ Sequence 20 BP; 8 A; 4 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4353 TATGAAATAAGGTTTGG 4371
DB 19 TATGAAATAAGGTTTGG 1

RESULT 486
ADL59601/C
ID ADL59601 standard; DNA; 20 BP.
XX XX
XX AC ADL59601;
XX XX
XX DT 03-JUN-2004 (first entry)
XX XX
XX DE Human ESM-1 antisense oligonucleotide seqid 1950.
```

XX cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
 KW gene therapy; endothelial specific molecule-1; ESM-1;
 KW ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
 KW angiogenic disorder; immunological disorder; cardiovascular disorder;
 KW neurological disorder; antisense technology; ss.
 XX Homo sapiens.
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone. All cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2004021978-A2.
 XX 18-MAR-2004.
 XX 19-AUG-2003; 2003WO-US025833.
 XX 19-AUG-2002; 2002US-0404495P.
 XX (PHAA) PHARMACIA CORP.
 XX Weinstein EJ, Griggs DW;
 XX WPI; 2004-248358/23.
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
 PT composition for treating e.g., diabetes, cancer or cardiovascular
 PT disorder.
 XX Claim 3; SEQ ID NO 1850; 555pp; English.
 XX The invention describes a new antisense compound, having a sequence
 CC comprising 8-30 bp targeted to a nucleic acid encoding endothelial
 CC specific molecule-1 (ESM-1), that specifically hybridises with the
 CC nucleic acid ESM-1 and inhibits its expression. Also described are: a
 CC composition; inhibiting the expression of ESM-1 in cells or tissues; and
 CC treating an animal having a disease or condition associated with ESM-1.
 CC The compound is useful for preparing a composition for treating diabetes,
 CC cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
 CC cardiovascular or neurological disorder. This sequence represents an
 CC antisense oligonucleotide that can be used to modulate expression of
 CC endothelial specific molecule-1 (ESM-1).
 XX SQ Sequence 20 BP; 7 A; 5 C; 0 G; 8 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 4355 TGAATAAGTTTGGGA 4373
 DB 20 TGAATAAGTTTGGGA 2
 RESULT 487
 ADL59376/c
 ID ADL59376 standard; DNA; 20 BP.
 XX
 AC ADL59376;

XX 03-JUN-2004 (first entry)
 XX Human ESM-1 antisense oligonucleotide seqid 1625.
 XX cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
 KW gene therapy; endothelial specific molecule-1; ESM-1;
 KW ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
 KW angiogenic disorder; immunological disorder; cardiovascular disorder;
 KW neurological disorder; antisense technology; ss.
 XX Homo sapiens.
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone. All cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2004021978-A2.
 XX 18-MAR-2004.
 XX 19-AUG-2003; 2003WO-US025833.
 XX 19-AUG-2002; 2002US-0404495P.
 XX (PHAA) PHARMACIA CORP.
 XX Weinstein EJ, Griggs DW;
 XX WPI; 2004-248358/23.
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
 PT composition for treating e.g., diabetes, cancer or cardiovascular
 PT disorder.
 XX Claim 3; SEQ ID NO 1625; 555pp; English.
 XX The invention describes a new antisense compound, having a sequence
 CC comprising 8-30 bp targeted to a nucleic acid encoding endothelial
 CC specific molecule-1 (ESM-1), that specifically hybridises with the
 CC nucleic acid ESM-1 and inhibits its expression. Also described are: a
 CC composition; inhibiting the expression of ESM-1 in cells or tissues; and
 CC treating an animal having a disease or condition associated with ESM-1.
 CC The compound is useful for preparing a composition for treating diabetes,
 CC cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
 CC cardiovascular or neurological disorder. This sequence represents an
 CC antisense oligonucleotide that can be used to modulate expression of
 CC endothelial specific molecule-1 (ESM-1).
 XX SQ Sequence 20 BP; 8 A; 4 C; 0 G; 8 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 4351 GATATGAAATAAGGTTTT 4369
 DB 20 GGTATGAAATAAGTITTT 2
 RESULT 488

4350 AGATATGAAAATAAGGTTT 4368

KW cardiovascular disorder; dyslipidemia; atherosclerosis;
 KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
 KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
 KW ischemia; reperfusion; diagnostics; prophylaxis.
 XX
 OS Homo sapiens.
 XX
 PN WO2004030750-A1.
 XX
 PD 15-APR-2004.
 XX
 PP 25-SEP-2003; 2003WO-US030353.
 XX
 PR 25-SEP-2002; 2002US-0413588P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Kane CD;
 XX
 DR WPI; 2004-347928/32.
 XX
 PS New antisense oligonucleotides useful for modulating expression of
 FT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
 PT e.g. diabetes, immunological disorders, cardiovascular disorders,
 PT gallstones or obesity.
 XX
 PS Claim 4; SEQ ID NO 877; 150pp; English.
 XX
 CC The invention relates to an antisense compound 8-30 nucleobases in length
 CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
 CC where the antisense compound specifically hybridizes with and inhibits
 CC the expression of FXR. The composition and methods are useful for
 CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
 CC tissues, or for treating diseases or conditions associated with FXR, such
 CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
 CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
 CC lipoprotein), elevated LDL (low density lipoprotein) or
 CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
 CC neurological disorders, or ischemia/reperfusion injury. In addition, the
 CC composition is used for diagnostics, prophylaxis, or as research reagents
 CC or kits. This sequence corresponds to an antisense oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3477 GGAGAGTAAACCCACCA 3495
 DB 19 GGAGAGTAAACCCACCA 1
 RESULT 491
 ADO53202/c
 ID ADO53202 standard; DNA; 20 BP.
 XX
 AC ADO53202;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Farnesoid X receptor gene expression antisense inhibitory oligo #575.
 XX
 KW es; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
 KW antihypertensive; hepatotropic; litholytic; anorectic;
 KW neuroprotective; vasotropic; antisense; gene therapy;
 KW Farnesoid X receptor; diabetes; immunological disorder;
 KW cardiovascular disorder; dyslipidemia; atherosclerosis;
 KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
 KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
 KW ischemia; reperfusion; diagnostics; prophylaxis.
 XX

OS Homo sapiens.
 XX
 PN WO2004030750-A1.
 XX
 PD 15-APR-2004.
 XX
 PP 25-SEP-2003; 2003WO-US030353.
 XX
 PR 25-SEP-2002; 2002US-0413588P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Kane CD;
 XX
 DR WPI; 2004-347928/32.
 XX
 PS New antisense oligonucleotides useful for modulating expression of
 FT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
 PT e.g. diabetes, immunological disorders, cardiovascular disorders,
 PT gallstones or obesity.
 XX
 PS Claim 4; SEQ ID NO 575; 150pp; English.
 XX
 CC The invention relates to an antisense compound 8-30 nucleobases in length
 CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
 CC where the antisense compound specifically hybridizes with and inhibits
 CC the expression of FXR. The composition and methods are useful for
 CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
 CC tissues, or for treating diseases or conditions associated with FXR, such
 CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
 CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
 CC lipoprotein), elevated LDL (low density lipoprotein) or
 CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
 CC neurological disorders, or ischemia/reperfusion injury. In addition, the
 CC composition is used for diagnostics, prophylaxis, or as research reagents
 CC or kits. This sequence corresponds to an antisense oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3477 GGAGAGTAAACCCACCA 3495
 DB 20 GGAGAGTAAACCCACCA 2
 RESULT 492
 ADO53202/c
 ID ADO53202 standard; DNA; 20 BP.
 XX
 AC ADO53202;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Endothelial differentiation gene 2 antisense oligonucleotide seqid 71.
 XX
 KW cytostatic; gene therapy; endothelial differentiation gene 2;
 KW antisense technology; disease identification;
 KW hyperproliferative disorder; human; antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 KW Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= Phosphorothioate backbone. All cytidines
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= a
 FT

```
FT FT /mod_base= OTHER
FT FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT FT 15..20
FT FT /*tag= C
FT FT /mod_base= OTHER
FT FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT FT
XX US2004092462-A1.
XX
XX 13-MAY-2004.
XX
XX 13-NOV-2002; 2002US-00292337.
XX
XX 13-NOV-2002; 2002US-00292337.
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Dean NM, Dobie KW;
XX WPI; 2004-374980/35.
XX
XX New compound that modulates endothelial differentiation gene 2
XX expression, useful in treating an animal having a disease or condition,
XX i.e. hyperproliferative disorder.
XX
XX Example 15; SEQ ID NO 71; 121pp; English.
XX
XX The invention describes a compound targeted to a nucleic acid molecule
XX encoding endothelial differentiation gene 2. The compound, 8-80
XX nucleobases in length, is targeted to a nucleic acid molecule encoding
XX endothelial differentiation gene 2, where the compound specifically
XX hybridises with the nucleic acid molecule encoding the endothelial
XX differentiation gene 2 comprising a sequence of 1576 bp (SEQ ID NO: 4)
XX and inhibits the expression of endothelial differentiation gene 2. Also
XX described are: a method of inhibiting the expression of the endothelial
XX differentiation gene 2 in cells or tissues; a method of screening for a
XX modulator of endothelial differentiation gene 2; a diagnostic method for
XX identifying a disease state; a kit or assay device comprising the
XX compound; and treating an animal having a disease or condition associated
XX with endothelial differentiation gene 2 compound so that expression of
XX endothelial differentiation gene 2 is inhibited. The compound and the
XX methods are useful in treating an animal having a disease or condition,
XX i.e. hyperproliferative disorder. This sequence represents a human
XX endothelial differentiation gene 2 antisense oligonucleotide.
XX
XX Sequence 20 BP; 9 A; 2 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 4926 ATTTGTATTGAAAAGAT 4944
XX ||||| |||||
XX Db 1 ATTTGCAATGAAAAGAT 19
XX
XX RESULT 493
XX ADQ59323
XX ID ADQ59323 standard; DNA; 20 BP.
XX
XX AC ADQ59323;
XX
XX DT 09-SEP-2004 (first entry)
XX
XX DE KIAA1096 forward PCR primer.
XX
XX coding mononucleotide repeat; cMNR; antibody; MSI-H tumour;
XX MSI-H carcinoma; high microsatellite instability tumour;
XX high microsatellite instability carcinoma; cytostatic; PCR; primer; ss.
XX
XX OS Homo sapiens.
XX Synthetic.
XX
```

```
PN KR2004008012-A.
XX
XX 28-JAN-2004.
XX
XX 15-JUL-2002; 2002KR-00041304.
XX
XX 15-JUL-2002; 2002KR-00041304.
XX
XX (KIMH/) KIM H G.
XX (KIMN/) KIM N G.
XX (LEEJ/) LEE J S.
XX (RHEE/) RHEE H S.
XX
XX Kim HG, Kim NG, Lee JS, Rhee HS;
XX WPI; 2004-386326/36.
XX
XX Genes containing coding mononucleotide repeats are useful in developing
XX an antibody against MSI-H (hugh (sic high) microsatellite instability)
XX tumor.
XX
XX Example 3; Page 9; 578pp; Korean.
XX
XX The present invention describes genes containing coding mononucleotide
XX repeats (cMNRs). The genes are useful for the development of an antibody
XX against MSI-H (hugh microsatellite instability) tumour. Also described:
XX (1) cDNA genes containing cMNRs with 10 or more nucleotide sequences, and
XX selected from the cDNA genes having the nucleotide sequences of SEQ ID
XX Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35,
XX 37, 39, 41 and 43; (2) cDNA genes, which are frameshift mutated by
XX deletion or insertion of one or more base in the cMNRs; (3) genomic DNA
XX genes containing cMNRs with 10 or more nucleotide sequences, and selected
XX from the genomic DNA genes having the nucleotide sequences of SEQ ID
XX Nos: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,
XX 38, 40, 42 and 44; and (4) genomic DNA genes, which are frameshift
XX mutated by deletion or insertion of one or more base in the cMNRs. The
XX genes have cytostatic activity. The present sequence represents a PCR
XX primer which is used in an example from the present invention.
XX
XX Sequence 20 BP; 10 A; 1 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 3130 GTAAATGAAGAATGGAAA 3148
XX ||||| |||||
XX Db 2 GCAATGAAGAATGGAAA 20
XX
XX RESULT 494
XX ADQ14094
XX ID ADQ14094 standard; DNA; 20 BP.
XX
XX AC ADQ14094;
XX
XX DT 07-OCT-2004 (first entry)
XX
XX DE CAPN3/DYSF PCR primer, SEQ ID 491.
XX
XX Human; SCAIP; CAPN3; DYSF; calpain; calcium-activated neutral protease;
XX limb-girdle muscular dystrophy type 2A; LGMD2A; dysferlin;
XX limb-girdle muscular dystrophy type 2B; LGMD2B; PCR; primer; ss;
XX Single Condition Amplification/ Internal Primer.
XX
XX OS Homo sapiens.
XX
XX WO2004058985-A2.
XX
XX 15-JUL-2004.
XX
XX 17-DEC-2003; 2003WO-US040278.
XX
```


PR 17-DEC-2002; 2002US-0433774P.
 XX (UTAH) UNIV UTAH RES FOUND.
 PA Planigan KM, Weiss RB, Dunn DM, Von Niederhausern A;
 XX WPI; 2004-525893/50.
 XX Characterizing a nucleic acid region, useful for detecting genetic
 PT mutations in any large multi-exon gene e.g., those indicating
 PT dystrophinopathy, comprises using a Single Condition
 PT Amplification/Internal Primer (SCAP) sequencing method.
 XX Example 9; Page 45; 174pp; English.
 XX The present invention relates to a Single Condition Amplification/
 CC Internal Primer (SCAP) sequencing method for direct sequence analysis of
 CC large multi-exon genes from genomic DNA samples and identifying mutations
 CC in multi-exon genes e.g. the dystrophin gene, CAPN3 gene and DYSF gene.
 CC Mutations in the dystrophin gene result in both Duchenne Muscular
 CC Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). Mutations in the
 CC CAPN3 gene, encoding calpain (calcium-activated neutral protease) result
 CC in limb-girdle muscular dystrophy type 2A (LGMD2A) and mutations in the
 CC DYSF gene, encoding dysferlin, result in limb-girdle muscular dystrophy
 CC type 2B (LGMD2B). The method comprises bringing into contact in each of
 CC the reaction chambers an amplicon from a different one of the
 CC amplification reactions and one or more internal sequencing primers
 CC corresponding to the amplicon and analysing the sequences of the
 CC amplicons. The method allows for the rapid, accurate, and economical
 CC analysis of any large multi-exon gene. The method is useful in detecting
 CC genetic mutations in any large multi-exon gene. It is also useful for the
 CC identification and analysis of specific individual genomic mutations
 CC including deletions, point mutations, or its combinations, gene complexes
 CC with multiple exons/introns spanning large genomic regions. The present
 CC sequence is a PCR primer, used in the method of the invention.
 XX Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.3%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 4190 ACCAAGTGTCCATGTGGGA 4208
 DB | | | | | | | | | | | | | | | | | | | | | |
 2 AGGAAGATCCATGTGGGA 20
 RESULT 495
 AAV37276
 ID AAV37276 standard; DNA; 21 BP.
 XX AAV37276;
 AC AAV37276;
 XX 10-SEP-1998 (first entry)
 DT 5' PCR primer for constant region of anti-Fas antibody heavy chain.
 DE Variable region; heavy chain; anti-Fas antibody; human; mouse;
 XX immunoglobulin G; IGG; light chain; treatment; diagnosis;
 KW autoimmune disease; PCR primer; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX JP10165178-A.
 PN 23-JUN-1998.
 XX 01-JUL-1997; 97JP-00191769.
 PF 02-JUL-1996; 96JP-00172228.
 PR 09-OCT-1996; 96OP-00268737.
 XX

PA (IGAK-) IGAKU SEIBUTSUGAKU KENKYUSHO KK.
 XX WPI; 1998-406105/35.
 DR DNA encoding, e.g. variable region of anti-Fas antibody - useful for,
 XX e.g. diagnosis and treatment of auto-immune diseases.
 PT Example 3; Page 7; 16pp; Japanese.
 PS PCR primers AAV37276-77 are used to amplify the constant region of the
 CC heavy chain of human immunoglobulin G (IGG). The PCR product is used to
 CC create an anti-Fas antibody. The anti-Fas antibody can be used for the
 CC treatment and diagnosis of autoimmune diseases
 XX Sequence 21 BP; 4 A; 10 C; 5 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.3%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 366 CCTCCACCAACAGCCCATC 384
 DB | | | | | | | | | | | | | | | | | | | | | |
 2 CCTCCACCAAGGCCCATC 20
 RESULT 496
 AAX27520/C
 ID AAX27520 standard; DNA; 21 BP.
 XX AAX27520;
 AC AAX27520;
 XX 26-MAY-1999 (first entry)
 DT Banana EFE gene fragment amplifying 5' primer.
 XX 1-aminocyclopropane-1-carboxylic acid synthase; ACS; EFE; banana;
 KW ethylene forming enzyme; ethylene biosynthesis; plant; fruit ripening;
 XX transgenic; enzyme; inhibition; flavour; texture; PCR primer; ss.
 XX Synthetic.
 OS US5886164-A.
 PN 23-MAR-1999.
 PD 15-APR-1996; 96US-00632598.
 XX 15-APR-1996; 96US-00632598.
 XX (ZENE) ZENECA LTD.
 PA Bird CR, Fletcher JD;
 XX WPI; 1999-228611/19.
 DR Novel isolated cDNA molecules ((pASC6) and (pACOS7)) encoding 1-
 PT aminocyclopropane-1-carboxylic acid synthase (ACS) and an ethylene
 PT forming enzyme (EFE) - useful for modifying fruit ripening
 PT characteristics, especially in bananas.
 XX Example 2; Col 7-8; 22pp; English.
 PS The invention relates to two isolated cDNA molecules ((pASC6) and
 CC (pACOS7)) encoding 1-aminocyclopropane-1-carboxylic acid synthase (ACS)
 CC and an ethylene forming enzyme (EFE), respectively. The clones are
 CC deposited under the Accession Numbers NCIMB 40813 and NCIMB 40814,
 CC respectively. pASC6 and pACOS7 may be used to genetically control
 CC ethylene biosynthesis in plants and hence regulate the ethylene-induced
 CC processes involved in fruit ripening (and other ethylene related
 CC processes). Vectors comprising the cDNA sequences may be used to produce
 CC transgenic bananas with altered fruit ripening characteristics. The
 CC orientation of the pASC6 and pACOS7 used in the construct, will determine
 CC how the ripening process is affected. If the genes have a sense

```
CC orientation, and transcribe mRNA that encodes an active enzyme, the rate
CC of ripening will be increased (up-regulation) (however, full-length sense
CC constructs can also be used to inhibit enzyme expression by co-
CC inhibition). If genes encode antisense mRNA, they will inhibit the
CC expression of the genes involved in fruit ripening and hence slow the
CC process down (down-regulation). In this manner different spatial and
CC temporal patterns of genes expression can be produced. Retardation of the
CC rate of ripening will reduce the rate of deterioration of banana fruit
CC after harvest. This helps in production of high quality fruit that has
CC improved flavour and texture. Sequences AAX27517-531 represent primers
CC based on sequences conserved between 6 species, for PCR amplification of
CC EFE gene fragments from bananas
XX
SQ Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2880 GAAGAAGTGTCTCTCACAG 2898
DB 21 GAAGAAGTGTCTCTCCCCAG 3
RESULT 497
AAZ74371
ID AAZ74371 standard; DNA; 21 BP.
XX
AC AAZ74371;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:8727.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
FN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB0000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST ) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
XX WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 2091; 2745pp; English.
XX
XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
```

```
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 21 BP; 5 A; 6 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 4736 TTTTCAAAATTATGCTCC 4754
DB 3 TTTTCAAAATGATGCCCC 21
RESULT 498
ABA81997
ID ABA81997 standard; DNA; 21 BP.
XX
AC ABA81997;
XX
DT 25-JAN-2002 (first entry)
XX
DE Wound healing related PCR primer SEQ ID NO 66.
XX
KW Human; mouse; vulnery; dermatological; skin disorder; wound healing;
KW gene therapy; PCR primer; ss.
XX
OS Synthetic.
XX
FN CA2325226-A1.
XX
PD 17-MAY-2001.
XX
PF 16-NOV-2000; 2000CA-02325226.
XX
PR 17-NOV-1999; 99DE-01055349.
PR 17-DEC-1999; 99US-0172511P.
PR 20-JUN-2000; 2000DE-01030149.
XX
PA (SWIT-) SWITCH BIOTECH AG.
XX
PI Regenbogen J, Wolf E, Goppelt A, Werner S, Halle J;
XX
XX WPI; 2001-433142/47.
XX
PT Use of novel polypeptide or its variant or nucleic acid encoding the
PT polypeptide for diagnosing and/or preventing and/or treating skin
PT disorders and/or treatment in wound healing or for identifying active
PT substances.
XX
PS Example 2; Page 53; 265pp; English.
XX
XX The invention relates to the use of a polypeptide (ABB44544-ABB44601,
CC ABB44606-ABB44623) or its variant or encoding nucleic acid (ABA81990-
CC ABA81995, ABA82016-ABA82032) with vulnery and/or dermatological
CC activity for the diagnosis, prevention and treatment of skin disorders
CC and treatment in wound healing or for the identification of
CC pharmacologically active substances. The nucleic acids are useful in gene
CC therapy. The present sequence is that of a PCR primer, useful to the
CC invention. Note: The printed sequence listing for this specification was
CC incomplete, terminating part way through SEQ ID NO 106. The remaining
CC data was obtained from EPO data for an equivalent patent (EP1114862)
XX
SQ Sequence 21 BP; 3 A; 6 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3258 CATTTGTGTCCTTTGTCA 3276
||| ||||| ||||| ||||| |||||
```

Db 3 CAGTTGTGTCCTTCATGCA 21

RESULT 499

ABA81999

ID ABA81999 standard; DNA; 21 BP.

XX

AC ABA81999;

XX

DT 25-JAN-2002 (first entry)

XX

DE Mouse wound healing related PCR primer SEQ ID NO 68.

XX

KW Human; mouse; vulvar; dermatological; skin disorder; wound healing;

KW Gene therapy; PCR primer; ss.

XX

OS Mus musculus.

XX

PN CA2325226-A1.

XX

PD 17-MAY-2001.

XX

XX

PF 16-NOV-2000; 2000CA-02325226.

XX

PR 17-NOV-1999; 99DE-01055349.

PR 17-DEC-1999; 99US-0172511P.

PR 20-JUN-2000; 2000DE-01030149.

XX

PA (SWIT-) SWITCH BIOTECH AG.

XX

PI Regenbogen J, Wolf E, Goppelt A, Werner S, Halle J;

XX

XX WPI; 2001-433142/47.

XX

PT Use of novel polypeptide or its variant or nucleic acid encoding the

PT polypeptide for diagnosing and/or preventing and/or treating skin

PT disorders and/or treatment in wound healing or for identifying active

PT substances.

XX

PS Example 5; Page 58; 265pp; English.

XX

CC The invention relates to the use of a polypeptide (ABB44544-ABB44601,

CC ABB44608-ABB44623) or its variant or encoding nucleic acid (ABA81990-

CC ABA81995, ABA82016-ABA82032) with vulvar and/or dermatological

CC activity for the diagnosis, prevention and treatment of skin disorders

CC and treatment in wound healing or for the identification of

CC pharmacologically active substances. The nucleic acids are useful in gene

CC therapy. The present sequence is that of a PCR primer, useful to the

CC invention. Note: The printed sequence listing for this specification was

CC incomplete, terminating part way through SEQ ID NO 106. The remaining

CC data was obtained from EPO data for an equivalent patent (EP1114862)

XX

XX Sequence 21 BP; 3 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 3.3e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3258 CATTGTGTCCTTCATGCA 3276

DB 3 CAGTTGTGTCCTTCATGCA 21

RESULT 500

AAS0920/C

ID AAS0920 standard; DNA; 21 BP.

XX

AC AAS0920;

XX

DT 24-OCT-2001 (first entry)

XX

DE PCR primer #4 used to clone ethylene-forming enzyme (EFE) from banana.

XX

KW 1-aminocyclopropane-1-carboxylic acid synthase; ACS; banana;

KW ethylene biosynthesis; ethylene-forming enzyme; EFE; fruit ripening;

XX fruit storage; PCR primer; avocado; ss.

OS Persea sp.

XX

PN US6262346-B1.

XX

PD 17-JUL-2001.

XX

PF 15-JAN-1999; 99US-00231240.

XX

PR 15-APR-1996; 96US-00632598.

XX

PA (ZENE) ZENECA LTD.

XX

PI Bird CR, Fletcher JD;

XX

XX WPI; 2001-450497/48.

XX

PT Modifying level of ethylene biosynthesis in plant of genus Musa, involves

PT inserting into genome of plant a DNA sequence encoding banana 1-

PT aminocyclopropane-1-carboxylic acid synthase or ethylene-forming enzyme.

XX

PS Example 2; Col 8; 23pp; English.

XX

CC The sequence represents PCR primer #4 from avocado used to design a

CC degenerate PCR primer, BEFE-5 (AAS09924) which was used to clone ethylene

CC -forming enzyme (EFE) from banana, used in the method of the invention.

CC The method involves modifying the level of ethylene biosynthesis in a

CC plant of the genus Musa by inserting into the genome of the plant a DNA

CC sequence (I) encoding a banana 1-aminocyclopropane-1- carboxylic acid

CC synthase (ACS) or an ethylene-forming enzyme (EFE), where (I) is in sense

CC or antisense configuration, and modifies the level of activity of ACS or

CC EFE. This retards the rate of ripening in banana fruits which reduces the

CC rate of deterioration of banana fruit after harvest. As a result, fruit

CC may be harvested when they have reached partial or full ripeness and

CC still have the robustness to withstand handling and transport to reach

CC the consumer in good condition. In this way high quality ripe fruit can

CC be made available to the consumer with reduced requirement for post-

CC harvest treatment. High quality fruit will have improved flavour and

CC texture. High quality fruit can be produced consistently over a wide

CC harvest period, and such fruit can be held in store for long periods and

CC ripened to optimal quality by the supply of exogenous ethylene

XX

XX Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 3.3e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2880 GAAGAAGTGTCTCTCACAG 2898

DB 21 GAAGAAGTGTCTCTCCAG 3

RESULT 501

AAH62183

ID AAH62183 standard; DNA; 21 BP.

XX

AC AAH62183;

XX

DT 09-SEP-2004 (revised)

DT 12-SEP-2001 (first entry)

XX

DE APLP2 polymorphism containing DNA fragment #84.

XX

KW Single nucleotide polymorphism; SNP; human; cancer; inflammation;

KW heart disease; paternity testing; forensic science; ds.

XX

OS Homo sapiens.

XX Unidentified.

XX

XX	Key	Location/Qualifiers	XX	31-AUG-2001; 2001WO-EP010087.
PF	variation	11	XX	19-SEP-2000; 2000EP-00120123.
FT		/tag= a	XX	(EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
FT		/standard_name= "single nucleotide polymorphism"	PA	Brinkmann U, Hoffmeyer S;
XX	WO200138576-A2.		PI	WPI; 2002-435060/46.
XX	31-MAY-2001.		DR	Novel polynucleotide of the endothelin/endothelin converting
XX	17-NOV-2000; 2000WO-US031639.		XX	enzyme/receptors of endothelin and endothelin converting enzyme signaling
XX	24-NOV-1999; 99US-0167334P.		PT	system associated with cardiovascular disease, useful for treating the
XX	(WHED) WHITEHEAD INST BIOMEDICAL RES.		PT	disease.
XX	Cargill M, Ireland JS, Lander ES;		XX	Example 6; Page 67; 190pp; English.
XX	WPI; 2001-367705/38.		XX	The invention describes a polynucleotide (I) of the endothelin
XX	New nucleic acid segments of the human genome, particularly from genes		CC	(EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
XX	including polymorphic sites,for phenotype correlation, forensics,		CC	signaling system which is associated with a cardiovascular disease. (I),
PT	paternity testing, medicine and genetic analysis.		CC	the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I)
XX	Claim 1; Page 36; 80pp; English.		CC	or (II) is useful for producing cells capable of expressing a molecular
XX	DNA sequences AAH62100 - AAH62688 represent segments of human genes which		CC	variant polypeptide which is associated with a cardiovascular disease.
XX	contain single nucleotide polymorphisms (SNPs). A method is included in		CC	(II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing a
CC	the invention for analysing a nucleic acid sample, which consists of		CC	molecular variant gene comprising (I) is useful for identifying and
CC	determining the base occupying any one of the polymorphic sites given in		CC	obtaining a pro-drug or drug capable of modulating the activity of a
CC	the SNP containing sequences. The nucleotide sequences can be used in the		CC	molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system
CC	diagnosis or monitoring of diseases, such as cancer, inflammation, heart		CC	or its gene product, or for identifying and obtaining an inhibitor of the
CC	diseases, diseases of the cardiovascular system, and infection by		CC	activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE
CC	microorganisms. The oligonucleotides are also useful in the manufacture		CC	signaling system or its gene product. The isolated proteins and
CC	of a pharmaceutical for the treatment or prophylaxis of the diseases, and as		CC	polynucleotides encoding them are useful for preparation of a
CC	a pharmaceutical. SNP containing oligonucleotides are useful in		CC	pharmaceutical composition for treating a cardiovascular disease such as
CC	applications such as phenotype correlation, forensics, paternity testing,		CC	coronary heart disease, hypertension, atherosclerosis, or related to
CC	medicine and genetic analysis		CC	abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial
CC	Revised record issued on 09-SEP-2004 : Correction to Feature Table Key		CC	hypercholesterolaemia. The gene or a polynucleotide fragment of the
XX	Sequence 21 BP; 11 A; 0 C; 9 G; 1 T; 0 U; 0 Other;		CC	EDN/ECV/EDNR signaling system are useful as forensic markers, for
XX	Query Match 0.3%; Score 15.8; DB 1; Length 21;		CC	creating a transgenic animal and in creation of a solid support
XX	Best Local Similarity 89.5%; Pred. No. 3.3e+02;		CC	comprising polynucleotides, genes, vectors, polypeptides, antibodies or
XX	Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		CC	host cells of the invention. This sequence represents a PCR primer used
QY	2907 AGAGGAAGAGGAAGACAA 2925		CC	to identify single nucleotide polymorphisms in DNA encoding
Db	2 AGAGGAAGAGGAAGATGAA 20		CC	cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway
XX	RESULT 502		XX	Sequence 21 BP; 4 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
XX	ABK94358/c		XX	Query Match 0.3%; Score 15.8; DB 1; Length 21;
ID	ABK94358 standard; DNA; 21 BP.		XX	Best Local Similarity 89.5%; Pred. No. 3.3e+02;
XX	ABK94358;		XX	Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX	27-AUG-2002 (first entry)		QY	4515 CCTCTGAAGGGGCCAGAG 4533
XX	Endothelin converting enzyme 1 (ECE-1) SNP detection primer #146.		Db	19 CCTCTGATGTGCCAGAG 1
XX	Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;		XX	RESULT 503
KW	EDNR; signaling system; cardiovascular disease; coronary heart disease;		XX	ABK94357
KW	hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;		ID	ABK94357 standard; DNA; 21 BP.
KW	diabetes; familial hypercholesterolaemia; forensic marker;		XX	ABK94357;
KW	transgenic animal; solid support; cardiovascular regulator; SNP;		XX	27-AUG-2002 (first entry)
KW	single nucleotide polymorphism; PCR; primer; ss.		DT	Endothelin converting enzyme 1 (ECE-1) SNP detection primer #145.
XX	Synthetic.		XX	Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
XX	WO200224747-A2.		XX	EDNR; signaling system; cardiovascular disease; coronary heart disease;
PD	28-MAR-2002.		KW	hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
XX			KW	diabetes; familial hypercholesterolaemia; forensic marker;
XX			KW	transgenic animal; solid support; cardiovascular regulator; SNP;
XX			KW	single nucleotide polymorphism; PCR; primer; ss.
OS			XX	Synthetic.
XX			XX	
PN			XX	
PD			XX	

```

PN WO200224747-A2.
XX
XX 28-MAR-2002.
XX
XX 31-AUG-2001; 2001WO-EP010087.
XX
XX 19-SEP-2000; 2000EP-00120123.
XX
XX (SPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
XX
XX Brinkmann U, Hoffmeyer S;
XX
XX WPI; 2002-435060/46.
XX
XX Novel polynucleotide of the endothelin/endothelin converting
XX enzyme/receptors of endothelin and endothelin converting enzyme signaling
XX PT system associated with cardiovascular disease, useful for treating the
XX PT disease.
XX
XX Example 6; Page 67; 190pp; English.
XX
XX The invention describes a polynucleotide (I) of the endothelin
XX (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
XX signaling system which is associated with a cardiovascular disease. (I),
XX the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I),
XX or (II) is useful for producing cells capable of expressing a molecular
XX variant polypeptide which is associated with a cardiovascular disease.
XX (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing a
XX molecular variant gene comprising (I) is useful for identifying and
XX obtaining a pro-drug or drug capable of modulating the activity of a
XX molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system
XX or its gene product, or for identifying and obtaining an inhibitor of the
XX activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE
XX signaling system or its gene product. The isolated proteins and
XX polynucleotides encoding them are useful for preparation of a
XX pharmaceutical composition for treating a cardiovascular disease such as
XX coronary heart disease, hypertension, atherosclerosis, or related to
XX abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial
XX hypercholesterolaemia. The gene or a polynucleotide fragment of the
XX EDN/ECE/EDNR signaling system are useful as forensic markers, for
XX creating a transgenic animal and in creation of a solid support
XX comprising polynucleotides, genes, vectors, polypeptides, antibodies or
XX host cells of the invention. This sequence represents a PCR primer used
XX to identify single nucleotide polymorphisms in DNA encoding
XX cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway
XX
XX Sequence 21 BP; 3 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 4515 CCTCGAAGGGGCCAGAG 4533
DB 3 CCTCGATGTGGCCAGAG 21
RESULT 504
ABV76147
ID ABV76147 standard; DNA; 21 BP.
XX
XX AC ABV76147;
XX
XX 07-MAR-2003 (first entry)
XX
XX Mouse alpha 1-antichymotrypsin PCR primer.
XX
XX Alpha 1-antichymotrypsin; protease; inhibitor; mouse; vulnery;
XX antilucer; wound healing; gene therapy; PCR; primer; ss.
XX
XX Mus musculus.
XX
XX WO200288180-A2.
XX
XX
XX 07-NOV-2002.
XX
XX 30-APR-2002; 2002WO-EP004757.
XX
XX 30-APR-2001; 2001DE-01021255.
XX
XX 18-SEP-2001; 2001US-0323348P.
XX
XX (SWIT-) SWITCH BIOTECH AG.
XX
XX Halle J, Goppelt A, Hof P;
XX
XX WPI; 2003-103450/09.
XX
XX Use of alpha 1-antichymotrypsin polypeptide or nucleic acids encoding the
XX polypeptide, or of a cell expressing the polypeptide, or of antibody
XX PT against the polypeptide, for diagnosing, treating or preventing poorly-
XX PT healing wounds.
XX
XX Example 1; Page 38; 70pp; English.
XX
XX The present sequence is a PCR primer for murine alpha 1-antichymotrypsin
XX (ACT) cDNA (see ABV76143). It was used, with the primer given in
XX ABV76148, in examples from the invention describing the PCR amplification
XX of murine ACT to examine expression in normally healing, well healing and
XX 3 different types of poorly healing wounds with different pathogenic
XX backgrounds, and to examine the kinetics of ACT expression during wound
XX healing in healthy and diabetic mice. The invention is based on the
XX discovery that decreased expression of ACT is causally involved in poor
XX wound healing, specifically in poorly healing diabetes-associated and
XX poorly healing arterial wounds. An ACT polypeptide, including murine ACT,
XX a nucleic acid encoding it, or a cell expressing the ACT polypeptide or
XX nucleic acid encoding it, can be used for the diagnosis, treatment and/or
XX prevention of diabetes-associated and/or arterial wounds which heal
XX poorly. The wound may be a diabetic ulcer or an arterial ulcer, and the
XX cells are autologous or allogenic cells, including skin cells such as
XX keratinocytes, fibroblasts or endothelial cells
XX
XX Sequence 21 BP; 3 A; 6 C; 4 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3258 CATTGTGTCCCTTTGTCA 3276
DB 3 CAGTTGTGTCCCTTTGTCA 21
RESULT 505
ACC58762/c
ID ACC58762 standard; DNA; 21 BP.
XX
XX AC ACC58762;
XX
XX 26-AUG-2003 (first entry)
XX
XX Pro-alpha(III) chain 5' PCR primer.
XX
XX Collagen; procollagen; pro-alpha chain; vulnery; gene therapy;
XX drug delivery; PCR; primer; ss.
XX
XX Unidentified.
XX
XX WO2003035692-A2.
XX
XX 01-MAY-2003.
XX
XX 23-OCT-2002; 2002WO-GB004785.
XX
XX 23-OCT-2001; 2001GB-00025369.
XX
XX 23-OCT-2001; 2001GB-00025372.
XX

```


CC (M3) and (M4) are useful for identifying compounds capable of modulating
 CC mRNA transcription of an IGF2 gene and/or modulating binding of a nuclear
 CC factor to an IGF2 gene. Compounds identified are potentially useful for
 CC treating obesity, muscle deficiencies and diabetes. The present sequence
 CC is a primer which was used to produce porcine sequence tagged sites (STS)
 CC in an example from the invention.

XX Sequence 21 BP; 4 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.8; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 3.4e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4311 TCTGCGAGATGGAATCTT 4329

DB 19 TCTGCGAGATGGAATCTT 1

RESULT 508

ABK00063/C

ID ABK00063 standard; RNA; 17 BP.

XX

AC ABK00063;

XX

DT 12-MAR-2002 (first entry)

XX

DE Human NOGO Hammerhead Ribozyme #63.

XX

KW Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberyne; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.

OS Synthetic.

XX WO200159103-A2.

XX

XX 16-AUG-2001.

XX

PF 09-FEB-2001; 2001WO-US004273.

XX

PR 11-FEB-2000; 2000US-0181797P.

PR 28-FEB-2000; 2000US-0185516P.

PR 06-MAR-2000; 2000US-0187128P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.

PA (CHOW/) CHOWRIRA B M.

XX

PI Blatt L, Mcswiggen J, Chowrira BM;

XX

XX WPI; 2001-607195/69.

DR

Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 constructs, which down regulate expression of a CD20 gene or neurite
 growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 central nervous system injury.

XX Claim 88; Page 67; 200pp; English.

PS

XX The invention relates to a nucleic acid molecule which down regulates

expression of a CD20 gene and a nucleic acid molecule which down

regulates expression of a neurite growth inhibitor gene (NOGO). The

CC

CC

CC

CC

CC

CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberyne (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke). Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention

Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 3.4e+02;

Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1577 TTCTGCGAGATGAGCGT 1593

DB 17 TTCTGCGAGAGGCGT 1

RESULT 509

ABK00962/C

ID ABK00962 standard; RNA; 17 BP.

XX

AC ABK00962;

XX

DT 12-MAR-2002 (first entry)

XX

DE Human NOGO Inozyme #232.

XX

Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberyne; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.

OS Synthetic.

XX

PN WO200159103-A2.

XX

PD 16-AUG-2001.

XX

PF 09-FEB-2001; 2001WO-US004273.

XX

PR 11-FEB-2000; 2000US-0181797P.

PR

cerebroprotective; nootropic; neuroprotective; antiparkinsonian; muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme; DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia; B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia; human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia; inflammatory arthropathy; central nervous system injury; cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis; chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS; Parkinson's disease; ataxia; Huntington's disease; Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

Homo sapiens.
Synthetic.

WO200159103-A2.
16-AUG-2001.

09-FEB-2001; 2001WO-US004273.

11-FEB-2000; 2000US-0181797P.
28-FEB-2000; 2000US-0185516P.
06-MAR-2000; 2000US-0187128P.

(RIBO-) RIBOZYME PHARM INC.
(BLAT/) BLATT L.
(MCSW/) MCSWIGGEN J.
(CHOW/) CHOWRIRA B M.

Blatt L, Mcswiggen J, Chowrira BM;
WPI; 2001-607195/69.

Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.

Claim 88; Page 81; 200pp; English.

The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NOGO). The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a DNazyme) an Inozyme (an endolytic nucleic acid cleaving with an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA with a GYV motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg^{2+} . Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-targeting nucleic acid is used to cleave RNA of the NOGO gene in the presence of a divalent cation that is preferably Mg^{2+} . Furthermore, the nucleic acid may be contacted with a cell to reduce NOGO activity of the cell and treat a patient having a condition associated with the level of NOGO. The treatment may further comprise the use of one or more therapies. In particular, the NOGO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression. The present sequence is an inozyme of the invention

28-FEB-2000; 2000US-0185516P.
06-MAR-2000; 2000US-0187128P.
(RIBO-) RIBOZYME PHARM INC.
(BLAT/) BLATT L.
(MCSW/) MCSWIGGEN J.
(CHOW/) CHOWRIRA B M.
Blatt L, Mcswiggen J, Chowrira BM;
WPI; 2001-607195/69.
Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.
Claim 88; Page 81; 200pp; English.
The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NIGO). The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an ambenzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, lymphoma thrombocytopaenia, and inflammatory arthropathy. The NIGO-targeting nucleic acid is used to cleave RNA of the NIGO gene in the presence of a divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid may be contacted with a cell to reduce NIGO activity of the cell and treat a patient having a condition associated with the level of NIGO. The treatment may further comprise the use of one or more therapies. In particular, the NIGO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NIGO expression. The present sequence is an inozyme of the invention
Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1579 TCTGCAGATGAGCGTAT 1595
| | | | | | | | | | | | | | | | | |
Db 17 TCTGCAGAGGAGCGTAT 1
RESULT 510
ID ABK00963/C
XX AC ABK00963;
XX AC ABK00963;
XX 12-MAR-2002 (first entry)
XX Human NIGO Inozyme #233.
XX


```

SQ Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
  Query Match      0.3%; Score 15.4; DB 1; Length 17;
  Best Local Similarity 94.1%; Pred. No. 3.4e+02;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1578 TTCTGCAGATGAGCGTA 1594
Db 17 TTCTGCAGAGGAGCGTA 1

RESULT 511
ACC68083
ID ACC68083 standard; DNA; 17 BP.
XX AC ACC68083;
XX AC
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5330.
XX KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001PR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX PI WPI; 2003-333167/31.
XX DR New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 654; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68083), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia
XX CC
XX CC Sequence 17 BP; 3 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match      0.3%; Score 15.4; DB 1; Length 17;
  Best Local Similarity 94.1%; Pred. No. 3.4e+02;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 960 GATCCTGACAGCTGTGG 976
Db 1 GATCCTGAGAGCTGTGG 17

RESULT 512
ACC65135/C
ID ACC65135 standard; DNA; 17 BP.

```

```

XX AC ACC65135;
XX AC
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2382.
XX KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001PR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX PI WPI; 2003-333167/31.
XX DR New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 309; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68083), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia
XX CC
XX CC Sequence 17 BP; 4 A; 3 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match      0.3%; Score 15.4; DB 1; Length 17;
  Best Local Similarity 94.1%; Pred. No. 3.4e+02;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1401 AAATAAAATTGAAGATC 1417
Db 17 AAATAGATTGAATC 1

RESULT 513
ADB39787/C
ID ADB39787 standard; DNA; 17 BP.
XX AC ADB39787;
XX AC
XX DT 18-DEC-2003 (revised)
XX DT 04-DEC-2003 (first entry)
XX DE Tumour suppression/reversion associated nucleotide #110.
XX KW cytotostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;
XX KW primer; probe; tumour suppression; tumour reversion; apoptosis;
XX KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX KW diagnosis.
XX OS Homo sapiens.

```

```
XX PN WO2003040369-A2.
XX PD
XX PF
XX PR 15-MAY-2003.
XX FF 17-SEP-2002; 2002WO-IB004219.
XX PR 17-SEP-2001; 2001FR-00011981.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-441574/41.
XX PT New nucleic acid encoding human prostate membrane-specific antigen,
XX PT useful e.g. for treatment of tumors and viral infection, also related
XX PT polypeptide and antibodies.
XX PS Disclosure; Page 45; 77lpp; French.
XX CC The invention relates to the isolation of 6327 nucleotide sequences,
XX CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX CC sequence having at least 80% identity, after optimal alignment, with the
XX CC nucleotides, a sequence that hybridizes under stringent conditions with
XX CC the nucleotides, or the complement, or corresponding RNA, of the
XX CC nucleotides. The nucleotides are used as probes or primers for detecting,
XX CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX CC sense and antisense sequences, of nucleotides involved in tumour
XX CC suppression or reversion, apoptosis and or viral resistance, to produce
XX CC recombinant polypeptides, and to prepare transgenic animals, as
XX CC experimental models. The nucleotides (also vectors containing them and
XX CC cells containing the vectors), the encoded polypeptides and antibodies
XX CC (Ab) against the polypeptide are useful for prevention and/or treatment
XX CC of viral infections or diseases characterized by development of tumours
XX CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX CC Analysis of the expression of the nucleotides can be used for diagnosis
XX CC and/or prognosis of these diseases. The nucleotides and polypeptides can
XX CC also be used to screen for their specific interactive molecules,
XX CC potentially useful for treating diseases associated with abnormal
XX CC expression of the nucleotides.
XX SQ Sequence 17 BP; 9 A; 2 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1332 TGTACCATTTATTGATC 1348
DB 17 TGTACCTTTATTGATC 1
RESULT 514
ADB42797
ID ADB42797 standard; DNA; 17 BP.
XX AC ADB42797;
XX DT 18-DEC-2003 (revised)
XX DT 04-DEC-2003 (first entry)
XX DE Tumour suppression/reversion associated nucleotide #3120.
XX KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX KW primer; probe; tumour suppression; tumour reversion; apoptosis;
XX KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX KW diagnosis.
XX OS Homo sapiens.
XX PN WO2003040369-A2.
XX PD
```

```
PD XX 15-MAY-2003.
XX PF 17-SEP-2002; 2002WO-IB004219.
XX PR 17-SEP-2001; 2001FR-00011981.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-441574/41.
XX PT New nucleic acid encoding human prostate membrane-specific antigen,
XX PT useful e.g. for treatment of tumors and viral infection, also related
XX PT polypeptide and antibodies.
XX PS Disclosure; Page 396; 77lpp; French.
XX CC The invention relates to the isolation of 6327 nucleotide sequences,
XX CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX CC sequence having at least 80% identity, after optimal alignment, with the
XX CC nucleotides, a sequence that hybridizes under stringent conditions with
XX CC the nucleotides, or the complement, or corresponding RNA, of the
XX CC nucleotides. The nucleotides are used as probes or primers for detecting,
XX CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX CC sense and antisense sequences, of nucleotides involved in tumour
XX CC suppression or reversion, apoptosis and or viral resistance, to produce
XX CC recombinant polypeptides, and to prepare transgenic animals, as
XX CC experimental models. The nucleotides (also vectors containing them and
XX CC cells containing the vectors), the encoded polypeptides and antibodies
XX CC (Ab) against the polypeptide are useful for prevention and/or treatment
XX CC of viral infections or diseases characterized by development of tumours
XX CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX CC Analysis of the expression of the nucleotides can be used for diagnosis
XX CC and/or prognosis of these diseases. The nucleotides and polypeptides can
XX CC also be used to screen for their specific interactive molecules,
XX CC potentially useful for treating diseases associated with abnormal
XX CC expression of the nucleotides.
XX SQ Sequence 17 BP; 7 A; 4 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3061 GATCTTGTATAAACCAA 3077
DB 1 GATCTTGTATAAACCAA 17
RESULT 515
ADB05333/c
ID ADR05333 standard; DNA; 17 BP.
XX AC ADR05333;
XX DT 21-OCT-2004 (first entry)
XX DE Silkorm juvenile hormone acid transmethylease cDNA PCR primer PPL.
XX KW ss; primer; insect repellent; insect attractant;
XX KW reproductive maturation regulator; imago; diapause inducer;
XX KW diapause inhibitor; larva; transformation regulator; pupa;
XX KW juvenile hormone acid transmethylease; silkorm; Bombyx mori;
XX KW Drosophila melanogaster; mosquito; Anopheles gambia; Spodoptera litura;
XX KW Helicoverpa armigera; molting; transformation; diapause; blastogenesis;
XX KW polymorphism; arthropod; cotton bollworm; PCR primer.
XX OS Bombyx mori.
XX PN WO2004065604-A1.
XX PD 05-AUG-2004.
```

```

XX PF 20-JAN-2003; 2003WO-JP000415.
XX PR 20-JAN-2003; 2003WO-JP000415.
XX PA (NAAG-) NAT AGRIC RES ORG JAPAN.
XX PI Shinoda T, Itoyama K, Hamamura T;
XX DR WPI; 2004-580727/56.
XX XX
XX XX New DNA encoding protein having juvenile-hormone acid transmethylease
XX PT activity, useful for screening for a compound controlling the expression
XX PT level of juvenile-hormone acid transmethylease DNA.
XX XX
XX PS Example 1; SEQ ID NO 11; 118pp; Japanese.
XX CC
XX CC The invention relates to a DNA (I) encoding a protein (II) having
XX CC juvenile-hormone acid transmethylease activity selected from the DNA from
XX CC silkworm (Bombyx mori), Drosophila melanogaster, mosquito (Anopheles
XX CC gambiae), Spodoptera litura and Helicoverpa armigera, their encoded
XX CC proteins (S2), DNAs (D2) that hybridize under stringent conditions with
XX CC the nucleic acids or an amino acid sequence (S3) comprising any one of
XX CC (S2) in which one or more amino acids are substituted, deleted, inserted
XX CC and/or added. (I) is useful for screening a compound that controls the
XX CC expression level of (I), and as a controlling agent of molting and
XX CC transformation, reproductive, diapause, blastogenesis, action,
XX CC polymorphism or lifetime of arthropod. (II) is useful for screening a
XX CC compound having binding affinity with respect to (II), which involves
XX CC contacting test compound with (II), detecting the binding of (II) with
XX CC test compound, and selecting the compound that binds with (II). (II) is
XX CC useful for screening a compound that controls the activity of (II), which
XX CC involves contacting test compound with (II), measuring the activity of
XX CC (II), and selecting the compound that decreases or increases the activity
XX CC of (II), based on comparison of the activity of (II) in absence of test
XX CC compound. (III) is useful for manufacturing activated juvenile hormone.
XX CC This sequence corresponds to a PCR primer used to amplify and isolate the
XX CC transmethylease cDNA from the silkworm Bombyx mori.
XX SQ Sequence 17 BP; 0 A; 1 C; 1 G; 15 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5023 GTAAAAAAGAAAAA 5039
Db 17 GCACAAAAAAGAAAAA 1

RESULT 516
AAZ08552/c
ID AAZ08552 standard; DNA; 18 BP.
XX AC AAZ08552;
XX DT 18-OCT-1999 (first entry)
XX DE Procollagen I reverse transcriptase PCR primer #1.
XX KW Osteocalcin; osteonectin; osteopontin; bone morphogenic protein; BMP;
XX KW parathyroid hormone receptor; alkaline phosphatase; procollagen; human;
XX KW osteoblast precursor cell; OPC; bony defect; osseous defect;
XX KW traumatic bone loss; congenital insufficiency; malformation;
XX KW osteoporosis; surgical resection; traumatic avulsion; PCR primer; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9939724-A1.
XX XX
XX PD 12-AUG-1999.
XX XX

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5023 GTAAAAAAGAAAAA 5039
Db 17 GCACAAAAAAGAAAAA 1

RESULT 517
ABK41074
ID ABK41074 standard; DNA; 18 BP.
XX AC ABK41074;
XX DT 21-MAY-2002 (first entry)
XX DE Human obesity-associated biallelic marker upstream PCR primer #151.
XX KW Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;
XX KW drug response; hyperuricaemia; digestive pathology; hypertension; cancer;
XX KW hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;
XX KW insulin disorder; atheromatous disease; cardiac insufficiency; primer.
XX OS Homo sapiens.
XX PN WO200206525-A2.
XX PD 24-JAN-2002.
XX PF 28-JUN-2001; 2001WO-IB001477.
XX PR 18-JUL-2000; 2000US-0219704P.
XX PA (GEST ) GENSET.
XX PI Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;

The present invention describes composition (I) for treating osseous
defects comprising a porous matrix and a cell that is committed to an
osteogenic lineage. The composition is useful for healing a bone defect,
especially those caused by osteoporosis, cyst like cavities, surgical
resection, traumatic avulsion and congenital insufficiency. The
compositions assist in the repair and regeneration of bone. Osteoblast
precursor cells (OPC's) boost bone making capability of an ill or aged
individual where OPC's are numerically deficient or functionally
impaired. OPC's can be administered to express BMP to repair bone
defects. The implant is useful for promoting vascular ingrowth and bone
formation, especially in treating bone defects e.g. osteopenic spine. The
composition promotes vascular ingrowth and bone formation without
becoming a barrier to the progression of bone formation. OPC's can be
gently introduced into the cavity without disrupting the cells in the
suspension and they also encourage additional bone formation in the
surrounding bone. The present sequence represents a reverse transcription
PCR primer used to phenotype OPC cells for procollagen I expression
SQ Sequence 18 BP; 7 A; 4 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1896 AGTCTTCTGCTCGTCA 1912
Db 17 AGTCTTCTGCTCGTCA 1

RESULT 517
ABK41074
ID ABK41074 standard; DNA; 18 BP.
XX AC ABK41074;
XX DT 21-MAY-2002 (first entry)
XX DE Human obesity-associated biallelic marker upstream PCR primer #151.
XX KW Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;
XX KW drug response; hyperuricaemia; digestive pathology; hypertension; cancer;
XX KW hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;
XX KW insulin disorder; atheromatous disease; cardiac insufficiency; primer.
XX OS Homo sapiens.
XX PN WO200206525-A2.
XX PD 24-JAN-2002.
XX PF 28-JUN-2001; 2001WO-IB001477.
XX PR 18-JUL-2000; 2000US-0219704P.
XX PA (GEST ) GENSET.
XX PI Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;

```


CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.

XX
 SQ Sequence 19 BP; 6 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 541 CTAAGACACACAGGCT 557
 Db 3 CTAAGACACACAGGCT 19

RESULT 520

ID ADR79520 standard; DNA; 19 BP.

XX AC ADR79520;

XX 16-DEC-2004 (first entry)

DE Human apolipoprotein B (ApoB) oligonucleotide seqid 4012.

XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticoagulant; nootropic; muscular; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.

XX Homo sapiens.

OS WO2004080406-A2.

XX 23-SEP-2004.

PF 08-MAR-2004; 2004WO-US0007070.

XX 07-MAR-2003; 2003US-0452682P.

PR 12-MAR-2003; 2003US-0454265P.

PR 13-MAR-2003; 2003US-0454962P.

PR 13-MAR-2003; 2003US-0455050P.

PR 14-APR-2003; 2003US-0462894P.

PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.

XX (ALNY-) ALNYLAM PHARM.

XX Manoharan M, Bumcrot D;

XX WPI; 2004-677362/66.

PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.

XX Example 5; SEQ ID NO 4012; 378pp; English.

CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.

SQ Sequence 19 BP; 6 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 541 CTAAGACACACAGGCT 557
 Db 3 CTAAGACACACAGGCT 19

RESULT 521

AAQ75326/C
 ID AAQ75326 standard; DNA; 20 BP.

XX AC AAQ75326;

XX 25-MAR-2003 (revised)

DT 22-JUN-1995 (first entry)

XX Urease gene PCR primer.

PT kinase p110 delta expression, e.g. rheumatoid arthritis, asthma.
 PS Example 15; Col 40; 35pp; English.
 XX
 XX This sequence represents a phosphatidylinositol 3 kinase (PI3K)
 CC targeting antisense oligonucleotide. Phosphatidylinositol 3 kinases act
 CC as downstream effectors of hormone and growth factor receptors, and have
 CC been implicated in growth factor mediated cell transformation,
 CC mitogenesis, protein trafficking, cell survival and proliferation, and
 CC many other cellular activities. PI3K is a heterodimer, consisting of a
 CC 110kD catalytic subunit (p110), and an 85kD regulatory subunit (p85). The
 CC invention relates to antisense oligonucleotides which target the p110
 CC delta mRNA of PI3K. The antisense oligonucleotides specifically hybridise
 CC with various regions of the PI3K mRNA sequence, and inhibit the
 CC expression of PI3K. The antisense oligonucleotides may be used to treat
 CC an animal, particularly human, suspected of having or being prone to a
 CC disease or condition associated with the expression of PI3K, e.g.
 CC rheumatoid arthritis or asthma. The treatment works through the
 CC modulation (preferably inhibition) of the expression of PI3K. The
 CC antisense oligonucleotides may also be used for research and diagnostics,
 CC in pharmaceutical compositions and formulations, in the preparation of
 CC kits for detecting the level of PI3K in a sample, and as prophylaxis,
 CC e.g. to prevent or delay infection, inflammation or tumour formation.
 CC Antisense oligonucleotides, which are able to inhibit gene expression
 CC specifically, are used to elucidate the function of particular genes, and
 CC to distinguish between functions of various members of a biological
 CC pathway
 XX
 XX Sequence 20 BP; 2 A; 8 C; 6 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.3%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 19 GAATTCGGACGAGGGG 35
 DB 20 GAATTCGGACGAGCGG 4
 RESULT 524
 AA228930
 ID AA228930 standard; DNA; 20 BP.
 XX
 AC AA228930;
 XX
 DT 07-FEB-2000 (first entry)
 XX
 DE Forward primer aa2 for amplification of paraplegin gene exon.
 XX
 KW Forward primer aa2; paraplegin; human; hereditary spastic paraplegia;
 KW HSP; mutation; diagnosis; treatment; neurodegenerative condition;
 KW Amyotrophic Lateral Sclerosis; ALS; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN W09958556-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 06-MAY-1999; 99WO-EP003112.
 XX
 PR 08-MAY-1998; 98IT-MI001003.
 XX
 PA (TELS-) FOND TELETHON.
 XX
 PI Ballabio A, Casari G;
 XX
 DR WPI; 2000-039065/03.
 XX
 PT A novel protein associated to hereditary spastic paraplegia used for the
 PT diagnosis of neurodegenerative conditions.
 XX

PS Claim 4; Fig 3; 53pp; English.
 XX
 CC The present sequence is a forward primer aa2 used for amplification and
 CC detection of mutations in paraplegin gene exon from hereditary spastic
 CC paraplegia (HSP) patients. Detection of mutations in paraplegin gene
 CC helps in the diagnosis and treatment of various forms of HSP or other
 CC neurodegenerative conditions, such as Amyotrophic Lateral Sclerosis
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1715 CATCTGCTCCTACAGACC 1731
 DB 1 CATCTGCTCCTACAGACC 17
 RESULT 525
 AA271844/C
 ID AA271844 standard; DNA; 20 BP.
 XX
 AC AA271844;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Human biallelic marker upstream amplification primer SEQ ID NO:6200.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 21-APR-1999; 99WO-IB000822.
 XX
 PR 21-APR-1998; 98US-0082614P.
 XX
 PR 23-NOV-1998; 98US-0109732P.
 XX
 PA (GEST) GENSET.
 XX
 PI Cohen D, Blumenfeld M, Chumakov I;
 XX
 DR WPI; 2000-013267/01.
 XX
 PT Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.
 XX
 PS Claim 9; Page 1553; 2745pp; English.
 XX
 CC AA265654 to AA269578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AA269579 to AA277440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX

XX	CLLD8 exon 12 and ANGE exon 3 SNP identification primer #103.
XX	ANGE, CLLD8; CLLD7; ANGE-CLLD8; ANGE-CLLD7; CLLD7-CLLD8;
DE	ANGE-CLLD8-CLLD7; antiallergic; antiasthmatic; dermatological;
XX	antipyretic; antiinflammatory; gene therapy; IgE-mediated disease;
KW	primer; ss.
KW	Unidentified.
OS	WO2003000727-A2.
XX	03-JAN-2003.
XX	21-JUN-2002; 2002WO-CB002859.
XX	21-JUN-2001; 2001GB-00015211.
XX	21-JUN-2001; 2001GB-00015212.
XX	21-JUN-2001; 2001GB-00015213.
XX	(ISIS-) ISIS INNOVATIONS LTD.
PA	Zhang Y, Moffatt M, Cookson W, Tinsley J;
PI	WPI; 2003-201405/19.
XX	New nucleic acid sequence comprising an ANGE, CLLD8 or CLLD7 mRNA, or
XX	their hybrid, useful for screening agents for treating IgE-mediated
PT	diseases, e.g. asthma, atopy, hay fever, eczema, atopic dermatitis, or
PT	allergic rhinitis.
PT	Disclosure; Page 408; 429pp; English.
XX	The invention relates to a novel isolated or recombinant nucleic acid
XX	sequence comprising an ANGE, CLLD8 or CLLD7 mRNA, or ANGE-CLLD8, ANGE-
CC	CLLD7, CLLD7-CLLD8, or ANGE-CLLD8-CLLD7 hybrid mRNA sequence, its
CC	complement, homologue or fragment. The novel nucleic acid sequences have
CC	the following activities: antiallergic, antiasthmatic, dermatological,
CC	antipyretic, and antiinflammatory. The nucleic acids of the invention may
CC	be used in gene therapy to treat disorders. The nucleic acid sequences
CC	are useful for screening agents that inhibit or enhance activity of an
CC	ANGE, CLLD8 or CLLD7 gene. The agent or antibody is useful for treating
CC	IgE-mediated diseases, such as asthma, atopy, hay fever, eczema, atopic
CC	dermatitis, allergic rhinitis or non-atopic asthma. The antibody is
CC	useful in an assay detecting or measuring the polypeptide in the sample.
CC	The host cell is useful for producing, regulating and analyzing the
CC	polypeptide. The splice variant of ANGE, CLLD8, or CLLD7 is useful for
CC	diagnosing an IgE-mediated disease, atopy, a form of atopic disease or
CC	non-atopic asthma, or predicting the severity, or predisposition to a
CC	disease. This polynucleotide sequence represents a primer used in the
CC	exemplification of the invention.
XX	Sequence 20 BP; 5 A; 5 C; 3 G; 7 T; 0 U; 0 Other;
XX	Query Match 0.3%; Score 15.4; DB 1; Length 20;
XX	Best Local Similarity 94.1%; Pred. No. 3.5e+02;
XX	Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	2636 ATGCTCTACTGTAAACTG 2652
DB	17 ATGCTCTACTGTAAACAG 1
RESULT 528	
ACC82889	
ID	ACC82889 standard; DNA; 20 BP.
XX	ACC82889;
XX	27-AUG-2003 (first entry)
XX	Human TRIP6 antisense oligonucleotide ISIS #198761.

KW Human; antisense; thyroid hormone receptor interactor 6; TRIP6; tumour;
 KW OPA-interacting protein-1; OIP-1; zyxin-related protein-1; prophylaxis;
 KW inflammation; therapy; hyperproliferative disorder; infection; cancer;
 KW chromosome 7q22; ZRP-1; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT
 FT WO2003040328-A2.
 PN
 XX
 XX 15-MAY-2003.
 XX
 XX 05-NOV-2002; 2002WO-US035479.
 XX
 XX 08-NOV-2001; 2001US-00008789.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Bennett CF, Dobie K;
 PI
 XX
 XX WPI; 2003-430662/40.
 DR
 XX
 XX New antisense oligonucleotides targeted to nucleic acids encoding thyroid
 FT hormone receptor interactor 6, useful for diagnosing or treating
 FT hyperproliferative disorders, such as cancer.
 FT
 XX
 XX Example 15; Page 76; 111pp; English.
 PS
 XX
 XX The invention relates to antisense compounds targetted to a nucleic acid
 CC encoding thyroid hormone receptor interactor 6 (TRIP6) to inhibit its
 CC expression. TRIP6 is also known as OPA-interacting protein-1 (OIP-1) and
 CC zyxin-related protein-1 (ZRP-1). TRIP6 DNA is located on chromosome 7q22.
 CC Antisense compounds of the invention are useful for modulating the
 CC expression of TRIP6 and for treating diseases or conditions associated
 CC with the expression of TRIP6 such as hyperproliferative disorders (e.g.
 CC cancer). They are useful for diagnostics, therapeutics, prophylaxis e.g.
 CC to prevent or delay infection, inflammation or tumour formation, as
 CC research reagents and kits and in distinguishing between functions of
 CC various members of a biological pathway. They are also useful in antisense
 CC therapy. The present sequence is an antisense oligo targetted to human
 CC TRIP6 DNA. This oligo is used in the exemplification of the invention
 XX
 XX Sequence 20 BP; 8 A; 3 C; 3 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.3%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2699 AAAGAAACTTGTCTG 2715
 Db |||||
 2 AAAGAAACTTGTCTG 18
 RESULT 529
 ADH66356/c
 ID ADH66356 standard; DNA; 20 BP.
 XX
 XX ADH66356;
 AC

XX 25-MAR-2004 (first entry)
 DE Human glucocorticoid receptor-specific antisense oligonucleotide #3190.
 XX
 XX antisense oligonucleotide; glucocorticoid receptor; infection;
 KW inflammation; tumour formation; diabetes; obesity;
 KW cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
 KW phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
 XX
 OS Homo sapiens.
 OS
 PN WO2003099215-A2.
 XX
 XX 04-DEC-2003.
 PD
 XX
 XX 20-MAY-2003; 2003WO-US016084.
 PF
 XX
 XX 20-MAY-2002; 2002US-0381857P.
 PR
 XX
 XX (PHAA) PHARMACIA CORP.
 PA
 XX Crosby SD, Nalseth AE;
 PI
 XX WPI; 2004-035034/03.
 DR
 XX
 XX New antisense compound targeted to a nucleic acid molecule encoding
 FT mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
 FT cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
 FT
 XX
 XX Claim 4; SEQ ID NO 3190; 985pp; English.
 PS
 XX
 XX The invention comprises an antisense oligonucleotides that are targeted
 CC to nucleic acids encoding a mammalian glucocorticoid receptor. The
 CC antisense oligonucleotides of the invention are useful for preventing or
 CC delaying infection, inflammation or tumour formation. The antisense
 CC oligonucleotides are also useful for treating diabetes, obesity,
 CC cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
 CC present DNA sequence represents an antisense oligonucleotide that targets
 CC the human glucocorticoid receptor gene. NOTE: The present sequence
 CC contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
 XX
 XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.3%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 4205 GGGACATGGAGACTGGT 4221
 Db |||||
 19 GGGAGATGGAGACTGGT 3
 RESULT 530
 ADH66905/c
 ID ADH66905 standard; DNA; 20 BP.
 XX
 XX ADH66905;
 AC
 XX
 XX 25-MAR-2004 (first entry)
 DT
 XX
 XX Human glucocorticoid receptor-specific antisense oligonucleotide #3739.
 DE
 XX
 XX antisense oligonucleotide; glucocorticoid receptor; infection;
 KW inflammation; tumour formation; diabetes; obesity;
 KW cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
 KW phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
 XX
 OS Homo sapiens.
 OS
 PN WO2003099215-A2.
 XX
 XX 04-DEC-2003.
 PD

```
XX PF 20-MAY-2003; 2003WO-US016084.
XX PR
XX XX
XX PA (PHAA ) PHARMACIA CORP.
XX PI Crosby SD, Nalseth AE;
XX PS WPI; 2004-035034/03.
XX PT New antisense compound targeted to a nucleic acid molecule encoding
XX PT mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
XX PT cardiovascular disorder, hyperlipidaemia or Cushing's syndrome.
XX PS Claim 4; SEQ ID NO 3739; 985pp; English.
XX CC The invention comprises an antisense oligonucleotides that are targeted
XX CC to nucleic acids encoding a mammalian glucocorticoid receptor. The
XX CC antisense oligonucleotides of the invention are useful for preventing or
XX CC delaying infection, inflammation or tumour formation. The antisense
XX CC oligonucleotides are also useful for treating diabetes, obesity. The
XX CC cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
XX CC present DNA sequence represents an antisense oligonucleotide that targets
XX CC the human glucocorticoid receptor gene. NOTE: The present sequence
XX CC contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX SQ Sequence 20 BP; 4 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 4205 GGGACATGGAGCTGGT 4221
DB 20 GGGAGATGGAGCTGGT 4
RESULT 531
ADJ23055
ID ADJ23055 standard; DNA; 20 BP.
XX AC ADJ23055;
XX DT 20-MAY-2004 (first entry)
XX DE Human endothelial lipase antisense oligonucleotide, SEQ ID 1453.
XX KW Antilipaeamic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
XX KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
XX KW Cardiovascular disorder; metabolic syndrome X; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "This oligonucleotide has a phosphorothioate
XX FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5',
XX FT and 3' ends, which are 4 nucleotides in length. Also all
XX FT cytidine residues are 5-methylcytidines"
XX PN WO2004009541-A2.
XX PD 29-JAN-2004.
XX PF 18-JUL-2003; 2003WO-US022410.
XX PR 19-JUL-2002; 2002US-0397106P.
XX PA (PHAA ) PHARMACIA CORP.
XX PI Bhat BG;
XX PT WPI; 2004-132912/13.
XX PT New antisense oligonucleotide for modulating endothelial lipase
```

```
XX PI Bhat BG;
XX DR WPI; 2004-132912/13.
XX PT New antisense oligonucleotide for modulating endothelial lipase
XX PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
XX PT high density lipoprotein or cardiovascular disorders.
XX PS Claim 3; SEQ ID NO 1453; 1007pp; English.
XX CC The present invention relates to antisense oligonucleotides (ADJ21603-
XX CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
XX CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
XX CC with and inhibits the expression of EL. The antisense oligonucleotides
XX CC are useful for modulating the expression of endothelial lipase in cells
XX CC or tissues to treat diseases associated with EL expression, such as
XX CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
XX CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
XX CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX SQ Sequence 20 BP; 7 A; 5 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 983 CACACAAATCTGGAGTT 999
DB 4 CACACAAATCTGGACTT 20
RESULT 532
ADJ22915
ID ADJ22915 standard; DNA; 20 BP.
XX AC ADJ22915;
XX DT 20-MAY-2004 (first entry)
XX DE Human endothelial lipase antisense oligonucleotide, SEQ ID 1313.
XX KW Antilipaeamic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
XX KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
XX KW Cardiovascular disorder; metabolic syndrome X; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "This oligonucleotide has a phosphorothioate
XX FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5',
XX FT and 3' ends, which are 4 nucleotides in length. Also all
XX FT cytidine residues are 5-methylcytidines"
XX PN WO2004009541-A2.
XX PD 29-JAN-2004.
XX PF 18-JUL-2003; 2003WO-US022410.
XX PR 19-JUL-2002; 2002US-0397106P.
XX PA (PHAA ) PHARMACIA CORP.
XX PI Bhat BG;
XX PT WPI; 2004-132912/13.
XX PT New antisense oligonucleotide for modulating endothelial lipase
```

PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT high density lipoprotein or cardiovascular disorders.

XX Claim 3; SEQ ID NO 1313; 1007pp; English.

XX The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridizes
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.

XX SQ Sequence 20 BP; 7 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 983 CACACAAATCTGGAGTT 999
Db 3 CACACAAATCTGGACTT 19

RESULT 533

ADK81043
ID ADK81043 standard; DNA; 20 BP.

XX AC ADK81043;

XX DT 20-MAY-2004 (first entry)

XX DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8377.

XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.

XX OS Synthetic.

XX PN WO2004016754-A2.

XX PD 26-FEB-2004.

XX PF 14-AUG-2003; 2003WO-US025465.

XX PR 14-AUG-2002; 2002US-0403416P.

XX PA (PHAA) PHARMACIA CORP.

XX PI Roberds SL;

XX DR WPI; 2004-203785/19.

XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.

XX Claim 4; SEQ ID NO 8377; 417pp; English.

XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present

CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 4459 ACTGAAGTTGTCACGGA 4475
Db 1 ACTGAAGTTGTCACGGA 17

RESULT 534

ADK76762
ID ADK76762 standard; DNA; 20 BP.

XX AC ADK76762;

XX DT 20-MAY-2004 (first entry)

XX DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4096.

XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.

XX OS Synthetic.

XX PN WO2004016754-A2.

XX PD 26-FEB-2004.

XX PF 14-AUG-2003; 2003WO-US025465.

XX PR 14-AUG-2002; 2002US-0403416P.

XX PA (PHAA) PHARMACIA CORP.

XX PI Roberds SL;

XX DR WPI; 2004-203785/19.

XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.

XX Claim 4; SEQ ID NO 4096; 417pp; English.

XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

PN WQ2004030750-A1.
 XX 15-APR-2004.
 XX 25-SEP-2003; 2003WO-US030353.
 XX 25-SEP-2002; 2002US-0413588P.
 XX (PHAA) PHARMACIA CORP.
 XX Kane CD;
 XX WPI; 2004-347928/32.
 XX New antisense oligonucleotides useful for modulating expression of
 PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
 PT e.g. diabetes, immunological disorders, cardiovascular disorders,
 PT gallstones or obesity.
 PS Claim 4; SEQ ID NO 1053; 150pp; English.
 XX The invention relates to an antisense compound 8-30 nucleobases in length
 CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
 CC where the antisense compound specifically hybridizes with and inhibits
 CC the expression of FXR. The composition and methods are useful for
 CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
 CC tissues, or for treating diseases or conditions associated with FXR, such
 CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
 CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
 CC lipoprotein), elevated LDL (low density lipoprotein) or
 CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
 CC neurological disorders, or ischemia/reperfusion injury. In addition, the
 CC composition is used for diagnostics, prophylaxis, or as research reagents
 CC or kits. This sequence corresponds to an antisense oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3477 GGAGAGTAACCCACCAC 3493
 DB 18 GGAGAGTAACCCACCAC 2
 RESULT 538
 ADT01052
 ID ADT01052 standard; DNA; 20 BP.
 XX
 AC ADT01052;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID1040.
 XX
 KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
 KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
 KW GUCY2F; MCKK; MLK4; kinase domain; cytosolic; tyrosine kinase inhibitor;
 KW guanylate cyclase stimulator; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004082458-A2.
 XX 30-SEP-2004.
 XX 18-FEB-2004; 2004WO-US004452.
 XX 21-FEB-2003; 2003US-0448537P.
 PR 29-MAY-2003; 2003US-0473895P.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
 XX WPI; 2004-718702/70.
 XX Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
 PT associated methods for diagnosing cancer and screening for anti-cancer
 PT agents.
 XX
 XX Disclosure; SEQ ID NO 1040; 363pp; English.
 XX This invention relates to a novel activated mutant protein tyrosine
 CC kinases and associated methods for diagnosing cancer and screening for
 CC anti-cancer agents. Protein kinases are signalling molecules involved in
 CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
 CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
 CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
 CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
 CC may be useful for the production of compounds with a cytostatic activity
 CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
 CC stimulators. The invention may be useful for developing methods for
 CC detecting mutations involved in cancer or screening for anti-cancer
 CC agents. The present sequence is that of a human-derived oligonucleotide
 CC which is related to the invention.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 825 TTTCAGAGAACGATCAG 841
 DB 4 TTTCAGAGAACGATCAG 20
 RESULT 539
 ADH26724
 ID ADH26724 standard; DNA; 20 BP.
 XX
 AC ADH26724;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human PI3K regulatory subunit 4, p150 DNA antisense oligonucleotide #49.
 XX
 KW Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;
 KW PI3 kinase; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; Chediak-Higashi syndrome;
 KW neurodegenerative disorder; metabolic disorders; inflammation;
 KW cytosolic; immunomodulator; neurodegenerative; antimicrobial;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2003225013-A1.
 XX 04-DEC-2003.
 XX 31-MAY-2002; 2002US-00160786.
 XX 31-MAY-2002; 2002US-00160786.
 XX (ISIS-) ISIS PHARM INC.
 XX Preier SM, Dobie KW;
 XX WPI; 2004-051923/05.
 XX New antisense oligonucleotides inhibiting the expression of
 PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for

PT	preventing or treating diseases associated with the subunit, e.g.	CC	The invention relates to a compound targeted to a nucleic acid molecule
PT	hyperproliferative disorders.	CC	encoding human phosphoinositide-3-kinase (PI3K) regulatory subunit 4,
XX		CC	p150. The compound is an antisense oligonucleotide that specifically
PS		CC	hybridises with a nucleic acid molecule encoding PI3K regulatory subunit
XX	Example 15; SEQ ID NO 59; 62pp; English.	CC	4, p150 and inhibits expression of the polypeptide. The antisense
XX		CC	oligonucleotide comprises at least one modified internucleoside linkage
CC		CC	i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC		CC	preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC		CC	nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC		CC	useful for modulating the expression of PI3K regulatory subunit 4, p150
CC		CC	and for preventing or treating hyperproliferative disorders (i.e.
CC		CC	cancer), Chediak-Higashi syndrome, neurodegenerative disorders and
CC		CC	metabolic disorders. These may also be used in research and diagnostics
CC		CC	and in preventing or delaying infection or inflammation. This sequence
CC		CC	represents an antisense oligonucleotide of the invention.
XX		SQ	Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;
SQ			Query Match 0.3%; Score 15.2; DB 1; Length 20;
			Best Local Similarity 85.0%; Pred. No. 3.6e+02;
			Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY	3319 AAACGAGTAATACCGGTTTT 3338	OY	3319 AAACGAGTAATACCGGTTTT 3338
Db	1 AAACCGGTATTACTGGTTTT 20	Db	20 AAACCGGTATTACTGGTTTT 1
RESULT 540		RESULT 541	
ADH26792/c		ADL34613	
ID	ADH26792 standard; DNA; 20 BP.	ID	ADL34613 standard; DNA; 20 BP.
XX		XX	
AC	ADH26792;	AC	ADL34613;
XX		XX	
DT	11-MAR-2004 (first entry)	DT	17-JUN-2004 (first entry)
XX		XX	
DE	Human PI3K regulatory subunit 4, p150 DNA target region #39.	DE	ISIS antisense oligonucleotide ISIS 207005.
XX		XX	
KW	Human; phosphoinositide-3-kinase regulatory subunit 4; p150; PI3K;	XX	antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW	PI3 kinase; ds; antisense oligonucleotide; phosphorothioate linkage;	KW	regulatory subunit 4; p150; internucleoside linkage;
KW	2'-O-methoxyethyl sugar moiety; 5-methylcytosine;	KW	phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW	hyperproliferative disorder; cancer; Chediak-Higashi syndrome;	KW	infection; inflammation; tumour formation; hyperproliferative disorder;
KW	neurodegenerative disorder; metabolic disorders; inflammation;	KW	cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW	cytostatic; immunomodulator; neurodegenerative; antimicrobial;	KW	cytostatic; gene therapy; ss; primer.
KW	antiinflammatory.	XX	Synthetic.
XX		OS	
OS	Homo sapiens.	XX	
XX		PH	Key
XX		FT	modified_base 1..20
XX		FT	/tag= a
XX		FT	/mod_base= OTHER
XX		FT	/note= "phosphorothioate backbone"
XX		XX	
XX	US2003225013-A1.	XX	US2004063657-A1.
XX		XX	
PD	04-DEC-2003.	XX	01-APR-2004.
XX		XX	
PF	31-MAY-2002; 2002US-00160786.	XX	18-SEP-2003; 2003US-00667022.
XX		XX	
PR	31-MAY-2002; 2002US-00160786.	XX	31-MAY-2002; 2002US-00160786.
XX		XX	
PA	(ISIS-) ISIS PHARM INC.	XX	(FREI/) FREIER S. M.
XX		PA	(DOBI/) DOBIE K W.
PI	Freier SM, Dobie KW;	XX	
XX		PI	Freier SM, Dobie KW;
XX		XX	
DR	WPI; 2004-051923/05.	XX	WPI; 2004-282523/26.
XX		XX	
XX	New antisense oligonucleotides inhibiting the expression of	XX	New antisense compound targeted to a nucleic acid molecule encoding
PT	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for	XX	phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT	preventing or treating diseases associated with the subunit, e.g.	PT	treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
PT	hyperproliferative disorders.	XX	
XX		XX	
XX	Example 15; SEQ ID NO 127; 62pp; English.	XX	Example 15; SEQ ID NO 59; 60pp; English.

XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,
CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety.
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX
SQ Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3319 AAACCGTATACCGGTTT 3338
Db 1 AAACCGTATACCGGTTT 20

RESULT 542
ADL34681/C
ID ADL34681 standard; DNA; 20 BP.
XX
AC ADL34681;
DT
DT 17-JUN-2004 (first entry)
XX
DE Phosphoinositide-3-kinase regulatory subunit 4 p150 fragment 124641.
XX
KW antisense; inhibitor; hybridisation; human; phosphoinositide-3-kinase;
KW regulatory subunit 4; p150; internucleoside linkage;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
KW infection; inflammation; tumour formation; hyperproliferative disorder;
KW cancer; Chediak-Higashi syndrome; metabolic disorder; immunomodulator;
KW cytostatic; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN US2004063657-A1.
XX
PD 01-APR-2004.
XX
PF 18-SEP-2003; 2003US-00667022.
XX
PR 31-MAY-2002; 2002US-00160786.
XX
PA (FREI/) FREIER S M.
PA (DOBI/) DOBIE K W.
XX
PI Freier SM, Dobie KW;
XX
DR WPI; 2004-282523/26.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT phosphoinositide-3-kinase, regulatory subunit 4, p150, useful for
PT treating cancer, Chediak-Higashi syndrome or a metabolic disorder.
XX
PS Example 15; SEQ ID NO 127; 60pp; English.
XX
XX This invention describes a novel antisense oligonucleotides which
CC specifically hybridises to and inhibits the expression of human
CC phosphoinositide-3-kinase, regulatory subunit 4, p150. The
CC oligonucleotides comprises at least one modified internucleoside linkage,

CC preferably a phosphorothioate linkage. It also comprises at least one
CC modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety. The
CC antisense oligonucleotide further comprises at least one modified
CC nucleobase, preferably a 5-methylcytosine. The antisense oligonucleotide
CC can be used in diagnostics and as research reagents and kits. It can also
CC be used prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. It can also be used to treat a disease
CC or condition associated with phosphoinositide-3-kinase, regulatory
CC subunit 4, p150, e.g. hyperproliferative disorder, preferably cancer,
CC Chediak-Higashi syndrome or a metabolic disorder. The products of the
CC invention are immunomodulators with cytostatic activity and can be used
CC for gene therapy.

XX
SQ Sequence 20 BP; 8 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3319 AAACCGTATACCGGTTT 3338
Db 20 AAACCGTATACCGGTTT 1

Search completed: August 18, 2005, 08:37:31
Job time : 36 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 08:50:58 ; Search time 45 Seconds
(without alignments)
3.758 Million cell updates/sec

Title: US-10-667-022-4
Perfect score: 5085
Sequence: 1 ggaatccccgggctgcagga.....tcgaagggggggcccggtacc 5085

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 776 seqs, 16629 residues

Total number of hits satisfying chosen parameters: 1552

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 782 summaries

Database : fetchrnpb.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	60	1.2	60	1	US-09-908-975-10633
2	40.6	0.8	50	1	US-10-431-627-3
3	40.6	0.8	50	1	US-10-450-761-6
4	40	0.8	40	1	US-10-661-415-20
5	40	0.8	40	1	US-10-661-415-23
6	40	0.8	40	1	US-10-463-574A-1
7	40	0.8	40	1	US-10-463-574A-2
8	40	0.8	40	1	US-10-661-402-20
9	40	0.8	40	1	US-10-661-402-23
10	38.4	0.8	51	1	US-10-489-136-31
11	35	0.7	35	1	US-10-601-140A-11
12	35	0.7	35	1	US-10-601-140A-12
13	31.4	0.6	33	1	US-10-848-922-98
14	31.4	0.6	33	1	US-10-880-425A-41
15	31.4	0.6	40	1	US-10-450-761-4
16	30	0.6	30	1	US-11-021-367-10
17	28	0.6	29	1	US-10-764-798-8
18	28	0.6	37	1	US-10-085-906-225
19	27.4	0.5	31	1	US-10-933-118-136
20	27	0.5	27	1	US-10-831-778-911
21	27	0.5	36	1	US-10-085-906-294
22	26.8	0.5	31	1	US-10-849-491-1
23	26.8	0.5	32	1	US-10-942-251-29
24	26.4	0.5	28	1	US-10-942-251-8
25	26	0.5	26	1	US-10-160-786-7
26	26	0.5	26	1	US-10-667-022-7
27	26	0.5	26	1	US-10-787-442-38
28	26	0.5	26	1	US-10-969-164-7
29	25.2	0.5	26	1	US-10-969-164-6
30	25.2	0.5	27	1	US-09-859-012-37
31	25.2	0.5	27	1	US-10-838-122-51
32	25.2	0.5	27	1	US-11-015-461-51
33	25	0.5	25	1	US-10-956-157-104782

34	25	0.5	25	1	US-10-956-157-104783	Sequence 104783,
35	25	0.5	25	1	US-10-956-157-104784	Sequence 104784,
36	25	0.5	25	1	US-10-956-157-104785	Sequence 104785,
37	25	0.5	25	1	US-10-956-157-104786	Sequence 104786,
38	25	0.5	25	1	US-10-956-157-104787	Sequence 104787,
39	25	0.5	25	1	US-10-956-157-104788	Sequence 104788,
40	25	0.5	25	1	US-10-956-157-104789	Sequence 104789,
41	25	0.5	25	1	US-10-956-157-104790	Sequence 104790,
42	25	0.5	25	1	US-10-956-157-104791	Sequence 104791,
43	25	0.5	25	1	US-10-956-157-104792	Sequence 104792,
44	25	0.5	25	1	US-10-956-157-104793	Sequence 104793,
45	25	0.5	25	1	US-10-956-157-104794	Sequence 104794,
46	25	0.5	25	1	US-10-956-157-104795	Sequence 104795,
47	25	0.5	25	1	US-10-956-157-104796	Sequence 104796,
48	25	0.5	25	1	US-10-956-157-104797	Sequence 104797,
49	25	0.5	25	1	US-10-956-157-104798	Sequence 104798,
50	25	0.5	25	1	US-10-956-157-104799	Sequence 104799,
51	25	0.5	25	1	US-10-956-157-104800	Sequence 104800,
52	25	0.5	25	1	US-10-956-157-104801	Sequence 104801,
53	25	0.5	25	1	US-10-956-157-104802	Sequence 104802,
54	25	0.5	25	1	US-10-956-157-104803	Sequence 104803,
55	25	0.5	25	1	US-10-956-157-104804	Sequence 104804,
56	25	0.5	25	1	US-10-956-157-104805	Sequence 104805,
57	25	0.5	25	1	US-10-956-157-124169	Sequence 124169,
58	25	0.5	25	1	US-10-956-157-126622	Sequence 126622,
59	25	0.5	25	1	US-10-956-157-128602	Sequence 128602,
60	25	0.5	25	1	US-10-956-157-129535	Sequence 129535,
61	25	0.5	25	1	US-10-956-157-131620	Sequence 131620,
62	25	0.5	25	1	US-10-956-157-133529	Sequence 133529,
63	25	0.5	25	1	US-10-956-157-139829	Sequence 139829,
64	25	0.5	25	1	US-10-956-157-140192	Sequence 140192,
65	25	0.5	25	1	US-10-956-157-144934	Sequence 144934,
66	25	0.5	25	1	US-10-956-157-147843	Sequence 147843,
67	25	0.5	25	1	US-10-956-157-148887	Sequence 148887,
68	25	0.5	25	1	US-10-956-157-149222	Sequence 149222,
69	25	0.5	25	1	US-10-956-157-151977	Sequence 151977,
70	25	0.5	25	1	US-10-956-157-160340	Sequence 160340,
71	25	0.5	25	1	US-10-956-157-163394	Sequence 163394,
72	25	0.5	25	1	US-10-956-157-163576	Sequence 163576,
73	25	0.5	25	1	US-10-956-157-164911	Sequence 164911,
74	25	0.5	25	1	US-10-956-157-165780	Sequence 165780,
75	25	0.5	25	1	US-10-956-157-171456	Sequence 171456,
76	25	0.5	25	1	US-10-956-157-178113	Sequence 178113,
77	25	0.5	25	1	US-10-956-157-182818	Sequence 182818,
78	25	0.5	25	1	US-10-956-157-183524	Sequence 183524,
79	25	0.5	25	1	US-10-956-157-189683	Sequence 189683,
80	25	0.5	25	1	US-10-956-157-196619	Sequence 196619,
81	25	0.5	25	1	US-10-956-157-212316	Sequence 212316,
82	25	0.5	25	1	US-10-956-157-212854	Sequence 212854,
83	25	0.5	25	1	US-10-956-157-228189	Sequence 228189,
84	25	0.5	25	1	US-10-956-157-237441	Sequence 237441,
85	25	0.5	25	1	US-10-956-157-245906	Sequence 245906,
86	25	0.5	25	1	US-10-956-157-247128	Sequence 247128,
87	25	0.5	25	1	US-10-956-157-252174	Sequence 252174,
88	25	0.5	25	1	US-10-956-157-259129	Sequence 259129,
89	25	0.5	25	1	US-10-956-157-269842	Sequence 269842,
90	25	0.5	25	1	US-10-956-157-270613	Sequence 270613,
91	25	0.5	25	1	US-10-956-157-272237	Sequence 272237,
92	25	0.5	25	1	US-10-956-157-273285	Sequence 273285,
93	25	0.5	25	1	US-10-956-157-276167	Sequence 276167,
94	25	0.5	25	1	US-10-956-157-294257	Sequence 294257,
95	25	0.5	25	1	US-10-956-157-306258	Sequence 306258,
96	25	0.5	25	1	US-10-958-348-3	Sequence 3, Appl1
97	25	0.5	25	1	US-10-787-348-4	Sequence 4, Appl1
98	25	0.5	25	1	US-10-787-442-39	Sequence 39, Appl1
99	25	0.5	25	1	US-10-925-448-10	Sequence 10, Appl1
100	24.6	0.5	25	1	US-10-942-251-9	Sequence 9, Appl1
101	24.6	0.5	32	1	US-10-849-491-3	Sequence 3, Appl1
102	24	0.5	24	1	US-10-831-778-433	Sequence 433, App
103	24	0.5	24	1	US-10-831-778-961	Sequence 961, App
104	24	0.5	24	1	US-10-831-778-962	Sequence 962, App
105	24	0.5	24	1	US-10-357-930-14833	Sequence 14833, A
106	24	0.5	24	1	US-10-942-251-3	Sequence 3, Appl1

gibbs-10-667-022-4.rnpb

Thu Aug 18 08:58:56 2005

C 107	24	0.5	28	1	US-10-942-251-12	Sequence 12, Appl	C 180	20	0.4	20	1	US-10-160-786-55	Sequence 55, Appl
C 108	23.4	0.5	25	1	US-10-719-956-529365	Sequence 529365, Appl	C 181	20	0.4	20	1	US-10-160-786-56	Sequence 56, Appl
C 109	23	0.5	23	1	US-10-160-786-5	Sequence 5, Appl	C 182	20	0.4	20	1	US-10-160-786-57	Sequence 57, Appl
C 110	23	0.5	23	1	US-10-160-786-6	Sequence 6, Appl	C 183	20	0.4	20	1	US-10-160-786-58	Sequence 58, Appl
C 111	23	0.5	23	1	US-10-667-022-5	Sequence 5, Appl	C 184	20	0.4	20	1	US-10-160-786-59	Sequence 59, Appl
C 112	23	0.5	23	1	US-10-667-022-6	Sequence 6, Appl	C 185	20	0.4	20	1	US-10-160-786-60	Sequence 60, Appl
C 113	23	0.5	23	1	US-10-948-866D-10	Sequence 10, Appl	C 186	20	0.4	20	1	US-10-160-786-61	Sequence 61, Appl
C 114	22	0.4	24	1	US-10-721-793-285	Sequence 285, Appl	C 187	20	0.4	20	1	US-10-160-786-62	Sequence 62, Appl
C 115	21.8	0.4	25	1	US-10-719-956-45762	Sequence 45762, A	C 188	20	0.4	20	1	US-10-160-786-63	Sequence 63, Appl
C 116	21.8	0.4	25	1	US-10-719-956-150046	Sequence 150046, A	C 189	20	0.4	20	1	US-10-160-786-64	Sequence 64, Appl
C 117	21.8	0.4	25	1	US-10-719-956-159330	Sequence 159330, A	C 190	20	0.4	20	1	US-10-160-786-65	Sequence 65, Appl
C 118	21.8	0.4	25	1	US-10-719-956-529364	Sequence 529364, A	C 191	20	0.4	20	1	US-10-160-786-66	Sequence 66, Appl
C 119	21.2	0.4	27	1	US-10-085-906-78	Sequence 78, Appl	C 192	20	0.4	20	1	US-10-160-786-67	Sequence 67, Appl
C 120	21	0.4	21	1	US-08-805-813-4	Sequence 4, Appl	C 193	20	0.4	20	1	US-10-160-786-68	Sequence 68, Appl
C 121	21	0.4	21	1	US-10-831-778-912	Sequence 912, Appl	C 194	20	0.4	20	1	US-10-160-786-69	Sequence 69, Appl
C 122	21	0.4	21	1	US-10-830-287A-7	Sequence 7, Appl	C 195	20	0.4	20	1	US-10-160-786-70	Sequence 70, Appl
C 123	21	0.4	21	1	US-10-601-140A-43	Sequence 43, Appl	C 196	20	0.4	20	1	US-10-160-786-71	Sequence 71, Appl
C 124	20.4	0.4	26	1	US-10-930-301-4	Sequence 4, Appl	C 197	20	0.4	20	1	US-10-160-786-72	Sequence 72, Appl
C 125	20.4	0.4	26	1	US-10-930-301-44	Sequence 44, Appl	C 198	20	0.4	20	1	US-10-160-786-73	Sequence 73, Appl
C 126	20.4	0.4	26	1	US-10-930-301-98	Sequence 98, Appl	C 199	20	0.4	20	1	US-10-160-786-74	Sequence 74, Appl
C 127	20.2	0.4	22	1	US-10-664-000-3	Sequence 3, Appl	C 200	20	0.4	20	1	US-10-160-786-75	Sequence 75, Appl
C 128	20.2	0.4	22	1	US-10-601-140A-32	Sequence 32, Appl	C 201	20	0.4	20	1	US-10-160-786-76	Sequence 76, Appl
C 129	20.2	0.4	22	1	US-10-719-956-45761	Sequence 45, Appl	C 202	20	0.4	20	1	US-10-160-786-77	Sequence 77, Appl
C 130	20.2	0.4	25	1	US-10-719-956-150045	Sequence 45761, A	C 203	20	0.4	20	1	US-10-160-786-78	Sequence 78, Appl
C 131	20.2	0.4	25	1	US-10-719-956-159329	Sequence 150045, A	C 204	20	0.4	20	1	US-10-160-786-79	Sequence 79, Appl
C 132	20.2	0.4	25	1	US-10-719-956-159329	Sequence 159329, A	C 205	20	0.4	20	1	US-10-160-786-80	Sequence 80, Appl
C 133	20.2	0.4	25	1	US-10-085-906-144	Sequence 415353, A	C 206	20	0.4	20	1	US-10-160-786-81	Sequence 81, Appl
C 134	20.2	0.4	26	1	US-09-976-900A-55	Sequence 144, Appl	C 207	20	0.4	20	1	US-10-160-786-82	Sequence 82, Appl
C 135	20	0.4	20	1	US-10-160-786-11	Sequence 55, Appl	C 208	20	0.4	20	1	US-10-160-786-83	Sequence 83, Appl
C 136	20	0.4	20	1	US-10-160-786-11	Sequence 11, Appl	C 209	20	0.4	20	1	US-10-160-786-84	Sequence 84, Appl
C 137	20	0.4	20	1	US-10-160-786-12	Sequence 12, Appl	C 210	20	0.4	20	1	US-10-160-786-85	Sequence 85, Appl
C 138	20	0.4	20	1	US-10-160-786-13	Sequence 13, Appl	C 211	20	0.4	20	1	US-10-160-786-86	Sequence 86, Appl
C 139	20	0.4	20	1	US-10-160-786-14	Sequence 14, Appl	C 212	20	0.4	20	1	US-10-160-786-87	Sequence 87, Appl
C 140	20	0.4	20	1	US-10-160-786-15	Sequence 15, Appl	C 213	20	0.4	20	1	US-10-160-786-88	Sequence 88, Appl
C 141	20	0.4	20	1	US-10-160-786-16	Sequence 16, Appl	C 214	20	0.4	20	1	US-10-160-786-89	Sequence 89, Appl
C 142	20	0.4	20	1	US-10-160-786-17	Sequence 17, Appl	C 215	20	0.4	20	1	US-10-160-786-90	Sequence 90, Appl
C 143	20	0.4	20	1	US-10-160-786-18	Sequence 18, Appl	C 216	20	0.4	20	1	US-10-160-786-91	Sequence 91, Appl
C 144	20	0.4	20	1	US-10-160-786-19	Sequence 19, Appl	C 217	20	0.4	20	1	US-10-160-786-92	Sequence 92, Appl
C 145	20	0.4	20	1	US-10-160-786-20	Sequence 20, Appl	C 218	20	0.4	20	1	US-10-160-786-93	Sequence 93, Appl
C 146	20	0.4	20	1	US-10-160-786-21	Sequence 21, Appl	C 219	20	0.4	20	1	US-10-160-786-94	Sequence 94, Appl
C 147	20	0.4	20	1	US-10-160-786-22	Sequence 22, Appl	C 220	20	0.4	20	1	US-10-160-786-95	Sequence 95, Appl
C 148	20	0.4	20	1	US-10-160-786-23	Sequence 23, Appl	C 221	20	0.4	20	1	US-10-160-786-96	Sequence 96, Appl
C 149	20	0.4	20	1	US-10-160-786-24	Sequence 24, Appl	C 222	20	0.4	20	1	US-10-160-786-97	Sequence 97, Appl
C 150	20	0.4	20	1	US-10-160-786-25	Sequence 25, Appl	C 223	20	0.4	20	1	US-10-160-786-98	Sequence 98, Appl
C 151	20	0.4	20	1	US-10-160-786-26	Sequence 26, Appl	C 224	20	0.4	20	1	US-10-160-786-99	Sequence 99, Appl
C 152	20	0.4	20	1	US-10-160-786-27	Sequence 27, Appl	C 225	20	0.4	20	1	US-10-160-786-100	Sequence 100, Appl
C 153	20	0.4	20	1	US-10-160-786-28	Sequence 28, Appl	C 226	20	0.4	20	1	US-10-160-786-101	Sequence 101, Appl
C 154	20	0.4	20	1	US-10-160-786-29	Sequence 29, Appl	C 227	20	0.4	20	1	US-10-160-786-102	Sequence 102, Appl
C 155	20	0.4	20	1	US-10-160-786-30	Sequence 30, Appl	C 228	20	0.4	20	1	US-10-160-786-103	Sequence 103, Appl
C 156	20	0.4	20	1	US-10-160-786-31	Sequence 31, Appl	C 229	20	0.4	20	1	US-10-160-786-104	Sequence 104, Appl
C 157	20	0.4	20	1	US-10-160-786-32	Sequence 32, Appl	C 230	20	0.4	20	1	US-10-160-786-105	Sequence 105, Appl
C 158	20	0.4	20	1	US-10-160-786-33	Sequence 33, Appl	C 231	20	0.4	20	1	US-10-160-786-106	Sequence 106, Appl
C 159	20	0.4	20	1	US-10-160-786-34	Sequence 34, Appl	C 232	20	0.4	20	1	US-10-160-786-107	Sequence 107, Appl
C 160	20	0.4	20	1	US-10-160-786-35	Sequence 35, Appl	C 233	20	0.4	20	1	US-10-160-786-108	Sequence 108, Appl
C 161	20	0.4	20	1	US-10-160-786-36	Sequence 36, Appl	C 234	20	0.4	20	1	US-10-160-786-109	Sequence 109, Appl
C 162	20	0.4	20	1	US-10-160-786-37	Sequence 37, Appl	C 235	20	0.4	20	1	US-10-160-786-110	Sequence 110, Appl
C 163	20	0.4	20	1	US-10-160-786-38	Sequence 38, Appl	C 236	20	0.4	20	1	US-10-160-786-111	Sequence 111, Appl
C 164	20	0.4	20	1	US-10-160-786-39	Sequence 39, Appl	C 237	20	0.4	20	1	US-10-160-786-112	Sequence 112, Appl
C 165	20	0.4	20	1	US-10-160-786-40	Sequence 40, Appl	C 238	20	0.4	20	1	US-10-160-786-113	Sequence 113, Appl
C 166	20	0.4	20	1	US-10-160-786-41	Sequence 41, Appl	C 239	20	0.4	20	1	US-10-160-786-114	Sequence 114, Appl
C 167	20	0.4	20	1	US-10-160-786-42	Sequence 42, Appl	C 240	20	0.4	20	1	US-10-160-786-115	Sequence 115, Appl
C 168	20	0.4	20	1	US-10-160-786-43	Sequence 43, Appl	C 241	20	0.4	20	1	US-10-160-786-116	Sequence 116, Appl
C 169	20	0.4	20	1	US-10-160-786-44	Sequence 44, Appl	C 242	20	0.4	20	1	US-10-160-786-117	Sequence 117, Appl
C 170	20	0.4	20	1	US-10-160-786-45	Sequence 45, Appl	C 243	20	0.4	20	1	US-10-160-786-118	Sequence 118, Appl
C 171	20	0.4	20	1	US-10-160-786-46	Sequence 46, Appl	C 244	20	0.4	20	1	US-10-160-786-119	Sequence 119, Appl
C 172	20	0.4	20	1	US-10-160-786-47	Sequence 47, Appl	C 245	20	0.4	20	1	US-10-160-786-120	Sequence 120, Appl
C 173	20	0.4	20	1	US-10-160-786-48	Sequence 48, Appl	C 246	20	0.4	20	1	US-10-160-786-121	Sequence 121, Appl
C 174	20	0.4	20	1	US-10-160-786-49	Sequence 49, Appl	C 247	20	0.4	20	1	US-10-160-786-122	Sequence 122, Appl
C 175	20	0.4	20	1	US-10-160-786-50	Sequence 50, Appl	C 248	20	0.4	20	1	US-10-160-786-123	Sequence 123, Appl
C 176	20	0.4	20	1	US-10-160-786-51	Sequence 51, Appl	C 249	20	0.4	20	1	US-10-160-786-124	Sequence 124, Appl
C 177	20	0.4	20	1	US-10-160-786-52	Sequence 52, Appl	C 250	20	0.4	20	1	US-10-160-786-125	Sequence 125, Appl
C 178	20	0.4	20	1	US-10-160-786-53	Sequence 53, Appl	C 251	20	0.4	20	1	US-10-160-786-126	Sequence 126, Appl
C 179	20	0.4	20	1	US-10-160-786-54	Sequence 54, Appl	C 252	20	0.4	20	1	US-10-160-786-127	Sequence 127, Appl

C 399	20	0.4	1	US-10-667-022-137	Sequence 137, App	C 472	19	0.4	19	1	US-10-940-360-1	Sequence 1, Appli
C 400	20	0.4	20	US-10-667-022-138	Sequence 138, App	C 473	19	0.4	20	1	US-10-728-078-14	Sequence 14, Appl
C 401	20	0.4	20	US-10-667-022-139	Sequence 139, App	C 474	19	0.4	20	1	US-10-620-642-33	Sequence 33, Appl
C 402	20	0.4	20	US-10-667-022-140	Sequence 140, App	C 475	19	0.4	20	1	US-10-831-901A-29731	Sequence 29731, A
C 403	20	0.4	20	US-10-667-022-141	Sequence 141, App	C 476	19	0.4	25	1	US-10-463-881-15	Sequence 15, Appl
C 404	20	0.4	20	US-10-667-022-142	Sequence 142, App	C 477	19	0.4	25	1	US-10-719-900-642313	Sequence 642313,
C 405	20	0.4	20	US-10-667-022-143	Sequence 143, App	C 478	18.8	0.4	22	1	US-10-831-778-61	Sequence 61, Appl
C 406	20	0.4	20	US-10-667-022-144	Sequence 144, App	C 479	18.8	0.4	25	1	US-10-719-900-516700	Sequence 516700,
C 407	20	0.4	20	US-10-667-022-145	Sequence 145, App	C 480	18.8	0.4	25	1	US-10-719-900-899255	Sequence 899255,
C 408	20	0.4	20	US-10-667-022-146	Sequence 146, App	C 481	18.8	0.4	25	1	US-10-719-900-899256	Sequence 899256,
C 409	20	0.4	20	US-10-667-022-147	Sequence 147, App	C 482	18.8	0.4	25	1	US-10-809-189-82442	Sequence 82442, A
C 410	20	0.4	20	US-10-661-415-15	Sequence 15, Appl	C 483	18.8	0.4	25	1	US-10-809-189-108648	Sequence 108648,
C 411	20	0.4	20	US-10-831-778-226	Sequence 226, App	C 484	18.8	0.4	25	1	US-10-809-189-119803	Sequence 119803,
C 412	20	0.4	20	US-10-831-778-556	Sequence 556, App	C 485	18.8	0.4	25	1	US-10-681-773-63115	Sequence 63115, A
C 413	20	0.4	20	US-10-831-778-560	Sequence 560, App	C 486	18.8	0.4	25	1	US-10-719-956-185866	Sequence 185866,
C 414	20	0.4	20	US-10-728-078-23	Sequence 23, Appl	C 487	18.8	0.4	25	1	US-10-719-956-455343	Sequence 455343,
C 415	20	0.4	20	US-10-601-140A-1	Sequence 1, Appli	C 488	18.8	0.4	25	1	US-10-719-956-643653	Sequence 643653,
C 416	20	0.4	20	US-10-601-140A-2	Sequence 2, Appli	C 489	18.8	0.4	25	1	US-10-719-956-643654	Sequence 643654,
C 417	20	0.4	20	US-10-601-140A-3	Sequence 3, Appli	C 490	18.4	0.4	24	1	US-10-831-901A-29730	Sequence 29730, A
C 418	20	0.4	20	US-10-601-140A-4	Sequence 4, Appli	C 491	18.4	0.4	24	1	US-10-374-366-201	Sequence 201, App
C 419	20	0.4	20	US-10-601-140A-6	Sequence 6, Appli	C 492	18	0.4	18	1	US-10-849-072-21	Sequence 21, Appl
C 420	20	0.4	20	US-10-601-140A-7	Sequence 7, Appli	C 493	18	0.4	18	1	US-10-849-072-23	Sequence 23, Appl
C 421	20	0.4	20	US-10-601-140A-8	Sequence 8, Appli	C 494	18	0.4	18	1	US-10-831-778-913	Sequence 913, App
C 422	20	0.4	20	US-10-601-140A-9	Sequence 9, Appli	C 495	18	0.4	18	1	US-10-831-778-939	Sequence 939, App
C 423	20	0.4	20	US-10-601-140A-10	Sequence 10, Appl	C 496	18	0.4	18	1	US-10-776-933-150	Sequence 150, App
C 424	20	0.4	20	US-10-601-140A-23	Sequence 23, Appl	C 497	18	0.4	18	1	US-10-674-159A-112	Sequence 112, App
C 425	20	0.4	20	US-10-601-140A-34	Sequence 34, Appl	C 498	18	0.4	18	1	US-10-776-917-141	Sequence 141, App
C 426	20	0.4	20	US-10-601-140A-44	Sequence 44, Appl	C 499	18	0.4	18	1	US-10-766-096-9	Sequence 9, Appli
C 427	20	0.4	20	US-10-876-086-49	Sequence 49, Appl	C 500	18	0.4	18	1	US-10-638-141-10	Sequence 10, Appl
C 428	20	0.4	20	US-10-831-901A-29732	Sequence 29732, A	C 501	18	0.4	18	1	US-10-776-934-741	Sequence 741, App
C 429	20	0.4	20	US-10-831-901A-29733	Sequence 29733, A	C 502	18	0.4	18	1	US-10-601-140A-24	Sequence 24, Appl
C 430	20	0.4	20	US-10-831-901A-29734	Sequence 29734, A	C 503	18	0.4	18	1	US-10-884-617-2	Sequence 2, Appli
C 431	20	0.4	20	US-10-831-901A-29735	Sequence 29735, A	C 504	18	0.4	18	1	US-10-669-962-27	Sequence 27, Appl
C 432	20	0.4	20	US-10-789-831-22	Sequence 22, Appl	C 505	18	0.4	18	1	US-10-503-120-1	Sequence 1, Appli
C 433	20	0.4	20	US-10-789-831-23	Sequence 23, Appl	C 506	18	0.4	18	1	US-10-503-120-8	Sequence 8, Appli
C 434	20	0.4	20	US-10-789-831-24	Sequence 24, Appl	C 507	18	0.4	18	1	US-10-503-120-9	Sequence 9, Appli
C 435	20	0.4	20	US-10-789-831-25	Sequence 25, Appl	C 508	18	0.4	18	1	US-10-503-120-10	Sequence 10, Appl
C 436	20	0.4	20	US-10-661-402-12	Sequence 12, Appl	C 509	18	0.4	18	1	US-10-503-120-11	Sequence 11, Appl
C 437	20	0.4	20	US-10-661-402-15	Sequence 15, Appl	C 510	18	0.4	18	1	US-10-775-973-10	Sequence 10, Appl
C 438	20	0.4	20	US-10-847-502-10	Sequence 10, Appl	C 511	18	0.4	18	1	US-11-024-428-7	Sequence 7, Appli
C 439	20	0.4	20	US-10-847-502-15	Sequence 15, Appl	C 512	18	0.4	19	1	US-10-913-246-22	Sequence 22, Appl
C 440	20	0.4	20	US-10-847-502-35	Sequence 35, Appl	C 513	18	0.4	19	1	US-10-934-890-22	Sequence 22, Appl
C 441	20	0.4	21	US-10-025-145A-35	Sequence 35, Appl	C 514	18	0.4	20	1	US-10-620-642-34	Sequence 34, Appl
C 442	20	0.4	21	US-10-913-246-23	Sequence 23, Appl	C 515	18	0.4	20	1	US-10-820-642-34	Sequence 34, Appl
C 443	20	0.4	21	US-10-934-890-23	Sequence 23, Appl	C 516	17.8	0.4	21	1	US-10-786-720-113	Sequence 113, App
C 444	20	0.4	21	US-10-394-388A-6	Sequence 6, Appli	C 517	17.4	0.3	20	1	US-10-712-795-850	Sequence 850, App
C 445	20	0.4	24	US-10-688-299-54	Sequence 54, Appl	C 518	17.4	0.3	20	1	US-10-920-612-850	Sequence 850, App
C 446	19.8	0.4	25	US-10-681-773-75257	Sequence 75257, A	C 519	17.4	0.3	20	1	US-10-831-901A-29729	Sequence 29729, A
C 447	19.2	0.4	24	US-09-776-479-60	Sequence 60, Appl	C 520	17.4	0.3	21	1	US-10-374-686-4	Sequence 4, Appli
C 448	19.2	0.4	24	US-09-776-479-60	Sequence 60, Appl	C 521	17.4	0.3	22	1	US-10-412-137-34	Sequence 34, Appl
C 449	19.2	0.4	24	US-10-112-653-54	Sequence 54, Appl	C 522	17.4	0.3	22	1	US-10-723-947-34	Sequence 34, Appl
C 450	19.2	0.4	24	US-10-011-995-60	Sequence 60, Appl	C 523	17.2	0.3	22	1	US-09-263-959-808	Sequence 808, App
C 451	19.2	0.4	24	US-10-011-995-60	Sequence 60, Appl	C 524	17.2	0.3	22	1	US-10-361-002-33	Sequence 33, Appl
C 452	19.2	0.4	24	US-10-314-578-60	Sequence 60, Appl	C 525	17.2	0.3	22	1	US-10-361-004-33	Sequence 3, Appl
C 453	19.2	0.4	24	US-10-831-778-60	Sequence 60, Appl	C 526	17	0.3	17	1	US-08-865-579-5	Sequence 5, Appli
C 454	19.2	0.4	25	US-10-098-263B-76253	Sequence 60, Appl	C 527	17	0.3	17	1	US-09-746-731-5	Sequence 5, Appli
C 455	19.2	0.4	25	US-10-098-263B-76254	Sequence 76253, A	C 528	17	0.3	17	1	US-09-952-768-6	Sequence 6, Appli
C 456	19.2	0.4	25	US-10-098-263B-76254	Sequence 76254, A	C 529	17	0.3	17	1	US-09-944-851-6	Sequence 5, Appli
C 457	19.2	0.4	25	US-10-719-900-18911	Sequence 18911, A	C 530	17	0.3	17	1	US-10-059-749-5	Sequence 5, Appli
C 458	19.2	0.4	25	US-10-719-900-228029	Sequence 228029, A	C 531	17	0.3	17	1	US-10-337-060-6	Sequence 6, Appli
C 459	19.2	0.4	25	US-10-719-900-228030	Sequence 228030, A	C 532	17	0.3	17	1	US-10-668-955-6	Sequence 28, Appl
C 460	19.2	0.4	25	US-10-719-900-286591	Sequence 286591, A	C 533	17	0.3	17	1	US-10-669-962-28	Sequence 29, Appl
C 461	19.2	0.4	25	US-10-719-900-334399	Sequence 334399, A	C 534	17	0.3	18	1	US-10-669-962-29	Sequence 29, Appl
C 462	19.2	0.4	25	US-10-719-900-872675	Sequence 872675, A	C 535	17	0.3	19	1	US-10-669-962-29	Sequence 300, App
C 463	19.2	0.4	25	US-10-719-900-872676	Sequence 872676, A	C 536	17	0.3	19	1	US-10-871-222-300	Sequence 23, Appl
C 464	19.2	0.4	25	US-10-719-900-956708	Sequence 956708, A	C 537	17	0.3	20	1	US-08-809-423A-23	Sequence 23, Appl
C 465	19.2	0.4	25	US-10-719-956-68653	Sequence 68653, A	C 538	17	0.3	20	1	US-10-271-344-23	Sequence 23, Appl
C 466	19.2	0.4	25	US-10-719-956-369528	Sequence 369528, A	C 539	17	0.3	20	1	US-10-148-355A-10	Sequence 10, Appl
C 467	19.2	0.4	25	US-10-719-956-467347	Sequence 467347, A	C 540	17	0.3	22	1	US-10-397-131-7	Sequence 7, Appli
C 468	19.2	0.4	25	US-10-719-956-520734	Sequence 520734, A	C 541	16.8	0.3	20	1	US-10-160-786-72	Sequence 72, Appl
C 469	19	0.4	19	US-10-760-940-1	Sequence 1, Appli	C 542	16.8	0.3	20	1	US-10-667-022-72	Sequence 72, Appl
C 470	19	0.4	19	US-10-913-246-24	Sequence 24, Appl	C 543	16.8	0.3	20	1	US-10-831-901A-29728	Sequence 29728, A
C 471	19	0.4	19	US-10-934-890-24	Sequence 24, Appl	C 544	16.8	0.3	21	1	US-10-274-095-21	Sequence 21, Appl

545	16.8	0.3	21	1	US-10-666-980-12	Sequence 12, Appl	618	15.8	0.3	19	1	US-10-251-117-496	Sequence 496, App
546	16.8	0.3	21	1	US-10-786-720-112	Sequence 112, App	619	15.8	0.3	19	1	US-10-225-023-100	Sequence 100, App
547	16.8	0.3	21	1	US-10-786-720-114	Sequence 114, App	620	15.8	0.3	19	1	US-10-225-023-838	Sequence 838, App
548	16.8	0.3	21	1	US-10-786-720-12304	Sequence 12304, A	621	15.8	0.3	19	1	US-10-349-143-4157	Sequence 4157, Ap
549	16.8	0.3	21	1	US-10-786-720-12306	Sequence 12306, A	622	15.8	0.3	19	1	US-10-883-218-138	Sequence 138, App
550	16.8	0.3	21	1	US-10-751-736-5549	Sequence 5549, Ap	623	15.8	0.3	19	1	US-10-883-218-540	Sequence 540, App
551	16.8	0.3	21	1	US-10-751-736-14784	Sequence 14784, A	624	15.8	0.3	19	1	US-10-892-922-73	Sequence 73, Appl
552	16.8	0.3	21	1	US-10-751-736-18930	Sequence 18930, A	625	15.8	0.3	19	1	US-10-892-922-166	Sequence 166, App
553	16.8	0.3	21	1	US-10-751-736-36929	Sequence 36929, A	626	15.8	0.3	19	1	US-10-923-580-148	Sequence 148, App
554	16.8	0.3	22	1	US-09-972-175-52	Sequence 52, Appl	627	15.8	0.3	19	1	US-10-923-580-296	Sequence 296, App
555	16.8	0.3	22	1	US-10-200-522-52	Sequence 52, Appl	628	15.8	0.3	20	1	US-09-453-234-4	Sequence 4, Appli
556	16.8	0.3	22	1	US-10-855-535-52	Sequence 52, Appl	629	15.8	0.3	20	1	US-09-908-671-6	Sequence 6, Appli
557	16.8	0.3	22	1	US-10-473-683-41	Sequence 41, Appl	630	15.8	0.3	20	1	US-10-094-546-1	Sequence 1, Appli
558	16.8	0.3	22	1	US-10-999-188-52	Sequence 52, Appl	631	15.8	0.3	20	1	US-10-148-844-6	Sequence 6, Appli
559	16.4	0.3	18	1	US-10-108-260A-4995	Sequence 4995, Ap	632	15.8	0.3	20	1	US-10-218-654-143	Sequence 143, App
560	16.4	0.3	18	1	US-10-872-984-5	Sequence 5, Appli	633	15.8	0.3	20	1	US-10-000-213-39	Sequence 39, Appl
561	16.4	0.3	18	1	US-10-872-984-6	Sequence 6, Appli	634	15.8	0.3	20	1	US-10-262-439-143	Sequence 143, App
562	16.4	0.3	18	1	US-10-872-984-7	Sequence 7, Appli	635	15.8	0.3	20	1	US-10-167-241-3	Sequence 3, Appli
563	16.4	0.3	19	1	US-10-800-487-162	Sequence 162, App	636	15.8	0.3	20	1	US-10-108-733-5	Sequence 5, Appli
564	16.4	0.3	19	1	US-10-800-487-328	Sequence 328, App	637	15.8	0.3	20	1	US-10-362-817-13	Sequence 13, Appl
565	16.4	0.3	19	1	US-10-871-222-404	Sequence 404, App	638	15.8	0.3	20	1	US-10-173-718-19	Sequence 19, Appl
566	16.4	0.3	19	1	US-10-871-222-508	Sequence 508, App	639	15.8	0.3	20	1	US-10-173-718-89	Sequence 89, Appl
567	16.4	0.3	20	1	US-10-454-224-29	Sequence 29, Appl	640	15.8	0.3	20	1	US-10-665-216-107	Sequence 107, App
568	16.4	0.3	20	1	US-10-476-021-57	Sequence 57, Appl	641	15.8	0.3	20	1	US-10-292-337-71	Sequence 71, Appl
569	16.4	0.3	21	1	US-09-802-320A-22	Sequence 22, Appl	642	15.8	0.3	20	1	US-10-479-510-1	Sequence 1, Appli
570	16.4	0.3	21	1	US-10-004-378A-153	Sequence 153, App	643	15.8	0.3	20	1	US-10-476-021-138	Sequence 138, App
571	16.4	0.3	21	1	US-10-428-275-390	Sequence 390, App	644	15.8	0.3	20	1	US-10-466-894-1687	Sequence 1687, Ap
572	16.4	0.3	21	1	US-10-786-720-12305	Sequence 12305, A	645	15.8	0.3	20	1	US-10-831-901A-21487	Sequence 21487, A
573	16.4	0.3	21	1	US-10-751-736-53486	Sequence 53486, A	646	15.8	0.3	20	1	US-10-831-901A-21488	Sequence 21488, A
574	16.4	0.3	21	1	US-10-847-918-3425	Sequence 3425, Ap	647	15.8	0.3	20	1	US-10-831-901A-23727	Sequence 23727, A
575	16.2	0.3	21	1	US-10-105-101A-23	Sequence 23, Appl	648	15.8	0.3	20	1	US-10-704-263-84	Sequence 84, Appl
576	16.2	0.3	21	1	US-10-431-599-26	Sequence 26, Appl	649	15.8	0.3	20	1	US-10-825-593-48	Sequence 48, Appl
577	16.2	0.3	21	1	US-10-786-720-3343	Sequence 3343, Ap	650	15.8	0.3	21	1	US-10-931-260-167	Sequence 167, App
578	16.2	0.3	21	1	US-10-786-720-3345	Sequence 3345, Ap	651	15.8	0.3	21	1	US-10-135-629-13	Sequence 13, Appl
579	16.2	0.3	21	1	US-10-786-720-3371	Sequence 3371, Ap	652	15.8	0.3	21	1	US-10-349-143-8727	Sequence 8727, Ap
580	16.2	0.3	21	1	US-10-786-720-4045	Sequence 4045, Ap	653	15.8	0.3	21	1	US-10-479-510-2	Sequence 2, Appli
581	16.2	0.3	21	1	US-10-786-720-4047	Sequence 4047, Ap	654	15.8	0.3	21	1	US-10-786-720-379	Sequence 379, App
582	16.2	0.3	21	1	US-10-786-720-4073	Sequence 4073, Ap	655	15.8	0.3	21	1	US-10-786-720-14848	Sequence 14848, A
583	16.2	0.3	21	1	US-10-786-720-4783	Sequence 4783, Ap	656	15.8	0.3	21	1	US-10-786-720-14850	Sequence 14850, A
584	16.2	0.3	21	1	US-10-786-720-4795	Sequence 4785, Ap	657	15.8	0.3	21	1	US-10-751-736-1933	Sequence 1933, Ap
585	16.2	0.3	21	1	US-10-786-720-4811	Sequence 4811, Ap	658	15.8	0.3	21	1	US-10-751-736-1933	Sequence 1933, Ap
586	16.2	0.3	21	1	US-10-786-720-13221	Sequence 13221, A	659	15.8	0.3	21	1	US-10-751-736-7896	Sequence 7896, Ap
587	16.2	0.3	21	1	US-10-786-720-13756	Sequence 13756, A	660	15.8	0.3	21	1	US-10-751-736-13970	Sequence 13970, A
588	16.2	0.3	21	1	US-10-786-720-13757	Sequence 13757, A	661	15.8	0.3	21	1	US-10-751-736-18927	Sequence 18927, A
589	16.2	0.3	21	1	US-10-786-720-13758	Sequence 13758, A	662	15.8	0.3	21	1	US-10-751-736-21281	Sequence 21281, A
590	16.2	0.3	21	1	US-10-786-720-14484	Sequence 14484, A	663	15.8	0.3	21	1	US-10-751-736-21929	Sequence 21929, A
591	16.2	0.3	21	1	US-10-786-720-17384	Sequence 17384, A	664	15.8	0.3	21	1	US-10-751-736-23285	Sequence 23285, A
592	16.2	0.3	21	1	US-10-786-720-18572	Sequence 18572, A	665	15.8	0.3	21	1	US-10-751-736-36664	Sequence 36664, A
593	16.2	0.3	21	1	US-10-751-736-1936	Sequence 1936, Ap	666	15.8	0.3	21	1	US-10-751-736-44650	Sequence 44650, A
594	16.2	0.3	21	1	US-10-751-736-2183	Sequence 2183, Ap	667	15.8	0.3	21	1	US-10-847-918-3467	Sequence 3467, Ap
595	16.2	0.3	21	1	US-10-751-736-5694	Sequence 5694, Ap	668	15.8	0.3	21	1	US-10-847-918-3467	Sequence 3467, Ap
596	16.2	0.3	21	1	US-10-751-736-19985	Sequence 19985, A	669	15.8	0.3	21	1	US-09-780-533A-63	Sequence 63, Appl
597	16.2	0.3	21	1	US-10-751-736-48150	Sequence 48150, A	670	15.4	0.3	17	1	US-09-780-533A-362	Sequence 362, App
598	16.2	0.3	21	1	US-10-839-686-23	Sequence 23, Appl	671	15.4	0.3	17	1	US-09-780-533A-963	Sequence 963, App
599	16	0.3	16	1	US-10-755-118-94	Sequence 94, Appl	672	15.4	0.3	17	1	US-10-333-429-322	Sequence 322, App
600	16	0.3	17	1	US-09-780-533A-643	Sequence 643, Appl	673	15.4	0.3	18	1	US-10-333-429-322	Sequence 322, App
601	16	0.3	17	1	US-10-608-863-3	Sequence 3, Appli	674	15.4	0.3	20	1	US-09-752-639-98	Sequence 98, Appl
602	16	0.3	17	1	US-10-608-863-4	Sequence 4, Appli	675	15.4	0.3	20	1	US-09-984-198-98	Sequence 98, Appl
603	16	0.3	17	1	US-10-608-863-5	Sequence 5, Appli	676	15.4	0.3	20	1	US-10-238-443-65	Sequence 65, Appl
604	16	0.3	20	1	US-09-380-728A-5	Sequence 5, Appli	677	15.4	0.3	20	1	US-10-188-404-49	Sequence 49, Appl
605	16	0.3	20	1	US-09-945-952A-34	Sequence 34, Appl	678	15.4	0.3	20	1	US-10-309-363-65	Sequence 65, Appl
606	16	0.3	20	1	US-10-233-942-34	Sequence 34, Appl	679	15.4	0.3	20	1	US-10-260-451-6	Sequence 6, Appli
607	16	0.3	20	1	US-10-316-755-44	Sequence 44, Appl	680	15.4	0.3	20	1	US-10-008-789-12	Sequence 12, Appl
608	16	0.3	20	1	US-10-714-796-233	Sequence 233, App	681	15.4	0.3	20	1	US-10-349-143-6200	Sequence 6200, Ap
609	16	0.3	20	1	US-10-607-806-25	Sequence 25, Appl	682	15.4	0.3	20	1	US-10-620-532-9	Sequence 9, Appli
610	16	0.3	20	1	US-10-644-052A-376	Sequence 376, App	683	15.4	0.3	20	1	US-10-481-613-156	Sequence 156, App
611	16	0.3	20	1	US-10-644-052A-377	Sequence 377, App	684	15.4	0.3	20	1	US-10-967-092-98	Sequence 98, Appl
612	16	0.3	21	1	US-09-928-796A-6	Sequence 6, Appli	685	15.4	0.3	20	1	US-11-011-500-98	Sequence 98, Appl
613	16	0.3	21	1	US-09-928-796A-12	Sequence 12, Appl	686	15.2	0.3	17	1	US-10-872-645-29	Sequence 29, Appl
614	16	0.3	21	1	US-10-871-302-36	Sequence 36, Appl	687	15.2	0.3	20	1	US-10-160-786-59	Sequence 59, Appl
615	16	0.3	21	1	US-10-847-918-3424	Sequence 3424, Ap	688	15.2	0.3	20	1	US-10-160-786-127	Sequence 127, App
616	16	0.3	21	1	US-10-847-918-3426	Sequence 3426, Ap	689	15.2	0.3	20	1	US-10-667-022-59	Sequence 59, Appl
617	15.8	0.3	19	1	US-10-251-117-247	Sequence 247, App	690	15.2	0.3	20	1	US-10-667-022-127	Sequence 127, App

; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct
; US-10-431-627-3

Query Match 0.8%; Score 40.6; DB 1; Length 50;
Best Local Similarity 91.5%; Pred. No. 14;
Matches 43; Conservative 0; Mismatches 0; Gaps 0;

QY 5018 AACTCTTAAAAA 5064
||| |||||
DB 50 AAAAAA 4

RESULT 3

US-10-450-761-6/c
; Sequence 6, Application US/10450761
; Publication No. US20040248098A1
; GENERAL INFORMATION:
; APPLICANT: Inoko, Hidetoshi et al.
; TITLE OF INVENTION: METHOD OF DETECTING POLYMORPHISMS IN DNA USING MASS SPECTROMETRY
; FILE REFERENCE: 532842000600
; CURRENT APPLICATION NUMBER: US/10/450,761
; CURRENT FILING DATE: 2003-06-12
; PRIOR APPLICATION NUMBER: PCT/JP01/10892
; PRIOR FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: JP 2000-378091
; PRIOR FILING DATE: 2000-12-12
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized DNA sequence
; US-10-450-761-6

Query Match 0.8%; Score 40.6; DB 1; Length 50;
Best Local Similarity 91.5%; Pred. No. 14;
Matches 43; Conservative 0; Mismatches 0; Gaps 0;

QY 5018 AACTCTTAAAAA 5064
||| |||||
DB 50 AAAAAA 4

RESULT 4

US-10-661-415-20
; Sequence 20, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: JUTEAU, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 20

; LENGTH: 40
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; US-10-661-415-20

Query Match 0.8%; Score 40; DB 1; Length 40;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAA 5064
||| |||||
DB 1 AAAAAA 40

RESULT 5

US-10-661-415-23/c
; Sequence 23, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: JUTEAU, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
; LENGTH: 40
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; US-10-661-415-23

Query Match 0.8%; Score 40; DB 1; Length 40;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAA 5064
||| |||||
DB 40 AAAAAA 1

RESULT 6

US-10-463-574A-1
; Sequence 1, Application US/10463574A
; Publication No. US20040259088A1
; GENERAL INFORMATION:
; APPLICANT: Okamoto, Tadashi
; APPLICANT: Takase, Hiromitsu
; APPLICANT: Hashimoto, Hiroyuki
; TITLE OF INVENTION: A Method for Analyzing RNA Using Time of Flight Secondary Ion Mass
; TITLE OF INVENTION: Spectrometry
; FILE REFERENCE: 03560.003311
; CURRENT APPLICATION NUMBER: US/10/463,574A
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: JP 2002-189838
; PRIOR FILING DATE: 2002-06-28
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 1
; LENGTH: 40
; TYPE: DNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence for Hybridization Test
US-10-463-574A-1

Query Match          0.8%; Score 40; DB 1; Length 40;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5064
    |||
Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 40

RESULT 7
US-10-463-574A-2/c
; Sequence 2, Application US/10463574A
; Publication No. US20040259088A1
; GENERAL INFORMATION:
; APPLICANT: Takase, Hiromitsu
; APPLICANT: Okamoto, Tadashi
; APPLICANT: Hashimoto, Hiroyuki
; TITLE OF INVENTION: A Method for Analyzing RNA Using Time of Flight Secondary Ion Mass Spectrometry
; FILE REFERENCE: 03560.003311
; CURRENT APPLICATION NUMBER: US/10/463,574A
; PRIOR FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: JP 2002-189838
; PRIOR FILING DATE: 2002-06-28
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 40
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence for Hybridization Test
US-10-463-574A-2

Query Match          0.8%; Score 40; DB 1; Length 40;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5064
    |||
Db 40 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 8
US-10-661-402-20
; Sequence 20, Application US/10661402
; Publication No. US20050153912A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
; FILE REFERENCE: 029849/0207
; CURRENT APPLICATION NUMBER: US/10/661,402
; PRIOR FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 20
; LENGTH: 40
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
```

```
US-10-661-402-20

Query Match          0.8%; Score 40; DB 1; Length 40;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5064
    |||
Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 40

RESULT 9
US-10-661-402-23/c
; Sequence 23, Application US/10661402
; Publication No. US20050153912A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
; FILE REFERENCE: 029849/0207
; CURRENT APPLICATION NUMBER: US/10/661,402
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
; LENGTH: 40
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-402-23

Query Match          0.8%; Score 40; DB 1; Length 40;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5064
    |||
Db 40 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 10
US-10-489-136-31
; Sequence 31, Application US/10489136
; Publication No. US20050014150A1
; GENERAL INFORMATION:
; APPLICANT: Atabekov, Joseph
; APPLICANT: Dorokhov, Yurii
; APPLICANT: Skulachev, Maxim
; APPLICANT: Ivanov, Peter
; APPLICANT: Gleba, Yuri
; TITLE OF INVENTION: IDENTIFICATION OF EUKARYOTIC INTERNAL RIBOSOME ENTRY SITE (IRES)
; FILE REFERENCE: 9286.30
; CURRENT APPLICATION NUMBER: US/10/489,136
; CURRENT FILING DATE: 2004-03-02
; PRIOR APPLICATION NUMBER: PCT/EP02/09844
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: DE 101 43 238.0
; PRIOR FILING DATE: 2001-09-04
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 51
; TYPE: DNA
; ORGANISM: Nicotiana tabacum
```


US-10-489-136-31

Query Match 0.8%; Score 38.4; DB 1; Length 51;
 Best Local Similarity 97.5%; Pred. No. 21;
 Matches 39; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5064
 Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 40

RESULT 11

US-10-601-140A-11/c
 ; Sequence 11, Application US/10601140A
 ; Publication No. US20050053942A1
 ; GENERAL INFORMATION:
 ; APPLICANT: KAUPPINEN, SAKARI
 ; APPLICANT: JACOBSEN, NANA
 ; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
 ; FILE REFERENCE: 57764 (71994)
 ; CURRENT APPLICATION NUMBER: US/10/601,140A
 ; CURRENT FILING DATE: 2003-06-20
 ; PRIOR APPLICATION NUMBER: US 60/390,928
 ; PRIOR FILING DATE: 2002-06-24
 ; NUMBER OF SEQ ID NOS: 45
 ; SOFTWARE: PatentIn Ver. 3.2
 ; SEQ ID NO 11
 ; LENGTH: 35
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: oligonucleotide
 US-10-601-140A-11

Query Match 0.7%; Score 35; DB 1; Length 35;
 Best Local Similarity 100.0%; Pred. No. 27;
 Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5059
 Db 35 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 12

US-10-601-140A-12/c
 ; Sequence 12, Application US/10601140A
 ; Publication No. US20050053942A1
 ; GENERAL INFORMATION:
 ; APPLICANT: KAUPPINEN, SAKARI
 ; APPLICANT: JACOBSEN, NANA
 ; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
 ; FILE REFERENCE: 57764 (71994)
 ; CURRENT APPLICATION NUMBER: US/10/601,140A
 ; CURRENT FILING DATE: 2003-06-20
 ; PRIOR APPLICATION NUMBER: US 60/390,928
 ; PRIOR FILING DATE: 2002-06-24
 ; NUMBER OF SEQ ID NOS: 45
 ; SOFTWARE: PatentIn Ver. 3.2
 ; SEQ ID NO 12
 ; LENGTH: 35
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: oligonucleotide
 ; NAME/KEY: modified_base
 ; LOCATION: (16)
 ; OTHER INFORMATION: LNA monomer
 ; FEATURE:

; NAME/KEY: modified_base
 ; LOCATION: (18)
 ; OTHER INFORMATION: LNA monomer
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (20)
 ; OTHER INFORMATION: LNA monomer
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (22)
 ; OTHER INFORMATION: LNA monomer
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (24)
 ; OTHER INFORMATION: LNA monomer
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (26)
 ; OTHER INFORMATION: LNA monomer
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (28)
 ; OTHER INFORMATION: LNA monomer
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (30)
 ; OTHER INFORMATION: LNA monomer
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (32)
 ; OTHER INFORMATION: LNA monomer
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (34)
 ; OTHER INFORMATION: LNA monomer
 ; OTHER INFORMATION: LNA monomer
 US-10-601-140A-12

Query Match 0.7%; Score 35; DB 1; Length 35;
 Best Local Similarity 100.0%; Pred. No. 27;
 Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5059
 Db 35 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 13

US-10-848-922-98
 ; Sequence 98, Application US/10848922
 ; Publication No. US20040235138A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Weisburg, William G.
 ; APPLICANT: Bungo, Jennifer J.
 ; TITLE OF INVENTION: Compositions, Methods and Kits for Determining the Presence of
 ; FILE REFERENCE: Trichomonas vaginalis in a Test Sample
 ; FILE REFERENCE: GPI142-02.UT
 ; CURRENT APPLICATION NUMBER: US/10/848,922
 ; CURRENT FILING DATE: 2004-05-18
 ; PRIOR APPLICATION NUMBER: 60/472,028
 ; PRIOR FILING DATE: 2003-05-19
 ; NUMBER OF SEQ ID NOS: 105
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 98
 ; LENGTH: 33
 ; TYPE: DNA
 ; ORGANISM: Artificial
 ; FEATURE:
 ; OTHER INFORMATION: Polynucleotide having a 3' poly (dA)30 tail and a 5' poly (dT)3
 ; OTHER INFORMATION: flexible linker for use in a capture probe
 US-10-848-922-98

Query Match 0.6%; Score 31.4; DB 1; Length 33;
 Best Local Similarity 97.0%; Pred. No. 51;

Thu Aug 18 08:58:56 2005

gibbs-10-667-022-4.rnpb

```
Matches 32; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5022 TGTAAAAA..... 5054
Db 1 TTTAAAAA..... 33

RESULT 14
US-10-880-425A-41
; Sequence 41, Application US/10880425A
; Publication No. US20050164223A1
; GENERAL INFORMATION:
; APPLICANT: Schalken, Jack A.
; APPLICANT: Smit, Frank
; APPLICANT: Hessels, Daphne
; APPLICANT: Verhaegh, Gerald
; TITLE OF INVENTION: Specific Method of Prostate Cancer Detection Based on PCA3 Gene,
; TITLE OF INVENTION: and Kits Therefor
; FILE REFERENCE: 1619.0190000/JAG/CMB
; CURRENT APPLICATION NUMBER: US/10/880,425A
; CURRENT FILING DATE: 2004-06-30
; PRIOR APPLICATION NUMBER: CA 2,432,365
; PRIOR FILING DATE: 2003-06-30
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 41
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-880-425A-41

Query Match 0.6%; Score 31.4; DB 1; Length 33;
Best Local Similarity 97.0%; Pred. No. 51;
Matches 32; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5022 TGTAAAAA..... 5054
Db 1 TTTAAAAA..... 33

RESULT 15
US-10-450-761-4
; Sequence 4, Application US/10450761
; Publication No. US20040248098A1
; GENERAL INFORMATION:
; APPLICANT: Inoko, Hidetoshi et al.
; TITLE OF INVENTION: METHOD OF DETECTING POLYMORPHISMS IN DNA USING MASS SPECTROMETRY
; FILE REFERENCE: 532842000600
; CURRENT APPLICATION NUMBER: US/10/450,761
; CURRENT FILING DATE: 2003-06-12
; PRIOR APPLICATION NUMBER: PCT/JP01/10892
; PRIOR FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: JP 2000-378091
; PRIOR FILING DATE: 2000-12-12
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 4
; LENGTH: 40
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:an artificially
; OTHER INFORMATION: synthesized DNA sequence
US-10-450-761-4

Query Match 0.6%; Score 31.4; DB 1; Length 40;
Best Local Similarity 97.0%; Pred. No. 63;
Matches 32; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5022 TGTAAAAA..... 5054
Db 1 TTTAAAAA..... 33
```

```
Db 8 TTTAAAAA..... 40

RESULT 16
US-11-021-367-10
; Sequence 10, Application US/11021367
; Publication No. US20050158772A1
; GENERAL INFORMATION:
; APPLICANT: Lockhart, David J.
; APPLICANT: Chee, Mark
; APPLICANT: Gunderson, Kevin
; APPLICANT: Chaoqiang, Lai
; APPLICANT: Wodicka, Lisa
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Lee, Danny
; APPLICANT: Tran, Huu M.
; APPLICANT: Matsuzaki, Hajime
; APPLICANT: McCall, Glenn H.
; TITLE OF INVENTION: NUCLEIC ACID ANALYSIS TECHNIQUES
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Joe Liebeschuetz
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/11/021,367
; FILING DATE: 23-Dec-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/882,649
; FILING DATE: 25-Jun-1997
; APPLICATION NUMBER: US 60/010,471
; FILING DATE: 23-JAN-1996
; APPLICATION NUMBER: US 60/035,170
; FILING DATE: 09-JAN-1997
; APPLICATION NUMBER: PCT/US97/01603
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-019410US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: YES
; (ix) Features:
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-11-021-367-10

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 60;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAA..... 5054
Db 1 AAAAAA..... 30

RESULT 17
```

US-10-764-799-8
; Sequence 8, Application US/10764799
; Publication No. US20040253612A1
; GENERAL INFORMATION:
; APPLICANT: Szostak, Jack W.
; APPLICANT: Roberts, Richard W.
; APPLICANT: Liu, Rihc
; TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
; FILE REFERENCE: FUSIONS
; CURRENT APPLICATION NUMBER: US/10/764,799
; CURRENT FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US/09/247,190
; PRIOR FILING DATE: 1999-02-09
; PRIOR APPLICATION NUMBER: 60/035,963
; PRIOR FILING DATE: 1997-01-21
; PRIOR APPLICATION NUMBER: 60/064,491
; PRIOR FILING DATE: 1997-11-06
; PRIOR APPLICATION NUMBER: 09/007,005
; PRIOR FILING DATE: 1998-01-14
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Translation template
US-10-764-799-8

Query Match 0.6%; Score 28; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5038 AAAAAAAAAAAAAAAAAAAAAAAAC 5065
DB 1 AAAAAAAAAAAAAAAAAAAAAAAAC 28

RESULT 18
US-10-085-906-225/c
; Sequence 225, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 225
; LENGTH: 37
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-225

Query Match 0.6%; Score 28; DB 1; Length 37;
Best Local Similarity 86.1%; Pred. No. 1.1e+02;
Matches 31; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAC 5060
DB 37 AAAAAAAAAAAAAAAAAAAAAAAATATAAATAA 2

RESULT 19
US-10-933-118-136/c
; Sequence 136, Application US/10933118
; Publication No. US20050142580A1
; GENERAL INFORMATION:
; APPLICANT: Kuie, Tay Sun
; APPLICANT: Weiping, Hu
; TITLE OF INVENTION: Methods and Probes for Diagnosing a Gynaecological Condition
; FILE REFERENCE: POF3AUSA
; CURRENT APPLICATION NUMBER: US/10/933,118
; CURRENT FILING DATE: 2004-09-02
; PRIOR APPLICATION NUMBER: US 60/500,072
; PRIOR FILING DATE: 2003-09-03
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 136
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic pcr primer
US-10-933-118-136

Query Match 0.5%; Score 27.4; DB 1; Length 31;
Best Local Similarity 96.6%; Pred. No. 1e+02;
Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5038 AAAAAAAAAAAAAAAAAAAAAAAACT 5066
DB 30 AAAAAAAAAAAAAAAAAAAAAAAAGCT 2

RESULT 20
US-10-831-778-911/c
; Sequence 911, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 911
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-911

Query Match 0.5%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAA 5051
DB 27 AAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 21
US-10-085-906-294
; Sequence 294, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:

```
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; FILE REFERENCE: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
; CURRENT APPLICATION NUMBER: GNN-5343CP2
; CURRENT FILING DATE: 2002-02-27
; PRIOR FILING DATE: 1999-03-25
; PRIOR FILING DATE: 2000-03-24
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 294
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-294

Query Match      0.5%; Score 27; DB 1; Length 36;
Best Local Similarity 85.7%; Pred. No. 1.3e+02;
Matches 30; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5059
Db 2 AAAAAAAAAACAAACAAACAAACAAACAAACAAACAA 36

RESULT 22
US-10-849-491-1
; Sequence 1, Application US/10849491
; Publication No. US20050055167A1
; GENERAL INFORMATION:
; APPLICANT: BHARADWAJ, LALIT M.
; APPLICANT: SHUKLA, AWDHESH KOMAR M.
; APPLICANT: BHONDEKAR, AMOL P.
; APPLICANT: KUMAR, RAKESH P.
; APPLICANT: BAJPAL, RAM PRAKASH
; TITLE OF INVENTION: DNA BASED NUMBER SYSTEM AND ARITHMETIC
; FILE REFERENCE: U 0152019
; CURRENT APPLICATION NUMBER: US/10/849,491
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: DNA bases used to represent integers in DNA based number system
US-10-849-491-1

Query Match      0.5%; Score 26.8; DB 1; Length 31;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5054
Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAACGACCAAAAAA 30

RESULT 23
US-10-942-251-29/c
; Sequence 29, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; FILE REFERENCE: 11639/1
```

```
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-29

Query Match      0.5%; Score 26.8; DB 1; Length 32;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5041 AAAAAAAAAAAAAAAAAAAAAAAAAAACTCGAG 5070
Db 32 AAAAAAAAAAAAAAAAAAAAAAAAAAACTAGTG 3

RESULT 24
US-10-942-251-8/c
; Sequence 8, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-8

Query Match      0.5%; Score 26.4; DB 1; Length 28;
Best Local Similarity 96.4%; Pred. No. 1.1e+02;
Matches 27; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5041 AAAAAAAAAAAAAAAAAAAAAAAAAAACTCG 5068
Db 28 AAAAAAAAAAAAAAAAAAAAAAAAAAACTAG 1

RESULT 25
US-10-160-786-7
; Sequence 7, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Preier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: PCR Probe
US-10-160-786-7

Query Match      0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2447 CTGAGGAATTTGTCATTGTGAAGCT 2472
Db 1 CTGAGGAATTTGTCATTGTGAAGCT 26

RESULT 26
US-10-667-022-7
; Sequence 7, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-667-022-7

Query Match      0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2447 CTGAGGAATTTGTCATTGTGAAGCT 2472
Db 1 CTGAGGAATTTGTCATTGTGAAGCT 26

RESULT 27
US-10-787-442-38/c
; Sequence 38, Application US/10787442
; Publication No. US20040260065A1
; GENERAL INFORMATION:
; APPLICANT: Novak, Julia E.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Foster, Donald C.
; APPLICANT: Holly, Richard D.
; APPLICANT: Gross, Jane A.
; APPLICANT: Johnston, Janet V.
; APPLICANT: Nelson, Andrew J.
; APPLICANT: Dillon, Stacey R.
; APPLICANT: Hammond, Angela K.
; TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
; FILE REFERENCE: 99-16
; CURRENT APPLICATION NUMBER: US/10/787,442
; CURRENT FILING DATE: 2004-02-26
; PRIOR APPLICATION NUMBER: US/09/522,217
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: US 60/123,547
; PRIOR FILING DATE: 1999-03-09
; PRIOR APPLICATION NUMBER: US 60/123,904
; PRIOR FILING DATE: 1999-03-11
; PRIOR APPLICATION NUMBER: US 60/142,013
; PRIOR FILING DATE: 1999-07-01
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 38
; LENGTH: 26
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7764a
US-10-787-442-38

Query Match      0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAAAATTTGTCATTGTGAAGCT 5049
Db 26 TAAAAAATTTGTCATTGTGAAGCT 1

RESULT 28
US-10-969-164-7/c
; Sequence 7, Application US/10969164
; Publication No. US20050065322A1
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
; CURRENT APPLICATION NUMBER: US/10/969,164
; CURRENT FILING DATE: 2004-10-20
; PRIOR APPLICATION NUMBER: US/09/527,345
; PRIOR FILING DATE: 1999-03-17
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7764a
US-10-969-164-7

Query Match      0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAAAATTTGTCATTGTGAAGCT 5049
Db 26 TAAAAAATTTGTCATTGTGAAGCT 1

RESULT 29
US-10-969-164-6/c
; Sequence 6, Application US/10969164
; Publication No. US20050065322A1
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
; CURRENT APPLICATION NUMBER: US/10/969,164
; CURRENT FILING DATE: 2004-10-20
; PRIOR APPLICATION NUMBER: US/09/527,345
; PRIOR FILING DATE: 1999-03-17
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7231
US-10-969-164-6
```

```

; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (27)
; OTHER INFORMATION: a, t, c or g
US-10-838-122-51

Query Match      0.5%; Score 25.2; DB 1; Length 27;
Best Local Similarity 96.2%; Pred. No. 1.3e+02;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5024 TAAAAA 5049
Db 26 BAAAAA 1

RESULT 30
US-09-859-012-37/c
; Sequence 37, Application US/09859012
; Publication No. US20040253632A1
; GENERAL INFORMATION:
; APPLICANT: RHODE, PETER
; APPLICANT: WITTMAN, VAUGHAN
; APPLICANT: WEIDANZ, JON A.
; APPLICANT: BURKHARDT, MARTIN
; APPLICANT: CARD, KIMBERLYN F.
; APPLICANT: TAL, RONY
; APPLICANT: ACEVEDO, JORGE
; APPLICANT: WONG, HING C.
; TITLE OF INVENTION: MODULATION OF T CELL RECEPTOR INTERACTIONS
; FILE REFERENCE: 49444 (71/758)
; CURRENT APPLICATION NUMBER: US/09/859,012
; CURRENT FILING DATE: 2001-05-16
; PRIOR APPLICATION NUMBER: 60/206,920
; PRIOR FILING DATE: 2000-05-25
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; NAME/KEY: modified_base
; LOCATION: (27)
; OTHER INFORMATION: A, C, G, or T
US-09-859-012-37

Query Match      0.5%; Score 25.2; DB 1; Length 27;
Best Local Similarity 96.2%; Pred. No. 1.3e+02;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5024 TAAAAA 5049
Db 26 HAAAAA 1

RESULT 31
US-10-838-122-51/c
; Sequence 51, Application US/10838122
; Publication No. US20050064554A1
; GENERAL INFORMATION:
; APPLICANT: FISHER, LAURENT BERNARD
; APPLICANT: CACHET, NATHALIE MICHELE
; APPLICANT: BARZU-LE-ROUX, SIMONA
; TITLE OF INVENTION: CANINE GHRH GENE, POLYPEPTIDES AND METHODS OF USE
; FILE REFERENCE: MER 03-007
; CURRENT APPLICATION NUMBER: US/10/838,122
; CURRENT FILING DATE: 2004-05-03
; PRIOR APPLICATION NUMBER: 60/467,405
; PRIOR FILING DATE: 2003-05-01
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 51
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (27)
; OTHER INFORMATION: a, t, c or g
US-10-838-122-51

Query Match      0.5%; Score 25.2; DB 1; Length 27;
Best Local Similarity 96.2%; Pred. No. 1.3e+02;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5024 TAAAAA 5049
Db 26 BAAAAA 1

RESULT 32
US-11-015-461-51/c
; Sequence 51, Application US/11015461
; Publication No. US20050164946A1
; GENERAL INFORMATION:
; APPLICANT: FISHER, LAURENT BERNARD
; APPLICANT: CACHET, NATHALIE MICHELE
; APPLICANT: BARZU-LE-ROUX, SIMONA
; TITLE OF INVENTION: CANINE GHRH GENE, POLYPEPTIDES AND METHODS OF USE
; FILE REFERENCE: MER 03-007
; CURRENT APPLICATION NUMBER: US/11/015,461
; CURRENT FILING DATE: 2004-12-17
; PRIOR APPLICATION NUMBER: 60/467,405
; PRIOR FILING DATE: 2003-05-01
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 51
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (27)
; OTHER INFORMATION: a, t, c or g
US-11-015-461-51

Query Match      0.5%; Score 25.2; DB 1; Length 27;
Best Local Similarity 96.2%; Pred. No. 1.3e+02;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5024 TAAAAA 5049
Db 26 BAAAAA 1

RESULT 33
US-10-956-157-104782
; Sequence 104782, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104782
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104782
```

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4446 AATAATTGAAGGCACTGAAGTTGTC 4470
DB 1 AATAATTGAAGGCACTGAAGTTGTC 25

RESULT 34

US-10-956-157-104783
; Sequence 104783, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104783
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104783

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4447 ATAATTGAAGGCACTGAAGTTGTC 4471
DB 1 ATAATTGAAGGCACTGAAGTTGTC 25

RESULT 35

US-10-956-157-104784
; Sequence 104784, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104784
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104784

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4448 TAATTGAAGGCACTGAAGTTGTC 4472
DB 1 TAATTGAAGGCACTGAAGTTGTC 25

RESULT 36

US-10-956-157-104785
; Sequence 104785, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104785
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104785

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4481 AGAATAAGCAGAAAGTAGGACCAAG 4505
DB 1 AGAATAAGCAGAAAGTAGGACCAAG 25

RESULT 37

US-10-956-157-104786
; Sequence 104786, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104786
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104786

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4482 GAATAAGCAGAAAGTAGGACCAAGT 4506
DB 1 GAATAAGCAGAAAGTAGGACCAAGT 25

RESULT 38

US-10-956-157-104787
; Sequence 104787, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104787
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104787

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4480 CAGAATAAGCAGAAAGTAGGACCAA 4504
|||||
DB 1 CAGAATAAGCAGAAAGTAGGACCAA 25

RESULT 39
US-10-956-157-104788
; Sequence 104788, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104788
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104788

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4483 AATAAGCAGAAAGTAGGACCAAGTG 4507
|||||
DB 1 AATAAGCAGAAAGTAGGACCAAGTG 25

RESULT 40
US-10-956-157-104789
; Sequence 104789, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104789
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104789

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4445 AAATAATTGAAGCAGCACTGAAGTTCT 4469
|||||
DB 1 AAATAATTGAAGCAGCACTGAAGTTCT 25

RESULT 41
US-10-956-157-104790
; Sequence 104790, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4480 CAGAATAAGCAGAAAGTAGGACCAA 4504
|||||
DB 1 CAGAATAAGCAGAAAGTAGGACCAA 25

RESULT 39
US-10-956-157-104788
; Sequence 104788, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104788
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104788

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4483 AATAAGCAGAAAGTAGGACCAAGTG 4507
|||||
DB 1 AATAAGCAGAAAGTAGGACCAAGTG 25

RESULT 40
US-10-956-157-104789
; Sequence 104789, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104789
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104789

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4445 AAATAATTGAAGCAGCACTGAAGTTCT 4469
|||||
DB 1 AAATAATTGAAGCAGCACTGAAGTTCT 25

RESULT 41
US-10-956-157-104790
; Sequence 104790, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4478 TTCAGAAATAAGCAGAAAGTAGGACC 4502
|||||
DB 1 TTCAGAAATAAGCAGAAAGTAGGACC 25

RESULT 42
US-10-956-157-104791
; Sequence 104791, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104791
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104790

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4478 TTCAGAAATAAGCAGAAAGTAGGACC 4502
|||||
DB 1 TTCAGAAATAAGCAGAAAGTAGGACC 25

RESULT 42
US-10-956-157-104791
; Sequence 104791, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104791
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104791

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4479 TCAGAAATAAGCAGAAAGTAGGACCA 4503
|||||
DB 1 TCAGAAATAAGCAGAAAGTAGGACCA 25

RESULT 43
US-10-956-157-104792
; Sequence 104792, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104792
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104792

Query Match 0.5%; Score 25; DB 1; Length 25;


```
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4465 GTGTCCAGGAATTCAGATAAGC 4489
      |||||||
Db 1 GTGTCCAGGAATTCAGATAAGC 25

RESULT 44
US-10-956-157-104793
; Sequence 104793, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104793
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104793

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4466 TTGTCCAGGAATTCAGATAAGCA 4490
      |||||||
Db 1 TTGTCCAGGAATTCAGATAAGCA 25

RESULT 45
US-10-956-157-104794
; Sequence 104794, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104794
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104794

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4621 GGGATTGTGAAGTGTGGAATAAA 4645
      |||||||
Db 1 GGGATTGTGAAGTGTGGAATAAA 25

RESULT 46
US-10-956-157-104795
; Sequence 104795, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104795
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104795

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4485 TAAGCAGAAAGTAGGACCAAGTGAT 4509
      |||||||
Db 1 TAAGCAGAAAGTAGGACCAAGTGAT 25

RESULT 47
US-10-956-157-104796
; Sequence 104796, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104796
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104796

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4484 ATAAGCAGAAAGTAGGACCAAGTGA 4508
      |||||||
Db 1 ATAAGCAGAAAGTAGGACCAAGTGA 25

RESULT 48
US-10-956-157-104797
; Sequence 104797, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104797
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104797

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4484 ATAAGCAGAAAGTAGGACCAAGTGA 4508
      |||||||
Db 1 ATAAGCAGAAAGTAGGACCAAGTGA 25
```

```
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4468 GTCCAGGAATTCAGAATAAGCAGA 4492
Db 1 GTCCAGGAATTCAGAATAAGCAGA 25

RESULT 49
US-10-956-157-104798
; Sequence 104798, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104798
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104798

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4469 TCCAGGAATTCAGAATAAGCAGAA 4493
Db 1 TCCAGGAATTCAGAATAAGCAGAA 25

RESULT 50
US-10-956-157-104799
; Sequence 104799, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104799
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104799

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4470 CCAGGAATTCAGAATAAGCAGAAA 4494
Db 1 CCAGGAATTCAGAATAAGCAGAAA 25

RESULT 51
US-10-956-157-104800
; Sequence 104800, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104800
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104800

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4467 TGTCAGGAATTCAGAATAAGCAG 4491
Db 1 TGTCAGGAATTCAGAATAAGCAG 25

RESULT 52
US-10-956-157-104801
; Sequence 104801, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104801
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104801

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4464 AGTTGCCAGGAATTCAGAATAAG 4488
Db 1 AGTTGCCAGGAATTCAGAATAAG 25

RESULT 53
US-10-956-157-104802
; Sequence 104802, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104802
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104802

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 4462 GAAGTTGTCAGGAAATTCAGAATA 4486
|||||
Db 1 GAAGTTGTCAGGAAATTCAGAATA 25

RESULT 54
US-10-956-157-104803
; Sequence 104803, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104803

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4463 AAGTTGTCAGGAAATTCAGAATAA 4487
|||||
Db 1 AAGTTGTCAGGAAATTCAGAATAA 25

RESULT 55
US-10-956-157-104804
; Sequence 104804, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104804
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104804

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4472 AGGAATTCAGATAGCAGAAAGT 4496
|||||
Db 1 AGGAATTCAGATAGCAGAAAGT 25

RESULT 56
US-10-956-157-104805
; Sequence 104805, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
```

```
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 104805
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-104805

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4771 ACTGACTGACTAAATGACACCCCAA 4795
|||||
Db 1 ACTGACTGACTAAATGACACCCCAA 25

RESULT 57
US-10-956-157-124169
; Sequence 124169, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 124169
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-124169

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4757 ATTACTGTTTCATGACTGACTGACT 4781
|||||
Db 1 ATTACTGTTTCATGACTGACTGACT 25

RESULT 58
US-10-956-157-126622
; Sequence 126622, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 126622
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-126622

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4757 ATTACTGTTTCATGACTGACTGACT 4781
|||||
Db 1 ATTACTGTTTCATGACTGACTGACT 25

RESULT 59
US-10-956-157-126622
; Sequence 126622, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 126622
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-126622

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 4685 ATACTATACTCGAGAAAGGCATT 4709
|||||
Db 1 ATACTATACTCGAGAAAGGCATT 25

RESULT 59

US-10-956-157-128602
; Sequence 128602, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 128602
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-128602

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4600 ATCGTAACCTGCTTCTAGAGATGGGA 4624
|||||
Db 1 ATCGTAACCTGCTTCTAGAGATGGGA 25

RESULT 60

US-10-956-157-129535
; Sequence 129535, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 129535
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-129535

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4425 ATCTGTGCTCTACTACGAAATA 4449
|||||
Db 1 ATCTGTGCTCTACTACGAAATA 25

RESULT 61

US-10-956-157-131620
; Sequence 131620, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 131620
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-131620

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4768 ATGACTGACTGACTAAATGACACC 4792
|||||
Db 1 ATGACTGACTGACTAAATGACACC 25

RESULT 62

US-10-956-157-133529
; Sequence 133529, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 133529
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-133529

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4619 ATGGATTGTGAAGGTGGAAATA 4643
|||||
Db 1 ATGGATTGTGAAGGTGGAAATA 25

RESULT 63

US-10-956-157-139829
; Sequence 139829, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 139829
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-139829

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4953 AGATGGTTGTGAAGCTATTATAGTAT 4977

```
Db      1 AGATGGTTGTAAGCTATTAGTAT 25
|||||
RESULT 64
US-10-956-157-140192
; Sequence 140192, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 140192
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-140192

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4713 AGAGAACAGATTCATTGCTTAATT 4737
|||||
Db      1 AGAGAACAGATTCATTGCTTAATT 25
|||||

RESULT 65
US-10-956-157-144934
; Sequence 144934, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 144934
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-144934

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4585 ACCACACAGGGCTTCATCGTAACGT 4609
|||||
Db      1 ACCACACAGGGCTTCATCGTAACGT 25
|||||

RESULT 66
US-10-956-157-147843
; Sequence 147843, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
```

```
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 147843
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-147843

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4775 ACTGACTAAATGACACCCCAAAATGG 4799
|||||
Db      1 ACTGACTAAATGACACCCCAAAATGG 25
|||||

RESULT 67
US-10-956-157-148887
; Sequence 148887, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 148887
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-148887

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4760 ACTGTTTCATGACTGACTGACTAAA 4784
|||||
Db      1 ACTGTTTCATGACTGACTGACTAAA 25
|||||

RESULT 68
US-10-956-157-149222
; Sequence 149222, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 149222
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-149222

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4771 ACTGACTGACTAAATGACACCCAAA 4795
|||||
```

Db 1 ACTGACTGACTAAATGACACCCAAA 25

RESULT 69

US-10-956-157-151977

; Sequence 151977, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 151977

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-151977

Query Match 0.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4590 ACAGGGCTTCATCGTAAGTCTCT 4614

Db 1 ACAGGGCTTCATCGTAAGTCTCT 25

RESULT 70

US-10-956-157-160340

; Sequence 160340, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 160340

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-160340

Query Match 0.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4605 AACTGCTTCTAGAGATGGATTTGTG 4629

Db 1 AACTGCTTCTAGAGATGGATTTGTG 25

RESULT 71

US-10-956-157-163394

; Sequence 163394, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 163394

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-163394

Query Match 0.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4795 AATGGTTAAGATGTACTTGACTAGT 4819

Db 1 AATGGTTAAGATGTACTTGACTAGT 25

RESULT 72

US-10-956-157-163576

; Sequence 163576, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 163576

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-163576

Query Match 0.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4503 AAGTGATGACACCCCTCGAAGGGGC 4527

Db 1 AAGTGATGACACCCCTCGAAGGGGC 25

RESULT 73

US-10-956-157-164911

; Sequence 164911, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 164911

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-164911

Query Match 0.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4702 AAGCATTTCTAGAGACAGATTCA 4726

Db 1 AAGCATTTCTAGAGACAGATTCA 25

```
RESULT 74
US-10-956-157-165780
; Sequence 165780, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 165780
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-165780

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4999 AATGCTATTCAAAGCAGTTAAACTG 5023
      |||||
Db 1 AATGCTATTCAAAGCAGTTAAACTG 25

RESULT 75
US-10-956-157-171456
; Sequence 171456, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 171456
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-171456

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4999 AATGCTATTCAAAGCAGTTAAACTG 5023
      |||||
Db 1 AATGCTATTCAAAGCAGTTAAACTG 25

RESULT 76
US-10-956-157-178113
; Sequence 178113, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 178113
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-178113

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4552 CATGACATCATCTACTGTCGCCA 4576
      |||||
Db 1 CATGACATCATCTACTGTCGCCA 25

RESULT 77
US-10-956-157-182818
; Sequence 182818, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 182818
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-182818

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4834 CTTTGCAAGAAATCAGCCAGCCCAACA 4858
      |||||
Db 1 CTTTGCAAGAAATCAGCCAGCCCAACA 25

RESULT 78
US-10-956-157-183524
; Sequence 183524, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 183524
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-183524

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4815 CTAGTTTACTTATGTCATCTCTTTGC 4839
      |||||
Db 1 CTAGTTTACTTATGTCATCTCTTTGC 25
```

```
RESULT 79
US-10-956-157-189683
; Sequence 189683, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189683
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-189683

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4863 CTGGGATTTTATTGTATATGTTAT 4887
Db      1 CTGGGATTTTATTGTATATGTTAT 25

RESULT 80
US-10-956-157-196619
; Sequence 196619, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 196619
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-196619

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4863 CTGGGATTTTATTGTATATGTTAT 4887
Db      1 CTGGGATTTTATTGTATATGTTAT 25

RESULT 81
US-10-956-157-212316
; Sequence 212316, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 212316
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-212316

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4541 CCGTGGGACATCATGCATCATCAC 4565
Db      1 CCGTGGGACATCATGCATCATCAC 25

RESULT 82
US-10-956-157-212854
; Sequence 212854, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 212854
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-212854

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4595 GCTTCATCGTAACGCTTCTAGAGA 4619
Db      1 GCTTCATCGTAACGCTTCTAGAGA 25

RESULT 83
US-10-956-157-228189
; Sequence 228189, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 228189
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228189

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4813 GACTAGTTTACTTATGCATCTCTTT 4837
Db      1 GACTAGTTTACTTATGCATCTCTTT 25
```

```
; SEQ ID NO 212316
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-212316

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4595 GCTTCATCGTAACGCTTCTAGAGA 4619
Db      1 GCTTCATCGTAACGCTTCTAGAGA 25

RESULT 82
US-10-956-157-212854
; Sequence 212854, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 212854
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-212854

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4828 GCATCTCTTTGCAAGAATCAGCCAG 4852
Db      1 GCATCTCTTTGCAAGAATCAGCCAG 25

RESULT 83
US-10-956-157-228189
; Sequence 228189, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 228189
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228189

Query Match      0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4813 GACTAGTTTACTTATGCATCTCTTT 4837
Db      1 GACTAGTTTACTTATGCATCTCTTT 25
```


RESULT 84

US-10-956-157-237441
; Sequence 237441, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 237441
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-237441

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4804 GATGACTTGCATCTCTTTTCTTATG 4828
|||||
DB 1 GATGACTTGCATCTCTTTTCTTATG 25

RESULT 85

US-10-956-157-245906
; Sequence 245906, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 245906
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-245906

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4818 GTTACTTATGCATCTCTTTTGCAG 4842
|||||
DB 1 GTTACTTATGCATCTCTTTTGCAG 25

RESULT 86

US-10-956-157-247128
; Sequence 247128, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 247128

; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-247128

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4495 GTAGGACCAAGTCATGACACCCCTC 4519
|||||
DB 1 GTAGGACCAAGTCATGACACCCCTC 25

RESULT 87

US-10-956-157-252174
; Sequence 252174, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 252174
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-252174

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4749 GTCTCCATATTACTGTTTCATGACT 4773
|||||
DB 1 GTCTCCATATTACTGTTTCATGACT 25

RESULT 88

US-10-956-157-259129
; Sequence 259129, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 259129
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-259129

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4545 GGGACATCATGACATCATCATGAT 4569
|||||
DB 1 GGGACATCATGACATCATCATGAT 25

RESULT 89

```
US-10-956-157-269842
; Sequence 269842, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 269842
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-269842
Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4637 GGAATAAACCCTACTGATTGTAT 4661
Db 1 GGAATAAACCCTACTGATTGTAT 25
RESULT 90
US-10-956-157-270613
; Sequence 270613, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 270613
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-270613
Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4442 GGAAATAATTGAAGCCTGAAGT 4466
Db 1 GGAAATAATTGAAGCCTGAAGT 25
RESULT 91
US-10-956-157-272237
; Sequence 272237, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 272237
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-272237
Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4442 GGAAATAATTGAAGCCTGAAGT 4466
Db 1 GGAAATAATTGAAGCCTGAAGT 25
```

```
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-272237
Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4456 GGCACCTGAAGTTGTCAGGAAATTC 4480
Db 1 GGCACCTGAAGTTGTCAGGAAATTC 25
RESULT 92
US-10-956-157-273285
; Sequence 273285, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 273285
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-273285
Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4594 GGCTTCATCGTAACCTGCTTCTAGAG 4618
Db 1 GGCTTCATCGTAACCTGCTTCTAGAG 25
RESULT 93
US-10-956-157-276167
; Sequence 276167, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 276167
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-276167
Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4506 TGATGACACCCCTCGAAGGGGCCCA 4530
Db 1 TGATGACACCCCTCGAAGGGGCCCA 25
RESULT 94
US-10-956-157-294257
```

```
; Sequence 294257, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 294257
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-294257

Query Match          0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4831 TCTCTTTCGAAGATCAGCCAGCCA 4855
Db      1 TCTCTTTCGAAGATCAGCCAGCCA 25

RESULT 95
US-10-956-157-306258
; Sequence 306258, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 306258
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-306258

Query Match          0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4746 TATGTCCTCCATATTACTGTTTCATG 4770
Db      1 TATGTCCTCCATATTACTGTTTCATG 25

RESULT 96
US-10-958-348-3
; Sequence 3, Application US/10958348
; Publication No. US20050158738A1
; GENERAL INFORMATION:
; APPLICANT: Okamura, Nobuyuki
; APPLICANT: Kameyama, Makoto
; TITLE OF INVENTION: Probe Carrier, Probe Fixing Carrier and Method of Manufacturing t
; CURRENT FILING DATE: 2004-10-06
; PRIOR APPLICATION NUMBER: US 10/958,348
; PRIOR FILING DATE: 2002-04-29
; PRIOR APPLICATION NUMBER: JP 2001-133698
; PRIOR FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: JP 2001-133697
```

```
; PRIOR FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Target sequence to be hybridized with a probe sequence
US-10-958-348-3

Query Match          0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAA 5049
Db      1 AAAAAAAAAAAAAAAAAAAAAAAAAA 25

RESULT 97
US-10-958-348-4/c
; Sequence 4, Application US/10958348
; Publication No. US20050158738A1
; GENERAL INFORMATION:
; APPLICANT: Okamura, Nobuyuki
; APPLICANT: Kameyama, Makoto
; TITLE OF INVENTION: Probe Carrier, Probe Fixing Carrier and Method of Manufacturing t
; FILE REFERENCE: 03500.016371.1
; CURRENT FILING DATE: 2004-10-06
; PRIOR APPLICATION NUMBER: US 10/133,675
; PRIOR FILING DATE: 2002-04-29
; PRIOR APPLICATION NUMBER: JP 2001-133698
; PRIOR FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: JP 2001-133697
; PRIOR FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Probe sequence to be hybridized with a target sequence
US-10-958-348-4

Query Match          0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAA 5049
Db      25 AAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 98
US-10-787-442-39/c
; Sequence 39, Application US/10787442
; Publication No. US20040260065A1
; GENERAL INFORMATION:
; APPLICANT: Novak, Julia E.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Foster, Donald D.
; APPLICANT: Holly, Richard D.
; APPLICANT: Gross, Jane A.
; APPLICANT: Johnston, Janet V.
; APPLICANT: Nelson, Andrew J.
; APPLICANT: Dillon, Stacey R.
; APPLICANT: Hammond, Angela K.
; TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
```

```

; FILE REFERENCE: 99-16
; CURRENT APPLICATION NUMBER: US/10/787,442
; CURRENT FILING DATE: 2004-02-26
; PRIOR APPLICATION NUMBER: US/09/522,217
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: US 60/123,547
; PRIOR FILING DATE: 1999-03-09
; PRIOR APPLICATION NUMBER: US 60/123,904
; PRIOR FILING DATE: 1999-03-11
; PRIOR APPLICATION NUMBER: US 60/142,013
; PRIOR FILING DATE: 1999-07-01
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7764b
US-10-787-442-39

Query Match          0.5%; Score 25; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5049
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 99
US-10-925-448-10/c
; Sequence 10, Application US/10925448
; Publication No. US20050019820A1
; GENERAL INFORMATION:
; APPLICANT: BILLING-MEDEL, PATRICIA
; COHEN, MAURICE
; COLPITTS, TRACEY L.
; FRIEDMAN, PAULA N.
; KLASS, MICHAEL R.
; RUSSELL, JOHN C.
; STROUPE, STEPHEN D.
; TITLE OF INVENTION: REAGENTS AND METHODS USEFUL
; FOR DETECTING DISEASES OF THE LUNG
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Road
; CITY: Abbott Park
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/925,448
; FILING DATE: 25-Aug-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/092,296
; FILING DATE: 05-JUNE-1998
; APPLICATION NUMBER: 60/048,810
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Becker, Cheryl L.
; REGISTRATION NUMBER: 35,441
; REFERENCE/DOCKET NUMBER: 6104.US.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 847/935-1729
; TELEFAX: 847/938-2623

```

```

; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-925-448-10

Query Match          0.5%; Score 25; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5049
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 100
US-10-942-251-9/c
; Sequence 9, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; NUCLEIC ACIDS INTO CIRCULAR VECTORS
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-9

Query Match          0.5%; Score 24.6; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.4e+02;
Matches 24; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5041 AAAAAAAAAAAAAAAAAAAAAA 5065
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 101
US-10-849-491-3
; Sequence 3, Application US/10849491
; Publication No. US20050055167A1
; GENERAL INFORMATION:
; APPLICANT: BHARADWAJ, LALIT M.
; APPLICANT: SHUKLA, AWDHESH KUMAR M.
; APPLICANT: BHONDEKAR, AMOL P.
; APPLICANT: KUMAR, RAKESH P.
; APPLICANT: BAJPAL, RAM PRAKASH
; TITLE OF INVENTION: DNA BASED NUMBER SYSTEM AND ARITHMETIC
; FILE REFERENCE: U 0152019
; CURRENT APPLICATION NUMBER: US/10/849,491
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: DNA bases used to represent integers in DNA based number system

```

US-10-849-491-3

Query Match 0.5%; Score 24.6; DB 1; Length 32;
Best Local Similarity 87.1%; Pred. No. 1.8e+02;
Matches 27; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 5024 TAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5054
DB 1 TAAAAAAAAAAAAAAAAAAAAAAAAATCTTAAAAAAAA 31

RESULT 102

US-10-831-778-433/c
; Sequence 433, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 433
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-433

Query Match 0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5048
DB 24 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 103

US-10-831-778-961/c
; Sequence 961, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 961
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-961

Query Match 0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5048
DB 24 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 104

US-10-831-778-962
; Sequence 962, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 962
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-962

Query Match 0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5048
DB 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 24

RESULT 105

US-10-357-930-14833/c
; Sequence 14833, Application US/10357930
; Publication No. US20040259086A1
; GENERAL INFORMATION:
; APPLICANT: Schlegel, Robert
; APPLICANT: Endegge, Wilson
; APPLICANT: Monahan, John
; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR
; TITLE OF INVENTION: IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF
; FILE REFERENCE: MRI-007BCN
; CURRENT APPLICATION NUMBER: US/10/357,930
; CURRENT FILING DATE: 2003-02-04
; PRIOR APPLICATION NUMBER: 09/785,276
; PRIOR FILING DATE: 2003-02-16
; PRIOR APPLICATION NUMBER: 60/183,319
; PRIOR FILING DATE: 2000-02-17
; PRIOR APPLICATION NUMBER: 60/189,862
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/207,454
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: 60/211,314
; PRIOR FILING DATE: 2000-06-09
; PRIOR APPLICATION NUMBER: 60/219,007
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: 60/255,281
; PRIOR FILING DATE: 2000-12-13
; NUMBER OF SEQ ID NOS: 62232
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14833
; LENGTH: 24
; TYPE: DNA

```
; ORGANISM: Homo sapiens
US-10-357-930-14833

Query Match          0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 106
US-10-942-251-3/c
; Sequence 3, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-3

Query Match          0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 107
US-10-942-251-12/c
; Sequence 12, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-12

Query Match          0.5%; Score 24; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1
```

```
Db 28 AAAAAAAAAAAAAAAAAAAAAA 5

RESULT 108
US-10-719-956-529365
; Sequence 529365, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 529365
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-529365

Query Match          0.5%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4495 GTAGGACCAAGTGATGACACCCCTC 4519
Db 1 GTTGACCAAGTGATGACACCCCTC 25

RESULT 109
US-10-160-786-5
; Sequence 5, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 5
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-160-786-5

Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2422 CTGCTGCACCAAGTCTTAGTGA 2444
Db 1 CTGCTGCACCAAGTCTTAGTGA 23

RESULT 110
US-10-160-786-6/c
; Sequence 6, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
```

; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 6
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-160-786-6

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2476 TATGCCCTTACTTGTATGTGCCA 2498
|||
DB 23 TATGCCCTTACTTGTATGTGCCA 1

RESULT 111

US-10-667-022-5
; Sequence 5, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 5
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-667-022-5

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2422 CTGCTGCAACAAGTCTTAGTGA 2444
|||
DB 1 CTGCTGCAACAAGTCTTAGTGA 23

RESULT 112

US-10-667-022-6/c
; Sequence 6, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 6
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-667-022-6

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2476 TATGCCCTTACTTGTATGTGCCA 2498
|||
DB 23 TATGCCCTTACTTGTATGTGCCA 1

RESULT 113

US-10-048-866D-10/c
; Sequence 10, Application US/10048866D
; Publication No. US20050003476A1
; GENERAL INFORMATION:
; APPLICANT: SUNTORY LIMITED
; TITLE OF INVENTION: Novel gene encoding glycosyltransferase
; FILE REFERENCE: 1003552
; CURRENT APPLICATION NUMBER: US/10/048,866D
; CURRENT FILING DATE: 2002-02-04
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Primer
US-10-048-866D-10

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5048 AAAAAAAAAAAAAAAAAAAGTCGAG 5070
|||
DB 23 AAAAAAAAAAAAAAAAAAAGTCGAG 1

RESULT 114

US-10-721-793-285/c
; Sequence 285, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerra Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; FILE REFERENCE: 2099.0070001
; CURRENT APPLICATION NUMBER: US/10/721,793
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 285
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PCR Reverse oligonucleotide primer
; NAME/KEY: misc feature
; LOCATION: (23)..(23)
; OTHER INFORMATION: n is a, t, g, or c
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: (1)..(24)
; OTHER INFORMATION: oligonucleotide T22NN
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (24)..(24)
; OTHER INFORMATION: n is a, t, g, or c

US-10-721-793-285

Query Match 0.4%; Score 22; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5046
|||||
DB 22 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 115

US-10-719-956-45762
; Sequence 45762, Application US/10719956
; Publication No. US20040146910A1

GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 45762
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-45762

Query Match 0.4%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4454 AAGGCACTGAAGTTCTCCAGGAAT 4478
|||||
DB 1 AAGGCACGAGGTTCTCCAGGAAT 25

RESULT 116

US-10-719-956-150046
; Sequence 150046, Application US/10719956
; Publication No. US20040146910A1

GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 150046
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-150046

Query Match 0.4%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4592 AGGGCTTCATGTAACGTCTCTAG 4616
|||||
DB 1 AGGGCTTCATGTAACGTCTCTAG 25

RESULT 117

US-10-719-956-159330
; Sequence 159330, Application US/10719956
; Publication No. US20040146910A1

GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 159330
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-159330

Query Match 0.4%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4532 AGTCCTGCCCGTGGGACATCATGA 4556
|||||
DB 1 AGTCCTGCCCGTGGGACATCATGA 25

RESULT 118

US-10-719-956-529364
; Sequence 529364, Application US/10719956
; Publication No. US20040146910A1

GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 529364
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-529364

Query Match 0.4%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4495 GTAGGACCAAGTGATGACACCCCTC 4519
|||||
DB 1 GTTGGACCAAGTGATGACACCCCTC 25

RESULT 119

US-10-085-906-78/c
; Sequence 78, Application US/10085906
; Publication No. US20030054371A1

GENERAL INFORMATION:

; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; FILE OF INVENTION: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	5025	AAAAAAAAAAAAAAAAAAAA	5045
Dp	21	AAAAAAAAAAAAAAAAAAAA	1

```
RESULT 123
US-10-601-140A-43
; Sequence 43, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: NUCLEOTIDE SEQUENCE
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 43
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-601-140A-43

Query Match          0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5045
Db 1 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 124
US-10-930-301-4
; Sequence 4, Application US/10930301
; Publication No. US20050026207A1
; GENERAL INFORMATION:
; APPLICANT: Issa, Jean-Pierre
; TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
; FILE REFERENCE: JHU1590
; CURRENT APPLICATION NUMBER: US/10/930,301
; CURRENT FILING DATE: 2004-08-30
; PRIOR APPLICATION NUMBER: US/09/398,522
; PRIOR FILING DATE: 1999-09-15
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Bisulfite-PCR primer
; NAME/KEY: misc_feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: r = G or A
US-10-930-301-4

Query Match          0.4%; Score 20.4; DB 1; Length 26;
Best Local Similarity 87.5%; Pred. No. 3.1e+02;
Matches 21; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 5044 AAAAAAAAAAAAAAAAAAACTC 5067
Db 1 ACRAAAAAAAAAAAAAAAAAATCTC 24

RESULT 125
US-10-930-301-98/c
; Sequence 98, Application US/10930301
; Publication No. US20050026207A1
; GENERAL INFORMATION:
; APPLICANT: Issa, Jean-Pierre
; TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
; FILE REFERENCE: JHU1590
; CURRENT APPLICATION NUMBER: US/10/930,301
; CURRENT FILING DATE: 2004-08-30
; PRIOR APPLICATION NUMBER: US/09/398,522
; PRIOR FILING DATE: 1999-09-15
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 98
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Target sequence
; NAME/KEY: misc_feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: y = C or T
US-10-930-301-98

Query Match          0.4%; Score 20.4; DB 1; Length 26;
Best Local Similarity 87.5%; Pred. No. 3.1e+02;
Matches 21; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 5044 AAAAAAAAAAAAAAAAAAACTC 5067
Db 26 ACRAAAAAAAAAAAAAAAAAATCTC 3

RESULT 127
US-10-664-000-3/c
; Sequence 3, Application US/10664000
; Publication No. US20040248144A1
```

```
RESULT 123
US-10-601-140A-43
; Sequence 43, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: NUCLEOTIDE SEQUENCE
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 43
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-601-140A-43

Query Match          0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5045
Db 1 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 124
US-10-930-301-4
; Sequence 4, Application US/10930301
; Publication No. US20050026207A1
; GENERAL INFORMATION:
; APPLICANT: Issa, Jean-Pierre
; TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
; FILE REFERENCE: JHU1590
; CURRENT APPLICATION NUMBER: US/10/930,301
; CURRENT FILING DATE: 2004-08-30
; PRIOR APPLICATION NUMBER: US/09/398,522
; PRIOR FILING DATE: 1999-09-15
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Bisulfite-PCR primer
; NAME/KEY: misc_feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: r = G or A
US-10-930-301-4

Query Match          0.4%; Score 20.4; DB 1; Length 26;
Best Local Similarity 87.5%; Pred. No. 3.1e+02;
Matches 21; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 5044 AAAAAAAAAAAAAAAAAAACTC 5067
Db 1 ACRAAAAAAAAAAAAAAAAAATCTC 24

RESULT 125
US-10-930-301-44
; Sequence 44, Application US/10930301
; Publication No. US20050026207A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Mir, Kalim
/ TITLE OF INVENTION: Arrays and Methods of Use
/ FILE REFERENCE: 8654/2182
/ CURRENT APPLICATION NUMBER: US/10/664,000
/ CURRENT FILING DATE: 2003-09-16
/ PRIOR APPLICATION NUMBER: PCT/GB02/01245
/ PRIOR FILING DATE: 2002-03-18
/ PRIOR APPLICATION NUMBER: GB0106635.6
/ PRIOR FILING DATE: 2001-03-16
/ PRIOR APPLICATION NUMBER: GB0118879.6
/ PRIOR FILING DATE: 2001-08-02
/ NUMBER OF SEQ ID NOS: 3
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 3
/ LENGTH: 22
/ TYPE: DNA
/ ORGANISM: Artificial
/ FEATURE:
/ OTHER INFORMATION: Anchored capture oligonucleotide
/ NAME/KEY: misc feature
/ LOCATION: (22)_(22)
/ OTHER INFORMATION: n is a, c, g, or t
/
US-10-664-000-3

Query Match          0.4%; Score 20.2; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 2.7e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAGAAAAA 5044
Db 21 BAAAAA 1

RESULT 128
US-10-601-140A-32/c
/ Sequence 32, Application US/10601140A
/ Publication No. US20050053942A1
/ GENERAL INFORMATION:
/ APPLICANT: KAUPPINEN, SAKARI
/ APPLICANT: JACOBSEN, NANA
/ TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
/ FILE REFERENCE: 57764(71994)
/ CURRENT APPLICATION NUMBER: US/10/601,140A
/ CURRENT FILING DATE: 2003-06-20
/ PRIOR APPLICATION NUMBER: US 60/390,928
/ PRIOR FILING DATE: 2002-06-24
/ NUMBER OF SEQ ID NOS: 45
/ SOFTWARE: PatentIn Ver. 3.2
/ SEQ ID NO 32
/ LENGTH: 22
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ OTHER INFORMATION: oligonucleotide
/ NAME/KEY: modified_base
/ LOCATION: (1)
/ FEATURE:
/ OTHER INFORMATION: LNA monomer
/ NAME/KEY: modified_base
/ LOCATION: (3)
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (5)
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (7)
```

```
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (9)
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (11)
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (13)
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (15)
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (17)
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (19)
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (22)
/ OTHER INFORMATION: a, t, c or g
/
US-10-601-140A-32

Query Match          0.4%; Score 20.2; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 2.7e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAGAAAAA 5044
Db 21 BAAAAA 1

RESULT 129
US-10-601-140A-45/c
/ Sequence 45, Application US/10601140A
/ Publication No. US20050053942A1
/ GENERAL INFORMATION:
/ APPLICANT: KAUPPINEN, SAKARI
/ APPLICANT: JACOBSEN, NANA
/ TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
/ FILE REFERENCE: 57764(71994)
/ CURRENT APPLICATION NUMBER: US/10/601,140A
/ CURRENT FILING DATE: 2003-06-20
/ PRIOR APPLICATION NUMBER: US 60/390,928
/ PRIOR FILING DATE: 2002-06-24
/ NUMBER OF SEQ ID NOS: 45
/ SOFTWARE: PatentIn Ver. 3.2
/ SEQ ID NO 45
/ LENGTH: 22
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ OTHER INFORMATION: oligonucleotide
/ NAME/KEY: modified_base
/ LOCATION: (1)..(20)
/ OTHER INFORMATION: LNA monomer
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: (22)
/ OTHER INFORMATION: a, t, c or g
/
US-10-601-140A-45
```

```
Query Match          0.4%; Score 20.2; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 2.7e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5024 TAAAAAATAAAAAATAAAAA 5044
    :|||||
Db 21 BAAAAAATAAAAAATAAAAA 1

RESULT 130
US-10-719-956-45761
; Sequence 45761, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 45761
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-45761

Query Match          0.4%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4454 AAGGACTGAAGTGTCCAGGAAT 4478
    |||||
Db 1 AAGGCACGGAGGATGTCCAGGAAT 25

RESULT 131
US-10-719-956-150045
; Sequence 150045, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 150045
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-150045

Query Match          0.4%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4592 AGGGCTTCATCGTAACGCTCTCTAG 4616
    |||||
Db 1 AGGGCTTCATGAGACTGCTCTCTAG 25

RESULT 132
US-10-719-956-159329
; Sequence 159329, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
```

```
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 159329
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-159329

Query Match          0.4%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4532 AGTCCTGCGCCGTGGGACATCATGA 4556
    |||||
Db 1 AGTCCTGCGCTGAGGACATCATGA 25

RESULT 133
US-10-719-956-415353
; Sequence 415353, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 415353
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-415353

Query Match          0.4%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4637 GGAATAAAACCTACTGATTGTAT 4661
    |||||
Db 1 GGAATAAAATCCTGCTGACTTGTAT 25

RESULT 134
US-10-085-906-144/c
; Sequence 144, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; FILE REFERENCE: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 144
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-144

Query Match      0.4%; Score 20.2; DB 1; Length 26;
Best Local Similarity 88.0%; Pred. No. 3.2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5049
Db 26 AAAAAAAAAATAAATAAATAAATAA 2

RESULT 135
US-09-976-900A-55
; Sequence 55, Application US/09976900A
; Publication No. US20040219520A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storchoff, James J.
; APPLICANT: Elghariani, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-123
; CURRENT APPLICATION NUMBER: US/09/976,900A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
US-09-976-900A-55

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 136
US-10-160-786-11/c
; Sequence 11, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-11
```

```
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-11

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CGTTTGCTGGGCTGCAGCA 62
Db 20 CGTTTGCTGGGCTGCAGCA 1

RESULT 137
US-10-160-786-12/c
; Sequence 12, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-12

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 CGGTCTGCACCTTCTCTCCCG 111
Db 20 CGGTCTGCACCTTCTCTCCCG 1

RESULT 138
US-10-160-786-13/c
; Sequence 13, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-13

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 CGGTCTGCACCTTCTCTCCCG 111
Db 20 CGGTCTGCACCTTCTCTCCCG 1
```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 377 AGCCCATCTCTGCTATGA 396
|||||
Db 20 AGCCCATCTCTGCTATGA 1

RESULT 139
US-10-160-786-14/c
; Sequence 14, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION: Antisense Oligonucleotide
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-14

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 391 CTATGAAGAAAGACCTTCG 410
|||||
Db 20 CTATGAAGAAAGACCTTCG 1

RESULT 140
US-10-160-786-15/c
; Sequence 15, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION: Antisense Oligonucleotide
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-15

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 486 CCTCTGAACGATTTTGACAC 505
|||||
Db 20 CCTCTGAACGATTTTGACAC 1

RESULT 141
US-10-160-786-16/c
; Sequence 16, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION: Antisense Oligonucleotide
; APPLICANT: Susan M. Freier

APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-16

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 534 AACCTTACTAAAGACCACAG 553
|||||
Db 20 AACCTTACTAAAGACCACAG 1

RESULT 142
US-10-160-786-17/c
; Sequence 17, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION: Antisense Oligonucleotide
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-17

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 559 CTTGCCATTATGGGAATCA 578
|||||
Db 20 CTTGCCATTATGGGAATCA 1

RESULT 143
US-10-160-786-18/c
; Sequence 18, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION: Antisense Oligonucleotide
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-18

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 GATATTCATGACTTTGAATA 650
|||||
Db 20 GATATTCATGACTTTGAATA 1

RESULT 144

US-10-160-786-19/c
; Sequence 19, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 19

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-19

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 703 CGAGAAGCGCTGCTGTTGT 722
|||||
Db 20 CGAGAAGCGCTGCTGTTGT 1

RESULT 145

US-10-160-786-20/c

; Sequence 20, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 20

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-20

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 726 GGTTTTGCATTCAGATC 745
|||||
Db 20 GGTTTTGCATTCAGATC 1

RESULT 146

US-10-160-786-21/c

; Sequence 21, Application US/10160786
; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 21

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-21

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 780 GGAGGAAGCTGAAATCAGGC 799
|||||
Db 20 GGAGGAAGCTGAAATCAGGC 1

RESULT 147

US-10-160-786-22/c

; Sequence 22, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 22

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-22

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 824 CTTTCAGAAAGCATCAGAA 843
|||||
Db 20 CTTTCAGAAAGCATCAGAA 1

RESULT 148

US-10-160-786-23/c

; Sequence 23, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 23

; LENGTH: 20

Thu Aug 18 08:58:56 2005

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-23

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      875 GGCAGTATGTCGAGACAAT 894
Db      20 GGCAGTATGTCGAGACAAT 1

RESULT 149
US-10-160-786-24/c
; Sequence 24, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-24

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      914 CCCGTCCATTCTTGAATAAC 933
Db      20 CCCGTCCATTCTTGAATAAC 1

RESULT 150
US-10-160-786-25/c
; Sequence 25, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-25

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      982 GCACACAAATCTGGAGTTCC 1001
Db      20 GCACACAAATCTGGAGTTCC 1
```

```
RESULT 151
US-10-160-786-26/c
; Sequence 26, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-26

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      998 TTCGTCATGGGACATCAAG 1017
Db      20 TTCGTCATGGGACATCAAG 1

RESULT 152
US-10-160-786-27/c
; Sequence 27, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-27

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1032 GGTCAACCAAGTTGGAATTGGG 1051
Db      20 GGTCAACCAAGTTGGAATTGGG 1

RESULT 153
US-10-160-786-28/c
; Sequence 28, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
```


; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-28

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 CACTTATCTCCAGACACA 1102
Db 20 CACTTATCTCCAGACACA 1

RESULT 154

US-10-160-786-29/c
; Sequence 29, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-29

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 TCAATTATTTCTTTGACACA 1134
Db 20 TCAATTATTTCTTTGACACA 1

RESULT 155

US-10-160-786-30/c
; Sequence 30, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-30

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1215 AGATCCTTCAACTCCGCTTG 1234
Db 20 AGATCCTTCAACTCCGCTTG 1

RESULT 156

US-10-160-786-31/c
; Sequence 31, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-31

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1268 AGTTGAAGAGAGCAATGGAC 1287
Db 20 AGTTGAAGAGAGCAATGGAC 1

RESULT 157

US-10-160-786-32/c
; Sequence 32, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-32

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1299 AGGTTGTGTAGCTGAGC 1318
Db 20 AGGTTGTGTAGCTGAGC 1

RESULT 158

US-10-160-786-33/c
; Sequence 33, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie

```

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-33

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1337 CATTATTGATCTCTCTCAA 1356
      |||||||
DB 20 CATTATTGATCTCTCTCAA 1

RESULT 159
US-10-160-786-34/c
; Sequence 34, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-34

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1414 GATCAGTATCAGAGAATT 1433
      |||||||
DB 20 GATCAGTATCAGAGAATT 1

RESULT 160
US-10-160-786-35/c
; Sequence 35, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-35

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1414 GATCAGTATCAGAGAATT 1433
      |||||||
DB 20 GATCAGTATCAGAGAATT 1

RESULT 161
US-10-160-786-36/c
; Sequence 36, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-36

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1498 CAGCGTGGCAATGCCITTCC 1517
      |||||||
DB 20 CAGCGTGGCAATGCCITTCC 1

RESULT 162
US-10-160-786-37/c
; Sequence 37, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-37

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1513 TTTCCTGAAATATTTTACAC 1532
      |||||||
DB 20 TTTCCTGAAATATTTTACAC 1

RESULT 163
US-10-160-786-38/c
; Sequence 38, Application US/10160786
```

```

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1441 CAGATGATTCACCGTGAGCC 1460
      |||||||
DB 20 CAGATGATTCACCGTGAGCC 1

RESULT 161
US-10-160-786-36/c
; Sequence 36, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-36

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1498 CAGCGTGGCAATGCCITTCC 1517
      |||||||
DB 20 CAGCGTGGCAATGCCITTCC 1

RESULT 162
US-10-160-786-37/c
; Sequence 37, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-37

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1513 TTTCCTGAAATATTTTACAC 1532
      |||||||
DB 20 TTTCCTGAAATATTTTACAC 1

RESULT 163
US-10-160-786-38/c
; Sequence 38, Application US/10160786
```

```
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-38

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1529 ACATTTTCTTCAGCCCTAC 1548
Db 20 ACATTTTCTTCAGCCCTAC 1

RESULT 164
US-10-160-786-39/c
; Sequence 39, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-39

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1630 CACAATCTCTGTGCACATGA 1649
Db 20 CACAATCTCTGTGCACATGA 1

RESULT 165
US-10-160-786-40/c
; Sequence 40, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-40

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1658 AAAAGCCGAAGGAGAGCCT 1677
Db 20 AAAAGCCGAAGGAGAGCCT 1

RESULT 166
US-10-160-786-41/c
; Sequence 41, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-41

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1706 CTGTATAACATCTCGCCTA 1725
Db 20 CTGTATAACATCTCGCCTA 1

RESULT 167
US-10-160-786-42/c
; Sequence 42, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-42

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1978 GCCCAAGATGATGCTACTAT 1997
Db 20 GCCCAAGATGATGCTACTAT 1
```

```

; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-45

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 2080 CTTAATATGAAAAATGACCC 2099
Db 20 CTTAATATGAAAAATGACCC 1

RESULT 171
US-10-160-786-46/c
; Sequence 46, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-46

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 2131 CCAAATGGAATATGACAC 2150
Db 20 CCAAATGGAATATGACAC 1

RESULT 172
US-10-160-786-47/c
; Sequence 47, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-47

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 2041 ACAGCTCTGAGATTCCTGGA 2060
Db 20 ACAGCTCTGAGATTCCTGGA 1

RESULT 170
US-10-160-786-45/c
; Sequence 45, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-44

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 2005 CTAGCCTATGCTGAAACAT 2024
Db 20 CTAGCCTATGCTGAAACAT 1

RESULT 169
US-10-160-786-44/c
; Sequence 44, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-44

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 2005 CTAGCCTATGCTGAAACAT 2024
Db 20 CTAGCCTATGCTGAAACAT 1

RESULT 168
US-10-160-786-43/c
; Sequence 43, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-43

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 2005 CTAGCCTATGCTGAAACAT 2024
Db 20 CTAGCCTATGCTGAAACAT 1
```

QY 2391 TGGCTGGCAAAGCTCTCTCAA 2410
Db 20 TGGCTGGCAAAGCTCTCTCAA 1

RESULT 173

US-10-160-786-48/c

; Sequence 48, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Doble

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 48

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-48

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2438 TTAGTGATGCTGAGGAATTT 2457

Db 20 TTAGTGATGCTGAGGAATTT 1

RESULT 174

US-10-160-786-49/c

; Sequence 49, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Doble

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 49

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-49

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2524 GTTTACGAATTTGCCAGTGA 2543

Db 20 GTTTACGAATTTGCCAGTGA 1

RESULT 175

US-10-160-786-50/c

; Sequence 50, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Doble

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 50

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-50

; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-50

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2555 TCCTGTGTCATCCCAATTTA 2574

Db 20 TCCTGTGTCATCCCAATTTA 1

RESULT 176

US-10-160-786-51/c

; Sequence 51, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Doble

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 51

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-51

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2587 GGTGCGTGGGATTTATCAC 2606

Db 20 GGTGCGTGGGATTTATCAC 1

RESULT 177

US-10-160-786-52/c

; Sequence 52, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Doble

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 52

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-52

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2731 GAACCAAGTAAGTCGTTCTAT 2750
| | | | | | | | | | | | | | | | | | | | | |
DB 20 GAACCAAGTAAGTCGTTCTAT 1

RESULT 178
US-10-160-786-53/c
; Sequence 53, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-53

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2843 GCCCTCCGCCAGAGGATCCT 2862
| | | | | | | | | | | | | | | | | | | | | |
DB 20 GCCCTCCGCCAGAGGATCCT 1

RESULT 179
US-10-160-786-54/c
; Sequence 54, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-54

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2860 CCTGCCATAGCAGAGTTCT 2879
| | | | | | | | | | | | | | | | | | | | | |
DB 20 CCTGCCATAGCAGAGTTCT 1

RESULT 180
US-10-160-786-55/c
; Sequence 55, Application US/10160786
; Publication No. US20030225013A1

GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-55

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2913 AGAGGAGAGACAACTTCTCG 2932
| | | | | | | | | | | | | | | | | | | | | |
DB 20 AGAGGAGAGACAACTTCTCG 1

RESULT 181
US-10-160-786-56/c
; Sequence 56, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-56

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3009 TCAGAAAGGTGTAATTGACT 3028
| | | | | | | | | | | | | | | | | | | | | |
DB 20 TCAGAAAGGTGTAATTGACT 1

RESULT 182
US-10-160-786-57/c
; Sequence 57, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-57

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3057 AGTTGATCTTGTTAAACCA 3076
    |||||
Db 20 AGTTGATCTTGTTAAACCA 1

RESULT 183
US-10-160-786-58/c
; Sequence 58, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-58

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3250 TCTGCTGGCATTGTGTCCC 3269
    |||||
Db 20 TCTGCTGGCATTGTGTCCC 1

RESULT 184
US-10-160-786-59/c
; Sequence 59, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-59

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3318 AAAACCAAGTAATACCGTTT 3337
    |||||
Db 20 AAAACCAAGTAATACCGTTT 1
```

```
RESULT 185
US-10-160-786-60/c
; Sequence 60, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-60

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3341 GTAGTACAATCTTACCATCC 3360
    |||||
Db 20 GTAGTACAATCTTACCATCC 1

RESULT 186
US-10-160-786-61/c
; Sequence 61, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-61

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3388 AAAACTGAACTTCAGCAACT 3407
    |||||
Db 20 AAAACTGAACTTCAGCAACT 1

RESULT 187
US-10-160-786-62/c
; Sequence 62, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
```

```
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-62

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3431 GCAATGCTGAGAGTAAGCT 3450
      |||||
Db 20 GCAATGCTGAGAGTAAGCT 1

RESULT 188
US-10-160-786-63/c
; Sequence 63, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-63

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3455 AGATGATGGAATGCTGAA 3474
      |||||
Db 20 AGATGATGGAATGCTGAA 1

RESULT 189
US-10-160-786-64/c
; Sequence 64, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-64

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3504 GCGTCTAAAGGCTGTAG 3523
```

```
Db 20 CCGTCTAAAGGCTGTAG 1
      |||||
```

```
RESULT 190
US-10-160-786-65/c
; Sequence 65, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-65
```

```
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 3523 GTTGCCCATCTTCATGAGCA 3542
      |||||
Db 20 GTTGCCCATCTTCATGAGCA 1
```

```
RESULT 191
US-10-160-786-66/c
; Sequence 66, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-66
```

```
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 3555 GAATCGAATTAGTCTCTG 3574
      |||||
Db 20 GAATCGAATTAGTCTCTG 1
```

```
RESULT 192
US-10-160-786-67/c
; Sequence 67, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-67
```

```
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```


; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-67

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3583 TCACCTTTTGCACATGTTTC 3602
|||||
Db 20 TCACCTTTTGCACATGTTTC 1

RESULT 193
US-10-160-786-68/c
; Sequence 68, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-68

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3762 TGTCCAGCTTCTTGGATTG 3781
|||||
Db 20 TGTCCAGCTTCTTGGATTG 1

RESULT 194
US-10-160-786-69/c
; Sequence 69, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-69

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3781 GAGGCTTCTAAGCTGCCCAA 3800
|||||
Db 20 GAGGCTTCTAAGCTGCCCAA 1

RESULT 195
US-10-160-786-70/c
; Sequence 70, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-70

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3899 TTCTTGCCTATGCCACTGTG 3918
|||||
Db 20 TTCTTGCCTATGCCACTGTG 1

RESULT 196
US-10-160-786-71/c
; Sequence 71, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-71

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3927 TCTGTGTTGGCTGGACCTTA 3946
|||||
Db 20 TCTGTGTTGGCTGGACCTTA 1

RESULT 197
US-10-160-786-72/c
; Sequence 72, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
US-10-160-786-72

```

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-74

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4050 CAGTGGTACCATGGCTTGTT 4069
|||||
Db 20 CAGTGGTACCATGGCTTGTT 1

RESULT 200
US-10-160-786-75/c
; Sequence 75, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUBU
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-75

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4166 TGATTGCAGCTGTTTCAGGCG 4185
|||||
Db 20 TGATTGCAGCTGTTTCAGGCG 1

RESULT 201
US-10-160-786-76/c
; Sequence 76, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUBU
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-76

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4212 GGAGACTGGTGACAGAAGAT 4231
|||||
Db 20 GGAGACTGGTGACAGAAGAT 1

RESULT 202

```

```
US-10-160-786-77/c
; Sequence 77, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-77
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 4258 CCACCTTCTGAATTACAGCC 4277
|||||
DB 20 CCACCTTCTGAATTACAGCC 1

RESULT 203
US-10-160-786-78/c
; Sequence 78, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-78
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 4292 TCCATGGTACTACTAGT 4311
|||||
DB 20 TCCATGGTACTACTAGT 1

RESULT 204
US-10-160-786-79/c
; Sequence 79, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 79
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-79
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 4309 AGTCCTGCAGATGGAATCC 4328
|||||
DB 20 AGTCCTGCAGATGGAATCC 1

RESULT 205
US-10-160-786-80/c
; Sequence 80, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-80
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 4355 TGAATAAGTTTGGGAC 4374
|||||
DB 20 TGAATAAGTTTGGGAC 1

RESULT 206
US-10-160-786-81/c
; Sequence 81, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-81
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 4397 ATGTTGTTCCAGAGTACT 4416
|||||
```

Db 20 ATGTTGTTGCAGGAAGTACT 1

RESULT 207
US-10-160-786-82/c
; Sequence 82, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-82

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4424 CATCTGTGTCCTACTACAGG 4443
|||||
Db 20 CATCTGTGTCCTACTACAGG 1

RESULT 208
US-10-160-786-83/c
; Sequence 83, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-83

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4461 TGAAGTTGTCAGGAATTC 4480
|||||
Db 20 TGAAGTTGTCAGGAATTC 1

RESULT 209
US-10-160-786-84/c
; Sequence 84, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-84

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4633 GTGTGGAATAAAACCTACT 4652
|||||
Db 20 GTGTGGAATAAAACCTACT 1

RESULT 210
US-10-160-786-85/c
; Sequence 85, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-85

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4761 CTGTTTCATGACTGACTGAC 4780
|||||
Db 20 CTGTTTCATGACTGACTGAC 1

RESULT 211
US-10-160-786-86/c
; Sequence 86, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-86

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4776 CTGACTAAATGACACCCAAA 4795
|||||
Db 20 CTGACTAAATGACACCCAAA 1

RESULT 212

US-10-160-786-87/c
; Sequence 87, Application US/10160786
; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 87

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-87

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4792 CAAAATGTTAAGATGTA 4811
|||||
Db 20 CAAAATGTTAAGATGTA 1

RESULT 213

US-10-160-786-88/c

; Sequence 88, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 88

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-88

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4823 CTTATGCATCTCTTTCGAG 4842
|||||
Db 20 CTTATGCATCTCTTTCGAG 1

RESULT 214

US-10-160-786-89

; Sequence 89, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 89

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-91

Query Match

0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 CGGTCGTGCACCTCTCTCCCG 111
|||||
Db 1 CGGTCGTGCACCTCTCTCCCG 20

RESULT 216

US-10-160-786-91

; Sequence 91, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 91

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-160-786-91

```

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-94

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 377 AGCCCATCTCTGCTATGA 396
|||||
Db 1 AGCCCATCTCTGCTATGA 20

RESULT 217
US-10-160-786-92
; Sequence 92, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 92
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-92

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CCTCTGAACGATTGTGACAC 505
|||||
Db 1 CCTCTGAACGATTGTGACAC 20

RESULT 218
US-10-160-786-93
; Sequence 93, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 93
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-93

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 534 AACCTTACTAAAGACCACAG 553
|||||
Db 1 AACCTTACTAAAGACCACAG 20

RESULT 219
US-10-160-786-94
; Sequence 94, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
```

```

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-94

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 559 CTTGCCATTATGGGAATCA 578
|||||
Db 1 CTTGCCATTATGGGAATCA 20

RESULT 220
US-10-160-786-95
; Sequence 95, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 95
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-95

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 703 CGAGAAGCCCTGTCGTTGT 722
|||||
Db 1 CGAGAAGCCCTGTCGTTGT 20

RESULT 221
US-10-160-786-96
; Sequence 96, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-96

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 703 CGAGAAGCCCTGTCGTTGT 722
|||||
Db 1 CGAGAAGCCCTGTCGTTGT 20
```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 780 GGAGAACTGAAATCAGGC 799
|||||
Db 1 GGAGAACTGAAATCAGGC 20

RESULT 222

US-10-160-786-97
; Sequence 97, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 97

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-97

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 824 CTTTCAGAAAGCATCAGAA 843
|||||
Db 1 CTTTCAGAAAGCATCAGAA 20

RESULT 223

US-10-160-786-98
; Sequence 98, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 98

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-98

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 875 GGCAGTATGTCGAGACAAT 894
|||||
Db 1 GGCAGTATGTCGAGACAAT 20

RESULT 224

US-10-160-786-99
; Sequence 99, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 99

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-99

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 914 CCGTCCATCTTGAATAAC 933
|||||
Db 1 CCGTCCATCTTGAATAAC 20

RESULT 225

US-10-160-786-100
; Sequence 100, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 100

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-100

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 982 GCACACAAATCTGGAGTTCG 1001
|||||
Db 1 GCACACAAATCTGGAGTTCG 20

RESULT 226

US-10-160-786-101
; Sequence 101, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 101

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-101

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy 998 TTGTCATGGGACATCAAG 1017
Db 1 TTGTCATGGGACATCAAG 20

RESULT 227
US-10-160-786-102
; Sequence 102, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-102

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1032 GGTCAACAGTTGGAAATGGG 1051
Db 1 GGTCAACAGTTGGAAATGGG 20

RESULT 228
US-10-160-786-103
; Sequence 103, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-103

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1083 CACTTATCTTCCAGAAGACA 1102
Db 1 CACTTATCTTCCAGAAGACA 20

RESULT 229
US-10-160-786-104
; Sequence 104, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION

```

```

; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 104
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-104

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1268 AGTTGAAGAGAGCAATGGAC 1287
Db 1 AGTTGAAGAGAGCAATGGAC 20

RESULT 230
US-10-160-786-105
; Sequence 105, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 105
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-105

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1299 AGTTGTGTGATGCTGAGC 1318
Db 1 AGTTGTGTGATGCTGAGC 20

RESULT 231
US-10-160-786-106
; Sequence 106, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 106
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-106

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```


QY 1414 GATCACAGTATCAGAGATT 1433
Db 1 GATCACAGTATCAGAGATT 20

RESULT 232

US-10-160-786-107
; Sequence 107, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 107
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-107

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1498 CAGCGTGGCAATGCTTTCC 1517
Db 1 CAGCGTGGCAATGCTTTCC 20

RESULT 233

US-10-160-786-108
; Sequence 108, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-108

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1630 CACAATCTCTGTGGACATGA 1649
Db 1 CACAATCTCTGTGGACATGA 20

RESULT 234

US-10-160-786-109
; Sequence 109, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-109

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1658 AAAAGCCGAAGGAGCCT 1677
Db 1 AAAAGCCGAAGGAGCCT 20

RESULT 235

US-10-160-786-110
; Sequence 110, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-110

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1706 CTGTTATAACATCTGCCTA 1725
Db 1 CTGTTATAACATCTGCCTA 20

RESULT 236

US-10-160-786-111
; Sequence 111, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-111

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1978 GCCCAAGATGATGCTACTAT 1997

```
Db      1  GCGCAAGATGATCTACTAT 20
|||||
RESULT 237
US-10-160-786-112
; Sequence 112, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 112
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-112

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Yy      2041  ACAGCTCTGAGATTCCTGGA 2060
|||||
Db      1  ACAGCTCTGAGATTCCTGGA 20

RESULT 238
US-10-160-786-113
; Sequence 113, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 113
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-113

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Yy      2080  CTTAATATGGAATGACCC 2099
|||||
Db      1  CTTAATATGGAATGACCC 20

RESULT 239
US-10-160-786-114
; Sequence 114, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
```

```
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 114
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-114

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Yy      2131  CCAAATGGAAATATGACAC 2150
|||||
Db      1  CCAAATGGAAATATGACAC 20

RESULT 240
US-10-160-786-115
; Sequence 115, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 115
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-115

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Yy      2391  TGGCTGGCAAAGCTCTCTCAA 2410
|||||
Db      1  TGGCTGGCAAAGCTCTCTCAA 20

RESULT 241
US-10-160-786-116
; Sequence 116, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 116
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-116

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Yy      2438  TTAGTGATGCTGAGGAATTT 2457
|||||
```

Db 1 TTAGTGATGCTGAGGAATTT 20

RESULT 242

US-10-160-786-117

; Sequence 117, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUBSTRATE

; TITLE OF INVENTION: P150 EXPRESSION

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 117

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-117

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2524 GTTTACGAATTTGCCAGTGA 2543

Db 1 GTTTACGAATTTGCCAGTGA 20

RESULT 243

US-10-160-786-118

; Sequence 118, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUBSTRATE

; TITLE OF INVENTION: P150 EXPRESSION

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 118

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-118

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2555 TCCTGTGTCATCCCAATTTA 2574

Db 1 TCCTGTGTCATCCCAATTTA 20

RESULT 244

US-10-160-786-119

; Sequence 119, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUBSTRATE

; TITLE OF INVENTION: P150 EXPRESSION

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 119

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-119

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2587 GGTGCGGTGGGATTTATCAC 2606

Db 1 GGTGCGGTGGGATTTATCAC 20

RESULT 245

US-10-160-786-120

; Sequence 120, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUBSTRATE

; TITLE OF INVENTION: P150 EXPRESSION

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 120

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-120

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2731 GAACCAAGTAAGTCGTTCTAT 2750

Db 1 GAACCAAGTAAGTCGTTCTAT 20

RESULT 246

US-10-160-786-121

; Sequence 121, Application US/10160786

; Publication No. US20030225013A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUBSTRATE

; TITLE OF INVENTION: P150 EXPRESSION

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/160,786

; CURRENT FILING DATE: 2002-05-31

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 121

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-160-786-121

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2843 GCCCTCCGCCAGAGGATCCT 2862

Db 1 GCCCTCCGCCAGAGGATCCT 20

```
RESULT 247
US-10-160-786-122
; Sequence 122, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-122

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2860 CCTGCCATAGCACAGCTTCT 2879
Db 1 CCTGCCATAGCACAGCTTCT 20

RESULT 248
US-10-160-786-123
; Sequence 123, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 123
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-123

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2913 AGAGGAAGACAACTTCTGG 2932
Db 1 AGAGGAAGACAACTTCTGG 20

RESULT 249
US-10-160-786-124
; Sequence 124, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
```

```
; SEQ ID NO 124
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-124

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3009 TCAGAAAGGTGTAATTGACT 3028
Db 1 TCAGAAAGGTGTAATTGACT 20

RESULT 250
US-10-160-786-125
; Sequence 125, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 125
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-125

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3057 AGTTGATCTTGTAAAACCA 3076
Db 1 AGTTGATCTTGTAAAACCA 20

RESULT 251
US-10-160-786-126
; Sequence 126, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 126
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-126

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3250 TCTGCTGGCATTGTGTCCC 3269
Db 1 TCTGCTGGCATTGTGTCCC 20
```


Thu Aug 18 08:58:56 2005

```
RESULT 257
US-10-160-786-132
; Sequence 132, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 132
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-132

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3504 GCGTCCTAAGGGCTGTAG 3523
Db 1 GCGTCCTAAGGGCTGTAG 20

RESULT 258
US-10-160-786-133
; Sequence 133, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 133
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-133

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3504 GCGTCCTAAGGGCTGTAG 3523
Db 1 GCGTCCTAAGGGCTGTAG 20

RESULT 259
US-10-160-786-134
; Sequence 134, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 134
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-134

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3555 GAATCGAATTAGAGTCTCTG 3574
Db 1 GAATCGAATTAGAGTCTCTG 20
```

```
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-134

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3583 TCACITTTTGCACATGTTTC 3602
Db 1 TCACITTTTGCACATGTTTC 20

RESULT 260
US-10-160-786-135
; Sequence 135, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 135
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-135

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3762 TGTCCAGCTTCTTGGAAATTG 3781
Db 1 TGTCCAGCTTCTTGGAAATTG 20

RESULT 261
US-10-160-786-136
; Sequence 136, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-136

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3899 TTCTTGCCATATGCCACTGTG 3918
Db 1 TTCTTGCCATATGCCACTGTG 20

RESULT 262
```

```
US-10-160-786-137
; Sequence 137, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-137

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3991 GGCTCATCACTTCCTTGC 4010
      |||||
Db 1 GGCTCATCACTTCCTTGC 20

RESULT 263
US-10-160-786-138
; Sequence 138, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-138

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4050 CAGTGTACCATGGCTTGTT 4069
      |||||
Db 1 CAGTGTACCATGGCTTGTT 20

RESULT 264
US-10-160-786-139
; Sequence 139, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 139
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-139

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4166 TGATTGCAGCTGTTTCAGGGC 4185
      |||||
Db 1 TGATTGCAGCTGTTTCAGGGC 20

RESULT 265
US-10-160-786-140
; Sequence 140, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 140
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-140

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4309 AGTCCTGCAGATGGAAATCC 4328
      |||||
Db 1 AGTCCTGCAGATGGAAATCC 20

RESULT 266
US-10-160-786-141
; Sequence 141, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-141

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4397 ATGTTGTTGCAGGAAGTACT 4416
      |||||
Db 1 ATGTTGTTGCAGGAAGTACT 20

RESULT 267
US-10-160-786-142
```

```
; Sequence 142, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 142
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-142

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4424 CATCTGTGCTCTACTACAGG 4443
      |||||
Db 1 CATCTGTGCTCTACTACAGG 20

RESULT 268
US-10-160-786-143
; Sequence 143, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 143
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-143

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4633 GTGTGGAATAAAACCTACT 4652
      |||||
Db 1 GTGTGGAATAAAACCTACT 20

RESULT 269
US-10-160-786-144
; Sequence 144, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 144
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
```

```
; FEATURE:
US-10-160-786-144

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4761 CTGTTTCATGACTGACTGAC 4780
      |||||
Db 1 CTGTTTCATGACTGACTGAC 20

RESULT 270
US-10-160-786-145
; Sequence 145, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-145

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4776 CTGACTAAATGACACCCAAA 4795
      |||||
Db 1 CTGACTAAATGACACCCAAA 20

RESULT 271
US-10-160-786-146
; Sequence 146, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 146
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-146

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4792 CAAAATGGTTAAGATGTACT 4811
      |||||
Db 1 CAAAATGGTTAAGATGTACT 20

RESULT 272
US-10-160-786-147
; Sequence 147, Application US/10160786
```



```

; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-786-147

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4823 CTATGCACTCTCTTTCGAG 4842
      |||||
Db 1 CTATGCACTCTCTTTCGAG 20

RESULT 273
US-10-667-022-11/c
; Sequence 11, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
US-10-667-022-11

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CGTTTCTGGGCTGCAGCA 62
      |||||
Db 20 CGTTTCTGGGCTGCAGCA 1

RESULT 274
US-10-667-022-12/c
; Sequence 12, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

```

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-12

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 CGGTCTGCACCTTCTCTCCCG 111
      |||||
Db 20 CGGTCTGCACCTTCTCTCCCG 1

RESULT 275
US-10-667-022-13/c
; Sequence 13, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
US-10-667-022-13

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 377 AGCCCATCTCTCTGTCTATCA 396
      |||||
Db 20 AGCCCATCTCTCTGTCTATCA 1

RESULT 276
US-10-667-022-14/c
; Sequence 14, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
US-10-667-022-14

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 CTATGAAGAAGACCCCTTCG 410
      |||||
Db 20 CTATGAAGAAGACCCCTTCG 1

```

```

RESULT 277
US-10-667-022-15/c
; Sequence 15, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-15
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 486 CCTCTGAACGATTTTGACAC 505
Db 20 CCTCTGAACGATTTTGACAC 1

RESULT 278
US-10-667-022-16/c
; Sequence 16, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-16
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 534 AACCTTACTAAAGACACAG 553
Db 20 AACCTTACTAAAGACACAG 1

RESULT 279
US-10-667-022-17/c
; Sequence 17, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147

```

```

; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-17
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 559 CTGCGCATTTATGGGAATCA 578
Db 20 CTGCGCATTTATGGGAATCA 1

RESULT 280
US-10-667-022-18/c
; Sequence 18, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-18
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 631 GATATTCATGACTTTGAATA 650
Db 20 GATATTCATGACTTTGAATA 1

RESULT 281
US-10-667-022-19/c
; Sequence 19, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-19
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 703 CGAGAAGCGCTGCTGTTGT 722

```

```
Db      20 CGAGAGCCCTGGTCGTGT 1
|||||
RESULT 282
US-10-667-022-20/c
; Sequence 20, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-20
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      726 GGTTTTGCATTCAGATC 745
|||||
Db      20 GGTTTTGCATTCAGATC 1
|||||
RESULT 283
US-10-667-022-21/c
; Sequence 21, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-21
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      780 GGAGGAACGAAATCAGGC 799
|||||
Db      20 GGAGGAACGAAATCAGGC 1
|||||
RESULT 284
US-10-667-022-22/c
; Sequence 22, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
```

```
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-22
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      824 CTTTCAGAAAGCATCAGAA 843
|||||
Db      20 CTTTCAGAAAGCATCAGAA 1
|||||
RESULT 285
US-10-667-022-23/c
; Sequence 23, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-23
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      875 GGCAGTATGTGCGAGACAAT 894
|||||
Db      20 GGCAGTATGTGCGAGACAAT 1
|||||
RESULT 286
US-10-667-022-24/c
; Sequence 24, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-24
Query Match      0.4%; Score 20; DB 1; Length 20;
```

Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 914 CCGGTCCATCTCTGAATAAC 933
|||||
Db 20 CCGGTCCATCTCTGAATAAC 1

RESULT 287
US-10-667-022-25/c
; Sequence 25, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-25

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 982 GCACACAAATCTGGAGTTTCG 1001
|||||
Db 20 GCACACAAATCTGGAGTTTCG 1

RESULT 288
US-10-667-022-26/c
; Sequence 26, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-26

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 998 TTCGTCATGGGACATCAAG 1017
|||||
Db 20 TTCGTCATGGGACATCAAG 1

RESULT 289
US-10-667-022-27/c
; Sequence 27, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-27

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-29

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 TCAATTATTTCTTTGACACA 1134
|||||
DB 20 TCAATTATTTCTTTGACACA 1

RESULT 292

US-10-667-022-30/c

; Sequence 30, Application US/10667022
; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 30

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-30

Query Match

Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1215 AGATCCTTCAACTCCGCTTG 1234
|||||
DB 20 AGATCCTTCAACTCCGCTTG 1

RESULT 293

US-10-667-022-31/c

; Sequence 31, Application US/10667022

; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 31

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-31

Query Match

Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1268 AGTTGAAGAGAGCAATGGAC 1287
|||||
DB 20 AGTTGAAGAGAGCAATGGAC 1

RESULT 294

US-10-667-022-32/c

; Sequence 32, Application US/10667022

; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 32

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-32

Query Match

Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1299 AGTTTGTGATAGCTGAGC 1318
|||||
DB 20 AGTTTGTGATAGCTGAGC 1

RESULT 295

US-10-667-022-33/c

; Sequence 33, Application US/10667022

; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 33

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-33

Query Match

Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1337 CATTATTGATCTCTCTCAA 1356
|||||
DB 20 CATTATTGATCTCTCTCAA 1

RESULT 296

US-10-667-022-34/c

; Sequence 34, Application US/10667022

; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 34

```

Db      20  CAGCGTGGCAATGCGCTTCC 1

RESULT 299
US-10-667-022-37/c
; Sequence 37, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGUL
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-37
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1513  TTTCTCGAAATATTTTACAC 1532
          ||||||||||||||||
Db      20  TTTCTCGAAATATTTTACAC 1

RESULT 300
US-10-667-022-38/c
; Sequence 38, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGUL
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-38
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1529  ACACCTTTCTTCAGCCCTAC 1548
          ||||||||||||||||
Db      20  ACACCTTTCTTCAGCCCTAC 1

RESULT 301
US-10-667-022-39/c
; Sequence 39, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGUL
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376

```

; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-39

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1630 CACAATCTCTGTGGACATGA 1649
|||||
Db 20 CACAATCTCTGTGGACATGA 1

RESULT 302
US-10-667-022-40/c
; Sequence 40, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-40

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1658 AAAAAGCCGAAGGAGAGCCT 1677
|||||
Db 20 AAAAAGCCGAAGGAGAGCCT 1

RESULT 303
US-10-667-022-41/c
; Sequence 41, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-41

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1706 CTGTATAACATCCTGCCTA 1725
|||||
Db 20 CTGTATAACATCCTGCCTA 1

RESULT 304
US-10-667-022-42/c
; Sequence 42, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-42

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1978 GCCCAAGATGATGCTACTAT 1997
|||||
Db 20 GCCCAAGATGATGCTACTAT 1

RESULT 305
US-10-667-022-43/c
; Sequence 43, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-43

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2005 CTAGCCTATGCTGAAAACAT 2024
|||||
Db 20 CTAGCCTATGCTGAAAACAT 1

RESULT 306
US-10-667-022-44/c
; Sequence 44, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier

APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
TITLE OF INVENTION: P150 EXPRESSION
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 44
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-44

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2041 ACAGCTCTGAGATTCCTGGA 2060
| | | | | | | | | | | | | | | | | | | | | |
Db 20 ACAGCTCTGAGATTCCTGGA 1

RESULT 307
US-10-667-022-45/c
Sequence 45, Application US/10667022
Publication No. US20040063657A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
TITLE OF INVENTION: P150 EXPRESSION
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 45
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-45

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2080 CTTAATATGGAATGACCC 2099
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CTTAATATGGAATGACCC 1

RESULT 308
US-10-667-022-46/c
Sequence 46, Application US/10667022
Publication No. US20040063657A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
TITLE OF INVENTION: P150 EXPRESSION
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 46
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-46

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2131 CCAAAATGGAATTTATGACAC 2150
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CCAAAATGGAATTTATGACAC 1

RESULT 309
US-10-667-022-47/c
Sequence 47, Application US/10667022
Publication No. US20040063657A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
TITLE OF INVENTION: P150 EXPRESSION
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 47
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-47

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2391 TGGCTGGCAAAGCTCTCAA 2410
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TGGCTGGCAAAGCTCTCAA 1

RESULT 310
US-10-667-022-48/c
Sequence 48, Application US/10667022
Publication No. US20040063657A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
TITLE OF INVENTION: P150 EXPRESSION
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 48
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-48

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2438 TTAGTGATGCTGAGGAATTT 2457
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TTAGTGATGCTGAGGAATTT 1

RESULT 311
US-10-667-022-49/c


```
; Sequence 49, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-49

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2524 GTTTACGAATTGCCAGTGA 2543
Db 20 GTTTACGAATTGCCAGTGA 1

RESULT 312
US-10-667-022-50/c
; Sequence 50, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-50

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2555 TCCTGTGTCATCCCAATTGA 2574
Db 20 TCCTGTGTCATCCCAATTGA 1

RESULT 313
US-10-667-022-51/c
; Sequence 51, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 51
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-51

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2587 GGTGCGGTGGGATTATCAC 2606
Db 20 GGTGCGGTGGGATTATCAC 1

RESULT 314
US-10-667-022-52/c
; Sequence 52, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-52

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2731 GAACCAAGTAGTCGTTCTAT 2750
Db 20 GAACCAAGTAGTCGTTCTAT 1

RESULT 315
US-10-667-022-53/c
; Sequence 53, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-53

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2843 GCCTCCGCCAGAGGATCCT 2862
Db 20 GCCTCCGCCAGAGGATCCT 1
```

```
RESULT 316
US-10-667-022-54/c
; Sequence 54, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-54
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2860 CCTGCCATAGCACAGCTTCT 2879
|||||
DB 20 CCTGCCATAGCACAGCTTCT 1

RESULT 317
US-10-667-022-55/c
; Sequence 55, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-55
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2860 CCTGCCATAGCACAGCTTCT 2879
|||||
DB 20 CCTGCCATAGCACAGCTTCT 1

RESULT 318
US-10-667-022-56/c
; Sequence 56, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
```

```
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-56
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3009 TCAGAAAGGTGTAATTGACT 3028
|||||
DB 20 TCAGAAAGGTGTAATTGACT 1

RESULT 319
US-10-667-022-57/c
; Sequence 57, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-57
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3057 AGTTGATCTTGTAAACCA 3076
|||||
DB 20 AGTTGATCTTGTAAACCA 1

RESULT 320
US-10-667-022-58/c
; Sequence 58, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-58
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 3250 TCTGCTGGCAATTTGTGTCCC 3269
Db 20 TCTGCTGGCAATTTGTGTCCC 1

RESULT 321

US-10-667-022-59/c

; Sequence 59, Application US/10667022

; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 59

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-59

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3318 AAAACAGTAATCCGGTTT 3337

Db 20 AAAACAGTAATCCGGTTT 1

RESULT 322

US-10-667-022-60/c

; Sequence 60, Application US/10667022

; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 60

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-60

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3341 GTAGTACAATCTTACCATCC 3360

Db 20 GTAGTACAATCTTACCATCC 1

RESULT 323

US-10-667-022-61/c

; Sequence 61, Application US/10667022

; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 61

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-61

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3388 AAAACTGAACCTCAGCAACT 3407

Db 20 AAAACTGAACCTCAGCAACT 1

RESULT 324

US-10-667-022-62/c

; Sequence 62, Application US/10667022

; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 62

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-62

Query Match

Best Local Similarity 0.4%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3431 GCAATGCTGAGAGATAGCT 3450

Db 20 GCAATGCTGAGAGATAGCT 1

RESULT 325

US-10-667-022-63/c

; Sequence 63, Application US/10667022

; Publication No. US20040063657A1

; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB

; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022

; CURRENT FILING DATE: 2003-09-18

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 63

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-667-022-63

```
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3455 AGATGATGGAATGCTGAA 3474
   |||||
Db 20 AGATGATGGAATGCTGAA 1

RESULT 326
US-10-667-022-64/c
; Sequence 64, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-64

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3504 GCGTCCTAAAGGCTGTAG 3523
   |||||
Db 20 GCGTCCTAAAGGCTGTAG 1

RESULT 327
US-10-667-022-65/c
; Sequence 65, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-65

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3523 GTTGCCCATCTTCATGAGCA 3542
   |||||
Db 20 GTTGCCCATCTTCATGAGCA 1

RESULT 328
US-10-667-022-66/c
; Sequence 66, Application US/10667022
```

```
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-66

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3555 GAATCGAATTAGTCTCTG 3574
   |||||
Db 20 GAATCGAATTAGTCTCTG 1

RESULT 329
US-10-667-022-67/c
; Sequence 67, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-67

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3583 TCACCTTTTGCAACATGTC 3602
   |||||
Db 20 TCACCTTTTGCAACATGTC 1

RESULT 330
US-10-667-022-68/c
; Sequence 68, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-68

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3762 TGTCACGCTTCTGGAAATG 3781
|||||
Db 20 TGTCACGCTTCTGGAAATG 1

RESULT 331

US-10-667-022-69/c
; Sequence 69, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-69

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3781 GAGGCTTCTAAGCTGCCCA 3800
|||||
Db 20 GAGGCTTCTAAGCTGCCCA 1

RESULT 332

US-10-667-022-70/c
; Sequence 70, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-70

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3899 TTCTTGCTATGCACGTG 3918
|||||
Db 20 TTCTTGCTATGCACGTG 1

RESULT 333

US-10-667-022-71/c
; Sequence 71, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-71

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3927 TCTGTTGGCTGGACCTTA 3946
|||||
Db 20 TCTGTTGGCTGGACCTTA 1

RESULT 334

US-10-667-022-72/c
; Sequence 72, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-72

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3967 ACTTTAAAGCATGATTTAAA 3986
|||||
Db 20 ACTTTAAAGCATGATTTAAA 1

RESULT 335

US-10-667-022-73/c
; Sequence 73, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18

Thu Aug 18 08:58:56 2005

gibbs-10-667-022-4.rnpb

```

; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-73

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3991 GGCCTCATCATCTCTCTTGC 4010
      |||||
Db 20 GGCCTCATCATCTCTCTTGC 1

RESULT 336
US-10-667-022-74/c
; Sequence 74, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-74

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4050 CAGTGGTACCATGGCTTGT 4069
      |||||
Db 20 CAGTGGTACCATGGCTTGT 1

RESULT 337
US-10-667-022-75/c
; Sequence 75, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-75

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 4166 TGATTGCAGCTGTTACAGGC 4185
      |||||
Db 20 TGATTGCAGCTGTTACAGGC 1

RESULT 338
US-10-667-022-76/c
; Sequence 76, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-76

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4212 GGAGACTGGTGACAGAAGAT 4231
      |||||
Db 20 GGAGACTGGTGACAGAAGAT 1

RESULT 339
US-10-667-022-77/c
; Sequence 77, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-77

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4258 CCACCTTCTCTGAATTACAGCC 4277
      |||||
Db 20 CCACCTTCTCTGAATTACAGCC 1

RESULT 340
US-10-667-022-78/c
; Sequence 78, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB

```

; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-78

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4292 TCCATGCTACTACTGTAGT 4311
Db 20 TCCATGCTACTACTGTAGT 1

RESULT 341
US-10-667-022-79/c
; Sequence 79, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-79

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4309 AGTCCTGCAGATGGAATCC 4328
Db 20 AGTCCTGCAGATGGAATCC 1

RESULT 342
US-10-667-022-80/c
; Sequence 80, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-80

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4355 TGAATAAAGTTTGGGAC 4374
Db 20 TGAATAAAGTTTGGGAC 1

RESULT 343
US-10-667-022-81/c
; Sequence 81, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-81

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4397 ATGTTGTCAGGAAGTACT 4416
Db 20 ATGTTGTCAGGAAGTACT 1

RESULT 344
US-10-667-022-82/c
; Sequence 82, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-82

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4424 CATCTGTCTCTACTACAG 4443
Db 20 CATCTGTCTCTACTACAG 1

RESULT 345
US-10-667-022-83/c
; Sequence 83, Application US/10667022
; Publication No. US20040063657A1

```
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-83

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4461 TGAAGTTGTCAGGAATTC 4480
Db 20 TGAAGTTGTCAGGAATTC 1

RESULT 346
US-10-667-022-84/c
; Sequence 84, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-84

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4461 TGAAGTTGTCAGGAATTC 4480
Db 20 TGAAGTTGTCAGGAATTC 1

RESULT 347
US-10-667-022-85/c
; Sequence 85, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-85
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-85

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4761 CTGTTTCATGACTGACTGAC 4780
Db 20 CTGTTTCATGACTGACTGAC 1

RESULT 348
US-10-667-022-86/c
; Sequence 86, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-86

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4776 CTGACTAAATGACACCCAAA 4795
Db 20 CTGACTAAATGACACCCAAA 1

RESULT 349
US-10-667-022-87/c
; Sequence 87, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHONOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 87
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-87

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4792 CAAAATGTTAAGATGTACT 4811
Db 20 CAAAATGTTAAGATGTACT 1
```



```
RESULT 350
US-10-667-022-88/c
; Sequence 88, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-88

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4823 CTTATGCATCTCTTGCAG 4842
      |||||
Db 20 CTTATGCATCTCTTGCAG 1

RESULT 351
US-10-667-022-89
; Sequence 89, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 89
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-89

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CGTTTGTGGGCTGCAGCA 62
      |||||
Db 1 CGTTTGTGGGCTGCAGCA 20

RESULT 352
US-10-667-022-90
; Sequence 90, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 90
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-90

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 CGGTCTGCACCTCTCTCCCG 111
      |||||
Db 1 CGGTCTGCACCTCTCTCCCG 20

RESULT 353
US-10-667-022-91
; Sequence 91, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 91
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-91

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 377 AGCCCATCTCTGTCTATGA 396
      |||||
Db 1 AGCCCATCTCTGTCTATGA 20

RESULT 354
US-10-667-022-92
; Sequence 92, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 92
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-92

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CCTCTGAACGATTTGCACAC 505
      |||||
Db 1 CCTCTGAACGATTTGCACAC 20
```

```
RESULT 355
US-10-667-022-93
; Sequence 93, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 93
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-93
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 534 AACCTTACTAAGACCACAG 553
| | | | | | | | | | | | | | | |
Db 1 AACCTTACTAAGACCACAG 20

RESULT 356
US-10-667-022-94
; Sequence 94, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-94
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 559 CTTGCCATTATGGGAATCA 578
| | | | | | | | | | | | | | | |
Db 1 CTTGCCATTATGGGAATCA 20

RESULT 357
US-10-667-022-95
; Sequence 95, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 95
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-95
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 703 CGAGAAGGCGCTGTCGTTGT 722
| | | | | | | | | | | | | | | |
Db 1 CGAGAAGGCGCTGTCGTTGT 20

RESULT 358
US-10-667-022-96
; Sequence 96, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-96
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 780 GGAGGAACCTGAAATCAGGC 799
| | | | | | | | | | | | | | | |
Db 1 GGAGGAACCTGAAATCAGGC 20

RESULT 359
US-10-667-022-97
; Sequence 97, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 97
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-97
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 824 CTTTCCAGAAAGCATCAGAA 843
| | | | | | | | | | | | | | | |
Db 1 CTTTCCAGAAAGCATCAGAA 20

RESULT 360
```

```
US-10-667-022-98
; Sequence 98, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-98

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      875 GGCAGTATGTCGAGACAAT 894
      |||||
Db      1 GGCAGTATGTCGAGACAAT 20

RESULT 361
US-10-667-022-99
; Sequence 99, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 99
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-99

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      914 CCGTCCATTCTTGATAAC 933
      |||||
Db      1 CCGTCCATTCTTGATAAC 20

RESULT 362
US-10-667-022-100
; Sequence 100, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 100
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-100

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      982 GCACACAAATCTGGAGTTGCG 1001
      |||||
Db      1 GCACACAAATCTGGAGTTGCG 20

RESULT 363
US-10-667-022-101
; Sequence 101, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-101

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      998 TTCGTCATGGGACATCAAG 1017
      |||||
Db      1 TTCGTCATGGGACATCAAG 20

RESULT 364
US-10-667-022-102
; Sequence 102, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-102

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1032 GGTCCACCACTTGGAAATGGG 1051
      |||||
Db      1 GGTCCACCACTTGGAAATGGG 20

RESULT 365
US-10-667-022-103
```

```
; Sequence 103, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-103

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 1083 CACTTATCTTCCAGAGACA 1102
      |||||||
Db 1 CACTTATCTTCCAGAGACA 20

RESULT 366
US-10-667-022-104
; Sequence 104, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 104
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-104

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 1268 AGTTGAAGAGAGCAATGGAC 1287
      |||||||
Db 1 AGTTGAAGAGAGCAATGGAC 20

RESULT 367
US-10-667-022-105
; Sequence 105, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 105
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
```

```
; FEATURE:
US-10-667-022-105

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 1299 AGTTGTGTGATAGCTGAGC 1318
      |||||||
Db 1 AGTTGTGTGATAGCTGAGC 20

RESULT 368
US-10-667-022-106
; Sequence 106, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 106
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-106

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 1414 GATCACAGTATCAGAGAATT 1433
      |||||||
Db 1 GATCACAGTATCAGAGAATT 20

RESULT 369
US-10-667-022-107
; Sequence 107, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 107
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-107

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

Qy 1498 CAGCGTGGCAATGCTTTCC 1517
      |||||||
Db 1 CAGCGTGGCAATGCTTTCC 20

RESULT 370
US-10-667-022-108
; Sequence 108, Application US/10667022
```

```

; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-108

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1630 CACAATCTCTGTGCACATGA 1649
Db 1 CACAATCTCTGTGCACATGA 20

RESULT 371
US-10-667-022-109
; Sequence 109, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-109

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1658 AAAAAGCCGAAGGAGAGCCT 1677
Db 1 AAAAAGCCGAAGGAGAGCCT 20

RESULT 372
US-10-667-022-110
; Sequence 110, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-110

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1706 CTGTATAACATCTGCCTA 1725
Db 1 CTGTATAACATCTGCCTA 20

RESULT 373
US-10-667-022-111
; Sequence 111, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-111

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1978 GCCCAAGATGATGCTACTAT 1997
Db 1 GCCCAAGATGATGCTACTAT 20

RESULT 374
US-10-667-022-112
; Sequence 112, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 112
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-112

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2041 ACAGCTCTGAGATTCCTGGA 2060
Db 1 ACAGCTCTGAGATTCCTGGA 20

RESULT 375
US-10-667-022-113
; Sequence 113, Application US/10667022
; Publication No. US20040063657A1
```

```

US-10-667-022-110

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1706 CTGTATAACATCTGCCTA 1725
Db 1 CTGTATAACATCTGCCTA 20

RESULT 373
US-10-667-022-111
; Sequence 111, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-111

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1978 GCCCAAGATGATGCTACTAT 1997
Db 1 GCCCAAGATGATGCTACTAT 20

RESULT 374
US-10-667-022-112
; Sequence 112, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 112
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-112

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2041 ACAGCTCTGAGATTCCTGGA 2060
Db 1 ACAGCTCTGAGATTCCTGGA 20

RESULT 375
US-10-667-022-113
; Sequence 113, Application US/10667022
; Publication No. US20040063657A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 113
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-113

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2080 CTTAATATGGAATGACCC 2099
DB 1 CTTAATATGGAATGACCC 20

RESULT 376
US-10-667-022-114
; Sequence 114, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 114
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-114

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2131 CCAATGGAATTTATGACAC 2150
DB 1 CCAATGGAATTTATGACAC 20

RESULT 377
US-10-667-022-115
; Sequence 115, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 115
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-115
```

```
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2391 TGGCTGGCAAGCTCTCTCAA 2410
DB 1 TGGCTGGCAAGCTCTCTCAA 20

RESULT 378
US-10-667-022-116
; Sequence 116, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 116
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-116

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2438 TTAGTGATGCTGAGGAATTT 2457
DB 1 TTAGTGATGCTGAGGAATTT 20

RESULT 379
US-10-667-022-117
; Sequence 117, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 117
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-117

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2524 GTTTACGAATTTGCCAGTGA 2543
DB 1 GTTTACGAATTTGCCAGTGA 20

RESULT 380
US-10-667-022-118
; Sequence 118, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
US-10-667-022-118
```

```
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 118
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-118

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2555 TCCTGTGTCATCCCAATTGA 2574
      ||||||||||||||||||
Db 1 TCCTGTGTCATCCCAATTGA 20

RESULT 381
US-10-667-022-119
; Sequence 119, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 119
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-119

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2587 GGTGCCGTGGGATTTATCAC 2606
      ||||||||||||||||||
Db 1 GGTGCCGTGGGATTTATCAC 20

RESULT 382
US-10-667-022-120
; Sequence 120, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-120
```

```
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2731 GAACCAAGTAAGTCGTTCTAT 2750
      ||||||||||||||||||
Db 1 GAACCAAGTAAGTCGTTCTAT 20

RESULT 383
US-10-667-022-121
; Sequence 121, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 121
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-121

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2843 GCCCTCCGCCAGAGGATCCT 2862
      ||||||||||||||||||
Db 1 GCCCTCCGCCAGAGGATCCT 20

RESULT 384
US-10-667-022-122
; Sequence 122, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-122

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2860 CCTGCCATAGCACAGCTTCT 2879
      ||||||||||||||||||
Db 1 CCTGCCATAGCACAGCTTCT 20

RESULT 385
US-10-667-022-123
; Sequence 123, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
```

APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 123
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-667-022-123

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2913 AGAGGAAGACAACTTCTGG 2932
|||||
Db 1 AGAGGAAGACAACTTCTGG 20

RESULT 386
US-10-667-022-124
Sequence 124, Application US/10667022
Publication No. US20040063657A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 124
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-667-022-124

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3009 TCAGAAAGGTGTAATTGACT 3028
|||||
Db 1 TCAGAAAGGTGTAATTGACT 20

RESULT 387
US-10-667-022-125
Sequence 125, Application US/10667022
Publication No. US20040063657A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 125
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-667-022-125

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3057 AGTTGATCTTGTAAACCA 3076
|||||
Db 1 AGTTGATCTTGTAAACCA 20

RESULT 388
US-10-667-022-126
Sequence 126, Application US/10667022
Publication No. US20040063657A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 126
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-667-022-126

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3250 TCTGCTGGCATTGTGTCCC 3269
|||||
Db 1 TCTGCTGGCATTGTGTCCC 20

RESULT 389
US-10-667-022-127
Sequence 127, Application US/10667022
Publication No. US20040063657A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
FILE REFERENCE: RTS-0376
CURRENT APPLICATION NUMBER: US/10/667,022
CURRENT FILING DATE: 2003-09-18
NUMBER OF SEQ ID NOS: 147
SEQ ID NO 127
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-667-022-127

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3318 AAAACCAAGTAATACCGGTTT 3337
|||||
Db 1 AAAACCAAGTAATACCGGTTT 20

RESULT 390
US-10-667-022-128
Sequence 128, Application US/10667022
Publication No. US20040063657A1
GENERAL INFORMATION:
APPLICANT: Susan M. Freier
APPLICANT: Kenneth W. Dobie


```
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 128
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-128

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3341 GTAGTACAATCTTACCATCC 3360
Db 1 GTAGTACAATCTTACCATCC 20

RESULT 391
US-10-667-022-129
; Sequence 129, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 129
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-129

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3388 AAAACTGAACCTTCAGCAACT 3407
Db 1 AAAACTGAACCTTCAGCAACT 20

RESULT 392
US-10-667-022-130
; Sequence 130, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 130
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-130

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3388 AAAACTGAACCTTCAGCAACT 3407
Db 1 AAAACTGAACCTTCAGCAACT 20

RESULT 393
US-10-667-022-131
; Sequence 131, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 131
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-131

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3455 AGATGATGGAATAATGCTGAA 3474
Db 1 AGATGATGGAATAATGCTGAA 20

RESULT 394
US-10-667-022-132
; Sequence 132, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 132
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-132

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3504 GCGTCCTCTAAAGGCTGTAG 3523
Db 1 GCGTCCTCTAAAGGCTGTAG 20

RESULT 395
US-10-667-022-133
; Sequence 133, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
```

; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 133
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-133

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3555 GAATCGAATTAGACTCTCTG 3574
Db 1 GAATCGAATTAGACTCTCTG 20

RESULT 396
US-10-667-022-134
; Sequence 134, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 134
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-134

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3583 TCACCTTTTGCACATGTC 3602
Db 1 TCACCTTTTGCACATGTC 20

RESULT 397
US-10-667-022-135
; Sequence 135, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 135
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-135

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3762 TGTCCAGCTTCTTGGAAATG 3781
Db 1 TGTCCAGCTTCTTGGAAATG 20

RESULT 398
US-10-667-022-136
; Sequence 136, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-136

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3899 TTCTTGCTATGCCACTGTG 3918
Db 1 TTCTTGCTATGCCACTGTG 20

RESULT 399
US-10-667-022-137
; Sequence 137, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-137

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3991 GGCCTCATCACTTCCTTTC 4010
Db 1 GGCCTCATCACTTCCTTTC 20

RESULT 400
US-10-667-022-138
; Sequence 138, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: P150 EXPRESSION

; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-138

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4050 CAGTGGTACCAGCTGTGTT 4069
Db 1 CAGTGGTACCAGCTGTGTT 20

RESULT 401

US-10-667-022-139
; Sequence 139, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 139
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-667-022-139

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4166 TGATTGCAGCTGTTACAGGC 4185
Db 1 TGATTGCAGCTGTTACAGGC 20

RESULT 402

US-10-667-022-140
; Sequence 140, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 140
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-667-022-140

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4309 AGTCCTGCAGATGGAATCC 4328
Db 1 AGTCCTGCAGATGGAATCC 20

RESULT 403

US-10-667-022-141
; Sequence 141, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-667-022-141

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4397 ATGTTGTCGAGGAGTACT 4416
Db 1 ATGTTGTCGAGGAGTACT 20

RESULT 404

US-10-667-022-142
; Sequence 142, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 142
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-667-022-142

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4424 CATCTGTCTCTACTACAG 4443
Db 1 CATCTGTCTCTACTACAG 20

RESULT 405

US-10-667-022-143
; Sequence 143, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376

; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 143
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-143

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4633 GTGTGGAATAAAACCTACT 4652
|||||
Db 1 GTGTGGAATAAAACCTACT 20

RESULT 406
US-10-667-022-144
; Sequence 144, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 144
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-144

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4761 CTGTTTCATGACTGACTGAC 4780
|||||
Db 1 CTGTTTCATGACTGACTGAC 20

RESULT 407
US-10-667-022-145
; Sequence 145, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-145

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4776 CTGACTAAATGACACCCAAA 4795

Db 1 CTGACTAAATGACACCCAAA 20
|||||

RESULT 408
US-10-667-022-146
; Sequence 146, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 146
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-146

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4792 CAAAATGGTTAAGATGTACT 4811
|||||
Db 1 CAAAATGGTTAAGATGTACT 20

RESULT 409
US-10-667-022-147
; Sequence 147, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-147

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4823 CTTATGCATCTCTTTGCAAG 4842
|||||
Db 1 CTTATGCATCTCTTTGCAAG 20

RESULT 410
US-10-661-415-12
; Sequence 12, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12

; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-12

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 411

US-10-661-415-15/c
; Sequence 15, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-15

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 412

US-10-831-778-226/c
; Sequence 226, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy

; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-226

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 413

US-10-831-778-556/c
; Sequence 556, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 556
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-556

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 414

US-10-831-778-560
; Sequence 560, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03

```

; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 560
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-560

```

```
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels
```

Qy	5025	AAAAAAAAAAAAAAAAAAAAA	5044
pb	1	AAAAAAAAAAAAAAAAAAAAA	20

```

RESULT 415
US-10-728-078-23/c
; Sequence 23, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; TITLE OF INVENTION: AND OTHER BINDING PROTEINS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIORITY APPLICATION NUMBER: US/09/688,566
; PRIORITY FILING DATE: 2000-10-16
; PRIORITY APPLICATION NUMBER: US 60/111,737
; PRIORITY FILING DATE: 1998-12-10
; PRIORITY APPLICATION NUMBER: US 09/456,693
; PRIORITY FILING DATE: 1999-12-09
; PRIORITY APPLICATION NUMBER: US 09/515,260
; PRIORITY FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: Fast-Seq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-728-078-23

```

Query Match	0.4%;	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 2.6e+02;		
Matches 20:	Conservative	0;	Mismatches 0;	Indels 0;
Gaps 0:				

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||
nb 20 AAAAAAAAAAAAAAAAAAAAAA 1

```

RESULT 416
US-10-601-140A-1/c
; Sequence 1, Application US/10601140A
; Publication No. US2005053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764 (71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2

```

```

; SEQ ID NO 1
;
; LENGTH: 20
;
; TYPE: DNA
;
; ORGANISM: Artificial Sequence
;
; FEATURE:
;
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-1

```

```
Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels
```

Qy 5025 AAAAAAAAAAAAAAAAAA 5044
 Db 20 AAAAAAAAAAAAAAAAAA 1

```

RESULT 417
US-10-601-140A-2/G
; Sequence 2, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
; LENGTH: 20

```

```

1 ORGANISM: Artificial Sequence
2
3 FEATURE:
4 OTHER INFORMATION: Description of Artificial Sequence: Synthetic
5 OTHER INFORMATION: oligonucleotide
6
7 FEATURE:
8 NAME/KEY: modified_base
9 LOCATION: (1)
10 OTHER INFORMATION: LNA monomer
11
12 FEATURE:
13 NAME/KEY: modified_base
14 LOCATION: (3)
15 OTHER INFORMATION: LNA monomer
16
17 FEATURE:
18 NAME/KEY: modified_base
19 LOCATION: (5)
20 OTHER INFORMATION: LNA monomer
21
22 FEATURE:
23 NAME/KEY: modified_base
24 LOCATION: (7)
25 OTHER INFORMATION: LNA monomer
26
27 FEATURE:
28 NAME/KEY: modified_base
29 LOCATION: (9)
30 OTHER INFORMATION: LNA monomer
31
32 FEATURE:
33 NAME/KEY: modified_base
34 LOCATION: (11)
35 OTHER INFORMATION: LNA monomer
36
37 FEATURE:
38 NAME/KEY: modified_base
39 LOCATION: (13)
40 OTHER INFORMATION: LNA monomer
41
42 FEATURE:
43 NAME/KEY: modified_base
44 LOCATION: (15)
45 OTHER INFORMATION: LNA monomer

```

```
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-2
```

```
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
    |||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1
```

RESULT 418

```
US-10-601-140A-3/c
; Sequence 3, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; US-10-601-140A-3
```

```
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
    |||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1
```

RESULT 419

```
US-10-601-140A-4/c
; Sequence 4, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
```

```
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
```

```
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
```

```
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

```
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

```
; LOCATION: (10)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

```
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

```
; LOCATION: (16)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

```
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-4
```

```
Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
    |||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1
```

RESULT 420

```
US-10-601-140A-6/c
; Sequence 6, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
```

```
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-6

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 421
US-10-601-140A-7/c
; Sequence 7, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-8

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 422
US-10-601-140A-8/c
; Sequence 8, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-8

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 423
US-10-601-140A-9/c
; Sequence 9, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)..(4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (8)..(9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)..(14)
; OTHER INFORMATION: LNA monomer
;

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

US-10-601-140A-7
```


; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (18)..(19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-9

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 424

US-10-601-140A-10/c
; Sequence 10, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764 (71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)..(5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)..(12)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)..(19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-10

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 425

US-10-601-140A-23/c
; Sequence 23, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764 (71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20

; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide capture probe
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-23

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 426

US-10-601-140A-34
; Sequence 34, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764 (71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45

```

; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide linker
; US-10-601-140A-34

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 427
US-10-601-140A-40/c
; Sequence 40, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; US-10-601-140A-40

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 428
US-10-601-140A-44
; Sequence 44, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 44
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; US-10-601-140A-44

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 429
US-10-876-086-49/c
; Sequence 49, Application US/10876086
; Publication No. US20050066389A1
; GENERAL INFORMATION:
; APPLICANT: Gallie, Daniel R.
; APPLICANT: Young, Todd E.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Genes Which Produce Staygreen Characteristics in Maize
; TITLE OF INVENTION: and Their Uses
; FILE REFERENCE: 023070-137010US
; CURRENT APPLICATION NUMBER: US/10/876,086
; CURRENT FILING DATE: 2004-06-23
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligo-dt(20)
; US-10-876-086-49

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 430
US-10-831-901A-29732/c
; Sequence 29732, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sammes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (E10L0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30

```

;; PRIOR APPLICATION NUMBER: 60/468,627
;; PRIOR FILING DATE: 2003-05-06
;; PRIOR APPLICATION NUMBER: 60/477,637
;; PRIOR FILING DATE: 2003-06-10
;; PRIOR APPLICATION NUMBER: 60/483,579
;; PRIOR FILING DATE: 2003-06-27
;; NUMBER OF SEQ ID NOS: 30063
;; SOFTWARE: FastSEQ for Windows Version 4.0
;; SEQ ID NO 29732
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Antisense compound
US-10-831-901A-29732

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
DB 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 431
US-10-831-901A-29733/c
; Sequence 29733, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29733
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29733

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||

DB 20 AAAAAAAAAAAAAAAAAAAAAA 1
RESULT 432
US-10-831-901A-29734/c
; Sequence 29734, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29734
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29734

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
DB 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 433
US-10-831-901A-29735/c
; Sequence 29735, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A

```

; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29735
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29735
```

```

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1
```

```

RESULT 434
US-10-831-901A-29736/c
; Sequence 29736, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29736
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29736
```

```

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 435
US-10-789-831-22
; Sequence 22, Application US/10789831
; Publication No. US20050130174A1
; GENERAL INFORMATION:
; APPLICANT: Bao, Yijia P.
; APPLICANT: Muller, Uwe R.
; TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH
; FILE REFERENCE: 03-214-A
; CURRENT APPLICATION NUMBER: US/10/789,831
; CURRENT FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US 60/450,268
; PRIOR FILING DATE: 2003-02-27
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: detection probe
; NAME/KEY: unsure
; LOCATION: (1)..(1)
; OTHER INFORMATION: a comprises an epiandrosterone disulfide group
US-10-789-831-22

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 436
US-10-789-831-23/c
; Sequence 23, Application US/10789831
; Publication No. US20050130174A1
; GENERAL INFORMATION:
; APPLICANT: Bao, Yijia P.
; APPLICANT: Muller, Uwe R.
; TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH
; FILE REFERENCE: 03-214-A
; CURRENT APPLICATION NUMBER: US/10/789,831
; CURRENT FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US 60/450,268
; PRIOR FILING DATE: 2003-02-27
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: detection probe
; NAME/KEY: unsure
; LOCATION: (1)..(1)
; OTHER INFORMATION: t comprises an epiandrosterone disulfide group
US-10-789-831-23/c
```

US-10-789-831-23

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
DB 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 437

US-10-789-831-24
; Sequence 24, Application US/10789831
; Publication No. US20050130174A1
; GENERAL INFORMATION:
; APPLICANT: Bao, Yijia P.
; APPLICANT: Muller, Uwe R.
; TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH UNIVERSAL NANOPARTICLES
; FILE REFERENCE: 03-214-A
; CURRENT APPLICATION NUMBER: US/10789,831
; PRIOR FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US 60/450,268
; PRIOR FILING DATE: 2003-02-27
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: detection probe
US-10-789-831-24

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
DB 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 438

US-10-661-402-12
; Sequence 12, Application US/10661402
; Publication No. US20050133912A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
; FILE REFERENCE: 029849/0207
; CURRENT APPLICATION NUMBER: US/10/661,402
; PRIOR FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-402-12

Query Match 0.4%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
DB 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 439

US-10-661-402-15/c
; Sequence 15, Application US/10661402
; Publication No. US20050153912A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
; FILE REFERENCE: 029849/0207
; CURRENT APPLICATION NUMBER: US/10/661,402
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-402-15

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
|||||
DB 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 440

US-10-847-502-10/c
; Sequence 10, Application US/10847502
; Publication No. US20050165226A1
; GENERAL INFORMATION:
; APPLICANT: Cole, Douglas L.
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Cheruvallath, Zacharia S.
; TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
; FILE REFERENCE: ISIS-4709
; CURRENT APPLICATION NUMBER: US/10/847,502
; CURRENT FILING DATE: 2004-05-17
; PRIOR APPLICATION NUMBER: US/10/181,200
; PRIOR FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: PCT/US01/00715
; PRIOR FILING DATE: 2001-01-10
; PRIOR APPLICATION NUMBER: US 09/481,486
; PRIOR FILING DATE: 2000-01-11
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; OTHER INFORMATION: misc_feature
; NAME/KEY: misc_feature

```

; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methoxyethyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: phosphorothioate 20-mer
US-10-847-502-10

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 441
US-10-847-502-15/c
; Sequence 15, Application US/10847502
; Publication No. US20050165226A1
; GENERAL INFORMATION:
; APPLICANT: Cole, Douglas L.
; APPLICANT: Ravikumar, Vasalinga T.
; APPLICANT: Cheruvallath, Zacharia S.
; TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
; FILE REFERENCE: ISIS-4709
; CURRENT APPLICATION NUMBER: US/10/847,502
; CURRENT FILING DATE: 2004-05-17
; PRIOR APPLICATION NUMBER: US/10/181,200
; PRIOR FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: PCT/US01/00715
; PRIOR FILING DATE: 2001-01-10
; PRIOR APPLICATION NUMBER: US 09/481,486
; PRIOR FILING DATE: 2000-01-11
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: phosphorothioate 20-mer
US-10-847-502-15

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 442
US-10-025-145A-35
; Sequence 35, Application US/10025145A
; Publication No. US20030175861A1
; GENERAL INFORMATION:
; APPLICANT: Croteau, Rodney B.
; APPLICANT: Bohlmann, Joerg
; APPLICANT: Steele, Christopher L.
; APPLICANT: Phillips, Michael A.
; TITLE OF INVENTION: Monoterpene Synthases from Grand Fir (Abies Grandis)
; FILE REFERENCE: WSUR118414

; CURRENT APPLICATION NUMBER: US/10/025,145A
; CURRENT FILING DATE: 2002-06-28
; PRIOR APPLICATION NUMBER: US 09/360,545
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: PCT/US98/14528
; PRIOR FILING DATE: 1998-07-10
; PRIOR APPLICATION NUMBER: US 60/052,249
; PRIOR FILING DATE: 1997-07-11
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Oligonucleotide Primer 3.18 EcorI
US-10-025-145A-35

Query Match          0.4%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 CTCGAGGAATTCGGCACGAG 32
Db 1 CTCGAGGAATTCGGCACGAG 20

RESULT 443
US-10-913-246-23
; Sequence 23, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 49269200500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-913-246-23

Query Match          0.4%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 2 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 444
US-10-934-890-23
; Sequence 23, Application US/10934890
; Publication No. US2005001492A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: AMPLIFICATION OF RNA SEQUENCES
```

```
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-23

Query Match          0.4%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 2 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 445
US-10-394-388A-6
; Sequence 6, Application US/10394388A
; Publication No. US20040053216A1
; GENERAL INFORMATION:
; APPLICANT: Hooper, Jay W.
; APPLICANT: Schmaljohn, Connie S.
; APPLICANT: Custer, Max
; TITLE OF INVENTION: DNA Vaccines Against Hantavirus Infections
; FILE REFERENCE: 003/259/SAP
; CURRENT APPLICATION NUMBER: US/10/394,388A
; CURRENT FILING DATE: 2003-03-21
; PRIOR APPLICATION NUMBER: US 09/941,074
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/367,128
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: US 60/398,985
; PRIOR FILING DATE: 2002-07-26
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Apple Macintosh Microsoft Word 6.0
; SEQ ID NO 6
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence of 24 bp extraneous sequence
US-10-394-388A-6

Query Match          0.4%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 CTCGAGGAATTCGGCAGCAG 32
Db 5 CTCGAGGAATTCGGCAGCAG 24

RESULT 446
US-10-688-299-54/c
; Sequence 54, Application US/10688299
; Publication No. US20040142892A1
; GENERAL INFORMATION:
; APPLICANT: Finn, John
; APPLICANT: Finn, John

; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-23

Query Match          0.4%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 2 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 445
US-10-394-388A-6
; Sequence 6, Application US/10394388A
; Publication No. US20040053216A1
; GENERAL INFORMATION:
; APPLICANT: Hooper, Jay W.
; APPLICANT: Schmaljohn, Connie S.
; APPLICANT: Custer, Max
; TITLE OF INVENTION: DNA Vaccines Against Hantavirus Infections
; FILE REFERENCE: 003/259/SAP
; CURRENT APPLICATION NUMBER: US/10/394,388A
; CURRENT FILING DATE: 2003-03-21
; PRIOR APPLICATION NUMBER: US 09/941,074
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/367,128
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: US 60/398,985
; PRIOR FILING DATE: 2002-07-26
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Apple Macintosh Microsoft Word 6.0
; SEQ ID NO 6
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence of 24 bp extraneous sequence
US-10-394-388A-6

Query Match          0.4%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 CTCGAGGAATTCGGCAGCAG 32
Db 5 CTCGAGGAATTCGGCAGCAG 24

RESULT 446
US-10-688-299-54/c
; Sequence 54, Application US/10688299
; Publication No. US20040142892A1
; GENERAL INFORMATION:
; APPLICANT: Finn, John
; APPLICANT: Finn, John

; APPLICANT: MacLachlan, Ian
; APPLICANT: Protiva Biopharmaceuticals Inc.
; TITLE OF INVENTION: Autogene Nucleic Acids Encoding a
; TITLE OF INVENTION: Secretable RNA Polymerase
; FILE REFERENCE: 020801-000320US
; CURRENT APPLICATION NUMBER: US/10/688,299
; CURRENT FILING DATE: 2003-10-16
; PRIOR APPLICATION NUMBER: US 60/287,974
; PRIOR FILING DATE: 2001-04-30
; PRIOR APPLICATION NUMBER: US 10/136,738
; PRIOR FILING DATE: 2002-04-30
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 54
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: NVSCI primer
US-10-688-299-54

Query Match          0.4%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGATCCCCCGGCTGCAGGA 20
Db 20 GGATCCCCCGGCTGCAGGA 1

RESULT 447
US-10-681-773-75257
; Sequence 75257, Application US/10681773
; Publication No. US20040146890A1
; GENERAL INFORMATION:
; APPLICANT: Matsuzaki, Hajime
; APPLICANT: Mei, Rui
; APPLICANT: Kennedy, Giulia
; TITLE OF INVENTION: Methods for Genotyping Polymorphisms in Humans
; FILE REFERENCE: 3522.2
; CURRENT APPLICATION NUMBER: US/10/681,773
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: 60/470,475
; PRIOR FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 60/417,190
; PRIOR FILING DATE: 2002-10-08
; NUMBER OF SEQ ID NOS: 124031
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 75257
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-681-773-75257

Query Match          0.4%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2137 GGAAATTATGACACAGCTCCA 2159
Db 1 GGAAATTTTGACACAGAGCTACA 23

RESULT 448
US-09-776-479-60/c
; Sequence 60, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
```

```

; NUMBER OF SEQ ID NOS: 1040
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 54
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-54

Query Match          0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
    ||||| ||||| ||||| ||||| |||||
DB 24 AAAAAACAAAAAACAAAAAACAA 1

RESULT 451
US-10-017-995-60/c
; Sequence 60, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-60

Query Match          0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
    ||||| ||||| ||||| ||||| |||||
DB 24 AAAAAACAAAAAACAAAAAACAA 1

RESULT 452
US-10-314-578-60/c
; Sequence 60, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jorg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 24
; TYPE: DNA

```



```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-60

Query Match          0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 453
US-10-931-778-60/c
; Sequence 60, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-60

Query Match          0.4%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 454
US-10-098-263B-76253/c
; Sequence 76253, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
; APPLICANT: Mittman, Michael
; TITLE OF INVENTION: Human Microarray
; FILE REFERENCE: 3118.1
; CURRENT APPLICATION NUMBER: US/10/098,263B
; PRIOR FILING DATE: 2003-01-08
; PRIOR APPLICATION NUMBER: 60/276,759
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 131066
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 76253
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-098-263B-76253

Query Match          0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 80 TCTTGGGACTGCGGTCGCACTT 103
Db 24 TCTTGGGACTGCGGTCGCACTT 1

RESULT 455
US-10-098-263B-76254/c
; Sequence 76254, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
; APPLICANT: Mittman, Michael
; TITLE OF INVENTION: Human Microarray
; FILE REFERENCE: 3118.1
; CURRENT APPLICATION NUMBER: US/10/098,263B
; PRIOR FILING DATE: 2003-01-08
; PRIOR APPLICATION NUMBER: 60/276,759
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 131066
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 76254
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-098-263B-76254

Query Match          0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 80 TCTTGGGACTGCGGTCGCACTT 103
Db 24 TCTTGGGACTGCGGTCGCACTT 1

RESULT 456
US-10-719-900-18911
; Sequence 18911, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 18911
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-18911

Query Match          0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4639 AAATAAACCTACTGATTTGTATA 4662
Db 1 AAATAACCTCTACTGTTTGTATA 24

RESULT 457
US-10-719-900-228029
; Sequence 228029, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
```

```
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 228029
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-228029

Query Match      0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 743 ATCCACATTGCCTTTAACAGCT 766
|||
Db 1 ATACACATTGCATTCAACAGCT 24
|||

RESULT 458
US-10-719-900-228030
; Sequence 228030, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 228030
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-228030

Query Match      0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 743 ATCCACATTGCCTTTAACAGCT 766
|||
Db 1 ATACACATTGCATTCAACAGCT 24
|||

RESULT 459
US-10-719-900-286591/c
; Sequence 286591, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 286591
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-286591

Query Match      0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3463 GAAATGCTGATGGAGAGTAAA 3486
|||||
```

```
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 872676
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-872676

Query Match          0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 591 TGTCTCCCTCCAGATCTTCTCT 614
      ||||| ||||| ||||| |||||
Db 1 TGTCTCCCTCTCATATGCTTCTCT 24

RESULT 463
US-10-719-900-956708/c
; Sequence 956708, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 956708
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-956708

Query Match          0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1950 ATCATCTTCCAGGATAGCCCA 1973
      ||||| ||||| ||||| |||||
Db 25 ACATCTTCCAGGCAAGCAAGCCCA 2

RESULT 464
US-10-719-956-68653
; Sequence 68653, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 68653
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-68653

Query Match          0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4092 AATTTCAGTCATGTCATCTTC 4115
      ||||| ||||| ||||| |||||
Db 1 AATTTCATCTAACTGTCATCTTC 24

RESULT 465
US-10-719-956-369528/c
; Sequence 369528, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 369528
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-369528

Query Match          0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4492 AAAGTAGGACCAAGTCATGACACC 4515
      ||||| ||||| ||||| |||||
Db 24 AAATTAGGACCAAGTGGTGACATC 1

RESULT 466
US-10-719-956-467347/c
; Sequence 467347, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 467347
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-467347

Query Match          0.4%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3829 AGAATTCTAGATCAGAAGGAGGAC 3852
      ||||| ||||| ||||| |||||
Db 25 AAAATTCTAGAACAGAGGAGAC 2

RESULT 467
US-10-719-956-520734/c
; Sequence 520734, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
```

```
/ SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
/ SEQ ID NO 520734
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Rattus norvegicus
US-10-719-956-520734
```

```
Query Match          0.4%; Score 19,2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      838 TCAGAAAAAGCATCTGAGAAAGCA 861
          |||||
Db       25 TCAGAAAAAGCATATGAGCAACA 2
```

RESULT 468

```
US-10-760-940-1/c
/ Sequence 1, Application US/10760940
/ Publication No. US20040219577A1
/ GENERAL INFORMATION:
/ APPLICANT: Ravikumar, Vasulinga
/ APPLICANT: Manoharan, Muthiah
/ APPLICANT: Capaldi, Daniel C.
/ APPLICANT: Krotz, Achim
/ APPLICANT: Cole, Douglas L.
/ APPLICANT: Guzaev, Andrei
/ TITLE OF INVENTION: IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS
/ FILE REFERENCE: ISIS-5422
/ CURRENT APPLICATION NUMBER: US/10/760,940
/ CURRENT FILING DATE: 2004-01-20
/ PRIOR APPLICATION NUMBER: US 10/232,881
/ PRIOR FILING DATE: 2002-08-30
/ PRIOR APPLICATION NUMBER: US 09/288,679
/ PRIOR FILING DATE: 1999-04-09
/ PRIOR APPLICATION NUMBER: US 60/118,564
/ PRIOR FILING DATE: 1999-02-04
/ NUMBER OF SEQ ID NOS: 5
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 1
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Construct
US-10-760-940-1
```

```
Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      5025 AAAAAAAAAAAAAAAAAAAAA 5043
          |||||
Db       19 AAAAAAAAAAAAAAAAAAAAA 1
```

RESULT 469

```
US-10-913-246-24
/ Sequence 24, Application US/10913246
/ Publication No. US20050003441A1
/ GENERAL INFORMATION:
/ APPLICANT: Kurn, Nurith
/ TITLE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES
/ FILE REFERENCE: 492692000500
/ CURRENT APPLICATION NUMBER: US/10/913,246
/ CURRENT FILING DATE: 2004-08-05
/ PRIOR APPLICATION NUMBER: US/10/100,321
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/274,550
/ PRIOR FILING DATE: 2001-03-09
/ NUMBER OF SEQ ID NOS: 25
/ SOFTWARE: FastSEQ for Windows Version 4.0
```

```
/ SEQ ID NO 24
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Primer
US-10-913-246-24
```

```
Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      5025 AAAAAAAAAAAAAAAAAAAAA 5043
          |||||
Db       1  AAAAAAAAAAAAAAAAAAAAA 19
```

RESULT 470

```
US-10-934-890-24
/ Sequence 24, Application US/10934890
/ Publication No. US20050014192A1
/ GENERAL INFORMATION:
/ APPLICANT: Kurn, Nurith
/ TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
/ FILE REFERENCE: 492692000500
/ CURRENT APPLICATION NUMBER: US/10/934,890
/ CURRENT FILING DATE: 2004-09-03
/ PRIOR APPLICATION NUMBER: US/10/100,321
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/274,550
/ PRIOR FILING DATE: 2001-03-09
/ NUMBER OF SEQ ID NOS: 25
/ SOFTWARE: FastSEQ for Windows Version 4.0
/ SEQ ID NO 24
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Primer
US-10-934-890-24
```

```
Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      5025 AAAAAAAAAAAAAAAAAAAAA 5043
          |||||
Db       1  AAAAAAAAAAAAAAAAAAAAA 19
```

RESULT 471

```
US-10-700-884-23/c
/ Sequence 23, Application US/10700884
/ Publication No. US20050118605A9
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Brenda F.
/ APPLICANT: Eldrup, Anne B.
/ APPLICANT: Manoharan, Muthiah
/ APPLICANT: Bhat, Balkrishen
/ APPLICANT: Griffey, Richard
/ APPLICANT: Swayze, Eric E.
/ APPLICANT: Crooke, Stanley T.
/ APPLICANT: Prakash, Thazha P.
/ TITLE OF INVENTION: OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE
/ FILE REFERENCE: ISIS-5317
/ CURRENT APPLICATION NUMBER: US/10/700,884
/ CURRENT FILING DATE: 2003-11-04
/ PRIOR APPLICATION NUMBER: US 10/635,380
/ PRIOR FILING DATE: 2003-08-06
/ NUMBER OF SEQ ID NOS: 25
/ SOFTWARE: FastSEQ for Windows Version 4.0
```

; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 10/078,949
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/479,783
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 08/870,608
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: US 08/659,440
; PRIOR FILING DATE: 1996-06-06
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-O-[2-(methoxy)ethyl]-2-thio-5-methyluridine
US-10-700-884-23

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5043
|||||
DB 19 AAAAAAAAAAAAAAAAAA 1

RESULT 472
US-10-940-360-1/c
; Sequence 1, Application US/10940360
; Publication No. US20050137391A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulunga
; APPLICANT: Manoharan, Muthia
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric Compounds
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/10/940,360
; CURRENT FILING DATE: 2004-09-14
; PRIOR APPLICATION NUMBER: US/09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Novel Sequence
US-10-940-360-1

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5043
|||||
DB 19 AAAAAAAAAAAAAAAAAA 1

RESULT 473
US-10-728-078-14
; Sequence 14, Application US/10728078

; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; TITLE OF INVENTION: AND OTHER BINDING PROTEINS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Puromycin linker oligonucleotide
US-10-728-078-14

Query Match 0.4%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5047 AAAAAAAAAAAAAAAAAA 5065
|||||
DB 1 AAAAAAAAAAAAAAAAAA 19

RESULT 474
US-10-620-642-33/c
; Sequence 33, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993

Thu Aug 18 08:58:56 2005

```
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-620-642-33
Query Match 0.4%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5024 TAAAAAATAAAAAAAAAA 5042
Db 19 TAAAAAATAAAAAAAAAA 1

RESULT 475
US-10-831-901A-29731/c
; Sequence 29731, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL00080US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 29731
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29731
Query Match 0.4%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAATAAAAAAAAAA 5043
Db 19 AAAAAAATAAAAAAAAAA 1

RESULT 476
US-10-469-881-15
; Sequence 15, Application US/10469881
; Publication No. US20040171824A1
; GENERAL INFORMATION:
; APPLICANT: The University of Virginia Patent Foundation
; APPLICANT: Scrabble, Heidi J
; APPLICANT: Cronin, Carolyn A
; TITLE OF INVENTION: A Lac Operator-Repressor System
; FILE REFERENCE: 00663-02
; CURRENT APPLICATION NUMBER: US/10/469,881
; CURRENT FILING DATE: 2003-09-04
; PRIOR APPLICATION NUMBER: 60/281,322
; PRIOR FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 60/273,480
; PRIOR FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic nucleic acid sequence linking the promoter to the codin
; OTHER INFORMATION: 9 region
US-10-469-881-15
Query Match 0.4%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 CCGCGGCTGCAGGAATTC 24
Db 7 CCGCGGCTGCAGGAATTC 25

RESULT 477
US-10-719-900-642313/c
; Sequence 642313, Application US/10719900
; Publication No. US200500506164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 642313
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-642313
```

```
Query Match      0.4%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2132 CAAATGGAAATTATGACAC 2150
Db 21 CAAATGGAAATTATGACAC 3

RESULT 478
US-10-831-778-61/c
; Sequence 61, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 61
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-61

Query Match      0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.5e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5046
Db 22 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 479
US-10-719-900-516700
; Sequence 516700, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 516700
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-516700

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1902 TGCTCTCGTCAAGAGGTTCTT 1923
Db 3 TGGTCTCTCAAGAGGTTCTT 24

RESULT 480
```

```
US-10-719-900-899255/c
; Sequence 899255, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 899255
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-899255

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 848 CATCTGAGAAAGCAGCTATGCT 869
Db 25 CATCTGAGACAGTAGCTATGCT 4

RESULT 481
US-10-719-900-899256/c
; Sequence 899256, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 899256
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-899256

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 848 CATCTGAGAAAGCAGCTATGCT 869
Db 25 CATCTGAGACAGTAGCTATGCT 4

RESULT 482
US-10-809-189-82442
; Sequence 82442, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
```

```
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 82442
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
; US-10-809-189-82442

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 191 GAGCCCGGGAAGCATGTGCC 212
Db 1 GAGGCCCTGGAAGCATGTGCC 22

RESULT 483
US-10-809-189-108648
; Sequence 108648, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 108648
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
; US-10-809-189-108648

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 266 TCTTAGCGTGGCTTCTCTCT 287
Db 4 TCTTAGCGTGGCTTCTCTCT 25

RESULT 484
US-10-809-189-119803
; Sequence 119803, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 119803
; LENGTH: 25

; TYPE: DNA
; ORGANISM: mus musculus
; US-10-809-189-119803

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4096 TCAAGTCACTGTCATCCCTTCCA 4117
Db 1 TAAAGTCACTGTCATCCCTTCCA 22

RESULT 485
US-10-681-773-63115
; Sequence 63115, Application US/10681773
; Publication No. US20040146890A1
; GENERAL INFORMATION:
; APPLICANT: Matsuzaki, Hajime
; APPLICANT: Mei, Rui
; APPLICANT: Kennedy, Giulia
; APPLICANT: Shen, Mei-Mei
; TITLE OF INVENTION: Methods for Genotyping Polymorphisms in Humans
; FILE REFERENCE: 3522.2
; CURRENT APPLICATION NUMBER: US/10/681,773
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: 60/470,475
; PRIOR FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 60/417,190
; PRIOR FILING DATE: 2002-10-08
; NUMBER OF SEQ ID NOS: 124031
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 63115
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
; US-10-681-773-63115

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2138 GAAATTATGACACAGAGCTTCCA 2159
Db 1 GAAATTTTGACACAGAGCTACA 22

RESULT 486
US-10-719-956-185866
; Sequence 185866, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 185866
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
; US-10-719-956-185866

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1690 CTGGTTATCTTGGTATCTGTTA 1711
||| ||||||| ||||||| |||||||
```



```
Db      3 CTGCTTATCTGGCATCTGTGA 24

RESULT 487
US-10-719-956-455343/c
; Sequence 455343, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 455343
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-455343

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      644 TTGAATATGATAAAGCCTGGG 665
Db      25 TAGAATAAGATAAAGCCTGGG 4

RESULT 488
US-10-719-956-643653/c
; Sequence 643653, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 643653
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-643653

Query Match      0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      848 CATCTGAGAAAGCAGCTATGCT 869
Db      25 CATCTGAGACAGTAGCTATGCT 4

RESULT 489
US-10-719-956-643654/c
; Sequence 643654, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20

Db      3 CTGCTTATCTGGCATCTGTGA 24

RESULT 490
US-10-831-901A-29730/c
; Sequence 29730, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (E10L000808U)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29730
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29730

Query Match      0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 3.4e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db      20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 491
US-10-374-366-201
; Sequence 201, Application US/10374366
; Publication No. US20040014085A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Tang, Xiao-Song
; APPLICANT: Milano, Joseph
; TITLE OF INVENTION: METHOD FOR THE RECOMBINATION OF GENETIC ELEMENTS
; FILE REFERENCE: C11794 US NA
; CURRENT APPLICATION NUMBER: US/10/374,366
; CURRENT FILING DATE: 2003-02-26
; PRIOR APPLICATION NUMBER: 60/360,279
; PRIOR FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 201
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Rhodosporidium glutinis
US-10-374-366-201

Query Match          0.4%; Score 18.4; DB 1; Length 24;
Best Local Similarity 95.0%; Pred. No. 4e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5063 AACTCGAGGGGGGCCCGGT 5082
Db 5 AGCTCGAGGGGGGCCCGGT 24

RESULT 492
US-10-849-072-21
; Sequence 21, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
; TITLE OF INVENTION: used
; FILE REFERENCE: 4780/00/WO
; CURRENT APPLICATION NUMBER: US/10/849,072
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: second
; OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-21

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5042
Db 1 AAAAAAAAAAAAAAAAAAAAAA 18

RESULT 493
US-10-849-072-23/c
; Sequence 23, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: used
; FILE REFERENCE: 4780/00/WO
; CURRENT APPLICATION NUMBER: US/10/849,072
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 18
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: second
; OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-23

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5042
Db 18 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 494
US-10-831-778-913/c
; Sequence 913, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 913
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-913

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5042
Db 18 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 495
US-10-831-778-939/c
; Sequence 939, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 939
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
```

US-10-931-778-939

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5042
| | | | | | | | | | | | | | | | | |
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 496

US-10-776-933-150/c
; Sequence 150, Application US/10776933
; Publication No. US2004024171A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THURUE, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDUXIN
; FILE REFERENCE: 58614(71432)
; CURRENT APPLICATION NUMBER: US/10/776,933
; PRIOR FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,374
; PRIOR FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 150
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: poly-T oligonucleotide
; FEATURE:
; OTHER INFORMATION: This sequence may encompass 12-18 nucleotides
; OTHER INFORMATION: according to the specification as filed
US-10-776-933-150

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5042
| | | | | | | | | | | | | | | | | |
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 497

US-10-674-159A-112/c
; Sequence 112, Application US/10674159A
; Publication No. US20040242518A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Jianzhu
; APPLICANT: Ge, Qing
; APPLICANT: Eiseen, Herman
; TITLE OF INVENTION: Influenza Therapeutic
; FILE REFERENCE: 0492611-0506
; CURRENT APPLICATION NUMBER: US/10/674,159A
; CURRENT FILING DATE: 2003-09-29
; NUMBER OF SEQ ID NOS: 271
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 112
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: mRNA
US-10-674-159A-112

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5042
| | | | | | | | | | | | | | | | | |
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 498

US-10-776-917-141/c
; Sequence 141, Application US/10776917
; Publication No. US2004024840A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THURUE, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION
; FILE REFERENCE: 58609(71432)
; CURRENT APPLICATION NUMBER: US/10/776,917
; CURRENT FILING DATE: 2004-02-10
; PRIOR FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: DK 2003-01539
; PRIOR FILING DATE: 2003-10-20
; NUMBER OF SEQ ID NOS: 201
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 141
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: poly-T oligonucleotide
; FEATURE:
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the
; OTHER INFORMATION: specification as filed
US-10-776-917-141

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5042
| | | | | | | | | | | | | | | | | |
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 499

US-10-766-096-9/c
; Sequence 9, Application US/10766096
; Publication No. US20040265786A1
; GENERAL INFORMATION:
; APPLICANT: Lin, Ching-I Patsy
; Wallace, Robert Bruce
; Cosman, Jeffrey
; French, Cynthia
; TITLE OF INVENTION: Lyophilization of Cultured Human Cells
; to Preserve RNA and DNA
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30

```

;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/766,096
; FILING DATE: 27-Jan-2004
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/884,029
; FILING DATE: 27-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Parent, Annette S.
; REGISTRATION NUMBER: 42,058
; REFERENCE/DOCKET NUMBER: 02558B-059100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 13..18
; OTHER INFORMATION: /mod_base= OTHER
; /note= "t at positions 13-18 may be
; present or absent"
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-766-096-9
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 500
US-10-638-141-10/c
; Sequence 10, Application US/10638141
; Publication No. US20050003364A1
; GENERAL INFORMATION:
; APPLICANT: Stanton, Lawrence W.
; APPLICANT: Kapoun, Ann Marie
; TITLE OF INVENTION: SECRETED FACTORS
; FILE REFERENCE: SCIOS.013A
; CURRENT APPLICATION NUMBER: US/10/638,141
; CURRENT FILING DATE: 2003-08-07
; PRIOR APPLICATION NUMBER: US/09/665,728
; PRIOR FILING DATE: 2000-09-20
; PRIOR APPLICATION NUMBER: 60/156,277
; PRIOR FILING DATE: 1999-09-27
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-638-141-10
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 500
US-10-601-140A-24/c
; Sequence 24, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-10-601-140A-24
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 501
US-10-776-934-741/c
; Sequence 741, Application US/10776934
; Publication No. US20050014712A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THRUUE, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
; FILE REFERENCE: 58610(71432)
; CURRENT APPLICATION NUMBER: US/10/776,934
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,372
; PRIOR FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: 60/523,591
; PRIOR FILING DATE: 2003-11-19
; NUMBER OF SEQ ID NOS: 741
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 741
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: poly-T oligonucleotide
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the
; OTHER INFORMATION: specification as filed
US-10-776-934-741
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 502
US-10-601-140A-24/c
; Sequence 24, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-10-601-140A-24
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 18 AAAAAAAAAAAAAAAAAA 1
```

Db 18 AAAAAAAAAAAAAAAAAAAAA 1
|||||

RESULT 503
US-10-884-617-2/c
; Sequence 2, Application US/10884617
; Publication No. US20050054730A1
; GENERAL INFORMATION:
; APPLICANT: Fu, Jin
; APPLICANT: Gaetani, Silvana
; APPLICANT: Picomelli, Daniele
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Compounds, Compositions and Treatments of
; TITLE OF INVENTION: Oleoylthanolamide-Like Modulators of PPARalpha
; FILE REFERENCE: 02307E-133310US
; CURRENT APPLICATION NUMBER: US/10/884,617
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US 60/279,542
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/336,289
; PRIOR FILING DATE: 2001-10-31
; PRIOR APPLICATION NUMBER: US 10/112,509
; PRIOR FILING DATE: 2002-03-27
; PRIOR APPLICATION NUMBER: US 60/485,062
; PRIOR FILING DATE: 2003-07-02
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Oligo(dT)-12-18
; OTHER INFORMATION: primer for reverse transcription of total RNA
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (13)..(18)
; OTHER INFORMATION: t at positions 13-18 may be present or absent
US-10-884-617-2

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||

Db 18 AAAAAAAAAAAAAAAAAAAAA 1

RESULT 504
US-10-669-962-27/c
; Sequence 27, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Brugliera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; TITLE OF INVENTION: AND USES THEREOF
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/05/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: FN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-27

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAAAAAAAAAAAAAAAAAA 5041
|||||

Db 18 TAAAAAAAAAAAAAAAAAAAA 1

RESULT 505
US-10-503-120-1/c
; Sequence 1, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-503-120-1

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||

Db 18 AAAAAAAAAAAAAAAAAAAAA 1

RESULT 506
US-10-503-120-8/c
; Sequence 8, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(17)
; OTHER INFORMATION: Residues 1, 3, 5, 7, 9, 11, 13, 15 and 17 are 2'-O-methyl-D-uridi
US-10-503-120-8

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||
DB 18 AAAAAAAAAAAAAAAAAAAAA 1

RESULT 507
US-10-503-120-g/c
; Sequence 9, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; 3 OTHER INFORMATION: Residues 1-3, 7-9, and 13-15 are 2'-O-methyl-D-uridine
US-10-503-120-9

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||
DB 18 AAAAAAAAAAAAAAAAAAAAA 1

RESULT 508
US-10-503-120-10/c
; Sequence 10, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: Residues 1-6 and 13-18 are 2'-O-methyl-D-uridine
US-10-503-120-10

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||
DB 18 AAAAAAAAAAAAAAAAAAAAA 1

RESULT 509
US-10-503-120-21
; Sequence 21, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Target RNA oligonucleotide
US-10-503-120-21

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||
DB 1 AAAAAAAAAAAAAAAAAAAAA 18

RESULT 510
US-10-775-973-10/c
; Sequence 10, Application US/10775973
; Publication No. US20050158729A1
; GENERAL INFORMATION:
; APPLICANT: Stanton, Lawrence W.
; APPLICANT: Kapoun, Ann Marie
; TITLE OF INVENTION: SECRETED FACTORS
; FILE REFERENCE: SCIOS.014A
; CURRENT APPLICATION NUMBER: US/10/775,973
; CURRENT FILING DATE: 2004-02-09
; PRIOR APPLICATION NUMBER: US/09/665,976
; PRIOR FILING DATE: 2000-09-20
; PRIOR APPLICATION NUMBER: 60/156,280
; PRIOR FILING DATE: 1999-09-27
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-775-973-10

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||
DB 18 AAAAAAAAAAAAAAAAAAAAA 1

RESULT 511
US-11-024-428-7/c
; Sequence 7, Application US/11024428
; Publication No. US20050106676A1

DB 18 AAAAAAAAAAAAAAAAAAAAA 1
|||||

RESULT 509
US-10-503-120-21
; Sequence 21, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Target RNA oligonucleotide
US-10-503-120-21

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||
DB 1 AAAAAAAAAAAAAAAAAAAAA 18

RESULT 510
US-10-775-973-10/c
; Sequence 10, Application US/10775973
; Publication No. US20050158729A1
; GENERAL INFORMATION:
; APPLICANT: Stanton, Lawrence W.
; APPLICANT: Kapoun, Ann Marie
; TITLE OF INVENTION: SECRETED FACTORS
; FILE REFERENCE: SCIOS.014A
; CURRENT APPLICATION NUMBER: US/10/775,973
; CURRENT FILING DATE: 2004-02-09
; PRIOR APPLICATION NUMBER: US/09/665,976
; PRIOR FILING DATE: 2000-09-20
; PRIOR APPLICATION NUMBER: 60/156,280
; PRIOR FILING DATE: 1999-09-27
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-775-973-10

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAA 5042
|||||
DB 18 AAAAAAAAAAAAAAAAAAAAA 1

RESULT 511
US-11-024-428-7/c
; Sequence 7, Application US/11024428
; Publication No. US20050106676A1

```
; GENERAL INFORMATION:
; APPLICANT: NAGAI, HIROSHI
; APPLICANT: KURODA, KYOKO
; APPLICANT: NAKAJIMA, TERUMI
; TITLE OF INVENTION: NOVEL PROTEINS HAVING HEMOLYTIC ACTIVITY AND GENES
; TITLE OF INVENTION: ENCODING THE PROTEIN
; FILE REFERENCE: 037181.90611US
; CURRENT APPLICATION NUMBER: US/11/024,428
; CURRENT FILING DATE: 2004-12-30
; PRIOR APPLICATION NUMBER: US/09/979,275
; PRIOR FILING DATE: 2003-05-27
; PRIOR APPLICATION NUMBER: PCT/JP01/02209
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: JP 2000-78967
; PRIOR FILING DATE: 2000-03-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-11-024-428-7

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5042
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 512
US-10-913-246-22
; Sequence 22, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-913-246-22

Query Match          0.4%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5042
Db 2 AAAAAAAAAAAAAAAAAA 19

RESULT 514
US-10-620-642-32/c
; Sequence 32, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosseiman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/10/620,642
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
```

```
RESULT 513
US-10-934-890-22
; Sequence 22, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-22

Query Match          0.4%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5042
Db 2 AAAAAAAAAAAAAAAAAA 19

RESULT 514
US-10-620-642-32/c
; Sequence 32, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosseiman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/10/620,642
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
```

FILING DATE: 24-MAY-1995
APPLICATION NUMBER: 08/172,329
FILING DATE: 21-DEC-1993
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
APPLICATION NUMBER: 07/684,535
FILING DATE: 10-APR-1991
APPLICATION NUMBER: 09/589,701
FILING DATE: 10-OCT-1991
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/35199
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-10-620-642-32

Query Match 0.4%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5042
DB 18 AAAAAAAAAAAAAAAAAA 1

RESULT 515
US-10-620-642-34/c
Sequence 34, Application US/10620642
Publication No. US20050080250A1
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristina M.
Bosselman, Robert A.
Suggs, Sidney V.
Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/620,642
FILING DATE: 16-Jul-2003
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/10/175,608
FILING DATE: 16-Oct-2002
APPLICATION NUMBER: 09/635,249

FILING DATE: 07-AUG-2000
APPLICATION NUMBER: 09/486,546
FILING DATE: 24-MAY-1995
APPLICATION NUMBER: 08/172,329
FILING DATE: 21-DEC-1993
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
APPLICATION NUMBER: 07/684,535
FILING DATE: 10-APR-1991
APPLICATION NUMBER: 09/589,701
FILING DATE: 10-OCT-1991
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/35199
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-10-620-642-34

Query Match 0.4%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAA 5042
DB 18 AAAAAAAAAAAAAAAAAA 1

RESULT 516
US-10-786-720-113/c
Sequence 113, Application US/10786720
Publication No. US2004019181A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: O'Toole, Margot
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
DISEASES
FILE REFERENCE: 031896-023000 (AM101331L)
CURRENT APPLICATION NUMBER: US/10/786,720
CURRENT FILING DATE: 2004-02-26
NUMBER OF SEQ ID NOS: 21135
SOFTWARE: PatentIn version 3.2
SEQ ID NO 113
LENGTH: 21
TYPE: RNA
ORGANISM: RNAi-sense strand
US-10-786-720-113

Query Match 0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 AAGCATCTGAGAAAGCAGCTA 865
DB 21 AAGCATCTAATAAGCAGCTA 1


```
RESULT 517
US-10-712-795-850
; Sequence 850, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 850
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-712-795-850

Query Match      0.3%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2903 TGACAGAGGAAGGAGGAAGA 2921
    ||||| ||||| ||||| |||||
Db 1 TGACAGATGAAGAGGAAGA 19

RESULT 518
US-10-920-612-850
; Sequence 850, Application US/10920612
; Publication No. US2005009088A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39634A
; CURRENT APPLICATION NUMBER: US/10/920,612
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-11-15
; PRIOR APPLICATION NUMBER: US 10/712,795
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 850
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-920-612-850

Query Match      0.3%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2903 TGACAGAGGAAGGAGGAAGA 2921
    ||||| ||||| ||||| |||||
Db 1 TGACAGATGAAGAGGAAGA 19

RESULT 519
US-10-831-901A-29729/c
; Sequence 29729, Application US/10831901A
; Publication No. US2005010088A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
```

```
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29729
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29729

Query Match      0.3%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5043
    ||||| ||||| ||||| |||||
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 520
US-10-374-686-4
; Sequence 4, Application US/10374686
; Publication No. US20040002089A1
; GENERAL INFORMATION:
; APPLICANT: Dubertret, Benoit
; APPLICANT: Calame, Michel
; APPLICANT: Libchaber, Albert
; TITLE OF INVENTION: Methods Employing Fluorescent Quenching
; FILE REFERENCE: by Metal Surfaces
; FILE REFERENCE: 600-1-260PCTUS
; CURRENT APPLICATION NUMBER: US/10/374,686
; CURRENT FILING DATE: 2003-02-26
; PRIOR APPLICATION NUMBER: PCT/US01/41941
; PRIOR FILING DATE: 2001-08-29
; PRIOR APPLICATION NUMBER: 60/228728
; PRIOR FILING DATE: 2000-08-29
; PRIOR APPLICATION NUMBER: 60/280350
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-374-686-4
```

Query Match 0.3%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 4.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5050 AAAAAAAAAAAAACTCG 5068
Db 2 AAAAAAAAAAAAACTCG 20

RESULT 521
US-10-137-34/c
; Sequence 34, Application US/10412137
; Publication No. US20040203141A1
; GENERAL INFORMATION:
; APPLICANT: Dubcovsky, Jorge
; APPLICANT: Yan, Liuling
; TITLE OF INVENTION: USE OF THE AP1 GENE PROMOTER TO CONTROL
; TITLE OF INVENTION: THE VERNALIZATION RESPONSE AND FLOWERING TIME IN GRASSES
; FILE REFERENCE: 51411200300
; CURRENT APPLICATION NUMBER: US/10/412,137
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-412-137-34

Query Match 0.3%; Score 17.4; DB 1; Length 22;
Best Local Similarity 94.7%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2785 AGCTTGTTTCAGACATCTTC 2803
Db 19 AGCTTGTTTCAGACATTTTC 1

RESULT 522
US-10-723-947-34/c
; Sequence 34, Application US/10723947
; Publication No. US20040205848A1
; GENERAL INFORMATION:
; APPLICANT: Dubcovsky, Jorge
; APPLICANT: Yan, Liuling
; APPLICANT: Loukianov, Artem
; TITLE OF INVENTION: GENES RESPONSIBLE FOR VERNALIZATION
; TITLE OF INVENTION: REGULATION IN TEMPERATE GRASSES AND USES THEREOF
; FILE REFERENCE: 51411200320
; CURRENT APPLICATION NUMBER: US/10/723,947
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 10/412,137
; PRIOR FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 159
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-723-947-34

Query Match 0.3%; Score 17.4; DB 1; Length 22;
Best Local Similarity 94.7%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2785 AGCTTGTTTCAGACATCTTC 2803
Db 19 AGCTTGTTTCAGACATTTTC 1

RESULT 523
US-09-263-959-808
; Sequence 808, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 808:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-808

Query Match 0.3%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 4.6e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5044 AAAAAAAAAAAAAAAAAAAC 5065
Db 1 AAAAAAAAAACAAACAAAC 22

RESULT 524
US-10-361-002-33/c
; Sequence 33, Application US/10361002
; Publication No. US20040170954A1
; GENERAL INFORMATION:
; APPLICANT: Clearant, Inc.
; APPLICANT: McKenney, Keith
; APPLICANT: Gillmeister, Lidja
; APPLICANT: Marlowe, Kristina
; APPLICANT: Armistead, David
; TITLE OF INVENTION: Pathogen Inactivation Assay
; FILE REFERENCE: CI-0043
; CURRENT APPLICATION NUMBER: US/10/361,002
; CURRENT FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 99
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Hepatitis B virus
US-10-361-002-33

```
Query Match          0.3%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 4.6e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 723 GAAGGTTTTCGAATTCAGGAT 744
DB 22 GAAGGAGTTTGCCATTCAGGAT 1

RESULT 525
US-10-361-004-33/c
; Sequence 33, Application US/10361004
; Publication No. US20040170981A1
; GENERAL INFORMATION:
; APPLICANT: Clearant, Inc.
; APPLICANT: McKenney, Keith
; APPLICANT: Gillmeister, Lidja
; APPLICANT: Marlowe, Kristina
; APPLICANT: Amistad, David
; TITLE OF INVENTION: Real-Time Polymerase Chain Reaction Using Large Target Amplicons
; FILE REFERENCE: CI-0042
; CURRENT APPLICATION NUMBER: US/10/361,004
; CURRENT FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 99
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Hepatitis B virus
US-10-361-004-33

Query Match          0.3%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 4.6e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 723 GAAGGTTTTCGAATTCAGGAT 744
DB 22 GAAGGAGTTTGCCATTCAGGAT 1

RESULT 526
US-08-865-579-5
; Sequence 5, Application US/08865579
; Publication No. US20010006779A1
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; APPLICANT: Fernandes-Alnemri, Teresa
; APPLICANT: Litwack, Gerald
; TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
; TITLE OF INVENTION: Encoding Same and Methods of Use
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/865,579
; FILING DATE: 29-MAY-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 2180
; TELECOMMUNICATION INFORMATION:
```

```
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-9849
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-865-579-5

Query Match          0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCACGAG 32
DB 1 CAGGAATTCGGCACGAG 17

RESULT 527
US-09-746-731-5
; Sequence 5, Application US/09746731
; Publication No. US20010016345A1
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; APPLICANT: Fernandes-Alnemri, Teresa
; APPLICANT: Litwack, Gerald
; TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
; TITLE OF INVENTION: Encoding Same and Methods of Use
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/746,731
; FILING DATE: 22-Dec-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/865,579
; FILING DATE: 29-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 2180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-9849
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-746-731-5

Query Match          0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCACGAG 32
DB 1 CAGGAATTCGGCACGAG 17
```

```
Db      1 CAGGAATTCGGCAGCAG 17

RESULT 528
US-09-952-768-6
; Sequence 6, Application US/09952768
; Patent No. US20020035242A1
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
;               Fernandes-Alnemri, Teresa
;               Litwack, Gerald
;               Armstrong, Robert
;               Tomaselli, Kevin
; TITLE OF INVENTION: MCH4 AND MCH5, APOPTOTIC PROTEASE,
;                   NUCLEIC ACIDS ENCODING AND METHODS OF USE
; NUMBER OF SEQUENCES: 75
; CORRESPONDENCE ADDRESS:
; ADDRESS: Seed Intellectual Property Law Group
; STREET: Suite 6300, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/952,768
; FILING DATE: 10-Sep-2001
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Christiansen, William T.
; REGISTRATION NUMBER: 44,614
; REFERENCE/DOCKET NUMBER: 480140.424C4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..17
; OTHER INFORMATION: /note= "SK-Zap"
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-952-768-6
Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      16 CAGGAATTCGGCAGCAG 32
|||||
Db      1 CAGGAATTCGGCAGCAG 17
|||||

RESULT 530
US-10-059-749-5
; Sequence 5, Application US/10059749
; Publication No. US20020183504A1
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
;               Fernandes-Alnemri, Teresa
;               Litwack, Gerald
; TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
;                   Encoding Same and Methods of Use
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/059,749
; FILING DATE: 29-Jan-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; US-09-944-851-6
Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      16 CAGGAATTCGGCAGCAG 32
|||||
Db      1 CAGGAATTCGGCAGCAG 17
|||||

RESULT 530
US-10-059-749-5
; Sequence 5, Application US/10059749
; Publication No. US20020183504A1
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
;               Fernandes-Alnemri, Teresa
;               Litwack, Gerald
; TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
;                   Encoding Same and Methods of Use
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/059,749
; FILING DATE: 29-Jan-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; US-09-944-851-6
Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      16 CAGGAATTCGGCAGCAG 32
|||||
Db      1 CAGGAATTCGGCAGCAG 17
|||||

RESULT 529
US-09-944-851-6
; Sequence 6, Application US/09944851
; Patent No. US20020102648A1
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
;               Fernandes-Alnemri, Teresa
;               Litwack, Gerald
;               Armstrong, Robert
;               Tomaselli, Kevin
; TITLE OF INVENTION: Mch3, A No. US20020102648A1el Apoptotic Protease,
;                   Nucleic Acids Encoding and Methods of Use
```

APPLICATION NUMBER: US/08/865,579
FILING DATE: 29-MAY-1997
ATTORNEY/AGENT INFORMATION:
NAME: Campbell, Cathryn A.
REGISTRATION NUMBER: 31,815
REFERENCE/DOCKET NUMBER: P-ID 2180
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-9849
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-059-749-5

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
|||||
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 531
US-10-337-060-6
Sequence 6, Application US/10337060
Publication No. US20030119169A1
GENERAL INFORMATION:
APPLICANT: Alnemri, Emad S.
APPLICANT: Fernandez-Alnemri, Teresa
APPLICANT: Litwack, Gerald
APPLICANT: Armstrong, Robert
APPLICANT: Tomaselli, Kevin
TITLE OF INVENTION: MCH5, A NOVEL APOPTOTIC PROTEASE,
TITLE OF INVENTION: NUCLEIC ACIDS ENCODING AND METHODS OF USE
FILE REFERENCE: 480140.423D2
CURRENT APPLICATION NUMBER: US/10/337,060
CURRENT FILING DATE: 2003-01-02
NUMBER OF SEQ ID NOS: 17
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 6
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer SK-Zap
US-10-337-060-6

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
|||||
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 532
US-10-668-955-6
Sequence 6, Application US/10668955
Publication No. US20040054148A1
GENERAL INFORMATION:
APPLICANT: Alnemri, Emad S.
Fernandes-Alnemri, Teresa
Litwack, Gerald
Armstrong, Robert
Tomaselli, Kevin
TITLE OF INVENTION: MCH4 AND MCH5, APOPTOTIC PROTEASE,

NUCLEIC ACIDS ENCODING AND METHODS OF USE
NUMBER OF SEQUENCES: 75
CORRESPONDENCE ADDRESS:
ADDRESSEE: Seed Intellectual Property Law Group
STREET: Suite 6300, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/668,955
FILING DATE: 22-Sep-2003
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Laherty, Carol D.
REGISTRATION NUMBER: 51,909
REFERENCE/DOCKET NUMBER: 480140.424D1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..17
OTHER INFORMATION: /note= "SK-Zap"
SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-668-955-6

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
|||||
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 533
US-10-669-962-28/c
Sequence 28, Application US/10669962
Publication No. US20050081264A1
GENERAL INFORMATION:
APPLICANT: Bugliera, Filippa
APPLICANT: Holton, Timothy A.
APPLICANT: Michael, Michael Z.
TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
TITLE OF INVENTION: AND USES THEREFOR
FILE REFERENCE: 11658
CURRENT APPLICATION NUMBER: US/10/669,962
CURRENT FILING DATE: 2003-09-24
PRIOR APPLICATION NUMBER: US/09/142,108C
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: PN8386
PRIOR FILING DATE: 1996-03-01
NUMBER OF SEQ ID NOS: 45
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 28
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-10-669-962-28

Query Match	0.3%; Score 17; DB 1; Length 18;	Best Local Similarity	100.0%; Pred. No. 4e+02;	Mismatches	0; Indels	Gaps	0;
5025	AAAAAAAAAAAAAAAAAAAA 5041						
17	AAAAAAAAAAAAAAAAAAAA 1						
<p>RESULT 534</p> <p>US-10-669-962-29/c</p> <p>Sequence 29, Application US/10669962</p> <p>Publication No. US20050081264A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: Bruggiera, Filippa</p> <p>APPLICANT: Holton, Timothy A.</p> <p>APPLICANT: Michael, Michael Z.</p> <p>TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES</p> <p>TITLE OF INVENTION: AND USES THEREFOR</p> <p>FILE REFERENCE: 11658</p> <p>CURRENT APPLICATION NUMBER: US/10/669,962</p> <p>CURRENT FILING DATE: 2003-09-24</p> <p>PRIOR APPLICATION NUMBER: US/09/142,108C</p> <p>PRIOR FILING DATE: 1998-09-01</p> <p>PRIOR APPLICATION NUMBER: PN8386</p> <p>PRIOR FILING DATE: 1996-03-01</p> <p>NUMBER OF SEQ ID NOS: 45</p> <p>SOFTWARE: PatentIn Ver. 2.1</p> <p>SEQ ID NO 29</p> <p>LENGTH: 18</p> <p>TYPE: DNA</p> <p>ORGANISM: Artificial Sequence</p> <p>FEATURE:</p> <p>OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide</p>							
<p>US-10-669-962-29</p> <p>Query Match 0.3%; Score 17; DB 1; Length 18;</p> <p>Best Local Similarity 100.0%; Pred. No. 4e+02;</p> <p>Mismatches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</p>							
5025	AAAAAAAAAAAAAAAAAAAA 5041						
17	AAAAAAAAAAAAAAAAAAAA 1						
<p>RESULT 535</p> <p>US-10-871-222-150</p> <p>Sequence 150, Application US/10871222</p> <p>Publication No. US20050119212A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: Sirna Therapeutics, Inc.</p> <p>APPLICANT: Haerberli, Peter</p> <p>APPLICANT: McSwiggen, James</p> <p>TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids</p> <p>TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering</p> <p>TITLE OF INVENTION: Nucleic Acid (SINA)</p> <p>FILE REFERENCE: 400/164 (MEHB04-487)</p> <p>CURRENT APPLICATION NUMBER: US/10/871,222</p> <p>CURRENT FILING DATE: 2004-06-18</p> <p>PRIOR APPLICATION NUMBER: PCT/US04/16390</p> <p>PRIOR FILING DATE: 2004-05-24</p> <p>PRIOR APPLICATION NUMBER: US10/826966</p> <p>PRIOR FILING DATE: 2004-04-16</p> <p>PRIOR APPLICATION NUMBER: US10/757803</p> <p>PRIOR FILING DATE: 2004-01-14</p> <p>PRIOR APPLICATION NUMBER: US10/720448</p> <p>PRIOR FILING DATE: 2003-11-24</p> <p>PRIOR APPLICATION NUMBER: US10/693059</p> <p>PRIOR FILING DATE: 2003-10-23</p> <p>PRIOR APPLICATION NUMBER: US10/444853</p> <p>PRIOR FILING DATE: 2003-05-23</p> <p>PRIOR APPLICATION NUMBER: PCT/US03/05346</p> <p>PRIOR FILING DATE: 2003-02-20</p> <p>PRIOR APPLICATION NUMBER: PCT/US03/05028</p> <p>PRIOR FILING DATE: 2003-02-20</p> <p>PRIOR APPLICATION NUMBER: US60/358580</p> <p>PRIOR FILING DATE: 2002-02-20</p> <p>PRIOR APPLICATION NUMBER: US60/363124</p> <p>PRIOR FILING DATE: 2002-03-11</p> <p>PRIOR APPLICATION NUMBER: US60/363124</p> <p>Remaining Prior Application data removed - See File Wrapper or PALM</p> <p>NUMBER OF SEQ ID NOS: 706</p> <p>SOFTWARE: PatentIn version 3.3</p> <p>SEQ ID NO 300</p> <p>LENGTH: 19</p> <p>TYPE: RNA</p> <p>ORGANISM: Artificial Sequence</p> <p>FEATURE:</p> <p>OTHER INFORMATION: Description of Artificial Sequence: siNA anti</p>							
<p>US-10-871-222-300</p> <p>Query Match 0.3%; Score 17; DB 1; Length 19;</p>							

Best Local Similarity 100.0%; Pred. No. 4.2e+02; Mismatches 0; Indels 0; Gaps 0;

QY 5023 GTAAAAA 5039
Db 17 GTAAAAA 1

RESULT 537

US-08-809-423A-23/c
; Sequence 23, Application US/0809423A
; Publication No. US20020169104A1
; GENERAL INFORMATION:
; APPLICANT: FRANK, GLENN R.
; APPLICANT: HUNTER, SHIRLEY WU
; APPLICANT: WALLENFELS, LYNDIA
; TITLE OF INVENTION: NOVEL ECTOPARASITE SALIVA PROTEINS
; TITLE OF INVENTION: AND APPARATUS TO COLLECT SUCH PROTEINS
; NUMBER OF SEQUENCES: 56
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheridan Ross & McIntosh
; STREET: 1700 Lincoln Street, Suite 3500
; CITY: Denver
; STATE: Colorado
; COUNTRY: U.S.A.
; ZIP: 80203
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/809,423A
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: CONNELL, GARY J.
; REGISTRATION NUMBER: 32,020
; REFERENCE/DOCKET NUMBER: 2618-17-C2PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 863-9700
; TELEFAX: (303) 863-0223
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; US-08-809-423A-23

Query Match 0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5069 AGGGGGGCGGTACC 5085
Db 20 AGGGGGGCGGTACC 4

RESULT 538

US-10-271-344-23/c
; Sequence 23, Application US/10271344
; Publication No. US20030185755A1
; GENERAL INFORMATION:
; APPLICANT: FRANK, GLENN R.
; APPLICANT: HUNTER, SHIRLEY WU
; APPLICANT: WALLENFELS, LYNDIA
; TITLE OF INVENTION: NOVEL ECTOPARASITE SALIVA PROTEINS
; TITLE OF INVENTION: AND APPARATUS TO COLLECT SUCH PROTEINS
; NUMBER OF SEQUENCES: 56
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheridan Ross & McIntosh

STREET: 1700 Lincoln Street, Suite 3500
CITY: Denver
STATE: Colorado
COUNTRY: U.S.A.
ZIP: 80203
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/271,344
FILING DATE: 14-Oct-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/809,423A
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: CONNELL, GARY J.
REGISTRATION NUMBER: 32,020
REFERENCE/DOCKET NUMBER: 2618-17-C2PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 863-9700
TELEFAX: (303) 863-0223
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (primer)
SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-10-271-344-23

Query Match 0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5069 AGGGGGGCGGTACC 5085
Db 20 AGGGGGGCGGTACC 4

RESULT 539

US-10-148-355A-10/c
; Sequence 10, Application US/10148355A
; Publication No. US20030207831A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowbert
; APPLICANT: ISIS PHARMACEUTICALS, INC.
; TITLE OF INVENTION: ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTSP-0082
; CURRENT APPLICATION NUMBER: US/10/148,355A
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: 09/467,642
; PRIOR FILING DATE: 1999-12-17
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-148-355A-10

Query Match 0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GGAATTCGGCAGGG 34
|||||

```
Db      20  GGAATTGGCAGGAGG 4
RESULT 540
US-10-397-131-7
; Sequence 7, Application US/10397131
; Publication No. US20030228627A1
; GENERAL INFORMATION:
; APPLICANT: Emerson, Beverly M.
; APPLICANT: Espinosa, Joaquin
; TITLE OF INVENTION: ASSAYS FOR p53 FUNCTION IN CELLS
; FILE REFERENCE: SALKINS.058A
; CURRENT APPLICATION NUMBER: US/10/397,131
; CURRENT FILING DATE: 2003-03-24
; PRIOR APPLICATION NUMBER: US 60/366,897
; PRIOR FILING DATE: 2002-03-22
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-397-131-7
Query Match      0.3%; Score 17; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      9  CGGGCTGCAGGAATTCG 25
Db      1  CGGGCTGCAGGAATTCG 17

RESULT 541
US-10-160-786-72
; Sequence 72, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-786-72
Query Match      0.3%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3969  TTTAAAGCATGATTTAAAGT 3988
Db      1  TTTAAATCATGCTTTAAAGT 20

RESULT 542
US-10-667-022-72
; Sequence 72, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
```

```
; TITLE OF INVENTION: P150 EXPRESSION
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-022-72
Query Match      0.3%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3969  TTTAAAGCATGATTTAAAGT 3988
Db      1  TTTAAATCATGCTTTAAAGT 20

RESULT 543
US-10-831-901A-29728/c
; Sequence 29728, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29728
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29728
Query Match      0.3%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      5022  TGTAAAAAATAAAAAAAAAA 5041
Db      20  TGACAAAAAATAAAAAAAAAA 1
```


RESULT 544
US-10-274-095-21
; Sequence 21, Application US/10274095
; Publication No. US20030120433A1
; GENERAL INFORMATION:
; APPLICANT: Yokota, Hiroki
; APPLICANT: Sun, Hui Bin
; TITLE OF INVENTION: Methods for Predicting Transcription
; FILE REFERENCE: ARTI.0137US
; CURRENT APPLICATION NUMBER: US/10/274,095
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/329,961
; PRIOR FILING DATE: 2001-10-17
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 21
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-274-095-21

Query Match 0.3%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 4.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3078 ACAAGAACCCAGATGACAAAC 3097
Db 2 ACAAGAACCCAGATCACATAC 21
|||||

RESULT 545
US-10-666-980-12
; Sequence 12, Application US/10666980
; Publication No. US20040133929A1
; GENERAL INFORMATION:
; APPLICANT: Davissen, Robin L.
; TITLE OF INVENTION: Animal Model for Preseclampsia
; FILE REFERENCE: P05473US01
; CURRENT APPLICATION NUMBER: US/10/666,980
; CURRENT FILING DATE: 2003-09-19
; PRIOR APPLICATION NUMBER: US 60/411,992
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-666-980-12

Query Match 0.3%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 4.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4591 CAGGGCTTCATCTGTAAGTCG 4610
Db 1 CAGGGCTTCATCTGTACGC 20
|||||

RESULT 546
US-10-786-720-112/c
; Sequence 112, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12304
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-112

; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 112
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-112

Query Match 0.3%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 4.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 847 GCATCTGAGAAAGCAGCTAT 866
Db 21 GCATCTAATAAAGCAGCTAT 2
|||||

RESULT 547
US-10-786-720-114
; Sequence 114, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 114
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-114

Query Match 0.3%; Score 16.8; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 4.7e+02;
Matches 14; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 847 GCATCTGAGAAAGCAGCTAT 866
Db 1 GCAUCUAUAAGACGCUAU 20
|||||

RESULT 548
US-10-786-720-12304/c
; Sequence 12304, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12304
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-12304

Query Match 0.3%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 4.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751.736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36929
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-36929

Query Match 0.3%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 4.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 AATTCGCACAGATTGTCT 821
Db 21 AATTCCTCACAGCATTGTCT 2

RESULT 554
US-09-972-175-52
; Sequence 52, Application US/09972175
; Publication No. US20030101482A1
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; Gilmer, Amy Jelen
; Mettus, Anne-Marie Light
; TITLE OF INVENTION: TRANSGENIC PLANTS EXPRESSING
; LEPIDOPTERAN-ACTIVE-DELTA-ENDOTOXINS
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/972,175
; FILING DATE: 05-Oct-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/337,635
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Kitchell, Barbara S.
; REGISTRATION NUMBER: 33,928
; REFERENCE/DOCKET NUMBER: MECO:206
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 52:
US-09-972-175-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 4.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GGATCCCCGGGCTGCAGGA 20

Db 1 GGATCCCTCGAGCTGCAGGA 20
RESULT 555
US-10-200-522-52
; Sequence 52, Application US/10200522
; Publication No. US20030195336A1
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; Gilmer, Amy Jelen
; Mettus, Anne Marie Light
; TITLE OF INVENTION: NUCLEIC ACID AND POLYPEPTIDE COMPOSITIONS ENCODING LEPIDOPTERAN-T
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: MECO:213 (11792.0213 DVUS01)
; CURRENT APPLICATION NUMBER: US/10/200,522
; CURRENT FILING DATE: 2002-07-22
; PRIOR APPLICATION NUMBER: 09/337,280
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 08/980,071
; PRIOR FILING DATE: 1997-11-26
; PRIOR APPLICATION NUMBER: 08/757,536
; PRIOR FILING DATE: 1996-11-27
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 52
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-200-522-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 4.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GGATCCCCGGGCTGCAGGA 20
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 556
US-10-855-535-52
; Sequence 52, Application US/10855535
; Publication No. US20040221334A1
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; Gilmer, Amy Jelen
; Mettus, Anne Marie Light
; TITLE OF INVENTION: Antibodies Immunoreactive with Lepidopteran-Toxic Polypeptides
; TITLE OF INVENTION: and Methods of Use (Amended)
; FILE REFERENCE: 11792.0214.DVUS02
; CURRENT APPLICATION NUMBER: US/10/855,535
; CURRENT FILING DATE: 2004-05-27
; PRIOR APPLICATION NUMBER: 09/337,635
; PRIOR FILING DATE: 1999-06-21
; PRIOR APPLICATION NUMBER: 08/980,071
; PRIOR FILING DATE: 1997-11-26
; PRIOR APPLICATION NUMBER: 08/757,536
; PRIOR FILING DATE: 1996-11-27
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 52
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-855-535-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 4.9e+02;

```
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
    ||||| || ||||| |||||
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 557
US-10-473-683-41/c
; Sequence 41, Application US/10473683
; Publication No. US20040254104A1
; GENERAL INFORMATION:
; APPLICANT: Blott, S.
; APPLICANT: Kim, J.
; APPLICANT: Schmidt-Kuntzel, A.
; APPLICANT: Cornet, A.
; APPLICANT: Berzi, P.
; APPLICANT: Cambisano, N.
; APPLICANT: Grisart, B.
; APPLICANT: Karim, L.
; APPLICANT: Simon, P.
; APPLICANT: Georges, M.
; APPLICANT: Farnir, F.
; APPLICANT: Coppieters, W.
; APPLICANT: Moiso, S.
; APPLICANT: Vilkki, J.
; APPLICANT: Johnson, D.
; APPLICANT: Speiman, R.
; APPLICANT: Ford, C.
; APPLICANT: Snell, R.
; TITLE OF INVENTION: MARKER ASSISTED SELECTION OF BOVINE FOR
; FILE REFERENCE: IMPROVED MILK COMPOSITION
; CURRENT APPLICATION NUMBER: US/10/473.683
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/NZ02/00157
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: NZ 520797
; PRIOR FILING DATE: 2002-08-15
; PRIOR APPLICATION NUMBER: NZ 519372
; PRIOR FILING DATE: 2002-06-05
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 41
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Bos taurus
US-10-473-683-41

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 4.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3270 TTGTCAACTCTTCACAGG 3289
    ||||| ||||| |||||
Db 22 TTGTCAACTCTTCACAGA 3

RESULT 558
US-10-999-188-52
; Sequence 52, Application US/10999188
; Publication No. US20050155103A1
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; APPLICANT: Gilmer, Amy Jelen
; APPLICANT: Mettus, Anne Marie Light
; TITLE OF INVENTION: Methods for Generating Lepidopteran-Toxic Polypeptides (Amended)
; FILE REFERENCE: 11792.0213 DVUS02
; CURRENT APPLICATION NUMBER: US/10/999,188
; CURRENT FILING DATE: 2004-11-29
; PRIOR APPLICATION NUMBER: 10/200,522
; PRIOR FILING DATE: 2002-07-22
; PRIOR APPLICATION NUMBER: 09/337,280
```

```
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 08/980,071
; PRIOR FILING DATE: 1997-11-26
; PRIOR APPLICATION NUMBER: 08/757,536
; PRIOR FILING DATE: 1996-11-27
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 52
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-999-188-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 4.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
    ||||| || ||||| |||||
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 559
US-10-108-260A-4995
; Sequence 4995, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1el full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4995
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized p
US-10-108-260A-4995

Query Match 0.3%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3813 CCATCCTCTACAAAGCAG 3830
    ||||| ||||| |||||
Db 1 CCATCCTCTACACAGCAG 18

RESULT 560
US-10-872-984-5/c
; Sequence 5, Application US/10872984
; Publication No. US20040265889A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
```

; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-5

Query Match 0.3%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5023 GTAAAAAAGAAAAA 5040
DB 18 GCAAAAAAAGAAAAA 1

RESULT 561

US-10-872-984-6/c

; Sequence 6, Application US/10872984
; Publication No. US20040265888A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-6

Query Match 0.3%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5025 AAAAAAAGAAAAA 5042
DB 18 AAAAAAAGAAAAA 1

RESULT 562

US-10-872-984-7/c

; Sequence 7, Application US/10872984
; Publication No. US20040265888A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-7

Query Match 0.3%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5022 TGTAAAAAAGAAAAA 5039
DB 18 TGAAAAAAAGAAAAA 1

RESULT 563

US-10-800-487-162/c

; Sequence 162, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of InterCellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 162
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-800-487-162

Query Match 0.3%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5048 AAAAAAAGAAAAA 5065
DB 18 AAAAAAAGAAAAA 1

RESULT 564

US-10-800-487-328

Sequence 328, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
TITLE OF INVENTION: Molecule (ICM) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (siNA)
FILE REFERENCE: 400/148 (MBHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
CURRENT FILING DATE: 2004-03-15
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-15
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/427,160
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 438
SOFTWARE: Patentin version 3.3
SEQ ID NO 328
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-328

Query Match 0.3%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5048 AAAAAAAAAAAAAAAC 5065
Db 2 AAAAAAAAAAAAAAUC 19

RESULT 565
US-10-871-222-404
Sequence 404, Application US/10871222
Publication No. US20050119212A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Haerberli, Peter
TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
TITLE OF INVENTION: Nucleic Acid (SINA)
FILE REFERENCE: 400/164 (MBHB04-487)
CURRENT APPLICATION NUMBER: US/10/871,222
CURRENT FILING DATE: 2004-06-18
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US10/826966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US10/757803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US10/720448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US10/693059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US10/444853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US60/358580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US60/363124
PRIOR FILING DATE: 2002-03-11
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 706
SOFTWARE: Patentin version 3.3
SEQ ID NO 508
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence

PRIOR APPLICATION NUMBER: US10/693059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US10/444853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US60/358580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US60/363124
PRIOR FILING DATE: 2002-03-11
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 706
SOFTWARE: Patentin version 3.3
SEQ ID NO 404
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-871-222-404

Query Match 0.3%; Score 16.4; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 4.6e+02;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 5024 TAAAAAAAAAAAAAAA 5041
Db 2 UACAAAAAAAAAAAAA 19

RESULT 566
US-10-871-222-508/c
Sequence 508, Application US/10871222
Publication No. US20050119212A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Haerberli, Peter
TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
TITLE OF INVENTION: Nucleic Acid (SINA)
FILE REFERENCE: 400/164 (MBHB04-487)
CURRENT APPLICATION NUMBER: US/10/871,222
CURRENT FILING DATE: 2004-06-18
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US10/826966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US10/757803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US10/720448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US10/693059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US10/444853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US60/358580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US60/363124
PRIOR FILING DATE: 2002-03-11
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 706
SOFTWARE: Patentin version 3.3
SEQ ID NO 508
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-871-222-508

Query Match      0.3%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5024 TAAAAAAGGGGAGGAGC 5041
Db 18 TACAAAAAAGGGGAGGAGC 1

RESULT 567
US-10-454-224-29
; Sequence 29, Application US/10454224
; Publication No. US20040010814A1
; GENERAL INFORMATION:
; APPLICANT: HERRMANN, Bernhard
; APPLICANT: KOSCHORZ, Birgit
; APPLICANT: KISPERT, Andreas
; TITLE OF INVENTION: NUCLEIC ACIDS INVOLVED IN THE RESPONDER PHENOTYPE AND APPLICATION THEREOF
; FILE REFERENCE: 258.0009 0101
; CURRENT APPLICATION NUMBER: US/10/454,224
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: US/09/554,726A
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: PCT/EP 98/07395
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: EP 98 10 3596.7
; PRIOR FILING DATE: 1998-03-02
; PRIOR APPLICATION NUMBER: EP 97 12 0190.0
; PRIOR FILING DATE: 1997-11-18
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-454-224-29

Query Match      0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3412 CAGCAAAAGCGGAGCAG 3429
Db 3 CAGCAAAAGCGGAGCAG 20

RESULT 568
US-10-476-021-57
; Sequence 57, Application US/10476021
; Publication No. US20040186069A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0216
; CURRENT APPLICATION NUMBER: US/10/476,021
; CURRENT FILING DATE: 2003-10-24
; PRIOR APPLICATION NUMBER: US/09/844,634
; PRIOR FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
```

```
US-10-476-021-57

Query Match      0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4106 GTCATCTTCCAGGGCTC 4123
Db 1 GTCATCTGCGAGGGCTC 18

RESULT 569
US-09-802-320A-22/c
; Sequence 22, Application US/09802320A
; Patent No. US20020155446A1
; GENERAL INFORMATION:
; APPLICANT: Engert, James
; APPLICANT: Vohl, Marie-Claude
; APPLICANT: Brewer, Carl
; APPLICANT: Morgan, Kenneth
; APPLICANT: Gaudet, Daniel
; APPLICANT: Hudson, Thomas
; TITLE OF INVENTION: Very Low Density Lipoprotein Receptor Polymorphisms and Uses Therefor
; FILE REFERENCE: 2825.2001-001
; CURRENT APPLICATION NUMBER: US/09/802,320A
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/187,787
; PRIOR FILING DATE: 2000-03-08
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-802-320A-22

Query Match      0.3%; Score 16.4; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3576 TGAACACTCATTGTCGAA 3595
Db 20 TGAACACTCGTCTTTGCAA 1

RESULT 570
US-10-004-378A-153
; Sequence 153, Application US/10004378A
; Publication No. US20030228301A1
; GENERAL INFORMATION:
; APPLICANT: Li, Li
; APPLICANT: Furtak, Kazarzyna
; APPLICANT: Perna, Amanda
; APPLICANT: Patturajan, Meera
; APPLICANT: Shimkets, Richard A
; APPLICANT: Guo, Xiaojia Sasha
; APPLICANT: Casman, Stacie J
; APPLICANT: Burgess, Catherine E
; APPLICANT: Malyankar, Uriel M
; APPLICANT: Tchernev, Vellizar T
; APPLICANT: Vernet, Corrine A
; APPLICANT: Spytek, Kimberly A
; APPLICANT: Agee, Michele
; APPLICANT: Rastelli, Luca
; APPLICANT: Shenoy, Suresh G
; APPLICANT: Grosse, William M
; APPLICANT: Alsobrook II, John P
; APPLICANT: Lepley, Denise M
; APPLICANT: Gerlach, Valerie
; APPLICANT: Edinger, Schlomit
; APPLICANT: MacDougall, John R
; APPLICANT: Peyman, John A
```


; ORGANISM: RNA1
US-10-751-736-53486

Query Match 0.3%; Score 16.4; DB 1; Length 21;
Best Local Similarity 72.2%; Pred. No. 5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 4044 TACAAGCAGTGGTACCAT 4061
: |||||:|:|:|:
Db 3 UGCAAGCAGUGGUACCAU 20

RESULT 574

US-10-847-918-3425
; Sequence 3425, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Sionim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101284)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3425
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1-sense strand
US-10-847-918-3425

Query Match 0.3%; Score 16.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 5e+02;
Matches 12; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 955 TTCGAGTCTCGACAGCT 972
: |||||:|:|:|:
Db 4 UUCCAGAUCUGACAGUU 21

RESULT 575

US-10-105-101A-23/c
; Sequence 23, Application US/10105101A
; Publication No. US20030134290A1
; GENERAL INFORMATION:
; APPLICANT: Varigenics, Inc
; TITLE OF INVENTION: A Method for Identifying Polymorphisms
; FILE REFERENCE: 272/160
; CURRENT APPLICATION NUMBER: US/10/105,101A
; CURRENT FILING DATE: 2002-09-30
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: G allele fragment of hypothetical sequence of Fig. 37.
US-10-105-101A-23

Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3757 GGTGCTGCCAGTCTCTGGA 3777
: |||||:|:|:|:
Db 21 GGTGCTGCCAGTCTCTCCGA 1

RESULT 576

US-10-431-599-26/c
; Sequence 26, Application US/10431599
; Publication No. US20040029271A1
; GENERAL INFORMATION:
; APPLICANT: Busslinger, Meinrad
; APPLICANT: Mikkola, Ingviild
; APPLICANT: Heavey, Barry
; TITLE OF INVENTION: Pax5-deficient pro-B cells, methods of producing them and the use
; FILE REFERENCE: 0652.2500001
; CURRENT APPLICATION NUMBER: US/10/431,599
; CURRENT FILING DATE: 2003-05-08
; PRIOR APPLICATION NUMBER: US 60/385,582
; PRIOR FILING DATE: 2002-06-05
; PRIOR APPLICATION NUMBER: EP 02 010 439.4
; PRIOR FILING DATE: 2002-05-08
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-431-599-26

Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2648 AACTGATGCCTTATCTTGACC 2668
: |||||:|:|:|:
Db 21 AACTGATGCCTTATTTGCC 1

RESULT 577

US-10-786-720-3343
; Sequence 3343, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3343
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-3343

Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3126 AAATGTAATGAAGAATGGAA 3146
: |||||:|:|:|:
Db 1 AAATGAAGATGAGAAATGGAA 21

RESULT 578

US-10-786-720-3345/c
; Sequence 3345, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

Thu Aug 18 08:58:56 2005

```

; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3345
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-3345

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3126 AAATGTAATGAAGATGGAA 3146
    ||||| ||||| ||||| |||||
Db 21 AAATGAAGATGAGGAATGGAA 1

RESULT 579
US-10-786-720-3371/c
; Sequence 3371, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3371
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-sense strand
US-10-786-720-3371

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3395 AACTTCAGCACTCATCCAGC 3415
    ||||| ||||| ||||| |||||
Db 21 AACTTCAGCGCTCTCCAGC 1

RESULT 580
US-10-786-720-4045
; Sequence 4045, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4045
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens

```

```

US-10-786-720-4045

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3126 AAATGTAATGAAGATGGAA 3146
    ||||| ||||| ||||| |||||
Db 1 AAATGAAGATGAGGAATGGAA 21

RESULT 581
US-10-786-720-4047/c
; Sequence 4047, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4047
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-4047

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3126 AAATGTAATGAAGATGGAA 3146
    ||||| ||||| ||||| |||||
Db 21 AAATGAAGATGAGGAATGGAA 1

RESULT 582
US-10-786-720-4073/c
; Sequence 4073, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4073
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-sense strand
US-10-786-720-4073

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3395 AACTTCAGCACTCATCCAGC 3415
    ||||| ||||| ||||| |||||
Db 21 AACTTCAGCGCTCTCCAGC 1

RESULT 583
US-10-786-720-4783

```

```
; Sequence 4783, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4783
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-4783

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3126 AAATGTAAGTGAAGATGGAA 3146
Db      1 AAATGAAGATGAGGATGGAA 21

RESULT 584
US-10-786-720-4785/c
; Sequence 4785, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4785
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-4785

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3126 AAATGTAAGTGAAGATGGAA 3146
Db      21 AAATGAAGATGAGGATGGAA 1

RESULT 585
US-10-786-720-4811/c
; Sequence 4811, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4783
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-4783

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3126 AAATGTAAGTGAAGATGGAA 3146
Db      21 AAATGAAGATGAGGATGGAA 1
```

```
; SEQ ID NO 4811
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-4811

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3395 AACTTCAGCAACTCATCCAGC 3415
Db      21 AACTTCAGCGCTCTCCACG 1

RESULT 586
US-10-786-720-13221/c
; Sequence 13221, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13221
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-13221

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3754 AATGGTGCTGTCCAGCTTCCT 3774
Db      21 AATGGCTGTCTCCATCTGCTT 1

RESULT 587
US-10-786-720-13756/c
; Sequence 13756, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13756
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-13756

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3987 GTCGGGCTTCATCCTTCCTT 4007
Db      21 GTCAGGCTGTTCACCTTCCTT 1
```

```
RESULT 588
US-10-786-720-13757/c
; Sequence 13757, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13757
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-13757

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3985 AAGTCGGCGCTCATCACTTCC 4005
      ||||| ||||| ||||| |||||
DB 21 AAGTCAGCGCTGTTCACCTTC 1

RESULT 589
US-10-786-720-13758
; Sequence 13758, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13758
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-13758

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 52.4%; Pred. No. 5.2e+02;
Matches 11; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 3987 GTCGGCGCTCATCACTTCTT 4007
      |: |||||: |||||: |||||:
DB 1 GUCAGCGCGUUCACUCCUU 21

RESULT 590
US-10-786-720-14484
; Sequence 14484, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
```

```
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14484
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-14484

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 5.2e+02;
Matches 10; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

QY 3988 TCGGGCGCTCATCACTTCTT 4008
      |: |||||: |||||: |||||:
DB 1 UCAGCGCGUUCACUCCUU 21

RESULT 591
US-10-786-720-17384
; Sequence 17384, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17384
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-17384

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 42.9%; Pred. No. 5.2e+02;
Matches 9; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 3263 GTGTCCCTTTGTCACTTCTT 3283
      |: : |||||: |||||: |||||:
DB 1 GUAUGCGCGUUCACUCCUU 21

RESULT 592
US-10-786-720-18572
; Sequence 18572, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18572
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-18572

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 42.9%; Pred. No. 5.2e+02;
Matches 9; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 3263 GTGTCCCTTTGTCACTTCTT 3283
      |: : |||||: |||||: |||||:
DB 1 GUAUGCGCGUUCACUCCUU 21
```


APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 46150
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-48150

Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3057 AGTTGATCTTGTAAACCAA 3077
||| ||||| ||||| |||||
Db 21 AGTAGATCTTGATGAACCAA 1

RESULT 598
US-10-839-686-23/c
; Sequence 23, Application US/10839686
; Publication No. US20050053972A1
; GENERAL INFORMATION:
; APPLICANT: Sequenom, Inc.
; TITLE OF INVENTION: A Method for Identifying Polymorphisms
; FILE REFERENCE: 7011463001
; CURRENT APPLICATION NUMBER: US/10/839,686
; CURRENT FILING DATE: 2004-05-04
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: G allele fragment of hypothetical sequence of Fig. 37.
US-10-839-686-23

Query Match 0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3757 GGTGCTGCCAGCTTCTTGA 3777
||| ||||| ||||| |||||
Db 21 GGTGCTGCCAGTTTCTCCGA 1

RESULT 599
US-10-755-118-94/c
; Sequence 94, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22

; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 94
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-755-118-94

Query Match 0.3%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAA 5040
||||| ||||| ||||| |||||
Db 16 AAAAAAAAAAAAAA 1

RESULT 600
US-09-780-533A-643/c
; Sequence 643, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MEH00.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 643
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-643

Query Match 0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3735 TTTAGCCATAGCATCT 3750
||||| ||||| ||||| |||||
Db 17 TTTAGCCATAGCATCT 2

RESULT 601
US-10-608-863-3/c
; Sequence 3, Application US/10608863
; Publication No. US2004021492A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yavoi, Yoshihiro
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREA
; FILE REFERENCE: 3462.1003-000
; CURRENT APPLICATION NUMBER: US/10/608,863
; CURRENT FILING DATE: 2003-06-27

; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially
; OTHER INFORMATION: Synthesized Primer Sequence
US-10-608-863-3

Query Match 0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAAAATAAAAAA 5039
Db 17 TAAAAAATAAAAAA 2

RESULT 602

US-10-608-863-4/c

; Sequence 4, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yayoi, Yoshihiro
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREA
; FILE REFERENCE: 3462.1003-000
; CURRENT APPLICATION NUMBER: US/10/608,863
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially
; OTHER INFORMATION: Synthesized Primer Sequence
US-10-608-863-4

Query Match 0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5050 AAAAAAATAAAAAA 5065
Db 16 AAAAAAATAAAAAA 1

RESULT 603

US-10-608-863-5/c

; Sequence 5, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yayoi, Yoshihiro
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREA
; FILE REFERENCE: 3462.1003-000
; CURRENT APPLICATION NUMBER: US/10/608,863

; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially
; OTHER INFORMATION: Synthesized Primer Sequence
US-10-608-863-5

Query Match 0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5050 AAAAAAATAAAAAA 5065
Db 16 AAAAAAATAAAAAA 1

RESULT 604

US-09-380-728A-5

; Sequence 5, Application US/09380728A
; Patent No. US20020081583A1
; GENERAL INFORMATION:
; APPLICANT: Abe, Satoshi
; APPLICANT: Kodama, Hirofumi
; TITLE OF INVENTION: Probes for detection of target nucleic acid, methods of detecti
; FILE REFERENCE: 400327
; CURRENT APPLICATION NUMBER: US/09/380,728A
; CURRENT FILING DATE: 1999-09-08
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: a synthetic probe nucleic acid, 5'-terminus:Phosphorylated,
; OTHER INFORMATION: 3'-terminus:Biotin
US-09-380-728A-5

Query Match 0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGATCCCCGGGCTGC 16
Db 5 GGATCCCCGGGCTGC 20

RESULT 605

US-09-945-952A-34

; Sequence 34, Application US/09945952A
; Publication No. US20020177137A1
; GENERAL INFORMATION:
; APPLICANT: Hodge, Timothy A.
; TITLE OF INVENTION: System for Automated Transgenic Screening
; FILE REFERENCE: 023131.41500
; CURRENT APPLICATION NUMBER: US/09/945,952A
; CURRENT FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: 60/230,371
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA

```

; ORGANISM: Streptomyces hygroscopicus
US-09-945-952A-34

Query Match      0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1610 AGGATTTGGGCAACAT 1625
Db 2 AGGATTTGGGCAACAT 17

RESULT 606
US-10-233-942-34
; Sequence 34, Application US/10233942
; Publication No. US20030165922A1
; GENERAL INFORMATION:
; APPLICANT: Hodge, Timothy et al
; TITLE OF INVENTION: System for Automated Transgenic Screening
; FILE REFERENCE: 023131.41500
; CURRENT APPLICATION NUMBER: US/10/233,942
; CURRENT FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: 60/230,371
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Streptomyces hygroscopicus
US-10-233-942-34

Query Match      0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1610 AGGATTTGGGCAACAT 1625
Db 2 AGGATTTGGGCAACAT 17

RESULT 607
US-10-316-755-44/c
; Sequence 44, Application US/10316755
; Publication No. US20040110152A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: MODULATION OF MATRIX METALLOPROTEINASE 11 EXPRESSION
; FILE REFERENCE: RTS-0381
; CURRENT APPLICATION NUMBER: US/10/316,755
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 277
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-755-44

Query Match      0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 47 TCGTGGGGCTGCAGCA 62
Db 16 TCGTGGGGCTGCAGCA 1

RESULT 608
US-10-714-796-233
; Sequence 233, Application US/10714796
; Publication No. US20040180847A1
; GENERAL INFORMATION:
; APPLICANT: Dobie, Kenneth W.
; APPLICANT: Koller, Erich
; TITLE OF INVENTION: ANTISENSE MODULATION OF KINESIN-LIKE 1 EXPRESSION
; FILE REFERENCE: ISHT-1004
; CURRENT APPLICATION NUMBER: US/10/714,796
; CURRENT FILING DATE: 2003-11-17
; PRIOR APPLICATION NUMBER: US 10/156,603
; PRIOR FILING DATE: 2002-05-23
; NUMBER OF SEQ ID NOS: 237
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-714-796-233

Query Match      0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3488 CACCACCACCTGGATG 3503
Db 5 CACCACCACCTGGATG 20

RESULT 609
US-10-607-806-25/c
; Sequence 25, Application US/10607806
; Publication No. US20050014158A1
; GENERAL INFORMATION:
; APPLICANT: Adam, Gail Isabel Reid
; APPLICANT: Langdown, Maria L.
; APPLICANT: Denissenko, Mikhaili F.
; APPLICANT: Dennis, Edward
; APPLICANT: Cantor, Charles
; APPLICANT: Rubin, Byron
; TITLE OF INVENTION: THERAPEUTIC METHODS FOR REDUCING FAT
; FILE REFERENCE: 524592003200
; CURRENT APPLICATION NUMBER: US/10/607,806
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/392,362
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-607-806-25

Query Match      0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3760 GCTGTCCAGCTTCTTG 3775
Db 16 GCTGTCCAGCTTCTTG 1

RESULT 610
US-10-644-052A-376/c
; Sequence 376, Application US/10644052A
; Publication No. US20050059619A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M
; APPLICANT: Samulowitz, Ulrike
; APPLICANT: Vollmer, Joerg
; APPLICANT: Uhlmann, Eugen

```


APPLICANT: Jurk, Marion
APPLICANT: Lipford, Grayson
APPLICANT: Rankin, Robert
TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
FILE REFERENCE: C1037.70048US00
CURRENT APPLICATION NUMBER: US/10/644,052A
CURRENT FILING DATE: 2003-08-19
PRIOR APPLICATION NUMBER: US 60/404,479
PRIOR FILING DATE: 2002-08-19
PRIOR APPLICATION NUMBER: US 60/404,820
PRIOR FILING DATE: 2002-08-19
PRIOR APPLICATION NUMBER: US 60/429,701
PRIOR FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: US 60/447,377
PRIOR FILING DATE: 2003-02-14
NUMBER OF SEQ ID NOS: 388
SOFTWARE: PatentIn version 3.2
SEQ ID NO 376
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-376

Query Match 0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5050 AAAAAAAAAAAAAAC 5065
Db 20 AAAAAAAAAAAAAAC 5

RESULT 611
US-10-644-052A-377/c
Sequence 377, Application US/10644052A
Publication No. US20050059619A1
GENERAL INFORMATION:
APPLICANT: Krieg, Arthur M
APPLICANT: Samulowitz, Ulrike
APPLICANT: Vollmer, Joerg
APPLICANT: Uhlmann, Eugen
APPLICANT: Jurk, Marion
APPLICANT: Lipford, Grayson
APPLICANT: Rankin, Robert
TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
FILE REFERENCE: C1037.70048US00
CURRENT APPLICATION NUMBER: US/10/644,052A
CURRENT FILING DATE: 2003-08-19
PRIOR APPLICATION NUMBER: US 60/404,479
PRIOR FILING DATE: 2002-08-19
PRIOR APPLICATION NUMBER: US 60/404,820
PRIOR FILING DATE: 2002-08-19
PRIOR APPLICATION NUMBER: US 60/429,701
PRIOR FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: US 60/447,377
PRIOR FILING DATE: 2003-02-14
NUMBER OF SEQ ID NOS: 388
SOFTWARE: PatentIn version 3.2
SEQ ID NO 377
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-377

Query Match 0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5050 AAAAAAAAAAAAAAC 5065

Db 20 AAAAAAAAAAAAAAC 5

RESULT 612
US-09-928-796A-6
Sequence 6, Application US/09928796A
Patent No. US20020042086A1
GENERAL INFORMATION:
APPLICANT: Schwarz, Margaret A.
APPLICANT: Zhang, Fangrong
APPLICANT: Gebb, Sarah A.
TITLE OF INVENTION: Methods of Facilitating Vascular Growth
FILE REFERENCE: EMAP2 and Vascularization
CURRENT APPLICATION NUMBER: US/09/928,796A
CURRENT FILING DATE: 2001-08-13
PRIOR APPLICATION NUMBER: 09/439,616
PRIOR FILING DATE: 1999-11-12
NUMBER OF SEQ ID NOS: 12
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 6
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-928-796A-6

Query Match 0.3%; Score 16; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2988 GAGCCATCTTCATGAT 3003
Db 5 GAGCCATCTTCATGAT 20

RESULT 613
US-09-928-796A-12
Sequence 12, Application US/09928796A
Patent No. US20020042086A1
GENERAL INFORMATION:
APPLICANT: Schwarz, Margaret A.
APPLICANT: Zhang, Fangrong
APPLICANT: Gebb, Sarah A.
TITLE OF INVENTION: Methods of Facilitating Vascular Growth
FILE REFERENCE: EMAP2 and Vascularization
CURRENT APPLICATION NUMBER: US/09/928,796A
CURRENT FILING DATE: 2001-08-13
PRIOR APPLICATION NUMBER: 09/439,616
PRIOR FILING DATE: 1999-11-12
NUMBER OF SEQ ID NOS: 12
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 12
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-928-796A-12

Query Match 0.3%; Score 16; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2988 GAGCCATCTTCATGAT 3003
Db 5 GAGCCATCTTCATGAT 20

RESULT 614
US-10-871-302-36/c
Sequence 36, Application US/10871302

RESULT 616
US-10-847-918-3426/c
; Sequence 3426, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918

RESULT 618
US-10-251-117-496
; Sequence 496, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McGsiggan, James
; TITLE OF INVENTION: RNA Interference Medi
; TITLE OF INVENTION: Gene Expression Usin
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24

```
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 08/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 496
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-496

Query Match          0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 5.1e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 5024 TAAAAAAGTACTAGTTCCC 5042
Db 1 UAAAAAACAAACAAACAAA 19

RESULT 619
US-10-225-023-100
; Sequence 100, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
; FILE REFERENCE: 400/054 (MBHB01-665-B)
; CURRENT APPLICATION NUMBER: US/10/225,023
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US 60/398,036
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/157,580
; NUMBER OF SEQ ID NOS: 1494
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 100
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-225-023-100

Query Match          0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 4405 GCAGGAAGTACTAGTTCCC 4423
Db 1 GCAGGAACUACUAGUACCC 19

RESULT 620
US-10-225-023-838/c
; Sequence 838, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
; TITLE OF INVENTION: Interfering RNA
; FILE REFERENCE: 400/054 (MBHB01-665-B)
; CURRENT APPLICATION NUMBER: US/10/225,023
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US 60/398,036
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/157,580
; NUMBER OF SEQ ID NOS: 1494
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 838
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-225-023-838

Query Match          0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4405 GCAGGAAGTACTAGTTCCC 4423
Db 19 GCAGGAAGTACTAGTACCC 1

RESULT 621
US-10-349-143-4157/c
; Sequence 4157, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4157
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-13598 for SEQ 223,
US-10-349-143-4157

Query Match          0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3884 CTGGAGCACAGTCTGTCT 3902
Db 19 CTGGAGCTGAGTCTGTCT 1

RESULT 622
US-10-883-218-138/c
; Sequence 138, Application US/10883218
```

```

; Publication No. US20050124567A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of TRPM7 Gene Expression
; TITLE OF INVENTION: Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/195 (MBHB04-535)
; CURRENT APPLICATION NUMBER: US/10/883,218
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2003-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 930
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 138
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-883-218-138

Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3351 CTTACCATCCACCTATCAG 3369
Db 19 CTTCCCATCCACATATCAG 1

RESULT 623
US-10-883-218-540
; Sequence 540, Application US/10883218
; Publication No. US20050124567A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of TRPM7 Gene Expression
; TITLE OF INVENTION: Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/195 (MBHB04-535)
; CURRENT APPLICATION NUMBER: US/10/883,218
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2003-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 930
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 138
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-883-218-138

Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3351 CTTACCATCCACCTATCAG 3369
Db 19 CTTCCCATCCACATATCAG 1

RESULT 623
US-10-883-218-540
; Sequence 540, Application US/10883218
; Publication No. US20050124567A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of TRPM7 Gene Expression
; TITLE OF INVENTION: Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/195 (MBHB04-535)
; CURRENT APPLICATION NUMBER: US/10/883,218
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2003-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 930
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 138
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-883-218-138
```

```

; Publication No. US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 930
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 540
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-883-218-540

Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 5.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3351 CTTACCATCCACCTATCAG 3369
Db 1 CUUCCCAUCCACAUCAUCAG 19

RESULT 624
US-10-892-922-73
; Sequence 73, Application US/10892922
; Publication No. US20050124569A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Gueriolini, Roberto
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of CXCR4 Gene Expression
; TITLE OF INVENTION: Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400-198
; CURRENT APPLICATION NUMBER: US/10/892,922
; CURRENT FILING DATE: 2004-07-16
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 73
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-892-922-73

Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 36.8%; Pred. No. 5.1e+02;
Matches 7; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

QY 4650 ACTGATTGTATAAATTTT 4668
Db 1 ACUUAUUUAUAAAAUUUU 19

RESULT 625
US-10-892-922-166/c
; Sequence 166, Application US/10892922
; Publication No. US20050124569A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Gueriolini, Roberto
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of CXCR4 Gene Expression
; TITLE OF INVENTION: Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400-198
```



```

; PRIOR APPLICATION NUMBER: US 60/157,415
; PRIOR FILING DATE: 1999-10-02
; NUMBER OF SEQ ID NOS: 112
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Oligo 952
US-09-453-234-4

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      366 CCTCCACCAAGGCCCATC 384
      ||||||| |||||
DB      19 CCTCCACCAAGGCCCATC 1

RESULT 629
US-09-908-671-6/c
; Sequence 6, Application US/09508671
; Publication No. US20030138928A1
; GENERAL INFORMATION:
; APPLICANT: CARSON, DENNIS A.
; NOBORI, TSUTOMU
; TITLE OF INVENTION: TUMOR SUPPRESSOR GENE AND METHODS FOR
; DETECTION OF CANCER, MONITORING OF TUMOR PROGRESSION AND CA
; TREATMENT
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: California
; COUNTRY: US
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/09/908,671
; FILING DATE: 18-Jul-2001
; CLASSIFICATION DATA: <Unknown>
; PRIOR APPLICATION NUMBER: US/08/227,800
; FILING DATE: 14-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: HOWELLS, STACY L.
; REGISTRATION NUMBER: 34,842
; REFERENCE/DOCKET NUMBER: 07340/023001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/678-5070
; TELEFAX: 619/678-5099
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; IMMEDIATE SOURCE:
; CLONE: CDK41' primer
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..20
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-908-671-6
```

```

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      4079 GCTTCAGTTGCCAATTTC 4097
      ||||||| |||||
DB      20 GCTTCAGTTGCCAATTTC 2

RESULT 630
US-10-094-546-1/c
; Sequence 1, Application US/10094546
; Publication No. US20020197677A1
; GENERAL INFORMATION:
; APPLICANT: Guttieri, Mary C.
; APPLICANT: Schmaljohn, Connie S.
; TITLE OF INVENTION: Antibodies Expressed in Insect Cells
; FILE REFERENCE: 003/245/SAP
; CURRENT APPLICATION NUMBER: US/10/094,546
; CURRENT FILING DATE: 2002-06-12
; PRIOR APPLICATION NUMBER: US 60/274,164
; PRIOR FILING DATE: 2001-03-08
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: Apple Macintosh Microsoft Word 6.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: linker sequence
US-10-094-546-1

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      366 CCTCCACCAAGGCCCATC 384
      ||||||| |||||
DB      19 CCTCCACCAAGGCCCATC 1

RESULT 631
US-10-148-844-6/c
; Sequence 6, Application US/10148844
; Publication No. US20030096403A1
; GENERAL INFORMATION:
; APPLICANT: Hyo-Jeong Hong
; APPLICANT: Keun-Soo Kim
; TITLE OF INVENTION: A HUMANIZED ANTIBODY TO SURFACE ANTIGEN S OF HEPATITIS B
; FILE REFERENCE: 118.15-US-WO
; CURRENT APPLICATION NUMBER: US/10/148,844
; CURRENT FILING DATE: 2002-06-03
; PRIOR APPLICATION NUMBER: KR 2000-57891
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: KR 2001-60966
; PRIOR FILING DATE: 2001-09-29
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HC
US-10-148-844-6

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      366 CCTCCACCAAGGCCCATC 384
      ||||||| |||||
```

Db 19 CCTCCACCAAGGGCCCATC 1

RESULT 632

US-10-218-654-143

; Sequence 143, Application US/10218654

; Publication No. US20030099609A1

; GENERAL INFORMATION:

; APPLICANT: Sim, Gek-Kee

; APPLICANT: Yang, Shumin

; APPLICANT: Dreitz, Matthew J.

; APPLICANT: Wonderling, Ramani S.

; TITLE OF INVENTION: CANINE AND FELINE IMMUNOREGULATORY PROTEINS, NUCLEIC

; FILE REFERENCE: IM-2-C1

; CURRENT APPLICATION NUMBER: US/10/218,654

; PRIOR FILING DATE: 2002-08-13

; PRIOR APPLICATION NUMBER: US/09/322,409

; PRIOR FILING DATE: 1999-05-28

; PRIOR APPLICATION NUMBER: 60/087,306

; PRIOR FILING DATE: 1998-05-29

; NUMBER OF SEQ ID NOS: 154

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 143

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: Primer

US-10-218-654-143

Query Match

Best Local Similarity 0.3%; Score 15.8; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3920 ATGGCTCTCTGGTTGGCTG 3938

Db 1 ATGGCGCTCTGGTTGACTG 19

RESULT 633

US-10-000-213-39/c

; Sequence 39, Application US/10000213

; Publication No. US20030125271A1

; GENERAL INFORMATION:

; APPLICANT: Brenda F. Baker

; APPLICANT: Mark P. Roach

; APPLICANT: Kenneth Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION

; FILE REFERENCE: RTS-0327

; CURRENT APPLICATION NUMBER: US/10/000,213

; CURRENT FILING DATE: 2001-11-14

; NUMBER OF SEQ ID NOS: 94

; SEQ ID NO 39

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-000-213-39

Query Match

Best Local Similarity 0.3%; Score 15.8; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 302 AGAGCTTTCCAGTCTCC 320

Db 20 AGAGCTGTCCAGCTCTCC 2

RESULT 634

US-10-262-439-143

; Sequence 143, Application US/10262439

; Publication No. US20030143196A1

; GENERAL INFORMATION:

; APPLICANT: Sim, Gek-Kee

; APPLICANT: Yang, Shumin

; APPLICANT: Dreitz, Matthew J.

; APPLICANT: Wonderling, Ramani S.

; TITLE OF INVENTION: CANINE AND FELINE IMMUNOREGULATORY PROTEINS, NUCLEIC

; FILE REFERENCE: IM-2-C2

; CURRENT APPLICATION NUMBER: US/10/262,439

; PRIOR FILING DATE: 2002-09-30

; PRIOR APPLICATION NUMBER: US/09/451,527

; PRIOR FILING DATE: 1999-12-01

; PRIOR APPLICATION NUMBER: 09/322,409

; PRIOR FILING DATE: 1999-05-28

; PRIOR APPLICATION NUMBER: 60/087,306

; PRIOR FILING DATE: 1998-05-29

; NUMBER OF SEQ ID NOS: 174

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 143

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: Primer

US-10-262-439-143

Query Match

Best Local Similarity 0.3%; Score 15.8; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3920 ATGGCTCTCTGGTTGGCTG 3938

Db 1 ATGGCGCTCTGGTTGACTG 19

RESULT 635

US-10-167-241-3/c

; Sequence 3, Application US/10167241

; Publication No. US20030165895A1

; GENERAL INFORMATION:

; APPLICANT: CZERNIAK, BOGDAN

; APPLICANT: JOHNSTON, DENNIS

; TITLE OF INVENTION: METHODS OF DETECTING, DIAGNOSING AND TREATING CANCER

; FILE REFERENCE: UISC:712US

; CURRENT APPLICATION NUMBER: US/10/167,241

; CURRENT FILING DATE: 2002-06-11

; PRIOR APPLICATION NUMBER: 60/297,813

; PRIOR FILING DATE: 2001-06-12

; NUMBER OF SEQ ID NOS: 20

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 3

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: Primer

US-10-167-241-3

Query Match

Best Local Similarity 0.3%; Score 15.8; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTGCCAATTC 4097

Db 20 GCTTCAGTTCCCAATTC 2

RESULT 636

US-10-108-732-5/c
; Sequence 5, Application US/10108732
; Publication No. US20030175721A1
; GENERAL INFORMATION:
; APPLICANT: Duffy, David L
; APPLICANT: Box, Neil F
; APPLICANT: Hayward, Nicholas K
; APPLICANT: Martin, Nicholas G
; APPLICANT: Sturm, Richard A
; APPLICANT: Gruis, Nelleke A
; APPLICANT: Van Der Velden, Pieter
; APPLICANT: Bergman, Wilma
; APPLICANT: Frants, Rune R
; TITLE OF INVENTION: MELANOMA RISK DETECTION
; FILE REFERENCE: 8795-27U1
; CURRENT APPLICATION NUMBER: US/10/108,732
; CURRENT FILING DATE: 2002-03-28
; PRIOR APPLICATION NUMBER: US 60/279,515
; PRIOR FILING DATE: 2001-03-28
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: CDKN2A Exon 2 primer
US-10-108-732-5

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTCCAGTTCCTCCAAATTC 4097
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GCTTCCAGTTCCTCCAAATTC 2

RESULT 637
US-10-362-817-13/c
; Sequence 13, Application US/10362817
; Publication No. US20030186294A1
; GENERAL INFORMATION:
; APPLICANT: Kong, Xiangyin
; APPLICANT: Bu, Lei
; APPLICANT: Zhao, Guoping
; APPLICANT: Yan, Shunsheng
; APPLICANT: Jin, Meilei
; APPLICANT: Sulitang, Yexiang
; APPLICANT: Jin, Yiping
; APPLICANT: Hu, Liandian
; TITLE OF INVENTION: METHOD OF DIAGNOSING AND TREATING LENS ILLNESSES USING HUMAN CRYC
; TITLE OF INVENTION: GENE AND CODED PRODUCT THEREOF
; FILE REFERENCE: 9548.77USWO
; CURRENT APPLICATION NUMBER: US/10/362,817
; CURRENT FILING DATE: 2003-02-25
; PRIOR APPLICATION NUMBER: PCT/CN01/01274
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: CN 00119756.8
; PRIOR FILING DATE: 2000-08-25
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-362-817-13

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4343 CTGGCTCAGATATGAAAAAT 4361
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CTGGCTTAGACATGAAAAAT 2

RESULT 638
US-10-173-718-19/c
; Sequence 19, Application US/10173718
; Publication No. US20030232437A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF VEGF-C EXPRESSION
; FILE REFERENCE: PTS-0036
; CURRENT APPLICATION NUMBER: US/10/173,718
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 125
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-173-718-19

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 966 GACAGCTGTGGACCAAGCA 984
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GACATCTGTGGACCAAAACA 2

RESULT 639
US-10-173-718-89
; Sequence 89, Application US/10173718
; Publication No. US20030232437A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF VEGF-C EXPRESSION
; FILE REFERENCE: PTS-0036
; CURRENT APPLICATION NUMBER: US/10/173,718
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 125
; SEQ ID NO 89
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-173-718-89

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 966 GACAGCTGTGGACCAAGCA 984
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GACATCTGTGGACCAAAACA 19

RESULT 640
US-10-665-216-107
; Sequence 107, Application US/10665216
; Publication No. US20040043957A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF UROKINASE PLASMINOGEN ACTIVATOR EXPRESSION
; FILE REFERENCE: RYS-0188
US-10-665-216-107

; CURRENT APPLICATION NUMBER: US/10/665,216
; CURRENT FILING DATE: 2003-09-19
; PRIOR APPLICATION NUMBER: US/09/821,972
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 107
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-665-216-107

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 TTTCCCGAGCGCTAGGCTA 524
Db 1 TTTCCCGAGCGCTAGGCTA 19

RESULT 641
US-10-292-337-71
; Sequence 71, Application US/10292337
; Publication No. US20040092462A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF ENDOTHELIAL DIFFERENTIATION GENE 2 EXPRESSION
; FILE REFERENCE: PFS-0058
; CURRENT APPLICATION NUMBER: US/10/292,337
; CURRENT FILING DATE: 2002-11-13
; NUMBER OF SEQ ID NOS: 139
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-292-337-71

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4926 ATTTGCTATTGAAAGAT 4944
Db 1 ATTTGCAATGAAAGAT 19

RESULT 642
US-10-479-510-1
; Sequence 1, Application US/10479510
; Publication No. US20040157230A1
; GENERAL INFORMATION:
; APPLICANT: Cavid Tech AB
; TITLE OF INVENTION: A method for measuring DNA polymerization and applications of the method.
; FILE REFERENCE: 110063501
; CURRENT APPLICATION NUMBER: US/10/479,510
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 60/297,773
; PRIOR FILING DATE: 2001-06-14
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: template

US-10-479-510-1

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4769 TGACTGACTGACTAAATGA 4787
Db 2 TGACTGACTGACTGACTGA 20

RESULT 643
US-10-476-021-138/c
; Sequence 138, Application US/10476021
; Publication No. US20040186069A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0216
; CURRENT APPLICATION NUMBER: US/10/476,021
; CURRENT FILING DATE: 2003-10-24
; PRIOR APPLICATION NUMBER: US/09/844,634
; PRIOR FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-476-021-138

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4489 CAGAAAGTAGGACCAAGTG 4507
Db 20 CAGCAAGTAGGAGCAAGTG 2

RESULT 644
US-10-466-894-1687
; Sequence 1687, Application US/10466894
; Publication No. US20040241671A1
; GENERAL INFORMATION:
; APPLICANT: Telerman, Adam
; APPLICANT: Amson, Robert
; APPLICANT: Tuijnder, Marius
; APPLICANT: Susini, Laurent
; TITLE OF INVENTION: SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION, TUMOUR REVERSION, APOPTOSIS AND/OR VIRUS RESISTANCE
; TITLE OF INVENTION: AND THEIR USE AS MEDICINES
; FILE REFERENCE: 10918-014-999
; CURRENT APPLICATION NUMBER: US/10/466,894
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: PCT/FR02/00273
; PRIOR FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: FR01/00899
; NUMBER OF SEQ ID NOS: 2270
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1687
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 17
; OTHER INFORMATION: n = A,T,C or G
US-10-466-894-1687

```
Query Match          0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 645
US-10-831-901A-21487/c
; Sequence 21487, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21487
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-21488

Query Match          0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4912 AAATGAATATGTTTATTTT 4930
Db 20 AAACGACATGTTTATTTT 2

RESULT 647
US-10-831-901A-29727/c
; Sequence 29727, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29727
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-21487

Query Match          0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4912 AAATGAATATGTTTATTTT 4930
Db 19 AAACGACATGTTTATTTT 1

RESULT 646
US-10-831-901A-21488/c
; Sequence 21488, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29727

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5022 TGTAAAAAATAAAAAA 5040
Db 19 TGACAAAAAATAAAAAA 1

RESULT 648
US-10-704-263-84
; Sequence 84, Application US/10704263
; Publication No. US20050101013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: MODULATION OF STATS EXPRESSION
; FILE REFERENCE: RTS-0569
; CURRENT APPLICATION NUMBER: US/10/704,263
; CURRENT FILING DATE: 2003-11-06
; NUMBER OF SEQ ID NOS: 213
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Compound
US-10-704-263-84

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4304 ACTGTAGTCTCGCAGTGG 4322
Db 1 ACTGTAGTCTCCAGGTGG 19

RESULT 649
US-10-825-593-48
; Sequence 48, Application US/10825593
; Publication No. US20050147604A1
; GENERAL INFORMATION:
; APPLICANT: NeuroNova AG
; TITLE OF INVENTION: A Method for Diagnosing and Treating Affective Disorders
; FILE REFERENCE: XXX
; CURRENT APPLICATION NUMBER: US/10/825,593
; CURRENT FILING DATE: 2004-04-16
; NUMBER OF SEQ ID NOS: 111
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-825-593-48

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3303 AACTGTCCAAATAAAAAA 3321
Db 2 AACTGTCCCAAAAAAATAAAAA 20

RESULT 650
```

```
US-10-931-260-167/c
; Sequence 167, Application US/10931260
; Publication No. US20050152927A1
; GENERAL INFORMATION:
; APPLICANT: Griffith, Irwin J.;
; Pollock, Joanne;
; Bond, Julian F.;
; Garman, Richard D.;
; Kuo, Mei-Chang;
; Powers, Stephen P.;
; Exley, Mark A.;
; Chen, Xian;
; Shaked, Ze'ev
; TITLE OF INVENTION: Allergenic Proteins And Peptides From
; Japanese Cedar Pollen
; NUMBER OF SEQUENCES: 283
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lahive & Cockfield, LLP
; STREET: 28 State St
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/931,260
; FILING DATE: 30-Aug-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/240,203
; FILING DATE: 29-Jan-1999
; APPLICATION NUMBER: 08/467,023
; FILING DATE: 1995-JUN-06
; APPLICATION NUMBER: 08/350,225
; FILING DATE: 1994-DEC-06
; APPLICATION NUMBER: 08/226,248
; FILING DATE: 1994-APR-08
; APPLICATION NUMBER: PCT/US93/00139
; FILING DATE: 1993-JAN-15
; APPLICATION NUMBER: 07/938,990
; FILING DATE: 1992-SEP-01
; APPLICATION NUMBER: 07/730,452
; FILING DATE: 1991-JUL-15
; APPLICATION NUMBER: 07/729,134
; FILING DATE: 1991-JUL-12
; APPLICATION NUMBER: 07/975,179
; FILING DATE: 1992-NOV-12
; APPLICATION NUMBER: PCT/US92/05661
; FILING DATE: 1992-JUL-10
; ATTORNEY/AGENT INFORMATION:
; NAME: Amy E. Mandragouras, Esq.
; REGISTRATION NUMBER: 36,207
; REFERENCE/DOCKET NUMBER: IMI-028CD2CCPA2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 742-4214
; INFORMATION FOR SEQ ID NO: 167:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 167:
US-10-931-260-167

Query Match      0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
US-10-349-143-8727
Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4736 TTTTCAAAATTTATGTCTCC 4754
Db      3 TTTTCAAAATGATGCCCC 21

RESULT 653
US-10-479-510-2
; Sequence 2, Application US/10479510
; Publication No. US20040157230A1
; GENERAL INFORMATION:
; APPLICANT: Cavidit Tech AB
; TITLE OF INVENTION: A method for measuring DNA polymerization and
; TITLE OF INVENTION: Which is Expressing an ACT Polypeptide, or a Nucleic Acid
; FILE REFERENCE: 110063501
; CURRENT APPLICATION NUMBER: US/10/479,510
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 60/297,773
; PRIOR FILING DATE: 2001-06-14
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: template
US-10-479-510-2

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4769 TGACTGACTGACTAAATGA 4787
Db      2 TGACTGACTGACTGACTGA 20

RESULT 654
US-10-786-720-379/c
; Sequence 379, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 379
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-379

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 847 GCATCTGAGAAAGCAGCTA 865
Db      19 GCATCTGAGAAAGCAGCTA 1

US-10-135-629-13
; Sequence 13, Application US/10135629
; Publication No. US20030073657A1
; GENERAL INFORMATION:
; APPLICANT: Hallie, Jorn-Peter
; APPLICANT: Goppelt, Andreas
; APPLICANT: Hof, Peter
; TITLE OF INVENTION: Use of Alpha 1-Antichymotrypsin
; TITLE OF INVENTION: Polypeptides, or Nucleic Acids Encoding Them, or of a Cell
; TITLE OF INVENTION: Which is Expressing an ACT Polypeptide, or a Nucleic Acid
; FILE REFERENCE: 50125/033002
; CURRENT APPLICATION NUMBER: US/10/135,629
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: DE 10121225.0
; PRIOR FILING DATE: 2001-04-30
; PRIOR APPLICATION NUMBER: US 60/323,348
; PRIOR FILING DATE: 2001-09-18
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-135-629-13

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3258 CATTGTGTCCCTTTGTCA 3276
Db      3 CAGTTGTGTCCCATTTGTCA 21

RESULT 652
US-10-349-143-8727
; Sequence 8727, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8727
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..21
; OTHER INFORMATION: downstream amplification primer 99-17833 for SEQ 862, in compleme
```

```
RESULT 655
US-10-786-720-14848
; Sequence 14848, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14848
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-14848

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3696 ACGAGTCAAGCGGCTCACA 3714
|||||
Db 2 ACGAGTCAAGTGGGCTCACA 20

RESULT 656
US-10-786-720-14850/c
; Sequence 14850, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14850
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-14850

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3696 ACGAGTCAAGCGGCTCACA 3714
|||||
Db 20 ACGAGTCAAGTGGGCTCACA 2

RESULT 657
US-10-751-736-1933
; Sequence 1933, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7896
; LENGTH: 21
```

```
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1933
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-1933

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4840 AAGAATCAGCCAGCAACA 4858
|||||
Db 2 AAGAATCAGCTAGCAACA 20

RESULT 658
US-10-751-736-2182
; Sequence 2182, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2182
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-2182

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4840 AAGAATCAGCCAGCAACA 4858
|||||
Db 3 AAGAATCAGCTAGCAACA 21

RESULT 659
US-10-751-736-7896
; Sequence 7896, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7896
; LENGTH: 21
```

; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-7896

Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.5e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2871 ACAGTCTCTGAAGAAGTTG 2889
||||:|:|||||:|:
DB 3 ACAGUGCUGAAGAAGUUG 21

RESULT 660

US-10-751-736-13970/c
; Sequence 13970, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13970
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-13970

Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 949 ATTGCTTCCAGATCCTGA 967
|||||||:|||||:
DB 20 ATTGCTTCCGATCATGA 2

RESULT 661

US-10-751-736-18927/c
; Sequence 18927, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18927
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-18927

Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2917 GAAGCAAACTTCTGGCAC 2935
|||||:|||||:
DB 21 GAAGAAACACTTCTGGCAC 3

RESULT 662

US-10-751-736-21281
; Sequence 21281, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 21281
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-21281

Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.5e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1097 AAGACAACCGCGCAGATTT 1115
|||||||:|||||:
DB 3 AAGACAACCGCGCAGAUUU 21

RESULT 663

US-10-751-736-21929
; Sequence 21929, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 21929
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-21929

Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.5e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1097 AAGACAACCGCGCAGATTT 1115
|||||||:|||||:
DB 3 AAGACAACCGCGCAGAUUU 21

RESULT 664

```

US-10-751-736-23285
; Sequence 23285, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23285
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-23285

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.5e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 4308 TAGTCTGCAGATGGAAAT 4326
Db 2 UAUCCAGCAGAGUAGAAU 20

RESULT 665
US-10-751-736-36664/c
; Sequence 36664, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36664
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-36664

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 803 ATTCTGCACAGATTGTCT 821
Db 20 ATTCTTCACAGCATTTGTCT 2

RESULT 666
US-10-751-736-44650/c
; Sequence 44650, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene

```

```

; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44650
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-44650

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3247 TCCTCTGCTGGCATTGTG 3265
Db 19 TCCTCTGATGGCATTGTG 1

RESULT 667
US-10-751-736-48472/c
; Sequence 48472, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 48472
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-48472

Query Match      0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2418 GCCTCTGCTGCAACAGGT 2436
Db 20 GCCTCTGCTTCAACAATGT 2

RESULT 668
US-10-847-918-3467/c
; Sequence 3467, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729

```

```

US-09-780-533A-63

Query Match          0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1577 TTCTGCAGATGAGCGT 1593
    |||||
DB 17 TTCTGCAGAGGCGT 1

RESULT 671
US-09-780-533A-962/c
; Sequence 962, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MEHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 962
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-962

Query Match          0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1579 TCTGCAGATGAGCGTAT 1595
    |||||
DB 17 TCTGCAGAGGCGTAT 1

RESULT 672
US-09-780-533A-963/c
; Sequence 963, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MEHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 963
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-963

Query Match          0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1578 TTCTGCAGATGAGCGTA 1594

```



```
Db      17 TTCTGCAGAGCGGTA 1
|||||
RESULT 673
US-10-333-429-322
; Sequence 322, Application US/10333429
; Publication No. US20040048265A1
; GENERAL INFORMATION:
; APPLICANT: GENSET
; TITLE OF INVENTION: Obesity Associated Biallelic Marker Maps
; FILE REFERENCE: G-08JUS02PCT
; CURRENT APPLICATION NUMBER: US/10/333,429
; CURRENT FILING DATE: 2003-01-17
; PRIOR APPLICATION NUMBER: PCT/IB01/01477
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: US 60/219,704
; PRIOR FILING DATE: 2000-07-18
; NUMBER OF SEQ ID NOS: 579
; SOFTWARE: Patent.pm
; SEQ ID NO 322
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-28352 for SEQ 151,
US-10-333-429-322

Query Match      0.3%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      4144 CACCCTCTGTATCAGTC 4160
|||||
Db      2 CACCCTTGTATCAGTC 18

RESULT 674
US-09-752-639-98
; Sequence 98, Application US/09752639
; Patent No. US20020091243A1
; GENERAL INFORMATION:
; APPLICANT: Gatanaga, T.
; TITLE OF INVENTION: Factors Altering Tumor Necrosis
; TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods
; TITLE OF INVENTION: of Use Thereof
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,639
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US99/10793
; FILING DATE:
; APPLICATION NUMBER: 09/081,385
; FILING DATE:
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:

Query Match      0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      4586 CCACACAGGGCTTCATC 4602
|||||
Db      2 CCACAGAGGGCTTCATC 18

RESULT 675
US-09-984-198-98
; Sequence 98, Application US/09984198
; Patent No. US20020106679A1
; GENERAL INFORMATION:
; APPLICANT: Gatanaga, T.
; TITLE OF INVENTION: Factors Altering Tumor Necrosis
; TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods
; TITLE OF INVENTION: of Use Thereof
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/984,198
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US99/10793
; FILING DATE:
; APPLICATION NUMBER: 09/081,385
; FILING DATE:
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:
```

[illegible]

```
; PRIOR FILING DATE: 1997-08-15
; PRIOR APPLICATION NUMBER: P03519
; PRIOR FILING DATE: 1996-11-08
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Hepatitis B virus
US-10-260-451-6

Query Match      0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 525 TTATATCCTAACCTTAC 541
Db 3 TTCTATCCTAACCTTAC 19

RESULT 680
US-10-008-789-12
; Sequence 12, Application US/10008789
; Publication No. US20030125276A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 6 EXH
; FILE REFERENCE: RTS-0333
; CURRENT APPLICATION NUMBER: US/10/008,789
; CURRENT FILING DATE: 2001-11-08
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-008-789-12

Query Match      0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2699 AAAGAAACTTGTCTG 2715
Db 2 AAAGAAACTTGTCTG 18

RESULT 681
US-10-349-143-6200/c
; Sequence 6200, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6200
; LENGTH: 20
; TYPE: DNA

; PRIOR FILING DATE: 1997-08-15
; PRIOR APPLICATION NUMBER: P03519
; PRIOR FILING DATE: 1996-11-08
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20_bind
; OTHER INFORMATION: upstream amplification primer 99-10046 for SEQ 2266,
US-10-349-143-6200

Query Match      0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4356 GAAATAAGCTTTGGG 4372
Db 17 GAAATAAGCTTTGGG 1

RESULT 682
US-10-620-532-9/c
; Sequence 9, Application US/10620532
; Publication No. US20040086916A1
; GENERAL INFORMATION:
; APPLICANT: Farnham, Peggy J.
; APPLICANT: Graveel, Carrie R.
; APPLICANT: Harkins-Perry, Sarah R.
; TITLE OF INVENTION: Liver Tumor marker Sequences
; FILE REFERENCE: 960296.98750
; CURRENT APPLICATION NUMBER: US/10/620,532
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: 60/396,626
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:PCR primer
US-10-620-532-9

Query Match      0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3890 CACAGTCTGTCTTGCC 3906
Db 20 CCAGTCTGTCTTGCC 4

RESULT 683
US-10-481-613-156/c
; Sequence 156, Application US/10481613
; Publication No. US20050085627A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Youming
; APPLICANT: Moffatt, Miriam
; APPLICANT: Cookson, William
; APPLICANT: Tinsley, Jon
; TITLE OF INVENTION: Atopy
; FILE REFERENCE: 16721-0003US1 / P32688WO/KVC
; CURRENT APPLICATION NUMBER: US/10/481,613
; CURRENT FILING DATE: 2003-12-19
; PRIOR APPLICATION NUMBER: PCT/GB02/02859
; PRIOR FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: GB 0115211.5
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: GB 0115212.3
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: GB 0115213.1
; NUMBER OF SEQ ID NOS: 326
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 156
```

```

4386 CCACAGAGGGCTTCATC 18
DB 2 CCACAGAGGGCTTCATC 18

RESULT 685
US-11-011-500-98
; Sequence 98, Application US/11011500
; Publication No. US20050158826A1
; GENERAL INFORMATION:
; APPLICANT: Gatanaga, T.
; Granger, G.A.
; TITLE OF INVENTION: Factors Altering Tumor Necrosis
; Factor Receptor Releasing Enzyme Activity, and Methods
; of Use Thereof
;
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FORSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/11/011,500
; FILING DATE: 13-Dec-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/967,092
; FILING DATE: 15-Oct-2004
; APPLICATION NUMBER: US/09/712,813
; FILING DATE: 13-Nov-2000
; APPLICATION NUMBER: US/09/081,385
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,385
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 98:
;
US-11-011-500-98
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4586 CCACACAGGGCTTCATC 4602
DB 2 CCACAGAGGGCTTCATC 18

RESULT 686
US-10-872-645-29/c
; Sequence 29, Application US/10872645
; Publication No. US20050100887A1

```

```

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-481-613-156

Query Match          0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2636 ATGCTACTGTAACTG 2652
      |||||
Db 17 ATGCTACTGTAAACAG 1

RESULT 684
US-10-967-092-98
; Sequence 98, Application US/10967092
; Publication No. US20050090647A1
; GENERAL INFORMATION:
; APPLICANT: Gatanaga, T.
; Granger, G.A.
; TITLE OF INVENTION: Factors Altering Tumor Necrosis
; Factor Receptor Releasing Enzyme Activity, and Methods
; of Use Thereof
;
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/967,092
; FILING DATE: 15-Oct-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/712,813
; FILING DATE: 13-Nov-2000
; APPLICATION NUMBER: US/09/081,385
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 98:
US-10-967-092-98

Query Match          0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

GENERAL INFORMATION:
; APPLICANT: AXIMA Pharmaceuticals AG
; APPLICANT: Salasidis, Konstadinos
; APPLICANT: Schubart, Daniel
; APPLICANT: Gutbrod, Heidrun
; APPLICANT: Mueller, Stefan
; APPLICANT: Kraetzer, Friedrich
; APPLICANT: Obert, Sabine
; TITLE OF INVENTION: Targets for Hepatitis C Virus Infections
; FILE REFERENCE: AXM-014.1 US
; CURRENT APPLICATION NUMBER: US/10/872,645
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: PCT/EP02/14578
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US 60/341,757
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: v = a or g or c
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: n=a or g or t or c
; US-10-872-645-29

Query Match 0.3%; Score 15.2; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5.1e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAAAATAACCGGTTTT 3338
Db 16 BAAAAAATAACCGGTTTT 20

RESULT 687
US-10-160-786-59
; Sequence 59, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-160-786-59

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3319 AAACCGTATTACTGTTTT 3338
Db 1 AAACCGTATTACTGTTTT 20

RESULT 688
US-10-160-786-127/c
; Sequence 127, Application US/10160786
; Publication No. US20030225013A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/160,786
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 127
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; US-10-160-786-127

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3319 AAACCGTATTACTGTTTT 3338
Db 20 AAACCGTATTACTGTTTT 1

RESULT 689
US-10-667-022-59
; Sequence 59, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-667-022-59

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3319 AAACCGTATTACTGTTTT 3338
Db 1 AAACCGTATTACTGTTTT 20

RESULT 690
US-10-667-022-127/c
; Sequence 127, Application US/10667022
; Publication No. US20040063657A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOINOSITIDE-3-KINASE, REGULATORY SUB
; FILE REFERENCE: RTS-0376
; CURRENT APPLICATION NUMBER: US/10/667,022
; CURRENT FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 127

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-667-022-127

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3319 AAACCGTAAATACCGTGTTTT 3338
Db 20 AAACCGGTATTACTGCTGTTT 1

RESULT 691
US-08-983-605-245/c
; Sequence 245, Application US/08983605A
; Publication No. US20020066118A1
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
; TITLE OF INVENTION: Triticum aestivum and Tribe Triticeae and the Use of
; TITLE OF INVENTION: Said Markers
; FILE REFERENCE: 2936.10400
; CURRENT APPLICATION NUMBER: US/08/983,605A
; CURRENT FILING DATE: 1998-05-01
; EARLIER APPLICATION NUMBER: DE 195 25 284.5
; EARLIER FILING DATE: 1995-06-28
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 245
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Triticum aestivum
US-08-983-605-245

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3857 GTGTTGTGGATATGCATCAC 3876
Db 20 GTGTTGTGGTCTGCTTCAC 1

RESULT 692
US-09-802-669-177
; Sequence 177, Application US/09802669
; Patent No. US20020004490A1
; GENERAL INFORMATION:
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Marcusson, Eric G.
; APPLICANT: Wyatt, Jacqueline
; APPLICANT: Zhang, Hong
; TITLE OF INVENTION: Antisense Compound Modulation of Fas Mediated Signaling
; FILE REFERENCE: ISPH-545
; CURRENT APPLICATION NUMBER: US/09/802,669
; CURRENT FILING DATE: 2001-03-09
; PRIOR APPLICATION NUMBER: US 09/665,615
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 09/290,640
; PRIOR FILING DATE: 1999-04-12
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 177
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-802-669-177
```

```
Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3312 AAATAAAAAACCAAGTAATAC 3331
Db 1 AAAGAGAAAAACCAAGAAATAC 20

RESULT 693
US-09-854-883-305/c
; Sequence 305, Application US/09854883
; Patent No. US20020055479A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsert
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Susan M. Freier
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
; FILE REFERENCE: ISPH-0576
; CURRENT APPLICATION NUMBER: US/09/854,883
; CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 09/629,644
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/487,368
; PRIOR FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 305
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-854-883-305

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2152 GAGCTCCAAAGCCTTACATGA 2171
Db 20 GGGCACCAAGCCTTTCATGA 1

RESULT 694
US-09-817-135B-15
; Sequence 15, Application US/09817135B
; Patent No. US20020123036A1
; GENERAL INFORMATION:
; APPLICANT: Clavel, Francois
; APPLICANT: Race, Esther
; APPLICANT: Obry, Veronique
; APPLICANT: Mammano, Fabrizio
; APPLICANT: Dam, Elisabeth
; APPLICANT: Troupin, Virginie
; TITLE OF INVENTION: Method for Analysing Human Immunodeficiency Virus (HIV) Phenotypi
; TITLE OF INVENTION: Characteristics
; FILE REFERENCE: 60240.000002
; CURRENT APPLICATION NUMBER: US/09/817,135B
; CURRENT FILING DATE: 2001-10-27
; PRIOR APPLICATION NUMBER: FR00/14495
; PRIOR FILING DATE: 2000-11-10
; PRIOR APPLICATION NUMBER: FR01/039970
; PRIOR FILING DATE: 2001-03-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

; OTHER INFORMATION: FIN-C sequence. Amplifies a region coding for envelope gene.
US-09-817-135B-15

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 765 CTATAACAAGAGCTGGAGG 784
|||||
Db 1 CTATTACACAGAGATGGTGG 20

RESULT 695

US-09-791-243-31
; Sequence 31, Application US/09791243
; Patent No. US20020147164A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Robert Rothlein
; APPLICANT: Takashi Kei Kishimoto
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF CYTOHESIN-1 EXPRESSION
; FILE REFERENCE: RTS-0095
; CURRENT APPLICATION NUMBER: US/09/791,243
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-791-243-31

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 365 CCCTCCACCAACAGCCCATC 384
|||||
Db 1 CCCTCCACCAACAGCCCGTC 20

RESULT 696

US-09-734-672-61
; Sequence 61, Application US/09734672
; Publication No. US20020183268A1
; GENERAL INFORMATION:
; APPLICANT: Murphy, Patricia D.
; Allen, Antonette C.
; Alvares, Christopher P.
; Critz, Brenda S.
; Olson, Sheri J.
; Schelter, Denise B.
; Zeng, Bin
; TITLE OF INVENTION: Coding Sequences of the Human
; BRCAL Gene
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morgan Lewis & Bockius LLP
; STREET: 1111 Pennsylvania Ave., N.W.
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/734,672
; FILING DATE: 03-Dec-2000

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/966,436
; FILING DATE: 07-No. US20020183268A1-97
; APPLICATION NUMBER: US 08/598,591
; FILING DATE: 12-Feb-96
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael S. Tuscan
; REGISTRATION NUMBER: 43,210
; REFERENCE/DOCKET NUMBER: 44921-5055-02-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-739-3000
; TELEFAX: 202-739-3001
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: No. US20020183268A1 Relevant
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ORIGINAL SOURCE:
; STRAIN: 19F primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 61:
US-09-734-672-61

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4104 CTGTATCTCTCCAGGGTC 4123
|||||
Db 1 CTGTATCTCTCTGTGTC 20

RESULT 697

US-09-982-828-61
; Sequence 61, Application US/09982828
; Publication No. US20030022184A1
; GENERAL INFORMATION:
; APPLICANT: Murphy, Patricia D.
; Allen, Antonette C.
; Alvares, Christopher P.
; Critz, Brenda S.
; Olson, Sheri J.
; Thurber, Denise
; Zeng, Bin
; TITLE OF INVENTION: Coding Sequences of the Human
; BRCAL Gene
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morgan Lewis & Bockius LLP
; STREET: 1111 Pennsylvania Avenue N. W.
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/982,828
; FILING DATE: 22-Oct-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/074,453
; FILING DATE: 1998-05-06
; APPLICATION NUMBER: US 08/798,691
; FILING DATE: 1997-02-12
; APPLICATION NUMBER: US 08/598,591
; FILING DATE: 1996-02-12
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael S. Tuscan

REGISTRATION NUMBER: 43,210
REFERENCE/DOCKET NUMBER: 44921-5053-01-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-739-3000
TELEFAX: 202-739-3001
INFORMATION FOR SEQ ID NO: 61:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: not relevant
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
STRAIN: 19f primer
SEQUENCE DESCRIPTION: SEQ ID NO: 61:
US-09-982-828-61

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4104 CTGTCATCTTCCTCCAGGGCTC 4123
||||| ||||| |||||
Db 1 CTGTCATCTTCCTCGTGCTC 20

RESULT 698
US-09-784-674-549/c
Sequence 549, Application US/09784674
Publication No. US20030054346A1
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
Wolber, Paul K.
Delenstarr, Glenda C.
Webb, Peter G.
Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
Company M/S 20BO
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/784,674
FILING DATE: 15-Feb-2001
CLASSIFICATION: No. US20030054346A1 available
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/021,701
FILING DATE: 10-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 549:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA

HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 549:
US-09-784-674-549

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3311 AAAATAAAACCAAGTAATA 3330
||||| ||||| |||||
Db 20 AAAAGAAAAAATCAGTAACA 1

RESULT 699
US-09-917-963-44/c
Sequence 44, Application US/09917963
Publication No. US20030086912A1
GENERAL INFORMATION:
APPLICANT: Rosanne M. Crooke
APPLICANT: Mark J. Graham
TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN
FILE REFERENCE: ISPH-0591
CURRENT APPLICATION NUMBER: US/09/917,963
CURRENT FILING DATE: 2001-07-30
NUMBER OF SEQ ID NOS: 137
SEQ ID NO 44
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-917-963-44

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2971 GCCAATATAGAGGTCACAGG 2990
||||| ||||| |||||
Db 20 GCCAATATAGAGGTCACAGG 1

RESULT 700
US-09-923-327-125
Sequence 125, Application US/09923327
Publication No. US20030096236A1
GENERAL INFORMATION:
APPLICANT: MURPHY, Patricia D.
TITLE OF INVENTION: Determining Common Functional Alleles in a Population and Uses Th
FILE REFERENCE: 044921-5054-02
CURRENT APPLICATION NUMBER: US/09/923,327
CURRENT FILING DATE: 2002-04-01
PRIOR APPLICATION NUMBER: US 08/598,591
PRIOR FILING DATE: 1996-02-12
PRIOR APPLICATION NUMBER: US 08/798,691
PRIOR FILING DATE: 1997-02-12
PRIOR APPLICATION NUMBER: US 08/905,772
PRIOR FILING DATE: 1997-08-04
PRIOR APPLICATION NUMBER: US 09/084,471
PRIOR FILING DATE: 1998-05-22
PRIOR APPLICATION NUMBER: US 09/129,134
PRIOR FILING DATE: 1998-08-04
PRIOR APPLICATION NUMBER: US 09/524,794
PRIOR FILING DATE: 2000-03-14
NUMBER OF SEQ ID NOS: 260
SOFTWARE: PatentIn version 3.1
SEQ ID NO 125
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-09-923-327-125


```
Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4104 CTGTCATCCTTCCAGGGCTC 4123
Db 1 CTGTCATCTCTCTGTGCTC 20

RESULT 701
US-09-954-679-77
; Sequence 77, Application US/09954679
; Publication No. US20030100522A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF RIBONUCLEASE L (2',5'-OLIGOISODENYLATE
; FILE REFERENCE: RTS-0212
; CURRENT APPLICATION NUMBER: US/09/954,679
; CURRENT FILING DATE: 2001-09-12
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-679-77

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3402 GCAACTCATCCAGCAAAAGC 3421
Db 1 GCAACTCATCCCTCACAAAGC 20

RESULT 702
US-09-782-604-4/c
; Sequence 4, Application US/09782604
; Publication No. US20030143534A1
; GENERAL INFORMATION:
; APPLICANT: GOSWAMI, USHA
; APPLICANT: BERNARDI, GIACOMO
; APPLICANT: GOSWAMI, SUBHASH CHANDER
; APPLICANT: JOHNSON, ROBERT K.
; TITLE OF INVENTION: PROBES FOR MYCTOPHID FISH AND A METHOD FOR DEVELOPING
; FILE REFERENCE: 05689/0117
; CURRENT APPLICATION NUMBER: US/09/782,604
; CURRENT FILING DATE: 2001-02-14
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-782-604-4

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4424 CATCTGTGCTCTACTACAGG 4443
Db 20 CATCTGGTTCCTACTTCAGG 1
```

```
RESULT 703
US-10-022-819-56
; Sequence 56, Application US/10022819
; Publication No. US20030027166A1
; GENERAL INFORMATION:
; APPLICANT: ALLEN, Antonette C. P.
; OLSEN, Sheri J.
; LAWRENCE, Tammy
; ANGELLY, Tracy S.
; RABIN, Mark B.
; TITLE OF INVENTION: CODING SEQUENCE HAPLOTYPE OF THE HUMAN
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morgan Lewis & Bockius LLP
; STREET: 1111 Pennsylvania Avenue
; CITY: Washington DC
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/022,819
; FILING DATE: 22-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/074,452
; FILING DATE: 1998-05-06
; ATTORNEY/AGENT INFORMATION:
; NAME: <Unknown>
; REGISTRATION NUMBER: <Unknown>
; REFERENCE/DOCKET NUMBER: 044921-5049-01-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-739-3000
; TELEFAX: 202-739-3001
; INFORMATION FOR SEQ ID NO: 56:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "PRIMER"
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; SEQUENCE DESCRIPTION: SEQ ID NO: 56:
US-10-022-819-56

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4104 CTGTCATCCTTCCAGGGCTC 4123
Db 1 CTGTCATCTCTCTGTGCTC 20

RESULT 704
US-10-238-443-51/c
; Sequence 51, Application US/10238443
; Publication No. US2003008302A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF REQL5 EXPRESSION
; FILE REFERENCE: RTS-0203
; CURRENT APPLICATION NUMBER: US/10/238,443
; CURRENT FILING DATE: 2002-09-09
```

```

; PRIOR APPLICATION NUMBER: US/09/798,185
; PRIOR FILING DATE: 2001-03-01
; NUMBER OF SEQ ID NOS: 92
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-238-443-51

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4083 CCAGTTGCCAATTTCAAGTC 4102
Db 20 CCAGTTGCCATCTTCAAGAC 1

RESULT 705
US-10-094-458A-15/c
; Sequence 15, Application US/10094458A
; Publication No. US20030097685A1
; GENERAL INFORMATION:
; APPLICANT: BENNING, CHRISTOPHER
; TITLE OF INVENTION: LIPID METABOLISM REGULATORS IN PLANTS
; FILE REFERENCE: 16313.0097
; CURRENT APPLICATION NUMBER: US/10/094,458A
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: 60/274,170
; PRIOR FILING DATE: 2001-03-08
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-094-458A-15

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2896 CAGGGAATGCACAGAGGAAGA 2915
Db 20 CAGAGAGTGACAAAGGAAGA 1

RESULT 706
US-10-309-362-51/c
; Sequence 51, Application US/10309362
; Publication No. US20030114412A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF RECOL5 EXPRESSION
; FILE REFERENCE: RTS-0203
; CURRENT APPLICATION NUMBER: US/10/309,362
; CURRENT FILING DATE: 2002-12-03
; PRIOR APPLICATION NUMBER: US/09/798,185
; PRIOR FILING DATE: 2001-03-01
; NUMBER OF SEQ ID NOS: 92
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-309-362-51
```

```

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4083 CCAGTTGCCAATTTCAAGTC 4102
Db 20 CCAGTTGCCATCTTCAAGAC 1

RESULT 707
US-10-174-794-9/c
; Sequence 9, Application US/10174794
; Publication No. US20030166220A1
; GENERAL INFORMATION:
; APPLICANT: University of Southern California
; TITLE OF INVENTION: CDNA, GENOMIC, AND PREDICTED PROTEIN
; FILE REFERENCE: 13761-707
; CURRENT APPLICATION NUMBER: US/10/174,794
; CURRENT FILING DATE: 2002-06-18
; PRIOR APPLICATION NUMBER: US/09/411,628
; PRIOR FILING DATE: 1999-10-01
; PRIOR APPLICATION NUMBER: US 60/102,906
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense primer
US-10-174-794-9

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2680 CAACCAATAATACAGATTGA 2699
Db 20 CAACCAAGAAAGAAAGATTGA 1

RESULT 708
US-10-109-349A-4
; Sequence 4, Application US/10109349A
; Publication No. US20030186246A1
; GENERAL INFORMATION:
; APPLICANT: Medical College of Ohio
; APPLICANT: Willey, James C.
; TITLE OF INVENTION: MULTIPLEX STANDARDIZED REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REA
; FILE REFERENCE: 01154/2001-203
; CURRENT APPLICATION NUMBER: US/10/109,349A
; CURRENT FILING DATE: 2002-06-12
; NUMBER OF SEQ ID NOS: 282
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-109-349A-4

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2144 ATGACACAGAGCTCCAGGCC 2163
Db 1 ATGACACAGAGCTGGTAGCC 20
```

```

RESULT 709
US-10-021-707-34
; Sequence 34, Application US/10021707
; Publication No. US20030186903A1
; GENERAL INFORMATION:
; APPLICANT: James Karras
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF MYD88 EXPRESSION
; FILE REFERENCE: RTS-0330
; CURRENT APPLICATION NUMBER: US/10/021.707
; CURRENT FILING DATE: 2001-11-23
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-021-707-34

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2395 TGGCAAGCTCCTCAATTCT 2414
      ||||| ||||| ||||| |||||
DB 1 TGGCAATCTCTCTCAATGCT 20

RESULT 710
US-10-263-655-15
; Sequence 15, Application US/10263655
; Publication No. US20030207294A1
; GENERAL INFORMATION:
; APPLICANT: CLAVEL, Francois
; APPLICANT: CLAVEL, Francois
; APPLICANT: MAMMANO, Fabrizio
; APPLICANT: RACE, Esther
; APPLICANT: OBRY, Veronique
; APPLICANT: TROUPLIN, Virginie
; TITLE OF INVENTION: Method for analysing human immunodeficiency virus (HIV) phenotypic
; TITLE OF INVENTION: characteristics
; FILE REFERENCE: B7780US
; CURRENT APPLICATION NUMBER: US/10/263.655
; CURRENT FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: US2001/xxxxx
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: primer
; LOCATION: (1)..(20)
; OTHER INFORMATION: FIN-C sequence. Amplifies a region coding for envelope gene.
US-10-263-655-15

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 765 CTATAAACAGAGCTGGAGG 784
      ||||| ||||| ||||| |||||
DB 1 CTATTAACAAGAGATGGTGG 20

RESULT 711
US-10-360-510-305/c
; Sequence 305, Application US/10360510
; Publication No. US20030220282A1

```

; TITLE OF INVENTION: ANTISENSE MODULATION OF NOTCH1 EXPRESSION
; FILE REFERENCE: RTS-0386
; CURRENT APPLICATION NUMBER: US/10/160,497
; CURRENT FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 145

; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-160-497-138

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 47 TGCTGGGGCTGCACGAGCTG 66
Db 20 TGCTGGGTCTGCACCAAGTG 1

RESULT 714

US-10-348-750-81
; Sequence 81, Application US/10348750
; Publication No. US20030225019A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: NOTCH1 INHIBITORS FOR INDUCING APOPTOSIS
; FILE REFERENCE: ISPH-0729
; CURRENT APPLICATION NUMBER: US/10/348,750
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: 10/160,497
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-348-750-81

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 47 TGCTGGGGCTGCACGAGCTG 66
Db 1 TGCTGGGTCTGCACCAAGTG 20

RESULT 715

US-10-348-750-138/c
; Sequence 138, Application US/10348750
; Publication No. US20030225019A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: NOTCH1 INHIBITORS FOR INDUCING APOPTOSIS
; FILE REFERENCE: ISPH-0729
; CURRENT APPLICATION NUMBER: US/10/348,750
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: 10/160,497
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens

US-10-348-750-138

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 47 TGCTGGGGCTGCACGAGCTG 66
Db 20 TGCTGGGTCTGCACCAAGTG 1

RESULT 716

US-10-175-492-42/c
; Sequence 42, Application US/10175492
; Publication No. US20030232442A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PAZ/PIWI DOMAIN-CONTAINING PROTEIN EXPRES
; FILE REFERENCE: RTS-0435
; CURRENT APPLICATION NUMBER: US/10/175,492
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 164
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-175-492-42

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2136 TGGAAATTATGACACAGAGC 2155
Db 20 TGGAAATTATGAAACAGATC 1

RESULT 717

US-10-175-492-120
; Sequence 120, Application US/10175492
; Publication No. US20030232442A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF PAZ/PIWI DOMAIN-CONTAINING PROTEIN EXPRES
; FILE REFERENCE: RTS-0435
; CURRENT APPLICATION NUMBER: US/10/175,492
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 164
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-175-492-120

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2136 TGGAAATTATGACACAGAGC 2155
Db 1 TGGAAATTATGAAACAGATC 20

RESULT 718

US-10-452-002A-42
; Sequence 42, Application US/10452002A
; Publication No. US20030236195A1
; GENERAL INFORMATION:
; APPLICANT: Jerald S. Feitelson
; APPLICANT: H. Ernest Schnepf
; APPLICANT: Kenneth E. Narva

```
; APPLICANT: Brian A. Stockhoff
; APPLICANT: James L. Schmeits
; APPLICANT: David Loewer
; APPLICANT: Charles J. Dullum
; APPLICANT: Judy Muller-Cohn
; APPLICANT: Lisa Stamp
; APPLICANT: George Morrill
; APPLICANT: Stacey Finshead Lee
; TITLE OF INVENTION: No. US20030236195A1el Pesticidal Proteins and Methods of Using Th
; FILE REFERENCE: MA708C2D1
; CURRENT APPLICATION NUMBER: US/10/452,002A
; CURRENT FILING DATE: 2003-05-30
; PRIOR APPLICATION NUMBER: 09/307,106
; PRIOR FILING DATE: 1999-05-07
; PRIOR APPLICATION NUMBER: 09/073,898
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 08/960,780
; PRIOR FILING DATE: 1997-10-30
; PRIOR APPLICATION NUMBER: 60/029,848
; PRIOR FILING DATE: 1996-10-30
; SOFTWARE: PatentIn Ver. 2.0
; NUMBER OF SEQ ID NOS: 54
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: primer
US-10-452-002A-42

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      827  TCCAGAAAGCATCAGAAAAA 846
Db      1    TCCCTAAAGCATCAGAAATA 20

RESULT 719
US-10-189-268-39
; Sequence 39, Application US/10189268
; Publication No. US20040005570A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF GERANYLGERANYL DIPHOSPHATE SYNTHASE 1 EXP
; FILE REFERENCE: PTS-0021
; CURRENT APPLICATION NUMBER: US/10/189,268
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 131
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-189-268-39

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2082  TAATATGGAATAATGACCCCA 2101
Db      1    TAATTTGGAATAAGAGCCCA 20

RESULT 720
US-10-189-268-109/c
; Sequence 109, Application US/10189268
; Publication No. US20040005570A1
; GENERAL INFORMATION:
; APPLICANT: Scott Cooper
; APPLICANT: Kenneth W. Dobie
```

```
; Publication No. US20040005570A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF GERANYLGERANYL DIPHOSPHATE SYNTHASE 1 EXP
; FILE REFERENCE: PTS-0021
; CURRENT APPLICATION NUMBER: US/10/189,268
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 131
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-189-268-109

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2082  TAATATGGAATAATGACCCCA 2101
Db      20    TAATTTGGAATAAGAGCCCA 1

RESULT 721
US-10-349-143-4301
; Sequence 4301, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4301
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-14598 for SEQ 367,
US-10-349-143-4301

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      4083  CCAGTTTCCAATTTCAAGTC 4102
Db      1    CCAGTTTCAACAATTTCAAGTC 20

RESULT 722
US-10-188-470-72/c
; Sequence 72, Application US/10188470
; Publication No. US20040005570A1
; GENERAL INFORMATION:
; APPLICANT: Scott Cooper
; APPLICANT: Kenneth W. Dobie
```

; TITLE OF INVENTION: ANTISENSE MODULATION OF INTEGRIN BETA 5 EXPRESSION
; FILE REFERENCE: PTS-0024
; CURRENT APPLICATION NUMBER: US/10/188,470
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-188-470-72

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 739 CAGGATCCCATTCGCTTT 758
||||| ||||| ||||| |||||
Db 20 CAGGAGCCACAGTGCCTGT 1

RESULT 723
US-10-188-470-128
; Sequence 128, Application US/10188470
; Publication No. US20040005707A1
; GENERAL INFORMATION:
; APPLICANT: Scott Cooper
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTEGRIN BETA 5 EXPRESSION
; FILE REFERENCE: PTS-0024
; CURRENT APPLICATION NUMBER: US/10/188,470
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 128
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-188-470-128

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 739 CAGGATCCCATTCGCTTT 758
||||| ||||| ||||| |||||
Db 1 CAGGAGCCACAGTGCCTGT 20

RESULT 724
US-10-289-762-4833
; Sequence 4833, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4833
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-4833

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1669 GGAGAGCCTAAGGAAATGG 1688
||||| ||||| ||||| |||||
Db 1 GGAGAGAGTAAGGAGATGG 20

RESULT 725
US-10-199-676-29
; Sequence 29, Application US/10199676
; Publication No. US20040014051A1
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF BREAST CANCER-1 EXPRESSION
; FILE REFERENCE: PTS-0017
; CURRENT APPLICATION NUMBER: US/10/199,676
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 84
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-199-676-29

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 853 GAGAAAGCAGCTATGCTCTT 872
||||| ||||| ||||| |||||
Db 1 GGGAAACCAGCTATTCTCTT 20

RESULT 726
US-10-199-676-65/c
; Sequence 65, Application US/10199676
; Publication No. US20040014051A1
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF BREAST CANCER-1 EXPRESSION
; FILE REFERENCE: PTS-0017
; CURRENT APPLICATION NUMBER: US/10/199,676
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 84
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-199-676-65

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 853 GAGAAAGCAGCTATGCTCTT 872
||||| ||||| ||||| |||||
Db 20 GGGAAACCAGCTATTCTCTT 1

RESULT 727
US-10-619-220-177
; Sequence 177, Application US/10619220
; Publication No. US20040033979A1
; GENERAL INFORMATION:
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Marcusson, Eric G.
; APPLICANT: Wyatt, Jacqueline
; APPLICANT: Zhang, Hong
; TITLE OF INVENTION: Antisense Compound Modulation of Fas Mediated Signaling
; FILE REFERENCE: ISPH-545

Query Match	Best Local Similarity	Score	DB 1	Length	DB 2	DB 3	DB 4	DB 5	DB 6	DB 7	DB 8	DB 9	DB 10	DB 11	DB 12	DB 13	DB 14	DB 15	DB 16	DB 17	DB 18	DB 19	DB 20	DB 21	DB 22	DB 23	DB 24	DB 25	DB 26	DB 27	DB 28	DB 29	DB 30	DB 31	DB 32	DB 33	DB 34	DB 35	DB 36	DB 37	DB 38	DB 39	DB 40	DB 41	DB 42	DB 43	DB 44	DB 45	DB 46	DB 47	DB 48	DB 49	DB 50	DB 51	DB 52	DB 53	DB 54	DB 55	DB 56	DB 57	DB 58	DB 59	DB 60	DB 61	DB 62	DB 63	DB 64	DB 65	DB 66	DB 67	DB 68	DB 69	DB 70	DB 71	DB 72	DB 73	DB 74	DB 75	DB 76	DB 77	DB 78	DB 79	DB 80	DB 81	DB 82	DB 83	DB 84	DB 85	DB 86	DB 87	DB 88	DB 89	DB 90	DB 91	DB 92	DB 93	DB 94	DB 95	DB 96	DB 97	DB 98	DB 99	DB 100	DB 101	DB 102	DB 103	DB 104	DB 105	DB 106	DB 107	DB 108	DB 109	DB 110	DB 111	DB 112	DB 113	DB 114	DB 115	DB 116	DB 117	DB 118	DB 119	DB 120	DB 121	DB 122	DB 123	DB 124	DB 125	DB 126	DB 127	DB 128	DB 129	DB 130	DB 131	DB 132	DB 133	DB 134	DB 135	DB 136	DB 137	DB 138	DB 139	DB 140	DB 141	DB 142	DB 143	DB 144	DB 145	DB 146	DB 147	DB 148	DB 149	DB 150	DB 151	DB 152	DB 153	DB 154	DB 155	DB 156	DB 157	DB 158	DB 159	DB 160	DB 161	DB 162	DB 163	DB 164	DB 165	DB 166	DB 167	DB 168	DB 169	DB 170	DB 171	DB 172	DB 173	DB 174	DB 175	DB 176	DB 177	DB 178	DB 179	DB 180	DB 181	DB 182	DB 183	DB 184	DB 185	DB 186	DB 187	DB 188	DB 189	DB 190	DB 191	DB 192	DB 193	DB 194	DB 195	DB 196	DB 197	DB 198	DB 199	DB 200	DB 201	DB 202	DB 203	DB 204	DB 205	DB 206	DB 207	DB 208	DB 209	DB 210	DB 211	DB 212	DB 213	DB 214	DB 215	DB 216	DB 217	DB 218	DB 219	DB 220	DB 221	DB 222	DB 223	DB 224	DB 225	DB 226	DB 227	DB 228	DB 229	DB 230	DB 231	DB 232	DB 233	DB 234	DB 235	DB 236	DB 237	DB 238	DB 239	DB 240	DB 241	DB 242	DB 243	DB 244	DB 245	DB 246	DB 247	DB 248	DB 249	DB 250	DB 251	DB 252	DB 253	DB 254	DB 255	DB 256	DB 257	DB 258	DB 259	DB 260	DB 261	DB 262	DB 263	DB 264	DB 265	DB 266	DB 267	DB 268	DB 269	DB 270	DB 271	DB 272	DB 273	DB 274	DB 275	DB 276	DB 277	DB 278	DB 279	DB 280	DB 281	DB 282	DB 283	DB 284	DB 285	DB 286	DB 287	DB 288	DB 289	DB 290	DB 291	DB 292	DB 293	DB 294	DB 295	DB 296	DB 297	DB 298	DB 299	DB 300	DB 301	DB 302	DB 303	DB 304	DB 305	DB 306	DB 307	DB 308	DB 309	DB 310	DB 311	DB 312	DB 313	DB 314	DB 315	DB 316	DB 317	DB 318	DB 319	DB 320	DB 321	DB 322	DB 323	DB 324	DB 325	DB 326	DB 327	DB 328	DB 329	DB 330	DB 331	DB 332	DB 333	DB 334	DB 335	DB 336	DB 337	DB 338	DB 339	DB 340	DB 341	DB 342	DB 343	DB 344	DB 345	DB 346	DB 347	DB 348	DB 349	DB 350	DB 351	DB 352	DB 353	DB 354	DB 355	DB 356	DB 357	DB 358	DB 359	DB 360	DB 361	DB 362	DB 363	DB 364	DB 365	DB 366	DB 367	DB 368	DB 369	DB 370	DB 371	DB 372	DB 373	DB 374	DB 375	DB 376	DB 377	DB 378	
-------------	-----------------------	-------	------	--------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--

; NUMBER OF SEQ ID NOS: 100
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide used as primer for PCR detection of NF-?Bp50 mRNA

US-10-409-107A-49

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1497 GCAGCGTGGCAATGCTTTC 1516
||||| ||| |||||
Db 1 GCAGCGAGCCATGCTTTC 20

RESULT 732

US-10-300-236-17/C
; Sequence 17, Application US/10300236
; Publication No. US20040097448A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: MODULATION OF CD24 EXPRESSION
; FILE REFERENCE: RTS-0178
; CURRENT APPLICATION NUMBER: US/10/300,236
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-236-17

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 582 TGCTGGCATTCCTCCCTCC 601
||||| ||||| |||||
Db 20 TGCTGGCACTGCTCTACCC 1

RESULT 733

US-10-435-659-15
; Sequence 15, Application US/10435659
; Publication No. US20040101828A1
; GENERAL INFORMATION:
; APPLICANT: Bioalliance Pharma
; APPLICANT: INSERM
; APPLICANT: Clavel, Francois
; APPLICANT: Mammano, Fabrizio
; APPLICANT: Race, Esther
; APPLICANT: Dam, Elisabeth
; APPLICANT: Oby, Veronique
; APPLICANT: Trouplin, Virginie
; TITLE OF INVENTION: Method for analysis of the phenotypic characteristics of the
; FILE REFERENCE: 60240.000005
; CURRENT APPLICATION NUMBER: US/10/435,659
; CURRENT FILING DATE: 2003-05-12
; PRIOR APPLICATION NUMBER: PCT/FR01/03512
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: FR 00/14495
; PRIOR FILING DATE: 2000-11-10
; PRIOR APPLICATION NUMBER: FR 01/03970
; PRIOR FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: US 09/817,135
; PRIOR FILING DATE: 2001-03-27

; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: Sequence FIN-C for the amplification of a region of gene of the
; OTHER INFORMATION: envelope
US-10-435-659-15

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 765 CTATAAACAGAGCTGGAGG 784
||||| ||||| |||||
Db 1 CTATTACAGAGATGGTGG 20

RESULT 734

US-10-303-566-37/C
; Sequence 37, Application US/10303566
; Publication No. US20040101852A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF CGG TRIPLET REPEAT BINDING PROTEIN 1 EXPRESSION
; FILE REFERENCE: HTS-0068
; CURRENT APPLICATION NUMBER: US/10/303,566
; CURRENT FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-566-37

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4170 TGCAGCTGTTTCAGGCAACA 4189
||||| ||||| |||||
Db 20 TGCATCTCTTCAGTGCACA 1

RESULT 735

US-10-303-566-70
; Sequence 70, Application US/10303566
; Publication No. US20040101852A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF CGG TRIPLET REPEAT BINDING PROTEIN 1 EXPRESSION
; FILE REFERENCE: HTS-0068
; CURRENT APPLICATION NUMBER: US/10/303,566
; CURRENT FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-303-566-70


```
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: MODULATION OF APOLIPOPROTEIN(A) EXPRESSION
; FILE REFERENCE: ISPH.0595US.P1
; CURRENT APPLICATION NUMBER: US/10/684,440
; CURRENT FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: 09/923,515
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: 60/475,402
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 73
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-684-440-70

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4170 TGCAGCTGTTTCAGGGCAACA 4189
DB 1 TGCATCTCTTTCAGTGCACA 20

RESULT 736
US-10-318-389-79
; Sequence 79, Application US/10318389
; Publication No. US20040121328A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: MODULATION OF PHOSPHODIESTERASE 8A EXPRESSION
; FILE REFERENCE: PFS-0062
; CURRENT APPLICATION NUMBER: US/10/318,389
; CURRENT FILING DATE: 2002-12-11
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-318-389-79

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3056 AAGTTGATCTTGTAAACC 3075
DB 1 AAGTTGATCTTGTAAATC 20

RESULT 737
US-10-342-311-9/c
; Sequence 9, Application US/10342311
; Publication No. US20040137531A1
; GENERAL INFORMATION:
; APPLICANT: Webb & Associates
; TITLE OF INVENTION: Method of Screening for Inhibitors of Phospholipid Synthesis Related Diseases
; FILE REFERENCE: 85189-4200
; CURRENT APPLICATION NUMBER: US/10/342,311
; CURRENT FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: unknown
US-10-342-311-9

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1277 GAGCAATGGACATCTTTTCA 1296
DB 20 GAGCAATGGTCAGTTTTC A 1

RESULT 738
US-10-684-440-70
; Sequence 70, Application US/10684440
; Publication No. US20040138164A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: MODULATION OF APOLIPOPROTEIN(A) EXPRESSION
; FILE REFERENCE: ISPH.0595US.P1
; CURRENT APPLICATION NUMBER: US/10/684,440
; CURRENT FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: 09/923,515
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: 60/475,402
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 73
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-684-440-70

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3999 CACTTCCTTTGCTGTGACA 4018
DB 1 CTCTTACTGTGCTGTGACA 20

RESULT 739
US-10-476-021-153/c
; Sequence 153, Application US/10476021
; Publication No. US20040186069A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0216
; CURRENT APPLICATION NUMBER: US/10/476,021
; CURRENT FILING DATE: 2003-10-24
; PRIOR APPLICATION NUMBER: US/09/844,634
; PRIOR FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 153
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-476-021-153

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3193 CCTAAAGGGAGTGATCAGGA 3212
DB 20 CCTAAAGGGTGCTTAAGGA 1

RESULT 740
US-10-712-795-273/c
; Sequence 273, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
```

```

; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 273
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-712-795-273

Query Match
Best Local Similarity 0.3%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4014 GGACATCCACCAATGCTGCG 4033
Db 20 GGACCTGCACCAAGCTGCG 1

RESULT 741
US-10-712-795-639
; Sequence 639, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 639
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
US-10-712-795-639

Query Match
Best Local Similarity 0.3%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4014 GGACATCCACCAATGCTGCG 4033
Db 1 GGACCTGCACCAAGCTGCG 20

RESULT 742
US-10-712-795-859
; Sequence 859, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 859
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-712-795-859

Query Match
Best Local Similarity 0.3%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3999 CACTTCCTTTGCTGTGGACA 4018
Db 1 CTCTTACTGTGCTGTGGACA 20

RESULT 743
US-10-719-370A-262
; Sequence 262, Application US/10719370A
; Publication No. US20040220393A1
; GENERAL INFORMATION:
; APPLICANT: Ward, Donna T.
; APPLICANT: Dobie, Kenneth W.
; APPLICANT: Marcussen, Eric G.
; APPLICANT: Freier, Susan M.
; TITLE OF INVENTION: MODULATION OF HIF1a AND HIF2a EXPRESSION
; FILE REFERENCE: ISPT-1010
; CURRENT APPLICATION NUMBER: US/10/719,370A
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 10/304,126
; PRIOR FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 262
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-719-370A-262

Query Match
Best Local Similarity 0.3%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 326 GGACACCGGGTTCTCTGAA 345
Db 1 GGAGCACCTGGGTTCTCTTAA 20

RESULT 744
US-10-719-370A-374/C
; Sequence 374, Application US/10719370A
; Publication No. US20040220393A1
; GENERAL INFORMATION:
; APPLICANT: Ward, Donna T.
; APPLICANT: Dobie, Kenneth W.
; APPLICANT: Marcussen, Eric G.
; APPLICANT: Freier, Susan M.
; TITLE OF INVENTION: MODULATION OF HIF1a AND HIF2a EXPRESSION
; FILE REFERENCE: ISPT-1010
; CURRENT APPLICATION NUMBER: US/10/719,370A
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 10/304,126
; PRIOR FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 374
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-370A-374

Query Match
Best Local Similarity 0.3%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 326 GGACACCGGGTTCTCTGAA 345
Db 20 GGAGCACCTGGGTTCTCTTAA 1

```

```
RESULT 745
US-10-839-202-3/c
; Sequence 3, Application US/10839202
; Publication No. US20040224342A1
; GENERAL INFORMATION:
; APPLICANT: OONAKA, SATORU
; APPLICANT: HAYASHI, TOSHINORI
; TITLE OF INVENTION: METHOD OF DETECTING MICROMETASTASIS
; FILE REFERENCE: 252361USO
; CURRENT APPLICATION NUMBER: US/10/839,202
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: JP 2003-129360
; PRIOR FILING DATE: 2003-05-07
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-10-839-202-3
Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3699 AGTCAGACGCTCACATTCT 3718
Db 20 AGTCAGACGATCACAGTCT 1
|||||
RESULT 746
US-10-831-778-431/c
; Sequence 431, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 431
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-431
Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5050 AAAAAAAAAAAAAAACTCGA 5069
Db 20 AAAAAAAAAAAAAACGACGA 1
|||||
RESULT 747
US-10-478-914-102/c
; Sequence 102, Application US/10478914
; Publication No. US2004025812A1
; GENERAL INFORMATION:
; APPLICANT: NAKAGAWARA, AKIRA
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39634A
; CURRENT APPLICATION NUMBER: US/10/920,612
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-11-15
; PRIOR APPLICATION NUMBER: US 10/712,795
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 273
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-920-612-273
Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4014 GGACATCCACCAATGCTGCG 4033
Db 20 GGACCTGCACCAAGCTGCG 1
|||||
RESULT 749
US-10-920-612-639
; Sequence 639, Application US/10920612
; Publication No. US2005009088A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39634A
; CURRENT APPLICATION NUMBER: US/10/920,612
; CURRENT FILING DATE: 2004-08-17
; TITLE OF INVENTION: NUCLEIC ACIDS ISOLATED IN NEUROBLASTOMA
; FILE REFERENCE: 7388-80899
; CURRENT APPLICATION NUMBER: US/10/478,914
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/JP02/05294
; PRIOR FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: JP 2001-162775
; PRIOR FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: JP 2001-255226
; PRIOR FILING DATE: 2001-08-24
; NUMBER OF SEQ ID NOS: 417
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
US-10-478-914-102
Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4262 TTCTCGAATTACAGCCTTCT 4281
Db 20 TTCTCGAATTACACCGTTCT 1
|||||
RESULT 748
US-10-920-612-273/c
; Sequence 273, Application US/10920612
; Publication No. US2005009088A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39634A
; CURRENT APPLICATION NUMBER: US/10/920,612
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-11-15
; PRIOR APPLICATION NUMBER: US 10/712,795
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 273
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-920-612-273
Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4014 GGACATCCACCAATGCTGCG 4033
Db 20 GGACCTGCACCAAGCTGCG 1
|||||
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-11-15
; PRIOR APPLICATION NUMBER: US 10/712,795
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 639
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
US-10-920-612-639

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4014 GGACATCCACCAATGCTGGC 4033
Db 1 GGACCTGCACCAAGCTGGC 20

RESULT 750
US-10-920-612-859
; Sequence 859, Application US/10920612
; Publication No. US2005009088A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39634A
; CURRENT APPLICATION NUMBER: US/10/920,612
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-11-15
; PRIOR APPLICATION NUMBER: US 10/712,795
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 859
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-920-612-859

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3999 CACTTCCTTTGCTGTGGACA 4018
Db 1 CTCCTTACTGTGCTGTGGACA 20

RESULT 751
US-10-858-500-597
; Sequence 597, Application US/10858500
; Publication No. US20050014257A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; TITLE OF INVENTION: MODULATION OF C-REACTIVE PROTEIN EXPRESSION
; FILE REFERENCE: BIOLO014US
; CURRENT APPLICATION NUMBER: US/10/858,500
; CURRENT FILING DATE: 2004-06-01
; PRIOR APPLICATION NUMBER: US 09/912,724
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/475,272
; PRIOR FILING DATE: 2003-06-02
; PRIOR APPLICATION NUMBER: US 60/540,042
; PRIOR FILING DATE: 2004-01-28

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3999 CACTTCCTTTGCTGTGGACA 4018
Db 1 CTCCTTACTGTGCTGTGGACA 20

RESULT 752
US-10-639-300-29
; Sequence 29, Application US/10639300
; Publication No. US20050026857A1
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; TITLE OF INVENTION: ANTISENSE MODULATION OF BREAST CANCER-1 EXPRESSION
; FILE REFERENCE: PTS-0017
; CURRENT APPLICATION NUMBER: US/10/639,300
; CURRENT FILING DATE: 2003-08-12
; PRIOR APPLICATION NUMBER: US/10/199,676
; PRIOR FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 84
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-639-300-29

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 853 GAGAAACGACGCTATGCTCTT 872
Db 1 GGGAAACGACGCTATGCTCTT 20

RESULT 753
US-10-639-300-65/c
; Sequence 65, Application US/10639300
; Publication No. US20050026857A1
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; TITLE OF INVENTION: ANTISENSE MODULATION OF BREAST CANCER-1 EXPRESSION
; FILE REFERENCE: PTS-0017
; CURRENT APPLICATION NUMBER: US/10/639,300
; CURRENT FILING DATE: 2003-08-12
; PRIOR APPLICATION NUMBER: US/10/199,676
; PRIOR FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 84
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-639-300-65
```

QY 853 GAGAAACGAGCTATGCTCTT 872
Db 20 GGGAAACGAGCTATGCTCTT 1

RESULT 754
US-10-877-231-549/c
; Sequence 549, Application US/10877231
; Publication No. US20050027461A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Karen W.
; Wolber, Paul K.
; Delenstarr, Glenda C.
; Webb, Peter G.
; Kincaid, Robert H.
; TITLE OF INVENTION: Methods for evaluating oligonucleotide
; probe sequences
; NUMBER OF SEQUENCES: 1165
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
; Company M/S 20BO
; STREET: 3000 Hanover Street
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/877,231
; FILING DATE: 24-Jun-2004
; CLASSIFICATION: Not available
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/784,674
; FILING DATE: 15-Feb-2001
; APPLICATION NUMBER: 09/021,701
; FILING DATE: 10-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Chol, Wendy A.
; REGISTRATION NUMBER: 36,697
; REFERENCE/DOCKET NUMBER: 10971464-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-236-2386
; TELEFAX: 650-852-8063
; INFORMATION FOR SEQ ID NO: 549:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 549:
US-10-877-231-549

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3311 AAAATAAAACCAAGTAATA 3330
Db 20 AAAAGAAAAAATCAGTAACA 1

RESULT 755
US-10-479-081-399/c
; Sequence 399, Application US/10479081
; Publication No. US20050059001A1

; GENERAL INFORMATION:
; APPLICANT: NAKAGAWARA, AKIRA
; TITLE OF INVENTION: NUCLEIC ACIDS ISOLATED FROM NEUROBLASTOMA
; FILE REFERENCE: 7388-80893
; CURRENT APPLICATION NUMBER: US/10/479,081
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/JP02/05295
; PRIOR FILING DATE: 2002-05-30
; PRIOR APPLICATION NUMBER: JP 2001-163666
; PRIOR FILING DATE: 2001-05-31
; PRIOR APPLICATION NUMBER: JP 2001-255260
; PRIOR FILING DATE: 2001-08-24
; NUMBER OF SEQ ID NOS: 742
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 399
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; US-10-479-081-399

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4262 TTCTGAATTACAGCCTTCT 4281
Db 20 TCCTGAATTACACCGTTCT 1

RESULT 756
US-10-773-678-396
; Sequence 396, Application US/10773678
; Publication No. US20050074879A1
; GENERAL INFORMATION:
; APPLICANT: Karas, James G
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3
; FILE REFERENCE: ISPH-0828
; CURRENT APPLICATION NUMBER: US/10/773,678
; CURRENT FILING DATE: 2004-02-06
; PRIOR APPLICATION NUMBER: 10/713,139
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 09/758,881
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: PCT/US00/09054
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 09/288,461
; PRIOR FILING DATE: 1999-04-08
; NUMBER OF SEQ ID NOS: 402
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 396
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
; US-10-773-678-396

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3999 CACTTCCTTGTGCTGGACA 4018
Db 1 CTCTTACTGTGCTGGACA 20

RESULT 757
US-10-991-147-81
; Sequence 81, Application US/10991147
; Publication No. US20050096292A1

```

; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Suan M. Freier
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Erich Koller
; TITLE OF INVENTION: NOTCH1 INHIBITORS FOR INDUCING APOPTOSIS
; FILE REFERENCE: ISPH-0729
; CURRENT APPLICATION NUMBER: US/10/991,147
; CURRENT FILING DATE: 2004-11-17
; PRIOR APPLICATION NUMBER: US/10/348,750
; PRIOR FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: 10/160,497
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
; US-10-991-147-81

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 47 TGCTGGGGCTGCACGAGTG 66
Db 1 TGCTGGGGTCTGCACGAGTG 20

RESULT 758
US-10-991-147-138/c
; Sequence 138, Application US/10991147
; Publication No. US20050096292A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Erich Koller
; TITLE OF INVENTION: NOTCH1 INHIBITORS FOR INDUCING APOPTOSIS
; FILE REFERENCE: ISPH-0729
; CURRENT APPLICATION NUMBER: US/10/991,147
; CURRENT FILING DATE: 2004-11-17
; PRIOR APPLICATION NUMBER: US/10/348,750
; PRIOR FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: 10/160,497
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; US-10-991-147-138

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 47 TGCTGGGGCTGCACGAGTG 66
Db 20 TGCTGGGGTCTGCACGAGTG 1

RESULT 759
US-10-831-901A-1494/c
; Sequence 1494, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian A.
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; US-10-831-901A-1494
```

```

; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1494
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
; US-10-831-901A-1494

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2375 GTGTGCTGCCTATGTGGC 2394
Db 20 GTGTGTTGCCTATGTGGC 1

RESULT 760
US-10-831-901A-1495/c
; Sequence 1495, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian A.
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; US-10-831-901A-1495
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1495
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1495

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2376 TGTGCTGCCTATGCTGGCT 2395
Db 20 TGTGTTGGCTATGCTGGCT 1

RESULT 761
US-10-831-901A-1496/c
; Sequence 1496, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1501
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1501

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2382 TGCCTATGTTGGCTGCAAA 2401
Db 20 TGCCTATGTTGGCTGCTATA 1

RESULT 763
US-10-831-901A-3731/c
; Sequence 3731, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-06-10
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1496
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1496

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2377 GTTGCTGCCTATGCTGGCTG 2396
Db 20 GTGTTGGCTATGCTGGCTG 1

RESULT 762
US-10-831-901A-1501/c
; Sequence 1501, Application US/10831901A
; Publication No. US20050100885A1
```

Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2458	GTCAATGTGAAAGCTCTTTA	2477
Db	20	GTCAATGACAAAGCTCTTTA	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db	20	TCAATGACAAAGCTCTTTAT	1
Qy	2460	CATTGTGAAAGCTCTTTATG	2479
Db	20	CAATGACAAAGCTCTTTATG	1
Qy	2459	TCATTGTGAAAGCTCTTTAT	2478
Db</			

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
CURRENT FILING DATE: 2004-04-26
PRIOR APPLICATION NUMBER: 60/466,426
PRIOR FILING DATE: 2003-04-28
PRIOR APPLICATION NUMBER: 60/468,562
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/467,770
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: 60/468,627
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/477,637
PRIOR FILING DATE: 2003-06-10
PRIOR APPLICATION NUMBER: 60/483,579
PRIOR FILING DATE: 2003-06-27
NUMBER OF SEQ ID NOS: 30063
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 5057
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense compound
US-10-831-901A-5057

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
CURRENT FILING DATE: 2004-04-26
PRIOR APPLICATION NUMBER: 60/466,426
PRIOR FILING DATE: 2003-04-28
PRIOR APPLICATION NUMBER: 60/468,562
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/467,770
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: 60/468,627
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/477,637
PRIOR FILING DATE: 2003-06-10
PRIOR APPLICATION NUMBER: 60/483,579
PRIOR FILING DATE: 2003-06-27
NUMBER OF SEQ ID NOS: 30063
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 13606
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense compound
US-10-831-901A-13606

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
CURRENT FILING DATE: 2004-04-26
PRIOR APPLICATION NUMBER: 60/466,426
PRIOR FILING DATE: 2003-04-28
PRIOR APPLICATION NUMBER: 60/468,562
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/467,770
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: 60/468,627
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/477,637
PRIOR FILING DATE: 2003-06-10
PRIOR APPLICATION NUMBER: 60/483,579
PRIOR FILING DATE: 2003-06-27
NUMBER OF SEQ ID NOS: 30063
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 15730
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense compound
US-10-831-901A-15730

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
CURRENT FILING DATE: 2004-04-26
PRIOR APPLICATION NUMBER: 60/466,426
PRIOR FILING DATE: 2003-04-28
PRIOR APPLICATION NUMBER: 60/468,562
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/467,770
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: 60/468,627
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/477,637
PRIOR FILING DATE: 2003-06-10
PRIOR APPLICATION NUMBER: 60/483,579
PRIOR FILING DATE: 2003-06-27
NUMBER OF SEQ ID NOS: 30063
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 15730
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense compound
US-10-831-901A-15730

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
CURRENT FILING DATE: 2004-04-26
PRIOR APPLICATION NUMBER: 60/466,426
PRIOR FILING DATE: 2003-04-28
PRIOR APPLICATION NUMBER: 60/468,562
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/467,770
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: 60/468,627
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/477,637
PRIOR FILING DATE: 2003-06-10
PRIOR APPLICATION NUMBER: 60/483,579
PRIOR FILING DATE: 2003-06-27
NUMBER OF SEQ ID NOS: 30063
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 15730
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense compound
US-10-831-901A-15730

```
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 20883
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-20883

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 627 TTCAGATATTCATGACTTTG 646
    ||||| || ||||| ||
DB 20 TTCAGATCTTAATGACTTCG 1

RESULT 770
US-10-831-901A-21489/c
; Sequence 21489, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21489
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-21489/c

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4905 AATATGAAAATGAATATGTT 4924
    ||||| ||||| ||||| ||
DB 1 AATAGAAAATAAACAATGTT 20

RESULT 772
US-10-831-901A-22366
; Sequence 22366, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
```

```
; SEQ ID NO 21489
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-21489

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4913 AATGAATATGTTTATTTTGT 4932
    ||||| ||||| ||||| ||
DB 20 AACGAACAATGTTTATTTTCT 1

RESULT 771
US-10-831-901A-21493
; Sequence 21493, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21493
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-21493

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4905 AATATGAAAATGAATATGTT 4924
    ||||| ||||| ||||| ||
DB 1 AATAGAAAATAAACAATGTT 20

RESULT 772
US-10-831-901A-22366
; Sequence 22366, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22366
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-22366

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2456 TTGTCATTGTCAAGCTCTT 2475
Db 1 TTGTCAATCTCAAGCTCTT 20

RESULT 773
US-10-831-901A-22367
; Sequence 22367, Application US/10831901A
; Publication No. US20050100895A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22367
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-22367

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3337 TTAAAGTAGTACATCTTACC 3356
Db 1 TTGTAGTAGTACATCTTACC 20
```

```
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22367
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-22367

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2455 TTGTCATTGTGAAAGCTCT 2474
Db 1 TTGTCAATCTCAAGCTCTT 20

RESULT 774
US-10-831-901A-27352
; Sequence 27352, Application US/10831901A
; Publication No. US20050100895A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27352
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-27352

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3337 TTAAAGTAGTACATCTTACC 3356
Db 1 TTGTAGTAGTACATCTTACC 20
```

```
RESULT 775
US-10-831-901A-27353
; Sequence 27353, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/467,627
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27353
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-27353

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3336 TTTAAGTAGTACAACTTTAC 3355
    ||| ||||| ||| |||
Db 1 TTTTAGTAGTACAGTCGTAC 20

RESULT 776
US-10-831-901A-29427/c
; Sequence 29427, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27353
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-27353

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3336 TTTAAGTAGTACAACTTTAC 3355
    ||| ||||| ||| |||
Db 1 TTTTAGTAGTACAGTCGTAC 20
```

```
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29427
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29427

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 720 TGTGAAGGTTTTCGAATTC 739
    ||| ||||| ||| |||
Db 20 TGTAAACGTTTTCGAATTC 1

RESULT 777
US-10-831-901A-29726/c
; Sequence 29726, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29726
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29726
```

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5020 ACTGTAAAAA 5039
| | | | | | | | | | | | | | | | | | | | | |
Db 20 AATGACAAAAA 1

RESULT 778

US-10-831-901A-30017
; Sequence 30017, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian A.
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: Acute Respiratory Syndrome (SARS)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 30017
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-30017

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3999 CACTTCCTTTGCTGTGACA 4018
| | | | | | | | | | | | | | | | | | | | | |
Db 1 CTCTTACTGTGCTGTGACA 20

RESULT 779

US-10-981-507-4/c
; Sequence 4, Application US/10981507
; Publication No. US20050132970A1
; GENERAL INFORMATION:
; APPLICANT: GOSWAMI, USHA
; APPLICANT: BERNARDI, GIACOMO
; APPLICANT: GOSWAMI, SUBHASH CHANDER
; APPLICANT: JOHNSON, ROBERT K.
; TITLE OF INVENTION: PROBES FOR MYCTOPHID FISH AND A METHOD FOR DEVELOPING
; FILE REFERENCE: THE SAME
; CURRENT APPLICATION NUMBER: US/10/981,507

; CURRENT FILING DATE: 2004-11-05
; PRIOR APPLICATION NUMBER: US/09/782,604
; PRIOR FILING DATE: 2001-02-14
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-981-507-4

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4424 CATCTGTCTCTACTACAG 4443
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CATCTGTCTCTACTTCAG 1

RESULT 780

US-10-257-158A-6109/c
; Sequence 6109, Application US/10257158A
; Publication No. US20050142543A1
; GENERAL INFORMATION:
; APPLICANT: Barany, Francis
; APPLICANT: Zirvi, Monib
; APPLICANT: Gerly, Norman P.
; APPLICANT: Favis, Reyna
; APPLICANT: Kliman, Richard
; TITLE OF INVENTION: METHOD OF DESIGNING ADDRESSABLE ARRAY FOR DETECTION OF NUCLEIC ACID
; FILE REFERENCE: 19603/2834
; CURRENT APPLICATION NUMBER: US/10/257,158A
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: PCT/US01/10958
; PRIOR FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: US 60/197,271
; PRIOR FILING DATE: 2000-04-14
; NUMBER OF SEQ ID NOS: 9544
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Hypothetical Probe Sequence
US-10-257-158A-6109

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3930 GGTTCGCTGGGACCTTAGGT 3949
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GGCTGGCTGGGAGCTGAGGT 1

RESULT 781

US-10-697-527-245/c
; Sequence 245, Application US/10697527
; Publication No. US20040146898A1
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: MICROSATELLITE MARKERS FOR PLANTS OF THE SPECIES TRITICUM AESTIVUM
; FILE REFERENCE: US 08/983,605
; CURRENT APPLICATION NUMBER: US/10/697,527
; CURRENT FILING DATE: 2003-10-30
; PRIOR APPLICATION NUMBER: PCT/DE96/01185
; PRIOR FILING DATE: 1996-06-27

;
; PRIOR APPLICATION NUMBER: DE 195 25 284.5
; PRIOR FILING DATE: 1995-06-28
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 245
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Triticum sp.
US-10-697-527-245

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3857 GTGTTGTGCATATCATCAC 3876
Db 20 GGTGTGGGCTGCTTCAC 1

RESULT 782

US-11-008-747-305/C
; Sequence 305, Application US/11008747
; Publication No. US20050095710A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Susan M. Preier
; APPLICANT: Brett P. Monla
; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
; FILE REFERENCE: ISPH-0576
; CURRENT APPLICATION NUMBER: US/11/008,747
; CURRENT FILING DATE: 2004-09-04
; PRIOR APPLICATION NUMBER: US/09/854,883
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 09/629,644
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/487,368
; PRIOR FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 305
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-11-008-747-305

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2152 GAGCTCCAAGCCTTACATGA 2171
Db 20 GGCACCAAGCCTTTCATGA 1

Search completed: August 18, 2005, 08:51:49
Job time : 50 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 08:39:57 ; Search time 14 Seconds
(without alignments)

3.422 Million cell updates/sec

Title: US-10-667-022-4

Perfect score: 5085

Sequence: 1 ggaatccccgggtgcagga.....tcgagggggggcccggtacc 5085

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 241 seqs, 4711 residues

Total number of hits satisfying chosen parameters: 482

Minimum DB seq length: 8

Maximum DB seq length: 80

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 241 summaries

Database : fetch4rni.seq *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	33.2	0.7	40	1	US-08-182-060A-11
2	33.2	0.7	40	1	US-08-712-702A-11
3	26.8	0.5	32	1	US-09-213-834B-29
4	26.4	0.5	28	1	US-09-213-834B-8
5	26	0.5	26	1	US-09-923-236-6
6	25.2	0.5	26	1	US-09-923-236-6
7	25	0.5	25	1	US-09-859-736-1
8	25	0.5	25	1	US-09-859-736-2
9	24.6	0.5	25	1	US-09-213-834B-9
10	24	0.5	24	1	US-09-926-028-28
11	24	0.5	24	1	US-09-190-976B-15
12	24	0.5	24	1	US-09-213-834B-3
13	24	0.5	24	1	US-10-009-962-10
14	24	0.5	24	1	US-09-859-736-5
15	24	0.5	28	1	US-09-213-834B-12
16	24	0.5	30	1	US-09-068-043-4
17	21.8	0.4	26	1	US-09-853-646A-3
18	21	0.4	21	1	US-08-805-813-4
19	21	0.4	21	1	US-09-859-736-6
20	21	0.4	24	1	US-09-377-502-24
21	20.8	0.4	25	1	US-09-853-646A-4
22	20	0.4	20	1	US-09-976-618A-55
23	20	0.4	20	1	US-09-976-968A-55
24	20	0.4	20	1	US-10-234-764-10
25	20	0.4	20	1	US-09-975-059A-55
26	20	0.4	20	1	US-09-859-736-3
27	20	0.4	21	1	US-09-859-736-4
28	20	0.4	21	1	US-09-360-545-35
29	18.8	0.4	25	1	US-09-538-709-391
30	18.8	0.4	25	1	US-09-396-196G-82442
31	18.8	0.4	25	1	US-09-396-196G-108648
32	18.8	0.4	25	1	US-09-396-196G-119803
33	18.4	0.4	20	1	US-08-849-536A-15

c 34	18	0.4	18	1	US-09-809-545A-84	Sequence 84, Appl
c 35	18	0.4	18	1	US-10-352-704-12	Sequence 12, Appl
c 36	18	0.4	18	1	US-10-352-704-18	Sequence 18, Appl
c 37	17.4	0.3	19	1	US-08-525-864A-15	Sequence 15, Appl
c 38	17.4	0.3	19	1	US-09-696-791-1273	Sequence 1273, Ap
c 39	17	0.3	17	1	US-08-665-220-6	Sequence 6, Appl
c 40	17	0.3	17	1	US-08-618-408B-6	Sequence 6, Appl
c 41	17	0.3	17	1	US-09-257-218-5	Sequence 5, Appl
c 42	17	0.3	17	1	US-09-311-760-5	Sequence 5, Appl
c 43	17	0.3	17	1	US-09-291-692-6	Sequence 6, Appl
c 44	17	0.3	17	1	US-08-865-579-5	Sequence 5, Appl
c 45	17	0.3	17	1	US-08-556-627A-6	Sequence 6, Appl
c 46	17	0.3	17	1	US-10-059-749-5	Sequence 5, Appl
c 47	17	0.3	17	1	US-09-163-099-6	Sequence 6, Appl
c 48	17	0.3	17	1	US-10-337-060-6	Sequence 6, Appl
c 49	17	0.3	17	1	US-09-952-768-6	Sequence 6, Appl
c 50	17	0.3	17	1	US-09-766-253-132	Sequence 132, App
c 51	17	0.3	20	1	US-08-319-590-23	Sequence 23, Appl
c 52	17	0.3	20	1	US-08-487-001A-23	Sequence 23, Appl
c 53	17	0.3	20	1	US-08-630-822A-23	Sequence 23, Appl
c 54	17	0.3	20	1	US-08-711-905-23	Sequence 23, Appl
c 55	17	0.3	20	1	US-09-005-069-23	Sequence 23, Appl
c 56	17	0.3	20	1	US-09-467-642-10	Sequence 10, Appl
c 57	16.8	0.3	20	1	US-08-882-046-44	Sequence 44, Appl
c 58	16.8	0.3	20	1	US-09-566-047-44	Sequence 44, Appl
c 59	16.8	0.3	22	1	US-08-980-071-52	Sequence 52, Appl
c 60	16.8	0.3	22	1	US-08-757-536-52	Sequence 52, Appl
c 61	16.8	0.3	22	1	US-09-314-093-52	Sequence 52, Appl
c 62	16.8	0.3	22	1	US-09-250-848-52	Sequence 52, Appl
c 63	16.8	0.3	22	1	US-09-251-885-52	Sequence 52, Appl
c 64	16.8	0.3	22	1	US-09-337-635-52	Sequence 52, Appl
c 65	16.8	0.3	22	1	US-09-337-280-52	Sequence 52, Appl
c 66	16.8	0.3	22	1	US-09-972-175-52	Sequence 52, Appl
c 67	16.8	0.3	22	1	US-10-200-522-52	Sequence 52, Appl
c 68	16.4	0.3	18	1	US-09-904-744-2	Sequence 2, Appl
c 69	16.4	0.3	19	1	US-09-308-003-31	Sequence 31, Appl
c 70	16.4	0.3	20	1	US-09-844-634-57	Sequence 57, Appl
c 71	16.4	0.3	20	1	US-09-554-726A-29	Sequence 29, Appl
c 72	16.4	0.3	21	1	US-09-802-320A-22	Sequence 22, Appl
c 73	16.2	0.3	21	1	US-10-105-01A-23	Sequence 23, Appl
c 74	16	0.3	21	1	US-09-766-253-131	Sequence 131, App
c 75	16	0.3	17	1	US-09-685-664B-1074	Sequence 1074, Ap
c 76	16	0.3	17	1	US-09-685-664B-1075	Sequence 1075, App
c 77	16	0.3	17	1	US-09-090-672B-105	Sequence 105, App
c 78	16	0.3	17	1	US-09-090-672B-106	Sequence 106, App
c 79	16	0.3	17	1	US-09-090-672B-107	Sequence 107, App
c 80	16	0.3	20	1	US-09-065-058-1	Sequence 1, Appl
c 81	16	0.3	21	1	US-09-439-616-6	Sequence 6, Appl
c 82	16	0.3	21	1	US-09-439-616-12	Sequence 12, Appl
c 83	15.8	0.3	19	1	US-08-582-539-21	Sequence 21, Appl
c 84	15.8	0.3	19	1	US-09-422-978-4157	Sequence 4157, Ap
c 85	15.8	0.3	20	1	US-08-474-177-8	Sequence 8, Appl
c 86	15.8	0.3	20	1	US-08-487-033-8	Sequence 8, Appl
c 87	15.8	0.3	20	1	US-08-480-810-8	Sequence 8, Appl
c 88	15.8	0.3	20	1	US-08-508-735-8	Sequence 8, Appl
c 89	15.8	0.3	20	1	US-08-848-251-8	Sequence 8, Appl
c 90	15.8	0.3	20	1	US-08-486-047-8	Sequence 8, Appl
c 91	15.8	0.3	20	1	US-09-120-130-8	Sequence 8, Appl
c 92	15.8	0.3	20	1	US-09-115-252-8	Sequence 8, Appl
c 93	15.8	0.3	20	1	US-08-467-023-167	Sequence 167, App
c 94	15.8	0.3	20	1	US-08-986-515-8	Sequence 8, Appl
c 95	15.8	0.3	20	1	US-09-120-128-8	Sequence 8, Appl
c 96	15.8	0.3	20	1	US-09-120-129-8	Sequence 8, Appl
c 97	15.8	0.3	20	1	US-09-201-139-8	Sequence 8, Appl
c 98	15.8	0.3	20	1	US-09-120-131-8	Sequence 8, Appl
c 99	15.8	0.3	20	1	US-09-662-250A-36	Sequence 36, Appl
c 100	15.8	0.3	20	1	US-09-844-634-138	Sequence 138, App
c 101	15.8	0.3	20	1	US-09-322-409-143	Sequence 143, App
c 102	15.8	0.3	20	1	US-09-451-527-143	Sequence 143, App
c 103	15.8	0.3	20	1	US-09-645-021-5	Sequence 5, Appl
c 104	15.8	0.3	20	1	US-09-456-090A-4	Sequence 4, Appl
c 105	15.8	0.3	20	1	US-08-227-800A-6	Sequence 6, Appl
c 106	15.8	0.3	20	1	US-08-921-954-6	Sequence 6, Appl

c 107	15.8	0.3	20	1	US-09-453-234-4	Sequence 4, Appli	180	14.4	0.3	16	1	US-08-461-859-7	Sequence 7, Appli
c 108	15.8	0.3	21	1	US-08-632-598-29	Sequence 29, Appl	181	14.4	0.3	16	1	US-08-462-498-7	Sequence 7, Appli
c 109	15.8	0.3	21	1	US-09-231-240-29	Sequence 29, Appl	182	14.4	0.3	16	1	US-08-879-860-10	Sequence 10, Appl
c 110	15.8	0.3	21	1	US-09-422-978-8727	Sequence 8727, Ap	183	14.4	0.3	16	1	US-08-554-385-7	Sequence 7, Appli
c 111	15.4	0.3	17	1	US-09-685-664B-1073	Sequence 1073, Ap	184	14.4	0.3	16	1	US-09-371-772B-7023	Sequence 7, Appli
c 112	15.4	0.3	17	1	US-09-685-664B-1076	Sequence 1076, Ap	185	14.4	0.3	16	1	PCT-US93-10069-7	Sequence 7, Appli
c 113	15.4	0.3	17	1	US-09-685-664B-1077	Sequence 1077, Ap	186	14.4	0.3	17	1	US-08-373-124A-596	Sequence 596, App
c 114	15.4	0.3	18	1	US-09-904-744-1	Sequence 1, Appli	187	14.4	0.3	17	1	US-08-373-124A-1635	Sequence 1635, App
c 115	15.4	0.3	20	1	US-08-467-822-6	Sequence 6, Appli	188	14.4	0.3	17	1	US-08-435-628-596	Sequence 596, App
c 116	15.4	0.3	20	1	US-09-357-070-8	Sequence 8, Appli	189	14.4	0.3	17	1	US-08-435-628-1635	Sequence 1635, App
c 117	15.4	0.3	20	1	US-08-432-697-6	Sequence 6, Appli	190	14.4	0.3	17	1	US-08-894-483-2	Sequence 2, Appli
c 118	15.4	0.3	20	1	US-08-466-248-6	Sequence 6, Appli	191	14.4	0.3	17	1	US-09-866-108A-630	Sequence 630, App
c 119	15.4	0.3	20	1	US-08-275-951-49	Sequence 49, Appl	192	14.4	0.3	17	1	US-09-866-108A-631	Sequence 631, App
c 120	15.4	0.3	20	1	US-09-422-978-6200	Sequence 6200, Ap	193	14.4	0.3	17	1	US-09-866-108A-6351	Sequence 6351, App
c 121	15.4	0.3	20	1	US-09-306-420C-6	Sequence 6, Appli	194	14.4	0.3	17	1	US-09-866-108A-6352	Sequence 6352, App
c 122	15.4	0.3	20	1	US-09-081-385-98	Sequence 98, Appl	195	14.4	0.3	17	1	US-09-866-108A-6352	Sequence 6352, App
c 123	15.2	0.3	20	1	US-07-977-284A-103	Sequence 103, App	196	14.4	0.3	17	1	US-09-866-108A-6352	Sequence 6352, App
c 124	15.2	0.3	20	1	US-08-406-635-14	Sequence 14, Appl	197	14.4	0.3	17	1	US-09-866-108A-6352	Sequence 6352, App
c 125	15.2	0.3	20	1	US-08-598-591-57	Sequence 57, Appl	198	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 126	15.2	0.3	20	1	US-08-637-902-7	Sequence 7, Appli	199	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 127	15.2	0.3	20	1	US-08-233-005-8	Sequence 8, Appli	200	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 128	15.2	0.3	20	1	US-08-798-691-61	Sequence 61, Appl	201	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 129	15.2	0.3	20	1	US-08-428-943-8	Sequence 8, Appli	202	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 130	15.2	0.3	20	1	US-08-639-501-120	Sequence 120, App	203	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 131	15.2	0.3	20	1	US-08-256-426B-103	Sequence 103, App	204	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 132	15.2	0.3	20	1	US-08-974-180-4	Sequence 4, Appli	205	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 133	15.2	0.3	20	1	US-09-044-946-120	Sequence 120, App	206	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 134	15.2	0.3	20	1	US-08-825-487A-61	Sequence 61, Appl	207	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 135	15.2	0.3	20	1	US-09-016-649-8	Sequence 8, Appli	208	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 136	15.2	0.3	20	1	US-09-044-908-120	Sequence 120, App	209	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 137	15.2	0.3	20	1	US-09-074-476-61	Sequence 61, Appl	210	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 138	15.2	0.3	20	1	US-08-765-340-10	Sequence 10, Appl	211	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 139	15.2	0.3	20	1	US-09-467-082-28	Sequence 28, Appl	212	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 140	15.2	0.3	20	1	US-09-021-701-549	Sequence 549, App	213	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 141	15.2	0.3	20	1	US-09-168-406A-28	Sequence 28, Appl	214	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 142	15.2	0.3	20	1	US-09-428-583-45	Sequence 45, Appl	215	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 143	15.2	0.3	20	1	US-09-702-246-31	Sequence 31, Appl	216	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 144	15.2	0.3	20	1	US-09-844-634-133	Sequence 133, App	217	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 145	15.2	0.3	20	1	US-09-411-628-9	Sequence 9, Appli	218	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 146	15.2	0.3	20	1	US-09-746-694-40	Sequence 40, Appl	219	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 147	15.2	0.3	20	1	US-09-422-978-4301	Sequence 4301, Ap	220	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 148	15.2	0.3	20	1	US-09-198-452A-4833	Sequence 4833, Ap	221	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 149	15.2	0.3	20	1	US-09-307-106-42	Sequence 42, Appl	222	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 150	15.2	0.3	20	1	US-09-665-615B-177	Sequence 177, App	223	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 151	15.2	0.3	20	1	US-10-174-794-9	Sequence 9, Appli	224	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 152	15.2	0.3	20	1	US-10-022-819-56	Sequence 56, Appl	225	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 153	15.2	0.3	20	1	US-08-983-605-245	Sequence 245, App	226	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 154	15.2	0.3	20	1	US-09-917-963-44	Sequence 44, Appl	227	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 155	15.2	0.3	20	1	US-09-734-672A-61	Sequence 61, Appl	228	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 156	15.2	0.3	20	1	PCT-US95-04858-8	Sequence 8, Appli	229	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 157	15	0.3	15	1	US-10-352-704-10	Sequence 10, Appl	230	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 158	15	0.3	15	1	US-10-352-704-16	Sequence 16, Appl	231	14.4	0.3	19	1	US-09-866-108A-6352	Sequence 6352, App
c 159	15	0.3	18	1	US-09-422-978-8771	Sequence 8771, Ap	232	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 160	15	0.3	19	1	US-09-422-978-6255	Sequence 6255, Ap	233	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 161	15	0.3	20	1	US-09-290-640-27	Sequence 27, Appl	234	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 162	15	0.3	20	1	US-09-517-467B-343	Sequence 343, App	235	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 163	15	0.3	20	1	US-09-665-615B-27	Sequence 27, Appl	236	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 164	14.8	0.3	18	1	US-09-256-496-45	Sequence 45, Appl	237	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 165	14.8	0.3	18	1	US-09-475-947A-340	Sequence 340, App	238	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 166	14.8	0.3	18	1	US-09-618-919A-3	Sequence 3, Appli	239	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 167	14.8	0.3	18	1	US-09-618-919A-7	Sequence 7, Appli	240	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 168	14.8	0.3	19	1	US-07-696-793A-47	Sequence 47, Appl	241	14.4	0.3	18	1	US-09-866-108A-6352	Sequence 6352, App
c 169	14.8	0.3	19	1	US-07-977-694-47	Sequence 47, Appl							
c 170	14.8	0.3	19	1	US-08-403-555-13	Sequence 13, Appl							
c 171	14.8	0.3	19	1	US-08-299-187-11	Sequence 11, Appl							
c 172	14.8	0.3	19	1	US-08-432-158-23	Sequence 23, Appl							
c 173	14.8	0.3	19	1	US-08-910-443-3	Sequence 3, Appli							
c 174	14.8	0.3	19	1	US-08-910-443-11	Sequence 11, Appl							
c 175	14.8	0.3	19	1	US-08-876-874-4	Sequence 4, Appli							
c 176	14.8	0.3	19	1	PCT-US95-11114-11	Sequence 11, Appl							
c 177	14.4	0.3	16	1	US-08-011-398B-7	Sequence 7, Appli							
c 178	14.4	0.3	16	1	US-08-370-225-7	Sequence 7, Appli							
c 179	14.4	0.3	16	1	US-08-464-051-7	Sequence 7, Appli							

ALIGNMENTS

RESULT 1

US-08-182-060A-11
; Sequence 11, Application US/08182060A
; Patent No. 5648210
; GENERAL INFORMATION:
; APPLICANT: John W. Pierce

APPLICANT: Phillip S. Kerr
APPLICANT: Mary F. Becker-Manley
APPLICANT: Richard W. Pearlstein
APPLICANT: Bruce J. Schweiger
TITLE OF INVENTION: Nucleotide Sequences
TITLE OF INVENTION: of Galactinol
TITLE OF INVENTION: Synthase from
TITLE OF INVENTION: Zucchini and Soybean
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: E. I. du Pont de Nemours
ADDRESSEE: and Company
STREET: 1007 Market Street
CITY: Wilmington
STATE: Delaware
COUNTRY: U.S.A.
ZIP: 19898
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.0 MB
COMPUTER: Macintosh
OPERATING SYSTEM: Macintosh System, 6.0
SOFTWARE: Microsoft Word 4.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/182.060A
FILING DATE:
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 92/06057
FILING DATE: 24 JULY 1992
FILING DATE: 24 JULY 1991
NAME: LINDA AXAMETHY FLOYD
REGISTRATION NUMBER: 33,692
REFERENCE/DOCKET NUMBER: BB-1032-A
TELEPHONE: (302)992-4929
TELEFAX: (302)892-7949
TELEX:
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 40 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-182-060A-11
Query Match 0.7%; Score 33.2; DB 1; Length 40;
Best Local Similarity 92.1%; Pred. No. 1.1;
Matches 35; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1 GGATCCCCGGGTGCAGGAATTCGGCACGAGGGAGT 38
Db 3 GGATCCCCGGGTGCAGGAATTCGGCACGAGTGTGT 40
RESULT 2
US-08-712-702A-11
Sequence 11, Application US/08/12702A
Patent No. 5773699
GENERAL INFORMATION:
APPLICANT: John W. Pierce
APPLICANT: Phillip S. Kerr
APPLICANT: Mary F. Becker-Manley
APPLICANT: Richard W. Pearlstein
APPLICANT: Bruce J. Schweiger
TITLE OF INVENTION: Nucleotide Sequences
TITLE OF INVENTION: of Galactinol Synthase from Zucchini and Soybean
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: E. I. du Pont de Nemours
ADDRESSEE: and Company
STREET: 1007 Market Street

CITY: Wilmington
STATE: Delaware
COUNTRY: U.S.A.
ZIP: 19898
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.0 MB
COMPUTER: Macintosh
OPERATING SYSTEM: Macintosh System, 6.0
SOFTWARE: Microsoft Word 4.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/712.702A
FILING DATE: 12-SEP-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/182.060
FILING DATE: 21-JAN-1994
APPLICATION NUMBER: US 92/06057
FILING DATE: 24 JULY 1992
APPLICATION NUMBER: 07/735.066
FILING DATE: 24 JULY 1991
NAME: LINDA AXAMETHY FLOYD
REGISTRATION NUMBER: 33,692
REFERENCE/DOCKET NUMBER: BB-1032-A
TELEPHONE: (302)992-4929
TELEFAX: (302)892-7949
TELEX:
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 40 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-712-702A-11
Query Match 0.7%; Score 33.2; DB 1; Length 40;
Best Local Similarity 92.1%; Pred. No. 1.1;
Matches 35; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1 GGATCCCCGGGTGCAGGAATTCGGCACGAGGGAGT 38
Db 3 GGATCCCCGGGTGCAGGAATTCGGCACGAGTGTGT 40
RESULT 3
US-09-213-834B-29/c
Sequence 29, Application US/09213834B
Patent No. 6825011
GENERAL INFORMATION:
APPLICANT: Romantchikov, Yuri
TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
TITLE OF INVENTION: NUCLEIC ACIDS INTO CIRCULAR VECTORS
FILE REFERENCE: 11639/1
CURRENT APPLICATION NUMBER: US/09/213.834B
CURRENT FILING DATE: 1998-12-17
NUMBER OF SEQ ID NOS: 50
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 29
LENGTH: 32
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Cloning Vector
US-09-213-834B-29
Query Match 0.5%; Score 26.8; DB 1; Length 32;
Best Local Similarity 93.3%; Pred. No. 6;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 5041 AAAAAAAAAAAAAAAAAAAAAAACTCGAG 5070
Db 32 AAAAAAAAAAAAAAAAAAAAAAACTAGTG 3

```

; CURRENT APPLICATION NUMBER: US/09/923,236
; CURRENT FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7231
US-09-923-236-6

Query Match          0.5%; Score 25.2; DB 1; Length 26;
Best Local Similarity 96.2%; Pred. No. 7.6;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAAAAAAAAAAAAAAAAAAA 5049
Db 26 BAAAAAAAAAAAAAAAAAAAAA 1

RESULT 7
US-09-859-736-1/c
; Sequence 1, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CATA oligonucleotide
US-09-859-736-1

Query Match          0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 7.7;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5049
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 8
US-09-859-736-2/c
; Sequence 2, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 25

; CURRENT APPLICATION NUMBER: US/09/923,236
; CURRENT FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-8

Query Match          0.5%; Score 26.4; DB 1; Length 28;
Best Local Similarity 96.4%; Pred. No. 5.7;
Matches 27; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5041 AAAAAAAAAAAAAAAAAAAAAA 5068
Db 28 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 5
US-09-923-236-7/c
; Sequence 7, Application US/09923236
; Patent No. 6828419
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
; CURRENT APPLICATION NUMBER: US/09/923,236
; CURRENT FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7764a
US-09-923-236-7

Query Match          0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 5.9;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAAAAAAAAAAAAAAAAAAA 5049
Db 26 TAAAAAAAAAAAAAAAAAAAAA 1

RESULT 6
US-09-923-236-6/c
; Sequence 6, Application US/09923236
; Patent No. 6828419
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CATB oligonucleotide
US-09-859-736-2

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 7.7; Mismatches 0; Indels 0; Gaps 0;
Matches 25; Conservative 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5049
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 9
US-09-213-834B-9/c
; Sequence 9, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-9

Query Match 0.5%; Score 24.6; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 8.8; Mismatches 1; Indels 0; Gaps 0;
Matches 24; Conservative 1;

Qy 5041 AAAAAAAAAAAAAAAAAAAAAA 5065
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 10
US-09-926-028-28
; Sequence 28, Application US/09926028
; Patent No. 6806049
; GENERAL INFORMATION:
; APPLICANT: MAEKAWA, TAKAMI
; APPLICANT: MITSUI, AKIRA
; APPLICANT: DATE, MASAYO
; APPLICANT: FUKUDA, HISAO
; APPLICANT: TAKAHARA, YOSHIYUKI
; TITLE OF INVENTION: METHOD FOR ANALYZING EXPRESSION FREQUENCIES OF GENES
; FILE REFERENCE: 212833USOPT
; CURRENT APPLICATION NUMBER: US/09/926,028
; PRIOR FILING DATE: 2001-08-16
; PRIOR APPLICATION NUMBER: PCT/JF00/00902
; PRIOR FILING DATE: 2000-02-17
; PRIOR APPLICATION NUMBER: JP 11-038538
; PRIOR FILING DATE: 1999-02-17
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA
; FEATURE:

; NAME/KEY: polyA_signal
; LOCATION: (1)..(24)
; OTHER INFORMATION:
US-09-926-028-28

Query Match 0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 10; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 1 AAAAAAAAAAAAAAAAAAAAAA 24

RESULT 11
US-09-190-976B-15/c
; Sequence 15, Application US/09190976B
; Patent No. 6815187
; GENERAL INFORMATION:
; APPLICANT: Simons, Michael
; Horowitz, Arie
; TITLE OF INVENTION: Stimulation of angiogenesis via
; syndecan-4 cytoplasmic domain signaling pathway
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David Prashker, Esq.
; STREET: P.O. Box 5387
; CITY: Magnolia
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 01930
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.40 Mb storage
; COMPUTER: Dell PC
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Microsoft Word version 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/190,976B
; FILING DATE: 12-No. 6815187-1998
; CLASSIFICATION: Unknown
; ATTORNEY/AGENT INFORMATION:
; NAME: David Prashker, Esq.
; REGISTRATION NUMBER: 29,693
; REFERENCE/DOCKET NUMBER: Bis-041
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (978) 525-3794
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-190-976B-15

Query Match 0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 10; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0;

Qy 5047 AAAAAAAAAAAAAAAAAAACTCGAG 5070
Db 24 AAAAAAAAAAAAAAAAAAACTCGAG 1

RESULT 12
US-09-213-834B-3/c
; Sequence 3, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; NUCLEIC ACIDS INTO CIRCULAR VECTORS

```
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
;
US-09-213-834B-3

Query Match      0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 13
US-10-009-962-10/c
; Sequence 10, Application US/10009962
; Patent No. 6825321
; GENERAL INFORMATION:
; APPLICANT: ITO, KIKUKATSU
; TITLE OF INVENTION: Plant Thermogenic Genes and Proteins
; FILE REFERENCE: 2001-1838A/LC/00653
; CURRENT APPLICATION NUMBER: US/10/009,962
; CURRENT FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: PCT/JP00/03806
; PRIOR FILING DATE: 2000-06-12
; PRIOR APPLICATION NUMBER: JP11-167439
; PRIOR FILING DATE: 1999-06-14
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: DNA Primer

US-10-009-962-10

Query Match      0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 14
US-09-859-736-5/c
; Sequence 5, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 24
; TYPE: DNA

;
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;
US-09-859-736-5

Query Match      0.5%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 15
US-09-213-834B-12/c
; Sequence 12, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romanchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector

US-09-213-834B-12

Query Match      0.5%; Score 24; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5048
Db 28 AAAAAAAAAAAAAAAAAAAAAA 5

RESULT 16
US-09-068-043-4
; Sequence 4, Application US/09068043
; Patent No. 6048694
; GENERAL INFORMATION:
; APPLICANT: MICHAEL GENE BRAMUCCI
; APPLICANT: VASANTHA NAGARAJAN
; TITLE OF INVENTION: POSITIVE SELECTION
; TITLE OF INVENTION: VECTOR FOR BACILLUS SP.
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: E. I. DU PONT DE NEMOURS AND
; STREET: 1007 MARKET STREET
; CITY: WILMINGTON
; STATE: DELAWARE
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 19898
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: MICROSOFT WINDOWS 95
; SOFTWARE: MICROSOFT OFFICE 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/068,043
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
```

APPLICATION NUMBER: 60/006,201
FILING DATE: NOVEMBER 3, 1995
ATTORNEY/AGENT INFORMATION:
NAME: FELTHAM, S. NEIL
REGISTRATION NUMBER: 36,506
REFERENCE/DOCKET NUMBER: CR-9807
TELEPHONE: 302-992-6460
TELEFAX: 302-773-0164
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
US-09-068-043-4

Query Match 0.5%; Score 24; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGATCCCCGGGCTGCAGGAATTC 24
Db 4 GGATCCCCGGGCTGCAGGAATTC 27

RESULT 17
US-09-853-646A-3
Sequence 3, Application US/09853646A
Patent No. 6825038
GENERAL INFORMATION:
APPLICANT: Nicolaides, Nicholas
APPLICANT: Sass, Philip
APPLICANT: Grasso, Luigi
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
TITLE OF INVENTION: A METHOD FOR GENERATING HYPERMUTABLE
TITLE OF INVENTION: ORGANISMS
FILE REFERENCE: 01107.00138
CURRENT APPLICATION NUMBER: US/09/853,646A
CURRENT FILING DATE: 2001-05-14
PRIOR APPLICATION NUMBER: 60/204,769
PRIOR FILING DATE: 2000-05-17
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 3
LENGTH: 26
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Recombinant DNA
US-09-853-646A-3

Query Match 0.4%; Score 21.6; DB 1; Length 26;
Best Local Similarity 92.0%; Pred. No. 22;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 5022 TGTAAAAAATAAAAAAAAAAAAAA 5046
Db 2 TGGCAAAAAAAAAAAAAAAAAAAAAA 26

RESULT 18
US-08-805-813-4
Sequence 4, Application US/09805813
Patent No. 6750381
GENERAL INFORMATION:
APPLICANT: Mitsuahara, Ichiro
APPLICANT: Ohshima, Masahiro
APPLICANT: Ohashi, Yuko
TITLE OF INVENTION: Pathogen-Resistant Plants and Method for

TITLE OF INVENTION: Production Thereof
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/805,813
FILING DATE: No. 6750381 yet assigned
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 8-068809
FILING DATE: 25-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 8-187763
FILING DATE: 17-JUL-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bastian, Kevin L.
REGISTRATION NUMBER: 34,774
REFERENCE/DOCKET NUMBER: 85760-000000
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: -
LOCATION: 1..21
OTHER INFORMATION: /note= "BKSBE primer"
US-08-805-813-4

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 TCCCCCGGGCTGCAGGAATTC 24
Db 1 TCCCCCGGGCTGCAGGAATTC 21

RESULT 19
US-09-859-736-6/c
Sequence 6, Application US/09859736
Patent No. 6838244
GENERAL INFORMATION:
APPLICANT: LI, WAN-LIANG ROBERT
APPLICANT: ZHOU, JIAN S.
TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
FILE REFERENCE: 16517.248
CURRENT APPLICATION NUMBER: US/09/859,736
CURRENT FILING DATE: 2001-05-18
PRIOR APPLICATION NUMBER: 60/205,452
PRIOR FILING DATE: 2000-05-19
NUMBER OF SEQ ID NOS: 7
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 6
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:

```

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;
; OTHER INFORMATION: dt oligonucleotide
US-09-859-736-6

```

Query Match	0.43	Score 21	DB 1	Length 21
Best Local Similarity	100.0%	Pred. No. 22		
Matches 21	Conservative	0	Mismatches	0
				Gaps 0

QY 5025 AAAAAAAAAAAAAAAAAAAAAA 5045
pb 21 AAAAAAAAAAAAAAAAAAAAAA 1

```

RESULT 20
US-09-377-502-24
; Sequence 24, Application US/09377502
; Patent No. 6791011
; GENERAL INFORMATION:
; APPLICANT: Gene Shears Pty. Limited
; APPLICANT: Paul, Wyatt
; APPLICANT: Perez, Pascal
; APPLICANT: Huttner, Eric
; APPLICANT: Betzner, Andreas S
; TITLE OF INVENTION: Protein Complementation In Transgenic Plants
; FILE REFERENCE: P19623US/TJF
; CURRENT APPLICATION NUMBER: US/09/377,502
; CURRENT FILING DATE: 1999-08-20
; PRIOR APPLICATION NUMBER: PCT/GB98/00542
; PRIOR FILING DATE: 1998-02-20
; PRIOR APPLICATION NUMBER: GB 97/03681.8
; PRIOR FILING DATE: 1997-02-21
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 24
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Figure 1G: Ubqla
US-09-377-502-24

```

Query Match	0.4%;	Score 21;	DB 1;	Length 24;
Best Local Similarity	100.0%;	Pred. No. 26;		
Matches 21;	Conservative	0;	Mismatches	0;
Indels				0;
Gaps				0;

QY 1 GGATCCCCCGGGCTGCAGGAA 21
|||
nB 4 GGATCCCCCGGGCTGCAGGAA 24

```

RESULT 21
US-09-853-646A-4
; Sequence 4, Application US/09853646A
; Patent No. 6825038
; GENERAL INFORMATION:
; APPLICANT: Nicolaides, Nicholas
; APPLICANT: Sass, Philip
; APPLICANT: Grasso, Luigi
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: A METHOD FOR GENERATING HYPERMUTABLE
; FILE REFERENCE: 01107.00138
; CURRENT APPLICATION NUMBER: US/09/853,646A
; CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: 60/204,769
; PRIOR FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

```

; FEATURE:
; OTHER INFORMATION: Recombinant DNA
US-09-853-646A-4

```

Query Match	0.4%	Score 20.8;	DB 1;	Length 25;
Best Local Similarity	91.7%;	Pred. No. 29;		
Matches 22;	Conservative	0;	Mismatches	2;
Indels	0;	Gaps	0;	

QY 5022 TGTAAGGAAAAAAAAAAAAAAAAAAAAA 5045
|||
nB 2 TGGCAAGGAAAAAAAAAAAAAAAAAAAAA 25

RESULT 22
 US-09-976-618A-55
 ; Sequence 55, Application US/09976618A
 ; Patent No. 6812334
 ; GENERAL INFORMATION:
 ; APPLICANT: Mirkin, Chad A.
 ; APPLICANT: Letsinger, Robert L.
 ; APPLICANT: Mucic, Robert C.
 ; APPLICANT: Storhoff, James J.
 ; APPLICANT: Elghanian, Robert
 ; APPLICANT: Taton, Thomas A.
 ; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
 ; TITLE OF INVENTION: AND USES THEREFOR
 ; FILE REFERENCE: 00-713-121
 ; CURRENT APPLICATION NUMBER: US/09/976,618A
 ; CURRENT FILING DATE: 2001-10-12
 ; PRIOR APPLICATION NUMBER: 09/603,830
 ; PRIOR FILING DATE: 2000-06-26
 ; PRIOR APPLICATION NUMBER: 09/344,667
 ; PRIOR FILING DATE: 1999-06-25
 ; PRIOR APPLICATION NUMBER: 09/240,755
 ; PRIOR FILING DATE: 1999-01-29
 ; PRIOR APPLICATION NUMBER: PCT/US97/12783
 ; PRIOR FILING DATE: 1997-07-21
 ; PRIOR APPLICATION NUMBER: 60/031,809
 ; PRIOR FILING DATE: 1996-07-29
 ; PRIOR APPLICATION NUMBER: 60/200,161
 ; PRIOR FILING DATE: 2000-04-26
 ; NUMBER OF SEQ ID NOS: 64
 ; SOFTWARE: Microsoft Word 2000
 ; SEQ ID NO 55
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: random
 ; OTHER INFORMATION: synthetic sequence
 US-09-976-618A-55

Query Match	0.4%;	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 28;		
Matches	20;	Conservative	0;	Mismatches
			0;	Indels
			0;	Gaps

Qy	5025	AAAAAAAAAAAAAAAAAAAAA	5044
rb	1	AAAAAAAAAAAAAAAAAAAAA	20

RESULT 23
US-09-976--968A-55
; Sequence 55, Application US/09976968A
; Patent No. 6818753
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Stornhoff, James J.
; APPLICANT: Elghamian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO

US-09-976-968A-55
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-713-117
; CURRENT APPLICATION NUMBER: US/09/976,968A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-976-968A-55

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 24

US-10-234-764-10/c
; Sequence 10, Application US/10234764
; Patent No. 6825331
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Lonnberg, Harri
; APPLICANT: Salo, Harri
; APPLICANT: Virta, Pasi
; TITLE OF INVENTION: Aminoxy Functionalized Oligomers
; FILE REFERENCE: ISIS5089
; CURRENT APPLICATION NUMBER: US/10/234,764
; CURRENT FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 09/344,260
; PRIOR FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-234-764-10

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 25

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;

US-09-975-059A-55
; Sequence 55, Application US/09975059A
; Patent No. 6828432
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-713-115
; CURRENT APPLICATION NUMBER: US/09/975,059A
; CURRENT FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-975-059A-55

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 26

US-09-859-736-3/c
; Sequence 3, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CAT1 oligonucleotide
US-09-859-736-3

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;

Thu Aug 18 08:45:54 2005

gibbs-10-667-022-4.rni

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 27
US-09-859-736-4/c
; Sequence 4, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517,248
; CURRENT APPLICATION NUMBER: US/09/859,736
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CAT2 oligonucleotide
US-09-859-736-4

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAAAAAA 5044
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 28
US-09-360-545-35
; Sequence 35, Application US/09360545
; Patent No. 6429014
; GENERAL INFORMATION:
; APPLICANT: Croteau, Rodney B
; APPLICANT: Bohlmann, Jorg
; APPLICANT: Steele, Christopher L
; APPLICANT: Phillips, Michael A
; TITLE OF INVENTION: MONOTERPENE SYNTHASES FROM GRAND FIR (ABIES GRANDIS)
; FILE REFERENCE: wsu13885
; CURRENT APPLICATION NUMBER: US/09/360,545
; CURRENT FILING DATE: 1999-07-26
; EARLIER APPLICATION NUMBER: 60/052,249
; EARLIER FILING DATE: 1997-11-07
; EARLIER APPLICATION NUMBER: PCT/US98/14528
; EARLIER FILING DATE: 1998-07-10
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 35
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR
; OTHER INFORMATION: oligonucleotide primer 3.18 EcoRI
US-09-360-545-35

Query Match 0.4%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

.Qy 13 CTCGAGGAATTCGGCAGCAG 32

Db 1 CTCGAGGAATTCGGCAGCAG 20

RESULT 29
US-09-538-709-391/c
; Sequence 391, Application US/09538709
; Patent No. 6468749
; GENERAL INFORMATION:
; APPLICANT: Ulanovsky, et al
; TITLE OF INVENTION: SEQUENCE-DEPENDENT GENE SORTING TECHNIQUES
; FILE REFERENCE: 540579-2006
; CURRENT APPLICATION NUMBER: US/09/538,709
; CURRENT FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1311
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 391
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-538-709-391

Query Match 0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 53;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2851 CCAGAGGATCCTGCTAGCAGC 2872
Db 25 CCAGAGGATCCTGCTAGCAGC 4

RESULT 30
US-09-396-196G-82442
; Sequence 82442, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 82442
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-82442

Query Match 0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 53;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 191 GAGGCCCGGAACGATGTCCTCC 212
Db 1 GAGGCCCTGGAACGATGTCCTCC 22

RESULT 31
US-09-396-196G-108648
; Sequence 108648, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart


```
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 108648
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-108648

Query Match          0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 53;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 266 TCTTTAGCGTGGCTTCTCTCT 287
      |||||
Db 4 TCTTGGCGTGGCTTCTCTCT 25

RESULT 32
US-09-396-196G-119803
; Sequence 119803, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 119803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-119803

Query Match          0.4%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 53;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4096 TCAAGTCACTGTCATCTTCCA 4117
      |||||
Db 1 TAAAGTCACTGTTATCTTCCA 22

RESULT 33
US-08-849-536A-15
; Sequence 15, Application US/08849536A
; Patent No. 5853976
; GENERAL INFORMATION:
; APPLICANT: HESSE, Friederike
; APPLICANT: AMBROSIO, Dorothee
; APPLICANT: BURTSCHER, Helmut
; TITLE OF INVENTION: RECOMBINANT PROTEINASE FROM CLOSTRIDIUM
; HISTOLYTICUM AND ITS USE FOR ISOLATING CELLS AND GROUPS OF CEL
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nikaido, Marmelstein, Murray & Oram LLP
; STREET: 655 15th St., N.W., Suite 330 - G St. Lobby
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
```

```
; ZIP: 20005-5701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,536A
; FILING DATE: Herewith
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Wong, King L.
; REGISTRATION NUMBER: 37,500
; REFERENCE/DOCKET NUMBER: 1614-7026
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638 - 5000
; TELEFAX: (202) 638 - 4810
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Primer NPC6"
US-08-849-536A-15

Query Match          0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 46;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 817 TGCTACCTTTCCAGAAAGC 836
      |||||
Db 1 TGCTACCATTCAGAAAGC 20

RESULT 34
US-09-809-545A-84/c
; Sequence 84, Application US/09809545A
; Patent No. 6800455
; GENERAL INFORMATION:
; APPLICANT: Stanton, Lawrence W.
; APPLICANT: White, R. Tyler
; TITLE OF INVENTION: SECRETED FACTORS
; FILE REFERENCE: SCIOS.017A
; CURRENT APPLICATION NUMBER: US/09/809,545A
; CURRENT FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 84
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligos corresponding to polylinker sequence.
US-09-809-545A-84

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
      |||||
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 35
US-10-352-704-12/c
; Sequence 12, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; APPLICANT: Kumarev, Viktor
```

```
;
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its
; Implementation
;
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C
; STATE: D.C
; COUNTRY: U.S.A.
; ZIP: 20004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/352,704
; FILING DATE: 28-Jan-2003
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/358,556A
; FILING DATE: 14-DEC-1994
; APPLICATION NUMBER: FR 9315164
; FILING DATE: 16-DEC-1993
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
;
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..18
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-352-704-12

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 36
US-10-352-704-18
; Sequence 18, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its
; Implementation
;
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C
```

```
;
; STATE: D.C
; COUNTRY: U.S.A.
; ZIP: 20004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/352,704
; FILING DATE: 28-Jan-2003
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/358,556A
; FILING DATE: 14-DEC-1994
; APPLICATION NUMBER: FR 9315164
; FILING DATE: 16-DEC-1993
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
;
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..18
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-352-704-18

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 1 AAAAAAAAAAAAAAAAAA 18

RESULT 37
US-08-525-864A-15
; Sequence 15, Application US/08525864A
; Patent No. 5912326
; GENERAL INFORMATION:
; APPLICANT: Chang, Han
; TITLE OF INVENTION: Cerebellum-derived Growth Factors, and Uses
; TITLE OF INVENTION: Related thereto
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII (text)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/525,864A
```

```
; FILING DATE: 8-SEP-1995
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: HUI-017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-525-864A-15

Query Match      0.3%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 58;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 19 GAATTCGGCAGCGGGAG 37
Db 1 GAATTCGGCAGCGGGAG 19

RESULT 38
US-09-696-791-1273/c
; Sequence 1273, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; FILE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1273
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk-we-hu ribozyme binding site
US-09-696-791-1273

Query Match      0.3%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 58;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1215 AGATCCTTCAACTCGGTT 1233
Db 19 AGATCCTTCAACTCGGTT 1

RESULT 39
US-08-665-220-6
; Sequence 6, Application US/08665220
; Patent No. 5786173
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; APPLICANT: Fernandes-Alnemri, Teresa
; APPLICANT: Litwack, Gerald
; APPLICANT: Armstrong, Robert
; APPLICANT: Tomaselli, Kevin
; TITLE OF INVENTION: Mch4 and Mch5, Apoptotic Proteases,
; TITLE OF INVENTION: Nucleic Acids Encoding and Methods of Use
; NUMBER OF SEQUENCES: 70
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
```

```
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/08/665,220
; APPLICATION NUMBER: US/08/665,220
; FILING DATE: 14-JUN-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/618,408
; FILING DATE: 19-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 2165
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..17
; OTHER INFORMATION: /note= "SK-Zap"
US-08-665-220-6

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CAGGAATTCGCACGAG 32
Db 1 CAGGAATTCGCACGAG 17

RESULT 40
US-08-618-408B-6
; Sequence 6, Application US/08618408B
; Patent No. 5851815
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; APPLICANT: Fernandes-Alnemri, Teresa
; APPLICANT: Litwack, Gerald
; APPLICANT: Armstrong, Robert
; APPLICANT: Tomaselli, Kevin
; TITLE OF INVENTION: Mch4 and Mch5, No. 5851815el Apoptotic
; TITLE OF INVENTION: Proteases, Nucleic Acids Encoding and Methods of Use
; NUMBER OF SEQUENCES: 63
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/618,408B
; FILING DATE: 19-MAR-1996
```

```
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Campbell, Cathryn A.
/ REGISTRATION NUMBER: 31,815
/ REFERENCE/DOCKET NUMBER: P-ID 1957
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (619) 535-9001
/ TELEFAX: (619) 535-8949
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: 1..17
/ OTHER INFORMATION: /note= "SK-Zap"
US-08-618-408B-6

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 41
US-09-257-218-5
; Sequence 5, Application US/09257218
; Patent No. 6271361
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; APPLICANT: Litwack, Gerald
; TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/257,218
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/865,579
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 2180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-9849
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-311-760-5

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 42
US-09-311-760-5
; Sequence 5, Application US/09311760
; Patent No. 6274318
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; APPLICANT: Litwack, Gerald
; TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/311,760
; FILING DATE: 13-May-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/865,579
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 2180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-9849
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-311-760-5

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 43
US-09-291-692-6
; Sequence 6, Application US/09291692
; Patent No. 6287795
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
```

```
US-09-257-218-5

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 42
US-09-311-760-5
; Sequence 5, Application US/09311760
; Patent No. 6274318
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; APPLICANT: Litwack, Gerald
; TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/311,760
; FILING DATE: 13-May-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/865,579
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 2180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-9849
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-311-760-5

Query Match      0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 43
US-09-291-692-6
; Sequence 6, Application US/09291692
; Patent No. 6287795
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
```

```

; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/865,579
; FILING DATE: 29-MAY-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 2180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-9849
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; US-08-865-579-5

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No.57;
Matches 17; Conservative 0; Mismatches 0; Indels 0;

QY 16 CAGGAATTCGGCAGCAG 32
DB 1 CAGGAATTCGGCAGCAG 17
|||||
|||||

RESULT 45
US-08-556-627A-6
; Sequence 6, Application US/08556627A
; Patent No. 6462175
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; APPLICANT: Fernandes-Alnemri, Teresa
; APPLICANT: Litwack, Gerald
; APPLICANT: Armstrong, Robert
; APPLICANT: Tomaselli, Kevin
; TITLE OF INVENTION: Mch3, A No. 6462175el Apoptotic Protease,
; TITLE OF INVENTION: Nucleic Acids Encoding and Methods of Use
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/556,627A
; FILING DATE: 13-NOV-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 1813
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-556-627A-6

```

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
|||||
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 46
US-10-059-749-5
; Sequence 5, Application US/10059749
; Patent No. 6566505
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; Fernandes-Alnemri, Teresa
; Litwack, Gerald
; TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
; Encoding Same and Methods of Use
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/059,749
; FILING DATE: 29-Jan-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/865,579
; FILING DATE: 29-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 2180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9849
; TELEFAX: (619) 535-9849
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:

US-10-059-749-5

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
|||||
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 47
US-09-163-099-6
; Sequence 6, Application US/09163099
; Patent No. 6686459
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; Fernandes-Alnemri, Teresa

; APPLICANT: Litwack, Gerald
; APPLICANT: Armstrong, Robert
; APPLICANT: Tomaselli, Kevin
; TITLE OF INVENTION: Mch3, A No. 6686459el Apoptotic Protease,
; Nucleic Acids Encoding and Methods of Use
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/163,099
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/556,627
; FILING DATE: 13-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-ID 1813
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-163-099-6

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGGAATTCGGCAGCAG 32
|||||
Db 1 CAGGAATTCGGCAGCAG 17

RESULT 48
US-10-337-060-6
; Sequence 6, Application US/10337060
; Patent No. 6716960
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; APPLICANT: Fernandez-Alnemri, Teresa
; APPLICANT: Litwack, Gerald
; APPLICANT: Armstrong, Robert
; APPLICANT: Tomaselli, Kevin
; TITLE OF INVENTION: MCH3, A NOVEL APOPTOTIC PROTEASE,
; NUCLEIC ACIDS ENCODING AND METHODS OF USE
; FILE REFERENCE: 480140.423D2
; CURRENT APPLICATION NUMBER: US/10/337,060
; CURRENT FILING DATE: 2003-01-02
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer SK-Zap
; US-10-337-060-6

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CAGGAATTCGCACGAG 32
| | | | | | | | | | | | | | | | | |
Db 1 CAGGAATTCGCACGAG 17

RESULT 49

US-09-952-768-6
; Sequence 6, Application US/09952768
; Patent No. 6730779

; GENERAL INFORMATION:

APPLICANT: Alnemri, Emad S.
; Fernandes-Alnemri, Teresa
; Litwack, Gerald
; Armstrong, Robert
; Tomaseilli, Kevin

TITLE OF INVENTION: MCH4 AND MCH5, APOPTOTIC PROTEASE,

NUCLEIC ACIDS ENCODING AND METHODS OF USE

NUMBER OF SEQUENCES: 75

CORRESPONDENCE ADDRESS:

ADDRESSEE: Seed Intellectual Property Law Group
STREET: Suite 6300, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/952,768

FILING DATE: 10-Sep-2001

CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: Christiansen, William T.

REGISTRATION NUMBER: 44,614

REFERENCE/DOCKET NUMBER: 480140.424C4

TELECOMMUNICATION INFORMATION:

TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

FEATURE:

NAME/KEY: misc feature

LOCATION: 1..17

OTHER INFORMATION: /note= "SK-Zap"

SEQUENCE DESCRIPTION: SEQ ID NO: 6:

US-09-952-768-6

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CAGGAATTCGCACGAG 32
| | | | | | | | | | | | | | | | | |
Db 1 CAGGAATTCGCACGAG 17

RESULT 50

US-09-766-253-132/c
; Sequence 132, Application US/09766253
; Patent No. 6808880

; GENERAL INFORMATION:

APPLICANT: Cech, Thomas R.
; Lingner, Joachim
; Nakamura, Toru
; Chapman, Karen B.
; Morin, Gregg B.
; Harley, Calvin
; Andrews, William H.
; TITLE OF INVENTION: NO. 680880e1 Telomerase
; NUMBER OF SEQUENCES: 171
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/766,253

FILING DATE: 19-Jan-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/846,017

FILING DATE: 1997-04-25

APPLICATION NUMBER: US 08/724,643

FILING DATE: 01-OCT-1996

ATTORNEY/AGENT INFORMATION:

NAME: Apple, Randolph T.

REGISTRATION NUMBER: 36,429

REFERENCE/DOCKET NUMBER: 015389-002920US

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 576-0200

TELEFAX: (415) 576-0300

INFORMATION FOR SEQ ID NO: 132:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 132:

US-09-766-253-132

Query Match 0.3%; Score 17; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 57;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5041
| | | | | | | | | | | | | | | | | |
Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 51

US-08-319-590-23/c

; Sequence 23, Application US/08319590

; Patent No. 5646115

; GENERAL INFORMATION:

APPLICANT: FRANK, GLENN R.

APPLICANT: WU HUNTER, SHIRLEY

APPLICANT: WALLENFELS, LYNDA

TITLE OF INVENTION: NOVEL ECTOPARASITE SALIVA PROTEINS AND

APPARATUS TO COLLECT SUCH PROTEINS

NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESS:

ADDRESSEE: SHERIDAN ROSS & MCINTOSH

STREET: 1700 LINCOLN ST., SUITE 3500

CITY: DENVER

STATE: CO

COUNTRY: USA

ZIP: 80203

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,590
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: VERSER, CAROL TALKINGTON
; REGISTRATION NUMBER: 37,459
; REFERENCE/DOCKET NUMBER: 2618-17
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 303/863-9700
; TELEFAX: 303/863-0223
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; US-08-319-590-23

Query Match      0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5069 AGGGGGGGCCCGGTACC 5085
Db      20 AGGGGGGGCCCGGTACC 4

RESULT 52
US-08-487-001A-23/c
; Sequence 23, Application US/08487001A
; Patent No. 5795862
; GENERAL INFORMATION:
; APPLICANT: FRANK, GLENN R.
; APPLICANT: HUNTER, SHIRLEY WU
; APPLICANT: WALLENFELS, LYNDA
; TITLE OF INVENTION: NOVEL ECTOPARASITE SALIVA
; NUMBER OF SEQUENCES: 54
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheridan Ross & McIntosh
; STREET: 1700 Lincoln Street, Suite 3500
; CITY: Denver
; STATE: Colorado
; COUNTRY: U.S.A.
; ZIP: 80203
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,001A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Verser, Carol Talkington
; REGISTRATION NUMBER: 37,459
; REFERENCE/DOCKET NUMBER: 2618-17-C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 863-9700
; TELEFAX: (303) 863-0223
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; US-08-487-001A-23
```

```
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; US-08-487-001A-23

Query Match      0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5069 AGGGGGGGCCCGGTACC 5085
Db      20 AGGGGGGGCCCGGTACC 4

RESULT 53
US-08-630-822A-23/c
; Sequence 23, Application US/08630822A
; Patent No. 5840695
; GENERAL INFORMATION:
; APPLICANT: FRANK, GLENN R.
; APPLICANT: HUNTER, SHIRLEY WU
; APPLICANT: WALLENFELS, LYNDA
; TITLE OF INVENTION: NOVEL ECTOPARASITE SALIVA PROTEINS
; NUMBER OF SEQUENCES: 107
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheridan Ross P.C.
; STREET: 1700 Lincoln Street, Suite 3500
; CITY: Denver
; STATE: Colorado
; COUNTRY: U.S.A.
; ZIP: 80203
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/630,822A
; FILING DATE: 11-APR-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: CONNELL, GARY J.
; REGISTRATION NUMBER: 32,020
; REFERENCE/DOCKET NUMBER: 2618-17-C3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 863-9700
; TELEFAX: (303) 863-0223
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; US-08-630-822A-23

Query Match      0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5069 AGGGGGGGCCCGGTACC 5085
Db      20 AGGGGGGGCCCGGTACC 4

RESULT 54
US-08-711-905-23/c
; Sequence 23, Application US/08711905
; Patent No. 5927230
; GENERAL INFORMATION:
; APPLICANT: FRANK, GLENN R.
; APPLICANT: WU HUNTER, SHIRLEY
; APPLICANT: WALLENFELS, LYNDA
```


;/ TITLE OF INVENTION: NOVEL ECTOPARASITE SALIVA PROTEINS AND
;/ TITLE OF INVENTION: APPARATUS TO COLLECT SUCH PROTEINS
;/ NUMBER OF SEQUENCES: 26
;/ CORRESPONDENCE ADDRESS:
;/ ADDRESSEE: SHERIDAN ROSS & MCINTOSH
;/ STREET: 1700 LINCOLN ST., SUITE 3500
;/ CITY: DENVER
;/ STATE: CO
;/ COUNTRY: USA
;/ ZIP: 80203
;/ COMPUTER READABLE FORM:
;/ MEDIUM TYPE: Floppy disk
;/ COMPUTER: IBM PC compatible
;/ OPERATING SYSTEM: PC-DOS/MS-DOS
;/ SOFTWARE: PatentIn Release #1.0, Version #1.25
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/08/711,905
;/ FILING DATE:
;/ CLASSIFICATION:
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: VERSER, CAROL TALKINGTON
;/ REGISTRATION NUMBER: 37,459
;/ REFERENCE/DOCKET NUMBER: 2618-17
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: 303/863-9700
;/ TELEFAX: 303/863-0223
;/ INFORMATION FOR SEQ ID NO: 23:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: DNA (primer)
;/ US-08-711-905-23
;
Query Match 0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Oy 5069 AGGGGGGCGCGGTACC 5085
Db 20 AGGGGGGCGCGGTACC 4
;
RESULT 55
US-09-005-069-23/c
; Sequence 23, Application US/09005069
; Patent No. 5932470
; GENERAL INFORMATION:
; APPLICANT: FRANK, GLENN R.
; APPLICANT: HUNTER, SHIRLEY WU
; APPLICANT: WALLENFELS, LYNDIA
; TITLE OF INVENTION: NOVEL ECTOPARASITE SALIVA PROTEINS
; TITLE OF INVENTION: AND APPARATUS TO COLLECT SUCH PROTEINS
; NUMBER OF SEQUENCES: 107
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheridan Ross P.C.
; STREET: 1700 Lincoln Street, Suite 3500
; CITY: Denver
; STATE: Colorado
; COUNTRY: U.S.A.
; ZIP: 80203
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/005,069
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/630,822

;/ FILING DATE: 11-APR-1996
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: CONNELL, GARY J.
;/ REGISTRATION NUMBER: 32,020
;/ REFERENCE/DOCKET NUMBER: 2618-17-C3
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (303) 863-9700
;/ TELEFAX: (303) 863-0223
;/ INFORMATION FOR SEQ ID NO: 23:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: DNA (primer)
;/ US-09-005-069-23
;
Query Match 0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Oy 5069 AGGGGGGCGCGGTACC 5085
Db 20 AGGGGGGCGCGGTACC 4
;
RESULT 56
US-09-467-642-10/c
; Sequence 10, Application US/09467642
; Patent No. 6300132
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 2 EXPRES
; FILE REFERENCE: RTS-0106
; CURRENT APPLICATION NUMBER: US/09/467,642
; CURRENT FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-467-642-10
;
Query Match 0.3%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Oy 18 GGAATTCGGCACGAGGG 34
Db 20 GGAATTCGGCACGAGGG 4
;
RESULT 57
US-08-882-046-44
; Sequence 44, Application US/08882046
; Patent No. 6136952
; GENERAL INFORMATION:
; APPLICANT: Li, Linheng
; APPLICANT: Hood, Leroy
; APPLICANT: Krantz, Ian D.
; APPLICANT: Spinner, Nancy B.
; TITLE OF INVENTION: Human Jagged Polypeptide, Encoding
; TITLE OF INVENTION: Nucleic Acids and Methods of Use
; NUMBER OF SEQUENCES: 110
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA

```

;
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-UW 4164
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (858) 535-9001
; TELEFAX: (858) 535-8949
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: intron
; LOCATION: 1..10
; FEATURE:
; NAME/KEY: exon
; LOCATION: 11..20
; SEQUENCE DESCRIPTION: SEQ ID NO: 44:
US-09-566-047-44
Query Match 0.3%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 2; Indels

Qy      622 TATTTTTCAGATATTTCATGA 641
          ||||| ||||| ||||| |||||
Db       1 TATTTTTCAGATATTTCATGA 20

RESULT 59
US-08-980-071-52
; Sequence 52, Application US/08980071
; Patent No. 5914318
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; APPLICANT: Gilmer, Amy Jelen
; APPLICANT: Mettus, Anne-Marie Light
; TITLE OF INVENTION: TRANSGENIC PLANTS EXPRESSING
; TITLE OF INVENTION: LEPIDOPTERAN-ACTIVE-DELTA-ENDOTOXINS
; NUMBER OF SEQUENCES: 76
CORRESPONDENCE ADDRESS:
STREET: Arnold, White & Durkee
P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/980,071
FILING DATE: Concurrently Herewith
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/757,536
FILING DATE: 27-NOV-1996
ATTORNEY/AGENT INFORMATION:
NAME: Kitchell, Barbara S.
REGISTRATION NUMBER: 33,928
REFERENCE/DOCKET NUMBER: MECO:206
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

```

US-08-980-071-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
||||| ||||| ||||| |||||
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 60
US-08-757-536-52
; Sequence 52, Application US/08757536
; Patent No. 5942664
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; APPLICANT: Gilmer, Amy Jelen
; APPLICANT: Mettus, Anne-Marie Light
; TITLE OF INVENTION: Bacillus thuringiensis CryIC
; TITLE OF INVENTION: Compositions Toxic to Lepidopteran Insects and Methods for
; TITLE OF INVENTION: Making CryIC Mutants
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White and Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: US/08/757,536
; APPLICATION NUMBER: 52
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/980,071
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kitchell, Barbara S.
; REGISTRATION NUMBER: 33,928
; REFERENCE/DOCKET NUMBER: MECO:206
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-314-093-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
||||| ||||| ||||| |||||
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 61
US-09-314-093-52
; Sequence 52, Application US/09314093
; Patent No. 6033874
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; APPLICANT: Gilmer, Amy Jelen
; APPLICANT: Mettus, Anne-Marie Light
; TITLE OF INVENTION: TRANSGENIC PLANTS EXPRESSING
; TITLE OF INVENTION: LEPIDOPTERAN-ACTIVE DELTA-ENDOTOXINS

NUMBER OF SEQUENCES: 76
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/314,093
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/980,071
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Kitchell, Barbara S.
REGISTRATION NUMBER: 33,928
REFERENCE/DOCKET NUMBER: MECO:206
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-314-093-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
||||| ||||| ||||| |||||
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 62
US-09-250-848-52
; Sequence 52, Application US/09250848
; Patent No. 6153814
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; APPLICANT: Gilmer, Amy Jelen
; APPLICANT: Mettus, Anne-Marie Light
; TITLE OF INVENTION: Bacillus thuringiensis CryIC
; TITLE OF INVENTION: Compositions Toxic to Lepidopteran Insects and Methods for
; TITLE OF INVENTION: Making CryIC Mutants
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White and Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/250,848
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: US/08/757,536
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kitchell, Barbara
; REGISTRATION NUMBER: 33,928
; REFERENCE/DOCKET NUMBER: MOBT:023
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-250-848-52

Query Match          0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GGATCCCCCGGCTGCAGGA 20
DB 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 63
US-09-251-885-52
; Sequence 52, Application US/09251885
; Patent No. 6177615
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; APPLICANT: Gilmer, Amy Jelen
; APPLICANT: Mettus, Anne-Marie Light
; TITLE OF INVENTION: Bacillus thuringiensis CryIc
; TITLE OF INVENTION: Compositions Toxic to Lepidopteran Insects and Methods for
; TITLE OF INVENTION: Making CryIc Mutants
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White and Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION NUMBER: US/09/251,885
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,536
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kitchell, Barbara
; REGISTRATION NUMBER: 33,928
; REFERENCE/DOCKET NUMBER: MOBT:023
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-251-885-52

Query Match          0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GGATCCCCCGGCTGCAGGA 20
DB 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 64
US-09-337-635-52
; Sequence 52, Application US/09337635
; Patent No. 6313378
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; APPLICANT: Gilmer, Amy Jelen
; APPLICANT: Mettus, Anne-Marie Light
; TITLE OF INVENTION: TRANSGENIC PLANTS EXPRESSING
; TITLE OF INVENTION: LEPIDOPTERAN-ACTIVE-DELTA-ENDOTOXINS
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION NUMBER: US/09/337,635
; FILING DATE: 21-Jun-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/980,071
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Kitchell, Barbara S.
; REGISTRATION NUMBER: 33,928
; REFERENCE/DOCKET NUMBER: MECO:206
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 52:
US-09-337-635-52

Query Match          0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GGATCCCCCGGCTGCAGGA 20
DB 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 65
US-09-337-280-52
; Sequence 52, Application US/09337280
; Patent No. 6423828
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; APPLICANT: Gilmer, Amy Jelen
; APPLICANT: Mettus, Anne-Marie Light
; TITLE OF INVENTION: TRANSGENIC PLANTS EXPRESSING
; TITLE OF INVENTION: LEPIDOPTERAN-ACTIVE-DELTA-ENDOTOXINS
```

```
/
/ NUMBER OF SEQUENCES: 76
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Arnold, White & Durkee
/ STREET: P.O. Box 4433
/ CITY: Houston
/ STATE: Texas
/ COUNTRY: USA
/ ZIP: 77210
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/337,280
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/980,071
/ FILING DATE:
/ APPLICATION NUMBER: US 08/757,536
/ FILING DATE: 27-NOV-1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kitchell, Barbara S.
/ REGISTRATION NUMBER: 33,928
/ REFERENCE/DOCKET NUMBER: MECO:206
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 512/418-3000
/ TELEFAX: 512/474-7577
/ INFORMATION FOR SEQ ID NO: 52:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 22 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-09-337-280-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 66
US-09-972-175-52
; Sequence 52, Application US/09972175
; Patent No. 6809078
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; Gilmer, Amy Jelen
; Mettus, Anne-Marie Light
; TITLE OF INVENTION: TRANSGENIC PLANTS EXPRESSING
; LEPIDOPTERAN-ACTIVE-DELTA-ENDOTOXINS
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/972,175
; FILING DATE: 05-Oct-2001
; CLASSIFICATION: <Unknown>
```

```
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 09/337,635
/ FILING DATE: <Unknown>
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kitchell, Barbara S.
/ REGISTRATION NUMBER: 33,928
/ REFERENCE/DOCKET NUMBER: MECO:206
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 512/418-3000
/ TELEFAX: 512/474-7577
/ INFORMATION FOR SEQ ID NO: 52:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 22 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ SEQUENCE DESCRIPTION: SEQ ID NO: 52:
US-09-972-175-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 67
US-10-200-522-52
; Sequence 52, Application US/10200522
; Patent No. 6825006
; GENERAL INFORMATION:
; APPLICANT: Baum, James A.
; Gilmer, Amy Jelen
; Mettus, Anne-Marie Light
; TITLE OF INVENTION: NUCLEIC ACID AND POLYPEPTIDE COMPOSITIONS ENCODING LEPIDOPTERAN-T
; FILE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: MECO:213 (11792,0213 DVUS01)
; CURRENT APPLICATION NUMBER: US/10/200,522
; CURRENT FILING DATE: 2002-07-22
; PRIOR APPLICATION NUMBER: 09/337,280
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 08/980,071
; PRIOR FILING DATE: 1997-11-26
; PRIOR APPLICATION NUMBER: 08/757,536
; PRIOR FILING DATE: 1996-11-27
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 52
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-200-522-52

Query Match 0.3%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGATCCCCCGGCTGCAGGA 20
Db 1 GGATCCCTCGAGCTGCAGGA 20

RESULT 68
US-09-904-744-2/c
; Sequence 2, Application US/09904744
; Patent No. 6828142
; GENERAL INFORMATION:
; APPLICANT: Barbera-Guillem, Emilio
; APPLICANT: Nelson, M. Bud
```

```
; APPLICANT: Castro, Stephanie
; TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
; FILE OF INVENTION: dendrimers in a signal amplification system
; FILE REFERENCE: B-73
; CURRENT APPLICATION NUMBER: US/09/904,744
; PRIOR FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/437076
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/107828
; PRIOR FILING DATE: 1998-11-10
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthesized
US-09-904-744-2

Query Match          0.3%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5050 AAAAAAAAAAAAACTC 5067
Db 18 AAAAAAAAAAAAAACCC 1

RESULT 69
US-09-308-003-31
; Sequence 31, Application US/09308003
; Patent No. 6326170
; GENERAL INFORMATION:
; APPLICANT: Burnham, Martin K. R.
; APPLICANT: Lonetto, Michael A.
; APPLICANT: Warren, Patrick V.
; TITLE OF INVENTION: NOVEL PROKARYOTIC POLYNUCLEOTIDES,
; TITLE OF INVENTION: POLYPEPTIDES AND THEIR USES
; FILE REFERENCE: GM10093
; CURRENT APPLICATION NUMBER: US/09/308,003
; CURRENT FILING DATE: 1999-05-10
; EARLIER APPLICATION NUMBER: 60/058,710
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 31
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Staphylococcus aureus
US-09-308-003-31

Query Match          0.3%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 18 GGAATTCGCACGAGGG 35
Db 1 GGAATTCGCACGAGCGG 18

RESULT 70
US-09-844-634-57
; Sequence 57, Application US/09844634
; Patent No. 6410324
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0216
; CURRENT APPLICATION NUMBER: US/09/844,634
; CURRENT FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 174
```

```
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-844-634-57

Query Match          0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4106 GTCATCTTCACAGGCTC 4123
Db 1 GTCATCTGCACGGGCTC 18

RESULT 71
US-09-554-726A-29
; Sequence 29, Application US/09554726A
; Patent No. 6642369
; GENERAL INFORMATION:
; APPLICANT: HERRMANN, Bernhard
; APPLICANT: KOSCHORZ, Birgit
; APPLICANT: KISPERT, Andreas
; TITLE OF INVENTION: NUCLEIC ACIDS INVOLVED IN THE RESPONDER PHENOTYPE AND APPLICATIONS
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 258.0009.0101
; CURRENT APPLICATION NUMBER: US/09/554,726A
; CURRENT FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: PCT/EP 98/07395
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: EP 98 10 3596.7
; PRIOR FILING DATE: 1998-03-02
; PRIOR APPLICATION NUMBER: EP 97 12 0190.0
; PRIOR FILING DATE: 1997-11-18
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-554-726A-29

Query Match          0.3%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3412 CAGCAAAAGCGGAGCAG 3429
Db 3 CAGCAAAAGCAGGAGCAG 20

RESULT 72
US-09-802-320A-22/c
; Sequence 22, Application US/09802320A
; Patent No. 6833240
; GENERAL INFORMATION:
; APPLICANT: Engert, James
; APPLICANT: Vohl, Marie-Claude
; APPLICANT: Brewer, Carl
; APPLICANT: Morgan, Kenneth
; APPLICANT: Gaudet, Daniel
; APPLICANT: Hudson, Thomas
; TITLE OF INVENTION: Very Low Density Lipoprotein Receptor
; TITLE OF INVENTION: Polymorphisms and Uses Therefor
; FILE REFERENCE: 2825.2001-001
; CURRENT APPLICATION NUMBER: US/09/802,320A
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/187,787
; PRIOR FILING DATE: 2000-03-08
```

```
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-802-320A-22

Query Match      0.3%; Score 16.4; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 87;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3576 TGAACACTCATTCTTTGCAA 3595
Db 20 TGAACACTCGTCTTTGCAA 1

RESULT 73
US-10-105-101A-23/c
; Sequence 23, Application US/10105101A
; Patent No. 6825009
; GENERAL INFORMATION:
; APPLICANT: Variagenics, Inc
; TITLE OF INVENTION: A Method for Identifying Polymorphisms
; FILE REFERENCE: 272/160
; CURRENT APPLICATION NUMBER: US/10/105,101A
; CURRENT FILING DATE: 2002-09-30
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: G allele fragment of hypothetical sequence of Fig. 37.
US-10-105-101A-23

Query Match      0.3%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 92;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3757 GGTGCTGTCCAGTCTTTGGA 3777
Db 21 GGTGCTGTCCAGTCTTCCGA 1

RESULT 74
US-09-766-253-131
; Sequence 131, Application US/09766253
; Patent No. 6808880
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; LINGNER, Joachim
; NAKAMURA, Toru
; CHAPMAN, Karen B.
; MORIN, Gregg B.
; HARLEY, Calvin
; ANDREWS, William H.
; TITLE OF INVENTION: No. 6808880el Telomerase
; NUMBER OF SEQUENCES: 171
; CORRESPONDENCE ADDRESS:
; STREET: Townsend and Crew LLP
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
```

```
; APPLICATION NUMBER: US/09/766,253
; FILING DATE: 19-Jan-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/846,017
; FILING DATE: 1997-04-25
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002920US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-09-766-253-131

Query Match      0.3%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAA 5040
Db 1 AAAAAAAAAAAAAAA 16

RESULT 75
US-09-685-664B-1074/c
; Sequence 1074, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1074
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1074

Query Match      0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAA 5040
Db 17 AAAAAAAAAAAAAAA 2

RESULT 76
US-09-685-664B-1075/c
```

```
; Sequence 1075, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1075
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1075

Query Match          0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5025 AAAAAAAAAAAAAA 5040
Db 16 AAAAAAAAAAAAAA 1

RESULT 77
US-09-090-672B-105/c
; Sequence 105, Application US/09090672B
; Patent No. 6828428
; GENERAL INFORMATION:
; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,
; APPLICANT: Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
; APPLICANT: Shigemasa; Takei, Masami
; TITLE OF INVENTION: Iga Nephropathy-Related Genes
; NUMBER OF SEQUENCES: 111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; ZIP: 10112-3801
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: Compaq PC
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/090,672B
; FILING DATE: 04-JUNE-1998
; CLASSIFICATION: 514
; PRIOR APPLICATION NUMBER: PCT/JP97/04468
; FILING DATE: 05-DEC-1996
; APPLICATION NUMBER: JP-8-325763
; FILING DATE: 05-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Perry, Lawrence S.
; REGISTRATION NUMBER: 31865
; REFERENCE/DOCKET NUMBER: 766.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 218-2100
; TELEFAX: (212) 218-2200
; INFORMATION FOR SEQ ID NO: 106:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-106

Query Match          0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5050 AAAAAAAAAAAAAA 5065
Db 16 AAAAAAAAAAAAAA 1

; INFORMATION FOR SEQ ID NO: 105:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-105

Query Match          0.3%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5024 TAAAAAAAAAAAAA 5039
Db 17 TAAAAAAAAAAAAA 2
```



```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/065,058
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO 97JP3232
; FILING DATE: 12-SEP-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 96243720
; FILING DATE: 13-SEP-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: KILYK JR., JOHN
; REGISTRATION NUMBER: 30763
; REFERENCE/DOCKET NUMBER: 72882
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 616-5600
; TELEFAX: (312) 616-5700
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE: 3'-end is labeled with biotin and 5'-end phosphorylated
US-09-065-058-1

Query Match 0.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 93; Mismatches 0; Indels 0;
Matches 16; Conservative 0;

QY 1 GGATCCCCCGGGCTGC 16
DB 5 GGATCCCCCGGGCTGC 20
|||||
|||||

RESULT 81
US-09-439-616-6
; Sequence 6, Application US/09439616
; Patent No. 6306612
; GENERAL INFORMATION:
; APPLICANT: Schwarz, Margaret A.
; APPLICANT: Zhang, Fangrong
; APPLICANT: Gebb, Sarah A.
; TITLE OF INVENTION: Methods of Facilitating Vascular Growth
; FILE REFERENCE: ENAP2 and Vascularization
; CURRENT APPLICATION NUMBER: US/09/439,616
; CURRENT FILING DATE: 1999-11-12
; EARLIER APPLICATION NUMBER: 60/108,435
; EARLIER FILING DATE: 1998-11-13
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-439-616-6

Query Match 0.3%; Score 16; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 98; Mismatches 0; Indels 0;
Matches 16; Conservative 0;

QY 2988 GAGCCATCTTCATGAT 3003
|||||
|||||

```

```

;
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30

```

```
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/474,177
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03537
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348-E
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-8300
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
;
; US-08-474-177-8
;
; Query Match 0.3%; Score 15.8; DB 1; Length 20;
; Best Local Similarity 89.5%; Pred. No. 98;
; Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; QY 4079 GGTTCAGTTCCTCAATTC 4097
; Db 20 GCTTCCAGTTTCCAATTC 2
;
; RESULT 86
; US-08-487-033-8/c
; Sequence 8, Application US/08487033
; Patent No. 5739027
; GENERAL INFORMATION:
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: MTS1-Beta GENE
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,033
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
```

```
;
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03316
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348-C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-8300
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
;
; US-08-487-033-8
;
; Query Match 0.3%; Score 15.8; DB 1; Length 20;
; Best Local Similarity 89.5%; Pred. No. 98;
; Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; QY 4079 GGTTCAGTTCCTCAATTC 4097
; Db 20 GCTTCCAGTTTCCAATTC 2
;
; RESULT 87
; US-08-480-810-8/c
; Sequence 8, Application US/08480810
; Patent No. 5801236
; GENERAL INFORMATION:
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: MTS1 GENE
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/480,810
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
```

gibbs-10-667-022-4.rni

Thu Aug 18 08:45:54 2005

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03316
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-8300
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-08-508-735-8

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCCAGTTTCCAATTC 2

RESULT 89
US-08-848-251-8/c
; Sequence 8, Application US/08848251
; Patent No. 5989815
; GENERAL INFORMATION:
; APPLICANT: Skolnick, Mark H.
; APPLICANT: Cannon-Albright, Lisa A.
; TITLE OF INVENTION: GERMINE MUTATIONS IN THE MTS GENE AND
; TITLE OF INVENTION: METHOD FOR DETECTING PREDISPOSITION TO CANCER AT THE MTS
; TITLE OF INVENTION: GENE
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/848,251
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/474,083
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: PCT/US95/03537
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE:
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03316
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-8300
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-08-480-810-8

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTC 4097
Db 20 GCTTCCAGTTTCCAATTC 2

RESULT 88
US-08-508-735-8/c
; Sequence 8, Application US/08508735
; Patent No. 5843756
; GENERAL INFORMATION:
; APPLICANT: Stone, Steven
; APPLICANT: Jiang, Ping
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: MTS GENE AND THERAPEUTIC USE THEREOF
; NUMBER OF SEQUENCES: 47
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/508,735
; FILING DATE:
; CLASSIFICATION: 435

```

; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348-G
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-4810
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-08-848-251-8

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCACAGTTCCTCAATTC 4097
Db 20 GCTTCCAGTTTCCCAATTC 2

RESULT 90
US-08-486-047-8/c
; Sequence 8, Application US/08486047
; Patent No. 5994095
; GENERAL INFORMATION:
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: MTS2 GENE
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,047
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03316
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348-B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-4810
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-08-486-047-8

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCACAGTTCCTCAATTC 4097
Db 20 GCTTCCAGTTTCCCAATTC 2

RESULT 91
US-09-120-130-8/c
; Sequence 8, Application US/09120130
; Patent No. 6037462
; GENERAL INFORMATION:
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: MTS1 GENE
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/120,130
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/480,810
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994

gibbs-10-667-022-4.rni

Thu Aug 18 08:45:54 2005

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-8300
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
;
; US-09-115-252-8
;
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTC 4097
| | | | | | | | | | | | | | | | | |
Db 20 GCTTCCAGTTTCCAATTC 2

RESULT 92
US-09-115-252-8/c
; Sequence 8, Application US/09115252
; Patent No. 6060301
; GENERAL INFORMATION:
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: MTS1 GENE
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/115,252
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/480,810
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: PCT/US95/03316
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-8300
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
;
; US-09-115-252-8
;
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTC 4097
| | | | | | | | | | | | | | | | | |
Db 20 GCTTCCAGTTTCCAATTC 2

RESULT 93
US-08-467-023-167/c
; Sequence 167, Application US/08467023
; Patent No. 6090386
; GENERAL INFORMATION:
; APPLICANT: Griffith, Irwin J.;
; APPLICANT: Pollock, Joanne;
; APPLICANT: Bond, Julian F.;
; APPLICANT: Garman, Richard D.;
; APPLICANT: Kuo, Mei-Chang;
; APPLICANT: Yeung, Siu-mei H.;
; APPLICANT: Brauer, Andrew;
; APPLICANT: Exley, Mark A.;
; APPLICANT: Powers, Steven P.
; TITLE OF INVENTION: Allergenic Proteins And Peptides From
; TITLE OF INVENTION: Japanese Cedar Pollen
; NUMBER OF SEQUENCES: 261
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Immunologic Pharmaceutical Corporation, Inc.
; STREET: 610 Lincoln St
; CITY: Waltham
; STATE: MA
; COUNTRY: USA
; ZIP: 02154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,023
; FILING DATE: June 6, 1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/350,225
; FILING DATE: December 6, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane E. Remillard

```

REGISTRATION NUMBER: 38,872
REFERENCE/DOCKET NUMBER: 025.6 USD2 (IMI-028CPD2)
TELEPHONE: (617) 227-7400
TELEFAX: (617) 227-5941
INFORMATION FOR SEQ ID NO: 167:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-467-023-167

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 57 GCAGCAGCTGAAGTGTACT 75
Db 20 GCAGAAAGCTGAAGTGCAGT 2

RESULT 94
US-08-986-515-8/c
Sequence 8, Application US/08986515
Patent No. 6090578
GENERAL INFORMATION:
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS1 GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/986,515
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/480,810
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-986-515-8
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 4079 GGTTCACAGTTCCTCAATTC 4097
Db 20 GCTTCCAGTTTCCAATTC 2
RESULT 95
US-09-120-128-8/c
Sequence 8, Application US/09120128
Patent No. 6140473
GENERAL INFORMATION:
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS2 GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/120,128
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/486,047
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: PCT/US95/03316
FILING DATE: 17-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348-B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-09-120-128-8

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTTC 4097
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GCTTCAGTTTCCAATTTC 2

RESULT 96

US-09-120-129-8/c
Sequence 8, Application US/09120129
Patent No. 6180776
GENERAL INFORMATION:
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS2 GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/120,129
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/486,047
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: PCT/US95/03316
FILING DATE: 17-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348-B
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-09-120-129-8

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTTC 4097
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GCTTCAGTTTCCAATTTC 2

RESULT 97

US-09-201-139-8/c
Sequence 8, Application US/09201139
Patent No. 6210949
GENERAL INFORMATION:
APPLICANT: Stone, Steven
APPLICANT: Jiang, Ping
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS GENE AND THERAPEUTIC USE THEREOF
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/201,139
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/508,735
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03316
FILING DATE: 17-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348
TELEPHONE: 202-962-4848
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-09-201-139-8

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTTC 4097
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GCTTCCAGTTTCCAATTTC 2

RESULT 98

US-09-120-131-8/c
; Sequence 8, Application US/09120131
; Patent No. 6218146
; GENERAL INFORMATION:
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: MTS2 GENE
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/120.131
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/486,047
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: PCT/US95/03316
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348-B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-4810
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-09-120-131-8

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4079 GGTTCAGTTGCCAATTTC 4097
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GCTTCCAGTTTCCAATTTC 2

RESULT 99

US-09-662-250A-36/c
; Sequence 36, Application US/09662250A
; Patent No. 6368856
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHORYLASE KINASE BETA EXPRESSION
; FILE REFERENCE: RTS-0129
; CURRENT APPLICATION NUMBER: US/09/662.250A
; CURRENT FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 102
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-662-250A-36
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3672 TCTTACATACAGCGCAATT 3690
| | | | | | | | | | | | | | | | | | | | | |
Db 19 TCTTGCATACAGCGCAATT 1
RESULT 100
US-09-844-634-138/c
; Sequence 138, Application US/09844634
; Patent No. 6410324
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0216
; CURRENT APPLICATION NUMBER: US/09/844.634
; CURRENT FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-844-634-138
Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 4489 CAGAAAGTAGGACCAAGTG 4507
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CAGCAAGTAGGACCAAGTG 2
RESULT 101
US-09-322-409-143
; Sequence 143, Application US/09322409
; Patent No. 6471957
; GENERAL INFORMATION:
; APPLICANT: Sim, Gek-Kee
US-09-322-409-143

```
; APPLICANT: Yang, Shumin
; APPLICANT: Dreitz, Matthew J.
; APPLICANT: Wonderling, Ramani S.
; TITLE OF INVENTION: CANINE AND FELINE IMMUNOREGULATORY PROTEINS, NUCLEIC
; TITLE OF INVENTION: ACID MOLECULES, AND USES THEREOF
; FILE REFERENCE: IM-2-C1
; CURRENT APPLICATION NUMBER: US/09/322,409
; CURRENT FILING DATE: 1999-05-28
; EARLIER APPLICATION NUMBER: 60/087,306
; EARLIER FILING DATE: 1998-05-29
; NUMBER OF SEQ ID NOS: 154
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 143
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-09-322-409-143

Query Match          0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3920 ATGGCTCTCTGGTTGGCTG 3938
      ||||| ||||| ||||| |||||
Db 1 ATGGCGCTCTGGTTGACTG 19

RESULT 102
US-09-451-527-143
; Sequence 143, Application US/09451527
; Patent No. 6482403
; GENERAL INFORMATION:
; APPLICANT: Sim, Gek-kee
; APPLICANT: Yang, Shumin
; APPLICANT: Dreitz, Matthew J.
; APPLICANT: Wonderling, Ramani S.
; TITLE OF INVENTION: CANINE AND FELINE IMMUNOREGULATORY PROTEINS, NUCLEIC
; TITLE OF INVENTION: ACID MOLECULES, AND USES THEREOF
; FILE REFERENCE: IM-2-C2
; CURRENT APPLICATION NUMBER: US/09/451,527
; CURRENT FILING DATE: 1999-12-01
; EARLIER APPLICATION NUMBER: 09/322,409
; EARLIER FILING DATE: 1999-05-28
; EARLIER APPLICATION NUMBER: 60/087,306
; EARLIER FILING DATE: 1998-05-29
; NUMBER OF SEQ ID NOS: 174
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 143
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-09-451-527-143

Query Match          0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3920 ATGGCTCTCTGGTTGGCTG 3938
      ||||| ||||| ||||| |||||
Db 1 ATGGCGCTCTGGTTGACTG 19

RESULT 103
US-09-645-021-5
; Sequence 5, Application US/09645021
; Patent No. 6589726
; GENERAL INFORMATION:
; APPLICANT: Yang, Shumin
; APPLICANT: Dreitz, Matthew J.
; APPLICANT: Wonderling, Ramani S.
; TITLE OF INVENTION: CANINE AND FELINE IMMUNOREGULATORY PROTEINS, NUCLEIC
; TITLE OF INVENTION: ACID MOLECULES, AND USES THEREOF
; FILE REFERENCE: IM-2-C1
; CURRENT APPLICATION NUMBER: US/09/322,409
; CURRENT FILING DATE: 1999-05-28
; EARLIER APPLICATION NUMBER: 60/087,306
; EARLIER FILING DATE: 1998-05-29
; NUMBER OF SEQ ID NOS: 154
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 143
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-09-322-409-143
```

```
; APPLICANT: Butler, John H.
; APPLICANT: Brennan, Thomas M.
; TITLE OF INVENTION: METHOD AND APPARATUS FOR IN SITU SYNTHESIS ON A SOLID SUPPORT
; FILE REFERENCE: 05871.0002.CPUS04
; CURRENT APPLICATION NUMBER: US/09/645,021
; CURRENT FILING DATE: 2000-08-23
; PRIOR APPLICATION NUMBER: 09/314,456
; PRIOR FILING DATE: 1999-05-18
; PRIOR APPLICATION NUMBER: 08/465,761
; PRIOR FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-09-645-021-5

Query Match          0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4769 TGACTGACTGACTAAATGA 4787
      ||||| ||||| ||||| |||||
Db 2 TGACTGACTGACTGACTGA 20

RESULT 104
US-09-456-090A-4/c
; Sequence 4, Application US/09456090A
; Patent No. 6680209
; GENERAL INFORMATION:
; APPLICANT: Buechler, Joe
; APPLICANT: Valkirs, Gunars
; APPLICANT: Gray, Jeff
; APPLICANT: Lonberg, Nils
; TITLE OF INVENTION: HUMAN ANTIBODIES AS DIAGNOSTIC REAGENTS
; FILE REFERENCE: 020015-000200US
; CURRENT APPLICATION NUMBER: US/09/456,090A
; CURRENT FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Oligo 952
US-09-456-090A-4

Query Match          0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 366 CCTCCACCACAGCCCATC 384
      ||||| ||||| ||||| |||||
Db 19 CCTCCACCAGGGCCCATC 1

RESULT 105
US-08-227-800A-6/c
; Sequence 6, Application US/08227800A
; Patent No. 6689561
; GENERAL INFORMATION:
; APPLICANT: CARSON, DENNIS A.
; APPLICANT: NOBORI, TSUTOMU
; TITLE OF INVENTION: TUMOR SUPPRESSOR GENE AND METHODS FOR
; TITLE OF INVENTION: DETECTION OF CANCER, MONITORING OF TUMOR PROGRESSION AND CANCE
; TITLE OF INVENTION: TREATMENT
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
```

ADDRESS: Fish & Richardson P.C.
STREET: 4225 Executive Square, Suite 1400
CITY: La Jolla
STATE: California
COUNTRY: US
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA: US/08/227,800A
APPLICATION NUMBER: US/08/227,800A
FILING DATE: 14-APR-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: HOWELLS, STACY L.
REGISTRATION NUMBER: 34,842
REFERENCE/DOCKET NUMBER: 07340/023001
TELEPHONE: 619/678-5070
TELEFAX: 619/678-5099
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE: DNA (genomic)
CLONE: CDK41' primer
FEATURE:
NAME/KEY: CDS
LOCATION: 1..20
US-08-227-800A-6

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTGCCAATTTC 4097
Db 20 GCTTCCAGTTTCCAATTTC 2

RESULT 106
US-08-921-954-6/c
Sequence 6, Application US/08921954
Patent No. 6689864
GENERAL INFORMATION:
APPLICANT: Carson, Dennis A.
No. 6689864ori, Tautomu
TITLE OF INVENTION: Tumor Suppressor Gene and Methods for
Detection of Cancer, Monitoring of Tumor Progression and
Cancer Treatment
NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/921,954
FILING DATE: 26-Aug-1997
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/908,671A
FILING DATE: 18-Jul-2001
APPLICATION NUMBER: US 08/921,954
FILING DATE: 20-AUG-1997
ATTORNEY/AGENT INFORMATION:
NAME: Hinisch, Matthew E.
REGISTRATION NUMBER: 47,651
REFERENCE/DOCKET NUMBER: 023070-104042US
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: -
LOCATION: 1..20
OTHER INFORMATION: /note= "CDK41' primer"
SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-08-921-954-6

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4079 GGTTCAGTTGCCAATTTC 4097
Db 20 GCTTCCAGTTTCCAATTTC 2

RESULT 107
US-09-453-234-4/c
Sequence 4, Application US/09453234
Patent No. 6794132
GENERAL INFORMATION:
APPLICANT: Buechler, Joe
APPLICANT: Walkers, Gunars
APPLICANT: Gray, Jeff
APPLICANT: Lonberg, Nils
APPLICANT: Biosite Diagnostics, Inc.
APPLICANT: GenPharm International
TITLE OF INVENTION: Human Antibodies
FILE REFERENCE: 020015-000110US
CURRENT APPLICATION NUMBER: US/09/453,234
CURRENT FILING DATE: 1999-12-01
PRIOR APPLICATION NUMBER: US 60/157,415
PRIOR FILING DATE: 1999-10-02
NUMBER OF SEQ ID NOS: 112
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 4
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Oligo 952
US-09-453-234-4

Query Match 0.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 366 CCTCCACCAACGCCCATC 384
Db 19 CCTCCACCAAGGCCCATC 1

RESULT 108
US-08-632-598-29/c
Sequence 29, Application US/08632598

```
; Patent No. 5886164
; GENERAL INFORMATION:
; APPLICANT: BIRD, COLIN R
; APPLICANT: FLETCHER, JONATHON D
; TITLE OF INVENTION: RIPENING-RELATED GENES FROM BANANA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CUSHMAN DABRY AND CUSHMAN
; STREET: 1100 NEW YORK AVENUE N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3918
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/632,598
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: KOKULIS, PAUL N.
; REGISTRATION NUMBER: 16,773
; REFERENCE/DOCKET NUMBER: 223355/SEES0112/US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 861-3000
; TELEFAX: 822-0944
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; ORIGINAL SOURCE:
; ORGANISM: AVOCADO
; IMMEDIATE SOURCE:
; CLONE: 5' PRIMER
; US-08-632-598-29

Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2880 GAAGAAGTGTCTCTCACAG 2898
Db 21 GAAGAAGTGTCTCTCCAG 3

RESULT 109
US-09-231-240-29/c
; Sequence 29, Application US/09231240
; Patent No. 6262346
; GENERAL INFORMATION:
; APPLICANT: BIRD, COLIN R
; APPLICANT: FLETCHER, JONATHON D
; TITLE OF INVENTION: RIPENING-RELATED GENES FROM BANANA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CUSHMAN DABRY AND CUSHMAN
; STREET: 1100 NEW YORK AVENUE N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3918
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
```

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/231,240
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/632,598
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: KOKULIS, PAUL N.
; REGISTRATION NUMBER: 16,773
; REFERENCE/DOCKET NUMBER: 223355/SEES0112/US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 861-3000
; TELEFAX: 822-0944
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; ORIGINAL SOURCE:
; ORGANISM: AVOCADO
; IMMEDIATE SOURCE:
; CLONE: 5' PRIMER
; US-09-231-240-29

Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2880 GAAGAAGTGTCTCTCACAG 2898
Db 21 GAAGAAGTGTCTCTCCAG 3

RESULT 110
US-09-422-978-8727
; Sequence 8727, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020Cp1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8727
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..21
; OTHER INFORMATION: downstream amplification primer 99-17833 for SEQ 862, in complement
; US-09-422-978-8727

Query Match 0.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4736 TTTTCAAAATATGTCTCC 4754
Db 3 TTTTCAAAATGATGTCCCC 21
```

RESULT 111
US-09-685-664B-1073/c
; Sequence 1073, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US 09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1073
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1073

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5050 AAAAAAAAAAAAAACT 5066
Db 17 AAAAAAAAAAAAAAAGT 1

RESULT 112
US-09-685-664B-1076/c
; Sequence 1076, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US 09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1076
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1076

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5023 GTAAAAAAAAAAAAAA 5039
Db 17 GGAAAAAAAAAAAAAA 1
RESULT 113
US-09-685-664B-1077/c
; Sequence 1077, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US 09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1077
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1077

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5022 TGTAAAAAAAAAAAAA 5038
Db 17 TGGAAAAAAAAAAAAA 1

RESULT 114
US-09-904-744-1
; Sequence 1, Application US/09904744
; Patent No. 6828142
; GENERAL INFORMATION:
; APPLICANT: Barbera-Guillem, Emilio
; APPLICANT: Nelson, M. Bud
; APPLICANT: Castro, Stephanie
; TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form dendrimers in a signal amplification system
; FILE REFERENCE: B-73
; CURRENT APPLICATION NUMBER: US 09/904,744
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/437076
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/107828
; PRIOR FILING DATE: 1998-11-10
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthesized
US-09-904-744-1

Query Match 0.3%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy 5023 GTAAAAA 5039
Db 2 GAAAAA 18

RESULT 115
US-08-467-822-6/c
; Sequence 6, Application US/08467822
; Patent No. 5843460
; GENERAL INFORMATION:
; APPLICANT: Labigne, Agnes
; APPLICANT: Sauerbaum, Sebastien
; APPLICANT: Ferrero, Richard L.
; APPLICANT: Thiberge, Jean-Michel
; TITLE OF INVENTION: IMMUNOGENIC COMPOSITIONS AGAINST
; TITLE OF INVENTION: HELICOBACTER INFECTION, POLYPEPTIDES
; TITLE OF INVENTION: COMPOSITIONS, AND NUCLEIC ACID SEQUENCES ENCODING SAID
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467.822
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/447,177
; FILING DATE: 19-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/432,697
; FILING DATE: 02-MAY-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Meyers, Kenneth J.
; REGISTRATION NUMBER: 25,146
; REFERENCE/DOCKET NUMBER: 03495.0137-02000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..6_
; OTHER INFORMATION: /note= "Restriction site introduced
; OTHER INFORMATION: in the amplified fragment (BamHI)."
US-08-467-822-6
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1800 TGAATCCTTTTGATC 1816
Db 18 TGAATCCTTTTGATC 2

RESULT 116
US-09-357-070-8/c
; Sequence 8, Application US/09357070
; Patent No. 6046049
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF P13 KINASE P110 DELTA EXPRESSION
; FILE REFERENCE: RTS-0076
; CURRENT APPLICATION NUMBER: US/09/357,070
; CURRENT FILING DATE: 1999-07-19
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-357-070-8
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 19 GAATTCGGCAGGCGG 35
Db 20 GAATTCGGCAGGCGG 4

RESULT 117
US-08-432-697-6/c
; Sequence 6, Application US/08432697
; Patent No. 6248330
; GENERAL INFORMATION:
; APPLICANT: Labigne, Agnes
; APPLICANT: Sauerbaum, Sebastien
; APPLICANT: Ferrero, Richard L.
; APPLICANT: Thiberge, Jean-Michel
; TITLE OF INVENTION: IMMUNOGENIC COMPOSITIONS AGAINST
; TITLE OF INVENTION: HELICOBACTER INFECTION, POLYPEPTIDES
; TITLE OF INVENTION: COMPOSITIONS, AND NUCLEIC ACID SEQUENCES ENCODING SAID
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/432,697
; FILING DATE: 02-MAY-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Meyers, Kenneth J.
; REGISTRATION NUMBER: 25,146
; REFERENCE/DOCKET NUMBER: 03495.0137-00000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
```

```
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..6
; OTHER INFORMATION: /note= "Restriction site introduced
; OTHER INFORMATION: in the amplified fragment (BamHI)."
US-08-432-697-6

Query Match      0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1800 TGAATCCTTTTGGATC 1816
Db 18 TGAATCCTTTTGGATC 2

RESULT 118
US-08-466-248-6/c
; Sequence 6, Application US/08466248
; Patent No. 6258359
; GENERAL INFORMATION:
; APPLICANT: Labigne, Agnes
; APPLICANT: Sauerbaum, Sebastien
; APPLICANT: Ferrero, Richard L.
; APPLICANT: Thiberge, Jean-Michel
; TITLE OF INVENTION: IMMUNOGENIC COMPOSITIONS AGAINST
; TITLE OF INVENTION: HELICOBACTER INFECTION, POLYPEPTIDES FOR USE IN THE
; TITLE OF INVENTION: COMPOSITIONS, AND NUCLEIC ACID SEQUENCES ENCODING SAID
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Parabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,248
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/447,177
; FILING DATE: 19-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/432,697
; FILING DATE: 02-MAY-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Meyers, Kenneth J.
; REGISTRATION NUMBER: 25,146
; REFERENCE/DOCKET NUMBER: 03495.0137-02000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
```

```
; NAME/KEY: misc_feature
; LOCATION: 1..6
; OTHER INFORMATION: /note= "Restriction site introduced
; OTHER INFORMATION: in the amplified fragment (BamHI)."
US-08-466-248-6

Query Match      0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1800 TGAATCCTTTTGGATC 1816
Db 18 TGAATCCTTTTGGATC 2

RESULT 119
US-08-275-951-49/c
; Sequence 49, Application US/08275951
; Patent No. 6451968
; GENERAL INFORMATION:
; APPLICANT: Egholm, Michael
; APPLICANT: Kiely, John
; APPLICANT: Griffin, Michael
; APPLICANT: Coull, James W.
; APPLICANT: Neilsen, Peter
; APPLICANT: Buchardt, Ole
; APPLICANT: Dueholm, Kim L.
; APPLICANT: Christensen, Leif
; TITLE OF INVENTION: Linked Peptide Nucleic Acids
; FILE REFERENCE: ISIS1577
; CURRENT APPLICATION NUMBER: US/08/275,951
; CURRENT FILING DATE: 1994-07-15
; PRIOR APPLICATION NUMBER: 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: 08/088,658
; PRIOR FILING DATE: 1993-07-02
; PRIOR APPLICATION NUMBER: 08/088,661
; PRIOR FILING DATE: 1993-07-02
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: 986/91
; PRIOR FILING DATE: 1991-05-22
; PRIOR APPLICATION NUMBER: 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: 510/92
; PRIOR FILING DATE: 1991-04-15
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6451968el Sequence
; NAME/KEY: misc_feature
; LOCATION: (10)..(11)
; OTHER INFORMATION: Ethylene Glycol, Ethylene Glycol, Ethylene Glycol
; OTHER INFORMATION: Linkage
; NAME/KEY: misc_feature
; LOCATION: (13)
; OTHER INFORMATION: N is Pseudoisocytosine
; NAME/KEY: misc_feature
; LOCATION: (20)
; OTHER INFORMATION: N is Pseudoisocytosine
US-08-275-951-49

Query Match      0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5042
Db 19 AAAAAAAAAAGAAAAAA 2
```

```
RESULT 120
US-09-422-978-6200/c
; Sequence 6200, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6200
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-10046 for SEQ 2266,
US-09-422-978-6200
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4356 GAAATATAGTTTGGG 4372
|||||
Db 17 GAAATATAGTTTGGG 1

RESULT 121
US-09-306-420C-6
; Sequence 6, Application US/09306420C
; Patent No. 6555311
; GENERAL INFORMATION:
; APPLICANT: LOCARNINI, STEPHEN A
; APPLICANT: BARTHOLOMEUSZ, ANGELINE I
; APPLICANT: AYE, THEIN T
; APPLICANT: DEMAN, ROBERT A
; TITLE OF INVENTION: VIRAL VARIANTS AND METHODS FOR DETECTING SAME
; FILE REFERENCE: 2551-28
; CURRENT APPLICATION NUMBER: US/09/306,420C
; CURRENT FILING DATE: 1999-05-06
; PRIOR APPLICATION NUMBER: PCT/AU97/00520
; PRIOR FILING DATE: 1997-08-15
; PRIOR APPLICATION NUMBER: P03519
; PRIOR FILING DATE: 1996-11-08
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Hepatitis B virus
US-09-306-420C-6
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 525 TTATATCTAACCTTAC 541
|||||
Db 3 TTCTATCTAACCTTAC 19

RESULT 122
US-09-081-385-98
; Sequence 98, Application US/09081385
; Patent No. 6593456
; GENERAL INFORMATION:
; APPLICANT: Gatanaga, T.
; APPLICANT: Granger, G.A.
; TITLE OF INVENTION: Factors Altering Tumor Necrosis
; TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods
; TITLE OF INVENTION: of Use Thereof
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/081,385
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-081-385-98
Query Match 0.3%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4586 CCACACAGGGCTTCATC 4602
|||||
Db 2 CCACACAGGGCTTCATC 18

RESULT 123
US-07-977-284A-103/c
; Sequence 103, Application US/07977284A
; Patent No. 5558988
; GENERAL INFORMATION:
; APPLICANT: Prockop, Darwin J.
; APPLICANT: Ala-Kokko, Leena
; APPLICANT: Williams, Charlene J.
; APPLICANT: Ritvanieni, Pertti
; APPLICANT: Baldwin, Clinton
; APPLICANT: Hopkinson, Ian
; APPLICANT: Ahmad, Nilofer Nina
; TITLE OF INVENTION: METHODS OF DETECTING A GENETIC
; TITLE OF INVENTION: PREDISPOSITION FOR OSTEOARTHRITIS
; NUMBER OF SEQUENCES: 261
```


;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5558988ris
;; STREET: One Liberty Place, 46th floor
;; CITY: Philadelphia
;; STATE: PA
;; COUNTRY: USA
;; ZIP: 19103
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Wordperfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/07/977.284A
;; FILING DATE: 13-NOV-1992
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER:
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DeLuca, Mark
;; REGISTRATION NUMBER: 33,229
;; REFERENCE/DOCKET NUMBER: TUU-0697
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (215) 568-3100
;; TELEFAX: (215) 568-3439
;; INFORMATION FOR SEQ ID NO: 103:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: NUCLEIC ACID
;; STRANDEDNESS: SINGLE
;; TOPOLOGY: LINEAR
;; ANTI-SENSE: YES
;; US-07-977-284A-103

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 3947 GGTCTTCAAGCAATGCGTGG 3966
Db 20 GGTCTTCAAGCAATGCGTGG 1

RESULT 124
US-08-406-635-14/c
; Sequence 14, Application US/08406635
; Patent No. 5599674
; GENERAL INFORMATION:
; APPLICANT: PENA, SERGIO D.J.
; APPLICANT: SIMPSON, ANDREW J.G.
; TITLE OF INVENTION: METHOD FOR RECOGNITION OF THE NUCLEOTIDE
; TITLE OF INVENTION: SEQUENCE OF A PURIFIED DNA SEGMENT
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/406.635
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/100,738
; FILING DATE: 29-JUL-1993

;; ATTORNEY/AGENT INFORMATION:
;; NAME: MURASHIGE, KATE H.
;; REGISTRATION NUMBER: 29,959
;; REFERENCE/DOCKET NUMBER: 45119-20001.00
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 813-5600
;; TELEFAX: (415) 494-0792
;; TELEX: 706141
;; INFORMATION FOR SEQ ID NO: 14:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-406-635-14

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 4424 CATCTGTGTCCTACTACAGG 4443
Db 20 CATCTGTGTCCTACTACAGG 1

RESULT 125
US-08-598-591-57
; Sequence 57, Application US/08598591
; Patent No. 5654155
; GENERAL INFORMATION:
; APPLICANT: Allen, Antonette C.
; APPLICANT: Alvares, Christopher P.
; APPLICANT: Critz, Brenda S.
; APPLICANT: Murphy Patricia D.
; APPLICANT: Olson, Sheri J.
; APPLICANT: Scheiter, Denise B.
; APPLICANT: Zeng, Bin
; TITLE OF INVENTION: A Consensus Sequence of the Human BRCA1 Gene
; Patent No. 5654155
; NUMBER OF SEQUENCES: 74
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince St.
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/598,591
; FILING DATE: herewith
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Swecker, Robert S.
; REGISTRATION NUMBER: 19,885
; REFERENCE/DOCKET NUMBER: 020160-282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-2021
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: not relevant
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ORIGINAL SOURCE:
; STRAIN: 19F primer
; US-08-598-591-57

```
Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      4104 CTGTCATCTTCCTCCAGGGCTC 4123
Db      1 CTGTCATCTTCCTGTGCTC 20

RESULT 126
US-08-637-902-7/c
; Sequence 7, Application US/08637902
; Patent No. 5683883
; GENERAL INFORMATION:
; APPLICANT: Ohashi, Tetsuo
; APPLICANT: Tanaka, Reiko
; TITLE OF INVENTION: Oligonucleotides for Detecting
; TITLE OF INVENTION: Salmonella Species and Detection Process Using the Same
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch and Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: VA
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/637.902
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Weiner, Marc S
; REGISTRATION NUMBER: 32,181
; REFERENCE/DOCKET NUMBER: 1422-251P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 205-8000
; TELEFAX: (703) 205-8050
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Salmonella typhimurium
; FEATURE:
; IDENTIFICATION METHOD: S
US-08-637-902-7

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      387 CTGTCATGAGAGACCC 406
Db      20 CTGTCATGTAGACGACCC 1

RESULT 127
US-08-233-005-8/c
; Sequence 8, Application US/08233005
; Patent No. 5710262
; GENERAL INFORMATION:
; APPLICANT: Tedder, Thomas F.
```

```
; APPLICANT: Zhou, Liang-Ji
; TITLE OF INVENTION: LYMPHOCYTE ACTIVATION ANTIGENS
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Weingarten, Schurgin, Gagnebin & Hayes
; STREET: Ten Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/233.005
; FILING DATE: 25-APR-1994
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/870,029
; FILING DATE: 17-APR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams Ph.D., Kathleen A.
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: DFCC-230AX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-2290
; TELEFAX: (617) 451-0313
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-233-005-8

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      3746 CATCTGATAATGGTGTGCTC 3765
Db      20 CTTCTGATGATGCTGTC 1

RESULT 128
US-08-798-691-61
; Sequence 61, Application US/08798691
; Patent No. 5750400
; GENERAL INFORMATION:
; APPLICANT: Murphy, Patricia D.
; APPLICANT: Allen, Antonette C.
; APPLICANT: Alvares, Christopher P.
; APPLICANT: Critz, Brenda S.
; APPLICANT: Olson, Sheri J.
; APPLICANT: Scheiter, Denise B.
; APPLICANT: Zeng, Bin
; TITLE OF INVENTION: Coding Sequences of the Human
; TITLE OF INVENTION: BRCA1 Gene
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ONCORMED
; STREET: 200 Perry Parkway
; CITY: Gaithersburg
; STATE: MD
; COUNTRY: USA
; ZIP: 20877
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/798,691
FILING DATE: 12-Feb-97
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Thomas Gallegos
REGISTRATION NUMBER: 32,692
REFERENCE/DOCKET NUMBER: PA-0054CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 301-527-2051
TELEFAX: 301-208-6997
INFORMATION FOR SEQ ID NO: 61:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: not relevant
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
STRAIN: 19F primer
US-08-798-691-61

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4104 CTGTCATCTTCCAGGGCTC 4123

Db 1 CTGTCATCTTCCCTGTGCTC 20

RESULT 129
US-08-943-8/C
Sequence 8, Application US/08428943
Patent No. 5766570
GENERAL INFORMATION:
APPLICANT: Tedder, Thomas F.
APPLICANT: Zhou, Liang-Ji
TITLE OF INVENTION: LYMPHOCYTE ACTIVATION ANTIGENS AND
NUMBER OF INVENTION: ANTIBODIES THERETO
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: Weingarten, Schurgin, Gagnebin & Hayes
STREET: Ten Post Office Square
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/428,943
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/233,005
FILING DATE: 25-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/870,029
FILING DATE: 17-APR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Holliday C. Heine, Ph.D.
REGISTRATION NUMBER: 34,346
REFERENCE/DOCKET NUMBER: DFCC-230BX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-2290
TELEFAX: (617) 451-0313

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-428-943-8

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3746 CATCTGTAATGGTGCTGTC 3765

Db 20 CTCTGATGATAGTGCIGTC 1

RESULT 130
US-08-639-501-120/c
Sequence 120, Application US/08639501
Patent No. 5837492
GENERAL INFORMATION:
APPLICANT: Tavtigian, Sean V.
APPLICANT: Kamb, Alexander
APPLICANT: Simard, Jacques
APPLICANT: Couch, Fergus
APPLICANT: Rommens, Johanna
APPLICANT: Weber, Barbara
TITLE OF INVENTION: Chromosome 13-Linked Breast Cancer
TITLE OF INVENTION: Susceptibility Gene
NUMBER OF SEQUENCES: 124
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti
STREET: 1201 New York Avenue N.W., Suite 1001
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 22204

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/639,501
FILING DATE: 29-APR-1996
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/585,391
FILING DATE: 11-JAN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/576,559
FILING DATE: 21-DEC-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/575,359
FILING DATE: 20-DEC-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/573,779
FILING DATE: 18-DEC-1995
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-116802-04
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 120:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Primer"
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
US-08-639-501-120

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      593 CTCCTCCAGATCCTTCT 612
Db      20 CTCCTCCAGATCTTCT 1

RESULT 131
US-08-256-426B-103/C
; Sequence 103, Application US/08256426B
; Patent No. 5948611
; GENERAL INFORMATION:
; APPLICANT: Prockop, Darwin J.
; APPLICANT: Ala-Kokko, Leena
; APPLICANT: Williams, Charlene J.
; APPLICANT: Ritvaniemi, Pertti
; APPLICANT: Baldwin, Clinton
; APPLICANT: Hopkinson, Ian
; APPLICANT: Ahmad, Nilofer Nina
; TITLE OF INVENTION: Methods of Detecting A Genetic
; NUMBER OF SEQUENCES: 293
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5948611ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 3.1
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/256,426B
; FILING DATE: 03-FEB-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/10964
; FILING DATE: 12-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/977,284
; FILING DATE: 13-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Mark DeLuca
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-1082
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 103:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: NUCLEIC ACID
; STRANDEDNESS: SINGLE
; TOPOLOGY: LINEAR
; ANTI-SENSE: YES
US-08-256-426B-103

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      593 CTCCTCCAGATCCTTCT 612
Db      20 CTCCTCCAGATCTTCT 1

RESULT 132
US-08-974-180-4
; Sequence 4, Application US/08974180
; Patent No. 6025194
; GENERAL INFORMATION:
; APPLICANT: Funk, Walter
; TITLE OF INVENTION: Methods for Modulating and Identifying
; TITLE OF INVENTION: Cellular Senescence
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Geron Corporation
; STREET: 230 Constitution Drive
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/974,180
; FILING DATE: 19-NOV-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kaster, Kevin R.
; REGISTRATION NUMBER: 32,704
; REFERENCE/DOCKET NUMBER: 206
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 473-7779
; TELEFAX: (650) 473-8654
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: -
; LOCATION: 1..20
; OTHER INFORMATION: /note= "primer KJC47"
US-08-974-180-4

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      15 GCAGGAATTCGCACGAGG 34
Db      1 GCAGGAAGGGCGCACGAG 20

RESULT 133
US-09-044-946-120/C
; Sequence 120, Application US/09044946
; Patent No. 6033857
; GENERAL INFORMATION:
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Kamb, Alexander
; APPLICANT: Simard, Jacques
; APPLICANT: Couch, Fergus
; APPLICANT: Rommens, Johanna
; APPLICANT: Weber, Barbara
; TITLE OF INVENTION: Chromosome 13-Linked Breast Cancer
; TITLE OF INVENTION: Susceptibility Gene
; NUMBER OF SEQUENCES: 124
```

```

Qy      3947 GGTCTTCAAGCAATCGTGG 3966
Db      20 GGTCTTCAAGGAATCGCTGG 1

RESULT 132
US-08-974-180-4
; Sequence 4, Application US/08974180
; Patent No. 6025194
; GENERAL INFORMATION:
; APPLICANT: Funk, Walter
; TITLE OF INVENTION: Methods for Modulating and Identifying
; TITLE OF INVENTION: Cellular Senescence
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Geron Corporation
; STREET: 230 Constitution Drive
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/974,180
; FILING DATE: 19-NOV-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kaster, Kevin R.
; REGISTRATION NUMBER: 32,704
; REFERENCE/DOCKET NUMBER: 206
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 473-7779
; TELEFAX: (650) 473-8654
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: -
; LOCATION: 1..20
; OTHER INFORMATION: /note= "primer KJC47"
US-08-974-180-4

Query Match          0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      15 GCAGGAATTCGCACGAGG 34
Db      1 GCAGGAAGGGCGCACGAG 20

RESULT 133
US-09-044-946-120/C
; Sequence 120, Application US/09044946
; Patent No. 6033857
; GENERAL INFORMATION:
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Kamb, Alexander
; APPLICANT: Simard, Jacques
; APPLICANT: Couch, Fergus
; APPLICANT: Rommens, Johanna
; APPLICANT: Weber, Barbara
; TITLE OF INVENTION: Chromosome 13-Linked Breast Cancer
; TITLE OF INVENTION: Susceptibility Gene
; NUMBER OF SEQUENCES: 124
```

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti
; STREET: 1201 New York Avenue N.W., Suite 1001
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 22204
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/044,946
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/639,501
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/576,559
; FILING DATE: 21-DEC-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/575,359
; FILING DATE: 20-DEC-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/573,779
; FILING DATE: 18-DEC-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-116802-04
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-4810
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 120:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Primer"
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-09-044-946-120

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 593 CTCCTCCAGATCTTCT 612
DB 20 CTCCTCCAGTTACTTCT 1

RESULT 134
US-08-825-487A-61
; Sequence 61, Application US/08825487A
; Patent No. 6048689
; GENERAL INFORMATION:
; APPLICANT: Murphy, Patricia D.
; APPLICANT: White, Marga B.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING VARIATIONS IN POLYNUCLEOTIDE SEQUENCE
; NUMBER OF SEQUENCES: 110
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Howrey & Simon
; STREET: 1299 Pennsylvania Avenue., N.W.
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/825,487A
; FILING DATE: 28-MAR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US98/060002
; FILING DATE: 26-Mar-1998
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Albert P. Halluin
; REGISTRATION NUMBER: 25,227
; REFERENCE/DOCKET NUMBER: 05371.0012.999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-463-8100
; TELEFAX: 650-463-8400
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: not relevant
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ORIGINAL SOURCE:
; STRAIN: 19F primer
; US-08-825-487A-61

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4104 CTGTCATCTTCAGGGCTC 4123
DB 1 CTGTCATCTTCCTGTGCTC 20

RESULT 135
US-09-016-649-8/c
; Sequence 8, Application US/09016649
; Patent No. 6068984
; GENERAL INFORMATION:
; APPLICANT: Tedder, Thomas F.
; APPLICANT: Zhou, Liang-Ji
; TITLE OF INVENTION: LYMPHOCYTE ACTIVATION ANTIGENS AND
; TITLE OF INVENTION: ANTIBODIES THERETO
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Weingarten, Schurgin, Gagnebin & Hayes
; STREET: Ten Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/016,649
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/428,943
; FILING DATE:
; APPLICATION NUMBER: US 08/233,005
; FILING DATE: 25-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/870,029
; FILING DATE: 17-APR-1992

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Holliday C. Heine, Ph.D.
; REGISTRATION NUMBER: 34,346
; REFERENCE/DOCKET NUMBER: DFCC-230BX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-2290
; TELEFAX: (617) 451-0313
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-09-016-649-8

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3746 CATCTGATAATGGTGCTGTC 3765
Db 20 CTCTGATGATAGTGTGTC 1

RESULT 136
US-09-044-908-120/c
; Sequence 120, Application US/09044908
; Patent No. 6124104
; GENERAL INFORMATION:
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Kamb, Alexander
; APPLICANT: Simard, Jacques
; APPLICANT: Couch, Fergus
; APPLICANT: Rommens, Johanna
; APPLICANT: Weber, Barbara
; TITLE OF INVENTION: Chromosome 13-Linked Breast Cancer
; TITLE OF INVENTION: Susceptibility Gene
; NUMBER OF SEQUENCES: 124
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti
; STREET: 1201 New York Avenue N.W., Suite 1001
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 22204
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/044,908
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/639,501
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/576,559
; FILING DATE: 21-DEC-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/575,359
; FILING DATE: 20-DEC-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/573,779
; FILING DATE: 18-DEC-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Innen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-116802-04

```

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-4810
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 120:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Primer"
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-09-044-908-120

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 593 CTCCTCCAGATCCTTCT 612
Db 20 CTCCTCCAGTACTTCT 1

RESULT 137
US-09-074-476-61
; Sequence 61, Application US/09074476
; Patent No. 6130322
; GENERAL INFORMATION:
; APPLICANT: Murphy, Patricia D.
; APPLICANT: Allen, Antonette C.
; APPLICANT: Alvares, Christopher P.
; APPLICANT: Critz, Brenda S.
; APPLICANT: Olson, Sheri J.
; APPLICANT: Thurber, Denise
; APPLICANT: Zeng, Bin
; TITLE OF INVENTION: Coding Sequences of the Human
; TITLE OF INVENTION: BRCA1 Gene
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Howrey & Simon
; STREET: 1299 Pennsylvania Avenue N. W.
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/074,476
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/074,453
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Albert P. Halluin
; REGISTRATION NUMBER: 25,227
; REFERENCE/DOCKET NUMBER: 5371.34.US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-463-8109
; TELEFAX: 650-463-8400
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: not relevant
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ORIGINAL SOURCE:

```

STRAIN: 19F primer
US-09-074-476-61

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4104 CTGTCATCTCTCCAGGGTC 4123
||||| ||||| |||||
Db 1 CTGTCATCTCTCTCTGCTC 20

RESULT 138

US-08-765-340-10
; Sequence 10, Application US/08765340
; Patent No. 6150092

GENERAL INFORMATION:

APPLICANT: UCHIDA, K.,
APPLICANT: UCHIDA, T.,
APPLICANT: TANAKA, Y.,
APPLICANT: MATSUDA, Y.,
APPLICANT: KONDO, S.,
TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID
TITLE OF INVENTION: COMPOUND
NUMBER OF SEQUENCES: 185
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
STREET: 345 PARK AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version
SOFTWARE: #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/765,340
FILING DATE: 23-DEC-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: JP 145146/94
FILING DATE: 27-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 311130/94
FILING DATE: 21-NOV-1994

ATTORNEY/AGENT INFORMATION:

NAME: SERUNIAN, LESLIE
REGISTRATION NUMBER: 35,353
REFERENCE/DOCKET NUMBER: 1452-4005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 758-4800

TELEFAX: (212) 751-6849

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "synthetic DNA"

US-08-765-340-10

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAAAAAA 5044
||||| ||||| |||||
Db 1 AAAAAAAAACAAAACAA 20

RESULT 139

US-09-467-082-28/c
; Sequence 28, Application US/09467082

GENERAL INFORMATION:

APPLICANT: Brett P. Monia
APPLICANT: Lex M. Cowsett
TITLE OF INVENTION: ANTISENSE MODULATION OF PKA CATALYTIC SUBUNIT C-ALPHA EXPRESSION
FILE REFERENCE: RTS-0088
CURRENT APPLICATION NUMBER: US/09/467,082
CURRENT FILING DATE: 1999-12-17
NUMBER OF SEQ ID NOS: 49
SEQ ID NO 28
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide

US-09-467-082-28

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 313 AGTTCTCTCTCCAGGACCAC 332
||||| ||||| |||||
Db 20 AGTTCTCTCTCAAGGACAAC 1

RESULT 140

US-09-021-701-549/c
; Sequence 549, Application US/09021701

GENERAL INFORMATION:

APPLICANT: Shannon, Karen W.
APPLICANT: Wolber, Paul K.
APPLICANT: Delenstarr, Glenda C.
APPLICANT: Webb, Peter G.
APPLICANT: Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
TITLE OF INVENTION: probe sequences
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/021,701
FILING DATE: 10-FEB-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063

INFORMATION FOR SEQ ID NO: 549:

SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO

US-09-021-701-549

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3311 AAAATAAAAAACCGTAGTA 3330

Db 20 AAAGAAAAATCAGTAACA 1

RESULT 141

US-09-168-406A-28/c

; Sequence 28, Application US/09168406A

; Patent No. 6258769

; GENERAL INFORMATION:

; APPLICANT: Welinder, Karen G.

; APPLICANT: Andersen, Morten B.

; TITLE OF INVENTION: Peroxidase Variants With Improved

; TITLE OF INVENTION: Hydrogen Peroxidase Stability

; FILE REFERENCE: 3769.214-US

; CURRENT APPLICATION NUMBER: US/09/168,406A

; CURRENT FILING DATE: 1998-10-06

; PRIOR APPLICATION NUMBER: 08/331,515

; PRIOR FILING DATE: 1994-11-01

; PRIOR APPLICATION NUMBER: PCT/DK93/00189

; PRIOR FILING DATE: 1993-06-01

; PRIOR APPLICATION NUMBER: 0792/92

; PRIOR FILING DATE: 1992-06-01

; NUMBER OF SEQ ID NOS: 43

; SOFTWARE: Fast-SEQ for Windows Version 4.0

; SEQ ID NO 28

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Primer

US-09-168-406A-28

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1273 AAGAGACCAATGGACATCTT 1292

Db 20 AAGAGACCAATGGACCTCAT 1

RESULT 142

US-09-428-583-45/c

; Sequence 45, Application US/09428583

; Patent No. 6271029

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Lex M. Cowsett

; TITLE OF INVENTION: ANTISENSE MODULATION OF CYTOSIN-2 EXPRESSION

; FILE REFERENCE: RTS-0096

; CURRENT APPLICATION NUMBER: US/09/428,583

; CURRENT FILING DATE: 1999-10-27

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 45

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-428-583-45

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3860 TTGTGGATATGCATCACTTC 3879

Db 20 TTGTGGATCTGCATGAGTTC 1

RESULT 143

US-09-702-246-31

; Sequence 31, Application US/09702246

; Patent No. 6383809

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Lex M. Cowsett

; TITLE OF INVENTION: ANTISENSE MODULATION OF CYTOSIN-1 EXPRESSION

; FILE REFERENCE: RTS-0195

; CURRENT APPLICATION NUMBER: US/09/702,246

; CURRENT FILING DATE: 2000-10-30

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 31

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-702-246-31

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 365 CCCTCCACCAACAGCCCATC 384

Db 1 CCCTCCACCAACAGCCCGCTC 20

RESULT 144

US-09-844-634-153/c

; Sequence 153, Application US/09844634

; Patent No. 6410324

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION

; FILE REFERENCE: RTS-0216

; CURRENT APPLICATION NUMBER: US/09/844,634

; CURRENT FILING DATE: 2001-04-27

; NUMBER OF SEQ ID NOS: 174

; SEQ ID NO 153

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-844-634-153

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3193 CCTAAGGGAGTGATCAGGA 3212

Db 20 CCTAAGGGAGTGCTAAGGA 1

RESULT 145

US-09-411-628-9/c

; Sequence 9, Application US/09411628

; Patent No. 6428994

; GENERAL INFORMATION:

; APPLICANT: University of Southern California

; TITLE OF INVENTION: CDNA, GENOMIC, AND PREDICTED PROTEIN

; TITLE OF INVENTION: SEQUENCES OF LEARNING-INDUCED KINASES

; FILE REFERENCE: 13761-707

; CURRENT APPLICATION NUMBER: US/09/411,628

; CURRENT FILING DATE: 1999-10-01

; EARLIER APPLICATION NUMBER: US 60/102,906
; EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense primer
US-09-411-628-9

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2680 CAACCAATAATACAGATTGA 2699
Db 20 CAACCAAGAAGAAGATTGA 1

RESULT 146
US-09-746-694-40
; Sequence 40, Application US/09746694
; Patent No. 6451538
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHK2 EXPRESSION
; FILE REFERENCE: RTS-0228
; CURRENT APPLICATION NUMBER: US/09/746,694
; CURRENT FILING DATE: 2000-12-22
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-746-694-40

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3276 AACTTCTTCACAGGTTCCAG 3295
Db 1 AACTTCTTCACAGGTTCCAG 20

RESULT 147
US-09-422-978-4301
; Sequence 4301, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilva
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4301
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:

; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-14598 for SEQ 367,
US-09-422-978-4301

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4083 CCAGTTCGAATTTCAAGTC 4102
Db 1 CCAGTTCGAATTTCAAGTC 20

RESULT 148
US-09-198-452A-4833
; Sequence 4833, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffois, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4833
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-4833

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1669 GGAGGCGCTAAGGAAATGG 1688
Db 1 GGAGGAGTAAAGNAGATGG 20

RESULT 149
US-09-307-106-42
; Sequence 42, Application US/09307106
; Patent No. 6603063
; GENERAL INFORMATION:
; APPLICANT: Feitelson, Jerald S.
; APPLICANT: Schneft, H. Ernest
; APPLICANT: Narva, Kenneth E.
; APPLICANT: Stockhoff, Brian A.
; APPLICANT: Schmeits, James
; APPLICANT: Loewer, David
; APPLICANT: Dullum, Charles Joseph
; APPLICANT: Muller-Cohn, Judy
; APPLICANT: Stamp, Lisa
; APPLICANT: Morrill, George
; APPLICANT: Finstad-Lee, Stacey
; TITLE OF INVENTION: No. 6603063el Pesticidal Toxins and Nucleotide
; TITLE OF INVENTION: Sequences Which Encode These Toxins
; NUMBER OF SEQUENCES: 54
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Saliwanchik, Lloyd & Saliwanchik
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: US
; ZIP: 32606-6669
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/307,106
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/029,848
; FILING DATE: 30-OCT-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/960,780
; FILING DATE: 30-OCT-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/073,898
; FILING DATE: 05-MAY-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Sanders, Jay M.
; REGISTRATION NUMBER: 39,355
; REFERENCE/DOCKET NUMBER: MA-708C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 352-375-8100
; TELEFAX: 352-372-5800
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-307-106-42

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 827 TCCAGAAAGCATCAGAAAA 846
Db 1 TCCCTAAGCATCAGAAATA 20

RESULT 150
US-09-665-615B-177
; Sequence 177, Application US/09665615B
; Patent No. 6653133
; GENERAL INFORMATION:
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Marcussen, Eric G.
; TITLE OF INVENTION: Antisense Modulation of Fas Mediated Signaling
; FILE REFERENCE: ISPH-0502
; CURRENT APPLICATION NUMBER: US/09/665,615B
; CURRENT FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 09/290,640
; PRIOR FILING DATE: 1999-04-12
; NUMBER OF SEQ ID NOS: 179
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 177
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-665-615B-177

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3312 AAATAAAAAACAGTAATAC 3331
Db 1 AAAGAGAAACAGAAATAC 20

RESULT 151
US-10-174-794-9/c

```

```

; Sequence 9, Application US/10174794
; Patent No. 6664086
; GENERAL INFORMATION:
; APPLICANT: University of Southern California
; TITLE OF INVENTION: cDNA, GENOMIC, AND PREDICTED PROTEIN
; FILE REFERENCE: 13761-707
; CURRENT APPLICATION NUMBER: US/10/174,794
; CURRENT FILING DATE: 2002-06-18
; PRIOR APPLICATION NUMBER: US/09/411,628
; PRIOR FILING DATE: 1999-10-01
; PRIOR APPLICATION NUMBER: US 60/102,906
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense primer
; US-10-174-794-9

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2680 CAACCAATAATACAGATTGA 2699
Db 20 CAACCAAGAAAGAAAGATTGA 1

RESULT 152
US-10-022-819-56
; Sequence 56, Application US/10022819
; Patent No. 6686163
; GENERAL INFORMATION:
; APPLICANT: ALLEN, Antonette C. P.
; APPLICANT: OLSEN, Sheri J.
; APPLICANT: LAWRENCE, Tammy
; APPLICANT: ANGELLY, Tracy S.
; APPLICANT: RABIN, Mark B.
; TITLE OF INVENTION: CODING SEQUENCE HAPLOTYPE OF THE HUMAN
; BRCA1 GENE
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morgan Lewis & Bockius LLP
; STREET: 1111 Pennsylvania Avenue
; CITY: Washington DC
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/022,819
; FILING DATE: 22-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/074,452
; FILING DATE: 1998-05-06
; ATTORNEY/AGENT INFORMATION:
; NAME: <Unknown>
; REGISTRATION NUMBER: <Unknown>
; REFERENCE/DOCKET NUMBER: 044921-5049-01-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-739-3000
; TELEFAX: 202-739-3001
; INFORMATION FOR SEQ ID NO: 56:
; SEQUENCE CHARACTERISTICS:

```

```
;
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "PRIMER"
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: Internal
; SEQUENCE DESCRIPTION: SEQ ID NO: 56:
US-10-022-819-56

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4104 CTGTCATCTTCCAGGGCTC 4123
Db 1 CTGTCATCTTCTCTGTGCTC 20

RESULT 153
US-08-983-605-245/c
; Sequence 245, Application US/08983605A
; Patent No. 6720137
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
; TITLE OF INVENTION: Triticum Aestivum and Tribe Triticeae and the Use of
; TITLE OF INVENTION: Said Markers
; FILE REFERENCE: 2936.10400
; CURRENT APPLICATION NUMBER: US/08/983,605A
; CURRENT FILING DATE: 1998-05-01
; EARLIER APPLICATION NUMBER: DE 195 25 284.5
; EARLIER FILING DATE: 1995-06-28
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 245
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Triticum aestivum
US-08-983-605-245

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3857 GTGTTGTGGATGATCATCAC 3876
Db 20 GTGTTGTGGTCTGCTTCAC 1

RESULT 154
US-09-917-963-44/c
; Sequence 44, Application US/09917963
; Patent No. 6767739
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0591
; CURRENT APPLICATION NUMBER: US/09/917,963
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 137
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-917-963-44
```

```
Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2971 GCCAATATAGTGGACACAG 2990
Db 20 GCCAATATAGAGTCCAGGG 1

RESULT 155
US-09-734-672A-61
; Sequence 61, Application US/09734672A
; Patent No. 6838256
; GENERAL INFORMATION:
; APPLICANT: Murphy, Patricia D.
; APPLICANT: Allen, Antonette C.
; APPLICANT: Alvares, Christopher P.
; APPLICANT: Critz, Brenda S.
; APPLICANT: Olson, Sheri J.
; APPLICANT: Schelter, Denise B.
; APPLICANT: Zeng, Bin
; TITLE OF INVENTION: Coding Sequences of the Human
; TITLE OF INVENTION: BRCA1 Gene
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morgan Lewis & Bockius LLP
; STREET: 1111 Pennsylvania Ave., N.W.
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/734,672A
; FILING DATE: 13-Dec-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/966,436
; FILING DATE: 1997-11-07
; APPLICATION NUMBER: US 08/598,591
; FILING DATE: 1996-02-12
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael S. Tuscan
; REGISTRATION NUMBER: 43,210
; REFERENCE/DOCKET NUMBER: 44921-5055-02-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-739-3000
; TELEFAX: 202-739-3001
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: No. 6838256 Relevant
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ORIGINAL SOURCE:
; STRAIN: 19F primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 61:
US-09-734-672A-61

Query Match      0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4104 CTGTCATCTTCCAGGGCTC 4123
Db 1 CTGTCATCTTCTCTGTGCTC 20

RESULT 156
```

gibbs-10-667-022-4.rni

Thu Aug 18 08:45:54 2005

```

PCT-US95-04858-8/c
; Sequence 8, Application PC/TUS9504858
; GENERAL INFORMATION:
; APPLICANT: LYMPHOCYTE ACTIVATION ANTIGENS AND
; TITLE OF INVENTION: ANTIBODIES THERETO
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Weingarten, Schurigin, Gagnebin & Hayes
; STREET: Ten Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/04858
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/233,005
; FILING DATE: 25-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/870,029
; FILING DATE: 17-APR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Holliday C. Heine, Ph.D.
; REGISTRATION NUMBER: 34,346
; REFERENCE/DOCKET NUMBER: DFCC-230Aq999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-2290
; TELEFAX: (617) 451-0313
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
PCT-US95-04858-8

Query Match 0.3%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3746 CATCTGATAATGCTGTC 3765
Db 20 CTTCTGATGATGCTGTC 1

RESULT 157
US-10-352-704-10/c
; Sequence 10, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its
; Implementation
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; STATE: D.C.
; COUNTRY: U.S.A.

```

```

; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/352,704
; FILING DATE: 28-Jan-2003
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/358,556A
; FILING DATE: 14-DEC-1994
; APPLICATION NUMBER: FR 9315164
; FILING DATE: 16-DEC-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; TELE: RCA 248593 IDEA UR
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..15
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-352-704-10

Query Match 0.3%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAA 5039
Db 15 AAAAAAAAAAAAAA 1

RESULT 158
US-10-352-704-16
; Sequence 16, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its
; Implementation
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/352,704

```

FILING DATE: 28-Jan-2003
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/358,556A
FILING DATE: 14-DEC-1994
APPLICATION NUMBER: FR 9315164
FILING DATE: 16-DEC-1993
ATTORNEY/AGENT INFORMATION:
NAME: Player, William E.
REGISTRATION NUMBER: 31,409
REFERENCE/DOCKET NUMBER: 10577/P58418
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)638-6666
TELEFAX: (202) 393-5350
TELEX: RCA 248593 IDBA UR
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: N-terminal
FEATURE:
NAME/KEY: CDS
LOCATION: 1..15
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-352-704-16

Query Match 0.3%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAA 5039
Db 1 AAAAAAAAAAAAAA 15

RESULT 159
US-09-422-978-8771
; Sequence 8771, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Cohen, Daniel
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US/09/422,978
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8771
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURES:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-18109 for SEQ 906, in compleme
US-09-422-978-8771

Query Match 0.3%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1124 TCTTTGACATCAC 1138
Db 1 TCTTTGACATCAC 15
RESULT 160
US-09-422-978-6255
; Sequence 6255, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6255
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURES:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-10436 for SEQ 2321,
US-09-422-978-6255

Query Match 0.3%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2435 GTCTTAGTGATGCTG 2449
Db 5 GTCTTAGTGATGCTG 19

RESULT 161
US-09-290-640-27/c
; Sequence 27, Application US/09290640
; Patent No. 6204055
; GENERAL INFORMATION:
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Marcussen, Eric G.
; TITLE OF INVENTION: Antisense Compound Modulation of Ras Mediated Signaling
; FILE REFERENCE: ISPH-0351
; CURRENT APPLICATION NUMBER: US/09/290,640
; CURRENT FILING DATE: 1999-04-12
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Synthetic Sequence
US-09-290-640-27

Query Match 0.3%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 43 CGTTTGCTGGGCTG 57
Db 17 CGTTTGCTGGGCTG 3

```

RESULT 162
US-09-517-467B-343
; Sequence 343, Application US/09517467B
; Patent No. 6451602
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PARP EXPRESSION
; FILE REFERENCE: RTS-0150
; CURRENT APPLICATION NUMBER: US/09/517,467B
; CURRENT FILING DATE: 2001-03-02
; PRIOR APPLICATION NUMBER: 09/517,467
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 345
; SEQ ID NO 343
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-467B-343

Query Match      0.3%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1408 ATTGAAGATCAGT 1422
Db 4 ATTGAAGATCAGT 18

RESULT 163
US-09-665-615B-27/c
; Sequence 27, Application US/09665615B
; Patent No. 6653133
; GENERAL INFORMATION:
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Marcussen, Eric G.
; APPLICANT: Wyatt, Jacqueline
; TITLE OF INVENTION: Antisense Modulation of Fas Mediated Signaling
; FILE REFERENCE: ISPH-0502
; CURRENT APPLICATION NUMBER: US/09/665,615B
; CURRENT FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 09/290,640
; PRIOR FILING DATE: 1999-04-12
; NUMBER OF SEQ ID NOS: 179
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-665-615B-27

Query Match      0.3%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 43 CGTTTGCTGGGGCTG 57
Db 17 CGTTTGCTGGGGCTG 3

RESULT 164
US-09-256-496-45
; Sequence 45, Application US/09256496
; Patent No. 5998206
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-APLHA-12 EXPRESSION
; FILE REFERENCE: RTS-0056
; CURRENT APPLICATION NUMBER: US/09/256,496

```

```

; CURRENT FILING DATE: 1999-02-23
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 45
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-256-496-45

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4463 AAGTTGTCAGGAATTC 4480
Db 1 AAGTTGTCAGGAATTC 18

RESULT 165
US-09-475-947A-340/c
; Sequence 340, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 340
; LENGTH: 18
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-340

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 47 TGCTGGGGCTGCAGCAGC 64
Db 18 TGCTGGGGCTGCCTGCTGC 1

RESULT 166
US-09-618-919A-3
; Sequence 3, Application US/09618919A
; Patent No. 6617312
; GENERAL INFORMATION:
; APPLICANT: Paesen, Guido Christiaan
; APPLICANT: Nuttall, Patricia Anne
; TITLE OF INVENTION: Vasoactive Amine Binding Molecules
; FILE REFERENCE: 2369-1-001CON
; CURRENT APPLICATION NUMBER: US/09/618,919A
; CURRENT FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: US 09/180,733
; PRIOR FILING DATE: 1998-11-13
; PRIOR APPLICATION NUMBER: GB 9610484.0
; PRIOR FILING DATE: 1996-05-18
; PRIOR APPLICATION NUMBER: GB 9707844.8
; PRIOR FILING DATE: 1997-04-18
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer

```

US-09-618-919A-3

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 15 GCAGGAATTCGGCAGCAG 32
||||| ||||| |||||
Db 1 GCAGGAGCTCGGCACGAG 18

RESULT 167

US-09-618-919A-7
; Sequence 7, Application US/09618919A
; Patent No. 6617312
; GENERAL INFORMATION:
; APPLICANT: Paesen, Guido Christiaan
; APPLICANT: Nuttall, Patricia Anne
; TITLE OF INVENTION: Vasoactive Amine Binding Molecules
; FILE REFERENCE: 2369-1-001CON
; CURRENT APPLICATION NUMBER: US/09/618,919A
; CURRENT FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: US 09/180,733
; PRIOR FILING DATE: 1998-11-13
; PRIOR APPLICATION NUMBER: GB 9610484.0
; PRIOR FILING DATE: 1996-05-18
; PRIOR APPLICATION NUMBER: GB 9707844.8
; PRIOR FILING DATE: 1997-04-18
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-618-919A-7

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 15 GCAGGAATTCGGCAGCAG 32
||||| ||||| |||||
Db 1 GCAGGAGCTCGGCACGAG 18

RESULT 168

US-07-696-793A-47/c
; Sequence 47, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 47:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-696-793A-47

Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2820 ACGAATGTTCTCTTCC 2837
||||| ||||| |||||
Db 19 AGGATATGTTCTCTTCC 2

RESULT 169

US-07-977-694-47/c
; Sequence 47, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingeland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Siab, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2863
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 47:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-977-694-47

Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2820 ACGAAATGGTTCTTCTCC 2837
| | | | | | | | | | | | | | | | | | | | | |
Db 19 AGGATATGGTTCTTCTCC 2

RESULT 170
US-08-403-555-13/c
; Sequence 13, Application US/08403555
; Patent No. 5643730
; GENERAL INFORMATION:
; APPLICANT: Banker, Michael J.
; APPLICANT: Davidson, Ralph E.
; APPLICANT: Pereira, Dennis A.
; TITLE OF INVENTION: Process for Detecting Specific mRNA and
; TITLE OF INVENTION: DNA in Cells
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patent Department, Pfizer Inc
; STREET: Eastern Point Road
; CITY: Groton
; STATE: Connecticut
; COUNTRY: U.S.A.
; ZIP: 06340
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/403,555
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/052,805
; FILING DATE:
; APPLICATION NUMBER: US/07/764,462
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Benson, Gregg C.
; REGISTRATION NUMBER: 30,997
; REFERENCE/DOCKET NUMBER: PC8036GCB
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 441-4901
; TELEFAX: (203) 441-5221
; TELEX: 420440 ITT
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-403-555-13
Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2820 ACGAAATGGTTCTTCTCC 2837
| | | | | | | | | | | | | | | | | | | | | |
Db 19 AGGATATGGTTCTTCTCC 2

RESULT 171
US-08-299-187-11
; Sequence 11, Application US/08299187
; Patent No. 5736325
; GENERAL INFORMATION:
; APPLICANT: Manowitz, Paul
; APPLICANT: Foretz, Ronald D.

; APPLICANT: Park, David
; APPLICANT: Ricketts, Michael H.
; TITLE OF INVENTION: MARKER FOR INDIVIDUALS SUSCEPTIBLE TO
; TITLE OF INVENTION: ALCOHOLISM
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/299,187
; FILING DATE: 31-AUG-1994
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 601-1-028
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521

; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens

US-08-299-187-11
Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 578 AGCTTGCTGCATTGCTC 595
| | | | | | | | | | | | | | | | | | | | | |
Db 1 AGCTTGCTGCATTGCTC 18

RESULT 172
US-08-432-158-23/c
; Sequence 23, Application US/08432158
; Patent No. 5861502
; GENERAL INFORMATION:
; APPLICANT: Prockop, Darwin J
; APPLICANT: Collige, Alain
; APPLICANT: Baserga, Renato
; APPLICANT: Nugent, Paul
; TITLE OF INVENTION: Antisense Oligonucleotides to
; TITLE OF INVENTION: Inhibit Expression of Mutated and
; TITLE OF INVENTION: Wild Type Genes for Collagen
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &
; ADDRESS: No. 5861502ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/432,158
FILING DATE: 30-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/10756
FILING DATE: 09-NOV-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/973,332
FILING DATE: 09-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: DeLuca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: TLU-1104
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
ANTI-SENSE: YES
US-08-432-158-23

Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1899 TCTTGCTCTGCTCAAGA 1916
Db 19 TCTTGCTCTGCTCACAGA 2

RESULT 173
US-08-910-443-3
Sequence 3, Application US/08910443
Patent No. 5935790
GENERAL INFORMATION:
APPLICANT: Poretz, Ronald D.
APPLICANT: Manowitz, Paul
TITLE OF INVENTION: METHOD FOR DETECTING A PREDISPOSITION TO
TITLE OF INVENTION: SUSCEPTIBILITY TO TOXIC EFFECTS OF DRUGS AND POISONS
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue, 4th Floor
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/910,443
FILING DATE: 05-AUG-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 601-1-056 R
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-487-5800
TELEFAX: 201-343-1684
TELEX: 133521

Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 578 AGCTTGCTGCGATTGCTC 595
Db 1 AGCTTGCTGCGATTGCCC 18

RESULT 174
US-08-910-443-11
Sequence 11, Application US/08910443
Patent No. 5935790
GENERAL INFORMATION:
APPLICANT: Poretz, Ronald D.
APPLICANT: Manowitz, Paul
TITLE OF INVENTION: METHOD FOR DETECTING A PREDISPOSITION TO
TITLE OF INVENTION: SUSCEPTIBILITY TO TOXIC EFFECTS OF DRUGS AND POISONS
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue, 4th Floor
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/910,443
FILING DATE: 05-AUG-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 601-1-056 R
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-487-5800
TELEFAX: 201-343-1684
TELEX: 133521

Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 578 AGCTTGCTGCGATTGCTC 595
Db 1 AGCTTGCTGCGATTGCCC 18

INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "PRIMER"
HYPOTHETICAL: NO
US-08-910-443-3

Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 578 AGCTTGCTGCGATTGCTC 595
Db 1 AGCTTGCTGCGATTGCCC 18

RESULT 174
US-08-910-443-11
Sequence 11, Application US/08910443
Patent No. 5935790
GENERAL INFORMATION:
APPLICANT: Poretz, Ronald D.
APPLICANT: Manowitz, Paul
TITLE OF INVENTION: METHOD FOR DETECTING A PREDISPOSITION TO
TITLE OF INVENTION: SUSCEPTIBILITY TO TOXIC EFFECTS OF DRUGS AND POISONS
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue, 4th Floor
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/910,443
FILING DATE: 05-AUG-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 601-1-056 R
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-487-5800
TELEFAX: 201-343-1684
TELEX: 133521

INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "PRIMER"
HYPOTHETICAL: NO
US-08-910-443-11

Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 578 AGCTTGCTGCGATTGCTC 595
Db 1 AGCTTGCTGCGATTGCCC 18

RESULT 175
US-08-876-874-4
; Sequence 4, Application US/08876874
; Patent No. 5942405
; GENERAL INFORMATION:
; APPLICANT: Ames, Robert
; APPLICANT: Bergsma, Derk
; APPLICANT: Foley, James
; APPLICANT: Kumar, Chandrika
; APPLICANT: Sarau, Henry
; TITLE OF INVENTION: THERAPEUTIC AND SCREENING
; METHODS USING C3A RECEPTOR AND C3A
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: RATNER & PRESTIA
; STREET: P.O. BOX 980
; CITY: VALLEY FORGE
; STATE: PA
; COUNTRY: USA
; ZIP: 19482
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Fast-SEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/876,874
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/019,627
; FILING DATE: 16-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: PRESTIA, PAUL F
; REGISTRATION NUMBER: 23,031
; REFERENCE/DOCKET NUMBER: P50501
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 610-407-0700
; TELEFAX: 610-407-0701
; TELEX: 846169
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-876-874-4
Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 4049 GCAGTGGTACCATGGCTT 4066
Db 1 GAAGTGGTACCATGGCGT 18
RESULT 176
PCT-US95-11114-11
; Sequence 11, Application PC/TUS9511114
; GENERAL INFORMATION:
; APPLICANT: Manowitz, Paul
; APPLICANT: Poretz, Ronald D.
; APPLICANT: Park, David
; APPLICANT: Ricketts, Michael H.
; TITLE OF INVENTION: MARKER FOR INDIVIDUALS SUSCEPTIBLE TO
; ALCOHOLISM
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue

CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/11114
FILING DATE: 30-AUG-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/
FILING DATE: 21-JUN-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/299,187
FILING DATE: 31-AUG-1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 1158-1-001PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201 487-5800
TELEFAX: 201 343-1684
TELEX: 133521
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
PCT-US95-11114-11
Query Match 0.3%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 578 AGCTTGCTGCATTCCTC 595
Db 1 AGCTTGCTGCATTCGCC 18
RESULT 177
US-08-011-398B-7
; Sequence 7, Application US/08011398B
; Patent No. 5512473
; GENERAL INFORMATION:
; APPLICANT: Roger Brent
; APPLICANT: Anconis S. Zervos
; TITLE OF INVENTION: MAX-INTERACTING PROTEINS AND RELATED
; MOLECULES AND METHODS
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)

```
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/011,398B
; FILING DATE: 29 JAN 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul T. Clark
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/160001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-011-398B-7

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 20 AATTCGGCACGAGGGG 35
Db 1 AATTCGGCACGAGGCG 16

RESULT 178
US-08-370-225-7
; Sequence 7, Application US/08370225
; Patent No. 5580736
; GENERAL INFORMATION:
; APPLICANT: Brent, Roger
; APPLICANT: Gyuris, Jeno
; APPLICANT: Golemis, Erica
; TITLE OF INVENTION: Interaction Trap System for Isolating
; TITLE OF INVENTION: No. 5580736el Proteins
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: Wordperfect (Version 5.1)
; CURRENT APPLICATION DATA:
; FILING DATE:
; APPLICATION NUMBER: US/08/370,225
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/969,038
; FILING DATE: 10/30/92
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/143001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16
```

```
;
; TYPE: nucleic acid
; STRANDEDNESS: Double
; TOPOLOGY: linear
;
US-08-370-225-7

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 20 AATTCGGCACGAGGGG 35
Db 1 AATTCGGCACGAGGCG 16

RESULT 179
US-08-464-051-7
; Sequence 7, Application US/08464051
; Patent No. 5780262
; GENERAL INFORMATION:
; APPLICANT: Roger Brent
; APPLICANT: Antonis S. Zervos
; TITLE OF INVENTION: MAX-INTERACTING PROTEINS AND RELATED
; TITLE OF INVENTION: MOLECULES AND METHODS
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: Wordperfect (Version 5.1)
; CURRENT APPLICATION DATA:
; FILING DATE: 05 JUN 1995
; APPLICATION NUMBER: US/08/464,051
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/011,398
; FILING DATE: 29 JAN 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul T. Clark
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/160002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-464-051-7

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 20 AATTCGGCACGAGGGG 35
Db 1 AATTCGGCACGAGGCG 16

RESULT 180
US-08-461-859-7
; Sequence 7, Application US/08461859
; Patent No. 5786169
; GENERAL INFORMATION:
```

APPLICANT: Brent, Roger
APPLICANT: Gyuris, Jeno
APPLICANT: Golemis, Erica
TITLE OF INVENTION: Interaction Trap System for Isolating
TITLE OF INVENTION: NO. 5786169el Proteins
NUMBER OF SEQUENCES: 35
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 50Z or 55SX
OPERATING SYSTEM: MS-DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/461,859
FILING DATE: June 5, 1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
PRIOR APPLICATION NUMBER: 08/370,225
FILING DATE: January 9, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/969,038
FILING DATE: October 30, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Lech, Karen F.
REGISTRATION NUMBER: 35,238
REFERENCE/DOCKET NUMBER: 00786/143002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 16
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-461-859-7

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 20 AATTCGGCAGCAGGGG 35
Db 1 AATTCGGCAGCAGGGG 16
|||||

RESULT 181
US-08-462-498-7
Sequence 7, Application US/08462498
Patent No. 5852169
GENERAL INFORMATION:
APPLICANT: Roger Brent
APPLICANT: Antonis S. Zervos
TITLE OF INVENTION: MAX-INTERACTING PROTEINS AND RELATED
TITLE OF INVENTION: MOLECULES AND METHODS
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 50Z or 55SX

OPERATING SYSTEM: MS-DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,498
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/011,398
FILING DATE: 29 JAN 1993
ATTORNEY/AGENT INFORMATION:
NAME: Paul T. Clark
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00786/160001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 16
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-462-498-7

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 20 AATTCGGCAGCAGGGG 35
Db 1 AATTCGGCAGCAGGGG 16
|||||

RESULT 182
US-08-879-260-10
Sequence 10, Application US/08879260
Patent No. 5935851
GENERAL INFORMATION:
APPLICANT: Murthy, Anita E.
APPLICANT: Guseilla, James F.
TITLE OF INVENTION: TPR-Containing Genes
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
STREET: 1100 New York Ave, N.W., Suite 600
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/879,260
FILING DATE: 19JUN1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/020,204
FILING DATE: 20JUN1996
ATTORNEY/AGENT INFORMATION:
NAME: Ludwig, Steven R.
REGISTRATION NUMBER: 36,203
REFERENCE/DOCKET NUMBER: 0609.4260001/JAG/SRL
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-2600
TELEFAX: 202-371-2540
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-879-260-10

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 20 AATTCGGCAGGAGGG 35
|||||
Db 1 AATTCGGCAGGAGGG 16

RESULT 183

US-08-554-385-7
; Sequence 7, Application US/08554385
; Patent No. 6017692

; GENERAL INFORMATION:
; APPLICANT: Roger Brent
; APPLICANT: Antonis S. Zervos
; TITLE OF INVENTION: MAX-INTERACTING PROTEINS AND RELATED
; TITLE OF INVENTION: MOLECULES AND METHODS
; NUMBER OF SEQUENCES: 32

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/554,385
; FILING DATE: No. 6017692ember 8, 1995

; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Karen F. Lech
; REGISTRATION NUMBER: 35,238
; REFERENCE/DOCKET NUMBER: 00786/252001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906

; TELEX: 200154

; INFORMATION FOR SEQ ID NO: 7:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 16

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-554-385-7

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 20 AATTCGGCAGGAGGG 35
|||||
Db 1 AATTCGGCAGGAGGG 16

RESULT 184

US-09-371-772B-7023

; Sequence 7023, Application US/09371772B
; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00,876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B

; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 7023

; LENGTH: 16

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-371-772B-7023

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.2e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1401 AATAAAATTGAAGAT 1416

|||||

Db 1 AAUAAAUUGAGUU 16

RESULT 185

PCT-US93-10069-7

; Sequence 7, Application PC/TUS9310069

; GENERAL INFORMATION:

; APPLICANT: Brent, Roger

; APPLICANT: Gyuris, Jeno

; APPLICANT: Golemis, Erica

; TITLE OF INVENTION: Interaction Trap System for Isolating

; TITLE OF INVENTION: Novel Proteins

; NUMBER OF SEQUENCES: 33

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fish & Richardson

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: U.S.A.

; ZIP: 02110-2804

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; COMPUTER: IBM PS/2 Model 50Z or 55SX

; OPERATING SYSTEM: MS-DOS (Version 5.0)

; SOFTWARE: WordPerfect (Version 5.1)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: PCT/US93/10069

; FILING DATE: 20-OCT-1993

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/969,038

; FILING DATE: 10/30/92

; ATTORNEY/AGENT INFORMATION:

; NAME: Clark, Paul T.

; REGISTRATION NUMBER: 30,162

; REFERENCE/DOCKET NUMBER: 00786/143001

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 542-5070

; TELEFAX: (617) 542-8906

; TELEX: 200154

; INFORMATION FOR SEQ ID NO: 7:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 16

; TYPE: nucleic acid

; STRANDEDNESS: double

TOPOLOGY: linear
PCT-US93-10069-7

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 20 AATTCGGCAGGAGGG 35
| | | | | | | | | | | | | | | | | | | | | |
Db 1 AATTCGGCAGGAGCG 16

RESULT 186
US-08-373-124A-596
; Sequence 596, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373.124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFORMATION FOR SEQ ID NO: 596:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.2e+02;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 2704 AAACUUCUCUCUCA 2719
| | | | | : : : : : | | | | |
US-08-373-124A-596

Db 1 AAACUUCUCUCUCA 16

RESULT 187
US-08-373-124A-1635
; Sequence 1635, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373.124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFORMATION FOR SEQ ID NO: 1635:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.2e+02;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 2704 AAACUUCUCUCUCA 2719
| | | | | : : : : : | | | | |
Db 1 AAACUUCUCUCUCA 16

RESULT 188
US-08-435-628-596
; Sequence 596, Application US/08435628
; Patent No. 5617796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.

APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 596:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-596
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. NO. 1.2e+02;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
Oy 2704 AAACCTGTCTGCTCA 2719
Db 1 AAACUUCUUGCUCA 16
RESULT 189
US-08-435-628-1635
Sequence 1635, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
CANCER USING RIBOZYMES

NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1635:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-1635
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. NO. 1.2e+02;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
Oy 2704 AAACCTGTCTGCTCA 2719
Db 1 AAACUUCUUGCUCA 16
RESULT 190
US-08-894-483-2
Sequence 2, Application US/08894483
Patent No. 6054163
GENERAL INFORMATION:
APPLICANT: WETTENHALL, RICHARD E.H.
APPLICANT: DAVIDSON, BARRIE E.
APPLICANT: HILLIER, ALAN J.
APPLICANT: HARMARK, KIM
APPLICANT: JACK, RALPH W.
APPLICANT: HICKEY, MALCOLM W.
APPLICANT: COVENTRY, JOHN
APPLICANT: WAN, JASON
TITLE OF INVENTION: NOVEL BACTERIOGIN PISCICOLIN 126
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Nixon & Vanderhye, P.C.
STREET: 1100 No. 6054163th Glebe Road, 8th Floor

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1169 GTTTTGTGGGGTGG 1184
Db 1 GTGTGTGGTGGTGG 16

RESULT 193
US-09-866-108A-6351/c
; Sequence 6351, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6351

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2393 GCTGGCAAGTCTCTC 2408
Db 17 GCTGGCAAGTCTCTC 2

RESULT 194
US-09-866-108A-6352/c
; Sequence 6352, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6352

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2393 GCTGGCAAGTCTCTC 2408
Db 16 GCTGGCAAGTCTCTC 1

RESULT 195
US-09-865-664B-1072/c
; Sequence 1072, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1072
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-09-685-664B-1072

```
;
;
; Query Match
; Best Local Similarity 0.3%; Score 14.4; DB 1; Length 17;
; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5051 AAAAAAAAAAAAACT 5066
Db 17 AAAAAAAAAAAAAAGT 2

RESULT 196
US-09-685-664B-1078/c
; Sequence 1078, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1078
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1078
```

```
Query Match
; Best Local Similarity 0.3%; Score 14.4; DB 1; Length 17;
; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy 5022 TGTAAAAA 5037
Db 16 TGGAAAAA 1

```
RESULT 197
US-08-585-684B-2626/c
; Sequence 2626, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
```

```
;
;
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2626:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-2626
```

```
Query Match
; Best Local Similarity 0.3%; Score 14.4; DB 1; Length 18;
; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy 841 GAAAAGCATCTGAGA 856
Db 18 GAAAAGCATCTGAGA 3

```
RESULT 198
US-09-205-144-32
; Sequence 32, Application US/09205144
; Patent No. 5958771
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Elizabeth J. Ackermann
; APPLICANT: Lex M. Cowsest
; TITLE OF INVENTION: ANTISENSE MODULATION OF CELLULAR INHIBITOR OF APOPTOSIS-2 EXPRESSION
; FILE REFERENCE: RFS-0021
; CURRENT APPLICATION NUMBER: US/09/205,144
; CURRENT FILING DATE: 1998-12-03
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 32
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-144-32
```

```
Query Match
; Best Local Similarity 0.3%; Score 14.4; DB 1; Length 18;
; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy 4554 TGACATCATCTGAT 4569
Db 3 TGACATCATCTGTT 18

```
RESULT 199
US-09-161-244-28
; Sequence 28, Application US/09161244
; Patent No. 6004814
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Cowsest, Lex M.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD71 EXPRESSION
; FILE REFERENCE: RFS-0007
; CURRENT APPLICATION NUMBER: US/09/161,244
```

; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-244-28

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3758 GTGCTGTCAGCTTCT 3773
|||||
Db 3 GTGCTGTCAGCTTCT 18

RESULT 200
US-09-038-073-2626/c
; Sequence 2626, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2626:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-2626

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 841 GAAAAGCATCTGAGA 856
|||||

Db 18 GAAACAGCATCTGAGA 3

RESULT 201
US-09-306-595C-30
; Sequence 30, Application US/09306595C
; Patent No. 6284506
; GENERAL INFORMATION:
; APPLICANT: HOSHINO, Tatsuo
; APPLICANT: OJIMA, Kazuyuki
; APPLICANT: SETOGUCHI, Yutaka
; TITLE OF INVENTION: ISOPRENOID PRODUCTION
; FILE REFERENCE: ISOPRENOID PRODUCTION
; CURRENT APPLICATION NUMBER: US/09/306,595C
; CURRENT FILING DATE: 1999-05-06
; PRIOR APPLICATION NUMBER: 98108210
; PRIOR FILING DATE: 1998-05-06
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sense primer
; OTHER INFORMATION: for cloning of 5'-adjacent region of MVK gene
US-09-306-595C-30

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2910 GGAAGAGGAGACAAA 2925
|||||
Db 1 GGAAGAGGAGAGAAA 16

RESULT 202
US-09-588-995A-31
; Sequence 31, Application US/09588995A
; Patent No. 6514697
; GENERAL INFORMATION:
; APPLICANT: PETERSEN, CAROLYN
; APPLICANT: BARNES, DEBRA A.
; APPLICANT: NELSON, RICHARD C.
; APPLICANT: GUT, JIRI
; TITLE OF INVENTION: METHODS FOR DETECTION OF CRYPTOSPORIDIUM SPECIES AND
; TITLE OF INVENTION: ISOLATES AND FOR DIAGNOSIS OF CRYPTOSPORIDIUM
; FILE REFERENCE: 480.19-5
; CURRENT APPLICATION NUMBER: US/09/588,995A
; CURRENT FILING DATE: 2000-06-06
; PRIOR APPLICATION NUMBER: 08/827,171
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 08/928,361
; PRIOR FILING DATE: 1997-09-12
; PRIOR APPLICATION NUMBER: 08/700,651
; PRIOR FILING DATE: 1996-08-14
; PRIOR APPLICATION NUMBER: 08/415,751
; PRIOR FILING DATE: 1995-04-03
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 31
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-588-995A-31

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2098 CCCAATAATGAAGAA 2113
Db 1 CCCAATAATGAAGAA 16

RESULT 203
US-09-422-978-5652
; Sequence 5652, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5652
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-5875 for SEQ 1718,
US-09-422-978-5652

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3449 CTAAGCAGATGATGA 3464
Db 2 CAAAGCAGATGATGA 17

RESULT 204
US-09-925-388-30
; Sequence 30, Application US/09925388
; Patent No. 6586202
; GENERAL INFORMATION:
; APPLICANT: HOSHINO, Tatsuo
; APPLICANT: OJIMA, Kazuyuki
; APPLICANT: SETOGUCHI, Yutaka
; TITLE OF INVENTION: ISOPRENOID PRODUCTION
; FILE REFERENCE: ISOPRENOID PRODUCTION
; CURRENT APPLICATION NUMBER: US/09/925,388
; CURRENT FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: 09/306,595
; PRIOR FILING DATE: 1999-05-06
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sense primer
; OTHER INFORMATION: for cloning of 5'-adjacent region of MVK gene
US-09-925-388-30

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2910 GGAAGAGAGACACAA 2925
Db 1 GGAAGAGAGAGAGAA 16

RESULT 205
US-08-671-978A-43/c
; Sequence 43, Application US/08671978A
; Patent No. 5959093
; GENERAL INFORMATION:
; APPLICANT: Saif, Linda J.
; APPLICANT: Parwani, Anil
; APPLICANT: Kim, Wonyong
; APPLICANT: Chang, Keong-OK
; TITLE OF INVENTION: ROTAVIRUS GENES
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CALFEE, HALTER & GRISWOLD
; STREET: 800 SUPERIOR AVENUE, SUITE 1400
; CITY: CLEVELAND
; STATE: OHIO
; COUNTRY: USA
; ZIP: 44114
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/671,978A
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: GOLDRICK, MARY E
; REGISTRATION NUMBER: 34,829
; REFERENCE/DOCKET NUMBER: 22727/00133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (216) 622-8200
; TELEFAX: (216) 241-0816
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-671-978A-43

Query Match 0.3%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4663 AATTTTAATAGTTATA 4678
Db 18 AATTTTAATAGTTATA 3

RESULT 206
US-08-434-099A-22/c
; Sequence 22, Application US/08434099A
; Patent No. 6083902
; GENERAL INFORMATION:
; APPLICANT: Cederholm-Wms., Stewart A.
; TITLE OF INVENTION: Recombinant Fibrin Chains,
; TITLE OF INVENTION: Fibrin and Fibrin-Homologs
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: E.R. Squibb & Sons, Inc.
; STREET: 100 Headquarters Park Drive
; CITY: Skillman
; STATE: NJ
; COUNTRY: USA
; ZIP: 08558

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Fast-Seq for Windows Version 2.0
CURRENT APPLICATION DATA: US/08/434,099A
APPLICATION NUMBER: US/08/434,099A
FILING DATE: 03-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/236,979
FILING DATE: 02-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Furman, Jr., Esq., Theodore R
REGISTRATION NUMBER: 30,942
REFERENCE/DOCKET NUMBER: CV0054a
TELECOMMUNICATION INFORMATION:
TELEPHONE: 908-281-2372
TELEFAX: 908-281-2373
TELEX:
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-434-099A-22

Query Match 0.3%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 558 GCTTGCCATTATGGGA 573
||| ||||| ||||| |||||
Db 19 GCATGCCATTATGGGA 4

RESULT 207
US-09-345-882-113
; Sequence 113, Application US/09345882
; Patent No. 639373
; GENERAL INFORMATION:
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: A NUCLEIC ACID ENCODING A RETINOBLASTOMA BINDING PROTEIN (RBP-7)
; TITLE OF INVENTION: AND POLYMORPHIC MARKERS ASSOCIATED WITH SAID NUCLEIC ACID.
; FILE REFERENCE: GENSET.031A
; CURRENT APPLICATION NUMBER: US/09/345,882
; CURRENT FILING DATE: 1999-06-30
; PRIOR APPLICATION NUMBER: US 60/091,315
; PRIOR FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/111,909
; PRIOR FILING DATE: 1998-12-10
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: Patent.pm
; SEQ ID NO 113
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: microsequencing oligo for 5-136-174.mis1
US-09-345-882-113

Query Match 0.3%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3613 ACAGTGAATCTGGA 3628
||| ||||| ||||| |||||
Db 4 ACAATGAATCTGGA 19

RESULT 208
US-09-261-115-53
; Sequence 53, Application US/09261115
; Patent No. 6458584
; GENERAL INFORMATION:
; APPLICANT: MIRZABEKOV, ANDREI
; APPLICANT: GUSCHIN, DMITRY Y.
; APPLICANT: SHIK, VALENTINE
; APPLICANT: DROBYSHEV, ALEKSEI
; APPLICANT: FOTIN, ALEXANDER
; APPLICANT: YERSHOV, GENNADIY
; APPLICANT: LYSOV, YU
; TITLE OF INVENTION: CUSTOMIZED OLIGONUCLEOTIDE MICROCHIPS THAT CONVERT
; TITLE OF INVENTION: MULTIPLE GENETIC INFORMATION TO SIMPLE PATTERNS, ARE
; FILE REFERENCE: 21416/90184
; CURRENT APPLICATION NUMBER: US/09/261,115
; CURRENT FILING DATE: 1999-03-03
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 53
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Customized
; OTHER INFORMATION: oligonucleotide
US-09-261-115-53

Query Match 0.3%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 132 GGTGTGAGGCCCTCG 147
||| ||||| ||||| |||||
Db 4 GGTGTGAGGCCCTCG 19

RESULT 209
US-09-422-978-7136/c
; Sequence 7136, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilva
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7136
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-24592 for SEQ 3202,
US-09-422-978-7136

Query Match 0.3%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2668 CCATATATTACCCAAAC 2683
||| ||||| ||||| |||||

```
Db      19 CCATTATTACCAAC 4

RESULT 210
US-09-698-295-5
; Sequence 5, Application US/09698295
; Patent No. 6689584
; GENERAL INFORMATION:
; APPLICANT: Jones, Michael H.
; TITLE OF INVENTION: TRANSCRIPTIONAL REGULATORY FACTOR
; FILE REFERENCE: 06501-068001
; CURRENT APPLICATION NUMBER: US/09/698,295
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: PCT/JP99/02340
; PRIOR FILING DATE: 1999-04-30
; PRIOR APPLICATION NUMBER: JAPAN 10/137631
; PRIOR FILING DATE: 1998-04-30
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for PCR
US-09-698-295-5

Query Match      0.3%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2419 CCTCTGCTGCAACAG 2434
||||| ||||| ||||| |||||
Db      1 CCTCAGCTGCAACAG 16

RESULT 211
US-09-696-791-33/c
; Sequence 33, Application US/09696791
; Patent No. 6770833
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 33
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk1 ribozyme binding site
US-09-696-791-33

Query Match      0.3%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      4870 TTTTATTGTATATGTT 4885
||||| ||||| ||||| |||||
Db      18 TTTTATTGTATATCTT 3

RESULT 212
US-09-232-338-43/c
; Sequence 43, Application US/09232338
; Patent No. 6805867
; GENERAL INFORMATION:
; APPLICANT: Saif, Linda

Db      19 CCATTATTACCAAC 4

APPLICANT: Parwani, Anil
APPLICANT: Kim, Wonyong
APPLICANT: Chang, Keong-OK
APPLICANT: Gadfield, Kathy
TITLE OF INVENTION: Bovine Rotavirus Genes
FILE REFERENCE: 22727/04026
CURRENT APPLICATION NUMBER: US/09/232,338
CURRENT FILING DATE: 1999-01-15
NUMBER OF SEQ ID NOS: 50
SOFTWARE: PatentIn version 3.0
SEQ ID NO 43
LENGTH: 19
TYPE: DNA
ORGANISM: Bovine rotavirus
US-09-232-338-43

Query Match      0.3%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      4663 AATTTTAATAGTTATA 4678
||||| ||||| ||||| |||||
Db      18 AATTTTAATAGTTATA 3

RESULT 213
US-08-294-424-33
; Sequence 33, Application US/08294424
; Patent No. 5800984
; GENERAL INFORMATION:
; APPLICANT: Vary, Calvin
; TITLE OF INVENTION: NUCLEIC ACID SEQUENCE DETECTION BY
; TITLE OF INVENTION: TRIPLE HELIX FORMATION
; NUMBER OF SEQUENCES: 49
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/294,424
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/000,922
; FILING DATE: 16 JAN 1993
; APPLICATION NUMBER: US/07/629,601B
; FILING DATE: 17-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 00088-037001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 33 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-294-424-33

Query Match      0.3%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
```

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2908 GAGGAAGAGGAAGA 2921
| | | | | | | | | | | | | | | | | |
Db 1 GAGGAAGAGGAAGA 14

RESULT 214
US-09-600-932-4
; Sequence 4, Application US/09600932
; Patent No. 6787639
; GENERAL INFORMATION:
; APPLICANT: Wakamiya, No. 6787639utaka
; TITLE OF INVENTION: NOVEL COLLECTIN
; FILE REFERENCE: 19036/36615
; CURRENT APPLICATION NUMBER: US/09/600,932
; CURRENT FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: PCT/JP98/03328
; PRIOR FILING DATE: 1998-07-24
; PRIOR APPLICATION NUMBER: JP 10-11281
; PRIOR FILING DATE: 1998-01-23
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Pre-sequence
; OTHER INFORMATION: of an Insert
US-09-600-932-4

Query Match 0.3%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 19 GAATTCGGCAGGAG 32
| | | | | | | | | | | | | | | | | |
Db 1 GAATTCGGCAGGAG 14

RESULT 215
US-09-043-861-15
; Sequence 15, Application US/09043861
; Patent No. 6793917
; GENERAL INFORMATION:
; APPLICANT: IMAI, Toshio
; APPLICANT: YOSHIDA, Tetsuya
; APPLICANT: YOSHIE, Osamu
; TITLE OF INVENTION: TYPE CC CHEMOKINE-LIKE PROTEIN
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY & LARDNER
; STREET: 3000 K Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/043,861
; FILING DATE: 27-MAR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/JP96/02801
; FILING DATE: 27-SEP-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 56044/1996
; FILING DATE: 13-MAR-1996

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 249457/1995
; FILING DATE: 27-SEP-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wegner, Harold C.
; REGISTRATION NUMBER: 25,258
; REFERENCE/DOCKET NUMBER: 74129/432
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 672-5300
; TELEFAX: (202) 672-5399
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Synthetic DNA"
US-09-043-861-15

Query Match 0.3%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 20 AATTCGGCAGGAG 33
| | | | | | | | | | | | | | | | | |
Db 1 AATTCGGCAGGAG 14

RESULT 216
US-09-190-976B-14
; Sequence 14, Application US/09190976B
; Patent No. 6815187
; GENERAL INFORMATION:
; APPLICANT: Simons, Michael
; Horowitz, Arie
; TITLE OF INVENTION: Stimulation of angiogenesis via
; syndecan-4 cytoplasmic domain signaling pathway
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David Prashker, Esq.
; STREET: P.O. Box 5387
; CITY: Magnolia
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 01930
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.40 Mb storage
; COMPUTER: Dell PC
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Microsoft Word version 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/190,976B
; FILING DATE: 12-No. 6815187-1998
; CLASSIFICATION: Unknown
; ATTORNEY/AGENT INFORMATION:
; NAME: David Prashker, Esq.
; REGISTRATION NUMBER: 29,693
; REFERENCE/DOCKET NUMBER: BIS-041
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (978) 525-3794
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-190-976B-14

Query Match 0.3%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 19 GAATTCGCACGAG 32
| | | | | | | | | |
Db 1 GAATTCGCACGAG 14

RESULT 217

US-09-859-736-7/c
; Sequence 7, Application US/09859736
; Patent No. 6938244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: Patentin ver. 2.1
; SEQ ID NO 7
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: dt oligonucleotide
US-09-859-736-7

Query Match 0.3%; Score 14; DB 1; Length 14;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5025 AAAAAAAAAAAAAA 5038
| | | | | | | | | |
Db 14 AAAAAAAAAAAAAA 1

RESULT 218

US-08-585-888-34/c
; Sequence 34, Application US/08588588
; Patent No. 5874215
; GENERAL INFORMATION:
; APPLICANT: KUIPER, Martin T.R.
; APPLICANT: ZABEAU, Marc
; APPLICANT: VOS, Pieter
; TITLE OF INVENTION: AMPLIFICATION OF SIMPLE SEQUENCE REPEATS
; NUMBER OF SEQUENCES: 47
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,888
; FILING DATE: 16-JAN-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95400080.8
; FILING DATE: 16-JAN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: McGowan, Malcolm K.
; REGISTRATION NUMBER: 39,300
; REFERENCE/DOCKET NUMBER: 010830-097

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-585-888-34

Query Match 0.3%; Score 14; DB 1; Length 16;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2802 TCACATCGTCAGA 2815
| | | | | | | | | |
Db 14 TCACATCGTCAGA 1

RESULT 219

US-09-195-991-34/c
; Sequence 34, Application US/09195991
; Patent No. 6218119
; GENERAL INFORMATION:
; APPLICANT: KUIPER, Martin T.R.
; APPLICANT: ZABEAU, Marc
; APPLICANT: VOS, Pieter
; TITLE OF INVENTION: AMPLIFICATION OF SIMPLE SEQUENCE REPEATS
; NUMBER OF SEQUENCES: 47
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/195,991
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,888
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: McGowan, Malcolm K.
; REGISTRATION NUMBER: 39,300
; REFERENCE/DOCKET NUMBER: 010830-097
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-195-991-34

Query Match 0.3%; Score 14; DB 1; Length 16;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2802 TCACATCGTCAGA 2815
| | | | | | | | | |
Db 14 TCACATCGTCAGA 1

RESULT 220
US-09-155-885A-236/c
; Sequence 236, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; ROSSAU, RUDI
; MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/155,885A
; FILING DATE: 08-Oct-1998
; CLASSIFICATION: <unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/02002
; FILING DATE: 21-APR-1997
; APPLICATION NUMBER: EP 96870053.4
; FILING DATE: 19-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 2551-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 236:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 236:
US-09-155-885A-236
Query Match 0.3%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1977 AGCCCAAGATGATG 1990
Db 14 AGCCCAAGATGATG 1
RESULT 221
US-08-292-620A-1731/c
; Sequence 1731, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS

; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1731:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1731
Query Match 0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 287 TCTGCTGAGACCCC 300
Db 17 TCTGCTGAGACCCC 4
RESULT 222
US-08-292-620A-1748/c
; Sequence 1748, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street

STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1748:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1748

Query Match 0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 287 TCTGCTGAGACCCC 300
Db 17 TCTGCTGAGACCCC 4

RESULT 223
US-09-071-845-1731/c
Sequence 1731, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1731:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1731

Query Match 0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 287 TCTGCTGAGACCCC 300
Db 17 TCTGCTGAGACCCC 4

RESULT 224
US-09-071-845-1748/c
Sequence 1748, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:

```
; CLASSIFICATION:
; PRIOR APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1748:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1748

Query Match      0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 287 TCTGCTGAGACCCC 300
Db 17 TCTGCTGAGACCCC 4

RESULT 225
US-09-535-012A-16
; Sequence 16, Application US/09535012A
; Patent No. 6531281
; GENERAL INFORMATION:
; APPLICANT: Elf Exploration Production
; TITLE OF INVENTION: Method of Detecting Sulphate- Reducing Bacteria
; FILE REFERENCE: 111628-00114
; CURRENT APPLICATION NUMBER: US/09/535,012A
; CURRENT FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 9903637
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patentin ver. 2.1
; SEQ ID NO 16
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Desulfovibrio vulgaris
; FEATURE:
; OTHER INFORMATION: aspl2 primer
; US-09-535-012A-16

Query Match      0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1138 CGGAGGAGAACTTG 1151
Db 2 CGGAGGAGAACTTG 15

RESULT 226
US-09-866-108A-10544
; Sequence 10544, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: A60MICA Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10544
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-10544

Query Match      0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2102 ATAATGAAGAAATA 2115
Db 4 ATAATGAAGAAATA 17

RESULT 227
US-09-866-108A-10545
; Sequence 10545, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10545
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10545

Query Match      0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2102 ATAATGAAGAAATA 2115
Db 3 ATAATGAAGAAATA 16

RESULT 228
US-09-866-108A-10546
; Sequence 10546, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10546
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10546

Query Match      0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2102 ATAATGAAGAAATA 2115
Db 3 ATAATGAAGAAATA 16

RESULT 228
US-09-866-108A-10546
; Sequence 10546, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10546
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10546

Query Match      0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2102 ATAATGAAGAAATA 2115
Db 3 ATAATGAAGAAATA 16

RESULT 228
US-09-866-108A-10547
; Sequence 10547, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10547
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10547

Query Match      0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2102 ATAATGAAGAAATA 2115
Db 1 ATAATGAAGAAATA 14

RESULT 230
US-09-155-885A-235/c
; Sequence 235, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: ROSSAU, RUDI
; APPLICANT: MAERTENS, GEERT
```

```
;
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/155,885A
; FILING DATE: 08-Oct-1998
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/02002
; FILING DATE: 21-APR-1997
; APPLICATION NUMBER: EP 96870053.4
; FILING DATE: 19-APR-1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 2551-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
;
; INFORMATION FOR SEQ ID NO: 235:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 235:
US-09-155-885A-235

Query Match 0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1977 AGCCCAAGATGATG 1990
Db 15 AGCCCAAGATGATG 2

RESULT 231
US-09-155-885A-237/C
; Sequence 237, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; ROSSAU, RUDI
; MAERTENS, GEERT
;
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
```

```
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/155,885A
; FILING DATE: 08-Oct-1998
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/02002
; FILING DATE: 21-APR-1997
; APPLICATION NUMBER: EP 96870053.4
; FILING DATE: 19-APR-1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 2551-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
;
; INFORMATION FOR SEQ ID NO: 237:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 237:
US-09-155-885A-237

Query Match 0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1977 AGCCCAAGATGATG 1990
Db 15 AGCCCAAGATGATG 2

RESULT 232
US-08-294-312B-11
; Sequence 11, Application US/08294312B
; Patent No. 6380369
; GENERAL INFORMATION:
; APPLICANT: Adams et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PFI06P2
; CURRENT APPLICATION NUMBER: US/08/294,312B
; CURRENT FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
US-08-294-312B-11

Query Match 0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4070 GGGACATGAGGTTTC 4083
Db 1 GGGACATGAGGTTTC 14

RESULT 233
US-08-468-024B-11
; Sequence 11, Application US/08468024B
```

```
; Patent No. 6416984
; GENERAL INFORMATION:
; APPLICANT: Haseltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P3
; CURRENT APPLICATION NUMBER: US/08/468,024B
; CURRENT FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/294,312
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
US-08-468-024B-11

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4070 GGGACATGAGGTTTC 4083
Db 1 GGGACATGAGGTTTC 14

RESULT 234
US-08-187-757D-9
; Sequence 9, Application US/08187757D
; Patent No. 6482606
; GENERAL INFORMATION:
; APPLICANT: Adams et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106
; CURRENT APPLICATION NUMBER: US/08/187,757D
; CURRENT FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
US-08-187-757D-9

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4070 GGGACATGAGGTTTC 4083
Db 1 GGGACATGAGGTTTC 14

RESULT 235
US-09-535-012A-10
; Sequence 10, Application US/09535012A
; Patent No. 6531281
; GENERAL INFORMATION:
; APPLICANT: Elf Exploration Production
; TITLE OF INVENTION: Method of Detecting Sulphate- Reducing Bacteria
; FILE REFERENCE: 111628-00114
; CURRENT APPLICATION NUMBER: US/09/535,012A
; CURRENT FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 9903637
; PRIOR FILING DATE: 1999-03-24
```

```
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Desulfovibrio vulgaris
; FEATURE:
; OTHER INFORMATION: APS14 primer
US-09-535-012A-10

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1138 CGGAGGAGGACTTG 1151
Db 3 CGGAGGAGGACTTG 16

RESULT 236
US-09-422-978-5372
; Sequence 5372, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5372
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1...18
; OTHER INFORMATION: upstream amplification primer 99-24441 for SEQ 1438,
US-09-422-978-5372

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 888 AGACAATCTCTATG 901
Db 1 AGACAATCTCTATG 14

RESULT 237
US-08-465-679-11
; Sequence 11, Application US/08465679
; Patent No. 6610477
; GENERAL INFORMATION:
; APPLICANT: Haseltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P4
; CURRENT APPLICATION NUMBER: US/08/465,679
; CURRENT FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/294,312
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
```

```
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
US-08-465-679-11

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4070 GGGACATGAGGTTTC 4083
      |||||
Db 1 GGGACATGAGGTTTC 14

RESULT 238
US-08-210-143C-9
; Sequence 9, Application US/08210143C
; Patent No. 6620619
; GENERAL INFORMATION:
; APPLICANT: Haseltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PFI06PI
; CURRENT APPLICATION NUMBER: US/08/210,143C
; CURRENT FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
US-08-210-143C-9

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4070 GGGACATGAGGTTTC 4083
      |||||
Db 1 GGGACATGAGGTTTC 14

RESULT 239
US-09-155-885A-145/c
; Sequence 145, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; MAERTENS, GEERT
; ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4070 GGGACATGAGGTTTC 4083
      |||||
Db 1 GGGACATGAGGTTTC 14

RESULT 240
US-09-155-885A-238/c
; Sequence 238, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; ROSSAU, RUDI
; MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1977 AGCCCAAGATGATG 1990
      |||||
Db 16 AGCCCAAGATGATG 3

US-09-155-885A-145
; Application Number: US/09/155,885A
; Filing Date: 08-Oct-1998
; Classification: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/02002
; Filing Date: 21-Apr-1997
; APPLICATION NUMBER: EP 96870053.4
; Filing Date: 19-Apr-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 2551-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 145:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 145:
US-09-155-885A-145

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1977 AGCCCAAGATGATG 1990
      |||||
Db 16 AGCCCAAGATGATG 3

US-09-155-885A-238/c
; Sequence 238, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; ROSSAU, RUDI
; MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:

Query Match          0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1977 AGCCCAAGATGATG 1990
      |||||
Db 16 AGCCCAAGATGATG 3

US-09-155-885A-145
; Application Number: US/09/155,885A
; Filing Date: 08-Oct-1998
; Classification: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/02002
; Filing Date: 21-Apr-1997
; APPLICATION NUMBER: EP 96870053.4
; Filing Date: 19-Apr-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 2551-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
```

```
;
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 238:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 18 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: DNA (genomic)
;   HYPOTHETICAL: NO
;   ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 238:
US-09-155-885A-238
```

```
Query Match      0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred.No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1977 AGCCCAAGATGATG 1990
Db 15 AGCCCAAGATGATG 2
```

RESULT 241

```
US-09-700-492-8
; Sequence 8, Application US/09700492
; Patent No. 6800476
; GENERAL INFORMATION:
; APPLICANT: OLIVER, STEPHEN GEORGE
; APPLICANT: STATEVA, LUOMIRA IOSSIF
; APPLICANT: ZHANG, NIANSHU
; TITLE OF INVENTION: YEAST
; FILE REFERENCE: 39-225
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/700,492
; PRIOR FILING DATE: 1998-05-16
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PRIMER
US-09-700-492-8
```

```
Query Match      0.3%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred.No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2379 TGCTGCCTATGTTG 2392
Db 3 TGCTGCCTATGTTG 16
```

Search completed: August 18, 2005, 08:40:13
Job time : 16 secs